0001070081-23-000065.txt : 20231026 0001070081-23-000065.hdr.sgml : 20231026 20231026163402 ACCESSION NUMBER: 0001070081-23-000065 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 94 CONFORMED PERIOD OF REPORT: 20230930 FILED AS OF DATE: 20231026 DATE AS OF CHANGE: 20231026 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PTC THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001070081 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043416587 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-35969 FILM NUMBER: 231350711 BUSINESS ADDRESS: STREET 1: 100 CORPORATE COURT CITY: SOUTH PLAINFIELD STATE: NJ ZIP: 07080-2449 BUSINESS PHONE: 9082227000 MAIL ADDRESS: STREET 1: 100 CORPORATE COURT CITY: SOUTH PLAINFIELD STATE: NJ ZIP: 07080-2449 FORMER COMPANY: FORMER CONFORMED NAME: PTC THERAPEUTICS INC DATE OF NAME CHANGE: 19980909 10-Q 1 tmb-20230930x10q.htm 10-Q
0001070081--12-312023Q3false7545902273104692P5DP5D0001070081us-gaap:CommonStockMember2023-07-012023-09-300001070081us-gaap:CommonStockMember2022-07-012022-09-300001070081us-gaap:CommonStockMember2022-01-012022-09-300001070081us-gaap:RetainedEarningsMember2023-09-300001070081us-gaap:AdditionalPaidInCapitalMember2023-09-300001070081us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300001070081us-gaap:RetainedEarningsMember2023-06-300001070081us-gaap:AdditionalPaidInCapitalMember2023-06-300001070081us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-3000010700812023-06-300001070081us-gaap:RetainedEarningsMember2022-12-310001070081us-gaap:AdditionalPaidInCapitalMember2022-12-310001070081us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001070081us-gaap:RetainedEarningsMember2022-09-300001070081us-gaap:AdditionalPaidInCapitalMember2022-09-300001070081us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-09-300001070081us-gaap:RetainedEarningsMember2022-06-300001070081us-gaap:AdditionalPaidInCapitalMember2022-06-300001070081us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-3000010700812022-06-300001070081us-gaap:RetainedEarningsMember2021-12-310001070081us-gaap:AdditionalPaidInCapitalMember2021-12-310001070081us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001070081us-gaap:CommonStockMember2023-09-300001070081us-gaap:CommonStockMember2023-06-300001070081us-gaap:CommonStockMember2022-12-310001070081us-gaap:CommonStockMember2022-09-300001070081us-gaap:CommonStockMember2022-06-300001070081us-gaap:CommonStockMember2021-12-310001070081us-gaap:StockOptionMember2022-12-310001070081us-gaap:StockOptionMember2023-09-300001070081ptct:InducementStockIncentivePlan2020Memberus-gaap:CommonStockMember2023-09-300001070081ptct:EmployeeDirectorAndConsultantStockOptionPlan1998EquityAndLongTermIncentivePlan2009AndStockIncentivePlan2013Memberus-gaap:CommonStockMember2023-09-300001070081ptct:AmendedAndRestated2013LongTermIncentivePlanMember2023-09-300001070081srt:MaximumMemberptct:AmendedAndRestated2013LongTermIncentivePlanMember2022-06-080001070081srt:MaximumMemberptct:InducementStockIncentivePlan2020Memberus-gaap:CommonStockMember2022-04-300001070081us-gaap:EmployeeStockMember2021-06-300001070081us-gaap:EmployeeStockMember2021-05-310001070081srt:MaximumMemberptct:InducementStockIncentivePlan2020Memberus-gaap:CommonStockMember2020-01-310001070081ptct:InducementStockIncentivePlan2020Memberus-gaap:CommonStockMember2022-12-012022-12-310001070081ptct:AmendedAndRestated2013LongTermIncentivePlanMember2022-06-082022-06-080001070081ptct:InducementStockIncentivePlan2020Memberus-gaap:CommonStockMember2020-12-012020-12-310001070081srt:MinimumMemberus-gaap:StockOptionMember2023-01-012023-09-300001070081srt:MaximumMemberus-gaap:StockOptionMember2023-01-012023-09-300001070081us-gaap:StockOptionMember2023-01-012023-09-300001070081srt:MaximumMemberus-gaap:StockOptionMemberptct:InducementStockIncentivePlan2020Member2023-01-012023-09-300001070081ptct:RestrictedStockAndRestrictedStockUnitsMember2023-09-300001070081ptct:RestrictedStockAndRestrictedStockUnitsMember2022-12-310001070081us-gaap:RestrictedStockUnitsRSUMemberptct:InducementStockIncentivePlan2020Member2023-01-012023-09-300001070081us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-09-300001070081ptct:RestrictedStockAndRestrictedStockUnitsMember2023-01-012023-09-300001070081ptct:AtMarketOfferingSalesAgreementMember2023-07-012023-09-300001070081ptct:AtMarketOfferingSalesAgreementMember2023-01-012023-09-300001070081ptct:AtMarketOfferingSalesAgreementMember2022-07-012022-09-300001070081ptct:AtMarketOfferingSalesAgreementMember2022-01-012022-09-3000010700812023-10-012023-09-300001070081country:USus-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMember2023-07-012023-09-300001070081us-gaap:RoyaltyMemberus-gaap:CollaborativeArrangementMember2023-07-012023-09-300001070081us-gaap:ProductMemberus-gaap:NonUsMember2023-07-012023-09-300001070081ptct:TranslarnaMemberus-gaap:NonUsMember2023-07-012023-09-300001070081ptct:EmflazaMembercountry:US2023-07-012023-09-300001070081ptct:CollaborationRevenueMemberus-gaap:CollaborativeArrangementMember2023-07-012023-09-300001070081us-gaap:RoyaltyMember2023-07-012023-09-300001070081us-gaap:ProductMember2023-07-012023-09-300001070081ptct:CollaborationRevenueMember2023-07-012023-09-300001070081country:USus-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMember2023-01-012023-09-300001070081country:RUus-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMember2023-01-012023-09-300001070081country:BRus-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMember2023-01-012023-09-300001070081us-gaap:RoyaltyMemberus-gaap:CollaborativeArrangementMember2023-01-012023-09-300001070081us-gaap:ProductMemberus-gaap:NonUsMember2023-01-012023-09-300001070081ptct:TranslarnaMemberus-gaap:NonUsMember2023-01-012023-09-300001070081ptct:EmflazaMembercountry:US2023-01-012023-09-300001070081us-gaap:RoyaltyMember2023-01-012023-09-300001070081us-gaap:ProductMember2023-01-012023-09-300001070081ptct:CollaborationRevenueMember2023-01-012023-09-300001070081country:USus-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMember2022-07-012022-09-300001070081country:RUus-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMember2022-07-012022-09-300001070081us-gaap:RoyaltyMemberus-gaap:CollaborativeArrangementMember2022-07-012022-09-300001070081us-gaap:ProductMemberus-gaap:NonUsMember2022-07-012022-09-300001070081ptct:TranslarnaMemberus-gaap:NonUsMember2022-07-012022-09-300001070081ptct:EmflazaMembercountry:US2022-07-012022-09-300001070081us-gaap:RoyaltyMember2022-07-012022-09-300001070081us-gaap:ProductMember2022-07-012022-09-300001070081ptct:ManufacturingMember2022-07-012022-09-300001070081ptct:CollaborationRevenueMember2022-07-012022-09-300001070081country:USus-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMember2022-01-012022-09-300001070081country:RUus-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMember2022-01-012022-09-300001070081us-gaap:RoyaltyMemberus-gaap:CollaborativeArrangementMember2022-01-012022-09-300001070081us-gaap:ProductMemberus-gaap:NonUsMember2022-01-012022-09-300001070081ptct:TranslarnaMemberus-gaap:NonUsMember2022-01-012022-09-300001070081ptct:EmflazaMembercountry:US2022-01-012022-09-300001070081us-gaap:RoyaltyMember2022-01-012022-09-300001070081us-gaap:ProductMember2022-01-012022-09-300001070081ptct:ManufacturingMember2022-01-012022-09-300001070081ptct:CollaborationRevenueMember2022-01-012022-09-300001070081ptct:MassBioMember2020-01-012020-12-310001070081us-gaap:ConvertibleDebtSecuritiesMember2020-01-012020-01-310001070081us-gaap:SecuredDebtMemberus-gaap:SubsequentEventMember2023-10-192023-10-190001070081ptct:SmaFoundationMemberus-gaap:CollaborativeArrangementMember2023-01-012023-09-300001070081us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300001070081us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-09-300001070081us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-07-012022-09-300001070081us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-09-300001070081us-gaap:RetainedEarningsMember2023-07-012023-09-300001070081us-gaap:RetainedEarningsMember2023-01-012023-09-300001070081us-gaap:RetainedEarningsMember2022-07-012022-09-300001070081us-gaap:RetainedEarningsMember2022-01-012022-09-300001070081ptct:LineOfCreditUncommittedLoanFacilityMember2022-10-270001070081ptct:LineOfCreditCommittedLoanFacilityMember2022-10-270001070081ptct:LineOfCreditCommittedDelayedDrawTermLoanFacilityMember2022-10-270001070081ptct:WarrenPremisesMemberptct:FifthAnniversaryMember2022-06-300001070081ptct:WarrenPremisesMemberptct:DepositsAndOtherNoncurrentAssetsMember2022-06-300001070081ptct:HopewellCampusMemberptct:FifthAnniversaryMember2019-12-310001070081ptct:HopewellCampusMemberptct:DepositsAndOtherNoncurrentAssetsMember2019-12-310001070081srt:MinimumMember2023-09-300001070081srt:MaximumMember2023-09-300001070081ptct:HopewellCampusMember2020-07-012020-07-010001070081us-gaap:IndefinitelivedIntangibleAssetsMemberptct:UpstazaMember2023-09-300001070081us-gaap:IndefinitelivedIntangibleAssetsMember2023-09-300001070081us-gaap:IndefinitelivedIntangibleAssetsMemberptct:UpstazaMember2022-12-310001070081us-gaap:IndefinitelivedIntangibleAssetsMemberptct:PtcFaMember2022-12-310001070081us-gaap:IndefinitelivedIntangibleAssetsMemberptct:PtcAsMember2022-12-310001070081us-gaap:IndefinitelivedIntangibleAssetsMember2022-12-310001070081us-gaap:IndefinitelivedIntangibleAssetsMemberptct:UpstazaMember2023-01-012023-09-300001070081us-gaap:IndefinitelivedIntangibleAssetsMemberptct:PtcFaMember2023-01-012023-09-300001070081us-gaap:IndefinitelivedIntangibleAssetsMemberptct:PtcFaAndPtcAsMember2023-01-012023-09-300001070081us-gaap:IndefinitelivedIntangibleAssetsMemberptct:PtcAsMember2023-01-012023-09-300001070081us-gaap:IndefinitelivedIntangibleAssetsMember2023-01-012023-09-300001070081ptct:PtcFaAndPtcAsMember2023-01-012023-09-300001070081ptct:DepositsAndOtherNoncurrentAssetsMember2023-09-3000010700812018-08-232023-09-300001070081ptct:AgilisMember2018-08-230001070081srt:WeightedAverageMember2023-09-300001070081us-gaap:FiniteLivedIntangibleAssetsMemberptct:WaylivraMember2023-09-300001070081us-gaap:FiniteLivedIntangibleAssetsMemberptct:UpstazaMember2023-09-300001070081us-gaap:FiniteLivedIntangibleAssetsMemberptct:TegsediMember2023-09-300001070081us-gaap:FiniteLivedIntangibleAssetsMemberptct:EmflazaMember2023-09-300001070081us-gaap:FiniteLivedIntangibleAssetsMember2023-09-300001070081us-gaap:FiniteLivedIntangibleAssetsMemberptct:WaylivraMember2022-12-310001070081us-gaap:FiniteLivedIntangibleAssetsMemberptct:UpstazaMember2022-12-310001070081us-gaap:FiniteLivedIntangibleAssetsMemberptct:TegsediMember2022-12-310001070081us-gaap:FiniteLivedIntangibleAssetsMemberptct:EmflazaMember2022-12-310001070081us-gaap:FiniteLivedIntangibleAssetsMember2022-12-310001070081ptct:MassBioMember2023-09-300001070081ptct:MassBioMember2022-12-310001070081ptct:MassBioMember2020-06-190001070081ptct:MassBioMember2023-07-012023-09-300001070081ptct:MassBioMember2023-01-012023-09-300001070081ptct:MassBioMember2022-07-012022-09-300001070081ptct:MassBioMember2022-01-012022-09-300001070081ptct:AgilisMemberptct:LiabilityNetSalesMilestonesandRoyaltiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:CommitmentsMember2023-09-300001070081ptct:AgilisMemberptct:LiabilityDevelopmentandRegulatoryMilestoneMemberus-gaap:FairValueInputsLevel3Memberus-gaap:CommitmentsMember2023-09-300001070081ptct:AgilisMemberus-gaap:FairValueInputsLevel3Memberptct:UpstazaMember2023-09-300001070081ptct:AgilisMemberus-gaap:FairValueInputsLevel3Memberptct:PtcFaAndPtcAsMember2023-09-300001070081ptct:AgilisMemberptct:LiabilityNetSalesMilestonesandRoyaltiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:CommitmentsMember2022-12-310001070081ptct:AgilisMemberptct:LiabilityDevelopmentandRegulatoryMilestoneMemberus-gaap:FairValueInputsLevel3Memberus-gaap:CommitmentsMember2022-12-310001070081ptct:AgilisMemberptct:LiabilityNetSalesMilestonesandRoyaltiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:CommitmentsMember2022-09-300001070081ptct:AgilisMemberptct:LiabilityDevelopmentandRegulatoryMilestoneMemberus-gaap:FairValueInputsLevel3Memberus-gaap:CommitmentsMember2022-09-300001070081ptct:AgilisMemberptct:LiabilityNetSalesMilestonesandRoyaltiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:CommitmentsMember2021-12-310001070081ptct:AgilisMemberptct:LiabilityDevelopmentandRegulatoryMilestoneMemberus-gaap:FairValueInputsLevel3Memberus-gaap:CommitmentsMember2021-12-310001070081ptct:AgilisMemberptct:LiabilityNetSalesMilestonesandRoyaltiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:CommitmentsMember2023-01-012023-09-300001070081ptct:AgilisMemberptct:LiabilityDevelopmentandRegulatoryMilestoneMemberus-gaap:FairValueInputsLevel3Memberus-gaap:CommitmentsMember2023-01-012023-09-300001070081ptct:AgilisMemberus-gaap:FairValueInputsLevel3Memberptct:PtcFaAndPtcAsMember2023-01-012023-09-300001070081ptct:AgilisMemberptct:LiabilityNetSalesMilestonesandRoyaltiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:CommitmentsMember2022-01-012022-09-300001070081ptct:AgilisMemberptct:LiabilityDevelopmentandRegulatoryMilestoneMemberus-gaap:FairValueInputsLevel3Memberus-gaap:CommitmentsMember2022-01-012022-09-300001070081ptct:ClearpointEquityInvestmentMember2022-07-012022-09-300001070081ptct:ClearpointEquityInvestmentMember2022-01-012022-09-300001070081ptct:ClearpointEquityInvestmentMember2023-07-012023-09-300001070081ptct:ClearpointEquityInvestmentMember2023-01-012023-09-300001070081us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:DebtSecuritiesMember2023-09-300001070081us-gaap:FairValueInputsLevel1Memberptct:ClearpointEquityInvestmentMember2023-09-300001070081us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:DebtSecuritiesMember2022-12-310001070081us-gaap:FairValueInputsLevel1Memberptct:ClearpointEquityInvestmentMember2022-12-3100010700812017-12-222017-12-220001070081ptct:AgilisMember2018-12-3100010700812023-05-012023-05-310001070081us-gaap:LineOfCreditMember2022-10-270001070081us-gaap:ConvertibleDebtSecuritiesMember2023-07-012023-09-300001070081us-gaap:ConvertibleDebtSecuritiesMember2023-01-012023-09-300001070081us-gaap:ConvertibleDebtSecuritiesMember2022-07-012022-09-300001070081us-gaap:ConvertibleDebtSecuritiesMember2022-01-012022-09-300001070081ptct:ConvertibleSeniorNotes1.5DueSeptember152026Member2023-09-300001070081ptct:ConvertibleSeniorNotes1.5DueSeptember152026Member2022-03-152022-04-080001070081ptct:ConvertibleSeniorNotes1.5DueSeptember152026Member2020-09-252022-03-140001070081ptct:ConvertibleSeniorNotes3.0PercentDue2022Memberus-gaap:ConvertibleDebtMember2022-09-300001070081ptct:ConvertibleSeniorNotes1.5DueSeptember152026Memberus-gaap:ConvertibleDebtMember2022-09-3000010700812020-07-310001070081ptct:ConvertibleSeniorNotes1.5DueSeptember152026Memberus-gaap:FairValueInputsLevel2Memberus-gaap:ConvertibleDebtMember2023-09-300001070081ptct:ConvertibleSeniorNotes1.5DueSeptember152026Memberus-gaap:FairValueInputsLevel2Memberus-gaap:ConvertibleDebtMember2022-12-310001070081ptct:ConvertibleSeniorNotes1.5DueSeptember152026Memberus-gaap:ConvertibleDebtMember2023-09-300001070081us-gaap:LineOfCreditMember2023-09-300001070081ptct:ConvertibleSeniorNotes1.5DueSeptember152026Memberus-gaap:ConvertibleDebtMember2022-12-310001070081us-gaap:LineOfCreditMember2022-12-310001070081us-gaap:SecuredDebtMember2022-10-270001070081ptct:ConvertibleSeniorNotes3.0PercentDue2022Memberus-gaap:ConvertibleDebtMember2015-08-310001070081ptct:ConvertibleSeniorNotes1.5DueSeptember152026Memberptct:DebtInstrumentConversionPeriodOnOrAfterSeptember202023Memberus-gaap:ConvertibleDebtMember2019-09-300001070081ptct:ConvertibleSeniorNotes1.5DueSeptember152026Memberptct:DebtInstrumentConversionPeriodOnOrAfterSeptember202023Memberus-gaap:ConvertibleDebtMember2019-09-012019-09-300001070081us-gaap:LineOfCreditMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember2022-10-272022-10-270001070081us-gaap:LineOfCreditMemberus-gaap:BaseRateMember2022-10-272022-10-270001070081ptct:DepositsAndOtherAssetsNoncurrentMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ConvertibleDebtSecuritiesMember2023-09-300001070081ptct:DepositsAndOtherAssetsNoncurrentMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ConvertibleDebtSecuritiesMember2022-12-310001070081ptct:ManufacturingMember2023-07-012023-09-300001070081ptct:ManufacturingMember2023-01-012023-09-300001070081ptct:ManufacturingMemberptct:DeferredRevenueMember2023-09-300001070081us-gaap:ProductMember2023-09-300001070081ptct:ManufacturingMemberptct:DeferredRevenueMember2022-12-310001070081us-gaap:ProductMember2022-12-310001070081ptct:ManufacturingMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMember2023-09-300001070081ptct:ManufacturingMember2023-09-300001070081ptct:ManufacturingMember2022-12-3100010700812021-12-310001070081ptct:LiabilityNetSalesMilestonesandRoyaltiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001070081ptct:LiabilityDevelopmentandRegulatoryMilestoneMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001070081ptct:LiabilityNetSalesMilestonesandRoyaltiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001070081ptct:LiabilityDevelopmentandRegulatoryMilestoneMemberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001070081ptct:LiabilityNetSalesMilestonesandRoyaltiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001070081ptct:LiabilityDevelopmentandRegulatoryMilestoneMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001070081ptct:LiabilityNetSalesMilestonesandRoyaltiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001070081ptct:LiabilityDevelopmentandRegulatoryMilestoneMemberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001070081us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:DebtSecuritiesMember2023-09-300001070081us-gaap:FairValueMeasurementsRecurringMemberus-gaap:DebtSecuritiesMember2023-09-300001070081us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:DebtSecuritiesMember2022-12-310001070081us-gaap:FairValueMeasurementsRecurringMemberus-gaap:DebtSecuritiesMember2022-12-310001070081us-gaap:CorporateDebtSecuritiesMember2023-09-300001070081us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember2022-12-310001070081us-gaap:EmployeeStockOptionMember2023-01-012023-09-300001070081ptct:RestrictedStockAndRestrictedStockUnitsMember2023-01-012023-09-300001070081us-gaap:EmployeeStockOptionMember2022-01-012022-09-300001070081ptct:RestrictedStockAndRestrictedStockUnitsMember2022-01-012022-09-300001070081us-gaap:FiniteLivedIntangibleAssetsMember2023-07-012023-09-300001070081us-gaap:FiniteLivedIntangibleAssetsMemberptct:UpstazaMember2023-01-012023-09-300001070081us-gaap:FiniteLivedIntangibleAssetsMember2022-07-012022-09-300001070081us-gaap:FiniteLivedIntangibleAssetsMember2022-01-012022-09-300001070081ptct:ConvertibleSeniorNotes1.5DueSeptember152026Memberus-gaap:ConvertibleDebtMember2023-07-012023-09-300001070081us-gaap:LineOfCreditMember2023-07-012023-09-300001070081ptct:ConvertibleSeniorNotes1.5DueSeptember152026Memberus-gaap:ConvertibleDebtMember2023-01-012023-09-300001070081ptct:ConvertibleSeniorNotes3.0PercentDue2022Memberus-gaap:ConvertibleDebtMember2022-07-012022-09-300001070081ptct:ConvertibleSeniorNotes1.5DueSeptember152026Memberus-gaap:ConvertibleDebtMember2022-07-012022-09-300001070081ptct:ConvertibleSeniorNotes3.0PercentDue2022Memberus-gaap:ConvertibleDebtMember2022-01-012022-09-300001070081ptct:ConvertibleSeniorNotes1.5DueSeptember152026Memberus-gaap:ConvertibleDebtMember2022-01-012022-09-300001070081us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-07-012023-09-300001070081us-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-300001070081us-gaap:EmployeeStockMember2023-07-012023-09-300001070081us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-09-300001070081us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-300001070081us-gaap:EmployeeStockMember2023-01-012023-09-300001070081us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-07-012022-09-300001070081us-gaap:ResearchAndDevelopmentExpenseMember2022-07-012022-09-300001070081us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-09-300001070081us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-09-300001070081us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300001070081us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-300001070081us-gaap:AdditionalPaidInCapitalMember2022-01-012022-09-300001070081ptct:AkceaMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMemberptct:WaylivraMember2023-09-300001070081ptct:AkceaMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMemberptct:TegsediMember2023-09-300001070081ptct:SmaFoundationMemberus-gaap:CollaborativeArrangementMember2023-09-300001070081srt:MinimumMemberptct:HopewellCampusMember2019-01-012019-12-310001070081us-gaap:LineOfCreditMember2023-01-012023-09-300001070081us-gaap:AdditionalPaidInCapitalMember2023-01-012023-09-300001070081us-gaap:CommonStockMember2023-01-012023-09-300001070081us-gaap:StockOptionMemberptct:InducementStockIncentivePlan2020Member2023-09-300001070081us-gaap:StockOptionMemberptct:InducementStockIncentivePlan2020Member2023-01-012023-09-300001070081srt:MaximumMemberus-gaap:StockOptionMemberptct:InducementStockIncentivePlan2020Member2023-09-300001070081srt:MinimumMemberus-gaap:StockOptionMemberptct:InducementStockIncentivePlan2020Member2023-09-300001070081ptct:ConvertibleSeniorNotes3.0PercentDue2022Member2023-01-012023-09-300001070081ptct:ConvertibleSeniorNotes1.5DueSeptember152026Member2023-01-012023-09-300001070081srt:MaximumMemberptct:AtMarketOfferingSalesAgreementMember2019-08-310001070081srt:MaximumMemberptct:AtMarketOfferingSalesAgreementMember2023-01-012023-09-300001070081ptct:RoyaltyPharmaInvestments2019IcavMemberus-gaap:SubsequentEventMemberptct:AmendedAndRestatedRoyaltyPurchaseAgreementMember2023-10-180001070081srt:MinimumMemberptct:AgilisMemberptct:LiabilityNetSalesMilestonesandRoyaltiesMemberus-gaap:CommitmentsMemberptct:SalesMilestonesMemberus-gaap:ValuationTechniqueOptionPricingModelMember2023-09-300001070081srt:MinimumMemberptct:AgilisMemberptct:LiabilityDevelopmentandRegulatoryMilestoneMemberus-gaap:CommitmentsMemberptct:DevelopmentandRegulatoryMilestoneMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2023-09-300001070081srt:MaximumMemberptct:AgilisMemberptct:LiabilityNetSalesMilestonesandRoyaltiesMemberus-gaap:CommitmentsMemberptct:SalesMilestonesMemberus-gaap:ValuationTechniqueOptionPricingModelMember2023-09-300001070081srt:MaximumMemberptct:AgilisMemberptct:LiabilityDevelopmentandRegulatoryMilestoneMemberus-gaap:CommitmentsMemberptct:DevelopmentandRegulatoryMilestoneMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2023-09-300001070081srt:MinimumMemberptct:AgilisMemberptct:LiabilityNetSalesMilestonesandRoyaltiesMemberus-gaap:CommitmentsMemberptct:SalesMilestonesMemberus-gaap:ValuationTechniqueOptionPricingModelMember2022-12-310001070081srt:MinimumMemberptct:AgilisMemberptct:LiabilityDevelopmentandRegulatoryMilestoneMemberus-gaap:CommitmentsMemberptct:DevelopmentandRegulatoryMilestoneMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2022-12-310001070081srt:MaximumMemberptct:AgilisMemberptct:LiabilityNetSalesMilestonesandRoyaltiesMemberus-gaap:CommitmentsMemberptct:SalesMilestonesMemberus-gaap:ValuationTechniqueOptionPricingModelMember2022-12-310001070081srt:MaximumMemberptct:AgilisMemberptct:LiabilityDevelopmentandRegulatoryMilestoneMemberus-gaap:CommitmentsMemberptct:DevelopmentandRegulatoryMilestoneMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2022-12-310001070081srt:WeightedAverageMemberptct:AgilisMemberptct:LiabilityNetSalesMilestonesandRoyaltiesMemberus-gaap:CommitmentsMemberus-gaap:MeasurementInputDiscountRateMemberus-gaap:ValuationTechniqueOptionPricingModelMember2023-09-300001070081srt:WeightedAverageMemberptct:AgilisMemberptct:LiabilityNetSalesMilestonesandRoyaltiesMemberus-gaap:CommitmentsMemberptct:ProbabilityofSuccessMemberus-gaap:ValuationTechniqueOptionPricingModelMember2023-09-300001070081srt:WeightedAverageMemberptct:AgilisMemberptct:LiabilityDevelopmentandRegulatoryMilestoneMemberus-gaap:CommitmentsMemberus-gaap:MeasurementInputDiscountRateMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2023-09-300001070081srt:WeightedAverageMemberptct:AgilisMemberptct:LiabilityDevelopmentandRegulatoryMilestoneMemberus-gaap:CommitmentsMemberptct:ProbabilityofSuccessMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2023-09-300001070081srt:MinimumMemberptct:AgilisMemberptct:LiabilityNetSalesMilestonesandRoyaltiesMemberus-gaap:CommitmentsMemberptct:ProbabilityofSuccessMemberus-gaap:ValuationTechniqueOptionPricingModelMember2023-09-300001070081srt:MinimumMemberptct:AgilisMemberptct:LiabilityDevelopmentandRegulatoryMilestoneMemberus-gaap:CommitmentsMemberus-gaap:MeasurementInputDiscountRateMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2023-09-300001070081srt:MinimumMemberptct:AgilisMemberptct:LiabilityDevelopmentandRegulatoryMilestoneMemberus-gaap:CommitmentsMemberptct:ProbabilityofSuccessMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2023-09-300001070081srt:MaximumMemberptct:AgilisMemberptct:LiabilityNetSalesMilestonesandRoyaltiesMemberus-gaap:CommitmentsMemberptct:ProbabilityofSuccessMemberus-gaap:ValuationTechniqueOptionPricingModelMember2023-09-300001070081srt:MaximumMemberptct:AgilisMemberptct:LiabilityDevelopmentandRegulatoryMilestoneMemberus-gaap:CommitmentsMemberus-gaap:MeasurementInputDiscountRateMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2023-09-300001070081srt:MaximumMemberptct:AgilisMemberptct:LiabilityDevelopmentandRegulatoryMilestoneMemberus-gaap:CommitmentsMemberptct:ProbabilityofSuccessMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2023-09-300001070081ptct:AgilisMemberptct:LiabilityNetSalesMilestonesandRoyaltiesMemberus-gaap:CommitmentsMemberus-gaap:MeasurementInputDiscountRateMemberus-gaap:ValuationTechniqueOptionPricingModelMember2023-09-300001070081ptct:AgilisMemberptct:LiabilityNetSalesMilestonesandRoyaltiesMemberus-gaap:CommitmentsMemberptct:PercentageofSalesforRoyaltiesMemberus-gaap:ValuationTechniqueOptionPricingModelMember2023-09-300001070081srt:MinimumMemberptct:AgilisMemberptct:LiabilityNetSalesMilestonesandRoyaltiesMemberus-gaap:CommitmentsMemberptct:ProbabilityofSuccessMemberus-gaap:ValuationTechniqueOptionPricingModelMember2022-12-310001070081srt:MinimumMemberptct:AgilisMemberptct:LiabilityNetSalesMilestonesandRoyaltiesMemberus-gaap:CommitmentsMemberptct:PercentageofSalesforRoyaltiesMemberus-gaap:ValuationTechniqueOptionPricingModelMember2022-12-310001070081srt:MinimumMemberptct:AgilisMemberptct:LiabilityDevelopmentandRegulatoryMilestoneMemberus-gaap:CommitmentsMemberus-gaap:MeasurementInputDiscountRateMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2022-12-310001070081srt:MinimumMemberptct:AgilisMemberptct:LiabilityDevelopmentandRegulatoryMilestoneMemberus-gaap:CommitmentsMemberptct:ProbabilityofSuccessMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2022-12-310001070081srt:MaximumMemberptct:AgilisMemberptct:LiabilityNetSalesMilestonesandRoyaltiesMemberus-gaap:CommitmentsMemberptct:ProbabilityofSuccessMemberus-gaap:ValuationTechniqueOptionPricingModelMember2022-12-310001070081srt:MaximumMemberptct:AgilisMemberptct:LiabilityNetSalesMilestonesandRoyaltiesMemberus-gaap:CommitmentsMemberptct:PercentageofSalesforRoyaltiesMemberus-gaap:ValuationTechniqueOptionPricingModelMember2022-12-310001070081srt:MaximumMemberptct:AgilisMemberptct:LiabilityDevelopmentandRegulatoryMilestoneMemberus-gaap:CommitmentsMemberus-gaap:MeasurementInputDiscountRateMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2022-12-310001070081srt:MaximumMemberptct:AgilisMemberptct:LiabilityDevelopmentandRegulatoryMilestoneMemberus-gaap:CommitmentsMemberptct:ProbabilityofSuccessMemberus-gaap:ValuationTechniqueDiscountedCashFlowMember2022-12-310001070081ptct:AgilisMemberptct:LiabilityNetSalesMilestonesandRoyaltiesMemberus-gaap:CommitmentsMemberus-gaap:MeasurementInputDiscountRateMemberus-gaap:ValuationTechniqueOptionPricingModelMember2022-12-310001070081ptct:SalesMilestonesMemberus-gaap:CollaborativeArrangementMember2023-09-300001070081ptct:ResearchAndDevelopmentEventMilestonesMemberus-gaap:CollaborativeArrangementMember2023-09-300001070081ptct:SalesMilestonesMembersrt:MaximumMemberus-gaap:CollaborativeArrangementMember2011-11-300001070081ptct:ResearchAndDevelopmentEventMilestonesMembersrt:MaximumMemberus-gaap:CollaborativeArrangementMember2011-11-300001070081ptct:ConvertibleSeniorNotes3.0PercentDue2022Memberus-gaap:ConvertibleDebtMember2022-08-152022-08-150001070081ptct:RoyaltyPurchaseAgreementMemberptct:AssignedRoyaltyPaymentsMember2020-07-172020-07-1700010700812020-07-012020-07-310001070081ptct:SmaFoundationMembersrt:MaximumMemberus-gaap:CollaborativeArrangementMember2023-01-012023-09-300001070081ptct:WarrenPremisesMember2022-06-012022-06-300001070081ptct:HopewellCampusMember2019-01-012019-12-310001070081ptct:RoyaltyPharmaInvestments2019IcavMemberus-gaap:SubsequentEventMemberptct:AmendedAndRestatedRoyaltyPurchaseAgreementMember2023-10-182023-10-180001070081ptct:AkceaMemberptct:WaylivraMember2023-01-012023-09-300001070081ptct:AkceaMemberptct:TegsediMember2023-01-012023-09-300001070081ptct:MarathonPharmaceuticalsLLCMemberus-gaap:NoncollaborativeArrangementTransactionsMember2023-01-012023-09-300001070081ptct:AgilisMember2022-01-012022-12-310001070081ptct:WellcomeTrustLimitedMember2016-04-012016-06-300001070081ptct:HopewellCampusMember2020-07-010001070081us-gaap:MutualFundMember2023-01-012023-09-300001070081us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2023-07-012023-09-300001070081us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2023-01-012023-09-300001070081us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2022-07-012022-09-300001070081us-gaap:RevenueFromContractWithCustomerMemberus-gaap:CustomerConcentrationRiskMember2022-01-012022-09-300001070081us-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMember2023-07-012023-09-300001070081country:USus-gaap:RevenueFromContractWithCustomerMember2023-07-012023-09-300001070081us-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMember2023-01-012023-09-300001070081us-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMember2022-07-012022-09-300001070081us-gaap:RevenueFromContractWithCustomerMemberus-gaap:GeographicConcentrationRiskMember2022-01-012022-09-300001070081ptct:SalesMilestonesMemberus-gaap:CollaborativeArrangementMember2022-09-012022-09-300001070081ptct:MarathonPharmaceuticalsLLCMemberptct:EmflazaassetacquisitionMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMember2023-09-3000010700812022-09-300001070081ptct:EmflazaassetacquisitionMember2023-01-012023-09-300001070081ptct:WarrenPremisesMember2022-05-012022-05-310001070081ptct:WarrenPremisesMember2022-05-310001070081ptct:ConvertibleSeniorNotes1.5DueSeptember152026Member2022-09-012022-09-300001070081ptct:ConvertibleSeniorNotes1.5DueSeptember152026Member2022-04-012022-04-300001070081us-gaap:FiniteLivedIntangibleAssetsMemberptct:WaylivraMember2023-01-012023-09-300001070081us-gaap:FiniteLivedIntangibleAssetsMemberptct:TegsediMember2023-01-012023-09-300001070081us-gaap:FiniteLivedIntangibleAssetsMemberptct:EmflazaMember2023-01-012023-09-300001070081us-gaap:FiniteLivedIntangibleAssetsMember2023-01-012023-09-300001070081us-gaap:MutualFundMember2023-07-012023-09-300001070081us-gaap:MutualFundMember2022-07-012022-09-300001070081us-gaap:MutualFundMember2022-01-012022-09-300001070081us-gaap:EmployeeStockMember2016-06-012016-06-300001070081ptct:WellcomeTrustLimitedMemberus-gaap:ProductMembersrt:MaximumMember2023-09-300001070081srt:MaximumMemberptct:BioElectronMember2023-09-300001070081ptct:AgilisMember2020-04-290001070081ptct:WellcomeTrustLimitedMember2022-12-310001070081ptct:FormerCensaSecurityholdersMember2023-01-012023-09-300001070081ptct:AgilisMember2023-01-012023-09-300001070081us-gaap:LineOfCreditMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember2022-10-270001070081us-gaap:LineOfCreditMemberus-gaap:BaseRateMember2022-10-270001070081ptct:LineOfCreditCommittedLoanFacilityMember2022-10-272022-10-270001070081srt:MinimumMemberus-gaap:LineOfCreditMember2022-10-270001070081ptct:ConvertibleSeniorNotes1.5DueSeptember152026Memberus-gaap:ConvertibleDebtMember2019-09-300001070081us-gaap:LineOfCreditMember2023-03-3100010700812022-07-012022-09-300001070081ptct:ConvertibleSeniorNotes1.5DueSeptember152026Memberus-gaap:ConvertibleDebtMember2019-09-012019-09-300001070081us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001070081us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001070081srt:MinimumMemberptct:AgilisMember2023-09-300001070081srt:MaximumMemberptct:AgilisMember2023-01-012023-09-300001070081srt:MaximumMemberptct:AgilisMember2023-09-300001070081ptct:AgilisMember2023-09-300001070081ptct:AgilisMemberptct:RightsExchangeAgreementMember2020-04-292020-04-290001070081us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-09-300001070081us-gaap:FairValueMeasurementsRecurringMember2023-09-300001070081us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-12-310001070081us-gaap:FairValueMeasurementsRecurringMember2022-12-3100010700812022-01-012022-09-300001070081us-gaap:SubsequentEventMemberptct:AmendedAndRestatedRoyaltyPurchaseAgreementMember2023-10-182023-10-180001070081us-gaap:CorporateDebtSecuritiesMember2022-12-310001070081us-gaap:ConvertibleDebtSecuritiesMember2020-01-3100010700812020-07-170001070081ptct:RoyaltyPharmaInvestments2019IcavMemberptct:RoyaltyPurchaseAgreementMember2023-09-300001070081ptct:RoyaltyPurchaseAgreementMemberptct:AssignedRoyaltyPaymentsMember2020-07-170001070081ptct:CensaMembersrt:MaximumMember2020-05-290001070081ptct:CensaMember2020-05-290001070081us-gaap:SubsequentEventMemberptct:AmendedAndRestatedRoyaltyPurchaseAgreementMember2023-10-1800010700812023-09-3000010700812022-12-310001070081ptct:PierreGravierMemberptct:RestrictedStockUnitTradingArrangementMember2023-07-012023-09-3000010700812023-07-012023-09-3000010700812023-10-2400010700812023-01-012023-09-30ptct:leaseptct:productptct:itemptct:periodutr:sqftptct:Dptct:segmentxbrli:sharesiso4217:USDxbrli:pureiso4217:USDxbrli:sharesptct:Optionptct:buildingptct:countryptct:Distributorptct:fund

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

     QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2023

or

         TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from            to

Commission file number: 001-35969

PTC Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware

    

04-3416587

(State or other jurisdiction of incorporation or organization)

(I.R.S. Employer Identification No.)

100 Corporate Court

    

South Plainfield, NJ

07080

(Address of principal executive offices)

(Zip Code)

(908) 222-7000

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

    

Trading Symbol(s)

    

Name of each exchange on which registered

Common Stock, $0.001 par value per share

PTCT

Nasdaq Global Select Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ  No 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes þ  No 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer,” “smaller reporting company,” and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer

þ

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes   No þ

As of October 24, 2023, there were 75,463,145 shares of Common Stock, $0.001 par value per share, outstanding.

FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this Quarterly Report on Form 10-Q, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

The forward-looking statements in this Quarterly Report on Form 10-Q include, among other things, statements about:

our ability to negotiate, secure and maintain adequate pricing, coverage and reimbursement terms and processes on a timely basis, or at all, with third-party payors for our products or product candidates that we commercialize or may commercialize in the future;
our ability to maintain our conditional marketing authorization of TranslarnaTM (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy, or nmDMD, in the European Economic Area, or EEA, and our marketing authorizations in other jurisdictions in which Translarna has been approved, including whether the European Medicines Agency, or EMA, determines in the re-examination process of the Committee for Medicinal Products for Human Use’s negative opinion that the benefit-risk balance of Translarna authorization supports renewal of such authorization;
our ability to utilize results from Study 041 to support a renewal of the conditional marketing authorization for Translarna for the treatment of nmDMD in the EEA and to support a marketing approval for Translarna for the treatment of nmDMD in the United States;
expectations with respect to our ability to commercialize UpstazaTM (eladocagene exuparvovec) for the treatment of Aromatic L-Amino Acid Decarboxylase, or AADC deficiency, in the EEA, any potential regulatory submissions and potential approvals for our product candidates, our manufacturing capabilities and the potential financial impact and benefits of our leased biologics manufacturing facility and the potential achievement of development, regulatory and sales milestones and contingent payments that we may be obligated to make;
the anticipated period of market exclusivity for Emflaza® (deflazacort) for the treatment of Duchenne muscular dystrophy in the United States under the Orphan Drug Act of 1983;
our expectations with respect to the commercial status of Evrysdi® (risdiplam) and our program directed against spinal muscular atrophy in collaboration with F. Hoffmann La Roche Ltd and Hoffmann La Roche Inc. and the Spinal Muscular Atrophy Foundation and our estimates regarding future revenues from sales-based royalty payments or the achievement of milestones in that program;
our expectations and the potential financial impact and benefits related to our Collaboration and License Agreement with a subsidiary of Ionis Pharmaceuticals, Inc. including with respect to the timing of regulatory approval of Tegsedi® (inotersen) and WaylivraTM (volanesorsen) in countries in which we are licensed to commercialize them, the commercialization of Tegsedi and Waylivra, and our expectations with respect to royalty payments by us based on our potential achievement of certain net sales thresholds;
the timing and scope of our commercialization of our products and product candidates;
our estimates regarding the potential market opportunity for our products or product candidates, including the size of eligible patient populations and our ability to identify such patients;
our ability to obtain additional and maintain existing reimbursed named patient and cohort early access programs for our products on adequate terms, or at all;

1

our estimates regarding expenses, future revenues, third-party discounts and rebates, capital requirements and needs for additional financing, including our ability to maintain the level of our expenses consistent with our internal budgets and forecasts and to secure additional funds on favorable terms or at all;
the timing and conduct of our ongoing, planned and potential future clinical trials and studies in our splicing, metabolic, Bio-e and oncology programs as well as studies in our products for maintaining authorizations, label extensions and additional indications, including the timing of initiation, enrollment and completion of the trials and the period during which the results of the trials will become available;
our ability to realize the anticipated benefits of our acquisitions or other strategic transactions, including the possibility that the expected impact of benefits from the acquisitions or strategic transactions will not be realized or will not be realized within the expected time period, significant transaction costs, the integration of operations and employees into our business, our ability to obtain marketing approval of our product candidates we acquired from the acquisitions or other strategic transactions and unknown liabilities;
the rate and degree of market acceptance and clinical utility of any of our products or product candidates;
the ability and willingness of patients and healthcare professionals to access our products and product candidates through alternative means if pricing and reimbursement negotiations in the applicable territory do not have a positive outcome;
the timing of, and our ability to obtain additional marketing authorizations for our products and product candidates;
the ability of our products and our product candidates to meet existing or future regulatory standards;
our ability to complete Study 041, a multicenter, randomized, double-blind, 18-month, placebo-controlled clinical trial of Translarna for the treatment of nmDMD followed by an 18-month open-label extension, according to the protocol agreed with the EMA;
the potential receipt of revenues from future sales of our products or product candidates;
our sales, marketing and distribution capabilities and strategy, including the ability of our third-party manufacturers to manufacture and deliver our products and product candidates in clinically and commercially sufficient quantities and the ability of distributors to process orders in a timely manner and satisfy their other obligations to us;
our ability to establish and maintain arrangements for the manufacture of our products and product candidates that are sufficient to meet clinical trial and commercial launch requirements;
the extent, timing and financial aspects of our strategic pipeline prioritization and reductions in workforce;
our ability to complete any post-marketing requirements imposed by regulatory agencies with respect to our products;
our expectations with respect to the potential financial impact and benefits of our leased biologics manufacturing facility and our ability to satisfy our obligations under the terms of the lease agreement for such facility;
our ability to satisfy our obligations under the indenture governing our 1.50% convertible senior notes due September 15, 2026;
our regulatory submissions, including with respect to timing and outcome of regulatory review;
our plans to advance our earlier stage programs and pursue research and development of other product candidates, including our splicing, metabolic, Bio-e and oncology programs;

2

our expectations with respect to the COVID-19 pandemic and related response measures and their effects on our business, operations, clinical trials, potential regulatory submissions and approvals, our collaborators, contract research organizations, suppliers and manufacturers;
whether we may pursue business development opportunities, including potential collaborations, alliances, and acquisition or licensing of assets and our ability to successfully develop or commercialize any assets to which we may gain rights pursuant to such business development opportunities;
the potential advantages of our products and any product candidate;
our intellectual property position;
the impact of government laws and regulations;
the impact of litigation that has been or may be brought against us or of litigation that we are pursuing against others; and
our competitive position.

We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We have included important factors in the cautionary statements included in this Quarterly Report on Form 10-Q, particularly in Part II, Item 1A. Risk Factors as well as in Part I, Item 1A. Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2022, that we believe could cause actual results or events to differ materially from the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments we may make.

You should read this Quarterly Report on Form 10-Q and the documents that we have filed as exhibits to this Quarterly Report on Form 10-Q and our Annual Report on Form 10-K for the year ended December 31, 2022 completely and with the understanding that our actual future results may be materially different from what we expect. We do not assume any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by applicable law.

In this Quarterly Report on Form 10-Q, unless otherwise stated or the context otherwise requires, references to “PTC,” “PTC Therapeutics,” “the Company,” “we,” “us,” “our,” and similar references refer to PTC Therapeutics, Inc. and, where appropriate, its subsidiaries. The trademarks, trade names and service marks appearing in this Quarterly Report on Form 10-Q are the property of their respective owners.

All website addresses given in this Quarterly Report on Form 10-Q are for information only and are not intended to be an active link or to incorporate any website information into this document.

3

PART I—FINANCIAL INFORMATION

Item 1. Financial Statements.

PTC Therapeutics, Inc.

Consolidated Balance Sheets (unaudited)

In thousands (except shares)

September 30, 

December 31, 

    

2023

    

2022

Assets

Current assets:

 

 

  

Cash and cash equivalents

$

165,157

$

279,834

Marketable securities

 

129,653

 

130,871

Trade and royalty receivables, net

 

165,718

 

155,614

Inventory, net

 

35,752

 

21,808

Prepaid expenses and other current assets

 

44,082

 

105,658

Total current assets

 

540,362

 

693,785

Fixed assets, net

 

85,031

 

72,590

Intangible assets, net

 

423,342

 

705,891

Goodwill

 

82,341

 

82,341

Operating lease ROU assets

94,072

102,430

Deposits and other assets

 

34,737

 

48,582

Total assets

$

1,259,885

$

1,705,619

Liabilities and stockholders’ deficit

 

  

 

  

Current liabilities:

 

  

 

  

Accounts payable and accrued expenses

$

370,731

$

320,366

Deferred revenue

 

1,224

 

1,351

Operating lease liabilities- current

11,703

9,370

Finance lease liabilities- current

2,611

3,000

Liability for sale of future royalties- current

105,849

72,149

Total current liabilities

 

492,118

 

406,236

Long-term debt

 

573,174

 

571,722

Contingent consideration payable

 

39,000

 

164,000

Deferred tax liability

 

51,927

 

102,834

Operating lease liabilities- noncurrent

99,682

100,860

Finance lease liabilities- noncurrent

17,184

18,675

Liability for sale of future royalties- noncurrent

657,469

685,737

Other long-term liabilities

141

2,641

Total liabilities

 

1,930,695

 

2,052,705

Stockholders’ deficit:

 

  

 

  

Common stock, $0.001 par value. Authorized 250,000,000 shares; issued and outstanding 75,459,022 shares at September 30, 2023. Authorized 250,000,000 shares; issued and outstanding 73,104,692 shares at December 31, 2022.

 

75

 

72

Additional paid-in capital

 

2,447,292

 

2,305,020

Accumulated other comprehensive income

 

9,609

 

4,796

Accumulated deficit

 

(3,127,786)

 

(2,656,974)

Total stockholders’ deficit

 

(670,810)

 

(347,086)

Total liabilities and stockholders’ deficit

$

1,259,885

$

1,705,619

See accompanying unaudited notes.

4

PTC Therapeutics, Inc.

Consolidated Statements of Operations (unaudited)

In thousands (except shares and per share amounts)

Three Months Ended September 30, 

Nine Months Ended September 30, 

    

2023

    

2022

    

2023

    

2022

Revenues:

 

  

 

  

  

 

  

Net product revenue

$

144,038

$

134,186

$

506,187

$

407,720

Collaboration revenue

 

50,017

 

6

 

50,024

Royalty revenue

50,173

32,924

117,857

73,645

Manufacturing revenue

2,365

6,716

Total revenues

 

196,576

 

217,127

 

630,766

 

531,389

Operating expenses:

Cost of product sales, excluding amortization of acquired intangible assets

 

9,493

14,011

 

36,368

 

33,785

Amortization of acquired intangible assets

 

58,649

31,023

 

145,461

 

80,790

Research and development

 

164,212

165,462

 

545,210

 

462,802

Selling, general and administrative

 

80,886

80,118

 

256,249

 

233,280

Change in the fair value of contingent consideration

 

1,500

(5,300)

 

(125,000)

 

(32,200)

Intangible asset impairment

217,800

Total operating expenses

 

314,740

 

285,314

 

1,076,088

 

778,457

Loss from operations

 

(118,164)

 

(68,187)

 

(445,322)

 

(247,068)

Interest expense, net

 

(28,160)

(20,880)

 

(84,905)

 

(66,371)

Other expense, net

 

(20,266)

(38,141)

 

(8,832)

 

(84,355)

Loss before income tax benefit

 

(166,590)

 

(127,208)

 

(539,059)

 

(397,794)

Income tax benefit

 

33,620

17,893

 

68,247

 

9,666

Net loss attributable to common stockholders

$

(132,970)

$

(109,315)

$

(470,812)

$

(388,128)

Weighted-average shares outstanding:

Basic and diluted (in shares)

 

75,377,997

71,654,671

 

74,618,611

 

71,415,849

Net loss per share—basic and diluted (in dollars per share)

$

(1.76)

$

(1.53)

$

(6.31)

$

(5.43)

See accompanying unaudited notes.

5

PTC Therapeutics, Inc.

Consolidated Statements of Comprehensive Loss (unaudited)

In thousands

Three Months Ended September 30, 

Nine Months Ended September 30, 

     

2023

     

2022

     

2023

     

2022

Net loss

$

(132,970)

$

(109,315)

$

(470,812)

$

(388,128)

Other comprehensive income (loss):

 

  

 

  

 

 

  

Unrealized gain (loss) on marketable securities, net of tax

 

19

736

 

470

 

(2,333)

Foreign currency translation gain, net of tax

 

11,021

25,218

 

4,343

 

62,820

Comprehensive loss

$

(121,930)

$

(83,361)

$

(465,999)

$

(327,641)

See accompanying unaudited notes.

6

PTC Therapeutics, Inc.

Consolidated Statements of Stockholders’ (Deficit) Equity (unaudited)

In thousands (except shares)

 

 

Accumulated

 

 

 

Additional

 

other

 

Total

Three months ended September 30, 2023

Common stock

paid-in

 

comprehensive

Accumulated

stockholders’

    

Shares

    

Amount

    

capital

    

(loss) income

    

deficit

    

deficit

Balance, June 30, 2023

75,318,233

$

75

$

2,416,904

$

(1,431)

$

(2,994,816)

$

(579,268)

Exercise of options

 

113,795

3,446

3,446

Restricted stock vesting and issuance, net

 

26,994

Share-based compensation expense

 

26,942

26,942

Net loss

 

(132,970)

(132,970)

Comprehensive income

 

11,040

11,040

Balance, September 30, 2023

 

75,459,022

$

75

$

2,447,292

$

9,609

$

(3,127,786)

$

(670,810)

 

 

Accumulated

 

 

 

Additional

 

other

 

Total

Three months ended September 30, 2022

Common stock

paid-in

 

comprehensive

Accumulated

stockholders’

    

Shares

    

Amount

    

capital

    

income

    

deficit

    

deficit

Balance, June 30, 2022

 

71,505,889

$

71

$

2,184,230

$

10,251

$

(2,376,770)

$

(182,218)

Exercise of options

 

331,379

10,005

10,005

Restricted stock vesting and issuance, net

 

17,624

Share-based compensation expense

 

28,670

28,670

Net loss

 

 

 

 

(109,315)

 

(109,315)

Comprehensive income

 

 

 

 

25,954

 

25,954

Balance, September 30, 2022

 

71,854,892

$

71

$

2,222,905

$

36,205

$

(2,486,085)

$

(226,904)

 

 

Accumulated

 

 

 

Additional

 

other

 

Total

Nine months ended September 30, 2023

Common stock

paid-in

 

comprehensive

Accumulated

stockholders’

    

Shares

    

Amount

    

capital

    

income

    

deficit

    

deficit

Balance, December 31, 2022

 

73,104,692

$

72

$

2,305,020

$

4,796

$

(2,656,974)

$

(347,086)

Exercise of options

 

806,407

1

23,770

23,771

Restricted stock vesting and issuance, net

 

773,157

1

1

Issuance of common stock in connection with an employee stock purchase plan

 

117,304

3,805

3,805

Issuance of common stock in connection with a milestone payable

657,462

1

29,569

29,570

Share-based compensation expense

 

85,128

85,128

Net loss

 

(470,812)

(470,812)

Comprehensive income

 

4,813

4,813

Balance, September 30, 2023

 

75,459,022

$

75

$

2,447,292

$

9,609

$

(3,127,786)

$

(670,810)

 

 

Accumulated

 

 

 

Additional

 

other

 

Total

Nine months ended September 30, 2022

Common stock

paid-in

 

comprehensive

Accumulated

stockholders’

    

Shares

    

Amount

    

capital

    

(loss) income

    

deficit

    

equity (deficit)

Balance, December 31, 2021

 

70,828,226

$

71

$

2,123,606

$

(24,282)

$

(2,097,957)

$

1,438

Exercise of options

456,399

 

 

13,203

 

 

13,203

Restricted stock vesting and issuance, net

479,004

 

 

 

 

Issuance of common stock in connection with an employee stock purchase plan

 

91,263

 

 

3,107

 

 

 

3,107

Share-based compensation expense

 

 

 

82,989

 

 

 

82,989

Net loss

 

 

 

 

 

(388,128)

 

(388,128)

Comprehensive income

 

 

 

 

60,487

 

 

60,487

Balance, September 30, 2022

 

71,854,892

$

71

$

2,222,905

$

36,205

$

(2,486,085)

$

(226,904)

See accompanying unaudited notes.

7

PTC Therapeutics, Inc.

Consolidated Statements of Cash Flows (unaudited)

In thousands

Nine Months Ended September 30, 

    

2023

    

2022

Cash flows from operating activities

Net loss

$

(470,812)

$

(388,128)

Adjustments to reconcile net loss to net cash used in operating activities:

 

  

Depreciation and amortization

 

155,885

89,971

Non-cash operating lease expense

 

8,156

7,505

Non-cash royalty revenue related to sale of future royalties

(50,599)

(31,617)

Non-cash interest expense on liability related to sale of future royalties

56,031

55,778

Intangible asset impairment

217,800

Change in valuation of contingent consideration

 

(125,000)

(32,200)

Unrealized loss on ClearPoint Equity Investments

 

3,107

1,113

Unrealized loss on ClearPoint convertible debt security

4,594

2,392

Unrealized (gain) loss on marketable securities- equity investments

(5,484)

11,319

Realized loss on the sale of Clearpoint Equity Investment

782

Non-cash stock consideration, milestone payment

29,570

Disposal of asset

135

81

Deferred income taxes

(50,909)

Amortization of (discounts) premiums on investments, net

 

(89)

1,792

Amortization of debt issuance costs

 

1,574

1,316

Share-based compensation expense

 

85,128

82,989

Unrealized foreign currency transaction losses, net

 

3,394

71,246

Changes in operating assets and liabilities:

 

Inventory, net

 

(14,121)

(768)

Prepaid expenses and other current assets

 

59,467

(35,615)

Trade and royalty receivables, net

 

(9,887)

(24,773)

Deposits and other assets

 

4,597

(3,752)

Accounts payable and accrued expenses

 

40,434

1,568

Other liabilities

 

(1,756)

(908)

Deferred revenue

 

(127)

Net cash used in operating activities

$

(58,130)

$

(190,691)

Cash flows from investing activities

 

 

Purchases of fixed assets

$

(22,872)

$

(23,394)

Purchases of marketable securities- available for sale

(40,429)

Purchases of marketable securities- equity investments

(26,378)

(22,787)

Sale and redemption of marketable securities- available for sale

21,544

341,990

Sale and redemption of marketable securities- equity investments

12,078

104,431

Sale and redemption of ClearPoint Equity Investments

2,594

Acquisition of product rights and licenses

(69,285)

(102,069)

Net cash (used in) provided by investing activities

$

(82,319)

$

257,742

Cash flows from financing activities

 

 

Proceeds from exercise of options

$

23,771

$

13,203

Repayment of Convertible Notes

(150,000)

Proceeds from employee stock purchase plan

 

3,805

3,107

Debt issuance costs related to senior secured term loan

(282)

Payment of finance lease principal

(1,379)

(1,276)

Net cash provided by (used in) financing activities

$

25,915

$

(134,966)

Effect of exchange rate changes on cash

 

19

(8,792)

Net decrease in cash and cash equivalents

 

(114,515)

 

(76,707)

Cash and cash equivalents, and restricted cash beginning of period

 

295,925

197,218

Cash and cash equivalents, and restricted cash end of period

$

181,410

$

120,511

Supplemental disclosure of cash information

 

 

Cash paid for interest

$

34,020

$

12,679

Cash paid for income taxes

13,631

4,029

Supplemental disclosure of non-cash investing and financing activity

 

 

  

Unrealized gain (loss) on marketable securities, net of tax

$

470

$

(2,333)

Right-of-use assets obtained in exchange for operating lease obligations

35,294

Acquisition of product rights and licenses

44,963

27,828

Milestone payable

2,500

50,000

See accompanying unaudited notes.

8

PTC Therapeutics, Inc.

Notes to Consolidated Financial Statements (unaudited)

September 30, 2023

In thousands (except share and per share amounts unless otherwise noted)

1.        The Company

PTC Therapeutics, Inc. (the “Company” or “PTC”) is a science-driven global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. PTC’s ability to innovate to identify new therapies and to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines. PTC’s mission is to provide access to best-in-class treatments for patients who have little to no treatment options. PTC’s strategy is to leverage its strong scientific and clinical expertise and global commercial infrastructure to bring therapies to patients.  PTC believes that this allows it to maximize value for all of its stakeholders.

PTC has a portfolio pipeline that includes several commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology, metabolism and oncology.

The Company has two products, Translarna™ (ataluren) and Emflaza® (deflazacort), for the treatment of Duchenne muscular dystrophy (“DMD”), a rare, life threatening disorder. Translarna has marketing authorization in the European Economic Area (the “EEA”) for the treatment of nonsense mutation Duchenne muscular dystrophy (“nmDMD”) in ambulatory patients aged 2 years and older and in Russia for the treatment of nmDMD in patients aged two years and older. Translarna also has marketing authorization in Brazil for the treatment of nmDMD in ambulatory patients two years and older and for continued treatment of patients that become non-ambulatory. In July 2020, the European Commission (“EC”) approved the removal of the statement “efficacy has not been demonstrated in non-ambulatory patients” from the indication statement for Translarna. Emflaza is approved in the United States for the treatment of DMD in patients two years and older.

The Company’s marketing authorization for Translarna in the EEA is subject to annual review and renewal by the EC following reassessment by the European Medicines Agency (“EMA”) of the benefit-risk balance of the authorization, which the Company refers to as the annual EMA reassessment. In September 2022, the Company submitted a Type II variation to the EMA to support conversion of the conditional marketing authorization for Translarna to a standard marketing authorization, which included a report on the placebo-controlled trial of Study 041 and data from the open-label extension. In February 2023, the Company also submitted an annual marketing authorization renewal request to the EMA. In September 2023, the Committee for Medicinal Products for Human Use (“CHMP’), gave a negative opinion on the conversion of the conditional marketing authorization to full marketing authorization of Translarna for the treatment of nmDMD and a negative opinion on the renewal of the existing conditional marketing authorization of Translarna for the treatment of nmDMD. The Company has requested re-examination of the CHMP opinion regarding the renewal of the existing conditional marketing authorization. In re-examination, the Company intends to address concerns raised during the previous review process on the benefit demonstrated in Translarna clinical trials and regarding the robustness of the Strategic Targeting of Registries and International Database of Excellence, or STRIDE, real world registry. In accordance with EMA guidelines, the Company expects the CHMP opinion following the re-examination process to occur in late January 2024, with EC ratification of the opinion within the following 67 days.

Translarna is an investigational new drug in the United States. Following the Company’s announcement of top-line results from the placebo-controlled trial of Study 041 in June 2022, the Company submitted a meeting request to the U.S. Food and Drug Administration (“FDA”) to gain clarity on the regulatory pathway for a potential re-submission of a New Drug Application (“NDA”) for Translarna. The FDA provided initial written feedback that Study 041 does not provide substantial evidence of effectiveness to support an NDA re-submission. The Company then had an informal meeting with the FDA, during which the Company discussed the potential path to an NDA re-submission for Translarna. Based on the meeting discussion, the Company has scheduled an additional Type C meeting with the FDA to review the totality of data

9

collected to date, including dystrophin and other mechanistic data as well as additional analyses that could support the benefit of Translarna.

The Company has developed Upstaza (eladocagene exuparvovec), a gene therapy used for the treatment of Aromatic L-Amino Acid Decarboxylase (“AADC”) deficiency (“AADC deficiency”), a rare central nervous system (“CNS”) disorder arising from reductions in the enzyme AADC that results from mutations in the dopa decarboxylase gene. In July 2022, the EC approved Upstaza for the treatment of AADC deficiency for patients 18 months and older within the EEA. In November 2022, the Medicines and Healthcare Products Regulatory Agency approved Upstaza for the treatment of AADC deficiency for patients 18 months and older within the United Kingdom. The Company is also preparing a biologics license application (“BLA”) for Upstaza for the treatment of AADC deficiency in the United States and anticipates submitting the BLA shortly after its pre-BLA meeting that is scheduled for December 2023, pending the outcome of such meeting.

The Company holds the rights for the commercialization of Tegsedi® (inotersen) and Waylivra® (volanesorsen) for the treatment of rare diseases in countries in Latin America and the Caribbean pursuant to the Collaboration and License Agreement (the “Tegsedi-Waylivra Agreement”), dated August 1, 2018, by and between the Company and Akcea Therapeutics, Inc. (“Akcea”), a subsidiary of Ionis Pharmaceuticals, Inc. Tegsedi has received marketing authorization in the United States, the European Union (the “EU”) and Brazil for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis (“hATTR amyloidosis”). The Company began to make commercial sales of Tegsedi for the treatment of hATTR amyloidosis in Brazil in the second quarter of 2022 and it continues to make Tegsedi available in certain other countries within Latin America and the Caribbean through early access programs (“EAP Programs”). In August 2021, ANVISA, the Brazilian health regulatory authority, approved Waylivra as the first treatment for familial chylomicronemia syndrome (“FCS”) in Brazil and the Company began to make commercial sales of Waylivra in Brazil in the third quarter of 2022 while continuing to make Waylivra available in certain other countries within Latin America and the Caribbean through EAP Programs. In December 2022, ANVISA approved Waylivra for the treatment of familial partial lipodystrophy (“FPL”). Waylivra has also received marketing authorization in the EU for the treatment of FCS.

The Company also has a spinal muscular atrophy (“SMA”) collaboration with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc. (referred to collectively as “Roche”) and the Spinal Muscular Atrophy Foundation (“SMA Foundation”). The SMA program has one approved product, Evrysdi® (risdiplam), which was approved by the FDA in August 2020 for the treatment of SMA in adults and children two months and older and by the EC in March 2021 for the treatment of 5q SMA in patients two months and older with a clinical diagnosis of SMA Type 1, Type 2 or Type 3 or with one to four SMN2 copies. Evrysdi also received marketing authorization for the treatment of SMA in Brazil in October 2020 and Japan in June 2021. In May 2022, the FDA approved a label expansion for Evrysdi to include infants under two months old with SMA. In August 2023, the EC approved an extension of the Evrysdi marketing authorization to include infants under two months old in the EU. In addition to the Company’s SMA program, the Company’s splicing platform also includes PTC518, which is being developed for the treatment of Huntington’s disease (“HD”). The Company initiated a Phase 2 study of PTC518 for the treatment of HD in the first quarter of 2022, which consists of an initial 12-week placebo-controlled phase focused on safety, pharmacology and pharmacodynamic effects followed by a nine-month placebo-controlled phase focused on PTC518 biomarker effect. In June 2023, the Company announced interim data from the 12-week placebo-controlled phase. The Company expects the next data update from the Phase 2 study of PTC518 for the treatment of HD in the first half of 2024. In the Phase 2 study, enrollment outside of the United States remains active and ongoing while enrollment within the United States is paused as the FDA requested additional data to allow the Phase 2 study to proceed. The Company had a Type A meeting with the FDA to review the clinical safety data needed to enable resumption of enrollment in the United States. At that meeting, the FDA stated that the existing three-month safety data could support 12-week dosing and that six months of clinical safety data could support dosing in the 12-month Phase 2 study.

The most advanced molecule in the Company’s metabolic platform is sepiapterin, a precursor to intracellular tetrahydrobiopterin, which is a critical enzymatic cofactor involved in metabolism and synthesis of numerous metabolic products, for orphan diseases. In May 2023, the Company announced that the primary endpoint was achieved in its registration-directed Phase 3 trial for sepiapterin for phenylketonuria (“PKU”). The primary endpoint of the study was the achievement of statistically-significant reduction in blood Phe level. The Company participated in a pre-NDA meeting with the FDA in the third quarter of 2023. At that meeting, the FDA stated that the sepiapterin clinical safety and efficacy

10

data supported NDA submission for the treatment of pediatric and adult PKU patients. However, the FDA has requested that PTC completes a 26-week nonclinical mouse study to assess sepiapterin carcinogenicity potential prior to NDA submission. PTC expects to submit an NDA to the FDA for sepiapterin for the treatment of PKU by the end of the third quarter of 2024 and PTC intends to discuss with the FDA the potential for an earlier submission if PTC is permitted to submit the 26-week mouse study report during the review process of the NDA. Additionally, PTC expects to submit a marketing authorization application (“MAA”) to the EMA for sepiapterin for the treatment of PKU in the EEA in the first half of 2024.

The Company’s Bio-e platform consists of small molecule compounds that target oxidoreductase enzymes that regulate oxidative stress and inflammatory pathways central to the pathology of a number of CNS diseases. The two most advanced molecules in the Company’s Bio-e platform are vatiquinone and utreloxastat. The Company announced topline results from a registration-directed Phase 3 trial of vatiquinone in children and young adults with Friedreich ataxia in May 2023. While the study did not meet its primary endpoint of statistically significant change, the Company participated in a Type C written response only meeting with the FDA in the third quarter of 2023 to discuss the potential for an NDA submission for vatiquinone for the treatment of Friedreich ataxia. In their written response, the FDA stated that while they see the value of upright stability as a clinically meaningful endpoint, they believed a confirmatory study would likely be needed to support NDA submission. PTC has requested a follow-up live meeting to address the issues raised by the FDA.  Additionally, PTC is participating in a scientific advice procedure with the EMA to determine if the data from the registration-directed Phase 3 trial of vatiquinone in children and young adults with Friedreich ataxia could support a conditional MAA in the EEA. The Company initiated a Phase 2 trial of utreloxastat for amyotrophic lateral sclerosis in the first quarter of 2022 and enrollment is ongoing.

Unesbulin is the Company’s most advanced oncology agent. The Company completed its Phase 1 trials evaluating unesbulin in leiomyosarcoma (“LMS”) and diffuse intrinsic pontine glioma (“DIPG”) in the fourth quarter of 2021. The Company initiated a registration-directed Phase 2/3 trial of unesbulin for the treatment of LMS in the first quarter of 2022 and enrollment is ongoing. The Company is evaluating its plans for a potential initiation of a registration-directed Phase 2/3 trial of unesbulin for the treatment of DIPG.

In addition, the Company has a pipeline of product candidates and discovery programs that are in early clinical, pre-clinical and research and development stages focused on the development of new treatments for multiple therapeutic areas for rare diseases.

As of September 30, 2023, the Company had an accumulated deficit of approximately $3,127.8 million. The Company has financed its operations to date primarily through the private offerings in September 2019 of 1.50% convertible senior notes due 2026 (see Note 9), public offerings of common stock in February 2014, October 2014, April 2018, January 2019, and September 2019, “at the market offering” of its common stock, its initial public offering of common stock in June 2013, proceeds from the Royalty Purchase Agreement dated as of July 17, 2020, by and among the Company, RPI 2019 Intermediate Finance Trust (“RPI”), and, solely for the limited purposes set forth therein, Royalty Pharma PLC (the “Royalty Purchase Agreement”) (see Note 2), net proceeds from the Company’s’ borrowings under its credit agreement with Blackstone (see Note 9), private placements of its convertible preferred stock and common stock, collaborations, bank and institutional lender debt, other convertible debt, grant funding and clinical trial support from governmental and philanthropic organizations and patient advocacy groups in the disease area addressed by the Company’s product candidates. The Company has also relied on revenue generated from net sales of Translarna for the treatment of nmDMD in territories outside of the United States since 2014, Emflaza for the treatment of DMD in the United States since 2017, and Upstaza for the treatment of AADC deficiency in the EEA since May 2022. The Company has also relied on revenue associated with milestone and royalty payments from Roche pursuant to the License and Collaboration Agreement (the “SMA License Agreement”) dated as of November 23, 2011, by and among the Company, Roche and, for the limited purposes set forth therein, the SMA Foundation, under its SMA program. The Company expects that cash flows from the sales of its products, milestone and royalty payments from Roche, together with the Company’s cash, cash equivalents and marketable securities, will be sufficient to fund its operations for at least the next twelve months.

 

11

2.        Summary of significant accounting policies

The Company’s complete listing of significant accounting policies is set forth in Note 2 of the notes to the Company’s audited financial statements as of December 31, 2022 included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC") on February 21, 2023 (the "2022 Form 10-K"). Selected significant accounting policies are discussed in further detail below.

Basis of presentation

The accompanying financial information as of September 30, 2023 and for the three and nine months ended September 30, 2023 and 2022 has been prepared by the Company, without audit, pursuant to the rules and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States ("GAAP") have been condensed or omitted pursuant to such rules and regulations. These interim financial statements should be read in conjunction with the Company’s audited financial statements as of December 31, 2022 and notes thereto included in the 2022 Form 10-K.

In the opinion of management, the unaudited financial information as of September 30, 2023 and for the three and nine months ended September 30, 2023 and 2022 reflects all adjustments, which are normal recurring adjustments, necessary to present a fair statement of financial position, results of operations, stockholders’ (deficit) equity, and cash flows. The results of operations for the three and nine months ended September 30, 2023 are not necessarily indicative of the results to be expected for the year ended December 31, 2023 or for any other interim period or for any other future year.

Use of estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates in these consolidated financial statements have been made in connection with the calculation of net product sales, royalty revenue, certain accruals related to the Company’s research and development expenses, valuation procedures for liability for sale of future royalties, valuation procedures for convertible notes, fair value of the contingent consideration, and the provision for or benefit from income taxes. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.

Restricted cash

Restricted cash included in deposits and other assets on the consolidated balance sheet contains an unconditional, irrevocable and transferable letter of credit that was entered into during the twelve-month period ended December 31, 2019 in connection with obligations under a facility lease for the Company’s leased biologics manufacturing facility in Hopewell Township, New Jersey. The amount of the letter of credit is $7.5 million, is to be maintained for a term of not less than five years and has the potential to be reduced to $3.8 million if after five years the Company is not in default of its lease. Restricted cash also contains an unconditional, irrevocable and transferable letter of credit that was entered into during June 2022 in connection with obligations for the Company’s new facility lease in Warren, New Jersey. The amount of the letter of credit is $8.1 million and has the potential to be reduced to $4.1 million if after five years the Company is not in default of its lease. Both amounts are classified within deposits and other assets on the consolidated balance sheet due to the long-term nature of the respective letters of credit. Restricted cash also includes a bank guarantee of $0.6 million denominated in a foreign currency.

12

The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheet that sum to the total of the same amounts shown in the statement of cash flows:

    

End of

    

Beginning of

 

period-

 

period-

 

September 30, 

 

December 31, 

 

2023

2022

Cash and cash equivalents

$

165,157

$

279,834

Restricted cash included in deposits and other assets

 

16,253

 

16,091

Total Cash, cash equivalents and restricted cash per statement of cash flows

$

181,410

$

295,925

Marketable securities

The Company’s marketable securities consists of both debt securities and equity investments. The Company considers its investments in debt securities with original maturities of greater than 90 days to be available for sale securities. Securities under this classification are recorded at fair value and unrealized gains and losses within accumulated other comprehensive income. The estimated fair value of the available for sale securities is determined based on quoted market prices or rates for similar instruments. In addition, the cost of debt securities in this category is adjusted for amortization of premium and accretion of discount to maturity. For available for sale debt securities in an unrealized loss position, the Company assesses whether it intends to sell or if it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security’s amortized cost basis is written down to fair value. If the criteria are not met, the Company evaluates whether the decline in fair value has resulted from a credit loss or other factors. In making this assessment, management considers, among other factors, the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and adverse conditions specifically related to the security. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security are compared to the amortized cost basis of the security. If the present value of the cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded for the credit loss, limited by the amount that the fair value is less than the amortized costs basis. Any impairment that has not been recorded through an allowance for credit losses is recognized in other comprehensive income. For the three and nine months ended September 30, 2023 and 2022, no allowance was recorded for credit losses.

Marketable securities that are equity investments are measured at fair value, as it is readily available, and as such are classified as Level 1 assets. Unrealized holding gains and losses for these equity investments are components of other (expense) income, net within the consolidated statement of operations.

Inventory and cost of product sales

Inventory

Inventories are stated at the lower of cost and net realizable value with cost determined on a first-in, first-out basis by product. The Company capitalizes inventory costs associated with products following regulatory approval when future commercialization is considered probable and the future economic benefit is expected to be realized. Products which may be used in clinical development programs are included in inventory and charged to research and development expense when the product enters the research and development process and no longer can be used for commercial purposes. Inventory used for marketing efforts are charged to selling, general and administrative expense. Amounts related to clinical development programs and marketing efforts are immaterial.

The following table summarizes the components of the Company’s inventory for the periods indicated:

    

September 30, 2023

    

December 31, 2022

Raw materials

$

907

$

1,078

Work in progress

 

24,595

 

14,074

Finished goods

 

10,250

 

6,656

13

Total inventory

$

35,752

$

21,808

The Company periodically reviews its inventories for excess amounts or obsolescence and writes down obsolete or otherwise unmarketable inventory to its estimated net realizable value. For the three months ended September 30, 2023, the Company’s inventory write-downs were immaterial. For the nine months ended September 30, 2023, the Company recorded inventory write-downs of $0.4 million primarily related to product approaching expiration. For the three and nine months ended September 30, 2022, the Company recorded inventory write-downs of $0.3 million and $1.2 million, respectively, primarily related to product approaching expiration. Additionally, though the Company’s product is subject to strict quality control and monitoring which it performs throughout the manufacturing processes, certain batches or units of product may not meet quality specifications resulting in a charge to cost of product sales. For the three and nine months ended September 30, 2023 and 2022, these amounts were immaterial.

Cost of product sales

Cost of product sales consists of the cost of inventory sold, manufacturing and supply chain costs, storage costs, amortization of the acquired intangible asset, royalty payments associated with net product sales, and royalty payments to collaborative partners associated with royalty revenues and collaboration revenue related to milestones. Production costs are expensed as cost of product sales when the related products are sold or royalty revenues and collaboration revenue milestones are earned.

Revenue recognition

Net product revenue

The Company’s net product revenue primarily consists of sales of Translarna in territories outside of the U.S. for the treatment of nmDMD and sales of Emflaza in the U.S. for the treatment of DMD. The Company recognizes revenue when its performance obligations with its customers have been satisfied. The Company’s performance obligations are to provide products based on customer orders from distributors, hospitals, specialty pharmacies or retail pharmacies. The performance obligations are satisfied at a point in time when the Company’s customer obtains control of the product, which is typically upon delivery. The Company invoices its customers after the products have been delivered and invoice payments are generally due within 30 to 90 days of the invoice date. The Company determines the transaction price based on fixed consideration in its contractual agreements. Contract liabilities arise in certain circumstances when consideration is due for goods the Company has yet to provide. As the Company has identified only one distinct performance obligation, the transaction price is allocated entirely to product sales. In determining the transaction price, a significant financing component does not exist since the timing from when the Company delivers product to when the customers pay for the product is typically less than one year. Customers in certain countries pay in advance of product delivery. In those instances, payment and delivery typically occur in the same month.

The Company records product sales net of any variable consideration, which includes discounts, allowances, rebates related to Medicaid and other government pricing programs, and distribution fees. The Company uses the expected value or most likely amount method when estimating its variable consideration, unless discount or rebate terms are specified within contracts. The identified variable consideration is recorded as a reduction of revenue at the time revenues from product sales are recognized. These estimates for variable consideration are adjusted to reflect known changes in factors and may impact such estimates in the quarter those changes are known. Revenue recognized does not include amounts of variable consideration that are constrained.

For the three months ended September 30, 2023 and 2022, net product sales outside of the United States were $76.6 million and $79.4 million, respectively, consisting of sales of Translarna, Tegsedi, Waylivra, and Upstaza. Translarna net revenues made up $69.0 million and $76.6 million of the net product sales outside of the United States for the three months ended September 30, 2023 and 2022, respectively. For the three months ended September 30, 2023 and 2022, net product sales in the United States were $67.4 million and $54.8 million, respectively, consisting solely of sales of Emflaza. During the three months ended September 30, 2023, one country, the United States, accounted for at least 10% of the Company’s net product sales, representing $67.4 million of net product sales. During the three months ended September 30, 2022, two

14

countries, the United States and Russia, accounted for at least 10% of the Company’s net product sales, representing $54.8 million and $28.3 million of net product sales, respectively.

For the nine months ended September 30, 2023 and 2022, net product sales outside of the United States were $318.5 million and $247.6 million, respectively, consisting of Translarna, Tegsedi, Waylivra, and Upstaza. Translarna net revenues made up $280.6 million and $232.9 million of the net product sales outside of the United States for the nine months ended September 30, 2023 and 2022, respectively. For the nine months ended September 30, 2023 and 2022, net product sales in the United States were $187.7 million and $160.1 million, respectively, consisting solely of Emflaza. During the nine months ended September 30, 2023, three countries, the United States, Russia, and Brazil, accounted for at least 10% of the Company’s net product sales, representing $187.7 million, $69.0 million, and $52.5 million of net product sales, respectively. During the nine months ended September 30, 2022, two countries, the United States and Russia,  accounted for at least 10% of the Company’s net product sales, representing $160.1 million and $57.1 million of net product sales, respectively.

In relation to customer contracts, the Company incurs costs to fulfill a contract but does not incur costs to obtain a contract. These costs to fulfill a contract do not meet the criteria for capitalization and are expensed as incurred. The Company considers any shipping and handling costs that are incurred after the customer has obtained control of the product as a cost to fulfill a promise. Shipping and handling costs associated with finished goods delivered to customers are recorded as a selling expense.

Collaboration and royalty revenue

The terms of these agreements typically include payments to the Company of one or more of the following: nonrefundable, upfront license fees; milestone payments; research funding and royalties on future product sales. In addition, the Company generates service revenue through agreements that generally provide for fees for research and development services and may include additional payments upon achievement of specified events.

At the inception of a collaboration arrangement, the Company needs to first evaluate if the arrangement meets the criteria in Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 808 “Collaborative Arrangements” to then determine if ASC Topic 606 is applicable by considering whether the collaborator meets the definition of a customer. If the criteria are met, the Company assesses the promises in the arrangement to identify distinct performance obligations.

For licenses of intellectual property, the Company assesses, at contract inception, whether the intellectual property is distinct from other performance obligations identified in the arrangement. If the licensing of intellectual property is determined to be distinct, revenue is recognized for nonrefundable, upfront license fees when the license is transferred to the customer and the customer can use and benefit from the license. If the licensing of intellectual property is determined not to be distinct, then the license will be bundled with other promises in the arrangement into one distinct performance obligation. The Company needs to determine if the bundled performance obligation is satisfied over time or at a point in time. If the Company concludes that the nonrefundable, upfront license fees will be recognized over time, the Company will need to assess the appropriate method of measuring proportional performance.

For milestone payments, the Company assesses, at contract inception, whether the development or sales-based milestones are considered probable of being achieved. If it is probable that a significant revenue reversal will occur, the Company will not record revenue until the uncertainty has been resolved. Milestone payments that are contingent upon regulatory approval are not considered probable of being achieved until the applicable regulatory approvals or other external conditions are obtained as such conditions are not within the Company’s control. If it is probable that a significant revenue reversal will not occur, the Company will estimate the milestone payments using the most likely amount method. The Company will re-assess the development and sales-based milestones each reporting period to determine the probability of achievement. The Company recognizes royalties from product sales at the later of when the related sales occur or when the performance obligation to which the royalty has been allocated has been satisfied. If it is probable that a significant revenue reversal will not occur, the Company will estimate the royalty payments using the most likely amount method.

15

The Company recognizes revenue for reimbursements of research and development costs under collaboration agreements as the services are performed. The Company records these reimbursements as revenue and not as a reduction of research and development expenses as the Company has the risks and rewards as the principal in the research and development activities.

For the three months ended September 30, 2023, the Company did not recognize collaboration revenue related to the SMA License Agreement with Roche. For the three months ended September 30, 2022, the Company recognized $50.0 million of collaboration revenue related to the SMA License Agreement. For the nine months ended September 30, 2023, the amounts recognized for the collaboration revenue related to the SMA License Agreement with Roche were immaterial. For the nine months ended September 30, 2022, the Company recognized $50.0 million of collaboration revenue related to the SMA License Agreement with Roche. In September 2022, the Company recognized a sales milestone of $50.0 million for the achievement of $750.0 million in worldwide annual net sales from Evrysdi.

For the three and nine months ended September 30, 2023, the Company has recognized $50.2 million and $117.9 million of royalty revenue, respectively, related to Evrysdi. For the three and nine months ended September 30, 2022, the Company has recognized $32.9 million and $73.6 million of royalty revenue, respectively, related to Evrysdi.

Manufacturing Revenue

The Company has manufacturing services related to the production of plasmid deoxyribonucleic acid (“DNA”) and adeno-associated virus (“AAV”) vectors for gene therapy applications for external customers. Performance obligations vary but may include manufacturing plasmid DNA and/or AAV vectors, material testing, stability studies, and other services related to material development. The transaction prices for these arrangements are fixed and include amounts stated in the contracts for each promised service. Typically, the performance obligations within a manufacturing contract are highly interdependent, in which case, the Company will combine them into a single performance obligation. The Company has determined that the assets created have no alternative use to the Company, and the Company has an enforceable right to payment for the performance completed to date, therefore revenue related to these services are recognized over time and is measured using an output method based on performance of manufacturing milestones completed to date.

Manufacturing service contracts may also include performance obligations related to project management services or obtaining materials from third parties. The Company has determined that these are separate performance obligations for which revenue is recognized at the point in time the services are performed. For performance obligations related to obtaining third party materials, the Company has determined that it is the principal as the Company has control of the materials and has discretion in setting the price. Therefore, the Company recognizes revenue on a gross basis related to obtaining third party materials.

Certain arrangements require a portion of the contract consideration to be received in advance at the commencement of the contract, and such advance payment is initially recorded as a contract liability. A contract asset may be recognized in the event the Company’s satisfaction of performance obligations outpaces customer billings.

For the three and nine months ended September 30, 2023, the Company recognized $2.4 million and $6.7 million of manufacturing revenue, respectively, related to plasmid DNA and AAV vector production for external customers. No manufacturing revenue was recognized for the three and nine months ended September 30, 2022. As of September 30, 2023, the Company has contract assets of $1.4 million and remaining performance obligations of $1.2 million related to the production of plasmid DNA and AAV vectors for gene therapy applications for external customers. For the period ended December 31, 2022, the Company had remaining performance obligations of $1.4 million and no contracts assets related to plasmid DNA and AAV production for external customers.

Allowance for doubtful accounts

The Company maintains an allowance for estimated losses resulting from the inability of its customers to make required payments. The Company estimates uncollectible amounts based upon current customer receivable balances, the age of customer receivable balances, the customer’s financial condition and current economic trends. The Company also assesses whether an allowance for expected credit losses may be required which includes a review of the Company’s receivables

16

portfolio, which are pooled on a customer basis or country basis.  In making its assessment of whether an allowance for credit losses is required, the Company considers its historical experience with customers, current balances, levels of delinquency, regulatory and legal environments, and other relevant current and future forecasted economic conditions. For the three and nine months ended September 30, 2023 and 2022, no allowance was recorded for credit losses. The allowance for doubtful accounts was $1.0 million as of September 30, 2023 and $0.3 million as of December 31, 2022. For the three and nine months ended September 30, 2023, bad debt expense was $0.4 million and $0.7 million, respectively. For the three and nine months ended September 30, 2022, bad debt expense was immaterial.

Liability for sale of future royalties

On July 17, 2020, the Company, RPI, and, for the limited purposes set forth in the agreement, Royalty Pharma PLC, entered into the Royalty Purchase Agreement. Pursuant to the Royalty Purchase Agreement, the Company sold to RPI 42.933% (the “Assigned Royalty Rights”) of the Company’s right to receive sales-based royalty payments (the “Royalty”) on worldwide net sales of Evrysdi and any other product developed pursuant to the SMA License Agreement. In consideration for the sale of the Assigned Royalty Rights, RPI paid the Company $650.0 million in cash consideration. The Company has retained a 57.067% interest in the Royalty and all economic rights to receive the remaining potential regulatory and sales milestone payments under the SMA License Agreement, which remaining milestone payments equal $250.0 million in the aggregate as of September 30, 2023. The Royalty Purchase Agreement will terminate 60 days following the earlier of the date on which Roche is no longer obligated to make any payments of the Royalty pursuant to the SMA License Agreement and the date on which RPI has received $1.3 billion in respect of the Assigned Royalty Rights.

The cash consideration obtained pursuant to the Royalty Purchase Agreement is classified as debt and is recorded as “liability for sale of future royalties-current” and “liability for sale of future royalties-noncurrent” on the Company’s consolidated balance sheet based on the timing of the expected payments to be made to RPI. The fair value for the liability for sale of future royalties at the time of the transaction was based on the Company’s estimates of future royalties expected to be paid to RPI over the life of the arrangement, which was determined using forecasts from market data sources, which are considered Level 3 inputs. The liability is being amortized using the effective interest method over the life of the arrangement, in accordance with the respective guidance. The Company utilizes the prospective method to account for subsequent changes in the estimated future payments to be made to RPI.  Refer to Note 9 for further details.

Indefinite-lived intangible assets

Indefinite-lived intangible assets consist of in process research and development ("IPR&D"). IPR&D acquired directly in a transaction other than a business combination is capitalized if the projects will be further developed or have an alternative future use; otherwise they are expensed. The fair values of IPR&D projects and license agreement assets acquired in business combinations are capitalized. Several methods may be used to determine the estimated fair value of the IPR&D and license agreement asset acquired in a business combination. The Company utilizes the "income method" and uses estimated future net cash flows that are derived from projected sales revenues and estimated costs. These projections are based on factors such as relevant market size, patent protection, and expected pricing and industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. These assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are amortized over the remaining useful life or written off, as appropriate. Intangible assets with indefinite lives, including IPR&D, are tested for impairment if impairment indicators arise and, at a minimum, annually. However, an entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that an indefinite-lived intangible asset’s fair value is less than its carrying amount. Otherwise, no further impairment testing is required. The indefinite-lived intangible asset impairment test consists of a one-step analysis that compares the fair value of the intangible asset with its carrying amount. If the carrying amount of an intangible asset exceeds its fair value, an impairment loss is recognized in an amount equal to that excess. The Company considers many factors in evaluating whether the value of its intangible assets with indefinite lives may not be recoverable, including, but not limited to, expected growth rates, the cost of equity and debt capital, general economic conditions, the Company’s outlook and market performance of the Company’s industry and recent and forecasted financial performance.

17

In May 2023, as part of the Company’s strategic portfolio prioritization, the Company decided to discontinue its preclinical and early research programs in its gene therapy platform, which included Friedreich ataxia and Angelman syndrome. As a result, the Company determined that the Friedreich ataxia and Angelman syndrome indefinite lived intangible assets were fully impaired and recorded impairment expense of $217.8 million during the nine months ended September 30, 2023, which is recorded as intangible asset impairment in the statement of operations. Refer to Note 12 for further information regarding the Company’s intangible assets.

Goodwill

Goodwill represents the amount of consideration paid in excess of the fair value of net assets acquired as a result of the Company’s business acquisitions accounted for using the acquisition method of accounting. Goodwill is not amortized and is subject to impairment testing at a reporting unit level on an annual basis or when a triggering event occurs that may indicate the carrying value of the goodwill is impaired. The Company reassesses its reporting units as part of its annual segment review. An entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that the fair value of the reporting unit is less than its carrying amount.

Income Taxes

The Organization for Economic Co-operation and Development (“OECD”), the European Community (“the EC”), and individual taxing jurisdictions where the Company and its affiliates do business have recently focused on issues related to the taxation of multinational corporations. The OECD has released its comprehensive plan to create an agreed set of international rules for fighting base erosion and profit shifting. In addition, the OECD, the EC and individual taxing jurisdictions are examining changes to how taxing rights should be allocated among countries considering the digital economy. As a result, the tax laws in the U.S. and other countries in which the Company and its affiliates do business could change on a prospective or retroactive basis and any such changes could materially adversely affect the Company’s business.

On December 22, 2017, the U.S. government enacted the 2017 Tax Act, which significantly revised U.S. tax law by, among other provisions, lowering the U.S. federal statutory corporate income tax rate to 21%, imposing a mandatory one-time transition tax on previously deferred foreign earnings, and eliminating or reducing certain income tax deductions. The Global Intangible Low-Taxed Income ("GILTI") provisions of the 2017 Tax Act require the Company to include in its U.S. income tax return foreign subsidiary earnings in excess of an allowable return on the foreign subsidiary’s tangible assets. The Company has elected to account for GILTI tax in the period in which it is incurred, and therefore has not provided any deferred tax impacts of GILTI in its consolidated financial statements for the period ended September 30, 2023.

Starting in 2022, TCJA amendments to IRC Section 174 no longer permits an immediate deduction for research and development (R&D) expenditures in the tax year that such costs are incurred. Instead, these IRC Section 174 development costs must now be capitalized and amortized over either a five- or 15-year period, depending on the location of the activities performed. The new amortization period begins with the midpoint of any taxable year that IRC Section 174 costs are first incurred, regardless of whether the expenditures were made prior to or after July 1, and runs until the midpoint of year five for activities conducted in the United States or year 15 in the case of development conducted on foreign soil.

Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and net operating loss and credit carryforwards. Deferred tax assets and liabilities are measured at rates expected to apply to taxable income in the years in which those temporary differences and carryforwards are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the statement of operations in the period that includes the enactment date. A valuation allowance is recorded when it is not more likely than not that all or a portion of the net deferred tax assets will be realized.

On August 23, 2018, the Company completed its acquisition of Agilis Biotherapeutics, Inc. (“Agilis”), pursuant to an Agreement and Plan of Merger, dated as of July 19, 2018 (the “Agilis Merger Agreement”), by and among the Company,

18

Agility Merger Sub, Inc., a Delaware corporation and the Company’s wholly owned, indirect subsidiary, Agilis and, solely in its capacity as the representative, agent and attorney-in-fact of the equityholders of Agilis, Shareholder Representative Services LLC, (the “Agilis Merger”). The Company recorded a deferred tax liability in conjunction with the Agilis Merger of $122.0 million in 2018, related to the tax basis difference in the IPRD indefinite-lived intangibles acquired. The Company’s policy is to record a deferred tax liability related to acquired IPR&D which may eventually be realized either upon amortization of the asset when the research is completed, and a product is successfully launched or the write-off of the asset if it is abandoned or unsuccessful. In July 2022, the Company received EMEA approval for a portion of the IPR&D assets, and thus, began the amortization of the intangible.

In May 2023, the Company announced the discontinuation of its preclinical and early research programs in gene therapy as part of a strategic portfolio prioritization. In conjunction with the announcement, the Company recorded an impairment to its indefinite-lived intangible for IP research and development relating to the Friedreich ataxia and Angelman syndrome gene therapy assets. As a result of the impairment, the Company recorded a deferred tax benefit of $50.9 million.

Leases

The Company determines if an arrangement is a lease at inception. This determination generally depends on whether the arrangement conveys to the Company the right to control the use of an explicitly or implicitly identified fixed asset for a period of time in exchange for consideration. Control of an underlying asset is conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using the underlying asset. The Company has lease agreements which include lease and non-lease components, which the Company accounts for as a single lease component for all leases. Operating and finance leases are classified as right of use ("ROU") assets, short term lease liabilities, and long term lease liabilities. Operating and finance lease ROU assets and lease liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. ROU assets are amortized and lease liabilities accrete to yield straight-line expense over the term of the lease. Lease payments included in the measurement of the lease liability are comprised of fixed payments.

Variable lease payments associated with the Company’s leases are recognized when the event, activity, or circumstance in the lease agreement on which those payments are assessed occurs. Variable lease payments are presented in the Company’s consolidated statements of operations in the same line item as expense arising from fixed lease payments for operating leases.

Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheet and the Company recognizes lease expense for these leases on a straight-line basis over the lease term. The Company applies this policy to all underlying asset categories.

A lessee is required to discount its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental borrowing rate. As most of the Company’s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The Company gives consideration to its recent debt issuances as well as publicly available data for instruments with similar characteristics when calculating its incremental borrowing rates.

The lease term for all of the Company’s leases includes the non-cancellable period of the lease plus any additional periods covered by either a Company option to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor. Leasehold improvements are capitalized and depreciated over the lesser of useful life or lease term. See Note 3 Leases for additional information.  

3.        Leases

The Company leases office space in South Plainfield, New Jersey for its principal office under two noncancelable operating leases through August 2024, in addition to office and laboratory space in Bridgewater, New Jersey and other locations throughout the United States and office space in various countries for international employees primarily through workspace providers.

19

The Company also leases approximately 220,500 square feet of office, manufacturing and laboratory space at a facility located in Hopewell Township, New Jersey pursuant to a Lease Agreement (the “Hopewell Lease”) with Hopewell Campus Owner LLC. The rental term of the Hopewell Lease commenced on July 1, 2020 and has an initial term of fifteen years (the “Hopewell Initial Term”), with two consecutive ten year renewal periods, each at the Company’s option. The aggregate rent for the Hopewell Initial Term will be approximately $111.5 million. The rental rate for the renewal periods will be 95% of the Prevailing Market Rate (as defined in the Hopewell Lease) and determined at the time of the exercise of the renewal. The Company is also responsible for maintaining certain insurance and the payment of proportional taxes, utilities and common area operating expenses. The Hopewell Lease contains customary events of default, representations, warranties and covenants.

In May 2022, the Company entered into a Lease Agreement (the “Warren Lease”) with Warren CC Acquisitions, LLC (the “Warren Landlord”) relating to the lease of two entire buildings comprised of approximately 360,000 square feet of shell condition, modifiable space (the “Warren Premises”) at a facility located in Warren, New Jersey. The rental term of the Warren Lease commenced on June 1, 2022, with an initial term of seventeen years (the “Warren Initial Term”), followed by three consecutive five-year renewal periods at the Company’s option. The aggregate base rent for the Warren Initial Term will be approximately $163.0 million; provided, however, that if the Company is not subject to an Event of Default (as defined in the Warren Lease), the Company will be entitled to a base rent abatement over the first three years of the Warren Initial Term of approximately $18.6 million, reducing the Company’s total base rent obligation to $144.4 million. The rental rate for the renewal periods will be at the Fair Market Rental Value (as defined in the Warren Lease) and determined at the time of the exercise of the renewal. Beginning in the second lease year, the Company is also responsible for the payment of all taxes and operating expenses for the Warren Premises. As a result, the Company recorded an operating lease ROU asset of $28.9 million and an operating lease ROU liability of $28.9 million as of the commencement date.

The Company is developing the Warren Premises into office and laboratory space. The Company is entitled to an allowance of approximately $36.2 million to be provided by the Warren Landlord to be used towards such improvements. The Landlord is providing the allowance to cover those assets that are real property improvements, such as structural components, roofs, flooring, etc., whose useful lives are typically longer in nature. The Company evaluated the leasehold improvements under ASC 842 and determined that the Company will be the owner of the improvements, and therefore the $36.2 million allowance and $5.0 million due from the Landlord were treated as lease incentives at the commencement of the lease and included in the calculation of the lease ROU asset and lease ROU liability, effectively reducing both at Commencement Date. In connection with the execution of the Warren Lease, the Company also committed to fund a construction account with $3.6 million to go towards the Company’s improvements of the Warren Premises. Subject to the terms of the Warren Lease, the Company has a right of first offer to purchase the Warren Premises if the Warren Landlord receives a bona fide third party offer to purchase the Warren Premises or the Warren Landlord decides to sell the Warren Premises.

On June 19, 2020, the Company entered into a commercial manufacturing service agreement for a term of 12.5 years with MassBiologics of the University of Massachusetts Medical School ("MassBio"). The Company determined that the agreement was a finance lease, for which the Company recorded a finance lease ROU asset for $41.4 million and corresponding finance lease liability for $41.4 million at the onset of the lease agreement. Given that the leased asset is designed for the production of PTC’s AADC program and would not have an alternate use outside the PTC gene therapy platform without incurring significant costs, the Company determined that the lease should be treated as research and development expense under ASC 730. Accordingly, the full $41.4 million relating to the finance lease ROU asset was written off and expensed to research and development during the year ended December 31, 2020. As of September 30, 2023, the balance of the finance lease liabilities-current and finance lease liabilities-noncurrent are $2.6 million and $17.2 million, respectively, and are directly related to the Company’s MassBio agreement. As of December 31, 2022, the balance of the finance lease liabilities-current and finance lease liabilities-noncurrent were $3.0 million and $18.7 million, respectively. Additionally, the Company recorded finance lease costs of $0.4 million and $1.1 million related to interest on the lease liability during the three and nine months ended September 30, 2023, respectively. The Company recorded finance lease costs of $0.4 million and $1.2 million related to interest on the lease liability during the three and nine months ended September 30, 2022, respectively.

20

The Company also leases certain vehicles, lab equipment, and office equipment under operating leases. The Company’s leases have remaining operating lease terms ranging from 0.4 years to 15.7 years and certain of the leases include renewal options to extend the lease for up to 20 years. Rent expense was $7.1 million and $6.8 million for the three months ended September 30, 2023 and 2022, respectively. Rent expense was $21.5 million and $18.0 million for the nine months ended September 30, 2023 and 2022, respectively.

The components of operating lease expense were as follows:

    

Three Months Ended

    

Three Months Ended

    

Nine Months Ended

    

Nine Months Ended

September 30, 2023

September 30, 2022

September 30, 2023

September 30, 2022

Operating Lease Cost

 

  

  

  

  

Fixed lease cost

$

5,490

$

5,377

$

16,463

$

14,267

Variable lease cost

 

1,376

 

1,151

 

4,140

 

3,152

Short-term lease cost

 

271

 

262

 

866

 

600

Total operating lease cost

$

7,137

$

6,790

$

21,469

$

18,019

Total operating lease cost is a component of operating expenses on the consolidated statements of operations.

Supplemental lease term and discount rate information related to leases was as follows as September 30, 2023 and December 31, 2022:

    

September 30, 2023

    

December 31, 2022

 

Weighted-average remaining lease terms - operating leases (years)

 

11.61

11.61

Weighted-average discount rate - operating leases

8.67

%

8.61

%

Weighted-average remaining lease terms - finance lease (years)

 

9.26

10.01

Weighted-average discount rate - finance lease

 

7.80

%

7.80

%

Supplemental cash flow information related to leases was as follows as of September 30, 2023 and 2022:

    

Nine Months Ended September 30, 

    

2023

    

2022

Cash paid for amounts included in the measurement of lease liabilities:

 

  

  

Operating cash flows from operating leases

$

11,479

$

10,954

Financing cash flows from finance lease

1,379

1,276

Operating cash flows from finance lease

1,621

1,724

Right-of-use assets obtained in exchange for lease obligations:

 

 

  

Operating leases

$

$

35,294

Future minimum lease payments under non-cancelable leases as of September 30, 2023 were as follows:

    

Operating Leases

    

Finance Lease

2023 (excludes the nine months ended September 30, 2023)

$

5,077

$

2024

 

18,369

 

3,000

2025

 

20,438

 

3,000

2026

 

19,988

 

3,000

2027 and thereafter

 

193,792

 

18,000

Total lease payments

 

257,664

 

27,000

Less: Imputed Interest expense

 

146,279

 

7,205

Total

$

111,385

$

19,795

21

4.        Fair value of financial instruments and marketable securities

The Company follows the fair value measurement rules, which provideguidance on the use of fair value in accounting and disclosure for assets and liabilities when such accounting and disclosure is called for by other accounting literature. These rules establish a fair value hierarchy for inputs to be used to measure fair value of financial assets and liabilities. This hierarchy prioritizes the inputs to valuation techniques used to measure fair value into three levels: Level 1 (highest priority), Level 2, and Level 3 (lowest priority).

Level 1—Unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the balance sheet date.
Level 2—Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates, yield curves, etc.), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).
Level 3—Inputs are unobservable and reflect the Company’s assumptions as to what market participants would use in pricing the asset or liability. The Company develops these inputs based on the best information available.

Cash equivalents and marketable securities are reflected in the accompanying financial statements at fair value. The carrying amount of receivables and accounts payable and accrued expenses approximates fair value due to the short-term nature of those instruments.

The Company owns common stock in ClearPoint Neuro, Inc. (“ClearPoint”) (formerly MRI Interventions, Inc.), a publicly traded medical device company. The ClearPoint equity investments (collectively, the “ClearPoint Equity Investments”) represent financial instruments, and therefore, are recorded at fair value, which is readily determinable. The ClearPoint Equity Investments are components of prepaids and other current assets on the consolidated balance sheet as of September 30, 2023, and deposits and other assets as of December 31, 2022. During three and nine months ended September 30, 2023, the Company recorded unrealized losses of $2.0 million and $3.1 million, respectively. During the three and nine months ended September 30, 2022, the Company recorded unrealized losses of $3.5 million and $1.1 million, respectively. During the three months ended September 30, 2023, the Company did not record any realized gains or losses for the sale of ClearPoint Equity Investments. During the nine months ended September 30, 2023, the Company recorded a realized loss of $0.8 million for the sale of ClearPoint Equity Investments. During the three and nine months ended September 30, 2022, the Company did not record any realized gains or losses for the sale of Clearpoint Equity Investments. These unrealized and realized losses are components of other expense, net within the consolidated statement of operations. The fair value of the ClearPoint Equity Investments was $4.5 million and $11.0 million as of September 30, 2023 and December 31, 2022, respectively. The Company classifies the ClearPoint Equity Investments as Level 1 assets within the fair value hierarchy, as the value is based on a quoted market price in an active market, which is not adjusted.

In January 2020, the Company purchased a $10.0 million convertible note from ClearPoint that the Company can convert into ClearPoint shares at a conversion rate of $6.00 per share at any point throughout the term of the loan, which matures five years from the purchase date. The Company determined that the convertible note represents an available for sale debt security and the Company has elected to record it at fair value under ASC 825. The Company classifies its ClearPoint convertible debt security as a Level 2 asset within the fair value hierarchy, as the value is based on inputs other than quoted prices that are observable. The fair value of the ClearPoint convertible debt security is determined at each reporting period by utilizing a Black-Scholes option pricing model, as well as a present value of expected cash flows from the debt security utilizing the risk free rate and the estimated credit spread as of the valuation date as the discount rate. During the three and nine months ended September 30, 2023, the Company recorded unrealized losses of $3.1 million and $4.6 million, respectively. During the three and nine months ended September 30, 2022, the Company recorded unrealized losses of $4.4 million and $2.4 million, respectively. These unrealized gains and losses are components of other expense, net within the consolidated statement of operations. The fair value of the convertible debt security was $10.6 million and $15.2

22

million as of September 30, 2023 and December 31, 2022, respectively. The convertible debt security is considered to be long term and is included as a component of deposits and other assets on the consolidated balance sheet. Other than the ClearPoint Equity Investments and the ClearPoint convertible debt security, no other items included in deposits and other assets and prepaids and other current assets on the consolidated balance sheets are fair valued.

The Company has investments in mutual funds, including one that is denominated in a foreign currency. All of these are equity investments and are classified as marketable securities on the Company’s consolidated balance sheets. These equity investments are reported at fair value, as they are readily available, and as such are classified as Level 1 assets. Unrealized holding gains and losses for these equity investments are included as components of other expense, net within the consolidated statement of operations. For the three and nine months ended September 30, 2023, the Company had unrealized gains of $1.1 million and of $5.5 million, respectively, relating to the equity investments still held at the reporting date. For the three and nine months ended September 30, 2022, the Company had unrealized gains of $0.1 million and unrealized losses of $11.3 million relating to the equity investments still held at the reporting date, respectively. For the three and nine months ended September 30, 2023, the Company had redemptions of $7.8 million and $12.1 million, respectively, which were primarily due to liquidation of one of the mutual funds. For the three and nine months ended September 30, 2022, the Company had redemptions of $100.8 million and $104.4 million, respectively, which were primarily due to liquidation of one of the mutual funds. For the three months ended September 30, 2023, the Company had foreign currency unrealized losses of $1.4 million relating to these equity investments. For the nine months ended September 30, 2023, the amounts recognized for foreign currency unrealized losses relating to these investments were immaterial. For the three and nine months ended September 30, 2022, the Company had foreign currency unrealized losses of $1.4 million and $1.0 million, respectively, relating to these equity investments.

Fair value of marketable securities that are classified as available for sale debt securities is based upon market prices using quoted prices in active markets for identical assets quoted on the last day of the period. In establishing the estimated fair value of the remaining available for sale debt securities, the Company used the fair value as determined by its investment advisors using observable inputs other than quoted prices.

The following represents the fair value using the hierarchy described above for the Company’s financial assets and liabilities that are required to be measured at fair value on a recurring basis as of September 30, 2023 and December 31, 2022:

September 30, 2023

 

 

Quoted prices

 

Significant

 

 

in active

 

other

 

Significant

 

markets for

 

observable

 

unobservable

 

identical assets

 

inputs

 

inputs

    

Total

    

(level 1)

    

(level 2)

    

(level 3)

Marketable securities - available for sale

$

1,625

$

$

1,625

$

Marketable securities - equity investments

$

128,028

$

128,028

$

$

ClearPoint Equity Investments - available for sale

$

4,482

$

4,482

$

$

ClearPoint convertible debt security

$

10,637

$

$

10,637

$

Contingent consideration payable- development and regulatory milestones

$

26,400

$

$

$

26,400

Contingent consideration payable- net sales milestones and royalties

$

12,600

$

$

$

12,600

December 31, 2022

 

 

Quoted prices

 

Significant

 

 

in active

 

other

 

Significant

 

markets for

 

observable

 

unobservable

 

identical assets

 

inputs

 

inputs

    

Total

    

(level 1)

    

(level 2)

    

(level 3)

Marketable securities - available for sale

$

22,610

$

$

22,610

$

Marketable securities - equity investments

$

108,261

$

108,261

$

$

ClearPoint Equity Investments

$

10,965

$

10,965

$

$

ClearPoint convertible debt security

$

15,231

$

$

15,231

$

23

Contingent consideration payable- development and regulatory milestones

$

82,500

$

$

$

82,500

Contingent consideration payable- net sales milestones and royalties

$

81,500

$

$

$

81,500

No transfers of assets between Level 1, Level 2, or Level 3 of the fair value measurement hierarchy occurred during the periods ended September 30, 2023 and December 31, 2022.

The following is a summary of marketable securities accounted for as available for sale debt securities at September 30, 2023 and December 31, 2022:

September 30, 2023

 

Amortized

 

Gross Unrealized

    

Cost

    

Gains

    

Losses

    

Fair Value

Corporate debt securities

$

1,649

$

$

(24)

$

1,625

Total

$

1,649

$

$

(24)

$

1,625

December 31, 2022

 

Amortized

 

Gross Unrealized

    

Cost

    

Gains

    

Losses

    

Fair Value

Commercial paper

$

12,419

$

5

$

$

12,424

Corporate debt securities

 

10,685

(499)

10,186

Total

$

23,104

$

5

$

(499)

$

22,610

For available for sale debt securities in an unrealized loss position, the Company assesses whether it intends to sell or if it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security’s amortized cost basis is written down to fair value. For the three and nine months ended September 30, 2023 and 2022, no write downs occurred. The Company does not intend to sell the investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost basis, which may be maturity. The Company also reviews its available for sale debt securities in an unrealized loss position and evaluates whether the decline in fair value has resulted from credit losses or other factors. This review is subjective, as it requires management to evaluate whether an event or change in circumstances has occurred in that period that may be related to credit issues. For the three and nine months ended September 30, 2023 and 2022, no allowance was recorded for credit losses. Unrealized gains and losses are reported as a component of accumulated other comprehensive (loss) income in stockholders’ equity.

For the three months ended September 30, 2023, the Company did not have any realized gains or losses from the sale of available for sale debt securities. For the nine months ended September 30, 2023, the Company had $0.3 million of realized losses from the sale of available for sale debt securities. For the three and nine months ended September 30, 2022, the Company had $1.3 million and $1.6 million of realized losses from the sale of available for sale debt securities, respectively.  Realized gains and losses are reported as a component of interest expense, net in the consolidated statement of operations. Reclassified amounts from other comprehensive items were determined using the actual realized gains and losses from the sales of marketable securities.

The unrealized losses and fair values of available for sale debt securities that have been in an unrealized loss position for a period of less than and greater than or equal to 12 months as of September 30, 2023 are as follows:

September 30, 2023

 

Securities in an unrealized loss

 

Securities in an unrealized loss

 

 

position less than 12 months

 

position greater than or equal to 12 months

Total

   

Unrealized losses

   

Fair Value

   

Unrealized losses

   

Fair Value

   

Unrealized losses

   

Fair Value

Corporate debt securities

$

(24)

1,625

(24)

$

1,625

Total

$

$

$

(24)

$

1,625

$

(24)

$

1,625

24

The unrealized losses and fair values of available for sale debt securities that have been in an unrealized loss position for a period of less than and greater than or equal to 12 months as of December 31, 2022 are as follows:

December 31, 2022

 

Securities in an unrealized loss

 

Securities in an unrealized loss

 

 

position less than 12 months

 

position greater than or equal to 12 months

Total

   

Unrealized losses

   

Fair Value

   

Unrealized losses

   

Fair Value

   

Unrealized losses

   

Fair Value

Corporate debt securities

$

(499)

10,186

(499)

$

10,186

Total

$

$

$

(499)

$

10,186

$

(499)

$

10,186

Available for sale debt securities at September 30, 2023 and December 31, 2022 mature as follows:

September 30, 2023

 

Less Than

 

More Than

    

12 Months

    

12 Months

Corporate debt securities

$

1,625

$

Total

$

1,625

$

December 31, 2022

 

Less Than

 

More Than

    

12 Months

    

12 Months

Commercial paper

$

12,424

$

Corporate debt securities

 

 

10,186

Total

$

12,424

$

10,186

The Company classifies all of its marketable securities as current as they are all either available for sale debt securities or equity investments and are available for current operations.

Convertible senior notes

In September 2019, the Company issued $287.5 million of 1.50% convertible senior notes due September 15, 2026 (the “2026 Convertible Notes,”). The fair value of the 2026 Convertible Notes, which differs from their carrying values, is influenced by interest rates, the Company’s stock price and stock price volatility and is determined by prices for the 2026 Convertible Notes observed in market trading which are Level 2 inputs. The estimated fair value of the 2026 Convertible Notes at September 30, 2023 and December 31, 2022 was $228.8 million and $281.7 million, respectively.

Level 3 valuation

The contingent consideration payable is fair valued each reporting period with the change in fair value recorded as a gain or loss within the change in the fair value of contingent consideration on the consolidated statements of operations. The fair value of the development and regulatory milestones is estimated utilizing a probability adjusted, discounted cash flow approach. The discount rates are estimated utilizing Corporate B rated bonds maturing in the years of expected payments based on the Company’s estimated development timelines for the acquired product candidate. The fair value of the net sales milestones is determined utilizing a valuation framework that estimates net sales volatility to simulate a range of possible payment scenarios. The average of the payments in these scenarios is then discounted to calculate present fair value.  

In May 2023, as part of the Company’s strategic portfolio prioritization, the Company decided to discontinue its preclinical and early research programs in its gene therapy platform, which included Friedreich ataxia and Angelman syndrome. As a result, the Company fully impaired the Friedreich ataxia and Angelman syndrome intangible assets and determined that the fair value for all of the contingent consideration payable related to Friedreich ataxia and Angelman syndrome was $0. The change in fair value for the contingent consideration payable related to Friedreich ataxia and Angelman syndrome for the nine months ended September 30, 2023 was $129.8 million and is included in the change in fair value of the contingent consideration in the statement of operations. The remaining contingent consideration as of September 30, 2023 is $39.0 million, which is solely related to the development and regulatory milestones, and net sales milestones, for Upstaza.

25

As of September 30, 2023, the weighted average discount rate for the Upstaza development and regulatory milestones was 7.1% and the weighted average probability of success was 90%. As of September 30, 2023, the weighted average discount rate for the Upstaza net sales milestones was 12.0% and the weighted average probability of success for the net sales milestones was 93%.

The table presented below is a summary of changes in the fair value of the Company’s Level 3 valuations for the contingent consideration payable for the periods ended September 30, 2023 and September 30, 2022:

Level 3 liabilities

Contingent consideration payable-

Contingent consideration payable-

development and regulatory

net sales milestones and royalties

    

milestones

    

Beginning balance as of December 31, 2022

$

82,500

$

81,500

Additions

 

 

Change in fair value

 

(56,100)

 

(68,900)

Payments

Ending balance as of September 30, 2023

$

26,400

$

12,600

Level 3 liabilities

Contingent consideration payable-

Contingent consideration payable-

development and regulatory

net sales milestones and royalties

    

milestones

    

Beginning balance as of December 31, 2021

$

139,300

$

100,600

Additions

 

 

Change in fair value

 

(10,800)

 

(21,400)

Reclass to accounts payable and accrued expenses

(50,000)

Payments

Ending balance as of September 30, 2022

$

78,500

$

79,200

The following significant unobservable inputs were used in the valuation of the contingent consideration payable for the periods ended September 30, 2023 and December 31, 2022:

September 30, 2023

    

Fair Value

    

Valuation Technique

    

Unobservable Input

    

Range

Contingent consideration payable-
development and regulatory milestones

$26,400

 

 Probability-adjusted discounted cash flow 

 

Potential development and regulatory milestones
Probabilities of success
Discount rates
Projected years of payments

$0 - $31 million
85% - 92%
6.9% - 7.6%
2023 - 2026

Contingent considerable payable- net sales
milestones and royalties

$12,600

 

Option-pricing model with Monte Carlo simulation  

 

Potential net sales milestones
Probabilities of success
Potential percentage of net sales for royalties
Discount rate
Projected years of payments

$0 - $50 million
85% - 100%
0%
12%
2025 - 2034

December 31, 2022

    

Fair Value

    

Valuation Technique

    

Unobservable Input

    

Range

Contingent consideration payable-
development and regulatory milestones

$82,500

 

 Probability-adjusted discounted cash flow 

 

Potential development and regulatory milestones
Probabilities of success
Discount rates
Projected years of payments

$0 - $331 million
25% - 92%
6.2% - 8.3%
2023 - 2029

Contingent considerable payable- net sales
milestones and royalties

$81,500

 

Option-pricing model with Monte Carlo simulation  

 

Potential net sales milestones
Probabilities of success
Potential percentage of net sales for royalties
Discount rate
Projected years of payments

$0 - $150 million
25% - 100%
2% - 6%
11.5%
2025 - 2041

The contingent consideration payables are classified Level 3 liabilities as their valuation requires substantial judgment and estimation of factors that are not currently observable in the market. If different assumptions were used for the various inputs to the valuation approaches, including but not limited to, assumptions involving probability adjusted sales estimates

26

for the gene therapy platform and estimated discount rates, the estimated fair value could be significantly higher or lower than the fair value determined.

5.        Accounts payable and accrued expenses

Accounts payable and accrued expenses at September 30, 2023 and December 31, 2022 consist of the following:

September 30, 

December 31, 

    

2023

    

2022

Employee compensation, benefits, and related accruals

$

70,778

$

62,669

Income tax payable

2,822

4,712

Consulting and contracted research

 

21,236

 

38,882

Professional fees

 

3,067

 

3,093

Sales allowance

 

72,202

 

63,787

Sales rebates

 

119,971

 

67,355

Royalties

52,087

40,546

Accounts payable

 

19,152

 

27,268

Other

 

9,416

 

12,054

Total

$

370,731

$

320,366

During the three and nine month periods ended September 30, 2023, the Company incurred $22.6 million and $30.6 million, respectively, of restructuring costs from a reduction in workforce in connection with the Company’s strategic pipeline prioritization and discontinuation of its preclinical and early research programs in its gene therapy platform. The costs are included in research and development and selling, general, and administrative expenses on the Company’s consolidated statement of operations. As of September 30, 2023, the remaining $23.4 million of accrued restructuring costs are included above within employee compensation, benefits, and related accruals.

6.        Capitalization

In August 2019, the Company entered into an At the Market Offering Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald and RBC Capital Markets, LLC (together, the “Sales Agents”), pursuant to which, the Company may offer and sell shares of its common stock, having an aggregate offering price of up to $125.0 million from time to time through the Sales Agents by any method that is deemed to be an “at the market offering” as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended. No shares were sold during the three and nine months ended September 30, 2023 and 2022. The remaining shares of the Company’s common stock available to be issued and sold, under the At the Market Offering, have an aggregate offering price of up to $93.0 million as of September 30, 2023.

7.        Net loss per share

Basic and diluted net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding. Potentially dilutive securities were excluded from the diluted calculation because their effect would be anti-dilutive.

27

The following tables set forth the computation of basic and diluted net loss per share:

Three Months Ended September 30, 

Nine Months Ended September 30, 

    

2023

    

2022

    

2023

    

2022

    

Numerator

Net loss

$

(132,970)

  

$

(109,315)

  

$

(470,812)

  

$

(388,128)

  

Denominator

Denominator for basic and diluted net loss per share

 

75,377,997

  

 

71,654,671

  

 

74,618,611

  

 

71,415,849

  

Net loss per share:

Basic and diluted

$

(1.76)

*

$

(1.53)

*

$

(6.31)

*

$

(5.43)

*

*     In the three and nine months ended September 30, 2023 and 2022, the Company experienced a net loss and therefore did not report any dilutive share impact.

The following table shows historical dilutive common share equivalents outstanding, which are not included in the above historical calculation, as the effect of their inclusion is anti-dilutive during each period.

As of September 30, 

    

2023

    

2022

    

Stock Options

11,436,783

11,478,421

Unvested restricted stock awards and units

 

3,414,102

 

2,488,944

 

Total

 

14,850,885

 

13,967,365

 

8.        Stock award plan

In May 2013, the Company’s Board of Directors and stockholders approved the 2013 Long-Term Incentive Plan, which became effective upon the closing of the Company’s initial public offering. On June 8, 2022 (the “Restatement Effective Date”), the Company’s stockholders approved the Amended and Restated 2013 Long-Term Incentive Plan (the “Amended 2013 LTIP”). The Amended 2013 LTIP provides for the grant of incentive stock options, nonstatutory stock options, restricted stock units and other stock-based awards. The number of shares of common stock reserved for issuance under the Amended 2013 LTIP is the sum of (A) the number of shares of the Company’s common stock (up to 16,724,212 shares) that is equal to the sum of (1) the number of shares issued under the 2013 Long-Term Incentive Plan prior to the Restatement Effective Date, (2) the number of shares that remain available for issuance under the 2013 Long-Term Incentive Plan immediately prior to the Restatement Effective Date and (3) the number of shares subject to awards granted under the 2013 Long-Term Incentive Plan prior to the Restatement Effective Date that are outstanding as of the Restatement Effective Date, plus (B) from and after the Restatement Effective Date, an additional 8,475,000 shares of Common Stock. As of September 30, 2023, awards for 6,802,210 shares of common stock are available for issuance under the Amended 2013 LTIP.

There are no additional shares of common stock available for issuance under the Company’s 1998 Employee, Director and Consultant Stock Option Plan, 2009 Equity and Long Term Incentive Plan or 2013 Stock Incentive Plan.

In January 2020, the Company’s Board of Directors approved the 2020 Inducement Stock Incentive Plan. The 2020 Inducement Stock Incentive Plan provides for the grant of incentive stock options, nonstatutory stock options, restricted stock awards and other stock-based awards for, initially, up to at the time, an aggregate of 1,000,000 shares of common stock. Any grants made under the 2020 Inducement Stock Incentive Plan must be made pursuant to the Nasdaq Listing Rule 5635(c)(4) inducement grant exception as a material component of the Company’s new hires’ employment compensation.  In December 2020, the Company’s Board of Directors approved an additional 1,000,000 shares of common stock that may be issued under the 2020 Inducement Stock Incentive Plan.  In April 2022, the Company’s Board of Directors approved a reduction in the total number of shares of common stock that may be issued under the 2020 Inducement Stock Incentive Plan to 1,300,000 shares. In December 2022, the Company’s Board of Directors approved an additional 1,700,000 shares of common stock that may be issued under the 2020 Inducement Stock Incentive Plan.  As of September 30, 2023, awards for 1,705,941 shares of common stock were available for issuance under the 2020 Inducement Stock Incentive Plan.

28

The Board of Directors has the authority to select the individuals to whom options are granted and determine the terms of each option, including (i) the number of shares of common stock subject to the option; (ii) the date on which the option becomes exercisable; (iii) the option exercise price, which, in the case of incentive stock options, must be at least 100% (110% in the case of incentive stock options granted to a stockholder owning in excess of 10% of the Company’s stock) of the fair market value of the common stock as of the date of grant; and (iv) the duration of the option (which, in the case of incentive stock options, may not exceed ten years). Options typically vest over a four-year period.

Inducement stock option awards

From January 1, 2023 through September 30, 2023, the Company issued a total of 1,059,054 stock options to various employees. Of those, 121,460 were inducement grants for non-statutory stock options, all of which were made pursuant to the 2020 Inducement Stock Incentive Plan.

Stock option activity—A summary of stock option activity is as follows:

    

    

    

Weighted-

    

  

Weighted-

average

Aggregate

average

remaining

intrinsic

Number of

exercise

contractual

value(in 

options

price

term

thousands)

 

Outstanding at December 31, 2022

 

11,502,417

$

43.33

 

  

 

  

Granted

 

1,059,054

$

41.29

 

  

 

  

Exercised

 

(806,407)

$

29.48

 

  

 

  

Forfeited/Cancelled

 

(318,281)

$

47.84

 

  

 

  

Outstanding at September 30, 2023

 

11,436,783

$

43.99

 

5.87

years

$

5,084

Vested or Expected to vest at September 30, 2023

 

2,357,250

$

46.72

 

8.23

years

$

Exercisable at September 30, 2023

 

8,533,144

$

43.18

 

5.05

years

$

5,084

The fair value of grants made in the nine months ended September 30, 2023 was contemporaneously estimated on the date of grant using the following assumptions:

    

Nine months ended

    

September 30, 2023

Risk-free interest rate

 

3.54% - 3.91%

Expected volatility

 

53% - 54%

Expected term

 

5.5 years

The Company assumed no expected dividends for all grants. The weighted average grant date fair value of options granted during the nine months ended September 30, 2023 was $21.83 per share.

The expected term of options was estimated based on the Company’s historical exercise data and the expected volatility of options was estimated based on the Company’s historical stock volatility. The risk-free rate of the options was based on U.S. Government Securities Treasury Constant Maturities yields at the date of grant for a term similar to the expected term of the option.

Restricted Stock Awards and Restricted Stock Units—Restricted stock awards and restricted stock units are granted subject to certain restrictions, including in some cases service or time conditions (restricted stock). The grant-date fair value of restricted stock awards and restricted stock units, which have been determined based upon the market value of the Company’s shares on the grant date, are expensed over the vesting period.  From January 1, 2023, through September 30, 2023, the Company issued a total of 1,973,973 restricted stock units to various employees. Of those, 83,210 were inducement grants for restricted stock units, all of which were made pursuant to the 2020 Inducement Stock Incentive Plan.

29

The following table summarizes information on the Company’s restricted stock awards and units:

Restricted Stock Awards and Units

Weighted

Average

Grant

Number of

Date

    

Shares

    

Fair Value

Unvested at December 31, 2022

2,516,336

$

45.67

Granted

 

1,973,973

40.00

Vested

 

(778,442)

46.34

Forfeited

 

(297,765)

42.65

Unvested at September 30, 2023

 

3,414,102

$

42.50

Employee Stock Purchase Plan—In June 2016, the Company established an Employee Stock Purchase Plan (as amended, “ESPP” or the "Plan”), for certain eligible employees. The Plan is administered by the Company’s Board of Directors or a committee appointed by the Company’s Board of Directors. In June 2021, the Plan was amended to increase the total number of shares available for purchase under the Plan from one million shares to two million shares of the Company’s common stock. Employees may participate over a six month period through payroll withholdings and may purchase, at the end of the six month period, the Company’s common stock at a purchase price of at least 85% of the closing price of a share of the Company’s common stock on the first business day of the offering period or the closing price of a share of the Company’s common stock on the last business day of the offering period, whichever is lower. No participant will be granted a right to purchase the Company’s common stock under the Plan if such participant would own more than 5% of the total combined voting power of the Company or any subsidiary of the Company after such purchase. For the three and nine months ended September 30, 2023, the Company recorded $0.7 million and $2.0 million, respectively, in compensation expense related to the ESPP.

The Company recorded share-based compensation expense in the statement of operations related to incentive stock options, nonstatutory stock options, restricted stock awards, restricted stock units and the ESPP as follows:

Three Months Ended September 30, 

Nine Months Ended September 30, 

    

2023

    

2022

    

2023

    

2022

Research and development

$

13,986

$

15,063

$

44,828

$

41,896

Selling, general and administrative

 

12,956

 

13,607

 

40,300

 

41,093

Total

$

26,942

$

28,670

$

85,128

$

82,989

As of September 30, 2023, there was approximately $179.3 million of total unrecognized compensation cost related to unvested share-based compensation arrangements granted under the Company’s equity award plans. This cost is expected to be recognized as share-based compensation expense over the weighted average remaining service period of approximately 1.9 years.

9.        Debt

Liability for sale of future royalties

In July 2020, the Company entered into the Royalty Purchase Agreement. As RPI’s interest is explicitly limited, the $650.0 million cash consideration was classified as debt and is recorded as “liability for sale of future royalties-current” and “liability for sale of future royalties-noncurrent” on the Company’s consolidated balance sheet based on the timing of the expected payments to be made to RPI. The fair value for the liability for sale of future royalties at the time of the transaction was based on the Company’s estimates of future royalties expected to be paid to RPI over the life of the arrangement, which was determined using forecasts from market data sources, which are considered Level 3 inputs. The liability is being amortized using the effective interest method over the life of the arrangement, in accordance with ASC 470 and ASC 835. The initial annual effective interest rate was determined to be 11.0%. The Company utilizes the prospective method to account for subsequent changes in the estimated future payments to be made to RPI and updates the effective interest rate on a quarterly basis. Issuance costs related to the transaction were determined to be immaterial.

30

The following table shows the activity within the “liability for sale of future royalties- current” and “liability for sale of future royalties- noncurrent” accounts for the nine months ended September 30, 2023:

    

Nine Months Ended September 30, 

Liability for sale of future royalties- (current and noncurrent)

2023

Beginning balance as of December 31, 2022

$

757,886

Less: Non-cash royalty revenue payable to RPI

(50,599)

Plus: Non-cash interest expense recognized

56,031

Ending balance

$

763,318

Effective interest rate as of September 30, 2023

 

9.3

%

Non-cash interest expense is recorded in the statement of operations within “Interest expense, net”.  

Senior Secured Term Loan

On October 27, 2022 (the “Closing Date”), the Company entered into a credit agreement (the “Blackstone Credit Agreement”) for fundings of up to $950.0 million consisting of a committed loan facility of $450.0 million and further contemplating the potential for up to $500.0 million of additional financing, to the extent that the Company requests such additional financing and subject to the Lenders’ agreement to provide such additional financing and to mutual agreement on terms, among the Company, certain subsidiaries of the Company (together with the Company, the “Loan Parties”) and funds and other affiliated entities advised or managed by Blackstone Life Sciences and Blackstone Credit (collectively, “Blackstone”, and such lenders, together with their permitted assignees, the “Lenders” and each a “Lender”) and Wilmington Trust, National Association, as the administrative agent for the Lenders.  

The Blackstone Credit Agreement provides for a senior secured term loan facility funded on the Closing Date in the aggregate principal amount of $300.0 million (the “Initial Loans”) and a committed delayed draw term loan facility of up to $150.0 million (the “Delayed Draw Loans” and, together with the Initial Loans, the “Loans”) to be funded at the Company’s request within 18 months of the Closing Date subject to specified conditions. In addition, the Blackstone Credit Agreement contemplates the potential for further financings by Blackstone, by providing for incremental discretionary uncommitted further financings of up to $500.0 million. The Company capitalized approximately $11.6 million of debt issuance costs which are presented on the balance sheet as a direct deduction from the debt liability and are being amortized over the term of the senior secured term loan facility using the effective interest rate method.

The Loans mature on the date that is seven years from the Closing Date. Borrowings under the Blackstone Credit Agreement bear interest at a variable rate equal to, at the Company’s option, either an adjusted Term SOFR rate plus seven and a quarter percent (7.25%) or the Base Rate plus six and a quarter percent (6.25%), subject to a floor of one percent (1%) and two percent (2%) with respect to Term SOFR rate and Base Rate (each as defined in the Blackstone Credit Agreement), respectively. Payment of the Loans are subject to certain premiums specified in the Blackstone Credit Agreement, in each case, from the date the applicable Loan is funded.

All obligations under the Blackstone Credit Agreement are secured, subject to certain exceptions and specified inclusions, by security interests in certain assets of the Loan Parties, including (1) intellectual property and other assets related to Translarna, Emflaza, Upstaza, sepiapterin and, until certain release conditions are met, vatiquinone, in each case, together with any other forms, formulations, or methods of delivery of any such products, and regardless of trade or brand name, (2) future acquired intellectual property (but not internally developed intellectual property unrelated to other intellectual property collateral) and other related assets, and (3) the equity interests held by the Loan Parties in certain of their subsidiaries. The Blackstone Credit Agreement contains certain negative covenants with which the Company must remain in compliance. The Blackstone Credit Agreement also requires that the Company maintains consolidated liquidity of at least $100.0 million as of the last day of each fiscal quarter, which shall be increased to $200.0 million upon the Company consummating acquisitions meeting certain consolidated thresholds described therein. In addition, the Company will be required under conditions specified in the Blackstone Credit Agreement to fund a reserve account up to certain amounts specified therein, including $50.0 million that the Company funded into the reserve account during the quarter ended March 31, 2023 and was released back to the Company during the quarter ended June 30, 2023.  The funds in the reserve

31

account are available to prepay the Loans at any time at the Company’s option, and are, if funded, subject to release upon certain further conditions. Upon any such release, such funds are freely available for use by the Company subject to the generally applicable terms and conditions of the Blackstone Credit Agreement. The Blackstone Credit Agreement contains certain customary representations and warranties, affirmative covenants and provisions relating to events of default.

The Blackstone Credit Agreement consists of the following:

September 30, 2023

December 31, 2022

Principal

$

300,000

$

300,000

Less: Debt issuance costs

 

(10,742)

 

(11,322)

Net carrying amount

$

289,258

$

288,678

As of September 30, 2023, the remaining contractual life of the Blackstone Credit Agreement is approximately 6.1 years.

The following table sets forth total interest expense recognized related to the Blackstone Credit Agreement:

Three Months Ended

Nine Months Ended

September 30, 

September 30, 

2023

2023

Contractual interest expense

$

9,554

$

28,087

Amortization of debt issuance costs

 

280

 

702

Total

$

9,834

$

28,789

Effective interest rate

13.1

%

13.1

%

2026 Convertible Notes

In September 2019, the Company issued, at par value, $287.5 million aggregate principal amount of 1.50% convertible senior notes due 2026, which included an option to purchase up to an additional $37.5 million in aggregate principal amount of the 2026 Convertible Notes, which was exercised in full by the initial purchasers. The 2026 Convertible Notes bear cash interest at a rate of 1.50% per year, payable semi-annually on March 15 and September 15 of each year, beginning on March 15, 2020. The 2026 Convertible Notes will mature on September 15, 2026, unless earlier repurchased or converted. The net proceeds to the Company from the offering were $279.3 million after deducting the initial purchasers’ discounts and commissions and the offering expenses payable by the Company.

The 2026 Convertible Notes are governed by an indenture (the "2026 Convertible Notes Indenture") with U.S Bank National Association as trustee (the "2026 Convertible Notes Trustee").

Holders of the 2026 Convertible Notes may convert their 2026 Convertible Notes at their option at any time prior to the close of business on the business day immediately preceding March 15, 2026 only under the following circumstances:

during any calendar quarter commencing on or after December 31, 2019 (and only during such calendar quarter), if the last reported sale price of the Company’s common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day;
during the five business day period after any five consecutive trading day period (the “measurement period”) in which the trading price (as defined in the 2026 Convertible Notes Indenture) per $1,000 principal amount of 2026 Convertible Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of the Company’s common stock and the conversion rate on each such trading day;
during any period after the Company has issued notice of redemption until the close of business on the scheduled trading day immediately preceding the relevant redemption date; or

32

upon the occurrence of specified corporate events.

On or after March 15, 2026, until the close of business on the business day immediately preceding the maturity date, holders may convert their 2026 Convertible Notes at any time, regardless of the foregoing circumstances. Upon conversion, the Company will pay or deliver, as the case may be, cash, shares of the Company’s common stock or any combination thereof at the Company’s election.

The conversion rate for the 2026 Convertible Notes was initially, and remains, 19.0404 shares of the Company’s common stock per $1,000 principal amount of the 2026 Convertible Notes, which is equivalent to an initial conversion price of approximately $52.52 per share of the Company’s common stock. The conversion rate may be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest.

The Company was not permitted to redeem the 2026 Convertible Notes prior to September 20, 2023. The Company may redeem for cash all or any portion of the 2026 Convertible Notes, at its option, if the last reported sale price of its common stock has been at least 130% of the conversion price then in effect on the last trading day of, and for at least 19 other trading days (whether or not consecutive) during, any 30 consecutive trading day period ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption, at a redemption price equal to 100% of the principal amount of the 2026 Convertible Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. No sinking fund is provided for the 2026 Convertible Notes, which means that the Company is not required to redeem or retire the 2026 Convertible Notes periodically.

If the Company undergoes a “fundamental change” (as defined in the 2026 Convertible Notes Indenture), subject to certain conditions, holders of the 2026 Convertible Notes may require the Company to repurchase for cash all or part of their 2026 Convertible Notes at a repurchase price equal to 100% of the principal amount of the 2026 Convertible Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date.

The 2026 Convertible Notes represent senior unsecured obligations and will rank senior in right of payment to the Company’s future indebtedness that is expressly subordinated in right of payment to the notes, equal in right of payment to the Company’s existing and future unsecured indebtedness that is not so subordinated, effectively junior in right of payment to any of the Company’s secured indebtedness to the extent of the value of the assets securing such indebtedness, and structurally subordinated to all existing and future indebtedness and other liabilities (including trade payables) incurred by the Company’s subsidiaries. The 2026 Convertible Notes Indenture contains customary events of default with respect to the 2026 Convertible Notes, including that upon certain events of default (including the Company’s failure to make any payment of principal or interest on the 2026 Convertible Notes when due and payable) occurring and continuing, the 2026 Convertible Notes Trustee by notice to the Company, or the holders of at least 25% in principal amount of the outstanding 2026 Convertible Notes by notice to the Company and the Convertible Notes Trustee, may, and the 2026 Convertible Notes Trustee at the request of such holders (subject to the provisions of the 2026 Convertible Notes Indenture) shall, declare 100% of the principal of and accrued and unpaid interest, if any, on all the 2026 Convertible Notes to be due and payable. In case of certain events of bankruptcy, insolvency or reorganization, involving the Company or a significant subsidiary, 100% of the principal of and accrued and unpaid interest on the 2026 Convertible Notes will automatically become due and payable. Upon such a declaration of acceleration, such principal and accrued and unpaid interest, if any, will be due and payable immediately.

The 2026 Convertible Notes consist of the following:

    

September 30, 2023

December 31, 2022

Principal

$

287,500

$

287,500

Less: Debt issuance costs

 

(3,584)

 

(4,456)

Net carrying amount

$

283,916

$

283,044

As of September 30, 2023, the remaining contractual life of the 2026 Convertible Notes is approximately 3.0 years.

The following table sets forth total interest expense recognized related to the 2026 Convertible Notes:

    

 

33

Three Months Ended September 30, 

Nine Months Ended September 30, 

2023

2022

    

2023

2022

Contractual interest expense

$

1,080

$

1,081

$

3,215

$

3,217

Amortization of debt issuance costs

 

294

289

872

856

Total

$

1,374

$

1,370

$

4,087

$

4,073

Effective interest rate

 

1.9

%

1.9

%

1.9

%

1.9

%

In April 2022, under the terms of the 2026 Convertible Notes Indenture, the Company paid additional interest on the 2026 Convertible Notes at a rate equal to 0.5% per annum, for a total interest payment of approximately $2.1 million, for the period beginning September 25, 2020 and ending March 14, 2022. In September 2022, under the terms of the 2026 Convertible Notes Indenture, the Company paid additional interest on the 2026 Convertible Notes at a rate equal to 0.5% per annum, for a total interest payment of approximately $0.1 million, for the period beginning March 15, 2022 and ending April 8, 2022. These amounts are not included in the table above, but were recorded as interest expense, net within the statement of operations for the nine months ended September 30, 2022.

2022 Convertible Notes

In August 2015, the Company issued, at par value, $150.0 million aggregate principal amount of 3.00% convertible senior notes due 2022, (the “2022 Convertible Notes”). On August 15, 2022, the Company repaid the outstanding principal amount and accrued interest, totaling $152.3 million, of the 2022 Convertible Notes that was due upon maturity in accordance with the terms of the notes.

The following table sets forth total interest expense recognized related to the 2022 Convertible Notes:

 

 

Three Months Ended September 30, 

 

Nine Months Ended September 30, 

 

    

2023

    

2022

    

2023

    

2022

 

Contractual interest expense

$

$

559

$

$

2,800

Amortization of debt issuance costs

 

 

92

 

 

460

Total

$

$

651

$

$

3,260

Effective interest rate

 

%  

 

3.5

%

 

%  

 

3.5

%

10.        Commitments and contingencies

Under various agreements, the Company will be required to pay royalties and milestone payments upon the successful development and commercialization of products. The Company has entered into funding agreements with The Wellcome Trust Limited ("Wellcome Trust") for the research and development of small molecule compounds in connection with the Company’s oncology and antibacterial programs. As the Company has discontinued development under its antibacterial program, it no longer expects that milestone and royalty payments from the Company to Wellcome Trust will apply under that agreement, resulting in a change to the total amount of development and regulatory milestone payments the Company may become obligated to pay for this program. Under the oncology program funding agreement, to the extent that the Company develops and commercializes program intellectual property on a for-profit basis itself or in collaboration with a partner (provided the Company retains overall control of worldwide commercialization), the Company may become obligated to pay to Wellcome Trust development and regulatory milestone payments and single-digit royalties on sales of any research program product. The Company’s obligation to pay such royalties would continue on a country-by-country basis until the longer of the expiration of the last patent in the program intellectual property in such country covering the research program product and the expiration of market exclusivity of such product in such country. The Company made the first development milestone payment of $0.8 million to Wellcome Trust under the oncology platform funding agreement during the second quarter of 2016. During the year ended December 31, 2022, the Company incurred $2.5 million of development milestones in connection with the enrollment of patients in the registration-directed Phase 2/3 trial of unesbulin for the treatment of LMS, which is recorded in accounts payable and accrued expenses on the balance sheet and will be payable upon the earlier to occur of the first dose administered to the last patient enrolled in the study or the

34

termination of dosing of all patients in the study. Additional milestone payments of up to an aggregate of $14.5 million may become payable by the Company to Wellcome Trust under this agreement.

The Company has also entered into a collaboration agreement with the SMA Foundation. The Company is obligated to pay the SMA Foundation single-digit royalties on worldwide net product sales of any collaboration product that is successfully developed and subsequently commercialized or, with respect to collaboration products the Company outlicenses, including Evrysdi, a specified percentage of certain payments the Company receives from its licensee. Since inception, the SMA Foundation has earned $40.3 million, $35.3 million which was paid and $5.0 million which was accrued as of September 30, 2023. The Company’s obligation to make such payments would end upon the Company’s payment to the SMA Foundation of an aggregate of $52.5 million.

Pursuant to the asset purchase agreement ("Asset Purchase Agreement") between the Company and Marathon Pharmaceuticals, LLC (now known as Complete Pharma Holdings, LLC) (“Marathon”), Marathon is entitled to receive contingent payments from the Company based on annual net sales of Emflaza up to a specified aggregate maximum amount over the expected commercial life of the asset. In addition, Marathon received a $50.0 million sales-based milestone during the nine months ended September 30, 2022.

Pursuant to the Agilis Merger Agreement, Agilis equityholders were previously entitled to receive contingent consideration payments from the Company based on (i) the achievement of certain development milestones up to an aggregate maximum amount of $60.0 million, (ii) the achievement of certain regulatory approval milestones together with a milestone payment following the receipt of a priority review voucher up to an aggregate maximum amount of $535.0 million, (iii) the achievement of certain net sales milestones up to an aggregate maximum amount of $150.0 million, and (iv) a percentage of annual net sales for Friedreich ataxia and Angelman syndrome during specified terms, ranging from 2%-6%. The Company was required to pay $40.0 million of the development milestone payments upon the passing of the second anniversary of the closing of the Agilis Merger, regardless of whether the applicable milestones have been achieved.

Pursuant to the terms of the Rights Exchange Agreement, the Participating Rightholders canceled and forfeited their rights under the Agilis Merger Agreement to receive (i) $174.0 million, in the aggregate, of potential milestone payments based on the achievement of certain regulatory milestones and (ii) $37.6 million, in the aggregate, of $40.0 million in development milestone payments that would have been due upon the passing of the second anniversary of the closing of the Agilis Merger, regardless of whether the milestones are achieved.

The Rights Exchange Agreement has no effect on the Agilis Merger Agreement other than to provide for the cancellation and forfeiture of the Participating Rightholders’ rights to receive $211.6 million, in the aggregate, of the milestone payments described above. As a result, all other rights and obligations under the Agilis Merger Agreement remain in effect pursuant to their terms, including the Company’s obligation to pay up to an aggregate maximum amount of $20.0 million upon the achievement of certain development milestones (representing the remaining portion of potential development milestone payments for which rights were not canceled and forfeited pursuant to the Rights Exchange Agreement while excluding the remaining $2.4 million milestone payment that was due and paid upon the passing of the second anniversary of the closing of the Agilis Merger), up to an aggregate maximum amount of $361.0 million upon the achievement of certain regulatory milestones (representing the remaining portion of potential regulatory milestone payments for which rights were not canceled and forfeited pursuant to the Rights Exchange Agreement), up to a maximum aggregate amount of $150.0 million upon the achievement of certain net sales milestones and a percentage of annual net sales for Friedreich ataxia and Angelman syndrome during specified terms, ranging from 2% to 6%, pursuant to the terms of the Agilis Merger Agreement.

In July 2022, the European Commission approved Upstaza for the treatment of AADC deficiency for patients 18 months and older within the EEA. As a result of such approval, the Company paid the former equityholders of Agilis $50.0 million in accordance with the terms of the Agilis Merger Agreement in the year ended December 31, 2022. In May 2023, as part of the Company’s strategic portfolio prioritization, the Company decided to discontinue its preclinical and early research programs in its gene therapy platform, which included Friedreich ataxia and Angelman syndrome. As a result, the Company does not expect the milestones related to Friedreich ataxia and Angelman syndrome to be achieved. In addition, the Company does not expect to pay the 2% to 6% royalties on annual net sales related to Friedreich ataxia and Angelman syndrome. As of September 30, 2023, the remaining potential development and regulatory milestones the Company

35

expects to achieve is $31.1 million, and the remaining potential sales milestones the Company expects to achieve is $50.0 million, both of which relate solely to Upstaza.

On October 25, 2019, the Company completed the acquisition of substantially all of the assets of BioElectron Technology Corporation (“BioElectron”), a Delaware corporation, including certain compounds that the Company has begun to develop as part of its Bio-e platform, pursuant to an asset purchase agreement by and between the Company and BioElectron, dated October 1, 2019 (the “BioElectron Asset Purchase Agreement”). BioElectron was a private company with a pipeline focused on inflammatory and central nervous system (CNS) disorders. The lead program, vatiquinone, is in late stage development for CNS disorders with substantial unmet need and significant commercial opportunity that are complementary to PTC’s existing pipeline.

Subject to the terms and conditions of the BioElectron Asset Purchase Agreement, BioElectron may become entitled to receive contingent milestone payments of up to $200.0 million (in cash or in shares of the Company’s common stock, as determined by the Company) from the Company based on the achievement of certain regulatory and net sales milestones. Subject to the terms and conditions of the BioElectron Asset Purchase Agreement, BioElectron may also become entitled to receive contingent payments based on a percentage of net sales of certain products.

Subject to the terms and conditions of the Agreement and Plan of Merger, dated as of May 5, 2020 (the “Censa Merger Agreement”) by and among the Company, Hydro Merger Sub, Inc., the Company’s wholly owned, indirect subsidiary, and, solely in its capacity as the representative, agent and attorney-in-fact of the securityholders of Censa, Shareholder Representative Services LLC (such merger pursuant thereto, the “Censa Merger”), former Censa securityholders may become entitled to receive contingent payments from the Company based on (i) the achievement of certain development and regulatory milestones up to an aggregate maximum amount of $217.5 million for sepiapterin’s two most advanced programs and receipt of a priority review voucher from the FDA as set forth in the Censa Merger Agreement, (ii) $109.0 million in development and regulatory milestones for each additional indication of sepiapterin, (iii) the achievement of certain net sales milestones up to an aggregate maximum amount of $160.0 million, (iv) a percentage of annual net sales during specified terms, ranging from single to low double digits of the applicable net sales threshold amount, and (v) any sublicense fees paid to the Company in consideration of any sublicense of Censa’s intellectual property to commercialize sepiapterin, on a country-by-country basis, which contingent payment shall equal to a mid-double digit percentage of any such sublicense fees.

In February 2023, the Company completed enrollment of its Phase 3 placebo-controlled clinical trial for sepiapterin for PKU.  In connection with this event and pursuant to the Censa Merger Agreement, the Company paid a $30.0 million development milestone to the former Censa securityholders during the nine months ended September 30, 2023. The Company elected to pay this milestone in the form of shares of its common stock, less certain cash payments in accordance with the Censa Merger Agreement. Pursuant to such election, the Company issued 657,462 shares of its common stock and paid $0.4 million to the former Censa securityholders.

The Company also has the Tegsedi-Waylivra Agreement for the commercialization of Tegsedi and Waylivra, and products containing those compounds in countries in Latin America and the Caribbean. Akcea is entitled to receive royalty payments subject to certain terms set forth in the Tegsedi-Waylivra Agreement.

The Company has employment agreements with certain employees which require the funding of a specific level of payments, if certain events, such as a change in control or termination without cause, occur. Additionally, the Company has royalty payments associated with Translarna, Emflaza, and Upstaza net product revenue, payable quarterly or annually in accordance with the terms of the related agreements.

From time to time in the ordinary course of its business, the Company is subject to claims, legal proceedings and disputes. The Company is not currently aware of any material legal proceedings against it.

36

11.        Revenue recognition

Net product sales

The Company views its operations and manages its business in one operating segment.

During the three months ended September 30, 2023 and 2022, net product sales outside of the United States were $76.6 million and $79.4 million, respectively, consisting of sales of Translarna, Tegsedi, Waylivra, and Upstaza. Translarna net revenues made up $69.0 million and $76.6 million of the net product sales outside of the United States for the three months ended September 30, 2023 and 2022, respectively. During the three months ended September 30, 2023, and 2022, net product sales in the United States were $67.4 million and $54.8 million, respectively, consisting solely of sales of Emflaza. During the three months ended September 30, 2023, one country, the United States, accounted for at least 10% of the Company’s net product sales, representing $67.4 million of the net product sales. During the three months ended September 30, 2022, two countries, the United States and Russia, accounted for at least 10% of the Company’s net product sales, representing $54.8 million and $28.3 million of the net product sales, respectively. For the three months ended September 30, 2023 and 2022, the Company had a total of three and two distributors, respectively, that each accounted for over 10% of the Company’s net product sales.

During the nine months ended September 30, 2023 and 2022, net product sales outside of the United States were $318.5 million and $247.6 million, respectively, consisting of Translarna, Tegsedi, Waylivra, and Upstaza. Translarna net revenues made up $280.6 million and $232.9 million of the net product sales outside of the United States for the nine months ended September 30, 2023 and 2022, respectively. For the nine months ended September 30, 2023 and 2022, net product sales in the United States were $187.7 million and $160.1 million, respectively, consisting solely of Emflaza. During the nine months ended September 30, 2023, three countries, the United States, Russia, and Brazil, accounted for at least 10% of the Company’s net product sales, representing $187.7 million, $69.0 million, and $52.5 million of net product sales, respectively. During the nine months ended September 30, 2022, two countries, the United States and Russia, accounted for at least 10% of the Company’s net product sales, representing $160.1 million and $57.1 million of net product sales, respectively. For the nine months ended September 30, 2023 and 2022, the Company had a total of two and two distributors, respectively, that each accounted for over 10% of the Company's net product sales.

As of September 30, 2023 and December 31, 2022, the Company does not have a contract liabilities balance related to net product sales, and has not made significant changes to the judgments made in applying ASC Topic 606.

Collaboration and Royalty revenue

In November 2011, the Company and the SMA Foundation entered into the SMA License Agreement with Roche. Under the terms of the SMA License Agreement, Roche acquired an exclusive worldwide license to the Company’s SMA program.

Under the SMA License Agreement, the Company is eligible to receive additional payments from Roche if specified events are achieved with respect to each licensed product, including up to $135.0 million in research and development event milestones, up to $325.0 million in sales milestones upon achievement of specified sales events, and up to double digit royalties on worldwide annual net sales of a commercial product.

The SMA program currently has one approved product, Evrysdi, which was approved in August 2020 by the FDA for the treatment of SMA in adults and children two months and older. As of September 30, 2023, the Company does not have any remaining research and development event milestones that can be received. The remaining potential sales milestones that can be received is $250.0 million.

For the three months ended September 30, 2023, the Company did not recognize collaboration revenue related to the SMA License Agreement with Roche. For the three months ended September 30, 2022, the Company recognized $50.0 million of collaboration revenue related to the SMA License Agreement. For the nine months ended September 30, 2023, the amounts recognized for the collaboration revenue related to the SMA License Agreement with Roche were immaterial. For the nine months ended September 30, 2022, the Company recognized $50.0 million of collaboration revenue related

37

to the SMA License Agreement. In September 2022, the Company recognized a sales milestone of $50.0 million for the achievement of $750.0 million in worldwide annual net sales from Evrysdi.

In addition to research and development and sales milestones, the Company is eligible to receive up to double-digit royalties on worldwide annual net sales of a commercial product under the SMA License Agreement. For the three and nine months ended September 30, 2023, the Company has recognized $50.2 million and $117.9 million of royalty revenue related to Evrysdi, respectively. For the three and nine months ended September 30, 2022, the Company has recognized $32.9 million and $73.6 million of royalty revenue, respectively, related to Evrysdi.

Manufacturing Revenue

For the three and nine months ended September 30, 2023, the Company recognized $2.4 million and $6.7 million of manufacturing revenue, respectively, related to the production of plasmid DNA and AAV vectors for gene therapy applications for external customers. No manufacturing revenue was recognized for the three and nine months ended September 30, 2022. The Company has not made significant changes to the judgments made in applying ASC Topic 606 for the three and nine months ended September 30, 2023 and 2022.

As of September 30, 2023 and December 31, 2022, the Company has a contract liabilities balance of $1.2 million and $1.4 million, respectively, related to the production of plasmid DNA and AAV vectors for gene therapy applications for external customers, which is recorded within deferred revenue on the consolidated balance sheet. For the three-month period ended September 30, 2023, the Company did not recognize any revenue related to the amount included in the contract liability balance at the beginning of the period. For the nine-month period ended September 30, 2023, the Company recognized $1.4 million related to the amounts included in the contract liability balance at the beginning of the period.

As of September 30, 2023, the Company has contract assets of $1.4 million related to plasmid DNA and AAV production for external customers, which is recorded within prepaid expenses and other current assets on the consolidated balance sheet. The Company did not have any contract assets for the period ending December 31, 2022.

Remaining performance obligations

As of September 30, 2023 and December 31, 2022, the Company has remaining performance obligations of $1.2 million and $1.4 million, respectively, related to the production of plasmid DNA and AAV vectors for gene therapy applications for external customers. The Company expects to recognize revenue over the next one year, as the specific timing for satisfying the performance obligations is contingent upon a number of factors, including customers’ needs and schedules.

12.        Intangible assets and goodwill

Definite-lived intangibles

Definite-lived intangible assets consisted of the following at September 30, 2023 and December 31, 2022:

Ending Balance at

Reclass from

Foreign

Ending Balance at

Definite-lived

December 31,

Indefinite Lived to

currency

September 30,

intangibles assets, gross

    

2022

    

Additions

    

Definite Lived

    

Impairment

    

translation

    

2023

Emflaza

$

420,253

$

76,454

$

$

$

$

496,707

Waylivra

9,316

157

(96)

9,377

Tegsedi

7,109

4,299

(183)

11,225

Upstaza

89,550

89,550

Total definite-lived intangibles, gross

$

526,228

$

80,910

$

$

$

(279)

$

606,859

Ending Balance at

Foreign

Ending Balance at

Definite-lived

December 31,

currency

September 30,

intangibles assets, accumulated amortization

    

2022

    

Amortization

    

translation

    

2023

Emflaza

$

(266,023)

$

(138,038)

$

$

(404,061)

38

Waylivra

(2,751)

(791)

45

(3,497)

Tegsedi

(1,709)

(1,035)

36

(2,708)

Upstaza

(3,420)

(5,597)

(9,017)

Total definite-lived intangibles, accumulated amortization

$

(273,903)

$

(145,461)

$

81

$

(419,283)

Total definite-lived intangibles, net

$

187,576

Marathon is entitled to receive contingent payments from the Company based on annual net sales of Emflaza beginning in 2018, up to a specified aggregate maximum amount over the expected commercial life of the asset. In accordance with the guidance for an asset acquisition, the Company records the milestone payment when it becomes payable to Marathon and increases the cost basis for the Emflaza rights intangible asset. For the nine months ended September 30, 2023, total milestone payments of $76.5 million were recorded. These payments are being amortized over the remaining useful life of the Emflaza rights asset on a straight line basis. As of September 30, 2023, a milestone payable to Marathon of $43.9 million was recorded on the consolidated balance sheet within accounts payable and accrued expenses.

Akcea is also entitled to receive royalty payments subject to certain terms set forth in the Tegsedi-Waylivra Agreement related to sales of Waylivra and Tegsedi. In accordance with the guidance for an asset acquisition, the Company records royalty payments when they become payable to Akcea and increase the cost basis for the Waylivra and Tegsedi intangible assets. For the nine months ended September 30, 2023, royalty payments of $4.3 million and $0.2 million were recorded for Tegsedi and Waylivra, respectively. As of September 30, 2023, a royalty payable of $0.9 million and $0.2 million for Tegsedi and Waylivra, respectively, was recorded on the consolidated balance sheet within accounts payable and accrued expenses.

For the three months ended September 30, 2023 and 2022, the Company recognized amortization expense of $58.6 million and $31.0 million, respectively, related to the Emflaza rights, Upstaza, Waylivra, and Tegsedi intangible assets. For the nine months ended September 30, 2023 and 2022, the Company recognized amortization expense of $145.5 million and $80.8 million, respectively, related to the Emflaza rights, Upstaza, Waylivra, and Tegsedi intangible assets. The estimated future amortization of the Emflaza rights, Upstaza, Waylivra, and Tegsedi intangible assets is expected to be as follows:

    

As of September 30, 2023

2023

$

58,640

2024

 

46,557

2025

 

10,041

2026

 

10,041

2027 and thereafter

 

62,297

Total

$

187,576

The weighted average remaining amortization period of the definite-lived intangibles as of September 30, 2023 is 5.3 years.

Indefinite-lived intangibles

Indefinite-lived intangible assets consisted of the following at September 30, 2023 and December 31, 2022:

Ending Balance at

Reclass from

Foreign

Ending Balance at

Indefinite-lived

December 31,

Indefinite Lived to

currency

September 30,

intangibles assets

    

2022

    

Additions

    

Definite Lived

    

Impairment

    

translation

    

2023

Upstaza

$

235,766

$

$

$

$

$

235,766

PTC-FA

112,500

(112,500)

PTC-AS

105,300

(105,300)

Total indefinite-lived intangibles

$

453,566

$

$

$

(217,800)

$

$

235,766

Total intangible assets, net

$

423,342

39

In connection with the acquisition of the Company’s gene therapy platform from Agilis, the Company acquired rights to Upstaza, for the treatment of AADC deficiency. AADC deficiency is a rare CNS disorder arising from reductions in the enzyme AADC that result from mutations in the dopa decarboxylase gene. The gene therapy platform also includes PTC-FA, an asset targeting Friedreich ataxia, a rare and life-shortening neurodegenerative disease caused by a single defect in the FXN gene which causes reduced production of the frataxin protein. Additionally, the gene therapy platform includes two other programs targeting CNS disorders, including PTC-AS for Angelman syndrome, a rare, genetic, neurological disorder characterized by severe developmental delays.

In accordance with the acquisition method of accounting, the Company allocated the acquisition cost for the Agilis Merger to the underlying assets acquired and liabilities assumed, based upon the estimated fair values of those assets and liabilities at the date of acquisition. The Company classified the fair value of the acquired IPR&D as indefinite lived intangible assets until the successful completion or abandonment of the associated research and development efforts. As of December 31, 2022, the value allocated to the indefinite lived intangible assets was $453.6 million.

In May 2023, as part of the Company’s strategic portfolio prioritization, the Company decided to discontinue its preclinical and early research programs in its gene therapy platform, which included PTC-FA and PTC-AS. As a result, the Company determined that the PTC-FA and PTC-AS indefinite-lived intangible assets were fully impaired and recorded impairment expense of $217.8 million during the nine month period ended September 30, 2023, which is recorded as intangible asset impairment in the statement of operations. As of September 30, 2023, the remaining indefinite lived intangible asset balance is $235.8 million, consisting solely of Upstaza, which the Company plans to continue to develop and commercialize.

Goodwill

As a result of the Agilis Merger on August 23, 2018, the Company recorded $82.3 million of goodwill. As of September 30, 2023, there have been no changes to the balance of goodwill since the date of the Agilis Merger. Accordingly, the goodwill balance as of September 30, 2023 is $82.3 million.

13.        Subsequent events

Royalty Purchase Agreement

On October 18, 2023, the Company, Royalty Pharma Investments 2019 ICAV (“Royalty Pharma”), and, for the limited purposes set forth in the agreement, Royalty Pharma plc, entered into an Amended and Restated Royalty Purchase Agreement (the “A&R Royalty Purchase Agreement”), which amends and restates in its entirety the Royalty Purchase Agreement.  Pursuant to the A&R Royalty Purchase Agreement, the Company has sold or agreed to sell to Royalty Pharma certain portions of the Company’s remaining Royalty on worldwide net sales of Evrysdi and any other product (the “Products”) developed pursuant to the SMA License Agreement (all such retained Royalty rights of the Company, the “Retained Royalty Rights,” and all such Royalty rights that are sold to Royalty Pharma pursuant to the A&R Royalty Purchase Agreement, the “A&R Assigned Royalty Rights”). At closing, Royalty Pharma paid the Company $1.0 billion in cash consideration for 38.0447% of the Company’s Retained Royalty Rights (which is in addition to the 42.9330% assigned to Royalty Pharma in connection with the Royalty Purchase Agreement, for a total of 80.9777% of the total Royalty) until such time as Royalty Pharma has received payments in respect of the A&R Assigned Royalty Rights equal to $1.3 billion in the aggregate, and thereafter 66.6667% of the total Royalty. In addition, the Company may sell to Royalty Pharma the remainder of the Company’s Retained Royalty Rights in exchange for an aggregate of $500.0 million in additional cash consideration after the closing of the A&R Royalty Purchase Agreement, less royalties received in respect of the Retained Royalty Rights put to Royalty Pharma, which will be payable by Royalty Pharma pursuant to five put options held by the Company that are exercisable at the Company’s option between January 1, 2024 and December 31, 2025. If the Company exercises two or fewer of the put options, Royalty Pharma may exercise a call option during the period from and after January 1, 2026 until and including March 31, 2026 for up to 50% of the remainder of the Company’s Retained Royalty Rights less amounts exercised by the Company via its put options at a purchase price that is proportional to the purchase price of the Company’s unexercised put options. Royalty Pharma’s exercise of the call option would result in Royalty Pharma owning 90.4888% of the total Royalty until such time as Royalty Pharma has received payments in respect of the A&R Assigned Royalty Rights equal to $1.3 billion in the aggregate, and thereafter 83.3333% of the total Royalty. The Company is evaluating the accounting impact of the A&R Royalty Purchase Agreement.

40

Under the A&R Royalty Purchase Agreement, and in connection with its sale of the A&R Assigned Royalty Rights, the Company has agreed to specified negative and affirmative covenants with respect to the exercise of its rights under the SMA License Agreement, including the Company’s right to amend, modify, assign or terminate the SMA License Agreement.  Subject to certain customary exceptions, the Company has agreed not to grant a security interest in its interest in the SMA License Agreement, the Products or the patent rights that cover the Products. The A&R Royalty Purchase Agreement also contains representations and warranties, covenants and other provisions, including information rights and confidentiality obligations, customary for transactions of this nature.

The A&R Royalty Purchase Agreement will terminate 60 days following the date on which Roche is no longer obligated to make any payments of the Royalty pursuant to the License Agreement.

Senior Secured Term Loan Termination

On October 19, 2023, the Company terminated the Blackstone Credit Agreement. In connection with the termination of the Blackstone Credit Agreement, the Company repaid outstanding principal and accrued interest thereunder totaling $302.1 million and paid an additional $82.1 million in prepayment premiums, expenses and other exit fees. All liens and security interests securing the loans made pursuant to the Blackstone Credit Agreement were released upon termination.

41

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

The following discussion and analysis is meant to provide material information relevant to an assessment of the financial condition and results of operations of our company, including an evaluation of the amounts and certainty of cash flows from operations and from outside resources, so as to allow investors to better view our company from management’s perspective. The following discussion of our financial condition and results of operations should be read in conjunction with our financial statements and the notes to those financial statements appearing elsewhere in this Quarterly Report on Form 10-Q and the audited consolidated financial statements and notes thereto and management’s discussion and analysis of financial condition and results of operations for the year ended December 31, 2022 included in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on February 21, 2023, as amended, or our 2022 Annual Report. This discussion contains forward-looking statements that involve significant risks and uncertainties. As a result of many factors, such as those set forth in Part II, Item 1A. (Risk Factors) of this Quarterly Report on Form 10-Q and Part I, Item 1A. (Risk Factors) of our 2022 Annual Report, our actual results may differ materially from those anticipated in these forward-looking statements.

Our Company

We are a science-driven global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. Our ability to innovate to identify new therapies and to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines. Our mission is to provide access to best-in-class treatments for patients who have little to no treatment options. Our strategy is to leverage our strong scientific and clinical expertise and global commercial infrastructure to bring therapies to patients.  We believe that this allows us to maximize value for all of our stakeholders. We have a portfolio pipeline that includes several commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology, metabolism and oncology.

Corporate Updates

Royalty Purchase Agreement

In October 2023, we entered into an Amended and Restated Royalty Purchase Agreement, or the A&R Royalty Purchase Agreement with Royalty Pharma Investments 2019 ICAV, or Royalty Pharma, and, for the limited purposes set forth in the agreement, Royalty Pharma plc which amends and restates in its entirety that certain Royalty Purchase Agreement dated as of July 17, 2020, or the Original Royalty Purchase Agreement.  Pursuant to the A&R Royalty Purchase Agreement, we have sold or agreed to sell to Royalty Pharma certain portions of our remaining retained right, title and interest in and to our right to receive sales-based royalty payments, or the Royalty, on worldwide net sales of Evrysdi and any other product developed pursuant to the License and Collaboration Agreement, or the SMA License Agreement, dated as of November 23, 2011, by and among us, F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., together with F. Hoffman-La Roche Ltd, Roche, and, for the limited purposes set forth therein, the Spinal Muscular Atrophy Foundation, or the SMA Foundation, under the spinal muscular atrophy, or SMA, program (all such Royalty rights retained by us, are referred to as the Retained Royalty Rights, and all such Royalty rights that are sold to Royalty Pharma pursuant to the A&R Royalty Purchase Agreement, are referred to as the A&R Assigned Royalty Rights).  At closing, Royalty Pharma paid us $1.0 billion in cash consideration for 38.0447% of our Retained Royalty Rights (which is in addition to the 42.9330% assigned to Royalty Pharma in connection with the Original Royalty Purchase Agreement, for a total of 80.9777% of the total Royalty) until such time as Royalty Pharma has received payments in respect of the A&R Assigned Royalty Rights equal to $1.3 billion in the aggregate, and thereafter 66.6667% of the total Royalty.

Blackstone Credit Agreement Termination

42

In October 2023, we terminated the Credit Agreement, dated October 27, 2022, by and among us and certain of our subsidiaries from time to time party thereto, as guarantors, or, collectively with us, the Loan Parties, funds and other affiliated entities advised or managed by Blackstone Life Sciences and Blackstone Credit, or collectively, Blackstone, as lenders, together with their permitted assignees, the Lenders, and Wilmington Trust, National Association, as the administrative agent for the Lenders, or the Blackstone Credit Agreement. In connection with the termination of the Blackstone Credit Agreement, we repaid outstanding principal and accrued interest thereunder totaling $302.1 million and paid an additional $82.1 million in prepayment premiums, expenses and other exit fees. All liens and security interests securing the loans made pursuant to the Blackstone Credit Agreement were released upon termination.

Global Commercial Footprint

Global DMD Franchise

We have two products, Translarna™ (ataluren) and Emflaza® (deflazacort), for the treatment of Duchenne muscular dystrophy, or DMD, a rare, life threatening disorder. Translarna has marketing authorization in the European Economic Area, or EEA, for the treatment of nonsense mutation Duchenne muscular dystrophy, or nmDMD, in ambulatory patients aged two years and older and in Russia for the treatment of nmDMD in patients aged two years and older. Translarna also has marketing authorization in Brazil for the treatment of nmDMD in ambulatory patients two years and older and for continued treatment of patients that become non-ambulatory. In July 2020, the European Commission, or the EC, approved the removal of the statement “efficacy has not been demonstrated in non-ambulatory patients” from the indication statement for Translarna. During the quarter ended September 30, 2023, we recognized $69.0 million in net sales from Translarna. We hold worldwide commercialization rights to Translarna for all indications in all territories. Emflaza is approved in the United States for the treatment of DMD in patients two years and older. During the quarter ended September 30, 2023, we recognized $67.4 million in net sales from Emflaza.

Our marketing authorization for Translarna in the EEA is subject to annual review and renewal by the EC following reassessment by the European Medicines Agency, or EMA, of the benefit-risk balance of the authorization, which we refer to as the annual EMA reassessment. In September 2022, we submitted a Type II variation to the EMA to support conversion of the conditional marketing authorization for Translarna to a standard marketing authorization, which included a report on the placebo-controlled trial of Study 041 and data from the open-label extension as further described below. In February 2023, we also submitted an annual marketing authorization renewal request to the EMA. In September 2023, the Committee for Medicinal Products for Human Use, or CHMP, gave a negative opinion on the conversion of the conditional marketing authorization to full marketing authorization of Translarna for the treatment of nmDMD and a negative opinion on the renewal of the existing conditional marketing authorization of Translarna for the treatment of nmDMD. We have requested re-examination of the CHMP opinion regarding the renewal of the existing conditional marketing authorization. In re-examination, we intend to address concerns raised during the previous review process on the benefit demonstrated in Translarna clinical trials and regarding the robustness of the Strategic Targeting of Registries and International Database of Excellence, or STRIDE, real world registry. In accordance with EMA guidelines, we expect the CHMP opinion following the re-examination process to occur in late January 2024, with EC ratification of the opinion within the following 67 days.

The conditional marketing authorization is further subject to a specific obligation to conduct and submit the results of an 18-month, placebo-controlled trial, followed by an 18-month open-label extension, which we refer to together as Study 041. In June 2022, we announced top-line results from the placebo-controlled trial of Study 041. Within the placebo-controlled trial, Translarna showed a statistically significant treatment benefit across the entire intent to treat population as assessed by the 6-minute walk test, assessing ambulation and endurance, and in lower-limb muscle function as assessed by the North Star Ambulatory Assessment, a functional scale designed for boys affected by DMD. Additionally, Translarna showed a statistically significant treatment benefit across the intent to treat population within the 10-meter run/walk and 4-stair stair climb, each assessing ambulation and burst activity, while also showing a positive trend in the 4-stair stair descend although not statistically significant. Within the primary analysis group, Translarna demonstrated a positive trend across all endpoints, however, statistical significance was not achieved. Translarna was also well tolerated.

Each country, including each member state of the EEA, has its own pricing and reimbursement regulations. In order to commence commercial sale of product pursuant to our Translarna marketing authorization in any particular country in the

43

EEA, we must finalize pricing and reimbursement negotiations with the applicable government body in such country. As a result, our commercial launch will continue to be on a country-by-country basis. We also have made, and expect to continue to make, product available under early access programs, or EAP programs, both in countries in the EEA and other territories. Our ability to negotiate, secure and maintain reimbursement for product under commercial and EAP programs can be subject to challenge in any particular country and can also be affected by political, economic and regulatory developments in such country.

There is substantial risk that if the EC ratifies the CHMP’s negative opinion, we are otherwise unable to renew our EEA marketing authorization during any annual renewal cycle, our product label is materially restricted, or Study 041 does not provide the data necessary to maintain our marketing authorization, we would lose all, or a significant portion of, our ability to generate revenue from sales of Translarna in the EEA and other territories. For more information regarding the risks associated with the a potential EC ratification of the CHMP’s negative opinion on Translarna’s marketing authorization, see Item 1A. Risk Factors, “We may be unable to continue to commercialize Translarna for nonsense mutation Duchenne muscular dystrophy in the European Economic Area if the Committee for Medicinal Products for Human Use of the European Medicines Agency does not reverse its negative opinion on the renewal of the existing conditional authorization for Translarna.

Translarna is an investigational new drug in the United States. During the first quarter of 2017, we filed a New Drug Application, or NDA, for Translarna for the treatment of nmDMD over protest with the United States Food and Drug Administration, or FDA. In October 2017, the Office of Drug Evaluation I of the FDA issued a Complete Response Letter for the NDA, stating that it was unable to approve the application in its current form. In response, we filed a formal dispute resolution request with the Office of New Drugs of the FDA. In February 2018, the Office of New Drugs of the FDA denied our appeal of the Complete Response Letter. In its response, the Office of New Drugs recommended a possible path forward for the ataluren NDA submission based on the accelerated approval pathway. This would involve a re-submission of an NDA containing the current data on effectiveness of ataluren with new data to be generated on dystrophin production in nmDMD patients’ muscles. We followed the FDA’s recommendation and collected, using newer technologies via procedures and methods that we designed, such dystrophin data in a new study, Study 045, and announced the results of Study 045 in February 2021. Study 045 did not meet its pre-specified primary endpoint. In June 2022, we announced top-line results from the placebo-controlled trial of Study 041. Following this announcement, we submitted a meeting request to the FDA to gain clarity on the regulatory pathway for a potential re-submission of an NDA for Translarna. The FDA provided initial written feedback that Study 041 does not provide substantial evidence of effectiveness to support NDA re-submission. We then had an informal meeting with the FDA, during which we discussed the potential path to an NDA re-submission for Translarna. Based on the meeting discussion, we have scheduled an additional Type C meeting with the FDA to review the totality of data collected to date, including dystrophin and other mechanistic data as well as additional analyses that could support the benefit of Translarna.

UpstazaTM (eladocagene exuparvovec)

We have developed Upstaza, a gene therapy used for the treatment of Aromatic L-Amino Decarboxylase, or AADC, deficiency, a rare central nervous system, or CNS, disorder arising from reductions in the enzyme AADC that results from mutations in the dopa decarboxylase gene. In July 2022, the EC approved Upstaza for the treatment of AADC deficiency for patients 18 months and older within the EEA. In November 2022, the Medicines and Healthcare Products Regulatory Agency approved Upstaza for the treatment of AADC deficiency for patients 18 months and older within the United Kingdom. We are also preparing a biologics license application, or BLA, for Upstaza for the treatment of AADC deficiency in the United States. In October 2022, we held a Type C meeting with the FDA to discuss the details of a potential submission package for Upstaza. At that meeting, the FDA asked for additional bioanalytical data in support of comparability between the drug product used in the clinical studies and the commercial drug product. We completed these analyses and provided the results to the FDA for review. The FDA stated that the data that we provided were still not sufficient. However, the FDA also said that the available data from the ongoing clinical study in the United States assessing the safety of the drug delivery cannula for Upstaza could be used to support a BLA for accelerated approval based on biomarker data demonstrating a treatment-related increase in de novo dopamine production. At the FDA’s suggestion, we have scheduled a pre-BLA meeting for December 2023 and, pending the outcome of that meeting, we expect to submit a BLA shortly thereafter.

44

Tegsedi® (inotersen) and Waylivra™ (volanesorsen)

We hold the rights for the commercialization of Tegsedi and Waylivra for the treatment of rare diseases in countries in Latin America and the Caribbean pursuant to a Collaboration and License Agreement, or the Tegsedi-Waylivra Agreement, dated August 1, 2018, by and between us and Akcea Therapeutics, Inc., or Akcea, a subsidiary of Ionis Pharmaceuticals, Inc. Tegsedi has received marketing authorization in the United States, European Union, or EU, and Brazil for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis, or hATTR amyloidosis. We began to make commercial sales of Tegsedi for the treatment of hATTR amyloidosis in Brazil in the second quarter of 2022 and we continue to make Tegsedi available in certain other countries within Latin America and the Caribbean through EAP programs. In August 2021, ANVISA, the Brazilian health regulatory authority, approved Waylivra as the first treatment for familial chylomicronemia syndrome, or FCS, in Brazil and we began to make commercial sales of Waylivra in Brazil in the third quarter of 2022 while continuing to make Waylivra available in certain other countries within Latin America and the Caribbean through EAP programs. In December 2022, ANVISA approved Waylivra for the treatment of familial partial lipodystrophy, or FPL. Waylivra has also received marketing authorization in the EU for the treatment of FCS.

Evrysdi® (risdiplam)

We also have an SMA collaboration with Roche and the SMA Foundation. The SMA program has one approved product, Evrysdi® (risdiplam), which was approved by the FDA in August 2020 for the treatment of SMA in adults and children two months and older and by the EC in March 2021 for the treatment of 5q SMA in patients two months and older with a clinical diagnosis of SMA Type 1, Type 2 or Type 3 or with one to four SMN2 copies. Evrysdi also received marketing authorization for the treatment of SMA in Brazil in October 2020 and Japan in June 2021. In May 2022, the FDA approved a label expansion for Evrysdi to include infants under two months old with SMA. In August 2023, the EC approved an extension of the Evrysdi marketing authorization to include infants under two months old in the EU.

Diversified Development Pipeline

Splicing Platform

In addition to our SMA program, our splicing platform also includes PTC518, which is being developed for the treatment of Huntington’s disease, or HD. We announced the results from our Phase 1 study of PTC518 in healthy volunteers in September 2021 demonstrating dose-dependent lowering of huntingtin messenger ribonucleic acid and protein levels, that PTC518 efficiently crosses blood brain barrier at significant levels and that PTC518 was well tolerated.  We initiated a Phase 2 study of PTC518 for the treatment of HD in the first quarter of 2022, which consists of an initial 12-week placebo-controlled phase focused on safety, pharmacology and pharmacodynamic effects followed by a nine-month placebo-controlled phase focused on PTC518 biomarker effect. In June 2023, we announced interim data from the 12-week placebo-controlled phase. The study demonstrated dose-dependent lowering of Huntingtin, or HTT, protein levels in peripheral blood cells, reaching an approximate mean 30% reduction in mutant HTT levels at the 10mg dose level. In addition, PTC518 exposure in the cerebrospinal fluid was consistent with or higher than plasma unbound drug levels. Furthermore, PTC518 was well tolerated with no treatment-related serious adverse events. We expect the next data update from the Phase 2 study of PTC518 for the treatment of HD in the first half of 2024. In the Phase 2 study, enrollment outside of the United States remains active and ongoing while enrollment within the United States is paused as the FDA requested additional data to allow the Phase 2 study to proceed. We had a Type A meeting with the FDA to review the clinical safety data needed to enable resumption of enrollment in the United States. At that meeting, the FDA stated that the existing three-month safety data could support 12-week dosing and that six months of clinical safety data could support dosing in the 12-month Phase 2 study.

Metabolic Platform

The most advanced molecule in our metabolic platform is sepiapterin, a precursor to intracellular tetrahydrobiopterin, which is a critical enzymatic cofactor involved in metabolism and synthesis of numerous metabolic products, for orphan diseases. In May 2023, we announced that the primary endpoint was achieved in our registration-directed Phase 3 trial for sepiapterin for phenylketonuria, or PKU. The primary endpoint of the study was the achievement of statistically-significant

45

reduction in blood Phe level. The primary analysis population included those patients who have a greater than 30% reduction in blood Phe levels during the Part 1 run-in phase of the trial. Sepiapterin demonstrated Phe level reduction of approximately 63% in the overall primary analysis population and Phe level reduction of approximately 69% in the subset for classical PKU patients. Additionally, sepiapterin was well tolerated with no serious adverse events. Following the placebo-controlled study, patients were eligible to enroll in a long-term open-label study, which is still ongoing and will evaluate long-term safety, durability and Phe tolerance. We participated in a pre-NDA meeting with the FDA in the third quarter of 2023. At that meeting, the FDA stated that the sepiapterin clinical safety and efficacy data supported NDA submission for the treatment of pediatric and adult PKU patients. However, the FDA has requested that we complete a 26-week nonclinical mouse study to assess sepiapterin carcinogenicity potential prior to NDA submission. This nonclinical study was not initially required when we acquired sepiapterin, as the NDA submission was planned under the Section 505(b)(2) pathway. With PTC’s decision to file under the Section 505(b)(1) pathway, the 26-week study is considered a required NDA component needed to inform labeling and is typically completed prior to submission. We expect to submit an NDA to the FDA for sepiapterin for the treatment of PKU by the end of the third quarter of 2024 and we intend to discuss with the FDA the potential for an earlier submission if we are permitted to submit the 26-week mouse study report during the review process of the NDA. Additionally, we expect to submit a marketing authorization application, or MAA, to the EMA for sepiapterin for the treatment of PKU in the EEA in the first half of 2024.

Bio-e Platform

Our Bio-e platform consists of small molecule compounds that target oxidoreductase enzymes that regulate oxidative stress and inflammatory pathways central to the pathology of a number of CNS diseases. The two most advanced molecules in our Bio-e platform are vatiquinone and utreloxastat.  We announced topline results from a registration-directed Phase 3 trial of vatiquinone in children and young adults with Friedreich ataxia in May 2023. While the study did not meet its primary endpoint of statistically significant change in modified Friedreich Ataxia Rating Scale, or mFARS, score at 72 weeks in the primary analysis population, vatiquinone treatment did demonstrate significant benefit on key disease subscales and secondary endpoints. In addition, in the population of subjects that completed the study protocol, significance was reached in the mFARS endpoint and several secondary endpoints, including the upright stability subscale. Furthermore, vatiquinone was well tolerated. We participated in a Type C written response only meeting with the FDA in the third quarter of 2023 to discuss the potential for an NDA submission for vatiquinone for the treatment of Friedreich ataxia. In their written response, the FDA stated that while they see the value of upright stability as a clinically meaningful endpoint, they believed a confirmatory study would likely be needed to support NDA submission. We have requested a follow-up live meeting to address the issues raised by the FDA. Additionally, we are participating in a scientific advice procedure with the EMA to determine if the data from the registration-directed Phase 3 trial of vatiquinone in children and young adults with Friedreich ataxia could support a conditional MAA in the EEA. In the third quarter of 2021, we completed a Phase 1 trial in healthy volunteers to evaluate the safety and pharmacology of utreloxastat. Utreloxastat was found to be well-tolerated with no reported serious adverse events while demonstrating predictable pharmacology. We initiated a Phase 2 trial of utreloxastat for amyotrophic lateral sclerosis in the first quarter of 2022 and enrollment is ongoing.

Oncology Platform

Unesbulin is our most advanced oncology agent. We completed our Phase 1 trials evaluating unesbulin in leiomyosarcoma, or LMS, and diffuse intrinsic pontine glioma, or DIPG, in the fourth quarter of 2021. We initiated a registration-directed Phase 2/3 trial of unesbulin for the treatment of LMS in the first quarter of 2022 and enrollment is ongoing. We are evaluating our plans for a potential initiation of a registration-directed Phase 2/3 trial of unesbulin for the treatment of DIPG.

Multi-Platform Discovery

In addition, we have a pipeline of product candidates and discovery programs that are in early clinical, pre-clinical and research and development stages focused on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology.

46

In September 2023, we announced further strategic prioritization following the continued review of our portfolio that we began in May 2023. In connection with the strategic prioritization, we committed to a reduction in workforce of approximately 25%, which will primarily affect employees in the United States, including those employees involved in early-stage research and gene therapy manufacturing and associated selling, general and administrative functions. We plan to substantially complete the reduction in workforce by January 15, 2024.

COVID 19 Impact

The global pandemic caused by a strain of novel coronavirus, COVID-19, has impacted the timing of certain of our clinical trials and regulatory submissions as well as other aspects of our business operations. We cannot be certain what the overall impact of the COVID-19 pandemic will be on our business and it has the potential to materially adversely affect our business, financial condition, results of operations, and prospects. For additional information, see “Item 1A. Risk Factors - We face risks related to health epidemics and other widespread outbreaks of contagious disease, which have previously, and may once again, delay our ability to complete our ongoing clinical trials and initiate future clinical trials, disrupt regulatory activities and have other adverse effects on our business and operations, including the novel coronavirus (COVID 19) pandemic, which disrupted, and may continue to disrupt, our operations and may significantly impact our operating results. In addition, the COVID 19 pandemic has caused substantial disruption in the financial markets and economies, which could result in adverse effects on our business and operations.” in our 2022 Annual Report.

Funding

The success of our products and any other product candidates we may develop, depends largely on obtaining and maintaining reimbursement from governments and third-party insurers. Our revenues are primarily generated from sales of Translarna for the treatment of nmDMD in countries where we were able to obtain acceptable commercial pricing and reimbursement terms and in select countries where we are permitted to distribute Translarna under our EAP programs and from sales of Emflaza for the treatment of DMD in the United States. We have also recognized revenue from sales of Upstaza for the treatment of AADC deficiency in the EEA and have recognized revenue associated with milestone and royalty payments from Roche pursuant to the SMA License Agreement.

To date, we have financed our operations primarily through our offering of  the 1.50% convertible senior notes due 2026, or the 2026 Convertible Notes, our public offerings of common stock in February 2014, in October 2014, in April 2018, in January 2019, and in September 2019, the common stock issued in our “at the marketing offering”, our initial public offering of common stock in June 2013, proceeds from the A&R Royalty Purchase Agreement, private placements of our convertible preferred stock and common stock, collaborations, bank and institutional lender debt, other convertible debt, grant funding and clinical trial support from governmental and philanthropic organizations and patient advocacy groups in the disease areas addressed by our product candidates. We have relied on revenue generated from net sales of Translarna for the treatment of nmDMD in territories outside of the United States since 2014, Emflaza for the treatment of DMD in the United States since 2017 and Upstaza for the treatment of AADC deficiency in the EEA since 2022. We have also relied on revenue associated with milestone and royalty payments from Roche pursuant to the SMA License Agreement, under our SMA program.

In October 2023, we entered into the A&R Royalty Purchase Agreement.  At closing, Royalty Pharma paid us $1.0 billion in cash consideration for 38.0447% of our Retained Royalty Rights (which is in addition to the Original Assigned Royalty Rights (as defined below), for a total of 80.9777% of the total Royalty) until such time as Royalty Pharma has received payments in respect of the A&R Assigned Royalty Rights equal to $1.3 billion in the aggregate, and thereafter 66.6667% of the total Royalty.  In addition, we may sell to Royalty Pharma the remainder of our Retained Royalty Rights in exchange for an aggregate of $500.0 million in additional cash consideration after the closing of the A&R Royalty Purchase Agreement, less royalties received in respect of the Retained Royalty Rights put to Royalty Pharma, which will be payable by Royalty Pharma pursuant to five put options held by us that are exercisable at our option between January 1, 2024 and December 31, 2025.  If we exercise two or fewer of the put options, Royalty Pharma may exercise a call option during the period from and after January 1, 2026 until and including March 31, 2026 for up to 50% of the remainder of our Retained Royalty Rights less amounts exercised by us via our put options at a purchase price that is proportional to the purchase price of our unexercised put options. Royalty Pharma’s exercise of the call option would result in Royalty Pharma owning

47

90.4888% of the total Royalty until such time as Royalty Pharma has received payments in respect of the A&R Assigned Royalty Rights equal to $1.3 billion in the aggregate, and thereafter 83.3333% of the total Royalty.

In October 2022, we entered into the Blackstone Credit Agreement for fundings of up to $950.0 million consisting of a committed loan facility consisting of a senior secured term loan facility funded on October 27, 2022, or the Closing Date, in the aggregate principal amount of $300.0 million, and a delayed draw term loan facility of up to $150.0 million to be funded at our request within 18 months of the Closing Date subject to specified conditions, and further contemplating the potential for up to $500.0 million of additional financing, to the extent that we request such additional financing and subject to the Lenders’ agreement to provide such additional financing and to mutual agreement on terms. In October 2023, we terminated the Blackstone Credit Agreement. In connection with the termination of the Blackstone Credit Agreement, we repaid outstanding principal and accrued interest thereunder totaling $302.1 million and paid an additional $82.1 million in prepayment premiums, expenses and other exit fees. All liens and security interests securing the loans made pursuant to the Blackstone Credit Agreement were released upon termination.

The 2026 Convertible Notes consist of $287.5 million aggregate principal amount of 1.50% convertible senior notes due 2026. The 2026 Convertible Notes bear cash interest at a rate of 1.50% per year, payable semi-annually on March 15 and September 15 of each year, beginning on March 15, 2020. The 2026 Convertible Notes will mature on September 15, 2026, unless earlier repurchased or converted. We received net proceeds of $279.3 million after deducting the initial purchasers’ discounts and commissions and the offering expenses payable by us.

In August 2019, we entered into an At the Market Offering Sales Agreement, or the Sales Agreement, with Cantor Fitzgerald and RBC Capital Markets, LLC, or together, the Sales Agents, pursuant to which, we may offer and sell shares of our common stock, having an aggregate offering price of up to $125.0 million from time to time through the Sales Agents by any method that is deemed to be an “at the market offering” as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended, or the Securities Act. During the three and nine months ended September 30, 2023, we did not issue or sell any shares of common stock pursuant to the Sales Agreement. The remaining shares of our common stock available to be issued and sold, under the Sales Agreement, have an aggregate offering price of up to $93.0 million as of September 30, 2023.

As of September 30, 2023, we had an accumulated deficit of $3,127.8 million. We had a net loss of $470.8 million and $388.1 million for the nine months ended September 30, 2023 and 2022, respectively.

We anticipate that our expenses will continue to increase in connection with our commercialization efforts in the United States, the EEA, Latin America and other territories, including the expansion of our infrastructure and corresponding sales and marketing, legal and regulatory and distribution and manufacturing expenses. In addition to the foregoing, we expect to continue to incur ongoing research and development expenses for our products and product candidates, including our splicing, metabolic, Bio-e and oncology programs as well as studies in our products for maintaining authorizations, including Study 041, label extensions and additional indications. In addition, we may incur substantial costs in connection with our efforts to advance our regulatory submissions. For example, in response to the CHMP’s negative opinion for Translarna for the treatment of nmDMD, we have submitted a request for re-examination to the EMA. We continue to seek marketing authorization for Translarna for the treatment of nmDMD in territories that we do not currently have marketing authorization in. We are preparing and anticipate submitting a BLA to the FDA for Upstaza for the treatment of AADC deficiency in the United States shortly after our pre-BLA meeting that is scheduled for December 2023. We also expect to submit an NDA to the FDA for sepiapterin for the treatment of PKU by the end of the third quarter of 2024 and we expect to submit an MAA to the EMA for sepiapterin for the treatment of PKU in the first half of 2024. These efforts may significantly impact the timing and extent of our commercialization expenses.

We may seek to expand and diversify our product pipeline through opportunistically in-licensing or acquiring the rights to products, product candidates or technologies and we may incur expenses, including with respect to transaction costs, subsequent development costs or any upfront, milestone or other payments or other financial obligations associated with any such transaction, which would increase our future capital requirements.

We expect to pay the former equityholders of Agilis Biotherapeutics, Inc., or Agilis, $20.0 million in regulatory milestone payments upon the acceptance for filing by the FDA of a BLA for Upstaza for the treatment of AADC deficiency pursuant

48

to the Agreement and Plan of Merger, dated as of July 19, 2018, or the Agilis Merger Agreement, by and among us, Agility Merger Sub, Inc., a Delaware corporation and our wholly owned, indirect subsidiary, Agilis and, solely in its capacity as the representative, agent and attorney-in-fact of the equityholders of Agilis, Shareholder Representative Services LLC. We expect to submit a BLA for Upstaza to the FDA shortly after our pre-BLA meeting that is scheduled for December 2023. We also expect to make payments to the former Censa Pharmaceuticals, Inc., or Censa, securityholders of $65.0 million in the aggregate in cash upon the potential achievement in 2024 of development and regulatory milestones relating to sepiapterin pursuant to the Agreement and Plan of Merger, dated as of May 5, 2020, or the Censa Merger Agreement, by and among us, Hydro Merger Sub, Inc., our wholly owned, indirect subsidiary, Censa and, solely in its capacity as the representative, agent and attorney-in-fact of the securityholders of Censa, Shareholder Representative Services LLC.

We also have certain significant contractual obligations and commercial commitments that require funding and we have disclosed these items under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations-Funding Obligations” in our 2022 Annual Report. There were no material changes to these obligations and commitments during the period ended September 30, 2023. Furthermore, since we are a public company, we have incurred and expect to continue to incur additional costs associated with operating as such including significant legal, accounting, investor relations and other expenses.

We have never been profitable and we will need to generate significant revenues to achieve and sustain profitability, and we may never do so. Accordingly, we may need to obtain substantial additional funding in connection with our continuing operations. Adequate additional financing may not be available to us on acceptable terms, or at all. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or eliminate our research and development programs or our commercialization efforts.

Financial operations overview

Revenues

Net product revenues. To date, our net product revenues have consisted primarily of sales of Translarna for the treatment of nmDMD in territories outside of the United States and sales of Emflaza for the treatment of DMD in the United States. We recognize revenue when performance obligations with customers have been satisfied. Our performance obligations are to provide products based on customer orders from distributors, hospitals, specialty pharmacies or retail pharmacies. The performance obligations are satisfied at a point in time when our customer obtains control of the product, which is typically upon delivery. We invoice customers after the products have been delivered and invoice payments are generally due within 30 to 90 days of invoice date. We determine the transaction price based on fixed consideration in its contractual agreements. Contract liabilities arise in certain circumstances when consideration is due for goods not yet provided. As we have identified only one distinct performance obligation, the transaction price is allocated entirely to the product sale. In determining the transaction price, a significant financing component does not exist since the timing from when we deliver product to when the customers pay for the product is typically less than one year. Customers in certain countries pay in advance of product delivery. In those instances, payment and delivery typically occur in the same month.

We record product sales net of any variable consideration, which includes discounts, allowances, rebates related to Medicaid and other government pricing programs, and distribution fees. We use the expected value or most likely amount method when estimating variable consideration, unless discount or rebate terms are specified within contracts. The identified variable consideration is recorded as a reduction of revenue at the time revenues from product sales are recognized. These estimates for variable consideration are adjusted to reflect known changes in factors and may impact such estimates in the quarter those changes are known. Revenue recognized does not include amounts of variable consideration that are constrained. For the three months ended September 30, 2023 and 2022, net product sales outside of the United States were $76.6 million and $79.4 million, respectively, consisting of sales of Translarna, Tegsedi, Waylivra and Upstaza. Translarna net revenues made up $69.0 million and $76.6 million of the net product sales outside of the United States for the three months ended September 30, 2023 and 2022, respectively. For the three months ended September 30, 2023 and 2022, net product sales in the United States were $67.4 million and $54.8 million, respectively, consisting solely of sales of Emflaza. During the three months ended September 30, 2023, one country, the United States, accounted for at least 10% of our net product sales, representing $67.4 million of the net product sales. During the three months ended September 30, 2022, two countries, the United States and Russia, accounted for at least 10% of our net

49

product sales, representing $54.8 million and $28.3 million of net product sales, respectively. For the three months ended September 30, 2023 and 2022, we had a total of three and two distributors, respectively, that each accounted for over 10% of our net product sales.

During the nine months ended September 30, 2023 and 2022, net product sales outside of the United States were $318.5 million and $247.6 million, respectively, consisting of sales of Translarna, Tegsedi, Waylivra and Upstaza. Translarna net revenues made up $280.6 million and $232.9 million of the net product sales outside of the United States for the nine months ended September 30, 2023 and 2022, respectively.  For the nine months ended September 30, 2023 and 2022, net product sales in the United States were $187.7 million and $160.1 million, respectively, consisting solely of sales of Emflaza. During the nine months ended September 30, 2023, three countries, the United States, Russia, and Brazil, accounted for at least 10% of our net product sales, representing $187.7 million, $69.0 million, and $52.5 million of net product sales, respectively. During the nine months ended September 30, 2022, two countries, the United States and Russia, accounted for at least 10% of our net product sales, representing $160.1 million and $57.1 million of net product sales, respectively. For the nine months ended September 30, 2023 and 2022, we had a total of two and two distributors, respectively, that each accounted for over 10% of our net product sales.

In relation to customer contracts, we incur costs to fulfill a contract but do not incur costs to obtain a contract. These costs to fulfill a contract do not meet the criteria for capitalization and are expensed as incurred. We consider any shipping and handling costs that are incurred after the customer has obtained control of the product as a cost to fulfill a promise. Shipping and handling costs associated with finished goods delivered to customers are recorded as a selling expense.

Roche and the SMA Foundation Collaboration. In November 2011, we entered into the SMA License Agreement pursuant to which we are collaborating with Roche and the SMA Foundation to further develop and commercialize compounds identified under our SMA program with the SMA Foundation. The research component of this agreement terminated effective December 31, 2014. We are eligible to receive additional payments from Roche if specified events are achieved with respect to each licensed product, including up to $135.0 million in research and development event milestones, up to $325.0 million in sales milestones upon achievement of specified sales events, and up to double digit royalties on worldwide annual net sales of a commercial product. As of September 30, 2023, we had recognized a total of $210.0 million in milestone payments and $290.8 million royalties on net sales pursuant to the SMA License Agreement. As of September 30, 2023, there are no remaining research and development event milestones that we can receive. The remaining potential sales milestones as of September 30, 2023 are $250.0 million upon achievement of certain sales events.

For the three months ended September 30, 2023, we did not recognize collaboration revenue related to the SMA License Agreement with Roche. For the three months ended September 30, 2022 we recognized $50.0 million of collaboration revenue related to the SMA License Agreement. For the nine months ended September 30, 2023, the amounts recognized for the collaboration revenue related to the SMA License Agreement with Roche were immaterial. For the nine months ended September 30, 2022, we recognized $50.0 million of collaboration revenue related to the SMA License Agreement. There were no milestones triggered from Roche in the three and nine months ended September 30, 2023. In September 2022, we recognized a sales milestone of $50.0 million for the achievement of $750.0 million in worldwide annual net sales from Evrysdi.

For the three and nine months ended September 30, 2023, we recognized $50.2 million and $117.9 million of royalty revenue related to Evrysdi, respectively. For the three and nine months ended September 30, 2022, the Company has recognized $32.9 million and $73.6 million of royalty revenue, respectively, related to Evrysdi.  

In July 2020, we entered into the Original Royalty Purchase Agreement. Pursuant to the Original Royalty Purchase Agreement, we sold to Royalty Pharma 42.933%, or the Original Assigned Royalty Rights, of the Royalty for $650.0 million. At that time, we retained a 57.067% interest in the Royalty and all economic rights to receive the remaining potential regulatory and sales milestone payments under the SMA License Agreement.

In October 2023, we entered into the A&R Royalty Purchase Agreement.  At closing, Royalty Pharma paid us $1.0 billion in cash consideration for 38.0447% of our Retained Royalty Rights (which is in addition to the Original Assigned Royalty Rights, for a total of 80.9777% of the total Royalty) until such time as Royalty Pharma has received payments in respect of the A&R Assigned Royalty Rights equal to $1.3 billion in the aggregate, and thereafter 66.6667% of the total Royalty.  

50

In addition, we may sell to Royalty Pharma the remainder of our Retained Royalty Rights in exchange for an aggregate of $500.0 million in additional cash consideration after the closing of the A&R Royalty Purchase Agreement, less royalties received in respect of the Retained Royalty Rights put to Royalty Pharma, which will be payable by Royalty Pharma pursuant to five put options held by us that are exercisable at our option between January 1, 2024 and December 31, 2025.  If we exercise two or fewer of the put options, Royalty Pharma may exercise a call option during the period from and after January 1, 2026 until and including March 31, 2026 for up to 50% of the remainder of our Retained Royalty Rights less amounts exercised by us via our put options at a purchase price that is proportional to the purchase price of our unexercised put options. Royalty Pharma’s exercise of the call option would result in Royalty Pharma owning 90.4888% of the total Royalty until such time as Royalty Pharma has received payments in respect of the A&R Assigned Royalty Rights equal to $1.3 billion in the aggregate, and thereafter 83.3333% of the total Royalty.

Manufacturing Revenue. We have manufacturing services related to the production of plasmid deoxyribonucleic acid, or DNA, and adeno-associated virus, or AAV, vectors for gene therapy applications for external customers. Performance obligations vary but may include manufacturing plasmid DNA and/or AAV vectors, material testing, stability studies, and other services related to material development. The transaction prices for these arrangements are fixed and include amounts stated in the contracts for each promised service. Typically, the performance obligations within a manufacturing contract are highly interdependent, in which case, we will combine them into a single performance obligation. We have determined that the assets created have no alternative use to us, and we have an enforceable right to payment for the performance completed to date, therefore revenue related to these services are recognized over time and is measured using an output method based on performance of manufacturing milestones completed to date.

Manufacturing service contracts may also include performance obligations related to project management services or obtaining materials from third parties. We have determined that these are separate performance obligations for which revenue is recognized at the point in time the obligation is performed. For performance obligations related to obtaining third party materials, we have determined that we are the principal as we have control of the materials and have discretion in setting the price. Therefore, we recognize revenue on a gross basis related to obtaining third party materials.

Certain arrangements require a portion of the contract consideration to be received in advance at the commencement of the contract, and such advance payment is initially recorded as a contract liability. A contract asset may be recognized in the event our satisfaction of performance obligations outpaces customer billings.

For the three and nine months ended September 30, 2023, we recognized $2.4 million and $6.7 million of manufacturing revenue, respectively, related to plasmid DNA and AAV vector production for external customers. No manufacturing revenue was recognized for the three and nine months ended September 30, 2022. As of September 30, 2023, we had contract assets of $1.4 million and remaining performance obligations of $1.2 million related to the production of plasmid DNA and AAV vectors for gene therapy applications for external customers. For the period ended December 31, 2022, we had remaining performance obligations of $1.4 million and no contracts assets related to plasmid DNA and AAV production for external customers.

Research and development expense

Research and development expenses consist of the costs associated with our research activities, as well as the costs associated with our drug discovery efforts, conducting preclinical studies and clinical trials, manufacturing development efforts and activities related to regulatory filings. Our research and development expenses consist of:

external research and development expenses incurred under agreements with third-party contract research organizations and investigative sites, third-party manufacturing organizations and consultants;
employee-related expenses, which include salaries and benefits, including share-based compensation, for the personnel involved in our drug discovery and development activities; and
facilities, depreciation and other allocated expenses, which include direct and allocated expenses for rent and maintenance of facilities, IT, human resources and other support functions, depreciation of leasehold improvements and equipment, and laboratory and other supplies.

51

We use our employee and infrastructure resources across multiple research projects, including our drug development programs. We track expenses related to our clinical programs and certain preclinical programs on a per project basis.

We expect our research and development expenses to fluctuate in connection with our ongoing activities, particularly in connection with Study 041 and other studies for Translarna for the treatment of nmDMD, our activities under our splicing, metabolic, Bio-e and oncology programs and performance of our post-marketing requirements imposed by regulatory agencies with respect to our products. The timing and amount of these expenses will depend upon the outcome of our ongoing clinical trials and the costs associated with our planned clinical trials. The timing and amount of these expenses will also depend on the costs associated with potential future clinical trials of our products or product candidates and the related expansion of our research and development organization, regulatory requirements, advancement of our preclinical programs, and product and product candidate manufacturing costs.

The following table provides research and development expense for our most advanced principal product development programs, for the three and nine months ended September 30, 2023 and 2022.

Three Months Ended September 30, 

    

2023

    

2022

(in thousands)

Global DMD Franchise

$

21,367

$

18,014

Metabolic

 

26,761

 

16,009

Gene Therapy

 

42,764

 

45,336

Bio-e

17,958

18,420

Oncology

 

9,929

 

15,857

Splicing

 

21,260

19,412

Discovery and other

 

24,173

 

32,414

Total research and development

$

164,212

$

165,462

Nine Months Ended September 30, 

    

2023

    

2022

(in thousands)

Global DMD Franchise

$

62,532

$

52,640

Metabolic

 

115,433

 

47,181

Gene Therapy

 

119,968

 

136,108

Bio-e

 

54,653

 

46,029

Oncology

 

31,617

 

30,927

Splicing

 

68,696

 

52,975

Discovery and other

 

92,311

 

96,942

Total research and development

$

545,210

$

462,802

The successful development of our products and product candidates is highly uncertain. This is due to the numerous risks and uncertainties associated with developing drugs, including the uncertainty of:

the scope, rate of progress and expense of our clinical trials and other research and development activities;
the potential benefits of our products and product candidates over other therapies;
our ability to market, commercialize and achieve market acceptance for any of our products or product candidates that we are developing or may develop in the future, including our ability to negotiate pricing and reimbursement terms acceptable to us;
clinical trial results;
the terms and timing of regulatory approvals; and

52

the expense of filing, prosecuting, defending and enforcing patent claims and other intellectual property rights.

A change in the outcome of any of these variables with respect to the development of our products or product candidates could mean a significant change in the costs and timing associated with the development of that product or product candidate. For example, if the EMA or FDA or other regulatory authority were to require us to conduct clinical trials beyond those which we currently anticipate will be required for the completion of clinical development of any of our products or product candidates or if we experience significant delays in enrollment in any of our clinical trials, we could be required to expend significant additional financial resources and time on the completion of clinical development. In addition, the uncertainty with respect to the duration, nature and extent of negative impacts of the COVID-19 pandemic and responsive measures relating thereto on our ability to successfully enroll our current and future clinical trials, has caused us to experience delays, and may cause us to experience further delays, in our clinical trials and regulatory submissions.

Selling, general and administrative expense

Selling, general and administrative expenses consist primarily of salaries and other related costs for personnel, including share-based compensation expenses, in our executive, legal, business development, commercial, finance, accounting, information technology and human resource functions. Other selling, general and administrative expenses include facility-related costs not otherwise included in research and development expense; advertising and promotional expenses; costs associated with industry and trade shows; and professional fees for legal services, including patent-related expenses, accounting services and miscellaneous selling costs.

We expect that selling, general and administrative expenses will increase in future periods in connection with our continued efforts to commercialize our products, including increased payroll, expanded infrastructure, commercial operations, increased consulting, legal, accounting and investor relations expenses.

Interest expense, net

Interest expense, net consists of interest expense from the liability for the sale of future royalties related to the Original Royalty Purchase Agreement, the 2026 Convertible Notes outstanding, the $150.0 million aggregate principal amount of 3.00% convertible senior notes due 2022 outstanding, the Blackstone Credit Agreement, offset by interest income earned on investments.

Critical accounting policies and significant judgments and estimates

Our management’s discussion and analysis of our financial condition and results of operations is based on our financial statements, which we have prepared in accordance with generally accepted accounting principles in the United States. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenues and expenses during the reporting periods. Actual results may differ from these estimates under different assumptions or conditions.

During the three and nine months ended September 30, 2023, there were no material changes to our critical accounting policies as reported in our 2022 Annual Report.

53

Results of operations

Three months ended September 30, 2023 compared to three months ended September 30, 2022

The following table summarizes revenues and selected expense and other income data for the three months ended September 30, 2023 and 2022.

Three Months Ended

September 30, 

Change

(in thousands)

    

2023

    

2022

    

2023 vs. 2022

Net product revenue

$

144,038

$

134,186

$

9,852

Collaboration revenue

50,017

(50,017)

Royalty revenue

50,173

32,924

17,249

Manufacturing revenue

2,365

2,365

Cost of product sales, excluding amortization of acquired intangible asset

 

9,493

 

14,011

(4,518)

Amortization of acquired intangible asset

 

58,649

 

31,023

27,626

Research and development expense

 

164,212

 

165,462

(1,250)

Selling, general and administrative expense

 

80,886

 

80,118

768

Change in the fair value of contingent consideration

 

1,500

 

(5,300)

6,800

Interest expense, net

 

(28,160)

 

(20,880)

(7,280)

Other expense, net

 

(20,266)

 

(38,141)

17,875

Income tax benefit

33,620

17,893

15,727

Net product revenues. Net product revenues were $144.0 million for the three months ended September 30, 2023, an increase of $9.9 million, or 7%, from $134.2 million for the three months ended September 30, 2022. The increase in net product revenue was primarily due to an increase in net product sales of Emflaza, offset by a decrease in net product sales of Translarna. Emflaza net product revenues were $67.4 million for the three months ended September 30, 2023, an increase of $12.6 million, or 23%, compared to $54.8 million for the three months ended September 30, 2022. These results reflect new patients and high compliance. Translarna net product revenues were $69.0 million for the three months ended September 30, 2023, a decrease of $7.6 million, or 10%, compared to $76.6 million for the three months ended September 30, 2022. The decrease was due to timing of bulk patient orders, partially offset by new patient starts in existing geographies and continued geographic expansion.

Collaboration revenues. Collaboration revenues were $0.0 million for the three months ended September 30, 2023, a decrease of $50.0 million, or 100%, from $50.0 million for the three months ended September 30, 2022. The decrease is due to a sales milestone of $50.0 million for the achievement of $750.0 million in worldwide annual net sales from Evrysdi in the three months ended September 30, 2022. No milestones were triggered in the three months ended September 30, 2023.

Royalty revenue. Royalty revenue was $50.2 million for the three months ended September 30, 2023, an increase of $17.2 million, or 52%, from $32.9 million for the three months ended September 30, 2022. The increase in royalty revenue was due to higher Evrysdi sales in the three months ended September 30, 2023 as compared to the three months ended September 30, 2022. In accordance with the SMA License Agreement, we are entitled to royalties on worldwide annual net sales of the product.

Manufacturing revenue. Manufacturing revenues were $2.4 million for the three months ended September 30, 2023 an increase of $2.4 million, or 100%, from $0.0 million for the three months ended September 30, 2022. The increase is due to the manufacturing services related to the production of plasmid DNA and AAV vectors for gene therapy applications for external customers.

Cost of product sales, excluding amortization of acquired intangible asset. Cost of product sales, excluding amortization of acquired intangible asset, were $9.5 million for the three months ended September 30, 2023, a decrease of $4.5 million, or 32%, from $14.0 million for the three months ended September 30, 2022. Cost of product sales consist primarily of

54

royalty payments associated with Emflaza, Translarna, and Upstaza net product sales, excluding contingent payments to Marathon Pharmaceuticals, LLC (now known as Complete Pharma Holdings, LLC), or Marathon, costs associated with Emflaza, Translarna, and Upstaza products sold during the period, and royalty expense related to royalty revenues and collaboration milestone revenues. The decrease in cost of product sales, excluding amortization of acquired intangible asset, is primarily due to a decrease in Translarna net product revenue driven by timing of bulk patient orders, as well as a decrease in the collaboration royalty earned by the SMA Foundation, due to a sales milestone of $50.0 million for the achievement of $750.0 million in worldwide annual net sales from Evrysdi in the three months ended September 30, 2022. No milestones were triggered in the three months ended September 30, 2023.

Amortization of acquired intangible asset. Amortization of our intangible assets was $58.6 million for the three months ended September 30, 2023, an increase of $27.6 million, or 89%, from $31.0 million for the three months ended September 30, 2022. These amounts are related to the Emflaza rights acquisition, as well as the Waylivra, Tegsedi, and Upstaza intangible assets, which are all being amortized on a straight-line basis over their estimated useful lives. The amortization increase is primarily related to additional Marathon contingent payments for Emflaza.

Research and development expense. Research and development expense was $164.2 million for the three months ended September 30, 2023, a decrease of $1.3 million, or 1%, from $165.5 million for the three months ended September 30, 2022. The decrease in research and development expenses reflects our strategic portfolio prioritization as the Company continues to focus its resources on its differentiated, high potential R&D programs.

Selling, general and administrative expense. Selling, general and administrative expense was $80.9 million for the three months ended September 30, 2023, an increase of $0.8 million, or 1%, from $80.1 million for the three months ended September 30, 2022. The increase reflects our continued investment to support our commercial activities including our expanding commercial portfolio. The increase also includes restructuring costs from a reduction in workforce in connection with our strategic pipeline prioritization and discontinuation of our preclinical and early research programs in our gene therapy platform in the three months ended September 30, 2023.

Change in the fair value of contingent consideration. The change in the fair value of contingent consideration was a loss of $1.5 million for the three months ended September 30, 2023, a change of $6.8 million, or over 100%, from a gain of $5.3 million for the three months ended September 30, 2022. The change is related to the fair valuation of the potential future consideration to be paid to former equityholders of Agilis as a result of our merger with Agilis which closed in August 2018. Changes in the fair value were due to the re-calculation of discounted cash flows for the passage of time and changes to certain other estimated assumptions.

Interest expense, net. Interest expense, net was $28.2 million for the three months ended September 30, 2023, an increase of $7.3 million, or 35%, from $20.9 million for the three months ended September 30, 2022. The increase in interest expense, net was primarily due to interest expense recorded from the liability for the sale of future royalties related to the Original Royalty Purchase Agreement and the Blackstone Credit Agreement.

Other expense, net. Other expense, net was $20.3 million for the three months ended September 30, 2023, a decrease of $17.9 million, or 47%, from other expense, net o­f $38.1 million for the three months ended September 30, 2022. Other expense, net for the three months ended September 30, 2023 was primarily related to realized and unrealized foreign exchange losses of $16.4 million, and unrealized losses on our equity investments in Clearpoint Neuro, Inc. of $2.0 million and unrealized losses on our convertible debt security in ClearPoint Neuro, Inc. of $3.1 million, offset by unrealized gains of $1.1 million on marketable securities – equity investments. Other expense, net for the three months ended September 30, 2022, was primarily related to an unrealized foreign exchange loss from the remeasurement of our intercompany loan, offset by unrealized losses on our equity investments and convertible debt security in ClearPoint Neuro, Inc. of $3.5 million and $4.4 million, respectively.

Income tax benefit. Income tax benefit was $33.6 million for the three months ended September 30, 2023, an increase of $15.7 million, or 88%, compared to income tax benefit of $17.9 million for the three months ended September 30, 2022. The increase in income tax benefit is attributable to the receipt of an outstanding state tax refund received during the three months ended September 30, 2023, and the subsequent release of the associated FIN48 reserve.

55

We also incur income tax expenses in various foreign jurisdictions, and our foreign tax liabilities are largely dependent upon the distribution of pre-tax earnings among these different jurisdictions.

Nine months ended September 30, 2023 compared to nine months ended September 30, 2022.

The following table summarizes revenues and selected expense and other income data for the nine months ended September 30, 2023 and 2022.

Nine Months Ended

September 30, 

Change

(in thousands)

    

2023

    

2022

    

2023 vs. 2022

Net product revenue

$

506,187

$

407,720

$

98,467

Collaboration revenue

 

6

 

50,024

(50,018)

Royalty revenue

117,857

73,645

44,212

Manufacturing revenue

6,716

6,716

Cost of product sales, excluding amortization of acquired intangible assets

 

36,368

 

33,785

2,583

Amortization of acquired intangible assets

 

145,461

 

80,790

64,671

Research and development expense

 

545,210

 

462,802

82,408

Selling, general and administrative expense

 

256,249

 

233,280

22,969

Change in the fair value of contingent consideration

 

(125,000)

 

(32,200)

(92,800)

Intangible asset impairment

217,800

217,800

Interest expense, net

 

(84,905)

 

(66,371)

(18,534)

Other expense, net

 

(8,832)

 

(84,355)

75,523

Income tax benefit

68,247

9,666

58,581

Net product revenues. Net product revenues were $506.2 million for the nine months ended September 30, 2023, an increase of $98.5 million, or 24%, from $407.7 million for the nine months ended September 30, 2022. The increase in net product revenue was primarily due to an increase in net product sales of Translarna and Emflaza. Translarna net product revenues were $280.6 million for the nine months ended September 30, 2023, an increase of $47.7 million, or 20%, compared to $232.9 million for the nine months ended September 30, 2022. These results were driven by treatment of new patients and continued geographic expansion. Emflaza net product revenues were $187.7 million for the nine months ended September 30, 2023, an increase of $27.6 million, or 17%, compared to $160.1 million for the nine months ended September 30, 2022. These results reflect new patients and high compliance.

Collaboration revenues. Collaboration revenues were $6.0 thousand for the three months ended September 30, 2023, a decrease of $50.0 million, or 100%, from $50.0 million for the three months ended September 30, 2022. The decrease is due to a sales milestone of $50.0 million for the achievement of $750.0 million in worldwide annual net sales from Evrysdi in the nine months ended September 30, 2022.No milestones were triggered in the nine months ended September 30, 2023.

Royalty revenue. Royalty revenue was $117.9 million for the nine months ended September 30, 2023, an increase of $44.2 million, or 60%, from $73.6 million for the nine months ended September 30, 2022. The increase in royalty revenue was due to higher Evrysdi sales in the nine months ended September 30, 2023 as compared to the nine months ended September 30, 2022. In accordance with the SMA License Agreement, we are entitled to royalties on worldwide annual net sales of the product.

Manufacturing revenue. Manufacturing revenues were $6.7 million for the nine months ended September 30, 2023, an increase of $6.7 million, or 100%, from $0.0 million for the nine months ended September 30, 2022. The increase is due to the manufacturing services related to the production of plasmid DNA and AAV vectors for gene therapy applications for external customers.

Cost of product sales, excluding amortization of acquired intangible asset. Cost of product sales, excluding amortization of acquired intangible asset, were $36.4 million for the nine months ended September 30, 2023, an increase of $2.6 million, or 8%, from $33.8 million for the nine months ended September 30, 2022. Cost of product sales consist primarily of royalty

56

payments associated with Emflaza and Translarna net product sales, excluding contingent payments to Marathon, costs associated with Emflaza and Translarna product sold during the period, and royalty expense related to royalty revenues and collaboration milestone revenues. The increase in cost of product sales, excluding amortization of acquired intangible asset, is primarily due to the increase in net product revenue, royalty revenue, and collaboration milestone revenue.

Amortization of acquired intangible asset. Amortization of our intangible assets was $145.5 million for the nine months ended September 30, 2023, an increase of $64.7 million, or 80%, from $80.8 million for the nine months ended September 30, 2022. These amounts are related to the Emflaza rights acquisition, as well as the Waylivra, Tegsedi, and Upstaza intangible assets, which are all being amortized on a straight-line basis over their estimated useful lives. The amortization increase is primarily related to additional Marathon contingent payments for Emflaza.

Research and development expense. Research and development expense was $545.2 million for the nine months ended September 30, 2023, an increase of $82.4 million, or 18%, from $462.8 million for the nine months ended September 30, 2022. The increase in R&D expenses includes the achievement of a $30.0 million success-based development milestone for the completion of enrollment of a Phase 3 clinical trial for sepiapterin for PKU. The increase also includes restructuring costs from a reduction in workforce in connection with our strategic pipeline prioritization and discontinuation of our preclinical and early research programs in our gene therapy platform in the nine months ended September 30, 2023.

Selling, general and administrative expense. Selling, general and administrative expense was $256.2 million for the nine months ended September 30, 2023, an increase of $23.0 million, or 10%, from $233.3 million for the nine months ended September 30, 2022. The increase reflects our continued investment to support our commercial activities including our expanding commercial portfolio. The increase also includes restructuring costs from a reduction in workforce in connection with our strategic pipeline prioritization and discontinuation of our preclinical and early research programs in our gene therapy platform in the nine months ended September 30, 2023.

Change in the fair value of contingent consideration. The change in the fair value of contingent consideration was a gain of $125.0 million for the nine months ended September 30, 2023, a change of $92.8 million, or over 100%, from a gain of $32.2 million for the nine months ended September 30, 2022. The change is primarily related to our strategic portfolio prioritization and decision to discontinue our preclinical and early research programs in our gene therapy platform, which included Friedreich ataxia and Angelman syndrome, which was announced in May 2023. As a result, we fully impaired the Friedreich ataxia and Angelman syndrome intangible assets and determined that the fair value for all of the contingent consideration payable related to Friedreich ataxia and Angelman syndrome was $0. As a result, we recorded a fair value change of $129.8 million for the contingent consideration related to Friedreich ataxia and Angelman syndrome during the nine months ended September 30, 2023.

Intangible asset impairment. Intangible asset impairment was $217.8 million for the nine months ended September 30, 2023, an increase of $217.8 million, or 100%, from intangible asset impairment of $0.0 million for the nine months ended September 30, 2022. The change is due to our strategic portfolio prioritization and decision to discontinue our preclinical and early research programs in our gene therapy platform, which included Friedreich ataxia and Angelman syndrome, which was announced in May 2023. As a result, we fully impaired the Friedreich ataxia and Angelman syndrome intangible assets and recorded impairment expense of $217.8 million during the nine months ended September 30, 2023.

Interest expense, net. Interest expense, net was $84.9 million for the nine months ended September 30, 2023, an increase of $18.5 million, or 28%, from $66.4 million for the nine months ended September 30, 2022. The increase in interest expense, net was primarily due to interest expense recorded from the liability for the sale of future royalties related to the Original Royalty Purchase Agreement and the Blackstone Credit Agreement.

Other expense, net. Other expense, net was $8.8 million for the nine months ended September 30, 2023, a decrease of $75.5 million, or 90%, from $84.4 million for the nine months ended September 30, 2022. Other expense, net for the nine months ended September 30, 2023 was primarily related to realized and unrealized foreign exchange losses of $5.2 million and unrealized and realized losses, net, on our equity investments in ClearPoint Neuro, Inc. of $3.9 million and unrealized losses on our convertible debt security in ClearPoint Neuro, Inc. of $4.6 million. These expenses were offset by unrealized gains of $5.5 million on marketable securities – equity investments for the nine months ended September 30, 2023. The

57

change in other expense, net for the nine months ended September 30, 2022, resulted primarily from an unrealized foreign exchange loss from the remeasurement of our intercompany loan and unrealized losses on our equity investments and convertible debt security in ClearPoint Neuro, Inc. of $1.1 million and $2.4 million, respectively.

Income tax benefit. Income tax benefit was $68.2 million for the nine months ended September 30, 2023, an increase of $58.6 million, or over 100%, from $9.7 million for the nine months ended September 30, 2022. The increase in income tax  benefit is attributable to the receipt of an outstanding state tax refund received during the nine months ended September 30, 2023, and the subsequent release of the associated FIN48 reserve.

Liquidity and capital resources

Sources of liquidity

Since inception, we have incurred significant operating losses.

As a growing commercial-stage biopharmaceutical company, we are engaging in significant commercialization efforts for our products while also devoting a substantial portion of our efforts on research and development related to our products, product candidates and other programs. To date, our product revenue has been primarily attributable to sales of Translarna for the treatment of nmDMD in territories outside of the United States and from Emflaza for the treatment of DMD in the United States. Our ongoing ability to generate revenue from sales of Translarna for the treatment of nmDMD is dependent upon our ability to maintain our marketing authorizations in Brazil, Russia and in the EEA and secure market access through commercial programs following the conclusion of pricing and reimbursement terms at sustainable levels in the member states of the EEA or through EAP Programs in the EEA and other territories. The marketing authorization requires annual review and renewal by the EC following reassessment by the EMA of the benefit-risk balance of the authorization and is subject to the specific obligation to conduct Study 041. In September 2023, the CHMP gave a negative opinion on the conversion of the conditional marketing authorization to full marketing authorization of Translarna for the treatment of nmDMD and a negative opinion on the renewal of the existing conditional marketing authorization of Translarna for the treatment of nmDMD. We have requested re-examination of the CHMP opinion regarding the renewal of the existing conditional marketing authorization. In accordance with EMA guidelines, we expect the CHMP opinion following the re-examination process to occur in late January 2024, with EC ratification of the opinion within the following 67 days. While we have requested a re-examination of the CHMP opinion, the re-examination process may not result in a change to the negative opinion. Our ability to generate product revenue from Emflaza will largely depend on the coverage and reimbursement levels set by governmental authorities, private health insurers and other third-party payors.

We have historically financed our operations primarily through the issuance and sale of our common stock in public offerings, our “at the market offering” of our common stock, proceeds from the A&R Royalty Purchase Agreement, the private placements of our preferred stock, collaborations, bank and institutional lender debt, convertible debt financings and grants and clinical trial support from governmental and philanthropic organizations and patient advocacy groups in the disease areas addressed by our product candidates. We expect to continue to incur significant expenses and operating losses for at least the next fiscal year. The net losses we incur may fluctuate significantly from quarter to quarter.

In August 2019, we entered into the Sales Agreement, pursuant to which, we may offer and sell shares of our common stock, having an aggregate offering price of up to $125.0 million from time to time through the Sales Agents by any method that is deemed to be an “at the market offering” as defined in Rule 415(a)(4) promulgated under the Securities Act. See “Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations—Corporate Updates—Funding” for additional information.

In September 2019, we closed a private offering of $287.5 million aggregate principal amount of 1.50% convertible senior notes due 2026 including the full exercise by the initial purchasers of an option to purchase an additional $37.5 million in aggregate principal amount of the 2026 Convertible Notes. The 2026 Convertible Notes bear cash interest at a rate of 1.50% per year, payable semi-annually on March 15 and September 15 of each year, beginning on March 15, 2020. The 2026 Convertible Notes will mature on September 15, 2026, unless earlier repurchased or converted. We received net proceeds of $279.3 million after deducting the initial purchasers’ discounts and commissions and the offering expenses payable by us.

58

In July 2020, we entered into the Original Royalty Purchase Agreement. Pursuant to the Original Royalty Purchase Agreement, we sold to Royalty Pharma the Original Assigned Royalty Rights in consideration for $650.0 million.

In October 2022, we entered into the Blackstone Credit Agreement for fundings of up to $950.0 million consisting of a committed loan facility of $450.0 million and further contemplating the potential for up to $500.0 million of additional financing, to the extent that we request such additional financing and subject to the Lenders’ agreement to provide such additional financing and to mutual agreement on terms.

The Blackstone Credit Agreement provided for a senior secured term loan facility funded on the Closing Date in the aggregate principal amount of $300.0 million and a committed delayed draw term loan facility of up to $150.0 million to be funded at our request within 18 months of the Closing Date subject to specified conditions. In addition, the Blackstone Credit Agreement contemplated the potential for further financings by Blackstone, by providing for incremental discretionary uncommitted further financings of up to $500.0 million.

In October 2023, we terminated the Blackstone Credit Agreement. In connection with the termination of the Blackstone Credit Agreement, we repaid outstanding principal and accrued interest thereunder totaling $302.1 million and paid an additional $82.1 million in prepayment premiums, expenses and other exit fees. All liens and security interests securing the loans made pursuant to the Blackstone Credit Agreement were released upon termination.

In October 2023, we entered into the A&R Royalty Purchase Agreement.  At closing, Royalty Pharma paid us $1.0 billion in cash consideration for 38.0447% of our Retained Royalty Rights (which is in addition to the Original Assigned Royalty Rights, for a total of 80.9777% of the total Royalty) until such time as Royalty Pharma has received payments in respect of the A&R Assigned Royalty Rights equal to $1.3 billion in the aggregate, and thereafter 66.6667% of the total Royalty.  In addition, we may sell to Royalty Pharma the remainder of our Retained Royalty Rights in exchange for an aggregate of $500.0 million in additional cash consideration after the closing of the A&R Royalty Purchase Agreement, less royalties received in respect of the Retained Royalty Rights put to Royalty Pharma, which will be payable by Royalty Pharma pursuant to five put options held by us that are exercisable at our option between January 1, 2024 and December 31, 2025.  If we exercise two or fewer of the put options, Royalty Pharma may exercise a call option during the period from and after January 1, 2026 until and including March 31, 2026 for up to 50% of the remainder of our Retained Royalty Rights less amounts exercised by us via our put options at a purchase price that is proportional to the purchase price of our unexercised put options. Royalty Pharma’s exercise of the call option would result in Royalty Pharma owning 90.4888% of the total Royalty until such time as Royalty Pharma has received payments in respect of the A&R Assigned Royalty Rights equal to $1.3 billion in the aggregate, and thereafter 83.3333% of the total Royalty.

The A&R Royalty Purchase Agreement includes specified negative and affirmative covenants with respect to our rights under the SMA License Agreement as well as other customary representations and warranties, covenants and other provisions. The A&R Royalty Purchase Agreement will terminate 60 days following the date on which Roche is no longer obligated to make any payments of the Royalty pursuant to the SMA License Agreement.

Cash flows

As of September 30, 2023, we had cash, cash equivalents and marketable securities of $294.8 million.

The following table provides information regarding our cash flows and our capital expenditures for the periods indicated.

Nine Months Ended

September 30, 

(in thousands)

    

2023

    

2022

Cash (used in) provided by:

 

  

 

  

Operating activities

(58,130)

(190,691)

Investing activities

(82,319)

257,742

Financing activities

25,915

(134,966)

59

Net cash used in operating activities was $58.1 million for the nine months ended September 30, 2023 and $190.7 million for the nine months ended September 30, 2022. The net cash used in operating activities primarily relates to supporting clinical development and commercial activities.

Net cash used in investing activities was $82.3 million for the nine months ended September 30, 2023 and net cash provided by investing activities was $257.7 million for the nine months ended September 30, 2022. Cash used in investing activities for the nine months ended September 30, 2023 was primarily related to the acquisition of product rights, purchases of marketable securities-equity investments, and purchases of fixed assets, partially offset by net sales and redemption of marketable securities. Cash provided by investing activities for the nine months ended September 30, 2022 was primarily related to net sales and redemption of marketable securities, partially offset by purchases of marketable securities, purchases of fixed assets, and the acquisition of product rights.

Net cash provided by financing activities was $25.9 million for the nine months ended September 30, 2023 and net cash used in by financing activities was $135.0 million for the nine months ended September 30, 2022. Cash provided by financing activities for the nine months ended September 30, 2023 was primarily attributable to cash received from the exercise of options, and proceeds from our Employee Stock Purchase Plan, partially offset by payments on our finance lease principal and debt issuance costs related to the senior secured term loan. Cash used in financing activities for the nine months ended September 30, 2022 was primarily attributable to the repayment of the 2022 Convertible Notes and payments on our finance lease principal, partially offset by cash received from the exercise of options and proceeds from our Employee Stock Purchase Plan.

Funding requirements

We anticipate that our expenses will continue to increase in connection with our commercialization efforts in the United States, the EEA, Latin America and other territories, including the expansion of our infrastructure and corresponding sales and marketing, legal and regulatory and distribution and manufacturing expenses. In addition to the foregoing, we expect to continue to incur significant costs in connection with the research and development of our splicing, metabolic, Bio-e and oncology programs as well as studies in our products for maintaining authorizations, including Study 041, label extensions and additional indications. In addition, we may incur substantial costs in connection with our efforts to advance our regulatory submissions. For example, in response to the CHMP’s negative opinion for Translarna for the treatment of nmDMD, we have submitted a request for re-examination to the EMA. We continue to seek marketing authorization for Translarna for the treatment of nmDMD in territories that we do not currently have marketing authorization in. We are preparing and anticipate submitting a BLA to the FDA for Upstaza for the treatment of AADC deficiency in the United States shortly after our pre-BLA meeting that is scheduled for December 2023. We also expect to submit an NDA to the FDA for sepiapterin for the treatment of PKU by the end of the third quarter of 2024 and we expect to submit an MAA to the EMA for sepiapterin for the treatment of PKU in the first half of 2024. These efforts may significantly impact the timing and extent of our commercialization expenses.

In addition, our expenses will increase if and as we:

seek to satisfy contractual and regulatory obligations that we assumed through our acquisitions and collaborations;
execute our commercialization strategy for our products, including initial commercialization launches of our products, label extensions or entering new markets;
are required to complete any additional clinical trials, non-clinical studies or Chemistry, Manufacturing and Controls, or CMC, assessments or analyses in order to advance Translarna for the treatment of nmDMD in the United States or elsewhere;
are required to take other steps, in addition to Study 041, to maintain our current marketing authorization in the EEA, Brazil and Russia for Translarna for the treatment of nmDMD or to obtain further marketing authorizations for Translarna for the treatment of nmDMD or other indications;

60

initiate or continue the research and development of our splicing, metabolic, Bio-e and oncology programs as well as studies in our products for maintaining authorizations, including Study 041, label extensions and additional indications;
continue to utilize the Hopewell Facility to manufacture program materials for third parties;
seek to discover and develop additional product candidates;
seek to expand and diversify our product pipeline through strategic transactions;
maintain, expand and protect our intellectual property portfolio; and
add operational, financial and management information systems and personnel, including personnel to support our product development and commercialization efforts.

We believe that our cash flows from product sales, together with existing cash and cash equivalents, including our offering of the 2026 Convertible Notes, public offerings and private placements of common stock, our “at the market offering” of our common stock, proceeds from the A&R Royalty Purchase Agreement and marketable securities, will be sufficient to fund our operating expenses and capital expenditure requirements for at least the next twelve months. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect.

Our future capital requirements will depend on many factors, including:

our ability to maintain our marketing authorization for Translarna for the treatment of nmDMD in the EEA following the CHMP’s negative opinion on the conversion of the conditional marketing authorization to full marketing authorization and the renewal of the existing conditional authorization;
our ability to maintain the marketing authorization for Translarna and our other products in territories outside of the EEA;
our ability to commercialize and market our products and product candidates that may receive marketing authorization;
our ability to negotiate, secure and maintain adequate pricing, coverage and reimbursement terms, on a timely basis, with third-party payors for our products and products candidates;
our ability to obtain marketing authorization for sepiapterin for the treatment of PKU in the United States and EEA;
the costs, timing and outcome of Study 041;
our ability to obtain marketing authorization for Upstaza for the treatment of AADC deficiency in the United States;
the costs, timing and outcome of our efforts to advance Translarna for the treatment of nmDMD in the United States, including, whether we will be required to perform additional clinical trials, non-clinical studies or CMC assessments or analyses at significant cost which, if successful, may enable FDA review of an NDA re-submission by us and, ultimately, may support approval of Translarna for nmDMD in the United States;
unexpected decreases in revenue or increase in expenses resulting from the COVID-19 pandemic or other potential widespread outbreaks of contagious disease;

61

our ability to maintain orphan exclusivity in the United States for Emflaza;
our ability to successfully complete all post-marketing requirements imposed by regulatory agencies with respect to our products;
the progress and results of activities under our splicing, metabolic, Bio-e and oncology programs as well as studies in our products for maintaining authorizations, label extensions and additional indications;
the scope, costs and timing of our commercialization activities, including product sales, marketing, legal, regulatory, distribution and manufacturing, for any of our products and for any of our other product candidates that may receive marketing authorization or any additional territories in which we receive authorization to market Translarna;
the costs, timing and outcome of regulatory review of our splicing, metabolic, Bio-e and oncology programs and Translarna and Upstaza in other territories;
our ability to satisfy our obligations under the indenture governing the 2026 Convertible Notes;
the scope, progress, results and costs of preclinical development, laboratory testing and clinical trials for our other product candidates, including those in our splicing, metabolic, Bio-e and oncology programs;
revenue received from commercial sales of our products or any of our product candidates;
our ability to obtain additional and maintain existing reimbursed named patient and cohort EAP programs for Translarna for the treatment of nmDMD on adequate terms, or at all;
the ability and willingness of patients and healthcare professionals to access Translarna through alternative means if pricing and reimbursement negotiations in the applicable territory do not have a positive outcome;
our ability to continue to utilize the Hopewell Facility to manufacture program materials for third parties;
the costs of preparing, filing and prosecuting patent applications, maintaining, and protecting our intellectual property rights and defending against intellectual property-related claims;
the extent to which we acquire or invest in other businesses, products, product candidates, and technologies, including the success of any acquisition, in-licensing or other strategic transaction we may pursue, and the costs of subsequent development requirements and commercialization efforts, including with respect to our acquisitions of Emflaza, Agilis, our Bio-e platform and Censa and our licensing of Tegsedi and Waylivra; and
our ability to establish and maintain collaborations, including our collaborations with Roche and the SMA Foundation, and our ability to obtain research funding and achieve milestones under these agreements.

With respect to our outstanding 2026 Convertible Notes, cash interest payments are payable on a semi-annual basis in arrears, which will require total funding of $4.3 million annually. Borrowings under the Blackstone Credit Agreement bore interest at a variable rate equal to, at our option, either an adjusted Term SOFR rate plus seven and a quarter percent (7.25%) or the Base Rate plus six and a quarter percent (6.25%), subject to a floor of one percent (1%) and two percent (2%) with respect to Term SOFR rate and Base Rate (each as defined in the Blackstone Credit Agreement), respectively.

We expect to pay the former equityholders of Agilis $20.0 million in regulatory milestone payments upon the acceptance for filing by the FDA of a BLA for Upstaza for the treatment of AADC deficiency pursuant to the Agilis Merger Agreement. We expect to submit a BLA for Upstaza to the FDA shortly after our pre-BLA meeting that is scheduled for December 2023. We also expect to make payments to the former Censa securityholders of $65.0 million in the aggregate

62

in cash upon the potential achievement in 2024 of development and regulatory milestones relating to sepiapterin pursuant to Censa Merger Agreement.

We also have certain significant contractual obligations and commercial commitments that require funding and we have disclosed these items under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations-Funding Obligations” in our 2022 Annual Report. There were no material changes to these obligations and commitments during the period ended September 30, 2023. Furthermore, since we are a public company, we have incurred and expect to continue to incur additional costs associated with operating as such including significant legal, accounting, investor relations and other expenses.

We have never been profitable and we will need to generate significant revenues to achieve and sustain profitability, and we may never do so. We may need to obtain substantial additional funding in connection with our continuing operations. Until such time, if ever, as we can generate substantial product revenues, we expect to finance our cash needs primarily through a combination of equity offerings, debt financings, collaborations, strategic alliances, grants and clinical trial support from governmental and philanthropic organizations and patient advocacy groups in the disease areas addressed by our product and product candidates and marketing, distribution or licensing arrangements. Adequate additional financing may not be available to us on acceptable terms, or at all. To the extent that we raise additional capital through the sale of equity or convertible debt securities, our shareholders ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us.

If we are unable to raise additional funds through equity, debt or other financings when needed or on attractive terms, we may be required to delay, limit, reduce or terminate our product development or commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves.

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

During the period ended September 30, 2023, there were no material changes in our market risk or how our market risk is managed, compared to those disclosed under the heading “Quantitative and Qualitative Disclosures about Market Risk” in our 2022 Annual Report.

Item 4. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2023. The term “disclosure controls and procedures”, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company’s management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of September 30, 2023, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.

63

Changes in Internal Control over Financial Reporting

No change in our internal control over financial reporting occurred during the quarter ended September 30, 2023 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II—OTHER INFORMATION

Item 1. Legal Proceedings.

From time to time in the ordinary course of our business, we are subject to claims, legal proceedings and disputes, including as a result of patients seeking to participate in our clinical trials or otherwise gain access to our product candidates. We are not currently aware of any material legal proceedings to which we are a party or of which any of our property is subject.

Item 1A. Risk Factors.

We have set forth in Item 1A to our Annual Report on Form 10-K for the year ended December 31, 2022, risk factors relating to our business, our industry, our structure and our common stock. Readers of this Quarterly Report on Form 10-Q are referred to such Item 1A for a more complete understanding of risks concerning us. The risk factor disclosure in our Annual Report on Form 10-K for the year ended December 31, 2022 is qualified by the additional information that is described in this Quarterly Report on Form 10-Q, including the updated risk factor disclosure set forth below.

We may be unable to continue to commercialize Translarna for nonsense mutation Duchenne muscular dystrophy in the European Economic Area if the Committee for Medicinal Products for Human Use of the European Medicines Agency does not reverse its negative opinion on the renewal of the existing conditional authorization for Translarna.

Our marketing authorization for Translarna for the treatment of nonsense mutation Duchenne muscular dystrophy, or nmDMD, in ambulatory patients aged two years and older in the European Economic Area, or EEA, is subject to annual review and renewal by the European Commission, or EC, following reassessment by the European Medicines Agency, or EMA, of the benefit-risk balance of the authorization. In September 2022, we submitted a Type II variation to the EMA to support conversion of the conditional marketing authorization for Translarna to a standard marketing authorization, which included a report on the placebo-controlled trial of Study 041 and data from the open-label extension. In February 2023, we also submitted an annual marketing authorization renewal request to the EMA. In September 2023, the Committee for Medicinal Products for Human Use, or CHMP, gave a negative opinion on the conversion of the conditional marketing authorization to full marketing authorization of Translarna for the treatment of nmDMD and a negative opinion on the renewal of the existing conditional marketing authorization of Translarna for the treatment of nmDMD. We have requested re-examination of the CHMP opinion regarding the renewal of the existing conditional marketing authorization. In re-examination, we intend to address concerns raised during the previous review process on the benefit demonstrated in Translarna clinical trials and regarding the robustness of the Strategic Targeting of Registries and International Database of Excellence, or STRIDE, real world registry. In accordance with EMA guidelines, we expect the CHMP opinion following the re-examination process to occur in late January 2024, with European Commission, or EC, ratification of the opinion within the following 67 days.

While we have requested a re-examination of the CHMP opinion, the re-examination process may not result in a change to the negative opinion. If the CHMP does not reverse its negative opinion, the EC is likely to refuse to renew the marketing authorization for Translarna. Alternatively, the CHMP may recommend the imposition of other conditions or restrictions on our current marketing authorization. As such, there is substantial risk to our ability to maintain our conditional marketing authorization in the EEA and our ability to commercialize Translarna for the treatment of nmDMD in the EEA. If we are unable to renew our conditional marketing authorization in the EEA, or if our product label is materially restricted, we would lose all, or a significant portion of, our ability to generate revenue from sales of Translarna in the EEA, which would have a material adverse effect on our business, results of operations and financial condition.

Additionally, the CHMP’s negative opinion for Translarna and potential loss of the Translarna marketing authorization in the EEA may influence regulatory entities in other jurisdictions in which Translarna has been approved to reassess such approvals. For example, certain countries reference or depend on the determination by the EMA when considering the grant of a marketing authorization. There is substantial risk that we would be unable to maintain our marketing

64

authorizations in these countries in the event the EC decides not to renew or otherwise varies, suspends or withdraws our marketing authorization in the EEA. Even in countries where our marketing authorization is maintained, there may be an impact on pricing and reimbursement of Translarna within those countries. Any potential reassessments of our marketing authorizations or impacts to pricing and reimbursement may lead to additional regulatory costs, requirements to complete additional clinical trials, restrictions on our marketing authorizations or loss of a significant portion of our revenue for Translarna in other jurisdictions, which could have a material adverse effect on our business, results of operations and financial condition.

Item 5. Other Information.

Director and Officer Trading Arrangements

A portion of the compensation of our directors and officers (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended, or the Exchange Act) is in the form of equity awards and, from time to time, directors and officers engage in open-market transactions with respect to the securities acquired pursuant to such equity awards or other Company securities, including to satisfy tax withholding obligations when equity awards vest or are exercised, and for diversification or other personal reasons.

Transactions in Company securities by directors and officers are required to be made in accordance with our insider trading policy, which requires that the transactions be in accordance with applicable U.S. federal securities laws that prohibit trading while in possession of material nonpublic information. Rule 10b5-1 under the Exchange Act provides an affirmative defense that enables directors and officers to prearrange transactions in Company securities in a manner that avoids concerns about initiating transactions while in possession of material nonpublic information.

The following table describes, for the quarterly period covered by this report, each trading arrangement for the sale or purchase of Company securities adopted or terminated by our directors and officers that is either (1) a contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c), or a “Rule 10b5-1 trading arrangement”, or (2) a “non-Rule 10b5-1 trading arrangement” (as defined in Item 408(c) of Regulation S-K):

Name
(Title)

Action Taken
(Date of Action)

Type of Trading
Arrangement

Nature of Trading
Arrangement

Duration of Trading
Arrangement

Aggregate Number
of Securities

Pierre Gravier
(Chief Financial Officer)

Adoption
(July 13, 2023)

Rule 10b5-1 trading arrangement for sell-to-cover transactions for RSUs granted on July 13, 2023

Sale

Until final settlement of RSUs on or around July 13, 2027

Indeterminable (1)

(1) The number of shares subject to this RSU grant that will be sold to satisfy applicable tax withholding obligations upon vesting is unknown as the number will vary based on the extent to which vesting conditions are satisfied and the market price of the Company’s common stock at the time of settlement.  This trading arrangement provides for the automatic sale of shares that would otherwise be issuable on each settlement date of the RSU in an amount sufficient to satisfy the applicable withholding obligation, with the proceeds of the sale delivered to the Company in satisfaction of the applicable withholding obligation.

65

Item 6. Exhibits.

Exhibit Number

 

Description of Exhibit

10.1+

Employment Agreement between PTC Therapeutics, Inc. and Pierre Gravier (incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed by the Registrant on July 17, 2023)

31.1*

 

Certification of Principal Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

31.2*

 

Certification of Principal Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1*

 

Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

32.2*

 

Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101.INS*

 

Inline XBRL Instance Document

101.SCH*

 

Inline XBRL Taxonomy Extension Schema Document

101.CAL*

 

Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.LAB*

 

Inline XBRL Taxonomy Extension Label Linkbase Database

101.PRE*

 

Inline XBRL Taxonomy Extension Presentation Linkbase Document

101.DEF*

 

Inline XBRL Taxonomy Extension Definition Linkbase Document

104

The cover page from this Quarterly Report on Form 10-Q, formatted in Inline XBRL

*     Submitted electronically herewith.

† Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.

+

Management contract, compensatory plan or arrangement.

In accordance with SEC Release 33-8238, Exhibits 32.1 and 32.2 are being furnished and not filed.

66

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

PTC THERAPEUTICS, INC.

 

 

 

 

 

 

Date: October 26, 2023

By:

/s/ Pierre Gravier

Pierre Gravier

Chief Financial Officer

(Principal Financial Officer and Duly Authorized Signatory)

67

EX-31.1 2 tmb-20230930xex31d1.htm EX-31.1

Exhibit 31.1

CERTIFICATIONS

I, Matthew B. Klein, certify that:

1.           I have reviewed this Quarterly Report on Form 10-Q of PTC Therapeutics, Inc.;

2.           Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.           Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.           The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)            Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)            Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)            Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)            Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.            The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)            All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)            Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: October 26, 2023

By:

/s/ MATTHEW B. KLEIN

 

 

Matthew B. Klein

 

 

Chief Executive Officer

 

 

(Principal Executive Officer)


EX-31.2 3 tmb-20230930xex31d2.htm EX-31.2

Exhibit 31.2

CERTIFICATIONS

I, Pierre Gravier, certify that:

1.            I have reviewed this Quarterly Report on Form 10-Q of PTC Therapeutics, Inc.;

2.            Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.            Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.            The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)           Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)           Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)           Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)           Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.            The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a)            All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)            Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: October 26, 2023

By:

/s/ PIERRE GRAVIER

 

 

Pierre Gravier

 

 

Chief Financial Officer

 

 

(Principal Financial Officer)


EX-32.1 4 tmb-20230930xex32d1.htm EX-32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of PTC Therapeutics, Inc. (the “Company”) for the period ended September 30, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Matthew B. Klein, Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that to his knowledge:

(1)            the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)            the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: October 26, 2023

By:

/s/ MATTHEW B. KLEIN

 

 

Matthew B. Klein

 

 

Chief Executive Officer

 

 

(Principal Executive Officer)


EX-32.2 5 tmb-20230930xex32d2.htm EX-32.2

Exhibit 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of PTC Therapeutics, Inc. (the “Company”) for the period ended September 30, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Pierre Gravier, Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that to his knowledge:

(1)            the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)             the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: October 26, 2023

By:

/s/ PIERRE GRAVIER

Pierre Gravier

 

 

Chief Financial Officer

 

 

(Principal Financial Officer)


EX-101.SCH 6 tmb-20230930.xsd EX-101.SCH 00100 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00200 - Statement - Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 00300 - Statement - Consolidated Statements of Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 00500 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 40204 - Disclosure - Summary of significant accounting policies - Inventory (Details) link:presentationLink link:calculationLink link:definitionLink 40301 - Disclosure - Leases - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 40302 - Disclosure - Leases - Lease costs (Details) link:presentationLink link:calculationLink link:definitionLink 40305 - Disclosure - Leases - Lease payments (Details) link:presentationLink link:calculationLink link:definitionLink 40403 - Disclosure - Fair value of financial instruments and investments - Marketable Securities, Unrealized Gains (Losses) (Details) link:presentationLink link:calculationLink link:definitionLink 40404 - Disclosure - Fair value of financial instruments and investments - Available-for-sale securities (Details) link:presentationLink link:calculationLink link:definitionLink 40501 - Disclosure - Accounts payable and accrued expenses - Components (Details) link:presentationLink link:calculationLink link:definitionLink 40902 - Disclosure - Debt - Senior Secured Term Loan (Details) link:presentationLink link:calculationLink link:definitionLink 40904 - Disclosure - Debt - Convertible Notes (Details) link:presentationLink link:calculationLink link:definitionLink 41202 - Disclosure - Intangible assets and goodwill - Future Amortization (Details) link:presentationLink link:calculationLink link:definitionLink 00400 - Statement - Consolidated Statements of Stockholders' (Deficit) Equity link:presentationLink link:calculationLink link:definitionLink 30903 - Disclosure - Debt - (Tables) link:presentationLink link:calculationLink link:definitionLink 40101 - Disclosure - The Company (Details) link:presentationLink link:calculationLink link:definitionLink 40201 - Disclosure - Summary of significant accounting policies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 40205 - Disclosure - Summary of significant accounting policies - Collaboration and Royalty Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 40206 - Disclosure - Summary of significant accounting policies - Manufacturing Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 40207 - Disclosure - Summary of significant accounting policies - Liability for Sale of Future Royalties (Details) link:presentationLink link:calculationLink link:definitionLink 40401 - Disclosure - Fair value of financial instruments and investments - Marketable Securities (Details) link:presentationLink link:calculationLink link:definitionLink 40402 - Disclosure - Fair value of financial instruments and investments - Hierarchy (Details) link:presentationLink link:calculationLink link:definitionLink 40405 - Disclosure - Fair value of financial instruments and investments - Marketable Securities, Balance Sheet Disclosures (Details) link:presentationLink link:calculationLink link:definitionLink 40406 - Disclosure - Fair value of financial instruments and investments - Convertible senior notes (Details) link:presentationLink link:calculationLink link:definitionLink 40407 - Disclosure - Fair value of financial instruments and investments - Summary of changes in the fair value of the Company's Level 3 valuation (Details) link:presentationLink link:calculationLink link:definitionLink 40408 - Disclosure - Fair value of financial instruments and investments - Fair Value Liabilities Measured (Details) link:presentationLink link:calculationLink link:definitionLink 40502 - Disclosure - Accounts payable and accrued expenses - Restructuring (Details) link:presentationLink link:calculationLink link:definitionLink 40601 - Disclosure - Capitalization - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 40702 - Disclosure - Net loss per share - Antidilutive (Details) link:presentationLink link:calculationLink link:definitionLink 40801 - Disclosure - Stock award plan - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 40802 - Disclosure - Stock award plan - Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 40803 - Disclosure - Stock award plan - Assumptions Used (Details) link:presentationLink link:calculationLink link:definitionLink 40804 - Disclosure - Stock award plan - Restricted Stock (Details) link:presentationLink link:calculationLink link:definitionLink 40805 - Disclosure - Stock award plan - Share-based compensation expense (Details) link:presentationLink link:calculationLink link:definitionLink 40901 - Disclosure - Debt - Liability for Sale of Future Royalties (Details) link:presentationLink link:calculationLink link:definitionLink 40903 - Disclosure - Debt - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 40905 - Disclosure - Debt - Convertible Notes Interest Expense (Details) link:presentationLink link:calculationLink link:definitionLink 41001 - Disclosure - Commitments and contingencies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 41101 - Disclosure - Revenue recognition - Net Product Sales (Details) link:presentationLink link:calculationLink link:definitionLink 41102 - Disclosure - Revenue recognition - Collaboration and Royalty Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 41103 - Disclosure - Revenue recognition - Manufacturing Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 41104 - Disclosure - Revenue recognition - Performance Obligations (Details) link:presentationLink link:calculationLink link:definitionLink 41104 - Disclosure - Revenue recognition - Performance Obligations Default (Details) link:presentationLink link:calculationLink link:definitionLink 41201 - Disclosure - Intangible assets and goodwill - Definite-lived Intangibles (Details) link:presentationLink link:calculationLink link:definitionLink 41203 - Disclosure - Intangible assets and goodwill - Indefinite-lived Intangibles (Details) link:presentationLink link:calculationLink link:definitionLink 41204 - Disclosure - Intangible assets and goodwill - Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 41301 - Disclosure - Subsequent events (Details) link:presentationLink link:calculationLink link:definitionLink 00090 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00105 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 10101 - Disclosure - The Company link:presentationLink link:calculationLink link:definitionLink 10201 - Disclosure - Summary of significant accounting policies link:presentationLink link:calculationLink link:definitionLink 10301 - Disclosure - Leases link:presentationLink link:calculationLink link:definitionLink 10401 - Disclosure - Fair value of financial instruments and investments link:presentationLink link:calculationLink link:definitionLink 10501 - Disclosure - Accounts payable and accrued expenses link:presentationLink link:calculationLink link:definitionLink 10601 - Disclosure - Capitalization link:presentationLink link:calculationLink link:definitionLink 10701 - Disclosure - Net loss per share link:presentationLink link:calculationLink link:definitionLink 10801 - Disclosure - Stock award plan link:presentationLink link:calculationLink link:definitionLink 10901 - Disclosure - Debt link:presentationLink link:calculationLink link:definitionLink 11001 - Disclosure - Commitments and contingencies link:presentationLink link:calculationLink link:definitionLink 11101 - Disclosure - Revenue recognition link:presentationLink link:calculationLink link:definitionLink 11201 - Disclosure - Intangible assets and goodwill link:presentationLink link:calculationLink link:definitionLink 11301 - Disclosure - Subsequent events link:presentationLink link:calculationLink link:definitionLink 20202 - Disclosure - Summary of significant accounting policies (Policies) link:presentationLink link:calculationLink link:definitionLink 30203 - Disclosure - Summary of significant accounting policies (Tables) link:presentationLink link:calculationLink link:definitionLink 30303 - Disclosure - Leases - (Tables) link:presentationLink link:calculationLink link:definitionLink 30403 - Disclosure - Fair value of financial instruments and investments - (Tables) link:presentationLink link:calculationLink link:definitionLink 30503 - Disclosure - Accounts payable and accrued expenses - (Tables) link:presentationLink link:calculationLink link:definitionLink 30703 - Disclosure - Net loss per share - (Tables) link:presentationLink link:calculationLink link:definitionLink 30803 - Disclosure - Stock award plan - (Tables) link:presentationLink link:calculationLink link:definitionLink 31203 - Disclosure - Intangible assets and goodwill - (Tables) link:presentationLink link:calculationLink link:definitionLink 40202 - Disclosure - Summary of significant accounting policies - Reconciliation of cash (Details) link:presentationLink link:calculationLink link:definitionLink 40303 - Disclosure - Leases - Supplemental lease terms (Details) link:presentationLink link:calculationLink link:definitionLink 40304 - Disclosure - Leases - Cash flow (Details) link:presentationLink link:calculationLink link:definitionLink 40701 - Disclosure - Net loss per share - Numerator and Denominator (Details) link:presentationLink link:calculationLink link:definitionLink 99900 - Disclosure - Standard And Custom Axis Domain Defaults link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 tmb-20230930_cal.xml EX-101.CAL EX-101.DEF 8 tmb-20230930_def.xml EX-101.DEF EX-101.LAB 9 tmb-20230930_lab.xml EX-101.LAB EX-101.PRE 10 tmb-20230930_pre.xml EX-101.PRE XML 11 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover - shares
9 Months Ended
Sep. 30, 2023
Oct. 24, 2023
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Sep. 30, 2023  
Document Transition Report false  
Entity File Number 001-35969  
Entity Registrant Name PTC Therapeutics, Inc.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 04-3416587  
Entity Address, Address Line One 100 Corporate Court  
Entity Address, City or Town South Plainfield  
Entity Address, State or Province NJ  
Entity Address, Postal Zip Code 07080  
City Area Code 908  
Local Phone Number 222-7000  
Title of 12(b) Security Common Stock, $0.001 par value per share  
Trading Symbol PTCT  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   75,463,145
Entity Central Index Key 0001070081  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2023  
Document Fiscal Period Focus Q3  
Amendment Flag false  
XML 12 R2.htm IDEA: XBRL DOCUMENT v3.23.3
Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:    
Cash and cash equivalents $ 165,157 $ 279,834
Marketable securities 129,653 130,871
Trade and royalty receivables, net 165,718 155,614
Inventory, net 35,752 21,808
Prepaid expenses and other current assets 44,082 105,658
Total current assets 540,362 693,785
Fixed assets, net 85,031 72,590
Intangible assets, net 423,342 705,891
Goodwill 82,341 82,341
Operating lease ROU assets 94,072 102,430
Deposits and other assets 34,737 48,582
Total assets 1,259,885 1,705,619
Current liabilities:    
Accounts payable and accrued expenses 370,731 320,366
Deferred revenue 1,224 1,351
Operating lease liabilities- current 11,703 9,370
Finance lease liabilities- current 2,611 3,000
Liability for sale of future royalties - current 105,849 72,149
Total current liabilities 492,118 406,236
Long-term debt 573,174 571,722
Contingent consideration payable 39,000 164,000
Deferred tax liability 51,927 102,834
Operating lease liabilities- noncurrent 99,682 100,860
Finance lease liabilities- noncurrent 17,184 18,675
Liability for sale of future royalties- noncurrent 657,469 685,737
Other long-term liabilities 141 2,641
Total liabilities 1,930,695 2,052,705
Stockholders' deficit:    
Common stock, $0.001 par value. Authorized 250,000,000 shares; issued and outstanding 75,459,022 shares at September 30, 2023. Authorized 250,000,000 shares; issued and outstanding 73,104,692 shares at December 31, 2022 75 72
Additional paid-in capital 2,447,292 2,305,020
Accumulated other comprehensive income 9,609 4,796
Accumulated deficit (3,127,786) (2,656,974)
Total stockholders' deficit (670,810) (347,086)
Total liabilities and stockholders' deficit $ 1,259,885 $ 1,705,619
XML 13 R3.htm IDEA: XBRL DOCUMENT v3.23.3
Consolidated Balance Sheets (Parenthetical) - $ / shares
Sep. 30, 2023
Dec. 31, 2022
Statement of Financial Position [Abstract]    
Common stock, par value (in dollars per share) $ 0.001 $ 0.001
Common stock, authorized shares (in shares) 250,000,000 250,000,000
Common stock, issued shares (in shares) 75,459,022 73,104,692
Common stock, outstanding shares (in shares) 75,459,022 73,104,692
XML 14 R4.htm IDEA: XBRL DOCUMENT v3.23.3
Consolidated Statements of Operations - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Revenues:        
Revenue $ 196,576 $ 217,127 $ 630,766 $ 531,389
Operating expenses:        
Cost of product sales, excluding amortization of acquired intangible assets 9,493 14,011 36,368 33,785
Amortization of intangible assets 58,649 31,023 145,461 80,790
Research and development 164,212 165,462 545,210 462,802
Selling, general and administrative 80,886 80,118 256,249 233,280
Change in the fair value of contingent consideration 1,500 (5,300) (125,000) (32,200)
Intangible asset impairment     217,800  
Total operating expenses 314,740 285,314 1,076,088 778,457
Loss from operations (118,164) (68,187) (445,322) (247,068)
Interest expense, net (28,160) (20,880) (84,905) (66,371)
Other expense, net (20,266) (38,141) (8,832) (84,355)
Loss before income tax benefit (166,590) (127,208) (539,059) (397,794)
Income tax benefit 33,620 17,893 68,247 9,666
Net loss attributable to common stockholders $ (132,970) $ (109,315) $ (470,812) $ (388,128)
Weighted-average shares outstanding:        
Basic 75,377,997 71,654,671 74,618,611 71,415,849
Diluted 75,377,997 71,654,671 74,618,611 71,415,849
Net loss per share-basic and diluted (in dollars per share)        
Basic $ (1.76) $ (1.53) $ (6.31) $ (5.43)
Diluted $ (1.76) $ (1.53) $ (6.31) $ (5.43)
Net product revenue        
Revenues:        
Revenue $ 144,038 $ 134,186 $ 506,187 $ 407,720
Collaboration revenue        
Revenues:        
Revenue 0 50,017 6 50,024
Royalty revenue        
Revenues:        
Revenue 50,173 32,924 117,857 73,645
Manufacturing revenue        
Revenues:        
Revenue $ 2,365 $ 0 $ 6,716 $ 0
XML 15 R5.htm IDEA: XBRL DOCUMENT v3.23.3
Consolidated Statements of Comprehensive Loss - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Statement of Comprehensive Income [Abstract]        
Net Income (Loss) $ (132,970) $ (109,315) $ (470,812) $ (388,128)
Other comprehensive income (loss):        
Unrealized gain (loss) on marketable securities, net of tax 19 736 470 (2,333)
Foreign currency translation gain, net of tax 11,021 25,218 4,343 62,820
Comprehensive loss $ (121,930) $ (83,361) $ (465,999) $ (327,641)
XML 16 R6.htm IDEA: XBRL DOCUMENT v3.23.3
Consolidated Statements of Stockholders' (Deficit) Equity - USD ($)
$ in Thousands
Common stock
Additional paid-in capital
Accumulated other comprehensive income (loss)
Accumulated deficit
Total
Balance (in shares) at Dec. 31, 2021 70,828,226        
Balance at the beginning of the period at Dec. 31, 2021 $ 71 $ 2,123,606 $ (24,282) $ (2,097,957) $ 1,438
Increase (Decrease) in Stockholders' Equity          
Exercise of options (in shares) 456,399        
Exercise of options   13,203     13,203
Restricted stock vesting and issuance (in shares) 479,004        
Issuance of common stock in connection with an employee stock purchase plan (in shares) 91,263        
Issuance of common stock in connection with an employee stock purchase plan   3,107     3,107
Share-based compensation expense   82,989     82,989
Net Income (Loss)       (388,128) (388,128)
Comprehensive income     60,487   60,487
Balance (in shares) at Sep. 30, 2022 71,854,892        
Balance at the end of the period at Sep. 30, 2022 $ 71 2,222,905 36,205 (2,486,085) (226,904)
Balance (in shares) at Jun. 30, 2022 71,505,889        
Balance at the beginning of the period at Jun. 30, 2022 $ 71 2,184,230 10,251 (2,376,770) (182,218)
Increase (Decrease) in Stockholders' Equity          
Exercise of options (in shares) 331,379        
Exercise of options   10,005     10,005
Restricted stock vesting and issuance (in shares) 17,624        
Share-based compensation expense   28,670     28,670
Net Income (Loss)       (109,315) (109,315)
Comprehensive income     25,954   25,954
Balance (in shares) at Sep. 30, 2022 71,854,892        
Balance at the end of the period at Sep. 30, 2022 $ 71 2,222,905 36,205 (2,486,085) (226,904)
Balance (in shares) at Dec. 31, 2022 73,104,692        
Balance at the beginning of the period at Dec. 31, 2022 $ 72 2,305,020 4,796 (2,656,974) (347,086)
Increase (Decrease) in Stockholders' Equity          
Exercise of options (in shares) 806,407        
Exercise of options $ 1 23,770     23,771
Restricted stock vesting and issuance (in shares) 773,157        
Restricted stock vesting and issuance, net $ 1       1
Issuance of common stock in connection with an employee stock purchase plan (in shares) 117,304        
Issuance of common stock in connection with an employee stock purchase plan   3,805     3,805
Issuance of common stock in connection with a milestone payable (in shares) 657,462        
Issuance of common stock in connection with a milestone payable $ 1 29,569     29,570
Share-based compensation expense   85,128     85,128
Net Income (Loss)       (470,812) (470,812)
Comprehensive income     4,813   4,813
Balance (in shares) at Sep. 30, 2023 75,459,022        
Balance at the end of the period at Sep. 30, 2023 $ 75 2,447,292 9,609 (3,127,786) (670,810)
Balance (in shares) at Jun. 30, 2023 75,318,233        
Balance at the beginning of the period at Jun. 30, 2023 $ 75 2,416,904 (1,431) (2,994,816) (579,268)
Increase (Decrease) in Stockholders' Equity          
Exercise of options (in shares) 113,795        
Exercise of options   3,446     3,446
Restricted stock vesting and issuance (in shares) 26,994        
Share-based compensation expense   26,942     26,942
Net Income (Loss)       (132,970) (132,970)
Comprehensive income     11,040   11,040
Balance (in shares) at Sep. 30, 2023 75,459,022        
Balance at the end of the period at Sep. 30, 2023 $ 75 $ 2,447,292 $ 9,609 $ (3,127,786) $ (670,810)
XML 17 R7.htm IDEA: XBRL DOCUMENT v3.23.3
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Cash flows from operating activities    
Net Income (Loss) $ (470,812) $ (388,128)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 155,885 89,971
Non-cash operating lease expense 8,156 7,505
Non-cash royalty revenue related to sale of future royalties (50,599) (31,617)
Non-cash interest expense on liability related to sale of future royalties 56,031 55,778
Intangible asset impairment 217,800  
Change in valuation of contingent consideration (125,000) (32,200)
Unrealized loss on ClearPoint Equity Investments 3,107 1,113
Unrealized loss on ClearPoint convertible debt security 4,594 2,392
Unrealized (gain) loss on marketable securities - equity investments (5,484) 11,319
Realized loss for the sale of Clearpoint Equity Investment 782  
Non-cash stock consideration, milestone payment 29,570  
Disposal of asset 135 81
Amortization of (discounts) premiums on investments, net (89) 1,792
Deferred income taxes (50,909)  
Amortization of debt issuance costs 1,574 1,316
Share-based compensation expense 85,128 82,989
Unrealized foreign currency transaction losses, net 3,394 71,246
Changes in operating assets and liabilities:    
Inventory, net (14,121) (768)
Prepaid expenses and other current assets 59,467 (35,615)
Trade and royalty receivables, net (9,887) (24,773)
Deposits and other assets 4,597 (3,752)
Accounts payable and accrued expenses 40,434 1,568
Other liabilities (1,756) (908)
Deferred revenue (127)  
Net cash used in operating activities (58,130) (190,691)
Cash flows from investing activities    
Purchases of fixed assets (22,872) (23,394)
Purchases of marketable securities - available for sale   (40,429)
Purchases of marketable securities - equity investments (26,378) (22,787)
Sale and redemption of marketable securities- available for sale 21,544 341,990
Sale and redemption of marketable securities - equity investments 12,078 104,431
Sale and redemption of ClearPoint Equity Investments 2,594  
Acquisition of product rights and licenses (69,285) (102,069)
Net cash (used in) provided by investing activities (82,319) 257,742
Cash flows from financing activities    
Proceeds from exercise of options 23,771 13,203
Debt issuance costs related to secured term loan (282)  
Repayment of Convertible Notes   (150,000)
Proceeds from employee stock purchase plan 3,805 3,107
Payment of finance lease principal (1,379) (1,276)
Net cash provided by (used in) financing activities 25,915 (134,966)
Effect of exchange rate changes on cash 19 (8,792)
Net decrease in cash and cash equivalents (114,515) (76,707)
Cash and cash equivalents, and restricted cash beginning of period 295,925 197,218
Cash and cash equivalents, and restricted cash end of period 181,410 120,511
Supplemental disclosure of cash information    
Cash paid for interest 34,020 12,679
Cash paid for income taxes 13,631 4,029
Supplemental disclosure of non-cash investing and financing activity    
Unrealized gain (loss) on marketable securities, net of tax 470 (2,333)
Right-of-use assets obtained in exchange for operating lease obligations   35,294
Acquisition of product rights and licenses 44,963 27,828
Milestone payable $ 2,500 $ 50,000
XML 18 R8.htm IDEA: XBRL DOCUMENT v3.23.3
The Company
9 Months Ended
Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
The Company

1.        The Company

PTC Therapeutics, Inc. (the “Company” or “PTC”) is a science-driven global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. PTC’s ability to innovate to identify new therapies and to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines. PTC’s mission is to provide access to best-in-class treatments for patients who have little to no treatment options. PTC’s strategy is to leverage its strong scientific and clinical expertise and global commercial infrastructure to bring therapies to patients.  PTC believes that this allows it to maximize value for all of its stakeholders.

PTC has a portfolio pipeline that includes several commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology, metabolism and oncology.

The Company has two products, Translarna™ (ataluren) and Emflaza® (deflazacort), for the treatment of Duchenne muscular dystrophy (“DMD”), a rare, life threatening disorder. Translarna has marketing authorization in the European Economic Area (the “EEA”) for the treatment of nonsense mutation Duchenne muscular dystrophy (“nmDMD”) in ambulatory patients aged 2 years and older and in Russia for the treatment of nmDMD in patients aged two years and older. Translarna also has marketing authorization in Brazil for the treatment of nmDMD in ambulatory patients two years and older and for continued treatment of patients that become non-ambulatory. In July 2020, the European Commission (“EC”) approved the removal of the statement “efficacy has not been demonstrated in non-ambulatory patients” from the indication statement for Translarna. Emflaza is approved in the United States for the treatment of DMD in patients two years and older.

The Company’s marketing authorization for Translarna in the EEA is subject to annual review and renewal by the EC following reassessment by the European Medicines Agency (“EMA”) of the benefit-risk balance of the authorization, which the Company refers to as the annual EMA reassessment. In September 2022, the Company submitted a Type II variation to the EMA to support conversion of the conditional marketing authorization for Translarna to a standard marketing authorization, which included a report on the placebo-controlled trial of Study 041 and data from the open-label extension. In February 2023, the Company also submitted an annual marketing authorization renewal request to the EMA. In September 2023, the Committee for Medicinal Products for Human Use (“CHMP’), gave a negative opinion on the conversion of the conditional marketing authorization to full marketing authorization of Translarna for the treatment of nmDMD and a negative opinion on the renewal of the existing conditional marketing authorization of Translarna for the treatment of nmDMD. The Company has requested re-examination of the CHMP opinion regarding the renewal of the existing conditional marketing authorization. In re-examination, the Company intends to address concerns raised during the previous review process on the benefit demonstrated in Translarna clinical trials and regarding the robustness of the Strategic Targeting of Registries and International Database of Excellence, or STRIDE, real world registry. In accordance with EMA guidelines, the Company expects the CHMP opinion following the re-examination process to occur in late January 2024, with EC ratification of the opinion within the following 67 days.

Translarna is an investigational new drug in the United States. Following the Company’s announcement of top-line results from the placebo-controlled trial of Study 041 in June 2022, the Company submitted a meeting request to the U.S. Food and Drug Administration (“FDA”) to gain clarity on the regulatory pathway for a potential re-submission of a New Drug Application (“NDA”) for Translarna. The FDA provided initial written feedback that Study 041 does not provide substantial evidence of effectiveness to support an NDA re-submission. The Company then had an informal meeting with the FDA, during which the Company discussed the potential path to an NDA re-submission for Translarna. Based on the meeting discussion, the Company has scheduled an additional Type C meeting with the FDA to review the totality of data

collected to date, including dystrophin and other mechanistic data as well as additional analyses that could support the benefit of Translarna.

The Company has developed Upstaza (eladocagene exuparvovec), a gene therapy used for the treatment of Aromatic L-Amino Acid Decarboxylase (“AADC”) deficiency (“AADC deficiency”), a rare central nervous system (“CNS”) disorder arising from reductions in the enzyme AADC that results from mutations in the dopa decarboxylase gene. In July 2022, the EC approved Upstaza for the treatment of AADC deficiency for patients 18 months and older within the EEA. In November 2022, the Medicines and Healthcare Products Regulatory Agency approved Upstaza for the treatment of AADC deficiency for patients 18 months and older within the United Kingdom. The Company is also preparing a biologics license application (“BLA”) for Upstaza for the treatment of AADC deficiency in the United States and anticipates submitting the BLA shortly after its pre-BLA meeting that is scheduled for December 2023, pending the outcome of such meeting.

The Company holds the rights for the commercialization of Tegsedi® (inotersen) and Waylivra® (volanesorsen) for the treatment of rare diseases in countries in Latin America and the Caribbean pursuant to the Collaboration and License Agreement (the “Tegsedi-Waylivra Agreement”), dated August 1, 2018, by and between the Company and Akcea Therapeutics, Inc. (“Akcea”), a subsidiary of Ionis Pharmaceuticals, Inc. Tegsedi has received marketing authorization in the United States, the European Union (the “EU”) and Brazil for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis (“hATTR amyloidosis”). The Company began to make commercial sales of Tegsedi for the treatment of hATTR amyloidosis in Brazil in the second quarter of 2022 and it continues to make Tegsedi available in certain other countries within Latin America and the Caribbean through early access programs (“EAP Programs”). In August 2021, ANVISA, the Brazilian health regulatory authority, approved Waylivra as the first treatment for familial chylomicronemia syndrome (“FCS”) in Brazil and the Company began to make commercial sales of Waylivra in Brazil in the third quarter of 2022 while continuing to make Waylivra available in certain other countries within Latin America and the Caribbean through EAP Programs. In December 2022, ANVISA approved Waylivra for the treatment of familial partial lipodystrophy (“FPL”). Waylivra has also received marketing authorization in the EU for the treatment of FCS.

The Company also has a spinal muscular atrophy (“SMA”) collaboration with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc. (referred to collectively as “Roche”) and the Spinal Muscular Atrophy Foundation (“SMA Foundation”). The SMA program has one approved product, Evrysdi® (risdiplam), which was approved by the FDA in August 2020 for the treatment of SMA in adults and children two months and older and by the EC in March 2021 for the treatment of 5q SMA in patients two months and older with a clinical diagnosis of SMA Type 1, Type 2 or Type 3 or with one to four SMN2 copies. Evrysdi also received marketing authorization for the treatment of SMA in Brazil in October 2020 and Japan in June 2021. In May 2022, the FDA approved a label expansion for Evrysdi to include infants under two months old with SMA. In August 2023, the EC approved an extension of the Evrysdi marketing authorization to include infants under two months old in the EU. In addition to the Company’s SMA program, the Company’s splicing platform also includes PTC518, which is being developed for the treatment of Huntington’s disease (“HD”). The Company initiated a Phase 2 study of PTC518 for the treatment of HD in the first quarter of 2022, which consists of an initial 12-week placebo-controlled phase focused on safety, pharmacology and pharmacodynamic effects followed by a nine-month placebo-controlled phase focused on PTC518 biomarker effect. In June 2023, the Company announced interim data from the 12-week placebo-controlled phase. The Company expects the next data update from the Phase 2 study of PTC518 for the treatment of HD in the first half of 2024. In the Phase 2 study, enrollment outside of the United States remains active and ongoing while enrollment within the United States is paused as the FDA requested additional data to allow the Phase 2 study to proceed. The Company had a Type A meeting with the FDA to review the clinical safety data needed to enable resumption of enrollment in the United States. At that meeting, the FDA stated that the existing three-month safety data could support 12-week dosing and that six months of clinical safety data could support dosing in the 12-month Phase 2 study.

The most advanced molecule in the Company’s metabolic platform is sepiapterin, a precursor to intracellular tetrahydrobiopterin, which is a critical enzymatic cofactor involved in metabolism and synthesis of numerous metabolic products, for orphan diseases. In May 2023, the Company announced that the primary endpoint was achieved in its registration-directed Phase 3 trial for sepiapterin for phenylketonuria (“PKU”). The primary endpoint of the study was the achievement of statistically-significant reduction in blood Phe level. The Company participated in a pre-NDA meeting with the FDA in the third quarter of 2023. At that meeting, the FDA stated that the sepiapterin clinical safety and efficacy

data supported NDA submission for the treatment of pediatric and adult PKU patients. However, the FDA has requested that PTC completes a 26-week nonclinical mouse study to assess sepiapterin carcinogenicity potential prior to NDA submission. PTC expects to submit an NDA to the FDA for sepiapterin for the treatment of PKU by the end of the third quarter of 2024 and PTC intends to discuss with the FDA the potential for an earlier submission if PTC is permitted to submit the 26-week mouse study report during the review process of the NDA. Additionally, PTC expects to submit a marketing authorization application (“MAA”) to the EMA for sepiapterin for the treatment of PKU in the EEA in the first half of 2024.

The Company’s Bio-e platform consists of small molecule compounds that target oxidoreductase enzymes that regulate oxidative stress and inflammatory pathways central to the pathology of a number of CNS diseases. The two most advanced molecules in the Company’s Bio-e platform are vatiquinone and utreloxastat. The Company announced topline results from a registration-directed Phase 3 trial of vatiquinone in children and young adults with Friedreich ataxia in May 2023. While the study did not meet its primary endpoint of statistically significant change, the Company participated in a Type C written response only meeting with the FDA in the third quarter of 2023 to discuss the potential for an NDA submission for vatiquinone for the treatment of Friedreich ataxia. In their written response, the FDA stated that while they see the value of upright stability as a clinically meaningful endpoint, they believed a confirmatory study would likely be needed to support NDA submission. PTC has requested a follow-up live meeting to address the issues raised by the FDA.  Additionally, PTC is participating in a scientific advice procedure with the EMA to determine if the data from the registration-directed Phase 3 trial of vatiquinone in children and young adults with Friedreich ataxia could support a conditional MAA in the EEA. The Company initiated a Phase 2 trial of utreloxastat for amyotrophic lateral sclerosis in the first quarter of 2022 and enrollment is ongoing.

Unesbulin is the Company’s most advanced oncology agent. The Company completed its Phase 1 trials evaluating unesbulin in leiomyosarcoma (“LMS”) and diffuse intrinsic pontine glioma (“DIPG”) in the fourth quarter of 2021. The Company initiated a registration-directed Phase 2/3 trial of unesbulin for the treatment of LMS in the first quarter of 2022 and enrollment is ongoing. The Company is evaluating its plans for a potential initiation of a registration-directed Phase 2/3 trial of unesbulin for the treatment of DIPG.

In addition, the Company has a pipeline of product candidates and discovery programs that are in early clinical, pre-clinical and research and development stages focused on the development of new treatments for multiple therapeutic areas for rare diseases.

As of September 30, 2023, the Company had an accumulated deficit of approximately $3,127.8 million. The Company has financed its operations to date primarily through the private offerings in September 2019 of 1.50% convertible senior notes due 2026 (see Note 9), public offerings of common stock in February 2014, October 2014, April 2018, January 2019, and September 2019, “at the market offering” of its common stock, its initial public offering of common stock in June 2013, proceeds from the Royalty Purchase Agreement dated as of July 17, 2020, by and among the Company, RPI 2019 Intermediate Finance Trust (“RPI”), and, solely for the limited purposes set forth therein, Royalty Pharma PLC (the “Royalty Purchase Agreement”) (see Note 2), net proceeds from the Company’s’ borrowings under its credit agreement with Blackstone (see Note 9), private placements of its convertible preferred stock and common stock, collaborations, bank and institutional lender debt, other convertible debt, grant funding and clinical trial support from governmental and philanthropic organizations and patient advocacy groups in the disease area addressed by the Company’s product candidates. The Company has also relied on revenue generated from net sales of Translarna for the treatment of nmDMD in territories outside of the United States since 2014, Emflaza for the treatment of DMD in the United States since 2017, and Upstaza for the treatment of AADC deficiency in the EEA since May 2022. The Company has also relied on revenue associated with milestone and royalty payments from Roche pursuant to the License and Collaboration Agreement (the “SMA License Agreement”) dated as of November 23, 2011, by and among the Company, Roche and, for the limited purposes set forth therein, the SMA Foundation, under its SMA program. The Company expects that cash flows from the sales of its products, milestone and royalty payments from Roche, together with the Company’s cash, cash equivalents and marketable securities, will be sufficient to fund its operations for at least the next twelve months.

XML 19 R9.htm IDEA: XBRL DOCUMENT v3.23.3
Summary of significant accounting policies
9 Months Ended
Sep. 30, 2023
Accounting Policies [Abstract]  
Summary of significant accounting policies

2.        Summary of significant accounting policies

The Company’s complete listing of significant accounting policies is set forth in Note 2 of the notes to the Company’s audited financial statements as of December 31, 2022 included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC") on February 21, 2023 (the "2022 Form 10-K"). Selected significant accounting policies are discussed in further detail below.

Basis of presentation

The accompanying financial information as of September 30, 2023 and for the three and nine months ended September 30, 2023 and 2022 has been prepared by the Company, without audit, pursuant to the rules and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States ("GAAP") have been condensed or omitted pursuant to such rules and regulations. These interim financial statements should be read in conjunction with the Company’s audited financial statements as of December 31, 2022 and notes thereto included in the 2022 Form 10-K.

In the opinion of management, the unaudited financial information as of September 30, 2023 and for the three and nine months ended September 30, 2023 and 2022 reflects all adjustments, which are normal recurring adjustments, necessary to present a fair statement of financial position, results of operations, stockholders’ (deficit) equity, and cash flows. The results of operations for the three and nine months ended September 30, 2023 are not necessarily indicative of the results to be expected for the year ended December 31, 2023 or for any other interim period or for any other future year.

Use of estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates in these consolidated financial statements have been made in connection with the calculation of net product sales, royalty revenue, certain accruals related to the Company’s research and development expenses, valuation procedures for liability for sale of future royalties, valuation procedures for convertible notes, fair value of the contingent consideration, and the provision for or benefit from income taxes. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.

Restricted cash

Restricted cash included in deposits and other assets on the consolidated balance sheet contains an unconditional, irrevocable and transferable letter of credit that was entered into during the twelve-month period ended December 31, 2019 in connection with obligations under a facility lease for the Company’s leased biologics manufacturing facility in Hopewell Township, New Jersey. The amount of the letter of credit is $7.5 million, is to be maintained for a term of not less than five years and has the potential to be reduced to $3.8 million if after five years the Company is not in default of its lease. Restricted cash also contains an unconditional, irrevocable and transferable letter of credit that was entered into during June 2022 in connection with obligations for the Company’s new facility lease in Warren, New Jersey. The amount of the letter of credit is $8.1 million and has the potential to be reduced to $4.1 million if after five years the Company is not in default of its lease. Both amounts are classified within deposits and other assets on the consolidated balance sheet due to the long-term nature of the respective letters of credit. Restricted cash also includes a bank guarantee of $0.6 million denominated in a foreign currency.

The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheet that sum to the total of the same amounts shown in the statement of cash flows:

    

End of

    

Beginning of

 

period-

 

period-

 

September 30, 

 

December 31, 

 

2023

2022

Cash and cash equivalents

$

165,157

$

279,834

Restricted cash included in deposits and other assets

 

16,253

 

16,091

Total Cash, cash equivalents and restricted cash per statement of cash flows

$

181,410

$

295,925

Marketable securities

The Company’s marketable securities consists of both debt securities and equity investments. The Company considers its investments in debt securities with original maturities of greater than 90 days to be available for sale securities. Securities under this classification are recorded at fair value and unrealized gains and losses within accumulated other comprehensive income. The estimated fair value of the available for sale securities is determined based on quoted market prices or rates for similar instruments. In addition, the cost of debt securities in this category is adjusted for amortization of premium and accretion of discount to maturity. For available for sale debt securities in an unrealized loss position, the Company assesses whether it intends to sell or if it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security’s amortized cost basis is written down to fair value. If the criteria are not met, the Company evaluates whether the decline in fair value has resulted from a credit loss or other factors. In making this assessment, management considers, among other factors, the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and adverse conditions specifically related to the security. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security are compared to the amortized cost basis of the security. If the present value of the cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded for the credit loss, limited by the amount that the fair value is less than the amortized costs basis. Any impairment that has not been recorded through an allowance for credit losses is recognized in other comprehensive income. For the three and nine months ended September 30, 2023 and 2022, no allowance was recorded for credit losses.

Marketable securities that are equity investments are measured at fair value, as it is readily available, and as such are classified as Level 1 assets. Unrealized holding gains and losses for these equity investments are components of other (expense) income, net within the consolidated statement of operations.

Inventory and cost of product sales

Inventory

Inventories are stated at the lower of cost and net realizable value with cost determined on a first-in, first-out basis by product. The Company capitalizes inventory costs associated with products following regulatory approval when future commercialization is considered probable and the future economic benefit is expected to be realized. Products which may be used in clinical development programs are included in inventory and charged to research and development expense when the product enters the research and development process and no longer can be used for commercial purposes. Inventory used for marketing efforts are charged to selling, general and administrative expense. Amounts related to clinical development programs and marketing efforts are immaterial.

The following table summarizes the components of the Company’s inventory for the periods indicated:

    

September 30, 2023

    

December 31, 2022

Raw materials

$

907

$

1,078

Work in progress

 

24,595

 

14,074

Finished goods

 

10,250

 

6,656

Total inventory

$

35,752

$

21,808

The Company periodically reviews its inventories for excess amounts or obsolescence and writes down obsolete or otherwise unmarketable inventory to its estimated net realizable value. For the three months ended September 30, 2023, the Company’s inventory write-downs were immaterial. For the nine months ended September 30, 2023, the Company recorded inventory write-downs of $0.4 million primarily related to product approaching expiration. For the three and nine months ended September 30, 2022, the Company recorded inventory write-downs of $0.3 million and $1.2 million, respectively, primarily related to product approaching expiration. Additionally, though the Company’s product is subject to strict quality control and monitoring which it performs throughout the manufacturing processes, certain batches or units of product may not meet quality specifications resulting in a charge to cost of product sales. For the three and nine months ended September 30, 2023 and 2022, these amounts were immaterial.

Cost of product sales

Cost of product sales consists of the cost of inventory sold, manufacturing and supply chain costs, storage costs, amortization of the acquired intangible asset, royalty payments associated with net product sales, and royalty payments to collaborative partners associated with royalty revenues and collaboration revenue related to milestones. Production costs are expensed as cost of product sales when the related products are sold or royalty revenues and collaboration revenue milestones are earned.

Revenue recognition

Net product revenue

The Company’s net product revenue primarily consists of sales of Translarna in territories outside of the U.S. for the treatment of nmDMD and sales of Emflaza in the U.S. for the treatment of DMD. The Company recognizes revenue when its performance obligations with its customers have been satisfied. The Company’s performance obligations are to provide products based on customer orders from distributors, hospitals, specialty pharmacies or retail pharmacies. The performance obligations are satisfied at a point in time when the Company’s customer obtains control of the product, which is typically upon delivery. The Company invoices its customers after the products have been delivered and invoice payments are generally due within 30 to 90 days of the invoice date. The Company determines the transaction price based on fixed consideration in its contractual agreements. Contract liabilities arise in certain circumstances when consideration is due for goods the Company has yet to provide. As the Company has identified only one distinct performance obligation, the transaction price is allocated entirely to product sales. In determining the transaction price, a significant financing component does not exist since the timing from when the Company delivers product to when the customers pay for the product is typically less than one year. Customers in certain countries pay in advance of product delivery. In those instances, payment and delivery typically occur in the same month.

The Company records product sales net of any variable consideration, which includes discounts, allowances, rebates related to Medicaid and other government pricing programs, and distribution fees. The Company uses the expected value or most likely amount method when estimating its variable consideration, unless discount or rebate terms are specified within contracts. The identified variable consideration is recorded as a reduction of revenue at the time revenues from product sales are recognized. These estimates for variable consideration are adjusted to reflect known changes in factors and may impact such estimates in the quarter those changes are known. Revenue recognized does not include amounts of variable consideration that are constrained.

For the three months ended September 30, 2023 and 2022, net product sales outside of the United States were $76.6 million and $79.4 million, respectively, consisting of sales of Translarna, Tegsedi, Waylivra, and Upstaza. Translarna net revenues made up $69.0 million and $76.6 million of the net product sales outside of the United States for the three months ended September 30, 2023 and 2022, respectively. For the three months ended September 30, 2023 and 2022, net product sales in the United States were $67.4 million and $54.8 million, respectively, consisting solely of sales of Emflaza. During the three months ended September 30, 2023, one country, the United States, accounted for at least 10% of the Company’s net product sales, representing $67.4 million of net product sales. During the three months ended September 30, 2022, two

countries, the United States and Russia, accounted for at least 10% of the Company’s net product sales, representing $54.8 million and $28.3 million of net product sales, respectively.

For the nine months ended September 30, 2023 and 2022, net product sales outside of the United States were $318.5 million and $247.6 million, respectively, consisting of Translarna, Tegsedi, Waylivra, and Upstaza. Translarna net revenues made up $280.6 million and $232.9 million of the net product sales outside of the United States for the nine months ended September 30, 2023 and 2022, respectively. For the nine months ended September 30, 2023 and 2022, net product sales in the United States were $187.7 million and $160.1 million, respectively, consisting solely of Emflaza. During the nine months ended September 30, 2023, three countries, the United States, Russia, and Brazil, accounted for at least 10% of the Company’s net product sales, representing $187.7 million, $69.0 million, and $52.5 million of net product sales, respectively. During the nine months ended September 30, 2022, two countries, the United States and Russia,  accounted for at least 10% of the Company’s net product sales, representing $160.1 million and $57.1 million of net product sales, respectively.

In relation to customer contracts, the Company incurs costs to fulfill a contract but does not incur costs to obtain a contract. These costs to fulfill a contract do not meet the criteria for capitalization and are expensed as incurred. The Company considers any shipping and handling costs that are incurred after the customer has obtained control of the product as a cost to fulfill a promise. Shipping and handling costs associated with finished goods delivered to customers are recorded as a selling expense.

Collaboration and royalty revenue

The terms of these agreements typically include payments to the Company of one or more of the following: nonrefundable, upfront license fees; milestone payments; research funding and royalties on future product sales. In addition, the Company generates service revenue through agreements that generally provide for fees for research and development services and may include additional payments upon achievement of specified events.

At the inception of a collaboration arrangement, the Company needs to first evaluate if the arrangement meets the criteria in Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 808 “Collaborative Arrangements” to then determine if ASC Topic 606 is applicable by considering whether the collaborator meets the definition of a customer. If the criteria are met, the Company assesses the promises in the arrangement to identify distinct performance obligations.

For licenses of intellectual property, the Company assesses, at contract inception, whether the intellectual property is distinct from other performance obligations identified in the arrangement. If the licensing of intellectual property is determined to be distinct, revenue is recognized for nonrefundable, upfront license fees when the license is transferred to the customer and the customer can use and benefit from the license. If the licensing of intellectual property is determined not to be distinct, then the license will be bundled with other promises in the arrangement into one distinct performance obligation. The Company needs to determine if the bundled performance obligation is satisfied over time or at a point in time. If the Company concludes that the nonrefundable, upfront license fees will be recognized over time, the Company will need to assess the appropriate method of measuring proportional performance.

For milestone payments, the Company assesses, at contract inception, whether the development or sales-based milestones are considered probable of being achieved. If it is probable that a significant revenue reversal will occur, the Company will not record revenue until the uncertainty has been resolved. Milestone payments that are contingent upon regulatory approval are not considered probable of being achieved until the applicable regulatory approvals or other external conditions are obtained as such conditions are not within the Company’s control. If it is probable that a significant revenue reversal will not occur, the Company will estimate the milestone payments using the most likely amount method. The Company will re-assess the development and sales-based milestones each reporting period to determine the probability of achievement. The Company recognizes royalties from product sales at the later of when the related sales occur or when the performance obligation to which the royalty has been allocated has been satisfied. If it is probable that a significant revenue reversal will not occur, the Company will estimate the royalty payments using the most likely amount method.

The Company recognizes revenue for reimbursements of research and development costs under collaboration agreements as the services are performed. The Company records these reimbursements as revenue and not as a reduction of research and development expenses as the Company has the risks and rewards as the principal in the research and development activities.

For the three months ended September 30, 2023, the Company did not recognize collaboration revenue related to the SMA License Agreement with Roche. For the three months ended September 30, 2022, the Company recognized $50.0 million of collaboration revenue related to the SMA License Agreement. For the nine months ended September 30, 2023, the amounts recognized for the collaboration revenue related to the SMA License Agreement with Roche were immaterial. For the nine months ended September 30, 2022, the Company recognized $50.0 million of collaboration revenue related to the SMA License Agreement with Roche. In September 2022, the Company recognized a sales milestone of $50.0 million for the achievement of $750.0 million in worldwide annual net sales from Evrysdi.

For the three and nine months ended September 30, 2023, the Company has recognized $50.2 million and $117.9 million of royalty revenue, respectively, related to Evrysdi. For the three and nine months ended September 30, 2022, the Company has recognized $32.9 million and $73.6 million of royalty revenue, respectively, related to Evrysdi.

Manufacturing Revenue

The Company has manufacturing services related to the production of plasmid deoxyribonucleic acid (“DNA”) and adeno-associated virus (“AAV”) vectors for gene therapy applications for external customers. Performance obligations vary but may include manufacturing plasmid DNA and/or AAV vectors, material testing, stability studies, and other services related to material development. The transaction prices for these arrangements are fixed and include amounts stated in the contracts for each promised service. Typically, the performance obligations within a manufacturing contract are highly interdependent, in which case, the Company will combine them into a single performance obligation. The Company has determined that the assets created have no alternative use to the Company, and the Company has an enforceable right to payment for the performance completed to date, therefore revenue related to these services are recognized over time and is measured using an output method based on performance of manufacturing milestones completed to date.

Manufacturing service contracts may also include performance obligations related to project management services or obtaining materials from third parties. The Company has determined that these are separate performance obligations for which revenue is recognized at the point in time the services are performed. For performance obligations related to obtaining third party materials, the Company has determined that it is the principal as the Company has control of the materials and has discretion in setting the price. Therefore, the Company recognizes revenue on a gross basis related to obtaining third party materials.

Certain arrangements require a portion of the contract consideration to be received in advance at the commencement of the contract, and such advance payment is initially recorded as a contract liability. A contract asset may be recognized in the event the Company’s satisfaction of performance obligations outpaces customer billings.

For the three and nine months ended September 30, 2023, the Company recognized $2.4 million and $6.7 million of manufacturing revenue, respectively, related to plasmid DNA and AAV vector production for external customers. No manufacturing revenue was recognized for the three and nine months ended September 30, 2022. As of September 30, 2023, the Company has contract assets of $1.4 million and remaining performance obligations of $1.2 million related to the production of plasmid DNA and AAV vectors for gene therapy applications for external customers. For the period ended December 31, 2022, the Company had remaining performance obligations of $1.4 million and no contracts assets related to plasmid DNA and AAV production for external customers.

Allowance for doubtful accounts

The Company maintains an allowance for estimated losses resulting from the inability of its customers to make required payments. The Company estimates uncollectible amounts based upon current customer receivable balances, the age of customer receivable balances, the customer’s financial condition and current economic trends. The Company also assesses whether an allowance for expected credit losses may be required which includes a review of the Company’s receivables

portfolio, which are pooled on a customer basis or country basis.  In making its assessment of whether an allowance for credit losses is required, the Company considers its historical experience with customers, current balances, levels of delinquency, regulatory and legal environments, and other relevant current and future forecasted economic conditions. For the three and nine months ended September 30, 2023 and 2022, no allowance was recorded for credit losses. The allowance for doubtful accounts was $1.0 million as of September 30, 2023 and $0.3 million as of December 31, 2022. For the three and nine months ended September 30, 2023, bad debt expense was $0.4 million and $0.7 million, respectively. For the three and nine months ended September 30, 2022, bad debt expense was immaterial.

Liability for sale of future royalties

On July 17, 2020, the Company, RPI, and, for the limited purposes set forth in the agreement, Royalty Pharma PLC, entered into the Royalty Purchase Agreement. Pursuant to the Royalty Purchase Agreement, the Company sold to RPI 42.933% (the “Assigned Royalty Rights”) of the Company’s right to receive sales-based royalty payments (the “Royalty”) on worldwide net sales of Evrysdi and any other product developed pursuant to the SMA License Agreement. In consideration for the sale of the Assigned Royalty Rights, RPI paid the Company $650.0 million in cash consideration. The Company has retained a 57.067% interest in the Royalty and all economic rights to receive the remaining potential regulatory and sales milestone payments under the SMA License Agreement, which remaining milestone payments equal $250.0 million in the aggregate as of September 30, 2023. The Royalty Purchase Agreement will terminate 60 days following the earlier of the date on which Roche is no longer obligated to make any payments of the Royalty pursuant to the SMA License Agreement and the date on which RPI has received $1.3 billion in respect of the Assigned Royalty Rights.

The cash consideration obtained pursuant to the Royalty Purchase Agreement is classified as debt and is recorded as “liability for sale of future royalties-current” and “liability for sale of future royalties-noncurrent” on the Company’s consolidated balance sheet based on the timing of the expected payments to be made to RPI. The fair value for the liability for sale of future royalties at the time of the transaction was based on the Company’s estimates of future royalties expected to be paid to RPI over the life of the arrangement, which was determined using forecasts from market data sources, which are considered Level 3 inputs. The liability is being amortized using the effective interest method over the life of the arrangement, in accordance with the respective guidance. The Company utilizes the prospective method to account for subsequent changes in the estimated future payments to be made to RPI.  Refer to Note 9 for further details.

Indefinite-lived intangible assets

Indefinite-lived intangible assets consist of in process research and development ("IPR&D"). IPR&D acquired directly in a transaction other than a business combination is capitalized if the projects will be further developed or have an alternative future use; otherwise they are expensed. The fair values of IPR&D projects and license agreement assets acquired in business combinations are capitalized. Several methods may be used to determine the estimated fair value of the IPR&D and license agreement asset acquired in a business combination. The Company utilizes the "income method" and uses estimated future net cash flows that are derived from projected sales revenues and estimated costs. These projections are based on factors such as relevant market size, patent protection, and expected pricing and industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. These assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are amortized over the remaining useful life or written off, as appropriate. Intangible assets with indefinite lives, including IPR&D, are tested for impairment if impairment indicators arise and, at a minimum, annually. However, an entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that an indefinite-lived intangible asset’s fair value is less than its carrying amount. Otherwise, no further impairment testing is required. The indefinite-lived intangible asset impairment test consists of a one-step analysis that compares the fair value of the intangible asset with its carrying amount. If the carrying amount of an intangible asset exceeds its fair value, an impairment loss is recognized in an amount equal to that excess. The Company considers many factors in evaluating whether the value of its intangible assets with indefinite lives may not be recoverable, including, but not limited to, expected growth rates, the cost of equity and debt capital, general economic conditions, the Company’s outlook and market performance of the Company’s industry and recent and forecasted financial performance.

In May 2023, as part of the Company’s strategic portfolio prioritization, the Company decided to discontinue its preclinical and early research programs in its gene therapy platform, which included Friedreich ataxia and Angelman syndrome. As a result, the Company determined that the Friedreich ataxia and Angelman syndrome indefinite lived intangible assets were fully impaired and recorded impairment expense of $217.8 million during the nine months ended September 30, 2023, which is recorded as intangible asset impairment in the statement of operations. Refer to Note 12 for further information regarding the Company’s intangible assets.

Goodwill

Goodwill represents the amount of consideration paid in excess of the fair value of net assets acquired as a result of the Company’s business acquisitions accounted for using the acquisition method of accounting. Goodwill is not amortized and is subject to impairment testing at a reporting unit level on an annual basis or when a triggering event occurs that may indicate the carrying value of the goodwill is impaired. The Company reassesses its reporting units as part of its annual segment review. An entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that the fair value of the reporting unit is less than its carrying amount.

Income Taxes

The Organization for Economic Co-operation and Development (“OECD”), the European Community (“the EC”), and individual taxing jurisdictions where the Company and its affiliates do business have recently focused on issues related to the taxation of multinational corporations. The OECD has released its comprehensive plan to create an agreed set of international rules for fighting base erosion and profit shifting. In addition, the OECD, the EC and individual taxing jurisdictions are examining changes to how taxing rights should be allocated among countries considering the digital economy. As a result, the tax laws in the U.S. and other countries in which the Company and its affiliates do business could change on a prospective or retroactive basis and any such changes could materially adversely affect the Company’s business.

On December 22, 2017, the U.S. government enacted the 2017 Tax Act, which significantly revised U.S. tax law by, among other provisions, lowering the U.S. federal statutory corporate income tax rate to 21%, imposing a mandatory one-time transition tax on previously deferred foreign earnings, and eliminating or reducing certain income tax deductions. The Global Intangible Low-Taxed Income ("GILTI") provisions of the 2017 Tax Act require the Company to include in its U.S. income tax return foreign subsidiary earnings in excess of an allowable return on the foreign subsidiary’s tangible assets. The Company has elected to account for GILTI tax in the period in which it is incurred, and therefore has not provided any deferred tax impacts of GILTI in its consolidated financial statements for the period ended September 30, 2023.

Starting in 2022, TCJA amendments to IRC Section 174 no longer permits an immediate deduction for research and development (R&D) expenditures in the tax year that such costs are incurred. Instead, these IRC Section 174 development costs must now be capitalized and amortized over either a five- or 15-year period, depending on the location of the activities performed. The new amortization period begins with the midpoint of any taxable year that IRC Section 174 costs are first incurred, regardless of whether the expenditures were made prior to or after July 1, and runs until the midpoint of year five for activities conducted in the United States or year 15 in the case of development conducted on foreign soil.

Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and net operating loss and credit carryforwards. Deferred tax assets and liabilities are measured at rates expected to apply to taxable income in the years in which those temporary differences and carryforwards are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the statement of operations in the period that includes the enactment date. A valuation allowance is recorded when it is not more likely than not that all or a portion of the net deferred tax assets will be realized.

On August 23, 2018, the Company completed its acquisition of Agilis Biotherapeutics, Inc. (“Agilis”), pursuant to an Agreement and Plan of Merger, dated as of July 19, 2018 (the “Agilis Merger Agreement”), by and among the Company,

Agility Merger Sub, Inc., a Delaware corporation and the Company’s wholly owned, indirect subsidiary, Agilis and, solely in its capacity as the representative, agent and attorney-in-fact of the equityholders of Agilis, Shareholder Representative Services LLC, (the “Agilis Merger”). The Company recorded a deferred tax liability in conjunction with the Agilis Merger of $122.0 million in 2018, related to the tax basis difference in the IPRD indefinite-lived intangibles acquired. The Company’s policy is to record a deferred tax liability related to acquired IPR&D which may eventually be realized either upon amortization of the asset when the research is completed, and a product is successfully launched or the write-off of the asset if it is abandoned or unsuccessful. In July 2022, the Company received EMEA approval for a portion of the IPR&D assets, and thus, began the amortization of the intangible.

In May 2023, the Company announced the discontinuation of its preclinical and early research programs in gene therapy as part of a strategic portfolio prioritization. In conjunction with the announcement, the Company recorded an impairment to its indefinite-lived intangible for IP research and development relating to the Friedreich ataxia and Angelman syndrome gene therapy assets. As a result of the impairment, the Company recorded a deferred tax benefit of $50.9 million.

Leases

The Company determines if an arrangement is a lease at inception. This determination generally depends on whether the arrangement conveys to the Company the right to control the use of an explicitly or implicitly identified fixed asset for a period of time in exchange for consideration. Control of an underlying asset is conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using the underlying asset. The Company has lease agreements which include lease and non-lease components, which the Company accounts for as a single lease component for all leases. Operating and finance leases are classified as right of use ("ROU") assets, short term lease liabilities, and long term lease liabilities. Operating and finance lease ROU assets and lease liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. ROU assets are amortized and lease liabilities accrete to yield straight-line expense over the term of the lease. Lease payments included in the measurement of the lease liability are comprised of fixed payments.

Variable lease payments associated with the Company’s leases are recognized when the event, activity, or circumstance in the lease agreement on which those payments are assessed occurs. Variable lease payments are presented in the Company’s consolidated statements of operations in the same line item as expense arising from fixed lease payments for operating leases.

Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheet and the Company recognizes lease expense for these leases on a straight-line basis over the lease term. The Company applies this policy to all underlying asset categories.

A lessee is required to discount its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental borrowing rate. As most of the Company’s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The Company gives consideration to its recent debt issuances as well as publicly available data for instruments with similar characteristics when calculating its incremental borrowing rates.

The lease term for all of the Company’s leases includes the non-cancellable period of the lease plus any additional periods covered by either a Company option to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor. Leasehold improvements are capitalized and depreciated over the lesser of useful life or lease term. See Note 3 Leases for additional information.  

XML 20 R10.htm IDEA: XBRL DOCUMENT v3.23.3
Leases
9 Months Ended
Sep. 30, 2023
Leases  
Leases

3.        Leases

The Company leases office space in South Plainfield, New Jersey for its principal office under two noncancelable operating leases through August 2024, in addition to office and laboratory space in Bridgewater, New Jersey and other locations throughout the United States and office space in various countries for international employees primarily through workspace providers.

The Company also leases approximately 220,500 square feet of office, manufacturing and laboratory space at a facility located in Hopewell Township, New Jersey pursuant to a Lease Agreement (the “Hopewell Lease”) with Hopewell Campus Owner LLC. The rental term of the Hopewell Lease commenced on July 1, 2020 and has an initial term of fifteen years (the “Hopewell Initial Term”), with two consecutive ten year renewal periods, each at the Company’s option. The aggregate rent for the Hopewell Initial Term will be approximately $111.5 million. The rental rate for the renewal periods will be 95% of the Prevailing Market Rate (as defined in the Hopewell Lease) and determined at the time of the exercise of the renewal. The Company is also responsible for maintaining certain insurance and the payment of proportional taxes, utilities and common area operating expenses. The Hopewell Lease contains customary events of default, representations, warranties and covenants.

In May 2022, the Company entered into a Lease Agreement (the “Warren Lease”) with Warren CC Acquisitions, LLC (the “Warren Landlord”) relating to the lease of two entire buildings comprised of approximately 360,000 square feet of shell condition, modifiable space (the “Warren Premises”) at a facility located in Warren, New Jersey. The rental term of the Warren Lease commenced on June 1, 2022, with an initial term of seventeen years (the “Warren Initial Term”), followed by three consecutive five-year renewal periods at the Company’s option. The aggregate base rent for the Warren Initial Term will be approximately $163.0 million; provided, however, that if the Company is not subject to an Event of Default (as defined in the Warren Lease), the Company will be entitled to a base rent abatement over the first three years of the Warren Initial Term of approximately $18.6 million, reducing the Company’s total base rent obligation to $144.4 million. The rental rate for the renewal periods will be at the Fair Market Rental Value (as defined in the Warren Lease) and determined at the time of the exercise of the renewal. Beginning in the second lease year, the Company is also responsible for the payment of all taxes and operating expenses for the Warren Premises. As a result, the Company recorded an operating lease ROU asset of $28.9 million and an operating lease ROU liability of $28.9 million as of the commencement date.

The Company is developing the Warren Premises into office and laboratory space. The Company is entitled to an allowance of approximately $36.2 million to be provided by the Warren Landlord to be used towards such improvements. The Landlord is providing the allowance to cover those assets that are real property improvements, such as structural components, roofs, flooring, etc., whose useful lives are typically longer in nature. The Company evaluated the leasehold improvements under ASC 842 and determined that the Company will be the owner of the improvements, and therefore the $36.2 million allowance and $5.0 million due from the Landlord were treated as lease incentives at the commencement of the lease and included in the calculation of the lease ROU asset and lease ROU liability, effectively reducing both at Commencement Date. In connection with the execution of the Warren Lease, the Company also committed to fund a construction account with $3.6 million to go towards the Company’s improvements of the Warren Premises. Subject to the terms of the Warren Lease, the Company has a right of first offer to purchase the Warren Premises if the Warren Landlord receives a bona fide third party offer to purchase the Warren Premises or the Warren Landlord decides to sell the Warren Premises.

On June 19, 2020, the Company entered into a commercial manufacturing service agreement for a term of 12.5 years with MassBiologics of the University of Massachusetts Medical School ("MassBio"). The Company determined that the agreement was a finance lease, for which the Company recorded a finance lease ROU asset for $41.4 million and corresponding finance lease liability for $41.4 million at the onset of the lease agreement. Given that the leased asset is designed for the production of PTC’s AADC program and would not have an alternate use outside the PTC gene therapy platform without incurring significant costs, the Company determined that the lease should be treated as research and development expense under ASC 730. Accordingly, the full $41.4 million relating to the finance lease ROU asset was written off and expensed to research and development during the year ended December 31, 2020. As of September 30, 2023, the balance of the finance lease liabilities-current and finance lease liabilities-noncurrent are $2.6 million and $17.2 million, respectively, and are directly related to the Company’s MassBio agreement. As of December 31, 2022, the balance of the finance lease liabilities-current and finance lease liabilities-noncurrent were $3.0 million and $18.7 million, respectively. Additionally, the Company recorded finance lease costs of $0.4 million and $1.1 million related to interest on the lease liability during the three and nine months ended September 30, 2023, respectively. The Company recorded finance lease costs of $0.4 million and $1.2 million related to interest on the lease liability during the three and nine months ended September 30, 2022, respectively.

The Company also leases certain vehicles, lab equipment, and office equipment under operating leases. The Company’s leases have remaining operating lease terms ranging from 0.4 years to 15.7 years and certain of the leases include renewal options to extend the lease for up to 20 years. Rent expense was $7.1 million and $6.8 million for the three months ended September 30, 2023 and 2022, respectively. Rent expense was $21.5 million and $18.0 million for the nine months ended September 30, 2023 and 2022, respectively.

The components of operating lease expense were as follows:

    

Three Months Ended

    

Three Months Ended

    

Nine Months Ended

    

Nine Months Ended

September 30, 2023

September 30, 2022

September 30, 2023

September 30, 2022

Operating Lease Cost

 

  

  

  

  

Fixed lease cost

$

5,490

$

5,377

$

16,463

$

14,267

Variable lease cost

 

1,376

 

1,151

 

4,140

 

3,152

Short-term lease cost

 

271

 

262

 

866

 

600

Total operating lease cost

$

7,137

$

6,790

$

21,469

$

18,019

Total operating lease cost is a component of operating expenses on the consolidated statements of operations.

Supplemental lease term and discount rate information related to leases was as follows as September 30, 2023 and December 31, 2022:

    

September 30, 2023

    

December 31, 2022

 

Weighted-average remaining lease terms - operating leases (years)

 

11.61

11.61

Weighted-average discount rate - operating leases

8.67

%

8.61

%

Weighted-average remaining lease terms - finance lease (years)

 

9.26

10.01

Weighted-average discount rate - finance lease

 

7.80

%

7.80

%

Supplemental cash flow information related to leases was as follows as of September 30, 2023 and 2022:

    

Nine Months Ended September 30, 

    

2023

    

2022

Cash paid for amounts included in the measurement of lease liabilities:

 

  

  

Operating cash flows from operating leases

$

11,479

$

10,954

Financing cash flows from finance lease

1,379

1,276

Operating cash flows from finance lease

1,621

1,724

Right-of-use assets obtained in exchange for lease obligations:

 

 

  

Operating leases

$

$

35,294

Future minimum lease payments under non-cancelable leases as of September 30, 2023 were as follows:

    

Operating Leases

    

Finance Lease

2023 (excludes the nine months ended September 30, 2023)

$

5,077

$

2024

 

18,369

 

3,000

2025

 

20,438

 

3,000

2026

 

19,988

 

3,000

2027 and thereafter

 

193,792

 

18,000

Total lease payments

 

257,664

 

27,000

Less: Imputed Interest expense

 

146,279

 

7,205

Total

$

111,385

$

19,795

XML 21 R11.htm IDEA: XBRL DOCUMENT v3.23.3
Fair value of financial instruments and investments
9 Months Ended
Sep. 30, 2023
Fair Value Disclosures [Abstract]  
Fair value of financial instruments and investments

4.        Fair value of financial instruments and marketable securities

The Company follows the fair value measurement rules, which provideguidance on the use of fair value in accounting and disclosure for assets and liabilities when such accounting and disclosure is called for by other accounting literature. These rules establish a fair value hierarchy for inputs to be used to measure fair value of financial assets and liabilities. This hierarchy prioritizes the inputs to valuation techniques used to measure fair value into three levels: Level 1 (highest priority), Level 2, and Level 3 (lowest priority).

Level 1—Unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the balance sheet date.
Level 2—Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates, yield curves, etc.), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).
Level 3—Inputs are unobservable and reflect the Company’s assumptions as to what market participants would use in pricing the asset or liability. The Company develops these inputs based on the best information available.

Cash equivalents and marketable securities are reflected in the accompanying financial statements at fair value. The carrying amount of receivables and accounts payable and accrued expenses approximates fair value due to the short-term nature of those instruments.

The Company owns common stock in ClearPoint Neuro, Inc. (“ClearPoint”) (formerly MRI Interventions, Inc.), a publicly traded medical device company. The ClearPoint equity investments (collectively, the “ClearPoint Equity Investments”) represent financial instruments, and therefore, are recorded at fair value, which is readily determinable. The ClearPoint Equity Investments are components of prepaids and other current assets on the consolidated balance sheet as of September 30, 2023, and deposits and other assets as of December 31, 2022. During three and nine months ended September 30, 2023, the Company recorded unrealized losses of $2.0 million and $3.1 million, respectively. During the three and nine months ended September 30, 2022, the Company recorded unrealized losses of $3.5 million and $1.1 million, respectively. During the three months ended September 30, 2023, the Company did not record any realized gains or losses for the sale of ClearPoint Equity Investments. During the nine months ended September 30, 2023, the Company recorded a realized loss of $0.8 million for the sale of ClearPoint Equity Investments. During the three and nine months ended September 30, 2022, the Company did not record any realized gains or losses for the sale of Clearpoint Equity Investments. These unrealized and realized losses are components of other expense, net within the consolidated statement of operations. The fair value of the ClearPoint Equity Investments was $4.5 million and $11.0 million as of September 30, 2023 and December 31, 2022, respectively. The Company classifies the ClearPoint Equity Investments as Level 1 assets within the fair value hierarchy, as the value is based on a quoted market price in an active market, which is not adjusted.

In January 2020, the Company purchased a $10.0 million convertible note from ClearPoint that the Company can convert into ClearPoint shares at a conversion rate of $6.00 per share at any point throughout the term of the loan, which matures five years from the purchase date. The Company determined that the convertible note represents an available for sale debt security and the Company has elected to record it at fair value under ASC 825. The Company classifies its ClearPoint convertible debt security as a Level 2 asset within the fair value hierarchy, as the value is based on inputs other than quoted prices that are observable. The fair value of the ClearPoint convertible debt security is determined at each reporting period by utilizing a Black-Scholes option pricing model, as well as a present value of expected cash flows from the debt security utilizing the risk free rate and the estimated credit spread as of the valuation date as the discount rate. During the three and nine months ended September 30, 2023, the Company recorded unrealized losses of $3.1 million and $4.6 million, respectively. During the three and nine months ended September 30, 2022, the Company recorded unrealized losses of $4.4 million and $2.4 million, respectively. These unrealized gains and losses are components of other expense, net within the consolidated statement of operations. The fair value of the convertible debt security was $10.6 million and $15.2

million as of September 30, 2023 and December 31, 2022, respectively. The convertible debt security is considered to be long term and is included as a component of deposits and other assets on the consolidated balance sheet. Other than the ClearPoint Equity Investments and the ClearPoint convertible debt security, no other items included in deposits and other assets and prepaids and other current assets on the consolidated balance sheets are fair valued.

The Company has investments in mutual funds, including one that is denominated in a foreign currency. All of these are equity investments and are classified as marketable securities on the Company’s consolidated balance sheets. These equity investments are reported at fair value, as they are readily available, and as such are classified as Level 1 assets. Unrealized holding gains and losses for these equity investments are included as components of other expense, net within the consolidated statement of operations. For the three and nine months ended September 30, 2023, the Company had unrealized gains of $1.1 million and of $5.5 million, respectively, relating to the equity investments still held at the reporting date. For the three and nine months ended September 30, 2022, the Company had unrealized gains of $0.1 million and unrealized losses of $11.3 million relating to the equity investments still held at the reporting date, respectively. For the three and nine months ended September 30, 2023, the Company had redemptions of $7.8 million and $12.1 million, respectively, which were primarily due to liquidation of one of the mutual funds. For the three and nine months ended September 30, 2022, the Company had redemptions of $100.8 million and $104.4 million, respectively, which were primarily due to liquidation of one of the mutual funds. For the three months ended September 30, 2023, the Company had foreign currency unrealized losses of $1.4 million relating to these equity investments. For the nine months ended September 30, 2023, the amounts recognized for foreign currency unrealized losses relating to these investments were immaterial. For the three and nine months ended September 30, 2022, the Company had foreign currency unrealized losses of $1.4 million and $1.0 million, respectively, relating to these equity investments.

Fair value of marketable securities that are classified as available for sale debt securities is based upon market prices using quoted prices in active markets for identical assets quoted on the last day of the period. In establishing the estimated fair value of the remaining available for sale debt securities, the Company used the fair value as determined by its investment advisors using observable inputs other than quoted prices.

The following represents the fair value using the hierarchy described above for the Company’s financial assets and liabilities that are required to be measured at fair value on a recurring basis as of September 30, 2023 and December 31, 2022:

September 30, 2023

 

 

Quoted prices

 

Significant

 

 

in active

 

other

 

Significant

 

markets for

 

observable

 

unobservable

 

identical assets

 

inputs

 

inputs

    

Total

    

(level 1)

    

(level 2)

    

(level 3)

Marketable securities - available for sale

$

1,625

$

$

1,625

$

Marketable securities - equity investments

$

128,028

$

128,028

$

$

ClearPoint Equity Investments - available for sale

$

4,482

$

4,482

$

$

ClearPoint convertible debt security

$

10,637

$

$

10,637

$

Contingent consideration payable- development and regulatory milestones

$

26,400

$

$

$

26,400

Contingent consideration payable- net sales milestones and royalties

$

12,600

$

$

$

12,600

December 31, 2022

 

 

Quoted prices

 

Significant

 

 

in active

 

other

 

Significant

 

markets for

 

observable

 

unobservable

 

identical assets

 

inputs

 

inputs

    

Total

    

(level 1)

    

(level 2)

    

(level 3)

Marketable securities - available for sale

$

22,610

$

$

22,610

$

Marketable securities - equity investments

$

108,261

$

108,261

$

$

ClearPoint Equity Investments

$

10,965

$

10,965

$

$

ClearPoint convertible debt security

$

15,231

$

$

15,231

$

Contingent consideration payable- development and regulatory milestones

$

82,500

$

$

$

82,500

Contingent consideration payable- net sales milestones and royalties

$

81,500

$

$

$

81,500

No transfers of assets between Level 1, Level 2, or Level 3 of the fair value measurement hierarchy occurred during the periods ended September 30, 2023 and December 31, 2022.

The following is a summary of marketable securities accounted for as available for sale debt securities at September 30, 2023 and December 31, 2022:

September 30, 2023

 

Amortized

 

Gross Unrealized

    

Cost

    

Gains

    

Losses

    

Fair Value

Corporate debt securities

$

1,649

$

$

(24)

$

1,625

Total

$

1,649

$

$

(24)

$

1,625

December 31, 2022

 

Amortized

 

Gross Unrealized

    

Cost

    

Gains

    

Losses

    

Fair Value

Commercial paper

$

12,419

$

5

$

$

12,424

Corporate debt securities

 

10,685

(499)

10,186

Total

$

23,104

$

5

$

(499)

$

22,610

For available for sale debt securities in an unrealized loss position, the Company assesses whether it intends to sell or if it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security’s amortized cost basis is written down to fair value. For the three and nine months ended September 30, 2023 and 2022, no write downs occurred. The Company does not intend to sell the investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost basis, which may be maturity. The Company also reviews its available for sale debt securities in an unrealized loss position and evaluates whether the decline in fair value has resulted from credit losses or other factors. This review is subjective, as it requires management to evaluate whether an event or change in circumstances has occurred in that period that may be related to credit issues. For the three and nine months ended September 30, 2023 and 2022, no allowance was recorded for credit losses. Unrealized gains and losses are reported as a component of accumulated other comprehensive (loss) income in stockholders’ equity.

For the three months ended September 30, 2023, the Company did not have any realized gains or losses from the sale of available for sale debt securities. For the nine months ended September 30, 2023, the Company had $0.3 million of realized losses from the sale of available for sale debt securities. For the three and nine months ended September 30, 2022, the Company had $1.3 million and $1.6 million of realized losses from the sale of available for sale debt securities, respectively.  Realized gains and losses are reported as a component of interest expense, net in the consolidated statement of operations. Reclassified amounts from other comprehensive items were determined using the actual realized gains and losses from the sales of marketable securities.

The unrealized losses and fair values of available for sale debt securities that have been in an unrealized loss position for a period of less than and greater than or equal to 12 months as of September 30, 2023 are as follows:

September 30, 2023

 

Securities in an unrealized loss

 

Securities in an unrealized loss

 

 

position less than 12 months

 

position greater than or equal to 12 months

Total

   

Unrealized losses

   

Fair Value

   

Unrealized losses

   

Fair Value

   

Unrealized losses

   

Fair Value

Corporate debt securities

$

(24)

1,625

(24)

$

1,625

Total

$

$

$

(24)

$

1,625

$

(24)

$

1,625

The unrealized losses and fair values of available for sale debt securities that have been in an unrealized loss position for a period of less than and greater than or equal to 12 months as of December 31, 2022 are as follows:

December 31, 2022

 

Securities in an unrealized loss

 

Securities in an unrealized loss

 

 

position less than 12 months

 

position greater than or equal to 12 months

Total

   

Unrealized losses

   

Fair Value

   

Unrealized losses

   

Fair Value

   

Unrealized losses

   

Fair Value

Corporate debt securities

$

(499)

10,186

(499)

$

10,186

Total

$

$

$

(499)

$

10,186

$

(499)

$

10,186

Available for sale debt securities at September 30, 2023 and December 31, 2022 mature as follows:

September 30, 2023

 

Less Than

 

More Than

    

12 Months

    

12 Months

Corporate debt securities

$

1,625

$

Total

$

1,625

$

December 31, 2022

 

Less Than

 

More Than

    

12 Months

    

12 Months

Commercial paper

$

12,424

$

Corporate debt securities

 

 

10,186

Total

$

12,424

$

10,186

The Company classifies all of its marketable securities as current as they are all either available for sale debt securities or equity investments and are available for current operations.

Convertible senior notes

In September 2019, the Company issued $287.5 million of 1.50% convertible senior notes due September 15, 2026 (the “2026 Convertible Notes,”). The fair value of the 2026 Convertible Notes, which differs from their carrying values, is influenced by interest rates, the Company’s stock price and stock price volatility and is determined by prices for the 2026 Convertible Notes observed in market trading which are Level 2 inputs. The estimated fair value of the 2026 Convertible Notes at September 30, 2023 and December 31, 2022 was $228.8 million and $281.7 million, respectively.

Level 3 valuation

The contingent consideration payable is fair valued each reporting period with the change in fair value recorded as a gain or loss within the change in the fair value of contingent consideration on the consolidated statements of operations. The fair value of the development and regulatory milestones is estimated utilizing a probability adjusted, discounted cash flow approach. The discount rates are estimated utilizing Corporate B rated bonds maturing in the years of expected payments based on the Company’s estimated development timelines for the acquired product candidate. The fair value of the net sales milestones is determined utilizing a valuation framework that estimates net sales volatility to simulate a range of possible payment scenarios. The average of the payments in these scenarios is then discounted to calculate present fair value.  

In May 2023, as part of the Company’s strategic portfolio prioritization, the Company decided to discontinue its preclinical and early research programs in its gene therapy platform, which included Friedreich ataxia and Angelman syndrome. As a result, the Company fully impaired the Friedreich ataxia and Angelman syndrome intangible assets and determined that the fair value for all of the contingent consideration payable related to Friedreich ataxia and Angelman syndrome was $0. The change in fair value for the contingent consideration payable related to Friedreich ataxia and Angelman syndrome for the nine months ended September 30, 2023 was $129.8 million and is included in the change in fair value of the contingent consideration in the statement of operations. The remaining contingent consideration as of September 30, 2023 is $39.0 million, which is solely related to the development and regulatory milestones, and net sales milestones, for Upstaza.

As of September 30, 2023, the weighted average discount rate for the Upstaza development and regulatory milestones was 7.1% and the weighted average probability of success was 90%. As of September 30, 2023, the weighted average discount rate for the Upstaza net sales milestones was 12.0% and the weighted average probability of success for the net sales milestones was 93%.

The table presented below is a summary of changes in the fair value of the Company’s Level 3 valuations for the contingent consideration payable for the periods ended September 30, 2023 and September 30, 2022:

Level 3 liabilities

Contingent consideration payable-

Contingent consideration payable-

development and regulatory

net sales milestones and royalties

    

milestones

    

Beginning balance as of December 31, 2022

$

82,500

$

81,500

Additions

 

 

Change in fair value

 

(56,100)

 

(68,900)

Payments

Ending balance as of September 30, 2023

$

26,400

$

12,600

Level 3 liabilities

Contingent consideration payable-

Contingent consideration payable-

development and regulatory

net sales milestones and royalties

    

milestones

    

Beginning balance as of December 31, 2021

$

139,300

$

100,600

Additions

 

 

Change in fair value

 

(10,800)

 

(21,400)

Reclass to accounts payable and accrued expenses

(50,000)

Payments

Ending balance as of September 30, 2022

$

78,500

$

79,200

The following significant unobservable inputs were used in the valuation of the contingent consideration payable for the periods ended September 30, 2023 and December 31, 2022:

September 30, 2023

    

Fair Value

    

Valuation Technique

    

Unobservable Input

    

Range

Contingent consideration payable-
development and regulatory milestones

$26,400

 

 Probability-adjusted discounted cash flow 

 

Potential development and regulatory milestones
Probabilities of success
Discount rates
Projected years of payments

$0 - $31 million
85% - 92%
6.9% - 7.6%
2023 - 2026

Contingent considerable payable- net sales
milestones and royalties

$12,600

 

Option-pricing model with Monte Carlo simulation  

 

Potential net sales milestones
Probabilities of success
Potential percentage of net sales for royalties
Discount rate
Projected years of payments

$0 - $50 million
85% - 100%
0%
12%
2025 - 2034

December 31, 2022

    

Fair Value

    

Valuation Technique

    

Unobservable Input

    

Range

Contingent consideration payable-
development and regulatory milestones

$82,500

 

 Probability-adjusted discounted cash flow 

 

Potential development and regulatory milestones
Probabilities of success
Discount rates
Projected years of payments

$0 - $331 million
25% - 92%
6.2% - 8.3%
2023 - 2029

Contingent considerable payable- net sales
milestones and royalties

$81,500

 

Option-pricing model with Monte Carlo simulation  

 

Potential net sales milestones
Probabilities of success
Potential percentage of net sales for royalties
Discount rate
Projected years of payments

$0 - $150 million
25% - 100%
2% - 6%
11.5%
2025 - 2041

The contingent consideration payables are classified Level 3 liabilities as their valuation requires substantial judgment and estimation of factors that are not currently observable in the market. If different assumptions were used for the various inputs to the valuation approaches, including but not limited to, assumptions involving probability adjusted sales estimates

for the gene therapy platform and estimated discount rates, the estimated fair value could be significantly higher or lower than the fair value determined.

XML 22 R12.htm IDEA: XBRL DOCUMENT v3.23.3
Accounts payable and accrued expenses
9 Months Ended
Sep. 30, 2023
Payables and Accruals [Abstract]  
Accounts payable and accrued expenses

5.        Accounts payable and accrued expenses

Accounts payable and accrued expenses at September 30, 2023 and December 31, 2022 consist of the following:

September 30, 

December 31, 

    

2023

    

2022

Employee compensation, benefits, and related accruals

$

70,778

$

62,669

Income tax payable

2,822

4,712

Consulting and contracted research

 

21,236

 

38,882

Professional fees

 

3,067

 

3,093

Sales allowance

 

72,202

 

63,787

Sales rebates

 

119,971

 

67,355

Royalties

52,087

40,546

Accounts payable

 

19,152

 

27,268

Other

 

9,416

 

12,054

Total

$

370,731

$

320,366

During the three and nine month periods ended September 30, 2023, the Company incurred $22.6 million and $30.6 million, respectively, of restructuring costs from a reduction in workforce in connection with the Company’s strategic pipeline prioritization and discontinuation of its preclinical and early research programs in its gene therapy platform. The costs are included in research and development and selling, general, and administrative expenses on the Company’s consolidated statement of operations. As of September 30, 2023, the remaining $23.4 million of accrued restructuring costs are included above within employee compensation, benefits, and related accruals.

XML 23 R13.htm IDEA: XBRL DOCUMENT v3.23.3
Capitalization
9 Months Ended
Sep. 30, 2023
Stockholders' Equity Note [Abstract]  
Capitalization

6.        Capitalization

In August 2019, the Company entered into an At the Market Offering Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald and RBC Capital Markets, LLC (together, the “Sales Agents”), pursuant to which, the Company may offer and sell shares of its common stock, having an aggregate offering price of up to $125.0 million from time to time through the Sales Agents by any method that is deemed to be an “at the market offering” as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended. No shares were sold during the three and nine months ended September 30, 2023 and 2022. The remaining shares of the Company’s common stock available to be issued and sold, under the At the Market Offering, have an aggregate offering price of up to $93.0 million as of September 30, 2023.

XML 24 R14.htm IDEA: XBRL DOCUMENT v3.23.3
Net loss per share
9 Months Ended
Sep. 30, 2023
Earnings Per Share [Abstract]  
Net loss per share

7.        Net loss per share

Basic and diluted net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding. Potentially dilutive securities were excluded from the diluted calculation because their effect would be anti-dilutive.

The following tables set forth the computation of basic and diluted net loss per share:

Three Months Ended September 30, 

Nine Months Ended September 30, 

    

2023

    

2022

    

2023

    

2022

    

Numerator

Net loss

$

(132,970)

  

$

(109,315)

  

$

(470,812)

  

$

(388,128)

  

Denominator

Denominator for basic and diluted net loss per share

 

75,377,997

  

 

71,654,671

  

 

74,618,611

  

 

71,415,849

  

Net loss per share:

Basic and diluted

$

(1.76)

*

$

(1.53)

*

$

(6.31)

*

$

(5.43)

*

*     In the three and nine months ended September 30, 2023 and 2022, the Company experienced a net loss and therefore did not report any dilutive share impact.

The following table shows historical dilutive common share equivalents outstanding, which are not included in the above historical calculation, as the effect of their inclusion is anti-dilutive during each period.

As of September 30, 

    

2023

    

2022

    

Stock Options

11,436,783

11,478,421

Unvested restricted stock awards and units

 

3,414,102

 

2,488,944

 

Total

 

14,850,885

 

13,967,365

 

XML 25 R15.htm IDEA: XBRL DOCUMENT v3.23.3
Stock award plan
9 Months Ended
Sep. 30, 2023
Share-based Payment Arrangement [Abstract]  
Stock award plan

8.        Stock award plan

In May 2013, the Company’s Board of Directors and stockholders approved the 2013 Long-Term Incentive Plan, which became effective upon the closing of the Company’s initial public offering. On June 8, 2022 (the “Restatement Effective Date”), the Company’s stockholders approved the Amended and Restated 2013 Long-Term Incentive Plan (the “Amended 2013 LTIP”). The Amended 2013 LTIP provides for the grant of incentive stock options, nonstatutory stock options, restricted stock units and other stock-based awards. The number of shares of common stock reserved for issuance under the Amended 2013 LTIP is the sum of (A) the number of shares of the Company’s common stock (up to 16,724,212 shares) that is equal to the sum of (1) the number of shares issued under the 2013 Long-Term Incentive Plan prior to the Restatement Effective Date, (2) the number of shares that remain available for issuance under the 2013 Long-Term Incentive Plan immediately prior to the Restatement Effective Date and (3) the number of shares subject to awards granted under the 2013 Long-Term Incentive Plan prior to the Restatement Effective Date that are outstanding as of the Restatement Effective Date, plus (B) from and after the Restatement Effective Date, an additional 8,475,000 shares of Common Stock. As of September 30, 2023, awards for 6,802,210 shares of common stock are available for issuance under the Amended 2013 LTIP.

There are no additional shares of common stock available for issuance under the Company’s 1998 Employee, Director and Consultant Stock Option Plan, 2009 Equity and Long Term Incentive Plan or 2013 Stock Incentive Plan.

In January 2020, the Company’s Board of Directors approved the 2020 Inducement Stock Incentive Plan. The 2020 Inducement Stock Incentive Plan provides for the grant of incentive stock options, nonstatutory stock options, restricted stock awards and other stock-based awards for, initially, up to at the time, an aggregate of 1,000,000 shares of common stock. Any grants made under the 2020 Inducement Stock Incentive Plan must be made pursuant to the Nasdaq Listing Rule 5635(c)(4) inducement grant exception as a material component of the Company’s new hires’ employment compensation.  In December 2020, the Company’s Board of Directors approved an additional 1,000,000 shares of common stock that may be issued under the 2020 Inducement Stock Incentive Plan.  In April 2022, the Company’s Board of Directors approved a reduction in the total number of shares of common stock that may be issued under the 2020 Inducement Stock Incentive Plan to 1,300,000 shares. In December 2022, the Company’s Board of Directors approved an additional 1,700,000 shares of common stock that may be issued under the 2020 Inducement Stock Incentive Plan.  As of September 30, 2023, awards for 1,705,941 shares of common stock were available for issuance under the 2020 Inducement Stock Incentive Plan.

The Board of Directors has the authority to select the individuals to whom options are granted and determine the terms of each option, including (i) the number of shares of common stock subject to the option; (ii) the date on which the option becomes exercisable; (iii) the option exercise price, which, in the case of incentive stock options, must be at least 100% (110% in the case of incentive stock options granted to a stockholder owning in excess of 10% of the Company’s stock) of the fair market value of the common stock as of the date of grant; and (iv) the duration of the option (which, in the case of incentive stock options, may not exceed ten years). Options typically vest over a four-year period.

Inducement stock option awards

From January 1, 2023 through September 30, 2023, the Company issued a total of 1,059,054 stock options to various employees. Of those, 121,460 were inducement grants for non-statutory stock options, all of which were made pursuant to the 2020 Inducement Stock Incentive Plan.

Stock option activity—A summary of stock option activity is as follows:

    

    

    

Weighted-

    

  

Weighted-

average

Aggregate

average

remaining

intrinsic

Number of

exercise

contractual

value(in 

options

price

term

thousands)

 

Outstanding at December 31, 2022

 

11,502,417

$

43.33

 

  

 

  

Granted

 

1,059,054

$

41.29

 

  

 

  

Exercised

 

(806,407)

$

29.48

 

  

 

  

Forfeited/Cancelled

 

(318,281)

$

47.84

 

  

 

  

Outstanding at September 30, 2023

 

11,436,783

$

43.99

 

5.87

years

$

5,084

Vested or Expected to vest at September 30, 2023

 

2,357,250

$

46.72

 

8.23

years

$

Exercisable at September 30, 2023

 

8,533,144

$

43.18

 

5.05

years

$

5,084

The fair value of grants made in the nine months ended September 30, 2023 was contemporaneously estimated on the date of grant using the following assumptions:

    

Nine months ended

    

September 30, 2023

Risk-free interest rate

 

3.54% - 3.91%

Expected volatility

 

53% - 54%

Expected term

 

5.5 years

The Company assumed no expected dividends for all grants. The weighted average grant date fair value of options granted during the nine months ended September 30, 2023 was $21.83 per share.

The expected term of options was estimated based on the Company’s historical exercise data and the expected volatility of options was estimated based on the Company’s historical stock volatility. The risk-free rate of the options was based on U.S. Government Securities Treasury Constant Maturities yields at the date of grant for a term similar to the expected term of the option.

Restricted Stock Awards and Restricted Stock Units—Restricted stock awards and restricted stock units are granted subject to certain restrictions, including in some cases service or time conditions (restricted stock). The grant-date fair value of restricted stock awards and restricted stock units, which have been determined based upon the market value of the Company’s shares on the grant date, are expensed over the vesting period.  From January 1, 2023, through September 30, 2023, the Company issued a total of 1,973,973 restricted stock units to various employees. Of those, 83,210 were inducement grants for restricted stock units, all of which were made pursuant to the 2020 Inducement Stock Incentive Plan.

The following table summarizes information on the Company’s restricted stock awards and units:

Restricted Stock Awards and Units

Weighted

Average

Grant

Number of

Date

    

Shares

    

Fair Value

Unvested at December 31, 2022

2,516,336

$

45.67

Granted

 

1,973,973

40.00

Vested

 

(778,442)

46.34

Forfeited

 

(297,765)

42.65

Unvested at September 30, 2023

 

3,414,102

$

42.50

Employee Stock Purchase Plan—In June 2016, the Company established an Employee Stock Purchase Plan (as amended, “ESPP” or the "Plan”), for certain eligible employees. The Plan is administered by the Company’s Board of Directors or a committee appointed by the Company’s Board of Directors. In June 2021, the Plan was amended to increase the total number of shares available for purchase under the Plan from one million shares to two million shares of the Company’s common stock. Employees may participate over a six month period through payroll withholdings and may purchase, at the end of the six month period, the Company’s common stock at a purchase price of at least 85% of the closing price of a share of the Company’s common stock on the first business day of the offering period or the closing price of a share of the Company’s common stock on the last business day of the offering period, whichever is lower. No participant will be granted a right to purchase the Company’s common stock under the Plan if such participant would own more than 5% of the total combined voting power of the Company or any subsidiary of the Company after such purchase. For the three and nine months ended September 30, 2023, the Company recorded $0.7 million and $2.0 million, respectively, in compensation expense related to the ESPP.

The Company recorded share-based compensation expense in the statement of operations related to incentive stock options, nonstatutory stock options, restricted stock awards, restricted stock units and the ESPP as follows:

Three Months Ended September 30, 

Nine Months Ended September 30, 

    

2023

    

2022

    

2023

    

2022

Research and development

$

13,986

$

15,063

$

44,828

$

41,896

Selling, general and administrative

 

12,956

 

13,607

 

40,300

 

41,093

Total

$

26,942

$

28,670

$

85,128

$

82,989

As of September 30, 2023, there was approximately $179.3 million of total unrecognized compensation cost related to unvested share-based compensation arrangements granted under the Company’s equity award plans. This cost is expected to be recognized as share-based compensation expense over the weighted average remaining service period of approximately 1.9 years.

XML 26 R16.htm IDEA: XBRL DOCUMENT v3.23.3
Debt
9 Months Ended
Sep. 30, 2023
Debt Disclosure [Abstract]  
Debt

9.        Debt

Liability for sale of future royalties

In July 2020, the Company entered into the Royalty Purchase Agreement. As RPI’s interest is explicitly limited, the $650.0 million cash consideration was classified as debt and is recorded as “liability for sale of future royalties-current” and “liability for sale of future royalties-noncurrent” on the Company’s consolidated balance sheet based on the timing of the expected payments to be made to RPI. The fair value for the liability for sale of future royalties at the time of the transaction was based on the Company’s estimates of future royalties expected to be paid to RPI over the life of the arrangement, which was determined using forecasts from market data sources, which are considered Level 3 inputs. The liability is being amortized using the effective interest method over the life of the arrangement, in accordance with ASC 470 and ASC 835. The initial annual effective interest rate was determined to be 11.0%. The Company utilizes the prospective method to account for subsequent changes in the estimated future payments to be made to RPI and updates the effective interest rate on a quarterly basis. Issuance costs related to the transaction were determined to be immaterial.

The following table shows the activity within the “liability for sale of future royalties- current” and “liability for sale of future royalties- noncurrent” accounts for the nine months ended September 30, 2023:

    

Nine Months Ended September 30, 

Liability for sale of future royalties- (current and noncurrent)

2023

Beginning balance as of December 31, 2022

$

757,886

Less: Non-cash royalty revenue payable to RPI

(50,599)

Plus: Non-cash interest expense recognized

56,031

Ending balance

$

763,318

Effective interest rate as of September 30, 2023

 

9.3

%

Non-cash interest expense is recorded in the statement of operations within “Interest expense, net”.  

Senior Secured Term Loan

On October 27, 2022 (the “Closing Date”), the Company entered into a credit agreement (the “Blackstone Credit Agreement”) for fundings of up to $950.0 million consisting of a committed loan facility of $450.0 million and further contemplating the potential for up to $500.0 million of additional financing, to the extent that the Company requests such additional financing and subject to the Lenders’ agreement to provide such additional financing and to mutual agreement on terms, among the Company, certain subsidiaries of the Company (together with the Company, the “Loan Parties”) and funds and other affiliated entities advised or managed by Blackstone Life Sciences and Blackstone Credit (collectively, “Blackstone”, and such lenders, together with their permitted assignees, the “Lenders” and each a “Lender”) and Wilmington Trust, National Association, as the administrative agent for the Lenders.  

The Blackstone Credit Agreement provides for a senior secured term loan facility funded on the Closing Date in the aggregate principal amount of $300.0 million (the “Initial Loans”) and a committed delayed draw term loan facility of up to $150.0 million (the “Delayed Draw Loans” and, together with the Initial Loans, the “Loans”) to be funded at the Company’s request within 18 months of the Closing Date subject to specified conditions. In addition, the Blackstone Credit Agreement contemplates the potential for further financings by Blackstone, by providing for incremental discretionary uncommitted further financings of up to $500.0 million. The Company capitalized approximately $11.6 million of debt issuance costs which are presented on the balance sheet as a direct deduction from the debt liability and are being amortized over the term of the senior secured term loan facility using the effective interest rate method.

The Loans mature on the date that is seven years from the Closing Date. Borrowings under the Blackstone Credit Agreement bear interest at a variable rate equal to, at the Company’s option, either an adjusted Term SOFR rate plus seven and a quarter percent (7.25%) or the Base Rate plus six and a quarter percent (6.25%), subject to a floor of one percent (1%) and two percent (2%) with respect to Term SOFR rate and Base Rate (each as defined in the Blackstone Credit Agreement), respectively. Payment of the Loans are subject to certain premiums specified in the Blackstone Credit Agreement, in each case, from the date the applicable Loan is funded.

All obligations under the Blackstone Credit Agreement are secured, subject to certain exceptions and specified inclusions, by security interests in certain assets of the Loan Parties, including (1) intellectual property and other assets related to Translarna, Emflaza, Upstaza, sepiapterin and, until certain release conditions are met, vatiquinone, in each case, together with any other forms, formulations, or methods of delivery of any such products, and regardless of trade or brand name, (2) future acquired intellectual property (but not internally developed intellectual property unrelated to other intellectual property collateral) and other related assets, and (3) the equity interests held by the Loan Parties in certain of their subsidiaries. The Blackstone Credit Agreement contains certain negative covenants with which the Company must remain in compliance. The Blackstone Credit Agreement also requires that the Company maintains consolidated liquidity of at least $100.0 million as of the last day of each fiscal quarter, which shall be increased to $200.0 million upon the Company consummating acquisitions meeting certain consolidated thresholds described therein. In addition, the Company will be required under conditions specified in the Blackstone Credit Agreement to fund a reserve account up to certain amounts specified therein, including $50.0 million that the Company funded into the reserve account during the quarter ended March 31, 2023 and was released back to the Company during the quarter ended June 30, 2023.  The funds in the reserve

account are available to prepay the Loans at any time at the Company’s option, and are, if funded, subject to release upon certain further conditions. Upon any such release, such funds are freely available for use by the Company subject to the generally applicable terms and conditions of the Blackstone Credit Agreement. The Blackstone Credit Agreement contains certain customary representations and warranties, affirmative covenants and provisions relating to events of default.

The Blackstone Credit Agreement consists of the following:

September 30, 2023

December 31, 2022

Principal

$

300,000

$

300,000

Less: Debt issuance costs

 

(10,742)

 

(11,322)

Net carrying amount

$

289,258

$

288,678

As of September 30, 2023, the remaining contractual life of the Blackstone Credit Agreement is approximately 6.1 years.

The following table sets forth total interest expense recognized related to the Blackstone Credit Agreement:

Three Months Ended

Nine Months Ended

September 30, 

September 30, 

2023

2023

Contractual interest expense

$

9,554

$

28,087

Amortization of debt issuance costs

 

280

 

702

Total

$

9,834

$

28,789

Effective interest rate

13.1

%

13.1

%

2026 Convertible Notes

In September 2019, the Company issued, at par value, $287.5 million aggregate principal amount of 1.50% convertible senior notes due 2026, which included an option to purchase up to an additional $37.5 million in aggregate principal amount of the 2026 Convertible Notes, which was exercised in full by the initial purchasers. The 2026 Convertible Notes bear cash interest at a rate of 1.50% per year, payable semi-annually on March 15 and September 15 of each year, beginning on March 15, 2020. The 2026 Convertible Notes will mature on September 15, 2026, unless earlier repurchased or converted. The net proceeds to the Company from the offering were $279.3 million after deducting the initial purchasers’ discounts and commissions and the offering expenses payable by the Company.

The 2026 Convertible Notes are governed by an indenture (the "2026 Convertible Notes Indenture") with U.S Bank National Association as trustee (the "2026 Convertible Notes Trustee").

Holders of the 2026 Convertible Notes may convert their 2026 Convertible Notes at their option at any time prior to the close of business on the business day immediately preceding March 15, 2026 only under the following circumstances:

during any calendar quarter commencing on or after December 31, 2019 (and only during such calendar quarter), if the last reported sale price of the Company’s common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day;
during the five business day period after any five consecutive trading day period (the “measurement period”) in which the trading price (as defined in the 2026 Convertible Notes Indenture) per $1,000 principal amount of 2026 Convertible Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of the Company’s common stock and the conversion rate on each such trading day;
during any period after the Company has issued notice of redemption until the close of business on the scheduled trading day immediately preceding the relevant redemption date; or
upon the occurrence of specified corporate events.

On or after March 15, 2026, until the close of business on the business day immediately preceding the maturity date, holders may convert their 2026 Convertible Notes at any time, regardless of the foregoing circumstances. Upon conversion, the Company will pay or deliver, as the case may be, cash, shares of the Company’s common stock or any combination thereof at the Company’s election.

The conversion rate for the 2026 Convertible Notes was initially, and remains, 19.0404 shares of the Company’s common stock per $1,000 principal amount of the 2026 Convertible Notes, which is equivalent to an initial conversion price of approximately $52.52 per share of the Company’s common stock. The conversion rate may be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest.

The Company was not permitted to redeem the 2026 Convertible Notes prior to September 20, 2023. The Company may redeem for cash all or any portion of the 2026 Convertible Notes, at its option, if the last reported sale price of its common stock has been at least 130% of the conversion price then in effect on the last trading day of, and for at least 19 other trading days (whether or not consecutive) during, any 30 consecutive trading day period ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption, at a redemption price equal to 100% of the principal amount of the 2026 Convertible Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. No sinking fund is provided for the 2026 Convertible Notes, which means that the Company is not required to redeem or retire the 2026 Convertible Notes periodically.

If the Company undergoes a “fundamental change” (as defined in the 2026 Convertible Notes Indenture), subject to certain conditions, holders of the 2026 Convertible Notes may require the Company to repurchase for cash all or part of their 2026 Convertible Notes at a repurchase price equal to 100% of the principal amount of the 2026 Convertible Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date.

The 2026 Convertible Notes represent senior unsecured obligations and will rank senior in right of payment to the Company’s future indebtedness that is expressly subordinated in right of payment to the notes, equal in right of payment to the Company’s existing and future unsecured indebtedness that is not so subordinated, effectively junior in right of payment to any of the Company’s secured indebtedness to the extent of the value of the assets securing such indebtedness, and structurally subordinated to all existing and future indebtedness and other liabilities (including trade payables) incurred by the Company’s subsidiaries. The 2026 Convertible Notes Indenture contains customary events of default with respect to the 2026 Convertible Notes, including that upon certain events of default (including the Company’s failure to make any payment of principal or interest on the 2026 Convertible Notes when due and payable) occurring and continuing, the 2026 Convertible Notes Trustee by notice to the Company, or the holders of at least 25% in principal amount of the outstanding 2026 Convertible Notes by notice to the Company and the Convertible Notes Trustee, may, and the 2026 Convertible Notes Trustee at the request of such holders (subject to the provisions of the 2026 Convertible Notes Indenture) shall, declare 100% of the principal of and accrued and unpaid interest, if any, on all the 2026 Convertible Notes to be due and payable. In case of certain events of bankruptcy, insolvency or reorganization, involving the Company or a significant subsidiary, 100% of the principal of and accrued and unpaid interest on the 2026 Convertible Notes will automatically become due and payable. Upon such a declaration of acceleration, such principal and accrued and unpaid interest, if any, will be due and payable immediately.

The 2026 Convertible Notes consist of the following:

    

September 30, 2023

December 31, 2022

Principal

$

287,500

$

287,500

Less: Debt issuance costs

 

(3,584)

 

(4,456)

Net carrying amount

$

283,916

$

283,044

As of September 30, 2023, the remaining contractual life of the 2026 Convertible Notes is approximately 3.0 years.

The following table sets forth total interest expense recognized related to the 2026 Convertible Notes:

    

 

Three Months Ended September 30, 

Nine Months Ended September 30, 

2023

2022

    

2023

2022

Contractual interest expense

$

1,080

$

1,081

$

3,215

$

3,217

Amortization of debt issuance costs

 

294

289

872

856

Total

$

1,374

$

1,370

$

4,087

$

4,073

Effective interest rate

 

1.9

%

1.9

%

1.9

%

1.9

%

In April 2022, under the terms of the 2026 Convertible Notes Indenture, the Company paid additional interest on the 2026 Convertible Notes at a rate equal to 0.5% per annum, for a total interest payment of approximately $2.1 million, for the period beginning September 25, 2020 and ending March 14, 2022. In September 2022, under the terms of the 2026 Convertible Notes Indenture, the Company paid additional interest on the 2026 Convertible Notes at a rate equal to 0.5% per annum, for a total interest payment of approximately $0.1 million, for the period beginning March 15, 2022 and ending April 8, 2022. These amounts are not included in the table above, but were recorded as interest expense, net within the statement of operations for the nine months ended September 30, 2022.

2022 Convertible Notes

In August 2015, the Company issued, at par value, $150.0 million aggregate principal amount of 3.00% convertible senior notes due 2022, (the “2022 Convertible Notes”). On August 15, 2022, the Company repaid the outstanding principal amount and accrued interest, totaling $152.3 million, of the 2022 Convertible Notes that was due upon maturity in accordance with the terms of the notes.

The following table sets forth total interest expense recognized related to the 2022 Convertible Notes:

 

 

Three Months Ended September 30, 

 

Nine Months Ended September 30, 

 

    

2023

    

2022

    

2023

    

2022

 

Contractual interest expense

$

$

559

$

$

2,800

Amortization of debt issuance costs

 

 

92

 

 

460

Total

$

$

651

$

$

3,260

Effective interest rate

 

%  

 

3.5

%

 

%  

 

3.5

%

XML 27 R17.htm IDEA: XBRL DOCUMENT v3.23.3
Commitments and contingencies
9 Months Ended
Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]  
Commitments and contingencies

10.        Commitments and contingencies

Under various agreements, the Company will be required to pay royalties and milestone payments upon the successful development and commercialization of products. The Company has entered into funding agreements with The Wellcome Trust Limited ("Wellcome Trust") for the research and development of small molecule compounds in connection with the Company’s oncology and antibacterial programs. As the Company has discontinued development under its antibacterial program, it no longer expects that milestone and royalty payments from the Company to Wellcome Trust will apply under that agreement, resulting in a change to the total amount of development and regulatory milestone payments the Company may become obligated to pay for this program. Under the oncology program funding agreement, to the extent that the Company develops and commercializes program intellectual property on a for-profit basis itself or in collaboration with a partner (provided the Company retains overall control of worldwide commercialization), the Company may become obligated to pay to Wellcome Trust development and regulatory milestone payments and single-digit royalties on sales of any research program product. The Company’s obligation to pay such royalties would continue on a country-by-country basis until the longer of the expiration of the last patent in the program intellectual property in such country covering the research program product and the expiration of market exclusivity of such product in such country. The Company made the first development milestone payment of $0.8 million to Wellcome Trust under the oncology platform funding agreement during the second quarter of 2016. During the year ended December 31, 2022, the Company incurred $2.5 million of development milestones in connection with the enrollment of patients in the registration-directed Phase 2/3 trial of unesbulin for the treatment of LMS, which is recorded in accounts payable and accrued expenses on the balance sheet and will be payable upon the earlier to occur of the first dose administered to the last patient enrolled in the study or the

termination of dosing of all patients in the study. Additional milestone payments of up to an aggregate of $14.5 million may become payable by the Company to Wellcome Trust under this agreement.

The Company has also entered into a collaboration agreement with the SMA Foundation. The Company is obligated to pay the SMA Foundation single-digit royalties on worldwide net product sales of any collaboration product that is successfully developed and subsequently commercialized or, with respect to collaboration products the Company outlicenses, including Evrysdi, a specified percentage of certain payments the Company receives from its licensee. Since inception, the SMA Foundation has earned $40.3 million, $35.3 million which was paid and $5.0 million which was accrued as of September 30, 2023. The Company’s obligation to make such payments would end upon the Company’s payment to the SMA Foundation of an aggregate of $52.5 million.

Pursuant to the asset purchase agreement ("Asset Purchase Agreement") between the Company and Marathon Pharmaceuticals, LLC (now known as Complete Pharma Holdings, LLC) (“Marathon”), Marathon is entitled to receive contingent payments from the Company based on annual net sales of Emflaza up to a specified aggregate maximum amount over the expected commercial life of the asset. In addition, Marathon received a $50.0 million sales-based milestone during the nine months ended September 30, 2022.

Pursuant to the Agilis Merger Agreement, Agilis equityholders were previously entitled to receive contingent consideration payments from the Company based on (i) the achievement of certain development milestones up to an aggregate maximum amount of $60.0 million, (ii) the achievement of certain regulatory approval milestones together with a milestone payment following the receipt of a priority review voucher up to an aggregate maximum amount of $535.0 million, (iii) the achievement of certain net sales milestones up to an aggregate maximum amount of $150.0 million, and (iv) a percentage of annual net sales for Friedreich ataxia and Angelman syndrome during specified terms, ranging from 2%-6%. The Company was required to pay $40.0 million of the development milestone payments upon the passing of the second anniversary of the closing of the Agilis Merger, regardless of whether the applicable milestones have been achieved.

Pursuant to the terms of the Rights Exchange Agreement, the Participating Rightholders canceled and forfeited their rights under the Agilis Merger Agreement to receive (i) $174.0 million, in the aggregate, of potential milestone payments based on the achievement of certain regulatory milestones and (ii) $37.6 million, in the aggregate, of $40.0 million in development milestone payments that would have been due upon the passing of the second anniversary of the closing of the Agilis Merger, regardless of whether the milestones are achieved.

The Rights Exchange Agreement has no effect on the Agilis Merger Agreement other than to provide for the cancellation and forfeiture of the Participating Rightholders’ rights to receive $211.6 million, in the aggregate, of the milestone payments described above. As a result, all other rights and obligations under the Agilis Merger Agreement remain in effect pursuant to their terms, including the Company’s obligation to pay up to an aggregate maximum amount of $20.0 million upon the achievement of certain development milestones (representing the remaining portion of potential development milestone payments for which rights were not canceled and forfeited pursuant to the Rights Exchange Agreement while excluding the remaining $2.4 million milestone payment that was due and paid upon the passing of the second anniversary of the closing of the Agilis Merger), up to an aggregate maximum amount of $361.0 million upon the achievement of certain regulatory milestones (representing the remaining portion of potential regulatory milestone payments for which rights were not canceled and forfeited pursuant to the Rights Exchange Agreement), up to a maximum aggregate amount of $150.0 million upon the achievement of certain net sales milestones and a percentage of annual net sales for Friedreich ataxia and Angelman syndrome during specified terms, ranging from 2% to 6%, pursuant to the terms of the Agilis Merger Agreement.

In July 2022, the European Commission approved Upstaza for the treatment of AADC deficiency for patients 18 months and older within the EEA. As a result of such approval, the Company paid the former equityholders of Agilis $50.0 million in accordance with the terms of the Agilis Merger Agreement in the year ended December 31, 2022. In May 2023, as part of the Company’s strategic portfolio prioritization, the Company decided to discontinue its preclinical and early research programs in its gene therapy platform, which included Friedreich ataxia and Angelman syndrome. As a result, the Company does not expect the milestones related to Friedreich ataxia and Angelman syndrome to be achieved. In addition, the Company does not expect to pay the 2% to 6% royalties on annual net sales related to Friedreich ataxia and Angelman syndrome. As of September 30, 2023, the remaining potential development and regulatory milestones the Company

expects to achieve is $31.1 million, and the remaining potential sales milestones the Company expects to achieve is $50.0 million, both of which relate solely to Upstaza.

On October 25, 2019, the Company completed the acquisition of substantially all of the assets of BioElectron Technology Corporation (“BioElectron”), a Delaware corporation, including certain compounds that the Company has begun to develop as part of its Bio-e platform, pursuant to an asset purchase agreement by and between the Company and BioElectron, dated October 1, 2019 (the “BioElectron Asset Purchase Agreement”). BioElectron was a private company with a pipeline focused on inflammatory and central nervous system (CNS) disorders. The lead program, vatiquinone, is in late stage development for CNS disorders with substantial unmet need and significant commercial opportunity that are complementary to PTC’s existing pipeline.

Subject to the terms and conditions of the BioElectron Asset Purchase Agreement, BioElectron may become entitled to receive contingent milestone payments of up to $200.0 million (in cash or in shares of the Company’s common stock, as determined by the Company) from the Company based on the achievement of certain regulatory and net sales milestones. Subject to the terms and conditions of the BioElectron Asset Purchase Agreement, BioElectron may also become entitled to receive contingent payments based on a percentage of net sales of certain products.

Subject to the terms and conditions of the Agreement and Plan of Merger, dated as of May 5, 2020 (the “Censa Merger Agreement”) by and among the Company, Hydro Merger Sub, Inc., the Company’s wholly owned, indirect subsidiary, and, solely in its capacity as the representative, agent and attorney-in-fact of the securityholders of Censa, Shareholder Representative Services LLC (such merger pursuant thereto, the “Censa Merger”), former Censa securityholders may become entitled to receive contingent payments from the Company based on (i) the achievement of certain development and regulatory milestones up to an aggregate maximum amount of $217.5 million for sepiapterin’s two most advanced programs and receipt of a priority review voucher from the FDA as set forth in the Censa Merger Agreement, (ii) $109.0 million in development and regulatory milestones for each additional indication of sepiapterin, (iii) the achievement of certain net sales milestones up to an aggregate maximum amount of $160.0 million, (iv) a percentage of annual net sales during specified terms, ranging from single to low double digits of the applicable net sales threshold amount, and (v) any sublicense fees paid to the Company in consideration of any sublicense of Censa’s intellectual property to commercialize sepiapterin, on a country-by-country basis, which contingent payment shall equal to a mid-double digit percentage of any such sublicense fees.

In February 2023, the Company completed enrollment of its Phase 3 placebo-controlled clinical trial for sepiapterin for PKU.  In connection with this event and pursuant to the Censa Merger Agreement, the Company paid a $30.0 million development milestone to the former Censa securityholders during the nine months ended September 30, 2023. The Company elected to pay this milestone in the form of shares of its common stock, less certain cash payments in accordance with the Censa Merger Agreement. Pursuant to such election, the Company issued 657,462 shares of its common stock and paid $0.4 million to the former Censa securityholders.

The Company also has the Tegsedi-Waylivra Agreement for the commercialization of Tegsedi and Waylivra, and products containing those compounds in countries in Latin America and the Caribbean. Akcea is entitled to receive royalty payments subject to certain terms set forth in the Tegsedi-Waylivra Agreement.

The Company has employment agreements with certain employees which require the funding of a specific level of payments, if certain events, such as a change in control or termination without cause, occur. Additionally, the Company has royalty payments associated with Translarna, Emflaza, and Upstaza net product revenue, payable quarterly or annually in accordance with the terms of the related agreements.

From time to time in the ordinary course of its business, the Company is subject to claims, legal proceedings and disputes. The Company is not currently aware of any material legal proceedings against it.

XML 28 R18.htm IDEA: XBRL DOCUMENT v3.23.3
Revenue recognition
9 Months Ended
Sep. 30, 2023
Revenue from Contract with Customer [Abstract]  
Revenue recognition

11.        Revenue recognition

Net product sales

The Company views its operations and manages its business in one operating segment.

During the three months ended September 30, 2023 and 2022, net product sales outside of the United States were $76.6 million and $79.4 million, respectively, consisting of sales of Translarna, Tegsedi, Waylivra, and Upstaza. Translarna net revenues made up $69.0 million and $76.6 million of the net product sales outside of the United States for the three months ended September 30, 2023 and 2022, respectively. During the three months ended September 30, 2023, and 2022, net product sales in the United States were $67.4 million and $54.8 million, respectively, consisting solely of sales of Emflaza. During the three months ended September 30, 2023, one country, the United States, accounted for at least 10% of the Company’s net product sales, representing $67.4 million of the net product sales. During the three months ended September 30, 2022, two countries, the United States and Russia, accounted for at least 10% of the Company’s net product sales, representing $54.8 million and $28.3 million of the net product sales, respectively. For the three months ended September 30, 2023 and 2022, the Company had a total of three and two distributors, respectively, that each accounted for over 10% of the Company’s net product sales.

During the nine months ended September 30, 2023 and 2022, net product sales outside of the United States were $318.5 million and $247.6 million, respectively, consisting of Translarna, Tegsedi, Waylivra, and Upstaza. Translarna net revenues made up $280.6 million and $232.9 million of the net product sales outside of the United States for the nine months ended September 30, 2023 and 2022, respectively. For the nine months ended September 30, 2023 and 2022, net product sales in the United States were $187.7 million and $160.1 million, respectively, consisting solely of Emflaza. During the nine months ended September 30, 2023, three countries, the United States, Russia, and Brazil, accounted for at least 10% of the Company’s net product sales, representing $187.7 million, $69.0 million, and $52.5 million of net product sales, respectively. During the nine months ended September 30, 2022, two countries, the United States and Russia, accounted for at least 10% of the Company’s net product sales, representing $160.1 million and $57.1 million of net product sales, respectively. For the nine months ended September 30, 2023 and 2022, the Company had a total of two and two distributors, respectively, that each accounted for over 10% of the Company's net product sales.

As of September 30, 2023 and December 31, 2022, the Company does not have a contract liabilities balance related to net product sales, and has not made significant changes to the judgments made in applying ASC Topic 606.

Collaboration and Royalty revenue

In November 2011, the Company and the SMA Foundation entered into the SMA License Agreement with Roche. Under the terms of the SMA License Agreement, Roche acquired an exclusive worldwide license to the Company’s SMA program.

Under the SMA License Agreement, the Company is eligible to receive additional payments from Roche if specified events are achieved with respect to each licensed product, including up to $135.0 million in research and development event milestones, up to $325.0 million in sales milestones upon achievement of specified sales events, and up to double digit royalties on worldwide annual net sales of a commercial product.

The SMA program currently has one approved product, Evrysdi, which was approved in August 2020 by the FDA for the treatment of SMA in adults and children two months and older. As of September 30, 2023, the Company does not have any remaining research and development event milestones that can be received. The remaining potential sales milestones that can be received is $250.0 million.

For the three months ended September 30, 2023, the Company did not recognize collaboration revenue related to the SMA License Agreement with Roche. For the three months ended September 30, 2022, the Company recognized $50.0 million of collaboration revenue related to the SMA License Agreement. For the nine months ended September 30, 2023, the amounts recognized for the collaboration revenue related to the SMA License Agreement with Roche were immaterial. For the nine months ended September 30, 2022, the Company recognized $50.0 million of collaboration revenue related

to the SMA License Agreement. In September 2022, the Company recognized a sales milestone of $50.0 million for the achievement of $750.0 million in worldwide annual net sales from Evrysdi.

In addition to research and development and sales milestones, the Company is eligible to receive up to double-digit royalties on worldwide annual net sales of a commercial product under the SMA License Agreement. For the three and nine months ended September 30, 2023, the Company has recognized $50.2 million and $117.9 million of royalty revenue related to Evrysdi, respectively. For the three and nine months ended September 30, 2022, the Company has recognized $32.9 million and $73.6 million of royalty revenue, respectively, related to Evrysdi.

Manufacturing Revenue

For the three and nine months ended September 30, 2023, the Company recognized $2.4 million and $6.7 million of manufacturing revenue, respectively, related to the production of plasmid DNA and AAV vectors for gene therapy applications for external customers. No manufacturing revenue was recognized for the three and nine months ended September 30, 2022. The Company has not made significant changes to the judgments made in applying ASC Topic 606 for the three and nine months ended September 30, 2023 and 2022.

As of September 30, 2023 and December 31, 2022, the Company has a contract liabilities balance of $1.2 million and $1.4 million, respectively, related to the production of plasmid DNA and AAV vectors for gene therapy applications for external customers, which is recorded within deferred revenue on the consolidated balance sheet. For the three-month period ended September 30, 2023, the Company did not recognize any revenue related to the amount included in the contract liability balance at the beginning of the period. For the nine-month period ended September 30, 2023, the Company recognized $1.4 million related to the amounts included in the contract liability balance at the beginning of the period.

As of September 30, 2023, the Company has contract assets of $1.4 million related to plasmid DNA and AAV production for external customers, which is recorded within prepaid expenses and other current assets on the consolidated balance sheet. The Company did not have any contract assets for the period ending December 31, 2022.

Remaining performance obligations

As of September 30, 2023 and December 31, 2022, the Company has remaining performance obligations of $1.2 million and $1.4 million, respectively, related to the production of plasmid DNA and AAV vectors for gene therapy applications for external customers. The Company expects to recognize revenue over the next one year, as the specific timing for satisfying the performance obligations is contingent upon a number of factors, including customers’ needs and schedules.

XML 29 R19.htm IDEA: XBRL DOCUMENT v3.23.3
Intangible assets and goodwill
9 Months Ended
Sep. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
Intangible assets and goodwill

12.        Intangible assets and goodwill

Definite-lived intangibles

Definite-lived intangible assets consisted of the following at September 30, 2023 and December 31, 2022:

Ending Balance at

Reclass from

Foreign

Ending Balance at

Definite-lived

December 31,

Indefinite Lived to

currency

September 30,

intangibles assets, gross

    

2022

    

Additions

    

Definite Lived

    

Impairment

    

translation

    

2023

Emflaza

$

420,253

$

76,454

$

$

$

$

496,707

Waylivra

9,316

157

(96)

9,377

Tegsedi

7,109

4,299

(183)

11,225

Upstaza

89,550

89,550

Total definite-lived intangibles, gross

$

526,228

$

80,910

$

$

$

(279)

$

606,859

Ending Balance at

Foreign

Ending Balance at

Definite-lived

December 31,

currency

September 30,

intangibles assets, accumulated amortization

    

2022

    

Amortization

    

translation

    

2023

Emflaza

$

(266,023)

$

(138,038)

$

$

(404,061)

Waylivra

(2,751)

(791)

45

(3,497)

Tegsedi

(1,709)

(1,035)

36

(2,708)

Upstaza

(3,420)

(5,597)

(9,017)

Total definite-lived intangibles, accumulated amortization

$

(273,903)

$

(145,461)

$

81

$

(419,283)

Total definite-lived intangibles, net

$

187,576

Marathon is entitled to receive contingent payments from the Company based on annual net sales of Emflaza beginning in 2018, up to a specified aggregate maximum amount over the expected commercial life of the asset. In accordance with the guidance for an asset acquisition, the Company records the milestone payment when it becomes payable to Marathon and increases the cost basis for the Emflaza rights intangible asset. For the nine months ended September 30, 2023, total milestone payments of $76.5 million were recorded. These payments are being amortized over the remaining useful life of the Emflaza rights asset on a straight line basis. As of September 30, 2023, a milestone payable to Marathon of $43.9 million was recorded on the consolidated balance sheet within accounts payable and accrued expenses.

Akcea is also entitled to receive royalty payments subject to certain terms set forth in the Tegsedi-Waylivra Agreement related to sales of Waylivra and Tegsedi. In accordance with the guidance for an asset acquisition, the Company records royalty payments when they become payable to Akcea and increase the cost basis for the Waylivra and Tegsedi intangible assets. For the nine months ended September 30, 2023, royalty payments of $4.3 million and $0.2 million were recorded for Tegsedi and Waylivra, respectively. As of September 30, 2023, a royalty payable of $0.9 million and $0.2 million for Tegsedi and Waylivra, respectively, was recorded on the consolidated balance sheet within accounts payable and accrued expenses.

For the three months ended September 30, 2023 and 2022, the Company recognized amortization expense of $58.6 million and $31.0 million, respectively, related to the Emflaza rights, Upstaza, Waylivra, and Tegsedi intangible assets. For the nine months ended September 30, 2023 and 2022, the Company recognized amortization expense of $145.5 million and $80.8 million, respectively, related to the Emflaza rights, Upstaza, Waylivra, and Tegsedi intangible assets. The estimated future amortization of the Emflaza rights, Upstaza, Waylivra, and Tegsedi intangible assets is expected to be as follows:

    

As of September 30, 2023

2023

$

58,640

2024

 

46,557

2025

 

10,041

2026

 

10,041

2027 and thereafter

 

62,297

Total

$

187,576

The weighted average remaining amortization period of the definite-lived intangibles as of September 30, 2023 is 5.3 years.

Indefinite-lived intangibles

Indefinite-lived intangible assets consisted of the following at September 30, 2023 and December 31, 2022:

Ending Balance at

Reclass from

Foreign

Ending Balance at

Indefinite-lived

December 31,

Indefinite Lived to

currency

September 30,

intangibles assets

    

2022

    

Additions

    

Definite Lived

    

Impairment

    

translation

    

2023

Upstaza

$

235,766

$

$

$

$

$

235,766

PTC-FA

112,500

(112,500)

PTC-AS

105,300

(105,300)

Total indefinite-lived intangibles

$

453,566

$

$

$

(217,800)

$

$

235,766

Total intangible assets, net

$

423,342

In connection with the acquisition of the Company’s gene therapy platform from Agilis, the Company acquired rights to Upstaza, for the treatment of AADC deficiency. AADC deficiency is a rare CNS disorder arising from reductions in the enzyme AADC that result from mutations in the dopa decarboxylase gene. The gene therapy platform also includes PTC-FA, an asset targeting Friedreich ataxia, a rare and life-shortening neurodegenerative disease caused by a single defect in the FXN gene which causes reduced production of the frataxin protein. Additionally, the gene therapy platform includes two other programs targeting CNS disorders, including PTC-AS for Angelman syndrome, a rare, genetic, neurological disorder characterized by severe developmental delays.

In accordance with the acquisition method of accounting, the Company allocated the acquisition cost for the Agilis Merger to the underlying assets acquired and liabilities assumed, based upon the estimated fair values of those assets and liabilities at the date of acquisition. The Company classified the fair value of the acquired IPR&D as indefinite lived intangible assets until the successful completion or abandonment of the associated research and development efforts. As of December 31, 2022, the value allocated to the indefinite lived intangible assets was $453.6 million.

In May 2023, as part of the Company’s strategic portfolio prioritization, the Company decided to discontinue its preclinical and early research programs in its gene therapy platform, which included PTC-FA and PTC-AS. As a result, the Company determined that the PTC-FA and PTC-AS indefinite-lived intangible assets were fully impaired and recorded impairment expense of $217.8 million during the nine month period ended September 30, 2023, which is recorded as intangible asset impairment in the statement of operations. As of September 30, 2023, the remaining indefinite lived intangible asset balance is $235.8 million, consisting solely of Upstaza, which the Company plans to continue to develop and commercialize.

Goodwill

As a result of the Agilis Merger on August 23, 2018, the Company recorded $82.3 million of goodwill. As of September 30, 2023, there have been no changes to the balance of goodwill since the date of the Agilis Merger. Accordingly, the goodwill balance as of September 30, 2023 is $82.3 million.

XML 30 R20.htm IDEA: XBRL DOCUMENT v3.23.3
Subsequent events
9 Months Ended
Sep. 30, 2023
Subsequent Events [Abstract]  
Subsequent events

13.        Subsequent events

Royalty Purchase Agreement

On October 18, 2023, the Company, Royalty Pharma Investments 2019 ICAV (“Royalty Pharma”), and, for the limited purposes set forth in the agreement, Royalty Pharma plc, entered into an Amended and Restated Royalty Purchase Agreement (the “A&R Royalty Purchase Agreement”), which amends and restates in its entirety the Royalty Purchase Agreement.  Pursuant to the A&R Royalty Purchase Agreement, the Company has sold or agreed to sell to Royalty Pharma certain portions of the Company’s remaining Royalty on worldwide net sales of Evrysdi and any other product (the “Products”) developed pursuant to the SMA License Agreement (all such retained Royalty rights of the Company, the “Retained Royalty Rights,” and all such Royalty rights that are sold to Royalty Pharma pursuant to the A&R Royalty Purchase Agreement, the “A&R Assigned Royalty Rights”). At closing, Royalty Pharma paid the Company $1.0 billion in cash consideration for 38.0447% of the Company’s Retained Royalty Rights (which is in addition to the 42.9330% assigned to Royalty Pharma in connection with the Royalty Purchase Agreement, for a total of 80.9777% of the total Royalty) until such time as Royalty Pharma has received payments in respect of the A&R Assigned Royalty Rights equal to $1.3 billion in the aggregate, and thereafter 66.6667% of the total Royalty. In addition, the Company may sell to Royalty Pharma the remainder of the Company’s Retained Royalty Rights in exchange for an aggregate of $500.0 million in additional cash consideration after the closing of the A&R Royalty Purchase Agreement, less royalties received in respect of the Retained Royalty Rights put to Royalty Pharma, which will be payable by Royalty Pharma pursuant to five put options held by the Company that are exercisable at the Company’s option between January 1, 2024 and December 31, 2025. If the Company exercises two or fewer of the put options, Royalty Pharma may exercise a call option during the period from and after January 1, 2026 until and including March 31, 2026 for up to 50% of the remainder of the Company’s Retained Royalty Rights less amounts exercised by the Company via its put options at a purchase price that is proportional to the purchase price of the Company’s unexercised put options. Royalty Pharma’s exercise of the call option would result in Royalty Pharma owning 90.4888% of the total Royalty until such time as Royalty Pharma has received payments in respect of the A&R Assigned Royalty Rights equal to $1.3 billion in the aggregate, and thereafter 83.3333% of the total Royalty. The Company is evaluating the accounting impact of the A&R Royalty Purchase Agreement.

Under the A&R Royalty Purchase Agreement, and in connection with its sale of the A&R Assigned Royalty Rights, the Company has agreed to specified negative and affirmative covenants with respect to the exercise of its rights under the SMA License Agreement, including the Company’s right to amend, modify, assign or terminate the SMA License Agreement.  Subject to certain customary exceptions, the Company has agreed not to grant a security interest in its interest in the SMA License Agreement, the Products or the patent rights that cover the Products. The A&R Royalty Purchase Agreement also contains representations and warranties, covenants and other provisions, including information rights and confidentiality obligations, customary for transactions of this nature.

The A&R Royalty Purchase Agreement will terminate 60 days following the date on which Roche is no longer obligated to make any payments of the Royalty pursuant to the License Agreement.

Senior Secured Term Loan Termination

On October 19, 2023, the Company terminated the Blackstone Credit Agreement. In connection with the termination of the Blackstone Credit Agreement, the Company repaid outstanding principal and accrued interest thereunder totaling $302.1 million and paid an additional $82.1 million in prepayment premiums, expenses and other exit fees. All liens and security interests securing the loans made pursuant to the Blackstone Credit Agreement were released upon termination.

XML 31 R21.htm IDEA: XBRL DOCUMENT v3.23.3
Summary of significant accounting policies (Policies)
9 Months Ended
Sep. 30, 2023
Accounting Policies [Abstract]  
Basis of presentation

Basis of presentation

The accompanying financial information as of September 30, 2023 and for the three and nine months ended September 30, 2023 and 2022 has been prepared by the Company, without audit, pursuant to the rules and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States ("GAAP") have been condensed or omitted pursuant to such rules and regulations. These interim financial statements should be read in conjunction with the Company’s audited financial statements as of December 31, 2022 and notes thereto included in the 2022 Form 10-K.

In the opinion of management, the unaudited financial information as of September 30, 2023 and for the three and nine months ended September 30, 2023 and 2022 reflects all adjustments, which are normal recurring adjustments, necessary to present a fair statement of financial position, results of operations, stockholders’ (deficit) equity, and cash flows. The results of operations for the three and nine months ended September 30, 2023 are not necessarily indicative of the results to be expected for the year ended December 31, 2023 or for any other interim period or for any other future year.

Use of estimates

Use of estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates in these consolidated financial statements have been made in connection with the calculation of net product sales, royalty revenue, certain accruals related to the Company’s research and development expenses, valuation procedures for liability for sale of future royalties, valuation procedures for convertible notes, fair value of the contingent consideration, and the provision for or benefit from income taxes. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.

Restricted Cash

Restricted cash

Restricted cash included in deposits and other assets on the consolidated balance sheet contains an unconditional, irrevocable and transferable letter of credit that was entered into during the twelve-month period ended December 31, 2019 in connection with obligations under a facility lease for the Company’s leased biologics manufacturing facility in Hopewell Township, New Jersey. The amount of the letter of credit is $7.5 million, is to be maintained for a term of not less than five years and has the potential to be reduced to $3.8 million if after five years the Company is not in default of its lease. Restricted cash also contains an unconditional, irrevocable and transferable letter of credit that was entered into during June 2022 in connection with obligations for the Company’s new facility lease in Warren, New Jersey. The amount of the letter of credit is $8.1 million and has the potential to be reduced to $4.1 million if after five years the Company is not in default of its lease. Both amounts are classified within deposits and other assets on the consolidated balance sheet due to the long-term nature of the respective letters of credit. Restricted cash also includes a bank guarantee of $0.6 million denominated in a foreign currency.

The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheet that sum to the total of the same amounts shown in the statement of cash flows:

    

End of

    

Beginning of

 

period-

 

period-

 

September 30, 

 

December 31, 

 

2023

2022

Cash and cash equivalents

$

165,157

$

279,834

Restricted cash included in deposits and other assets

 

16,253

 

16,091

Total Cash, cash equivalents and restricted cash per statement of cash flows

$

181,410

$

295,925

Marketable securities

Marketable securities

The Company’s marketable securities consists of both debt securities and equity investments. The Company considers its investments in debt securities with original maturities of greater than 90 days to be available for sale securities. Securities under this classification are recorded at fair value and unrealized gains and losses within accumulated other comprehensive income. The estimated fair value of the available for sale securities is determined based on quoted market prices or rates for similar instruments. In addition, the cost of debt securities in this category is adjusted for amortization of premium and accretion of discount to maturity. For available for sale debt securities in an unrealized loss position, the Company assesses whether it intends to sell or if it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security’s amortized cost basis is written down to fair value. If the criteria are not met, the Company evaluates whether the decline in fair value has resulted from a credit loss or other factors. In making this assessment, management considers, among other factors, the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and adverse conditions specifically related to the security. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security are compared to the amortized cost basis of the security. If the present value of the cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded for the credit loss, limited by the amount that the fair value is less than the amortized costs basis. Any impairment that has not been recorded through an allowance for credit losses is recognized in other comprehensive income. For the three and nine months ended September 30, 2023 and 2022, no allowance was recorded for credit losses.

Marketable securities that are equity investments are measured at fair value, as it is readily available, and as such are classified as Level 1 assets. Unrealized holding gains and losses for these equity investments are components of other (expense) income, net within the consolidated statement of operations.

Inventory and cost of product sales

Inventory and cost of product sales

Inventory

Inventories are stated at the lower of cost and net realizable value with cost determined on a first-in, first-out basis by product. The Company capitalizes inventory costs associated with products following regulatory approval when future commercialization is considered probable and the future economic benefit is expected to be realized. Products which may be used in clinical development programs are included in inventory and charged to research and development expense when the product enters the research and development process and no longer can be used for commercial purposes. Inventory used for marketing efforts are charged to selling, general and administrative expense. Amounts related to clinical development programs and marketing efforts are immaterial.

The following table summarizes the components of the Company’s inventory for the periods indicated:

    

September 30, 2023

    

December 31, 2022

Raw materials

$

907

$

1,078

Work in progress

 

24,595

 

14,074

Finished goods

 

10,250

 

6,656

Total inventory

$

35,752

$

21,808

The Company periodically reviews its inventories for excess amounts or obsolescence and writes down obsolete or otherwise unmarketable inventory to its estimated net realizable value. For the three months ended September 30, 2023, the Company’s inventory write-downs were immaterial. For the nine months ended September 30, 2023, the Company recorded inventory write-downs of $0.4 million primarily related to product approaching expiration. For the three and nine months ended September 30, 2022, the Company recorded inventory write-downs of $0.3 million and $1.2 million, respectively, primarily related to product approaching expiration. Additionally, though the Company’s product is subject to strict quality control and monitoring which it performs throughout the manufacturing processes, certain batches or units of product may not meet quality specifications resulting in a charge to cost of product sales. For the three and nine months ended September 30, 2023 and 2022, these amounts were immaterial.

Cost of product sales

Cost of product sales consists of the cost of inventory sold, manufacturing and supply chain costs, storage costs, amortization of the acquired intangible asset, royalty payments associated with net product sales, and royalty payments to collaborative partners associated with royalty revenues and collaboration revenue related to milestones. Production costs are expensed as cost of product sales when the related products are sold or royalty revenues and collaboration revenue milestones are earned.

Revenue recognition

Revenue recognition

Net product revenue

The Company’s net product revenue primarily consists of sales of Translarna in territories outside of the U.S. for the treatment of nmDMD and sales of Emflaza in the U.S. for the treatment of DMD. The Company recognizes revenue when its performance obligations with its customers have been satisfied. The Company’s performance obligations are to provide products based on customer orders from distributors, hospitals, specialty pharmacies or retail pharmacies. The performance obligations are satisfied at a point in time when the Company’s customer obtains control of the product, which is typically upon delivery. The Company invoices its customers after the products have been delivered and invoice payments are generally due within 30 to 90 days of the invoice date. The Company determines the transaction price based on fixed consideration in its contractual agreements. Contract liabilities arise in certain circumstances when consideration is due for goods the Company has yet to provide. As the Company has identified only one distinct performance obligation, the transaction price is allocated entirely to product sales. In determining the transaction price, a significant financing component does not exist since the timing from when the Company delivers product to when the customers pay for the product is typically less than one year. Customers in certain countries pay in advance of product delivery. In those instances, payment and delivery typically occur in the same month.

The Company records product sales net of any variable consideration, which includes discounts, allowances, rebates related to Medicaid and other government pricing programs, and distribution fees. The Company uses the expected value or most likely amount method when estimating its variable consideration, unless discount or rebate terms are specified within contracts. The identified variable consideration is recorded as a reduction of revenue at the time revenues from product sales are recognized. These estimates for variable consideration are adjusted to reflect known changes in factors and may impact such estimates in the quarter those changes are known. Revenue recognized does not include amounts of variable consideration that are constrained.

For the three months ended September 30, 2023 and 2022, net product sales outside of the United States were $76.6 million and $79.4 million, respectively, consisting of sales of Translarna, Tegsedi, Waylivra, and Upstaza. Translarna net revenues made up $69.0 million and $76.6 million of the net product sales outside of the United States for the three months ended September 30, 2023 and 2022, respectively. For the three months ended September 30, 2023 and 2022, net product sales in the United States were $67.4 million and $54.8 million, respectively, consisting solely of sales of Emflaza. During the three months ended September 30, 2023, one country, the United States, accounted for at least 10% of the Company’s net product sales, representing $67.4 million of net product sales. During the three months ended September 30, 2022, two

countries, the United States and Russia, accounted for at least 10% of the Company’s net product sales, representing $54.8 million and $28.3 million of net product sales, respectively.

For the nine months ended September 30, 2023 and 2022, net product sales outside of the United States were $318.5 million and $247.6 million, respectively, consisting of Translarna, Tegsedi, Waylivra, and Upstaza. Translarna net revenues made up $280.6 million and $232.9 million of the net product sales outside of the United States for the nine months ended September 30, 2023 and 2022, respectively. For the nine months ended September 30, 2023 and 2022, net product sales in the United States were $187.7 million and $160.1 million, respectively, consisting solely of Emflaza. During the nine months ended September 30, 2023, three countries, the United States, Russia, and Brazil, accounted for at least 10% of the Company’s net product sales, representing $187.7 million, $69.0 million, and $52.5 million of net product sales, respectively. During the nine months ended September 30, 2022, two countries, the United States and Russia,  accounted for at least 10% of the Company’s net product sales, representing $160.1 million and $57.1 million of net product sales, respectively.

In relation to customer contracts, the Company incurs costs to fulfill a contract but does not incur costs to obtain a contract. These costs to fulfill a contract do not meet the criteria for capitalization and are expensed as incurred. The Company considers any shipping and handling costs that are incurred after the customer has obtained control of the product as a cost to fulfill a promise. Shipping and handling costs associated with finished goods delivered to customers are recorded as a selling expense.

Collaboration and royalty revenue

The terms of these agreements typically include payments to the Company of one or more of the following: nonrefundable, upfront license fees; milestone payments; research funding and royalties on future product sales. In addition, the Company generates service revenue through agreements that generally provide for fees for research and development services and may include additional payments upon achievement of specified events.

At the inception of a collaboration arrangement, the Company needs to first evaluate if the arrangement meets the criteria in Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 808 “Collaborative Arrangements” to then determine if ASC Topic 606 is applicable by considering whether the collaborator meets the definition of a customer. If the criteria are met, the Company assesses the promises in the arrangement to identify distinct performance obligations.

For licenses of intellectual property, the Company assesses, at contract inception, whether the intellectual property is distinct from other performance obligations identified in the arrangement. If the licensing of intellectual property is determined to be distinct, revenue is recognized for nonrefundable, upfront license fees when the license is transferred to the customer and the customer can use and benefit from the license. If the licensing of intellectual property is determined not to be distinct, then the license will be bundled with other promises in the arrangement into one distinct performance obligation. The Company needs to determine if the bundled performance obligation is satisfied over time or at a point in time. If the Company concludes that the nonrefundable, upfront license fees will be recognized over time, the Company will need to assess the appropriate method of measuring proportional performance.

For milestone payments, the Company assesses, at contract inception, whether the development or sales-based milestones are considered probable of being achieved. If it is probable that a significant revenue reversal will occur, the Company will not record revenue until the uncertainty has been resolved. Milestone payments that are contingent upon regulatory approval are not considered probable of being achieved until the applicable regulatory approvals or other external conditions are obtained as such conditions are not within the Company’s control. If it is probable that a significant revenue reversal will not occur, the Company will estimate the milestone payments using the most likely amount method. The Company will re-assess the development and sales-based milestones each reporting period to determine the probability of achievement. The Company recognizes royalties from product sales at the later of when the related sales occur or when the performance obligation to which the royalty has been allocated has been satisfied. If it is probable that a significant revenue reversal will not occur, the Company will estimate the royalty payments using the most likely amount method.

The Company recognizes revenue for reimbursements of research and development costs under collaboration agreements as the services are performed. The Company records these reimbursements as revenue and not as a reduction of research and development expenses as the Company has the risks and rewards as the principal in the research and development activities.

For the three months ended September 30, 2023, the Company did not recognize collaboration revenue related to the SMA License Agreement with Roche. For the three months ended September 30, 2022, the Company recognized $50.0 million of collaboration revenue related to the SMA License Agreement. For the nine months ended September 30, 2023, the amounts recognized for the collaboration revenue related to the SMA License Agreement with Roche were immaterial. For the nine months ended September 30, 2022, the Company recognized $50.0 million of collaboration revenue related to the SMA License Agreement with Roche. In September 2022, the Company recognized a sales milestone of $50.0 million for the achievement of $750.0 million in worldwide annual net sales from Evrysdi.

For the three and nine months ended September 30, 2023, the Company has recognized $50.2 million and $117.9 million of royalty revenue, respectively, related to Evrysdi. For the three and nine months ended September 30, 2022, the Company has recognized $32.9 million and $73.6 million of royalty revenue, respectively, related to Evrysdi.

Manufacturing Revenue

The Company has manufacturing services related to the production of plasmid deoxyribonucleic acid (“DNA”) and adeno-associated virus (“AAV”) vectors for gene therapy applications for external customers. Performance obligations vary but may include manufacturing plasmid DNA and/or AAV vectors, material testing, stability studies, and other services related to material development. The transaction prices for these arrangements are fixed and include amounts stated in the contracts for each promised service. Typically, the performance obligations within a manufacturing contract are highly interdependent, in which case, the Company will combine them into a single performance obligation. The Company has determined that the assets created have no alternative use to the Company, and the Company has an enforceable right to payment for the performance completed to date, therefore revenue related to these services are recognized over time and is measured using an output method based on performance of manufacturing milestones completed to date.

Manufacturing service contracts may also include performance obligations related to project management services or obtaining materials from third parties. The Company has determined that these are separate performance obligations for which revenue is recognized at the point in time the services are performed. For performance obligations related to obtaining third party materials, the Company has determined that it is the principal as the Company has control of the materials and has discretion in setting the price. Therefore, the Company recognizes revenue on a gross basis related to obtaining third party materials.

Certain arrangements require a portion of the contract consideration to be received in advance at the commencement of the contract, and such advance payment is initially recorded as a contract liability. A contract asset may be recognized in the event the Company’s satisfaction of performance obligations outpaces customer billings.

For the three and nine months ended September 30, 2023, the Company recognized $2.4 million and $6.7 million of manufacturing revenue, respectively, related to plasmid DNA and AAV vector production for external customers. No manufacturing revenue was recognized for the three and nine months ended September 30, 2022. As of September 30, 2023, the Company has contract assets of $1.4 million and remaining performance obligations of $1.2 million related to the production of plasmid DNA and AAV vectors for gene therapy applications for external customers. For the period ended December 31, 2022, the Company had remaining performance obligations of $1.4 million and no contracts assets related to plasmid DNA and AAV production for external customers.

Allowance for doubtful accounts

Allowance for doubtful accounts

The Company maintains an allowance for estimated losses resulting from the inability of its customers to make required payments. The Company estimates uncollectible amounts based upon current customer receivable balances, the age of customer receivable balances, the customer’s financial condition and current economic trends. The Company also assesses whether an allowance for expected credit losses may be required which includes a review of the Company’s receivables

portfolio, which are pooled on a customer basis or country basis.  In making its assessment of whether an allowance for credit losses is required, the Company considers its historical experience with customers, current balances, levels of delinquency, regulatory and legal environments, and other relevant current and future forecasted economic conditions. For the three and nine months ended September 30, 2023 and 2022, no allowance was recorded for credit losses. The allowance for doubtful accounts was $1.0 million as of September 30, 2023 and $0.3 million as of December 31, 2022. For the three and nine months ended September 30, 2023, bad debt expense was $0.4 million and $0.7 million, respectively. For the three and nine months ended September 30, 2022, bad debt expense was immaterial.

Liability for sale of future royalties

Liability for sale of future royalties

On July 17, 2020, the Company, RPI, and, for the limited purposes set forth in the agreement, Royalty Pharma PLC, entered into the Royalty Purchase Agreement. Pursuant to the Royalty Purchase Agreement, the Company sold to RPI 42.933% (the “Assigned Royalty Rights”) of the Company’s right to receive sales-based royalty payments (the “Royalty”) on worldwide net sales of Evrysdi and any other product developed pursuant to the SMA License Agreement. In consideration for the sale of the Assigned Royalty Rights, RPI paid the Company $650.0 million in cash consideration. The Company has retained a 57.067% interest in the Royalty and all economic rights to receive the remaining potential regulatory and sales milestone payments under the SMA License Agreement, which remaining milestone payments equal $250.0 million in the aggregate as of September 30, 2023. The Royalty Purchase Agreement will terminate 60 days following the earlier of the date on which Roche is no longer obligated to make any payments of the Royalty pursuant to the SMA License Agreement and the date on which RPI has received $1.3 billion in respect of the Assigned Royalty Rights.

The cash consideration obtained pursuant to the Royalty Purchase Agreement is classified as debt and is recorded as “liability for sale of future royalties-current” and “liability for sale of future royalties-noncurrent” on the Company’s consolidated balance sheet based on the timing of the expected payments to be made to RPI. The fair value for the liability for sale of future royalties at the time of the transaction was based on the Company’s estimates of future royalties expected to be paid to RPI over the life of the arrangement, which was determined using forecasts from market data sources, which are considered Level 3 inputs. The liability is being amortized using the effective interest method over the life of the arrangement, in accordance with the respective guidance. The Company utilizes the prospective method to account for subsequent changes in the estimated future payments to be made to RPI.  Refer to Note 9 for further details.

Indefinite-lived intangible assets

Indefinite-lived intangible assets

Indefinite-lived intangible assets consist of in process research and development ("IPR&D"). IPR&D acquired directly in a transaction other than a business combination is capitalized if the projects will be further developed or have an alternative future use; otherwise they are expensed. The fair values of IPR&D projects and license agreement assets acquired in business combinations are capitalized. Several methods may be used to determine the estimated fair value of the IPR&D and license agreement asset acquired in a business combination. The Company utilizes the "income method" and uses estimated future net cash flows that are derived from projected sales revenues and estimated costs. These projections are based on factors such as relevant market size, patent protection, and expected pricing and industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. These assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are amortized over the remaining useful life or written off, as appropriate. Intangible assets with indefinite lives, including IPR&D, are tested for impairment if impairment indicators arise and, at a minimum, annually. However, an entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that an indefinite-lived intangible asset’s fair value is less than its carrying amount. Otherwise, no further impairment testing is required. The indefinite-lived intangible asset impairment test consists of a one-step analysis that compares the fair value of the intangible asset with its carrying amount. If the carrying amount of an intangible asset exceeds its fair value, an impairment loss is recognized in an amount equal to that excess. The Company considers many factors in evaluating whether the value of its intangible assets with indefinite lives may not be recoverable, including, but not limited to, expected growth rates, the cost of equity and debt capital, general economic conditions, the Company’s outlook and market performance of the Company’s industry and recent and forecasted financial performance.

In May 2023, as part of the Company’s strategic portfolio prioritization, the Company decided to discontinue its preclinical and early research programs in its gene therapy platform, which included Friedreich ataxia and Angelman syndrome. As a result, the Company determined that the Friedreich ataxia and Angelman syndrome indefinite lived intangible assets were fully impaired and recorded impairment expense of $217.8 million during the nine months ended September 30, 2023, which is recorded as intangible asset impairment in the statement of operations. Refer to Note 12 for further information regarding the Company’s intangible assets.

Goodwill

Goodwill

Goodwill represents the amount of consideration paid in excess of the fair value of net assets acquired as a result of the Company’s business acquisitions accounted for using the acquisition method of accounting. Goodwill is not amortized and is subject to impairment testing at a reporting unit level on an annual basis or when a triggering event occurs that may indicate the carrying value of the goodwill is impaired. The Company reassesses its reporting units as part of its annual segment review. An entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that the fair value of the reporting unit is less than its carrying amount.

Income Taxes

Income Taxes

The Organization for Economic Co-operation and Development (“OECD”), the European Community (“the EC”), and individual taxing jurisdictions where the Company and its affiliates do business have recently focused on issues related to the taxation of multinational corporations. The OECD has released its comprehensive plan to create an agreed set of international rules for fighting base erosion and profit shifting. In addition, the OECD, the EC and individual taxing jurisdictions are examining changes to how taxing rights should be allocated among countries considering the digital economy. As a result, the tax laws in the U.S. and other countries in which the Company and its affiliates do business could change on a prospective or retroactive basis and any such changes could materially adversely affect the Company’s business.

On December 22, 2017, the U.S. government enacted the 2017 Tax Act, which significantly revised U.S. tax law by, among other provisions, lowering the U.S. federal statutory corporate income tax rate to 21%, imposing a mandatory one-time transition tax on previously deferred foreign earnings, and eliminating or reducing certain income tax deductions. The Global Intangible Low-Taxed Income ("GILTI") provisions of the 2017 Tax Act require the Company to include in its U.S. income tax return foreign subsidiary earnings in excess of an allowable return on the foreign subsidiary’s tangible assets. The Company has elected to account for GILTI tax in the period in which it is incurred, and therefore has not provided any deferred tax impacts of GILTI in its consolidated financial statements for the period ended September 30, 2023.

Starting in 2022, TCJA amendments to IRC Section 174 no longer permits an immediate deduction for research and development (R&D) expenditures in the tax year that such costs are incurred. Instead, these IRC Section 174 development costs must now be capitalized and amortized over either a five- or 15-year period, depending on the location of the activities performed. The new amortization period begins with the midpoint of any taxable year that IRC Section 174 costs are first incurred, regardless of whether the expenditures were made prior to or after July 1, and runs until the midpoint of year five for activities conducted in the United States or year 15 in the case of development conducted on foreign soil.

Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and net operating loss and credit carryforwards. Deferred tax assets and liabilities are measured at rates expected to apply to taxable income in the years in which those temporary differences and carryforwards are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the statement of operations in the period that includes the enactment date. A valuation allowance is recorded when it is not more likely than not that all or a portion of the net deferred tax assets will be realized.

On August 23, 2018, the Company completed its acquisition of Agilis Biotherapeutics, Inc. (“Agilis”), pursuant to an Agreement and Plan of Merger, dated as of July 19, 2018 (the “Agilis Merger Agreement”), by and among the Company,

Agility Merger Sub, Inc., a Delaware corporation and the Company’s wholly owned, indirect subsidiary, Agilis and, solely in its capacity as the representative, agent and attorney-in-fact of the equityholders of Agilis, Shareholder Representative Services LLC, (the “Agilis Merger”). The Company recorded a deferred tax liability in conjunction with the Agilis Merger of $122.0 million in 2018, related to the tax basis difference in the IPRD indefinite-lived intangibles acquired. The Company’s policy is to record a deferred tax liability related to acquired IPR&D which may eventually be realized either upon amortization of the asset when the research is completed, and a product is successfully launched or the write-off of the asset if it is abandoned or unsuccessful. In July 2022, the Company received EMEA approval for a portion of the IPR&D assets, and thus, began the amortization of the intangible.

In May 2023, the Company announced the discontinuation of its preclinical and early research programs in gene therapy as part of a strategic portfolio prioritization. In conjunction with the announcement, the Company recorded an impairment to its indefinite-lived intangible for IP research and development relating to the Friedreich ataxia and Angelman syndrome gene therapy assets. As a result of the impairment, the Company recorded a deferred tax benefit of $50.9 million.

Leases

Leases

The Company determines if an arrangement is a lease at inception. This determination generally depends on whether the arrangement conveys to the Company the right to control the use of an explicitly or implicitly identified fixed asset for a period of time in exchange for consideration. Control of an underlying asset is conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using the underlying asset. The Company has lease agreements which include lease and non-lease components, which the Company accounts for as a single lease component for all leases. Operating and finance leases are classified as right of use ("ROU") assets, short term lease liabilities, and long term lease liabilities. Operating and finance lease ROU assets and lease liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. ROU assets are amortized and lease liabilities accrete to yield straight-line expense over the term of the lease. Lease payments included in the measurement of the lease liability are comprised of fixed payments.

Variable lease payments associated with the Company’s leases are recognized when the event, activity, or circumstance in the lease agreement on which those payments are assessed occurs. Variable lease payments are presented in the Company’s consolidated statements of operations in the same line item as expense arising from fixed lease payments for operating leases.

Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheet and the Company recognizes lease expense for these leases on a straight-line basis over the lease term. The Company applies this policy to all underlying asset categories.

A lessee is required to discount its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental borrowing rate. As most of the Company’s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The Company gives consideration to its recent debt issuances as well as publicly available data for instruments with similar characteristics when calculating its incremental borrowing rates.

The lease term for all of the Company’s leases includes the non-cancellable period of the lease plus any additional periods covered by either a Company option to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor. Leasehold improvements are capitalized and depreciated over the lesser of useful life or lease term. See Note 3 Leases for additional information.  

XML 32 R22.htm IDEA: XBRL DOCUMENT v3.23.3
Summary of significant accounting policies (Tables)
9 Months Ended
Sep. 30, 2023
Accounting Policies [Abstract]  
Reconciliation of cash

    

End of

    

Beginning of

 

period-

 

period-

 

September 30, 

 

December 31, 

 

2023

2022

Cash and cash equivalents

$

165,157

$

279,834

Restricted cash included in deposits and other assets

 

16,253

 

16,091

Total Cash, cash equivalents and restricted cash per statement of cash flows

$

181,410

$

295,925

Schedule of Inventory

    

September 30, 2023

    

December 31, 2022

Raw materials

$

907

$

1,078

Work in progress

 

24,595

 

14,074

Finished goods

 

10,250

 

6,656

Total inventory

$

35,752

$

21,808

XML 33 R23.htm IDEA: XBRL DOCUMENT v3.23.3
Leases - (Tables)
9 Months Ended
Sep. 30, 2023
Leases  
Schedule of lease costs

    

Three Months Ended

    

Three Months Ended

    

Nine Months Ended

    

Nine Months Ended

September 30, 2023

September 30, 2022

September 30, 2023

September 30, 2022

Operating Lease Cost

 

  

  

  

  

Fixed lease cost

$

5,490

$

5,377

$

16,463

$

14,267

Variable lease cost

 

1,376

 

1,151

 

4,140

 

3,152

Short-term lease cost

 

271

 

262

 

866

 

600

Total operating lease cost

$

7,137

$

6,790

$

21,469

$

18,019

    

September 30, 2023

    

December 31, 2022

 

Weighted-average remaining lease terms - operating leases (years)

 

11.61

11.61

Weighted-average discount rate - operating leases

8.67

%

8.61

%

Weighted-average remaining lease terms - finance lease (years)

 

9.26

10.01

Weighted-average discount rate - finance lease

 

7.80

%

7.80

%

Schedule of supplemental cash flow information related to leases

    

Nine Months Ended September 30, 

    

2023

    

2022

Cash paid for amounts included in the measurement of lease liabilities:

 

  

  

Operating cash flows from operating leases

$

11,479

$

10,954

Financing cash flows from finance lease

1,379

1,276

Operating cash flows from finance lease

1,621

1,724

Right-of-use assets obtained in exchange for lease obligations:

 

 

  

Operating leases

$

$

35,294

Schedule of future lease payments - Operating leases

    

Operating Leases

    

Finance Lease

2023 (excludes the nine months ended September 30, 2023)

$

5,077

$

2024

 

18,369

 

3,000

2025

 

20,438

 

3,000

2026

 

19,988

 

3,000

2027 and thereafter

 

193,792

 

18,000

Total lease payments

 

257,664

 

27,000

Less: Imputed Interest expense

 

146,279

 

7,205

Total

$

111,385

$

19,795

Schedule of future lease payments - Finance leases

    

Operating Leases

    

Finance Lease

2023 (excludes the nine months ended September 30, 2023)

$

5,077

$

2024

 

18,369

 

3,000

2025

 

20,438

 

3,000

2026

 

19,988

 

3,000

2027 and thereafter

 

193,792

 

18,000

Total lease payments

 

257,664

 

27,000

Less: Imputed Interest expense

 

146,279

 

7,205

Total

$

111,385

$

19,795

XML 34 R24.htm IDEA: XBRL DOCUMENT v3.23.3
Fair value of financial instruments and investments - (Tables)
9 Months Ended
Sep. 30, 2023
Fair Value Disclosures [Abstract]  
Schedule of financial assets and liabilities that are required to be measured at fair value on a recurring basis

September 30, 2023

 

 

Quoted prices

 

Significant

 

 

in active

 

other

 

Significant

 

markets for

 

observable

 

unobservable

 

identical assets

 

inputs

 

inputs

    

Total

    

(level 1)

    

(level 2)

    

(level 3)

Marketable securities - available for sale

$

1,625

$

$

1,625

$

Marketable securities - equity investments

$

128,028

$

128,028

$

$

ClearPoint Equity Investments - available for sale

$

4,482

$

4,482

$

$

ClearPoint convertible debt security

$

10,637

$

$

10,637

$

Contingent consideration payable- development and regulatory milestones

$

26,400

$

$

$

26,400

Contingent consideration payable- net sales milestones and royalties

$

12,600

$

$

$

12,600

December 31, 2022

 

 

Quoted prices

 

Significant

 

 

in active

 

other

 

Significant

 

markets for

 

observable

 

unobservable

 

identical assets

 

inputs

 

inputs

    

Total

    

(level 1)

    

(level 2)

    

(level 3)

Marketable securities - available for sale

$

22,610

$

$

22,610

$

Marketable securities - equity investments

$

108,261

$

108,261

$

$

ClearPoint Equity Investments

$

10,965

$

10,965

$

$

ClearPoint convertible debt security

$

15,231

$

$

15,231

$

Contingent consideration payable- development and regulatory milestones

$

82,500

$

$

$

82,500

Contingent consideration payable- net sales milestones and royalties

$

81,500

$

$

$

81,500

Summary of marketable securities accounted for as available-for-sale debt securities

September 30, 2023

 

Amortized

 

Gross Unrealized

    

Cost

    

Gains

    

Losses

    

Fair Value

Corporate debt securities

$

1,649

$

$

(24)

$

1,625

Total

$

1,649

$

$

(24)

$

1,625

December 31, 2022

 

Amortized

 

Gross Unrealized

    

Cost

    

Gains

    

Losses

    

Fair Value

Commercial paper

$

12,419

$

5

$

$

12,424

Corporate debt securities

 

10,685

(499)

10,186

Total

$

23,104

$

5

$

(499)

$

22,610

Summary of unrealized losses and fair values of available-for-sale debt securities in a continuous unrealized loss position

September 30, 2023

 

Securities in an unrealized loss

 

Securities in an unrealized loss

 

 

position less than 12 months

 

position greater than or equal to 12 months

Total

   

Unrealized losses

   

Fair Value

   

Unrealized losses

   

Fair Value

   

Unrealized losses

   

Fair Value

Corporate debt securities

$

(24)

1,625

(24)

$

1,625

Total

$

$

$

(24)

$

1,625

$

(24)

$

1,625

December 31, 2022

 

Securities in an unrealized loss

 

Securities in an unrealized loss

 

 

position less than 12 months

 

position greater than or equal to 12 months

Total

   

Unrealized losses

   

Fair Value

   

Unrealized losses

   

Fair Value

   

Unrealized losses

   

Fair Value

Corporate debt securities

$

(499)

10,186

(499)

$

10,186

Total

$

$

$

(499)

$

10,186

$

(499)

$

10,186

Schedule of marketable securities on the balance sheet

September 30, 2023

 

Less Than

 

More Than

    

12 Months

    

12 Months

Corporate debt securities

$

1,625

$

Total

$

1,625

$

December 31, 2022

 

Less Than

 

More Than

    

12 Months

    

12 Months

Commercial paper

$

12,424

$

Corporate debt securities

 

 

10,186

Total

$

12,424

$

10,186

Summary of changes in the fair value of the Company's Level 3 valuation for contingent consideration payable

Level 3 liabilities

Contingent consideration payable-

Contingent consideration payable-

development and regulatory

net sales milestones and royalties

    

milestones

    

Beginning balance as of December 31, 2022

$

82,500

$

81,500

Additions

 

 

Change in fair value

 

(56,100)

 

(68,900)

Payments

Ending balance as of September 30, 2023

$

26,400

$

12,600

Level 3 liabilities

Contingent consideration payable-

Contingent consideration payable-

development and regulatory

net sales milestones and royalties

    

milestones

    

Beginning balance as of December 31, 2021

$

139,300

$

100,600

Additions

 

 

Change in fair value

 

(10,800)

 

(21,400)

Reclass to accounts payable and accrued expenses

(50,000)

Payments

Ending balance as of September 30, 2022

$

78,500

$

79,200

Fair Value Measurement Inputs and Valuation Techniques

September 30, 2023

    

Fair Value

    

Valuation Technique

    

Unobservable Input

    

Range

Contingent consideration payable-
development and regulatory milestones

$26,400

 

 Probability-adjusted discounted cash flow 

 

Potential development and regulatory milestones
Probabilities of success
Discount rates
Projected years of payments

$0 - $31 million
85% - 92%
6.9% - 7.6%
2023 - 2026

Contingent considerable payable- net sales
milestones and royalties

$12,600

 

Option-pricing model with Monte Carlo simulation  

 

Potential net sales milestones
Probabilities of success
Potential percentage of net sales for royalties
Discount rate
Projected years of payments

$0 - $50 million
85% - 100%
0%
12%
2025 - 2034

December 31, 2022

    

Fair Value

    

Valuation Technique

    

Unobservable Input

    

Range

Contingent consideration payable-
development and regulatory milestones

$82,500

 

 Probability-adjusted discounted cash flow 

 

Potential development and regulatory milestones
Probabilities of success
Discount rates
Projected years of payments

$0 - $331 million
25% - 92%
6.2% - 8.3%
2023 - 2029

Contingent considerable payable- net sales
milestones and royalties

$81,500

 

Option-pricing model with Monte Carlo simulation  

 

Potential net sales milestones
Probabilities of success
Potential percentage of net sales for royalties
Discount rate
Projected years of payments

$0 - $150 million
25% - 100%
2% - 6%
11.5%
2025 - 2041

XML 35 R25.htm IDEA: XBRL DOCUMENT v3.23.3
Accounts payable and accrued expenses - (Tables)
9 Months Ended
Sep. 30, 2023
Payables and Accruals [Abstract]  
Schedule of components of accounts payable and accrued expenses

September 30, 

December 31, 

    

2023

    

2022

Employee compensation, benefits, and related accruals

$

70,778

$

62,669

Income tax payable

2,822

4,712

Consulting and contracted research

 

21,236

 

38,882

Professional fees

 

3,067

 

3,093

Sales allowance

 

72,202

 

63,787

Sales rebates

 

119,971

 

67,355

Royalties

52,087

40,546

Accounts payable

 

19,152

 

27,268

Other

 

9,416

 

12,054

Total

$

370,731

$

320,366

XML 36 R26.htm IDEA: XBRL DOCUMENT v3.23.3
Net loss per share - (Tables)
9 Months Ended
Sep. 30, 2023
Earnings Per Share [Abstract]  
Schedule of computation of basic and diluted net loss available to common stockholders

Three Months Ended September 30, 

Nine Months Ended September 30, 

    

2023

    

2022

    

2023

    

2022

    

Numerator

Net loss

$

(132,970)

  

$

(109,315)

  

$

(470,812)

  

$

(388,128)

  

Denominator

Denominator for basic and diluted net loss per share

 

75,377,997

  

 

71,654,671

  

 

74,618,611

  

 

71,415,849

  

Net loss per share:

Basic and diluted

$

(1.76)

*

$

(1.53)

*

$

(6.31)

*

$

(5.43)

*

*     In the three and nine months ended September 30, 2023 and 2022, the Company experienced a net loss and therefore did not report any dilutive share impact.

Schedule of historical dilutive common share equivalents outstanding

As of September 30, 

    

2023

    

2022

    

Stock Options

11,436,783

11,478,421

Unvested restricted stock awards and units

 

3,414,102

 

2,488,944

 

Total

 

14,850,885

 

13,967,365

 

XML 37 R27.htm IDEA: XBRL DOCUMENT v3.23.3
Stock award plan - (Tables)
9 Months Ended
Sep. 30, 2023
Share-based Payment Arrangement [Abstract]  
Summary of stock option activity

    

    

    

Weighted-

    

  

Weighted-

average

Aggregate

average

remaining

intrinsic

Number of

exercise

contractual

value(in 

options

price

term

thousands)

 

Outstanding at December 31, 2022

 

11,502,417

$

43.33

 

  

 

  

Granted

 

1,059,054

$

41.29

 

  

 

  

Exercised

 

(806,407)

$

29.48

 

  

 

  

Forfeited/Cancelled

 

(318,281)

$

47.84

 

  

 

  

Outstanding at September 30, 2023

 

11,436,783

$

43.99

 

5.87

years

$

5,084

Vested or Expected to vest at September 30, 2023

 

2,357,250

$

46.72

 

8.23

years

$

Exercisable at September 30, 2023

 

8,533,144

$

43.18

 

5.05

years

$

5,084

Schedule of assumptions used to estimate fair values of grants made on the date of grant

    

Nine months ended

    

September 30, 2023

Risk-free interest rate

 

3.54% - 3.91%

Expected volatility

 

53% - 54%

Expected term

 

5.5 years

Summary of information on the Company's restricted stock

Restricted Stock Awards and Units

Weighted

Average

Grant

Number of

Date

    

Shares

    

Fair Value

Unvested at December 31, 2022

2,516,336

$

45.67

Granted

 

1,973,973

40.00

Vested

 

(778,442)

46.34

Forfeited

 

(297,765)

42.65

Unvested at September 30, 2023

 

3,414,102

$

42.50

Schedule of share-based compensation expense recorded in the statement of operations

Three Months Ended September 30, 

Nine Months Ended September 30, 

    

2023

    

2022

    

2023

    

2022

Research and development

$

13,986

$

15,063

$

44,828

$

41,896

Selling, general and administrative

 

12,956

 

13,607

 

40,300

 

41,093

Total

$

26,942

$

28,670

$

85,128

$

82,989

XML 38 R28.htm IDEA: XBRL DOCUMENT v3.23.3
Debt - (Tables)
9 Months Ended
Sep. 30, 2023
Debt Instrument, Redemption [Line Items]  
Summary of liability for sale of future royalties

    

Nine Months Ended September 30, 

Liability for sale of future royalties- (current and noncurrent)

2023

Beginning balance as of December 31, 2022

$

757,886

Less: Non-cash royalty revenue payable to RPI

(50,599)

Plus: Non-cash interest expense recognized

56,031

Ending balance

$

763,318

Effective interest rate as of September 30, 2023

 

9.3

%

1.50% Convertible senior notes due 2026  
Debt Instrument, Redemption [Line Items]  
Summary of convertible notes

    

September 30, 2023

December 31, 2022

Principal

$

287,500

$

287,500

Less: Debt issuance costs

 

(3,584)

 

(4,456)

Net carrying amount

$

283,916

$

283,044

Summary of interest expense recognized related to the Convertible Notes

    

 

Three Months Ended September 30, 

Nine Months Ended September 30, 

2023

2022

    

2023

2022

Contractual interest expense

$

1,080

$

1,081

$

3,215

$

3,217

Amortization of debt issuance costs

 

294

289

872

856

Total

$

1,374

$

1,370

$

4,087

$

4,073

Effective interest rate

 

1.9

%

1.9

%

1.9

%

1.9

%

3.00% Convertible senior notes due 2022  
Debt Instrument, Redemption [Line Items]  
Summary of interest expense recognized related to the Convertible Notes

 

 

Three Months Ended September 30, 

 

Nine Months Ended September 30, 

 

    

2023

    

2022

    

2023

    

2022

 

Contractual interest expense

$

$

559

$

$

2,800

Amortization of debt issuance costs

 

 

92

 

 

460

Total

$

$

651

$

$

3,260

Effective interest rate

 

%  

 

3.5

%

 

%  

 

3.5

%

Blackstone Credit Agreement  
Debt Instrument, Redemption [Line Items]  
Schedule of credit agreement

September 30, 2023

December 31, 2022

Principal

$

300,000

$

300,000

Less: Debt issuance costs

 

(10,742)

 

(11,322)

Net carrying amount

$

289,258

$

288,678

Summary of interest expense recognized related to debt

Three Months Ended

Nine Months Ended

September 30, 

September 30, 

2023

2023

Contractual interest expense

$

9,554

$

28,087

Amortization of debt issuance costs

 

280

 

702

Total

$

9,834

$

28,789

Effective interest rate

13.1

%

13.1

%

XML 39 R29.htm IDEA: XBRL DOCUMENT v3.23.3
Intangible assets and goodwill - (Tables)
9 Months Ended
Sep. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of definite lived intangible assets

Definite-lived intangible assets consisted of the following at September 30, 2023 and December 31, 2022:

Ending Balance at

Reclass from

Foreign

Ending Balance at

Definite-lived

December 31,

Indefinite Lived to

currency

September 30,

intangibles assets, gross

    

2022

    

Additions

    

Definite Lived

    

Impairment

    

translation

    

2023

Emflaza

$

420,253

$

76,454

$

$

$

$

496,707

Waylivra

9,316

157

(96)

9,377

Tegsedi

7,109

4,299

(183)

11,225

Upstaza

89,550

89,550

Total definite-lived intangibles, gross

$

526,228

$

80,910

$

$

$

(279)

$

606,859

Ending Balance at

Foreign

Ending Balance at

Definite-lived

December 31,

currency

September 30,

intangibles assets, accumulated amortization

    

2022

    

Amortization

    

translation

    

2023

Emflaza

$

(266,023)

$

(138,038)

$

$

(404,061)

Waylivra

(2,751)

(791)

45

(3,497)

Tegsedi

(1,709)

(1,035)

36

(2,708)

Upstaza

(3,420)

(5,597)

(9,017)

Total definite-lived intangibles, accumulated amortization

$

(273,903)

$

(145,461)

$

81

$

(419,283)

Total definite-lived intangibles, net

$

187,576

Schedule of estimated future amortization of intangible assets

    

As of September 30, 2023

2023

$

58,640

2024

 

46,557

2025

 

10,041

2026

 

10,041

2027 and thereafter

 

62,297

Total

$

187,576

Schedule of indefinite lived intangible assets

Indefinite-lived intangible assets consisted of the following at September 30, 2023 and December 31, 2022:

Ending Balance at

Reclass from

Foreign

Ending Balance at

Indefinite-lived

December 31,

Indefinite Lived to

currency

September 30,

intangibles assets

    

2022

    

Additions

    

Definite Lived

    

Impairment

    

translation

    

2023

Upstaza

$

235,766

$

$

$

$

$

235,766

PTC-FA

112,500

(112,500)

PTC-AS

105,300

(105,300)

Total indefinite-lived intangibles

$

453,566

$

$

$

(217,800)

$

$

235,766

Total intangible assets, net

$

423,342

XML 40 R30.htm IDEA: XBRL DOCUMENT v3.23.3
The Company (Details)
$ in Thousands
9 Months Ended
Sep. 30, 2023
USD ($)
product
Dec. 31, 2022
USD ($)
Long-term debt    
Number of products | product 2  
Retained earnings (accumulated deficit) | $ $ (3,127,786) $ (2,656,974)
1.50% Convertible senior notes due 2026    
Long-term debt    
Interest rate ( as a percent ) 1.50%  
XML 41 R31.htm IDEA: XBRL DOCUMENT v3.23.3
Summary of significant accounting policies - Narrative (Details)
$ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Dec. 22, 2017
May 31, 2023
USD ($)
Jun. 30, 2022
USD ($)
Jul. 31, 2020
USD ($)
Sep. 30, 2023
USD ($)
country
segment
Sep. 30, 2022
USD ($)
segment
country
Sep. 30, 2023
USD ($)
country
segment
Sep. 30, 2022
USD ($)
segment
country
Dec. 31, 2019
USD ($)
Mar. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Dec. 31, 2018
USD ($)
New Accounting Pronouncements or Change in Accounting Principle [Line Items]                        
Number of operating segments | segment         1 1 1 1        
Allowance for credit loss         $ 0 $ 0 $ 0 $ 0        
Increase in allowance for credit losses         0 0 0 0        
Allowance for doubtful accounts receivable         1,000   1,000       $ 300  
Bad debt expense         400   700          
Revenue         196,576 $ 217,127 630,766 $ 531,389        
Cash consideration received from Royalty Purchase Agreement       $ 650,000                
Income taxes                        
Federal income tax statutory rate 21.00%                      
Deferred tax benefit   $ 50,900         50,909          
Impairment of indefinite-lived intangibles excluding goodwill             217,800          
PTC-FA and PTC-AS                        
Income taxes                        
Impairment of indefinite-lived intangibles excluding goodwill             217,800          
Indefinite-lived intangible assets                        
Income taxes                        
Impairment of indefinite-lived intangibles excluding goodwill             217,800          
Indefinite-lived intangible assets | PTC-FA and PTC-AS                        
Income taxes                        
Impairment of indefinite-lived intangibles excluding goodwill             217,800          
Agilis                        
Income taxes                        
Deferred tax liability                       $ 122,000
Deposits and other assets                        
New Accounting Pronouncements or Change in Accounting Principle [Line Items]                        
Bank guarantee         $ 600   $ 600          
Blackstone Credit Agreement                        
New Accounting Pronouncements or Change in Accounting Principle [Line Items]                        
Credit agreement reserve                   $ 50,000    
Hopewell Campus                        
New Accounting Pronouncements or Change in Accounting Principle [Line Items]                        
Period after which letter of credit may be reduced if lease is not in default                 5 years      
Hopewell Campus | Minimum                        
New Accounting Pronouncements or Change in Accounting Principle [Line Items]                        
Term for letter of credit (in years)                 5 years      
Hopewell Campus | Deposits and other assets                        
New Accounting Pronouncements or Change in Accounting Principle [Line Items]                        
Letters of credit                 $ 7,500      
Hopewell Campus | Fifth Anniversary                        
New Accounting Pronouncements or Change in Accounting Principle [Line Items]                        
Letters of credit                 $ 3,800      
Warren Premises                        
New Accounting Pronouncements or Change in Accounting Principle [Line Items]                        
Period after which letter of credit may be reduced if lease is not in default     5 years                  
Warren Premises | Deposits and other assets                        
New Accounting Pronouncements or Change in Accounting Principle [Line Items]                        
Letters of credit     $ 8,100                  
Warren Premises | Fifth Anniversary                        
New Accounting Pronouncements or Change in Accounting Principle [Line Items]                        
Letters of credit     $ 4,100                  
Net product revenue | United States                        
New Accounting Pronouncements or Change in Accounting Principle [Line Items]                        
Number of countries exceeding 10% of net product sales | country         1              
Net product revenue | Geographic concentration risk                        
New Accounting Pronouncements or Change in Accounting Principle [Line Items]                        
Number of countries exceeding 10% of net product sales | country         1 2 3 2        
Percentage of net product sales threshold         10.00% 10.00% 10.00% 10.00%        
Net product revenue | Geographic concentration risk | Russia                        
New Accounting Pronouncements or Change in Accounting Principle [Line Items]                        
Revenue           $ 28,300 $ 69,000 $ 57,100        
Net product revenue | Geographic concentration risk | Brazil                        
New Accounting Pronouncements or Change in Accounting Principle [Line Items]                        
Revenue             52,500          
Net product revenue | Geographic concentration risk | United States                        
New Accounting Pronouncements or Change in Accounting Principle [Line Items]                        
Revenue         $ 67,400 54,800 187,700 160,100        
Net product revenue                        
New Accounting Pronouncements or Change in Accounting Principle [Line Items]                        
Revenue         144,038 134,186 506,187 407,720        
Net product revenue | Non-US                        
New Accounting Pronouncements or Change in Accounting Principle [Line Items]                        
Revenue         76,600 79,400 318,500 247,600        
Emflaza | United States                        
New Accounting Pronouncements or Change in Accounting Principle [Line Items]                        
Revenue         67,400 54,800 187,700 160,100        
Translarna | Non-US                        
New Accounting Pronouncements or Change in Accounting Principle [Line Items]                        
Revenue         $ 69,000 $ 76,600 $ 280,600 $ 232,900        
XML 42 R32.htm IDEA: XBRL DOCUMENT v3.23.3
Summary of significant accounting policies - Reconciliation of cash (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Sep. 30, 2022
Dec. 31, 2021
Accounting Policies [Abstract]        
Cash and cash equivalents $ 165,157 $ 279,834    
Restricted cash included in deposits and other assets 16,253 16,091    
Total Cash, cash equivalents and restricted cash per statement of cash flows $ 181,410 $ 295,925 $ 120,511 $ 197,218
XML 43 R33.htm IDEA: XBRL DOCUMENT v3.23.3
Summary of significant accounting policies - Inventory (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Accounting Policies [Abstract]        
Raw materials   $ 907   $ 1,078
Work in progress   24,595   14,074
Finished goods   10,250   6,656
Total inventory   35,752   $ 21,808
Inventory write-down $ 300 $ 400 $ 1,200  
XML 44 R34.htm IDEA: XBRL DOCUMENT v3.23.3
Summary of significant accounting policies - Collaboration and Royalty Revenue (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Collaboration and royalty revenue          
Revenue   $ 196,576 $ 217,127 $ 630,766 $ 531,389
Collaboration revenue          
Collaboration and royalty revenue          
Revenue   0 50,017 6 50,024
Royalty revenue          
Collaboration and royalty revenue          
Revenue   50,173 32,924 117,857 73,645
SMA License Agreement | Collaboration revenue          
Collaboration and royalty revenue          
Revenue   0      
SMA License Agreement | Royalty revenue          
Collaboration and royalty revenue          
Revenue   $ 50,200 $ 32,900 $ 117,900 $ 73,600
SMA License Agreement | Sales Milestones          
Collaboration and royalty revenue          
Milestone payments due $ 50,000        
Net sales milestone threshold achieved $ 750,000        
XML 45 R35.htm IDEA: XBRL DOCUMENT v3.23.3
Summary of significant accounting policies - Manufacturing Revenue (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Revenue recognition          
Revenue $ 196,576 $ 217,127 $ 630,766 $ 531,389  
Remaining performance obligations 1,200   1,200   $ 1,400
Manufacturing revenue          
Revenue recognition          
Revenue 2,365 $ 0 6,716 $ 0  
Contract with customer, asset $ 1,400   $ 1,400   $ 0
XML 46 R36.htm IDEA: XBRL DOCUMENT v3.23.3
Summary of significant accounting policies - Liability for Sale of Future Royalties (Details) - USD ($)
$ in Millions
1 Months Ended
Jul. 17, 2020
Jul. 31, 2020
Sep. 30, 2023
Assigned royalty payments      
Cash consideration received from Royalty Purchase Agreement   $ 650.0  
Assigned royalty payment, retained percentage 57.067%    
Remaining potential milestones that can be achieved     $ 250.0
Royalty Purchase Agreement | Assigned Royalty Payments      
Assigned royalty payments      
Assigned royalty payment, percentage 42.933%    
Cash consideration received from Royalty Purchase Agreement $ 650.0    
Royalty purchase agreement termination period once there are no further royalty payment obligations 60 days    
Royalty purchase agreement, payment maximum $ 1,300.0    
XML 47 R37.htm IDEA: XBRL DOCUMENT v3.23.3
Leases - Narrative (Details)
$ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Jul. 01, 2020
USD ($)
ft²
item
May 31, 2022
USD ($)
ft²
building
period
Sep. 30, 2023
USD ($)
lease
Sep. 30, 2022
USD ($)
Sep. 30, 2023
USD ($)
lease
Sep. 30, 2022
USD ($)
Dec. 31, 2020
USD ($)
Dec. 31, 2022
USD ($)
Jun. 19, 2020
USD ($)
Leases                  
Number of operating leases | lease     2   2        
Operating lease, expense     $ 7,100 $ 6,800 $ 21,500 $ 18,000      
Finance Lease, Liability     19,795   19,795        
Finance lease liabilities- current     2,611   2,611     $ 3,000  
Finance lease liabilities- noncurrent     17,184   17,184     18,675  
Aggregate rent, Initial term     257,664   257,664        
Operating lease ROU assets     94,072   94,072     102,430  
Operating Lease, Liability     111,385   111,385        
Research and development     164,212 165,462 545,210 462,802      
MassBio                  
Leases                  
Finance lease cost     400 $ 400 1,100 $ 1,200      
Finance Lease, Liability                 $ 41,400
Finance lease liabilities- current     2,600   2,600     3,000  
Finance lease liabilities- noncurrent     $ 17,200   $ 17,200     $ 18,700  
Finance lease ROU asset                 $ 41,400
Finance lease, term of contract                 12 years 6 months
Research and development             $ 41,400    
Minimum                  
Leases                  
Operating lease, term of contract     4 months 24 days   4 months 24 days        
Maximum                  
Leases                  
Operating lease, term of contract     15 years 8 months 12 days   15 years 8 months 12 days        
Renewal term     20 years   20 years        
Hopewell Campus                  
Leases                  
Operating lease, term of contract 15 years                
Area of real estate property | ft² 220,500                
Renewal term 10 years                
Number of renewable terms | item 2                
Lessee, Operating Lease, Existence of Option to Extend [true false] true                
Aggregate rent, Initial term $ 111,500                
Percent of market rate 95.00%                
Warren Premises                  
Leases                  
Operating lease, term of contract   17 years              
Number of buildings leased | building   2              
Area of real estate property | ft²   360,000              
Renewal term   5 years              
Number of renewable terms | period   3              
Lessee, Operating Lease, Existence of Option to Extend [true false]   true              
Aggregate rent, Initial term   $ 163,000              
Operating lease ROU assets   28,900              
Operating Lease, Liability   $ 28,900              
Base rent abatement period   3 years              
Base rent abatement   $ 18,600              
Aggregate rent net of base rate abatement, initial term   144,400              
Allowance for lease improvements   36,200              
Commitment to fund construction account   3,600              
Payment due from lessor at issuance of temporary certificate of occupancy   $ 5,000              
XML 48 R38.htm IDEA: XBRL DOCUMENT v3.23.3
Leases - Lease costs (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Leases        
Fixed lease cost $ 5,490 $ 5,377 $ 16,463 $ 14,267
Variable lease cost 1,376 1,151 4,140 3,152
Short-term lease cost 271 262 866 600
Total operating lease cost $ 7,137 $ 6,790 $ 21,469 $ 18,019
XML 49 R39.htm IDEA: XBRL DOCUMENT v3.23.3
Leases - Supplemental lease terms (Details)
Sep. 30, 2023
Dec. 31, 2022
Leases    
Weighted-average remaining lease terms - operating leases (years) 11 years 7 months 9 days 11 years 7 months 9 days
Weighted-average discount rate - operating leases 8.67% 8.61%
Weighted-average remaining lease terms - finance lease (years) 9 years 3 months 3 days 10 years 3 days
Weighted-average discount rate - finance lease 7.80% 7.80%
XML 50 R40.htm IDEA: XBRL DOCUMENT v3.23.3
Leases - Cash flow (Details) - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Leases    
Operating cash flows from operating leases $ 11,479 $ 10,954
Financing cash flows from finance lease 1,379 1,276
Operating cash flows from finance leases $ 1,621 1,724
Right-of-use assets obtained in exchange for operating lease obligations   $ 35,294
XML 51 R41.htm IDEA: XBRL DOCUMENT v3.23.3
Leases - Lease payments (Details)
$ in Thousands
Sep. 30, 2023
USD ($)
Operating leases  
2023 (excludes the nine months ended September 30, 2023) $ 5,077
2024 18,369
2025 20,438
2026 19,988
2027 and thereafter 193,792
Total lease payments 257,664
Less: Imputed Interest expense 146,279
Total 111,385
Finance leases  
2024 3,000
2025 3,000
2026 3,000
2027 and thereafter 18,000
Total lease payments 27,000
Less: Imputed Interest expense 7,205
Total $ 19,795
XML 52 R42.htm IDEA: XBRL DOCUMENT v3.23.3
Fair value of financial instruments and investments - Marketable Securities (Details)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended
Jan. 31, 2020
USD ($)
$ / shares
Sep. 30, 2023
USD ($)
Sep. 30, 2022
USD ($)
Sep. 30, 2023
USD ($)
fund
Sep. 30, 2022
USD ($)
fund
Dec. 31, 2022
USD ($)
Equity Investments            
Purchase of marketable securities - equity investments       $ 26,378 $ 22,787  
Net unrealized gain (loss) on equity investments       5,484 (11,319)  
Redemption of marketable securities- equity investments       12,078 104,431  
ClearPoint Convertible note            
Purchase of convertible note         40,429  
Unrealized gain (loss) on convertible note       (4,594) (2,392)  
ClearPoint Equity Investment            
Equity Investments            
Net unrealized gain (loss) on equity investments   $ (2,000) $ (3,500) (3,100) (1,100)  
Loss on sale of equity investments   0   800    
ClearPoint Equity Investment | Quoted prices in active markets for identical assets (Level 1)            
Equity Investments            
Fair value of equity investment   4,500   4,500   $ 11,000
ClearPoint convertible debt            
ClearPoint Convertible note            
Purchase of convertible note $ 10,000          
Conversion price - convertible note | $ / shares $ 6.00          
Term of convertible note 5 years          
Unrealized gain (loss) on convertible note   (3,100) (4,400) (4,600) $ (2,400)  
ClearPoint convertible debt | Recurring basis | Significant other observable inputs (Level 2) | Deposits and Other Assets, Noncurrent            
ClearPoint Convertible note            
ClearPoint convertible debt security   10,600   $ 10,600   $ 15,200
Mutual Funds            
Equity Investments            
Number of mutual funds denominated in a foreign currency | fund       1    
Number of mutual funds liquidated | fund         1  
Net unrealized gain (loss) on equity investments   1,100 100 $ 5,500 $ (11,300)  
Redemption of marketable securities- equity investments   7,800 100,800 $ 12,100 104,400  
Unrealized foreign currency gains (losses) on equity investments   $ (1,400) $ (1,400)   $ (1,000)  
XML 53 R43.htm IDEA: XBRL DOCUMENT v3.23.3
Fair value of financial instruments and investments - Hierarchy (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Financial assets and liabilities measured at fair value on recurring basis    
Marketable securities - available for sale $ 1,625 $ 22,610
Contingent consideration payable 39,000 164,000
Transfers of assets measured between Level 1, Level 2, and Level 3 0 0
Recurring basis    
Financial assets and liabilities measured at fair value on recurring basis    
ClearPoint Equity Investments 4,482 10,965
ClearPoint convertible debt security 10,637 15,231
Recurring basis | Quoted prices in active markets for identical assets (Level 1)    
Financial assets and liabilities measured at fair value on recurring basis    
ClearPoint Equity Investments 4,482 10,965
Recurring basis | Significant other observable inputs (Level 2)    
Financial assets and liabilities measured at fair value on recurring basis    
ClearPoint convertible debt security 10,637 15,231
Recurring basis | Development and Regulatory Milestones    
Financial assets and liabilities measured at fair value on recurring basis    
Contingent consideration payable 26,400 82,500
Recurring basis | Development and Regulatory Milestones | Significant unobservable inputs (Level 3)    
Financial assets and liabilities measured at fair value on recurring basis    
Contingent consideration payable 26,400 82,500
Recurring basis | Net Sales Milestones and Royalties    
Financial assets and liabilities measured at fair value on recurring basis    
Contingent consideration payable 12,600 81,500
Recurring basis | Net Sales Milestones and Royalties | Significant unobservable inputs (Level 3)    
Financial assets and liabilities measured at fair value on recurring basis    
Contingent consideration payable 12,600 81,500
Recurring basis | Marketable securities    
Financial assets and liabilities measured at fair value on recurring basis    
Marketable securities - available for sale 1,625 22,610
Marketable securities - equity investments 128,028 108,261
Recurring basis | Marketable securities | Quoted prices in active markets for identical assets (Level 1)    
Financial assets and liabilities measured at fair value on recurring basis    
Marketable securities - equity investments 128,028 108,261
Recurring basis | Marketable securities | Significant other observable inputs (Level 2)    
Financial assets and liabilities measured at fair value on recurring basis    
Marketable securities - available for sale $ 1,625 $ 22,610
XML 54 R44.htm IDEA: XBRL DOCUMENT v3.23.3
Fair value of financial instruments and investments - Marketable Securities, Unrealized Gains (Losses) (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Debt Securities, Available-for-sale [Line Items]          
Amortized Cost $ 1,649   $ 1,649   $ 23,104
Gross Unrealized, Gain         5
Gross Unrealized, Loss (24)   (24)   (499)
Fair Value 1,625   1,625   22,610
Write downs of available for sale debt securities 0 $ 0 0 $ 0  
Increase in allowance for credit losses 0 0 0 0  
Realized gain (loss) from sale of marketable securities 0 $ (1,300) (300) $ (1,600)  
Commercial paper          
Debt Securities, Available-for-sale [Line Items]          
Amortized Cost         12,419
Gross Unrealized, Gain         5
Gross Unrealized, Loss         0
Fair Value         12,424
Corporate debt securities          
Debt Securities, Available-for-sale [Line Items]          
Amortized Cost 1,649   1,649   10,685
Gross Unrealized, Gain 0   0    
Gross Unrealized, Loss (24)   (24)   (499)
Fair Value $ 1,625   $ 1,625   $ 10,186
XML 55 R45.htm IDEA: XBRL DOCUMENT v3.23.3
Fair value of financial instruments and investments - Available-for-sale securities (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Debt Securities, Available-for-sale [Line Items]    
Securities in an unrealized loss position greater than 12 months - Unrealized losses $ (24) $ (499)
Securities in an unrealized loss position greater than 12 months - Fair Value 1,625 10,186
Total - Unrealized losses (24) (499)
Total - Fair Value 1,625 10,186
Corporate debt securities    
Debt Securities, Available-for-sale [Line Items]    
Securities in an unrealized loss position greater than 12 months - Unrealized losses (24) (499)
Securities in an unrealized loss position greater than 12 months - Fair Value 1,625 10,186
Total - Unrealized losses (24) (499)
Total - Fair Value $ 1,625 $ 10,186
XML 56 R46.htm IDEA: XBRL DOCUMENT v3.23.3
Fair value of financial instruments and investments - Marketable Securities, Balance Sheet Disclosures (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Debt Securities, Available-for-sale [Line Items]    
Marketable securities, Less Than 12 Months $ 1,625 $ 12,424
Marketable securities, More Than 12 Months   10,186
Commercial paper    
Debt Securities, Available-for-sale [Line Items]    
Marketable securities, Less Than 12 Months   12,424
Corporate debt securities    
Debt Securities, Available-for-sale [Line Items]    
Marketable securities, Less Than 12 Months $ 1,625  
Marketable securities, More Than 12 Months   $ 10,186
XML 57 R47.htm IDEA: XBRL DOCUMENT v3.23.3
Fair value of financial instruments and investments - Convertible senior notes (Details) - 1.50% Convertible senior notes due 2026 - USD ($)
Sep. 30, 2023
Dec. 31, 2022
Sep. 30, 2019
Long-term debt      
Interest rate ( as a percent ) 1.50%    
Convertible debt      
Long-term debt      
Principal $ 287,500,000 $ 287,500,000 $ 287,500,000
Interest rate ( as a percent ) 1.50%   1.50%
Convertible debt | Significant other observable inputs (level 2)      
Long-term debt      
Fair value of convertible notes $ 228,800,000 $ 281,700,000  
XML 58 R48.htm IDEA: XBRL DOCUMENT v3.23.3
Fair value of financial instruments and investments - Summary of changes in the fair value of the Company's Level 3 valuation (Details) - Significant unobservable inputs (Level 3) - Agilis - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
PTC-FA and PTC-AS    
Changes in the fair value of warrant liability and SARs liability    
Change in fair value $ 129,800  
Ending Balance 0  
Upstaza    
Changes in the fair value of warrant liability and SARs liability    
Ending Balance 39,000  
Development and Regulatory Milestones | Commitments    
Changes in the fair value of warrant liability and SARs liability    
Beginning Balance 82,500 $ 139,300
Additions 0 0
Change in fair value (56,100) (10,800)
Reclass to accounts payable and accrued expenses   (50,000)
Rights Exchange settlement 0 0
Ending Balance 26,400 78,500
Net Sales Milestones and Royalties | Commitments    
Changes in the fair value of warrant liability and SARs liability    
Beginning Balance 81,500 100,600
Additions 0 0
Change in fair value (68,900) (21,400)
Reclass to accounts payable and accrued expenses   0
Rights Exchange settlement 0 0
Ending Balance $ 12,600 $ 79,200
XML 59 R49.htm IDEA: XBRL DOCUMENT v3.23.3
Fair value of financial instruments and investments - Fair Value Liabilities Measured (Details) - Agilis - Commitments
$ in Thousands
Sep. 30, 2023
USD ($)
Dec. 31, 2022
USD ($)
Sep. 30, 2022
USD ($)
Dec. 31, 2021
USD ($)
Development and Regulatory Milestones | Valuation Technique, Discounted Cash Flow | Development and Regulatory Milestone | Minimum        
Fair Value Valuation Inputs        
Potential milestones $ 0 $ 0    
Development and Regulatory Milestones | Valuation Technique, Discounted Cash Flow | Development and Regulatory Milestone | Maximum        
Fair Value Valuation Inputs        
Potential milestones $ 31,000 $ 331,000    
Development and Regulatory Milestones | Valuation Technique, Discounted Cash Flow | Probability of Success | Minimum        
Fair Value Valuation Inputs        
Rights Exchange Settlement measurement 0.85 0.25    
Development and Regulatory Milestones | Valuation Technique, Discounted Cash Flow | Probability of Success | Maximum        
Fair Value Valuation Inputs        
Rights Exchange Settlement measurement 0.92 0.92    
Development and Regulatory Milestones | Valuation Technique, Discounted Cash Flow | Probability of Success | Weighted Average        
Fair Value Valuation Inputs        
Rights Exchange Settlement measurement 0.90      
Development and Regulatory Milestones | Valuation Technique, Discounted Cash Flow | Measurement Input, Discount Rate | Minimum        
Fair Value Valuation Inputs        
Rights Exchange Settlement measurement 0.069 0.062    
Development and Regulatory Milestones | Valuation Technique, Discounted Cash Flow | Measurement Input, Discount Rate | Maximum        
Fair Value Valuation Inputs        
Rights Exchange Settlement measurement 0.076 0.083    
Development and Regulatory Milestones | Valuation Technique, Discounted Cash Flow | Measurement Input, Discount Rate | Weighted Average        
Fair Value Valuation Inputs        
Rights Exchange Settlement measurement 0.071      
Development and Regulatory Milestones | Significant unobservable inputs (Level 3)        
Fair Value Valuation Inputs        
Fair value $ 26,400 $ 82,500 $ 78,500 $ 139,300
Net Sales Milestones and Royalties | Valuation Technique, Option Pricing Model | Sales Milestones | Minimum        
Fair Value Valuation Inputs        
Potential milestones 0 0    
Net Sales Milestones and Royalties | Valuation Technique, Option Pricing Model | Sales Milestones | Maximum        
Fair Value Valuation Inputs        
Potential milestones $ 50,000 $ 150,000    
Net Sales Milestones and Royalties | Valuation Technique, Option Pricing Model | Probability of Success | Minimum        
Fair Value Valuation Inputs        
Rights Exchange Settlement measurement 0.85 0.25    
Net Sales Milestones and Royalties | Valuation Technique, Option Pricing Model | Probability of Success | Maximum        
Fair Value Valuation Inputs        
Rights Exchange Settlement measurement 1 1    
Net Sales Milestones and Royalties | Valuation Technique, Option Pricing Model | Probability of Success | Weighted Average        
Fair Value Valuation Inputs        
Rights Exchange Settlement measurement 0.93      
Net Sales Milestones and Royalties | Valuation Technique, Option Pricing Model | Percentage of Sales for Royalties        
Fair Value Valuation Inputs        
Rights Exchange Settlement measurement 0      
Net Sales Milestones and Royalties | Valuation Technique, Option Pricing Model | Percentage of Sales for Royalties | Minimum        
Fair Value Valuation Inputs        
Rights Exchange Settlement measurement   0.02    
Net Sales Milestones and Royalties | Valuation Technique, Option Pricing Model | Percentage of Sales for Royalties | Maximum        
Fair Value Valuation Inputs        
Rights Exchange Settlement measurement   0.06    
Net Sales Milestones and Royalties | Valuation Technique, Option Pricing Model | Measurement Input, Discount Rate        
Fair Value Valuation Inputs        
Rights Exchange Settlement measurement 0.12 0.115    
Net Sales Milestones and Royalties | Valuation Technique, Option Pricing Model | Measurement Input, Discount Rate | Weighted Average        
Fair Value Valuation Inputs        
Rights Exchange Settlement measurement 0.120      
Net Sales Milestones and Royalties | Significant unobservable inputs (Level 3)        
Fair Value Valuation Inputs        
Fair value $ 12,600 $ 81,500 $ 79,200 $ 100,600
XML 60 R50.htm IDEA: XBRL DOCUMENT v3.23.3
Accounts payable and accrued expenses - Components (Details) - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Payables and Accruals [Abstract]    
Employee compensation, benefits, and related accruals $ 70,778 $ 62,669
Income tax payable 2,822 4,712
Consulting and contracted research 21,236 38,882
Professional fees 3,067 3,093
Sales allowance 72,202 63,787
Sales rebates 119,971 67,355
Royalties 52,087 40,546
Accounts payable 19,152 27,268
Other 9,416 12,054
Accounts payable and accrued expenses $ 370,731 $ 320,366
XML 61 R51.htm IDEA: XBRL DOCUMENT v3.23.3
Accounts payable and accrued expenses - Restructuring (Details)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2023
USD ($)
Sep. 30, 2023
USD ($)
Restructuring costs    
Restructuring costs $ 22.6 $ 30.6
Accrued restructuring costs $ 23.4 $ 23.4
XML 62 R52.htm IDEA: XBRL DOCUMENT v3.23.3
Capitalization - Narrative (Details) - Sales Agreement - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Aug. 31, 2019
Common stock          
Number of shares issued in transaction (in shares) 0 0 0 0  
Maximum          
Common stock          
Value of shares available to be issued and sold in transaction         $ 125.0
Aggregate value of remaining shares to be issued and sold     $ 93.0    
XML 63 R53.htm IDEA: XBRL DOCUMENT v3.23.3
Net loss per share - Numerator and Denominator (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Numerator        
Net loss - Basic $ (132,970) $ (109,315) $ (470,812) $ (388,128)
Net loss - Diluted $ (132,970) $ (109,315) $ (470,812) $ (388,128)
Denominator        
Basic 75,377,997 71,654,671 74,618,611 71,415,849
Diluted 75,377,997 71,654,671 74,618,611 71,415,849
Net loss per share - Basic $ (1.76) $ (1.53) $ (6.31) $ (5.43)
Net loss per share - Diluted $ (1.76) $ (1.53) $ (6.31) $ (5.43)
XML 64 R54.htm IDEA: XBRL DOCUMENT v3.23.3
Net loss per share - Antidilutive (Details) - shares
9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Net loss per share    
Total shares excluded from calculation (in shares) 14,850,885 13,967,365
Employee Stock Option    
Net loss per share    
Total shares excluded from calculation (in shares) 11,436,783 11,478,421
Restricted stock awards and units    
Net loss per share    
Total shares excluded from calculation (in shares) 3,414,102 2,488,944
XML 65 R55.htm IDEA: XBRL DOCUMENT v3.23.3
Stock award plan - Narrative (Details) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended
Jun. 08, 2022
Dec. 31, 2022
Dec. 31, 2020
Jun. 30, 2016
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Apr. 30, 2022
Jun. 30, 2021
May 31, 2021
Jan. 31, 2020
Stock option plan                        
Share-based compensation expense         $ 26,942 $ 28,670 $ 85,128 $ 82,989        
Unrecognized compensation cost         179,300   $ 179,300          
Weighted average remaining service period for recognition of unrecognized compensation cost             1 year 10 months 24 days          
Stock option                        
Stock option plan                        
Granted (in shares)             1,059,054          
Expected dividend yield (as a percent)             0.00%          
Weighted average grant date fair value (in dollars per share)             $ 21.83          
Restricted stock units                        
Stock option plan                        
Granted (in shares)             1,973,973          
Employee Stock Purchase Plan                        
Stock option plan                        
Number of shares authorized (in shares)                   2,000,000 1,000,000  
Award requisite service period       6 months                
Purchase price of common stock, percent       85.00%                
Employee stock purchase plan, voting percentage limit       5.00%                
Share-based compensation expense         $ 700   $ 2,000          
1998 Employee, Director, and Consultant Stock Option Plan, 2009 Equity and Long-term Incentive Plan, and 2013 Stock Incentive Plan | Common stock                        
Stock option plan                        
Number of shares available for issuance         0   0          
Amended 2013 LTIP                        
Stock option plan                        
Number of shares available for issuance         6,802,210   6,802,210          
Number of additional shares authorized (in shares) 8,475,000                      
Amended 2013 LTIP | Maximum                        
Stock option plan                        
Number of shares authorized (in shares) 16,724,212                      
2020 Inducement Stock Incentive Plan | Common stock                        
Stock option plan                        
Number of shares available for issuance         1,705,941   1,705,941          
Number of additional shares authorized (in shares)   1,700,000 1,000,000                  
2020 Inducement Stock Incentive Plan | Common stock | Maximum                        
Stock option plan                        
Number of shares authorized (in shares)                 1,300,000     1,000,000
2020 Inducement Stock Incentive Plan | Stock option                        
Stock option plan                        
Stockholder's specified ownership percentage         10.00%   10.00%          
Inducement grants for non-statutory stock options (in shares)             121,460          
Vesting period             4 years          
2020 Inducement Stock Incentive Plan | Stock option | Minimum                        
Stock option plan                        
Stock options granted, exercise price as percentage of the fair market value of common stock at grant date         100.00%   100.00%          
2020 Inducement Stock Incentive Plan | Stock option | Maximum                        
Stock option plan                        
Stock options granted to stockholder with specified ownership percentage, exercise price as percentage of the fair market value of common stock at grant date         110.00%   110.00%          
Expiration period             10 years          
2020 Inducement Stock Incentive Plan | Restricted stock units                        
Stock option plan                        
Granted (in shares)             83,210          
XML 66 R56.htm IDEA: XBRL DOCUMENT v3.23.3
Stock award plan - Stock Option Activity (Details) - Stock option - USD ($)
$ / shares in Units, $ in Thousands
9 Months Ended
Sep. 30, 2023
Number of options  
Outstanding at the beginning of the period (in shares) 11,502,417
Granted (in shares) 1,059,054
Exercised (in shares) (806,407)
Forfeited/Cancelled (in shares) (318,281)
Outstanding at the end of the period (in shares) 11,436,783
Vested or Expected to vest at the end of the period (in shares) 2,357,250
Exercisable at the end of the period (in shares) 8,533,144
Weighted- average exercise price  
Outstanding at the beginning of the period (in dollars per share) $ 43.33
Granted (in dollars per share) 41.29
Exercised (in dollars per share) 29.48
Forfeited/Cancelled (in dollars per share) 47.84
Outstanding at the end of the period (in dollars per share) 43.99
Vested or Expected to vest at the end of the period (in dollars per share) 46.72
Exercisable at the end of the period (in dollars per share) $ 43.18
Weighted- average remaining contractual term  
Outstanding at the end of the period 5 years 10 months 13 days
Vested or Expected to vest at the end of the period 8 years 2 months 23 days
Exercisable at the end of the period 5 years 18 days
Aggregate intrinsic value (in thousands)  
Outstanding at the end of the period (in dollars) $ 5,084
Exercisable at the end of the period (in dollars) $ 5,084
XML 67 R57.htm IDEA: XBRL DOCUMENT v3.23.3
Stock award plan - Assumptions Used (Details)
9 Months Ended
Sep. 30, 2023
Valuation assumptions  
Expected term (in years) 5 years 6 months
Stock option | Minimum  
Valuation assumptions  
Risk-free interest rate (as a percent) 3.54%
Expected volatility (as a percent) 53.00%
Stock option | Maximum  
Valuation assumptions  
Risk-free interest rate (as a percent) 3.91%
Expected volatility (as a percent) 54.00%
XML 68 R58.htm IDEA: XBRL DOCUMENT v3.23.3
Stock award plan - Restricted Stock (Details) - Restricted stock awards and units
9 Months Ended
Sep. 30, 2023
$ / shares
shares
Number of Shares  
Balance at the beginning of the period (in shares) | shares 2,516,336
Granted (in shares) | shares 1,973,973
Vested (in shares) | shares (778,442)
Forfeited (in shares) | shares (297,765)
Balance at the end of the period (in shares) | shares 3,414,102
Weighted Average Grant Date Fair Value  
Balance at the beginning of the period (in dollars per share) | $ / shares $ 45.67
Granted (in dollars per share) | $ / shares 40.00
Vested (in dollars per share) | $ / shares 46.34
Forfeited (in dollars per share) | $ / shares 42.65
Balance at the end of the period (in dollars per share) | $ / shares $ 42.50
XML 69 R59.htm IDEA: XBRL DOCUMENT v3.23.3
Stock award plan - Share-based compensation expense (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Stock option plan        
Share-based compensation expense $ 26,942 $ 28,670 $ 85,128 $ 82,989
Unrecognized compensation cost 179,300   $ 179,300  
Weighted average remaining service period for recognition of unrecognized compensation cost     1 year 10 months 24 days  
Research and development        
Stock option plan        
Share-based compensation expense 13,986 15,063 $ 44,828 41,896
Selling, general and administrative        
Stock option plan        
Share-based compensation expense $ 12,956 $ 13,607 $ 40,300 $ 41,093
XML 70 R60.htm IDEA: XBRL DOCUMENT v3.23.3
Debt - Liability for Sale of Future Royalties (Details) - USD ($)
$ in Thousands
1 Months Ended 9 Months Ended
Jul. 31, 2020
Sep. 30, 2023
Debt Disclosure [Abstract]    
Proceeds from sale of future royalties $ 650,000  
Beginning balance   $ 757,886
Less: Non-cash royalty revenue payable to RPI   (50,599)
Plus: non-cash interest expense recognized   56,031
Ending balance   $ 763,318
Effective interest rate of the liability component 11.00% 9.30%
XML 71 R61.htm IDEA: XBRL DOCUMENT v3.23.3
Debt - Senior Secured Term Loan (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Oct. 27, 2022
Sep. 30, 2023
Sep. 30, 2023
Sep. 30, 2022
Mar. 31, 2023
Dec. 31, 2022
Jul. 31, 2020
Interest expense              
Amortization of debt issuance costs     $ 1,574 $ 1,316      
Effective interest rate   9.30% 9.30%       11.00%
Blackstone Credit Agreement              
Debt Facility              
Maximum borrowing capacity $ 950,000            
Debt issuance costs capitalized 11,600            
Credit agreement reserve         $ 50,000    
Principal   $ 300,000 $ 300,000     $ 300,000  
Less: Debt issuance costs   (10,742) (10,742)     (11,322)  
Net carrying amount   289,258 $ 289,258     $ 288,678  
Loan term     6 years 1 month 6 days        
Interest expense              
Contractual interest expense   9,554 $ 28,087        
Amortization of debt issuance costs   280 702        
Total   $ 9,834 $ 28,789        
Effective interest rate   13.10% 13.10%        
Blackstone Credit Agreement | Minimum              
Debt Facility              
Minimum consolidated liquidity covenant 100,000            
Increased minimum consolidated liquidity covenant after consummation of acquisitions meeting specified thresholds $ 200,000            
Blackstone Credit Agreement | Adjusted Term SOFR              
Debt Facility              
Basis spread on variable rate 7.25%            
Floor interest rate 1.00%            
Blackstone Credit Agreement | Base Rate              
Debt Facility              
Basis spread on variable rate 6.25%            
Floor interest rate 2.00%            
Committed Loan Facility              
Debt Facility              
Maximum borrowing capacity $ 450,000            
Fund draw term 18 months            
Loan term 7 years            
Senior Secured Term Loan              
Debt Facility              
Principal $ 300,000            
Committed Delayed Draw Term Loan Facility              
Debt Facility              
Maximum borrowing capacity 150,000            
Uncommitted Incremental Facility              
Debt Facility              
Maximum borrowing capacity $ 500,000            
XML 72 R62.htm IDEA: XBRL DOCUMENT v3.23.3
Debt - Narrative (Details)
1 Months Ended 9 Months Ended 18 Months Ended
Aug. 15, 2022
USD ($)
Sep. 30, 2022
USD ($)
Apr. 30, 2022
USD ($)
Apr. 08, 2022
Sep. 30, 2019
USD ($)
D
$ / shares
Sep. 30, 2023
USD ($)
Mar. 14, 2022
Dec. 31, 2022
USD ($)
Aug. 31, 2015
USD ($)
Long-term debt                  
Long-term debt           $ 573,174,000   $ 571,722,000  
Additional paid-in capital           $ 2,447,292,000   2,305,020,000  
1.50% Convertible senior notes due 2026                  
Long-term debt                  
Interest rate ( as a percent )           1.50%      
Incremental interest rate per annum       0.50%     0.50%    
Additional interest paid   $ 100,000 $ 2,100,000            
Convertible debt | 1.50% Convertible senior notes due 2026                  
Long-term debt                  
Net carrying amount           $ 283,916,000   283,044,000  
Debt principal amount         $ 287,500,000 $ 287,500,000   $ 287,500,000  
Debt instrument additional amount available for repurchase         $ 37,500,000        
Interest rate ( as a percent )         1.50% 1.50%      
Net proceeds from issuance of convertible notes         $ 279,300,000        
Trading days, number | D         20        
Consecutive trading days, period | D         30        
Stock price trigger         130.00%        
Business days, period         5 days        
Consecutive trading-day period         5 days        
Maximum product of the closing sale price of shares of the Company's common stock and the applicable conversion rate for such trading day         98.00%        
Conversion ratio         19.0404        
Conversion price per share (in dollars per share) | $ / shares         $ 52.52        
Redemption price as percent of principal amount         100.00%        
Convertible instruments principal and unpaid interest payable upon events of default         100.00%        
Minimum percentage of principal held by convertible debt instrument holders required to issue notice for declaration of principal and unpaid interest payable upon events of default         25.00%        
Term of the convertible notes           3 years      
Convertible debt | 1.50% Convertible senior notes due 2026 | Redemption on or after September 20, 2023                  
Long-term debt                  
Trading days, number | D         19        
Consecutive trading days, period | D         30        
Stock price trigger         130.00%        
Redemption price as percent of principal amount         100.00%        
Sinking fund         $ 0        
Convertible debt | 3.00% Convertible senior notes due 2022                  
Long-term debt                  
Debt principal amount                 $ 150,000,000.0
Interest rate ( as a percent )                 3.00%
Repayment of convertible notes including accrued interest $ 152,300,000                
XML 73 R63.htm IDEA: XBRL DOCUMENT v3.23.3
Debt - Convertible Notes (Details) - 1.50% Convertible senior notes due 2026 - Convertible debt - USD ($)
Sep. 30, 2023
Dec. 31, 2022
Sep. 30, 2019
Long-term debt      
Principal $ 287,500,000 $ 287,500,000 $ 287,500,000
Less: Debt issuance costs (3,584,000) (4,456,000)  
Net carrying amount $ 283,916,000 $ 283,044,000  
XML 74 R64.htm IDEA: XBRL DOCUMENT v3.23.3
Debt - Convertible Notes Interest Expense (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Jul. 31, 2020
Long-term debt          
Amortization of debt issuance costs     $ 1,574 $ 1,316  
Effective interest rate of the liability component 9.30%   9.30%   11.00%
Convertible debt | 3.00% Convertible senior notes due 2022          
Long-term debt          
Contractual interest expense   $ 559   2,800  
Amortization of debt issuance costs   92   460  
Total   $ 651   $ 3,260  
Effective interest rate of the liability component   3.50%   3.50%  
Convertible debt | 1.50% Convertible senior notes due 2026          
Long-term debt          
Contractual interest expense $ 1,080 $ 1,081 $ 3,215 $ 3,217  
Amortization of debt issuance costs 294 289 872 856  
Total $ 1,374 $ 1,370 $ 4,087 $ 4,073  
Effective interest rate of the liability component 1.90% 1.90% 1.90% 1.90%  
XML 75 R65.htm IDEA: XBRL DOCUMENT v3.23.3
Commitments and contingencies - Narrative (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended 12 Months Ended
Apr. 29, 2020
Jun. 30, 2016
Sep. 30, 2023
Dec. 31, 2022
Sep. 30, 2022
May 29, 2020
Other Commitments            
Milestone payable     $ 2,500   $ 50,000  
Accrued royalties     52,087 $ 40,546    
Wellcome Trust            
Other Commitments            
Development milestone payment obligations       2,500    
Milestone obligation payments made   $ 800        
Censa            
Other Commitments            
Asset acquisition, development and regulatory milestones           $ 109,000
Censa | Maximum            
Other Commitments            
Asset acquisition, milestone, amount           217,500
Asset acquisition, net sales milestone           $ 160,000
Former Censa Securityholders            
Other Commitments            
Development milestone obligation payments made     30,000      
Development milestone obligation cash payments made     $ 400      
Shares issued for milestone payment     657,462      
SMA License Agreement | SMA Foundation            
Other Commitments            
Royalty expense     $ 40,300      
Royalty payments     35,300      
Accrued royalties     5,000      
SMA License Agreement | SMA Foundation | Maximum            
Other Commitments            
Potential royalty payments due on net product sales     52,500      
Agilis            
Other Commitments            
Development milestone payments which the entity is obligated to pay $ 40,000   40,000      
Potential developmental and regulatory milestones     31,100      
Potential sales milestones     50,000      
Milestone obligation payments made       $ 50,000    
Development milestone obligation payments made     $ 2,400      
Agilis | Minimum            
Other Commitments            
Product sales (as a percent)     2.00%      
Agilis | Maximum            
Other Commitments            
Development milestone payments which the entity is obligated to pay     $ 60,000      
Priority review voucher amount     535,000      
Potential sales milestones     $ 150,000      
Product sales (as a percent)     6.00%      
Development milestone payment obligations, net of cancellation and forfeiture     $ 20,000      
Contingent liability, milestone, potential achievements, priority review voucher amount, net of cancellation and forfeiture     361,000      
Agilis | Rights Exchange Agreement            
Other Commitments            
Contingent liability cancellation and forfeiture of potential milestone payments 174,000          
Development milestone payment obligations, cancellation and forfeiture 37,600          
Contingent liability, cancellation and forfeiture $ 211,600          
BioElectron | Maximum            
Other Commitments            
Development milestone payments which the entity is obligated to pay     200,000      
Marathon | Agilis Merger Agreement            
Other Commitments            
Milestone obligation payments made     50,000      
Net product revenue | Wellcome Trust | Maximum            
Other Commitments            
Development milestone payments which the entity is obligated to pay     $ 14,500      
XML 76 R66.htm IDEA: XBRL DOCUMENT v3.23.3
Revenue recognition - Net Product Sales (Details)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2023
USD ($)
segment
country
Distributor
Sep. 30, 2022
USD ($)
Distributor
segment
country
Sep. 30, 2023
USD ($)
country
Distributor
segment
Sep. 30, 2022
USD ($)
country
segment
Distributor
Dec. 31, 2022
USD ($)
Revenue recognition          
Number of operating segments | segment 1 1 1 1  
Revenue $ 196,576 $ 217,127 $ 630,766 $ 531,389  
Net product revenue | United States          
Revenue recognition          
Number of countries exceeding 10% of net product sales | country 1        
Net product revenue | Geographic concentration risk          
Revenue recognition          
Number of countries exceeding 10% of net product sales | country 1 2 3 2  
Percentage of net product sales threshold 10.00% 10.00% 10.00% 10.00%  
Net product revenue | Geographic concentration risk | United States          
Revenue recognition          
Revenue $ 67,400 $ 54,800 $ 187,700 $ 160,100  
Net product revenue | Geographic concentration risk | Russia          
Revenue recognition          
Revenue   $ 28,300 69,000 $ 57,100  
Net product revenue | Geographic concentration risk | Brazil          
Revenue recognition          
Revenue     $ 52,500    
Net product revenue | Customer concentration risk          
Revenue recognition          
Number of distributors | Distributor 3 2 2 2  
Percentage of net product sales threshold 10.00% 10.00% 10.00% 10.00%  
Net product revenue          
Revenue recognition          
Revenue $ 144,038 $ 134,186 $ 506,187 $ 407,720  
Contract with Customer, Liability 0   0   $ 0
Net product revenue | Non-US          
Revenue recognition          
Revenue 76,600 79,400 318,500 247,600  
Emflaza | United States          
Revenue recognition          
Revenue 67,400 54,800 187,700 160,100  
Translarna | Non-US          
Revenue recognition          
Revenue $ 69,000 $ 76,600 $ 280,600 $ 232,900  
XML 77 R67.htm IDEA: XBRL DOCUMENT v3.23.3
Revenue recognition - Collaboration and Royalty Revenue (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Nov. 30, 2011
Revenue recognition            
Remaining potential milestones that can be achieved   $ 250,000   $ 250,000    
Revenue   196,576 $ 217,127 630,766 $ 531,389  
Collaboration revenue            
Revenue recognition            
Revenue   0 50,017 6 50,024  
Royalty revenue            
Revenue recognition            
Revenue   50,173 32,924 117,857 73,645  
SMA License Agreement | Collaboration revenue            
Revenue recognition            
Revenue   0        
SMA License Agreement | Royalty revenue            
Revenue recognition            
Revenue   50,200 $ 32,900 117,900 $ 73,600  
Research And Development Event Milestones | SMA License Agreement            
Revenue recognition            
Remaining potential milestones that can be achieved   0   0    
Sales Milestones | SMA License Agreement            
Revenue recognition            
Remaining potential milestones that can be achieved   $ 250,000   $ 250,000    
Milestone payments due $ 50,000          
Net sales milestone threshold achieved $ 750,000          
Maximum | Research And Development Event Milestones | SMA License Agreement            
Revenue recognition            
Remaining potential milestones that can be achieved           $ 135,000
Maximum | Sales Milestones | SMA License Agreement            
Revenue recognition            
Remaining potential milestones that can be achieved           $ 325,000
XML 78 R68.htm IDEA: XBRL DOCUMENT v3.23.3
Revenue recognition - Manufacturing Revenue (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Revenue recognition          
Revenue $ 196,576 $ 217,127 $ 630,766 $ 531,389  
Manufacturing revenue          
Revenue recognition          
Revenue 2,365 $ 0 6,716 $ 0  
Contract with customer, asset 1,400   1,400   $ 0
Contract liability revenues recognized in period 0   1,400    
Manufacturing revenue | Deferred revenue          
Revenue recognition          
Contract with customer, liability 1,200   1,200   $ 1,400
Manufacturing revenue | Prepaids and other current assets          
Revenue recognition          
Contract with customer, asset $ 1,400   $ 1,400    
XML 79 R69.htm IDEA: XBRL DOCUMENT v3.23.3
Revenue recognition - Performance Obligations (Details) - USD ($)
$ in Millions
Sep. 30, 2023
Dec. 31, 2022
Remaining Performance Obligation    
Remaining performance obligations $ 1.2 $ 1.4
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-10-01    
Remaining Performance Obligation    
Remaining performance obligations $ 1.2  
Revenue, performance obligation, period 1 year  
XML 80 R70.htm IDEA: XBRL DOCUMENT v3.23.3
Intangible assets and goodwill - Definite-lived Intangibles (Details) - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Definite-lived intangible assets          
Milestone Payable $ 2,500 $ 50,000 $ 2,500 $ 50,000  
Accrued royalties 52,087   52,087   $ 40,546
Definite-lived intangibles          
Amortization (58,649) (31,023) (145,461) (80,790)  
Finite-Lived Intangible Assets, Net $ 187,576   $ 187,576    
Weighted Average          
Definite-lived intangible assets          
Remaining amortization period 5 years 3 months 18 days   5 years 3 months 18 days    
Emflaza asset acquisition          
Definite-lived intangible assets          
Milestone obligation payments recorded     $ 76,500    
Marathon | Emflaza asset acquisition | Accounts payable and accrued expenses          
Definite-lived intangible assets          
Milestone Payable $ 43,900   43,900    
Akcea | Waylivra          
Definite-lived intangible assets          
Royalty payments     200    
Akcea | Waylivra | Accounts payable and accrued expenses          
Definite-lived intangible assets          
Accrued royalties 200   200    
Akcea | Tegsedi          
Definite-lived intangible assets          
Royalty payments     4,300    
Akcea | Tegsedi | Accounts payable and accrued expenses          
Definite-lived intangible assets          
Accrued royalties 900   900    
Definite-lived intangible assets          
Definite-lived intangibles          
Beginning balance - Definite-lived assets, Gross     526,228    
Additions     80,910    
Foreign Currency Translation     (279)    
Ending balance - Definite-lived assets, Gross 606,859   606,859    
Beginning balance - Accumulated amortization     (273,903)    
Amortization (58,600) $ (31,000) (145,461) $ (80,800)  
Foreign Currency Translation - Accumulated amortization     81    
Ending balance - Accumulated amortization (419,283)   (419,283)    
Finite-Lived Intangible Assets, Net 187,576   187,576    
Definite-lived intangible assets | Emflaza          
Definite-lived intangibles          
Beginning balance - Definite-lived assets, Gross     420,253    
Additions     76,454    
Ending balance - Definite-lived assets, Gross 496,707   496,707    
Beginning balance - Accumulated amortization     (266,023)    
Amortization     (138,038)    
Ending balance - Accumulated amortization (404,061)   (404,061)    
Definite-lived intangible assets | Waylivra          
Definite-lived intangibles          
Beginning balance - Definite-lived assets, Gross     9,316    
Additions     157    
Foreign Currency Translation     (96)    
Ending balance - Definite-lived assets, Gross 9,377   9,377    
Beginning balance - Accumulated amortization     (2,751)    
Amortization     (791)    
Foreign Currency Translation - Accumulated amortization     45    
Ending balance - Accumulated amortization (3,497)   (3,497)    
Definite-lived intangible assets | Tegsedi          
Definite-lived intangibles          
Beginning balance - Definite-lived assets, Gross     7,109    
Additions     4,299    
Foreign Currency Translation     (183)    
Ending balance - Definite-lived assets, Gross 11,225   11,225    
Beginning balance - Accumulated amortization     (1,709)    
Amortization     (1,035)    
Foreign Currency Translation - Accumulated amortization     36    
Ending balance - Accumulated amortization (2,708)   (2,708)    
Definite-lived intangible assets | Upstaza          
Definite-lived intangibles          
Beginning balance - Definite-lived assets, Gross     89,550    
Ending balance - Definite-lived assets, Gross 89,550   89,550    
Beginning balance - Accumulated amortization     (3,420)    
Amortization     (5,597)    
Ending balance - Accumulated amortization $ (9,017)   $ (9,017)    
XML 81 R71.htm IDEA: XBRL DOCUMENT v3.23.3
Intangible assets and goodwill - Future Amortization (Details)
$ in Thousands
Sep. 30, 2023
USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]  
2023 $ 58,640
2024 46,557
2025 10,041
2026 10,041
2027 and thereafter 62,297
Total $ 187,576
XML 82 R72.htm IDEA: XBRL DOCUMENT v3.23.3
Intangible assets and goodwill - Indefinite-lived Intangibles (Details) - USD ($)
$ in Thousands
9 Months Ended
Sep. 30, 2023
Dec. 31, 2022
Indefinite-lived intangibles    
Impairment $ (217,800)  
Intangible assets, net 423,342 $ 705,891
PTC-FA and PTC-AS    
Indefinite-lived intangibles    
Impairment (217,800)  
Indefinite-lived intangible assets    
Indefinite-lived intangibles    
Beginning Balance 453,566  
Additions  
Impairment (217,800)  
Ending Balance 235,766  
Intangible assets, net 423,342  
Indefinite-lived intangible assets | Upstaza    
Indefinite-lived intangibles    
Beginning Balance 235,766  
Additions  
Ending Balance 235,766  
Indefinite-lived intangible assets | PTC-FA and PTC-AS    
Indefinite-lived intangibles    
Impairment (217,800)  
Indefinite-lived intangible assets | PTC-FA    
Indefinite-lived intangibles    
Beginning Balance 112,500  
Additions  
Impairment (112,500)  
Indefinite-lived intangible assets | PTC-AS    
Indefinite-lived intangibles    
Beginning Balance 105,300  
Additions  
Impairment $ (105,300)  
XML 83 R73.htm IDEA: XBRL DOCUMENT v3.23.3
Intangible assets and goodwill - Goodwill (Details) - USD ($)
$ in Thousands
61 Months Ended
Sep. 30, 2023
Dec. 31, 2022
Aug. 23, 2018
Goodwill      
Goodwill $ 82,341 $ 82,341  
Changes in goodwill $ 0    
Agilis      
Goodwill      
Goodwill     $ 82,300
XML 84 R74.htm IDEA: XBRL DOCUMENT v3.23.3
Subsequent events (Details)
$ in Millions
Oct. 19, 2023
USD ($)
Oct. 18, 2023
USD ($)
Option
Sep. 30, 2023
Royalty Purchase Agreement | Royalty Pharma      
Subsequent Event [Line Items]      
Previously assigned royalty payment, percentage     42.933%
Subsequent Event | Senior Secured Term Loan      
Subsequent Event [Line Items]      
Outstanding principal and accrued interest repaid $ 302.1    
Prepayment premiums, expenses and other exit fees $ 82.1    
Subsequent Event | A&R Royalty Purchase Agreement      
Subsequent Event [Line Items]      
Cash consideration   $ 1,000.0  
Retained Royalty Rights percentage sold   38.0447%  
Additional cash consideration   $ 500.0  
Number of put options held by the company | Option   5  
Maximum number of put options which can be exercised before Royalty Pharma can exercise a call option | Option   2  
Maximum percentage of remaining retained royalty rights that are available upon exercise of call option   50.00%  
Royalty purchase agreement termination period once there are no further royalty payment obligations   60 days  
Subsequent Event | A&R Royalty Purchase Agreement | Royalty Pharma      
Subsequent Event [Line Items]      
Total percentage of royalty rights assigned   80.9777%  
Royalty purchase agreement, payment maximum   $ 1,300.0  
Percentage of total royalty payable after threshold royalties received   66.6667%  
Percentage of maximum royalty payable until assigned royalty rights   90.4888%  
Percentage of maximum royalty payable thereafter assigned royalty rights   83.3333%  
XML 85 R75.htm IDEA: XBRL DOCUMENT v3.23.3
Pay vs Performance Disclosure - USD ($)
$ in Thousands
3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Pay vs Performance Disclosure        
Net Income (Loss) $ (132,970) $ (109,315) $ (470,812) $ (388,128)
XML 86 R76.htm IDEA: XBRL DOCUMENT v3.23.3
Insider Trading Arrangements
3 Months Ended
Sep. 30, 2023
Trading Arrangements, by Individual  
Material Terms of Trading Arrangement

Director and Officer Trading Arrangements

A portion of the compensation of our directors and officers (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended, or the Exchange Act) is in the form of equity awards and, from time to time, directors and officers engage in open-market transactions with respect to the securities acquired pursuant to such equity awards or other Company securities, including to satisfy tax withholding obligations when equity awards vest or are exercised, and for diversification or other personal reasons.

Transactions in Company securities by directors and officers are required to be made in accordance with our insider trading policy, which requires that the transactions be in accordance with applicable U.S. federal securities laws that prohibit trading while in possession of material nonpublic information. Rule 10b5-1 under the Exchange Act provides an affirmative defense that enables directors and officers to prearrange transactions in Company securities in a manner that avoids concerns about initiating transactions while in possession of material nonpublic information.

The following table describes, for the quarterly period covered by this report, each trading arrangement for the sale or purchase of Company securities adopted or terminated by our directors and officers that is either (1) a contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c), or a “Rule 10b5-1 trading arrangement”, or (2) a “non-Rule 10b5-1 trading arrangement” (as defined in Item 408(c) of Regulation S-K):

Name
(Title)

Action Taken
(Date of Action)

Type of Trading
Arrangement

Nature of Trading
Arrangement

Duration of Trading
Arrangement

Aggregate Number
of Securities

Pierre Gravier
(Chief Financial Officer)

Adoption
(July 13, 2023)

Rule 10b5-1 trading arrangement for sell-to-cover transactions for RSUs granted on July 13, 2023

Sale

Until final settlement of RSUs on or around July 13, 2027

Indeterminable (1)

(1) The number of shares subject to this RSU grant that will be sold to satisfy applicable tax withholding obligations upon vesting is unknown as the number will vary based on the extent to which vesting conditions are satisfied and the market price of the Company’s common stock at the time of settlement.  This trading arrangement provides for the automatic sale of shares that would otherwise be issuable on each settlement date of the RSU in an amount sufficient to satisfy the applicable withholding obligation, with the proceeds of the sale delivered to the Company in satisfaction of the applicable withholding obligation.

Restricted Stock Unit Trading Arrangement | Pierre Gravier  
Trading Arrangements, by Individual  
Name Pierre Gravier
Title Chief Financial Officer
Rule 10b5-1 Arrangement Adopted true
Adoption Date July 13, 2023
Expiration Date July 13, 2027
XML 87 tmb-20230930x10q_htm.xml IDEA: XBRL DOCUMENT 0001070081 us-gaap:CommonStockMember 2023-07-01 2023-09-30 0001070081 us-gaap:CommonStockMember 2022-07-01 2022-09-30 0001070081 us-gaap:CommonStockMember 2022-01-01 2022-09-30 0001070081 us-gaap:RetainedEarningsMember 2023-09-30 0001070081 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0001070081 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0001070081 us-gaap:RetainedEarningsMember 2023-06-30 0001070081 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001070081 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001070081 2023-06-30 0001070081 us-gaap:RetainedEarningsMember 2022-12-31 0001070081 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001070081 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001070081 us-gaap:RetainedEarningsMember 2022-09-30 0001070081 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0001070081 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-09-30 0001070081 us-gaap:RetainedEarningsMember 2022-06-30 0001070081 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001070081 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0001070081 2022-06-30 0001070081 us-gaap:RetainedEarningsMember 2021-12-31 0001070081 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001070081 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001070081 us-gaap:CommonStockMember 2023-09-30 0001070081 us-gaap:CommonStockMember 2023-06-30 0001070081 us-gaap:CommonStockMember 2022-12-31 0001070081 us-gaap:CommonStockMember 2022-09-30 0001070081 us-gaap:CommonStockMember 2022-06-30 0001070081 us-gaap:CommonStockMember 2021-12-31 0001070081 us-gaap:StockOptionMember 2022-12-31 0001070081 us-gaap:StockOptionMember 2023-09-30 0001070081 ptct:InducementStockIncentivePlan2020Member us-gaap:CommonStockMember 2023-09-30 0001070081 ptct:EmployeeDirectorAndConsultantStockOptionPlan1998EquityAndLongTermIncentivePlan2009AndStockIncentivePlan2013Member us-gaap:CommonStockMember 2023-09-30 0001070081 ptct:AmendedAndRestated2013LongTermIncentivePlanMember 2023-09-30 0001070081 srt:MaximumMember ptct:AmendedAndRestated2013LongTermIncentivePlanMember 2022-06-08 0001070081 srt:MaximumMember ptct:InducementStockIncentivePlan2020Member us-gaap:CommonStockMember 2022-04-30 0001070081 us-gaap:EmployeeStockMember 2021-06-30 0001070081 us-gaap:EmployeeStockMember 2021-05-31 0001070081 srt:MaximumMember ptct:InducementStockIncentivePlan2020Member us-gaap:CommonStockMember 2020-01-31 0001070081 ptct:InducementStockIncentivePlan2020Member us-gaap:CommonStockMember 2022-12-01 2022-12-31 0001070081 ptct:AmendedAndRestated2013LongTermIncentivePlanMember 2022-06-08 2022-06-08 0001070081 ptct:InducementStockIncentivePlan2020Member us-gaap:CommonStockMember 2020-12-01 2020-12-31 0001070081 srt:MinimumMember us-gaap:StockOptionMember 2023-01-01 2023-09-30 0001070081 srt:MaximumMember us-gaap:StockOptionMember 2023-01-01 2023-09-30 0001070081 us-gaap:StockOptionMember 2023-01-01 2023-09-30 0001070081 srt:MaximumMember us-gaap:StockOptionMember ptct:InducementStockIncentivePlan2020Member 2023-01-01 2023-09-30 0001070081 ptct:RestrictedStockAndRestrictedStockUnitsMember 2023-09-30 0001070081 ptct:RestrictedStockAndRestrictedStockUnitsMember 2022-12-31 0001070081 us-gaap:RestrictedStockUnitsRSUMember ptct:InducementStockIncentivePlan2020Member 2023-01-01 2023-09-30 0001070081 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-09-30 0001070081 ptct:RestrictedStockAndRestrictedStockUnitsMember 2023-01-01 2023-09-30 0001070081 ptct:AtMarketOfferingSalesAgreementMember 2023-07-01 2023-09-30 0001070081 ptct:AtMarketOfferingSalesAgreementMember 2023-01-01 2023-09-30 0001070081 ptct:AtMarketOfferingSalesAgreementMember 2022-07-01 2022-09-30 0001070081 ptct:AtMarketOfferingSalesAgreementMember 2022-01-01 2022-09-30 0001070081 2023-10-01 2023-09-30 0001070081 country:US us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2023-07-01 2023-09-30 0001070081 us-gaap:RoyaltyMember us-gaap:CollaborativeArrangementMember 2023-07-01 2023-09-30 0001070081 us-gaap:ProductMember us-gaap:NonUsMember 2023-07-01 2023-09-30 0001070081 ptct:TranslarnaMember us-gaap:NonUsMember 2023-07-01 2023-09-30 0001070081 ptct:EmflazaMember country:US 2023-07-01 2023-09-30 0001070081 ptct:CollaborationRevenueMember us-gaap:CollaborativeArrangementMember 2023-07-01 2023-09-30 0001070081 us-gaap:RoyaltyMember 2023-07-01 2023-09-30 0001070081 us-gaap:ProductMember 2023-07-01 2023-09-30 0001070081 ptct:CollaborationRevenueMember 2023-07-01 2023-09-30 0001070081 country:US us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2023-01-01 2023-09-30 0001070081 country:RU us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2023-01-01 2023-09-30 0001070081 country:BR us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2023-01-01 2023-09-30 0001070081 us-gaap:RoyaltyMember us-gaap:CollaborativeArrangementMember 2023-01-01 2023-09-30 0001070081 us-gaap:ProductMember us-gaap:NonUsMember 2023-01-01 2023-09-30 0001070081 ptct:TranslarnaMember us-gaap:NonUsMember 2023-01-01 2023-09-30 0001070081 ptct:EmflazaMember country:US 2023-01-01 2023-09-30 0001070081 us-gaap:RoyaltyMember 2023-01-01 2023-09-30 0001070081 us-gaap:ProductMember 2023-01-01 2023-09-30 0001070081 ptct:CollaborationRevenueMember 2023-01-01 2023-09-30 0001070081 country:US us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2022-07-01 2022-09-30 0001070081 country:RU us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2022-07-01 2022-09-30 0001070081 us-gaap:RoyaltyMember us-gaap:CollaborativeArrangementMember 2022-07-01 2022-09-30 0001070081 us-gaap:ProductMember us-gaap:NonUsMember 2022-07-01 2022-09-30 0001070081 ptct:TranslarnaMember us-gaap:NonUsMember 2022-07-01 2022-09-30 0001070081 ptct:EmflazaMember country:US 2022-07-01 2022-09-30 0001070081 us-gaap:RoyaltyMember 2022-07-01 2022-09-30 0001070081 us-gaap:ProductMember 2022-07-01 2022-09-30 0001070081 ptct:ManufacturingMember 2022-07-01 2022-09-30 0001070081 ptct:CollaborationRevenueMember 2022-07-01 2022-09-30 0001070081 country:US us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2022-01-01 2022-09-30 0001070081 country:RU us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2022-01-01 2022-09-30 0001070081 us-gaap:RoyaltyMember us-gaap:CollaborativeArrangementMember 2022-01-01 2022-09-30 0001070081 us-gaap:ProductMember us-gaap:NonUsMember 2022-01-01 2022-09-30 0001070081 ptct:TranslarnaMember us-gaap:NonUsMember 2022-01-01 2022-09-30 0001070081 ptct:EmflazaMember country:US 2022-01-01 2022-09-30 0001070081 us-gaap:RoyaltyMember 2022-01-01 2022-09-30 0001070081 us-gaap:ProductMember 2022-01-01 2022-09-30 0001070081 ptct:ManufacturingMember 2022-01-01 2022-09-30 0001070081 ptct:CollaborationRevenueMember 2022-01-01 2022-09-30 0001070081 ptct:MassBioMember 2020-01-01 2020-12-31 0001070081 us-gaap:ConvertibleDebtSecuritiesMember 2020-01-01 2020-01-31 0001070081 us-gaap:SecuredDebtMember us-gaap:SubsequentEventMember 2023-10-19 2023-10-19 0001070081 ptct:SmaFoundationMember us-gaap:CollaborativeArrangementMember 2023-01-01 2023-09-30 0001070081 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-01 2023-09-30 0001070081 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-09-30 0001070081 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-07-01 2022-09-30 0001070081 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-09-30 0001070081 us-gaap:RetainedEarningsMember 2023-07-01 2023-09-30 0001070081 us-gaap:RetainedEarningsMember 2023-01-01 2023-09-30 0001070081 us-gaap:RetainedEarningsMember 2022-07-01 2022-09-30 0001070081 us-gaap:RetainedEarningsMember 2022-01-01 2022-09-30 0001070081 ptct:LineOfCreditUncommittedLoanFacilityMember 2022-10-27 0001070081 ptct:LineOfCreditCommittedLoanFacilityMember 2022-10-27 0001070081 ptct:LineOfCreditCommittedDelayedDrawTermLoanFacilityMember 2022-10-27 0001070081 ptct:WarrenPremisesMember ptct:FifthAnniversaryMember 2022-06-30 0001070081 ptct:WarrenPremisesMember ptct:DepositsAndOtherNoncurrentAssetsMember 2022-06-30 0001070081 ptct:HopewellCampusMember ptct:FifthAnniversaryMember 2019-12-31 0001070081 ptct:HopewellCampusMember ptct:DepositsAndOtherNoncurrentAssetsMember 2019-12-31 0001070081 srt:MinimumMember 2023-09-30 0001070081 srt:MaximumMember 2023-09-30 0001070081 ptct:HopewellCampusMember 2020-07-01 2020-07-01 0001070081 us-gaap:IndefinitelivedIntangibleAssetsMember ptct:UpstazaMember 2023-09-30 0001070081 us-gaap:IndefinitelivedIntangibleAssetsMember 2023-09-30 0001070081 us-gaap:IndefinitelivedIntangibleAssetsMember ptct:UpstazaMember 2022-12-31 0001070081 us-gaap:IndefinitelivedIntangibleAssetsMember ptct:PtcFaMember 2022-12-31 0001070081 us-gaap:IndefinitelivedIntangibleAssetsMember ptct:PtcAsMember 2022-12-31 0001070081 us-gaap:IndefinitelivedIntangibleAssetsMember 2022-12-31 0001070081 us-gaap:IndefinitelivedIntangibleAssetsMember ptct:UpstazaMember 2023-01-01 2023-09-30 0001070081 us-gaap:IndefinitelivedIntangibleAssetsMember ptct:PtcFaMember 2023-01-01 2023-09-30 0001070081 us-gaap:IndefinitelivedIntangibleAssetsMember ptct:PtcFaAndPtcAsMember 2023-01-01 2023-09-30 0001070081 us-gaap:IndefinitelivedIntangibleAssetsMember ptct:PtcAsMember 2023-01-01 2023-09-30 0001070081 us-gaap:IndefinitelivedIntangibleAssetsMember 2023-01-01 2023-09-30 0001070081 ptct:PtcFaAndPtcAsMember 2023-01-01 2023-09-30 0001070081 ptct:DepositsAndOtherNoncurrentAssetsMember 2023-09-30 0001070081 2018-08-23 2023-09-30 0001070081 ptct:AgilisMember 2018-08-23 0001070081 srt:WeightedAverageMember 2023-09-30 0001070081 us-gaap:FiniteLivedIntangibleAssetsMember ptct:WaylivraMember 2023-09-30 0001070081 us-gaap:FiniteLivedIntangibleAssetsMember ptct:UpstazaMember 2023-09-30 0001070081 us-gaap:FiniteLivedIntangibleAssetsMember ptct:TegsediMember 2023-09-30 0001070081 us-gaap:FiniteLivedIntangibleAssetsMember ptct:EmflazaMember 2023-09-30 0001070081 us-gaap:FiniteLivedIntangibleAssetsMember 2023-09-30 0001070081 us-gaap:FiniteLivedIntangibleAssetsMember ptct:WaylivraMember 2022-12-31 0001070081 us-gaap:FiniteLivedIntangibleAssetsMember ptct:UpstazaMember 2022-12-31 0001070081 us-gaap:FiniteLivedIntangibleAssetsMember ptct:TegsediMember 2022-12-31 0001070081 us-gaap:FiniteLivedIntangibleAssetsMember ptct:EmflazaMember 2022-12-31 0001070081 us-gaap:FiniteLivedIntangibleAssetsMember 2022-12-31 0001070081 ptct:MassBioMember 2023-09-30 0001070081 ptct:MassBioMember 2022-12-31 0001070081 ptct:MassBioMember 2020-06-19 0001070081 ptct:MassBioMember 2023-07-01 2023-09-30 0001070081 ptct:MassBioMember 2023-01-01 2023-09-30 0001070081 ptct:MassBioMember 2022-07-01 2022-09-30 0001070081 ptct:MassBioMember 2022-01-01 2022-09-30 0001070081 ptct:AgilisMember ptct:LiabilityNetSalesMilestonesandRoyaltiesMember us-gaap:FairValueInputsLevel3Member us-gaap:CommitmentsMember 2023-09-30 0001070081 ptct:AgilisMember ptct:LiabilityDevelopmentandRegulatoryMilestoneMember us-gaap:FairValueInputsLevel3Member us-gaap:CommitmentsMember 2023-09-30 0001070081 ptct:AgilisMember us-gaap:FairValueInputsLevel3Member ptct:UpstazaMember 2023-09-30 0001070081 ptct:AgilisMember us-gaap:FairValueInputsLevel3Member ptct:PtcFaAndPtcAsMember 2023-09-30 0001070081 ptct:AgilisMember ptct:LiabilityNetSalesMilestonesandRoyaltiesMember us-gaap:FairValueInputsLevel3Member us-gaap:CommitmentsMember 2022-12-31 0001070081 ptct:AgilisMember ptct:LiabilityDevelopmentandRegulatoryMilestoneMember us-gaap:FairValueInputsLevel3Member us-gaap:CommitmentsMember 2022-12-31 0001070081 ptct:AgilisMember ptct:LiabilityNetSalesMilestonesandRoyaltiesMember us-gaap:FairValueInputsLevel3Member us-gaap:CommitmentsMember 2022-09-30 0001070081 ptct:AgilisMember ptct:LiabilityDevelopmentandRegulatoryMilestoneMember us-gaap:FairValueInputsLevel3Member us-gaap:CommitmentsMember 2022-09-30 0001070081 ptct:AgilisMember ptct:LiabilityNetSalesMilestonesandRoyaltiesMember us-gaap:FairValueInputsLevel3Member us-gaap:CommitmentsMember 2021-12-31 0001070081 ptct:AgilisMember ptct:LiabilityDevelopmentandRegulatoryMilestoneMember us-gaap:FairValueInputsLevel3Member us-gaap:CommitmentsMember 2021-12-31 0001070081 ptct:AgilisMember ptct:LiabilityNetSalesMilestonesandRoyaltiesMember us-gaap:FairValueInputsLevel3Member us-gaap:CommitmentsMember 2023-01-01 2023-09-30 0001070081 ptct:AgilisMember ptct:LiabilityDevelopmentandRegulatoryMilestoneMember us-gaap:FairValueInputsLevel3Member us-gaap:CommitmentsMember 2023-01-01 2023-09-30 0001070081 ptct:AgilisMember us-gaap:FairValueInputsLevel3Member ptct:PtcFaAndPtcAsMember 2023-01-01 2023-09-30 0001070081 ptct:AgilisMember ptct:LiabilityNetSalesMilestonesandRoyaltiesMember us-gaap:FairValueInputsLevel3Member us-gaap:CommitmentsMember 2022-01-01 2022-09-30 0001070081 ptct:AgilisMember ptct:LiabilityDevelopmentandRegulatoryMilestoneMember us-gaap:FairValueInputsLevel3Member us-gaap:CommitmentsMember 2022-01-01 2022-09-30 0001070081 ptct:ClearpointEquityInvestmentMember 2022-07-01 2022-09-30 0001070081 ptct:ClearpointEquityInvestmentMember 2022-01-01 2022-09-30 0001070081 ptct:ClearpointEquityInvestmentMember 2023-07-01 2023-09-30 0001070081 ptct:ClearpointEquityInvestmentMember 2023-01-01 2023-09-30 0001070081 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DebtSecuritiesMember 2023-09-30 0001070081 us-gaap:FairValueInputsLevel1Member ptct:ClearpointEquityInvestmentMember 2023-09-30 0001070081 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DebtSecuritiesMember 2022-12-31 0001070081 us-gaap:FairValueInputsLevel1Member ptct:ClearpointEquityInvestmentMember 2022-12-31 0001070081 2017-12-22 2017-12-22 0001070081 ptct:AgilisMember 2018-12-31 0001070081 2023-05-01 2023-05-31 0001070081 us-gaap:LineOfCreditMember 2022-10-27 0001070081 us-gaap:ConvertibleDebtSecuritiesMember 2023-07-01 2023-09-30 0001070081 us-gaap:ConvertibleDebtSecuritiesMember 2023-01-01 2023-09-30 0001070081 us-gaap:ConvertibleDebtSecuritiesMember 2022-07-01 2022-09-30 0001070081 us-gaap:ConvertibleDebtSecuritiesMember 2022-01-01 2022-09-30 0001070081 ptct:ConvertibleSeniorNotes1.5DueSeptember152026Member 2023-09-30 0001070081 ptct:ConvertibleSeniorNotes1.5DueSeptember152026Member 2022-03-15 2022-04-08 0001070081 ptct:ConvertibleSeniorNotes1.5DueSeptember152026Member 2020-09-25 2022-03-14 0001070081 ptct:ConvertibleSeniorNotes3.0PercentDue2022Member us-gaap:ConvertibleDebtMember 2022-09-30 0001070081 ptct:ConvertibleSeniorNotes1.5DueSeptember152026Member us-gaap:ConvertibleDebtMember 2022-09-30 0001070081 2020-07-31 0001070081 ptct:ConvertibleSeniorNotes1.5DueSeptember152026Member us-gaap:FairValueInputsLevel2Member us-gaap:ConvertibleDebtMember 2023-09-30 0001070081 ptct:ConvertibleSeniorNotes1.5DueSeptember152026Member us-gaap:FairValueInputsLevel2Member us-gaap:ConvertibleDebtMember 2022-12-31 0001070081 ptct:ConvertibleSeniorNotes1.5DueSeptember152026Member us-gaap:ConvertibleDebtMember 2023-09-30 0001070081 us-gaap:LineOfCreditMember 2023-09-30 0001070081 ptct:ConvertibleSeniorNotes1.5DueSeptember152026Member us-gaap:ConvertibleDebtMember 2022-12-31 0001070081 us-gaap:LineOfCreditMember 2022-12-31 0001070081 us-gaap:SecuredDebtMember 2022-10-27 0001070081 ptct:ConvertibleSeniorNotes3.0PercentDue2022Member us-gaap:ConvertibleDebtMember 2015-08-31 0001070081 ptct:ConvertibleSeniorNotes1.5DueSeptember152026Member ptct:DebtInstrumentConversionPeriodOnOrAfterSeptember202023Member us-gaap:ConvertibleDebtMember 2019-09-30 0001070081 ptct:ConvertibleSeniorNotes1.5DueSeptember152026Member ptct:DebtInstrumentConversionPeriodOnOrAfterSeptember202023Member us-gaap:ConvertibleDebtMember 2019-09-01 2019-09-30 0001070081 us-gaap:LineOfCreditMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2022-10-27 2022-10-27 0001070081 us-gaap:LineOfCreditMember us-gaap:BaseRateMember 2022-10-27 2022-10-27 0001070081 ptct:DepositsAndOtherAssetsNoncurrentMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ConvertibleDebtSecuritiesMember 2023-09-30 0001070081 ptct:DepositsAndOtherAssetsNoncurrentMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:ConvertibleDebtSecuritiesMember 2022-12-31 0001070081 ptct:ManufacturingMember 2023-07-01 2023-09-30 0001070081 ptct:ManufacturingMember 2023-01-01 2023-09-30 0001070081 ptct:ManufacturingMember ptct:DeferredRevenueMember 2023-09-30 0001070081 us-gaap:ProductMember 2023-09-30 0001070081 ptct:ManufacturingMember ptct:DeferredRevenueMember 2022-12-31 0001070081 us-gaap:ProductMember 2022-12-31 0001070081 ptct:ManufacturingMember us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember 2023-09-30 0001070081 ptct:ManufacturingMember 2023-09-30 0001070081 ptct:ManufacturingMember 2022-12-31 0001070081 2021-12-31 0001070081 ptct:LiabilityNetSalesMilestonesandRoyaltiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001070081 ptct:LiabilityDevelopmentandRegulatoryMilestoneMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001070081 ptct:LiabilityNetSalesMilestonesandRoyaltiesMember us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001070081 ptct:LiabilityDevelopmentandRegulatoryMilestoneMember us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001070081 ptct:LiabilityNetSalesMilestonesandRoyaltiesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001070081 ptct:LiabilityDevelopmentandRegulatoryMilestoneMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001070081 ptct:LiabilityNetSalesMilestonesandRoyaltiesMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001070081 ptct:LiabilityDevelopmentandRegulatoryMilestoneMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001070081 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DebtSecuritiesMember 2023-09-30 0001070081 us-gaap:FairValueMeasurementsRecurringMember us-gaap:DebtSecuritiesMember 2023-09-30 0001070081 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:DebtSecuritiesMember 2022-12-31 0001070081 us-gaap:FairValueMeasurementsRecurringMember us-gaap:DebtSecuritiesMember 2022-12-31 0001070081 us-gaap:CorporateDebtSecuritiesMember 2023-09-30 0001070081 us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2022-12-31 0001070081 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-09-30 0001070081 ptct:RestrictedStockAndRestrictedStockUnitsMember 2023-01-01 2023-09-30 0001070081 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-09-30 0001070081 ptct:RestrictedStockAndRestrictedStockUnitsMember 2022-01-01 2022-09-30 0001070081 us-gaap:FiniteLivedIntangibleAssetsMember 2023-07-01 2023-09-30 0001070081 us-gaap:FiniteLivedIntangibleAssetsMember ptct:UpstazaMember 2023-01-01 2023-09-30 0001070081 us-gaap:FiniteLivedIntangibleAssetsMember 2022-07-01 2022-09-30 0001070081 us-gaap:FiniteLivedIntangibleAssetsMember 2022-01-01 2022-09-30 0001070081 ptct:ConvertibleSeniorNotes1.5DueSeptember152026Member us-gaap:ConvertibleDebtMember 2023-07-01 2023-09-30 0001070081 us-gaap:LineOfCreditMember 2023-07-01 2023-09-30 0001070081 ptct:ConvertibleSeniorNotes1.5DueSeptember152026Member us-gaap:ConvertibleDebtMember 2023-01-01 2023-09-30 0001070081 ptct:ConvertibleSeniorNotes3.0PercentDue2022Member us-gaap:ConvertibleDebtMember 2022-07-01 2022-09-30 0001070081 ptct:ConvertibleSeniorNotes1.5DueSeptember152026Member us-gaap:ConvertibleDebtMember 2022-07-01 2022-09-30 0001070081 ptct:ConvertibleSeniorNotes3.0PercentDue2022Member us-gaap:ConvertibleDebtMember 2022-01-01 2022-09-30 0001070081 ptct:ConvertibleSeniorNotes1.5DueSeptember152026Member us-gaap:ConvertibleDebtMember 2022-01-01 2022-09-30 0001070081 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-07-01 2023-09-30 0001070081 us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-01 2023-09-30 0001070081 us-gaap:EmployeeStockMember 2023-07-01 2023-09-30 0001070081 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-01 2023-09-30 0001070081 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-09-30 0001070081 us-gaap:EmployeeStockMember 2023-01-01 2023-09-30 0001070081 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-07-01 2022-09-30 0001070081 us-gaap:ResearchAndDevelopmentExpenseMember 2022-07-01 2022-09-30 0001070081 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2022-01-01 2022-09-30 0001070081 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-09-30 0001070081 us-gaap:AdditionalPaidInCapitalMember 2023-07-01 2023-09-30 0001070081 us-gaap:AdditionalPaidInCapitalMember 2022-07-01 2022-09-30 0001070081 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-09-30 0001070081 ptct:AkceaMember us-gaap:AccountsPayableAndAccruedLiabilitiesMember ptct:WaylivraMember 2023-09-30 0001070081 ptct:AkceaMember us-gaap:AccountsPayableAndAccruedLiabilitiesMember ptct:TegsediMember 2023-09-30 0001070081 ptct:SmaFoundationMember us-gaap:CollaborativeArrangementMember 2023-09-30 0001070081 srt:MinimumMember ptct:HopewellCampusMember 2019-01-01 2019-12-31 0001070081 us-gaap:LineOfCreditMember 2023-01-01 2023-09-30 0001070081 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-09-30 0001070081 us-gaap:CommonStockMember 2023-01-01 2023-09-30 0001070081 us-gaap:StockOptionMember ptct:InducementStockIncentivePlan2020Member 2023-09-30 0001070081 us-gaap:StockOptionMember ptct:InducementStockIncentivePlan2020Member 2023-01-01 2023-09-30 0001070081 srt:MaximumMember us-gaap:StockOptionMember ptct:InducementStockIncentivePlan2020Member 2023-09-30 0001070081 srt:MinimumMember us-gaap:StockOptionMember ptct:InducementStockIncentivePlan2020Member 2023-09-30 0001070081 ptct:ConvertibleSeniorNotes3.0PercentDue2022Member 2023-01-01 2023-09-30 0001070081 ptct:ConvertibleSeniorNotes1.5DueSeptember152026Member 2023-01-01 2023-09-30 0001070081 srt:MaximumMember ptct:AtMarketOfferingSalesAgreementMember 2019-08-31 0001070081 srt:MaximumMember ptct:AtMarketOfferingSalesAgreementMember 2023-01-01 2023-09-30 0001070081 ptct:RoyaltyPharmaInvestments2019IcavMember us-gaap:SubsequentEventMember ptct:AmendedAndRestatedRoyaltyPurchaseAgreementMember 2023-10-18 0001070081 srt:MinimumMember ptct:AgilisMember ptct:LiabilityNetSalesMilestonesandRoyaltiesMember us-gaap:CommitmentsMember ptct:SalesMilestonesMember us-gaap:ValuationTechniqueOptionPricingModelMember 2023-09-30 0001070081 srt:MinimumMember ptct:AgilisMember ptct:LiabilityDevelopmentandRegulatoryMilestoneMember us-gaap:CommitmentsMember ptct:DevelopmentandRegulatoryMilestoneMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2023-09-30 0001070081 srt:MaximumMember ptct:AgilisMember ptct:LiabilityNetSalesMilestonesandRoyaltiesMember us-gaap:CommitmentsMember ptct:SalesMilestonesMember us-gaap:ValuationTechniqueOptionPricingModelMember 2023-09-30 0001070081 srt:MaximumMember ptct:AgilisMember ptct:LiabilityDevelopmentandRegulatoryMilestoneMember us-gaap:CommitmentsMember ptct:DevelopmentandRegulatoryMilestoneMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2023-09-30 0001070081 srt:MinimumMember ptct:AgilisMember ptct:LiabilityNetSalesMilestonesandRoyaltiesMember us-gaap:CommitmentsMember ptct:SalesMilestonesMember us-gaap:ValuationTechniqueOptionPricingModelMember 2022-12-31 0001070081 srt:MinimumMember ptct:AgilisMember ptct:LiabilityDevelopmentandRegulatoryMilestoneMember us-gaap:CommitmentsMember ptct:DevelopmentandRegulatoryMilestoneMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2022-12-31 0001070081 srt:MaximumMember ptct:AgilisMember ptct:LiabilityNetSalesMilestonesandRoyaltiesMember us-gaap:CommitmentsMember ptct:SalesMilestonesMember us-gaap:ValuationTechniqueOptionPricingModelMember 2022-12-31 0001070081 srt:MaximumMember ptct:AgilisMember ptct:LiabilityDevelopmentandRegulatoryMilestoneMember us-gaap:CommitmentsMember ptct:DevelopmentandRegulatoryMilestoneMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2022-12-31 0001070081 srt:WeightedAverageMember ptct:AgilisMember ptct:LiabilityNetSalesMilestonesandRoyaltiesMember us-gaap:CommitmentsMember us-gaap:MeasurementInputDiscountRateMember us-gaap:ValuationTechniqueOptionPricingModelMember 2023-09-30 0001070081 srt:WeightedAverageMember ptct:AgilisMember ptct:LiabilityNetSalesMilestonesandRoyaltiesMember us-gaap:CommitmentsMember ptct:ProbabilityofSuccessMember us-gaap:ValuationTechniqueOptionPricingModelMember 2023-09-30 0001070081 srt:WeightedAverageMember ptct:AgilisMember ptct:LiabilityDevelopmentandRegulatoryMilestoneMember us-gaap:CommitmentsMember us-gaap:MeasurementInputDiscountRateMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2023-09-30 0001070081 srt:WeightedAverageMember ptct:AgilisMember ptct:LiabilityDevelopmentandRegulatoryMilestoneMember us-gaap:CommitmentsMember ptct:ProbabilityofSuccessMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2023-09-30 0001070081 srt:MinimumMember ptct:AgilisMember ptct:LiabilityNetSalesMilestonesandRoyaltiesMember us-gaap:CommitmentsMember ptct:ProbabilityofSuccessMember us-gaap:ValuationTechniqueOptionPricingModelMember 2023-09-30 0001070081 srt:MinimumMember ptct:AgilisMember ptct:LiabilityDevelopmentandRegulatoryMilestoneMember us-gaap:CommitmentsMember us-gaap:MeasurementInputDiscountRateMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2023-09-30 0001070081 srt:MinimumMember ptct:AgilisMember ptct:LiabilityDevelopmentandRegulatoryMilestoneMember us-gaap:CommitmentsMember ptct:ProbabilityofSuccessMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2023-09-30 0001070081 srt:MaximumMember ptct:AgilisMember ptct:LiabilityNetSalesMilestonesandRoyaltiesMember us-gaap:CommitmentsMember ptct:ProbabilityofSuccessMember us-gaap:ValuationTechniqueOptionPricingModelMember 2023-09-30 0001070081 srt:MaximumMember ptct:AgilisMember ptct:LiabilityDevelopmentandRegulatoryMilestoneMember us-gaap:CommitmentsMember us-gaap:MeasurementInputDiscountRateMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2023-09-30 0001070081 srt:MaximumMember ptct:AgilisMember ptct:LiabilityDevelopmentandRegulatoryMilestoneMember us-gaap:CommitmentsMember ptct:ProbabilityofSuccessMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2023-09-30 0001070081 ptct:AgilisMember ptct:LiabilityNetSalesMilestonesandRoyaltiesMember us-gaap:CommitmentsMember us-gaap:MeasurementInputDiscountRateMember us-gaap:ValuationTechniqueOptionPricingModelMember 2023-09-30 0001070081 ptct:AgilisMember ptct:LiabilityNetSalesMilestonesandRoyaltiesMember us-gaap:CommitmentsMember ptct:PercentageofSalesforRoyaltiesMember us-gaap:ValuationTechniqueOptionPricingModelMember 2023-09-30 0001070081 srt:MinimumMember ptct:AgilisMember ptct:LiabilityNetSalesMilestonesandRoyaltiesMember us-gaap:CommitmentsMember ptct:ProbabilityofSuccessMember us-gaap:ValuationTechniqueOptionPricingModelMember 2022-12-31 0001070081 srt:MinimumMember ptct:AgilisMember ptct:LiabilityNetSalesMilestonesandRoyaltiesMember us-gaap:CommitmentsMember ptct:PercentageofSalesforRoyaltiesMember us-gaap:ValuationTechniqueOptionPricingModelMember 2022-12-31 0001070081 srt:MinimumMember ptct:AgilisMember ptct:LiabilityDevelopmentandRegulatoryMilestoneMember us-gaap:CommitmentsMember us-gaap:MeasurementInputDiscountRateMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2022-12-31 0001070081 srt:MinimumMember ptct:AgilisMember ptct:LiabilityDevelopmentandRegulatoryMilestoneMember us-gaap:CommitmentsMember ptct:ProbabilityofSuccessMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2022-12-31 0001070081 srt:MaximumMember ptct:AgilisMember ptct:LiabilityNetSalesMilestonesandRoyaltiesMember us-gaap:CommitmentsMember ptct:ProbabilityofSuccessMember us-gaap:ValuationTechniqueOptionPricingModelMember 2022-12-31 0001070081 srt:MaximumMember ptct:AgilisMember ptct:LiabilityNetSalesMilestonesandRoyaltiesMember us-gaap:CommitmentsMember ptct:PercentageofSalesforRoyaltiesMember us-gaap:ValuationTechniqueOptionPricingModelMember 2022-12-31 0001070081 srt:MaximumMember ptct:AgilisMember ptct:LiabilityDevelopmentandRegulatoryMilestoneMember us-gaap:CommitmentsMember us-gaap:MeasurementInputDiscountRateMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2022-12-31 0001070081 srt:MaximumMember ptct:AgilisMember ptct:LiabilityDevelopmentandRegulatoryMilestoneMember us-gaap:CommitmentsMember ptct:ProbabilityofSuccessMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2022-12-31 0001070081 ptct:AgilisMember ptct:LiabilityNetSalesMilestonesandRoyaltiesMember us-gaap:CommitmentsMember us-gaap:MeasurementInputDiscountRateMember us-gaap:ValuationTechniqueOptionPricingModelMember 2022-12-31 0001070081 us-gaap:CollaborativeArrangementMember ptct:SalesMilestonesMember 2023-09-30 0001070081 us-gaap:CollaborativeArrangementMember ptct:ResearchAndDevelopmentEventMilestonesMember 2023-09-30 0001070081 srt:MaximumMember us-gaap:CollaborativeArrangementMember ptct:SalesMilestonesMember 2011-11-30 0001070081 srt:MaximumMember us-gaap:CollaborativeArrangementMember ptct:ResearchAndDevelopmentEventMilestonesMember 2011-11-30 0001070081 ptct:ConvertibleSeniorNotes3.0PercentDue2022Member us-gaap:ConvertibleDebtMember 2022-08-15 2022-08-15 0001070081 ptct:RoyaltyPurchaseAgreementMember ptct:AssignedRoyaltyPaymentsMember 2020-07-17 2020-07-17 0001070081 2020-07-01 2020-07-31 0001070081 ptct:SmaFoundationMember srt:MaximumMember us-gaap:CollaborativeArrangementMember 2023-01-01 2023-09-30 0001070081 ptct:WarrenPremisesMember 2022-06-01 2022-06-30 0001070081 ptct:HopewellCampusMember 2019-01-01 2019-12-31 0001070081 ptct:RoyaltyPharmaInvestments2019IcavMember us-gaap:SubsequentEventMember ptct:AmendedAndRestatedRoyaltyPurchaseAgreementMember 2023-10-18 2023-10-18 0001070081 ptct:AkceaMember ptct:WaylivraMember 2023-01-01 2023-09-30 0001070081 ptct:AkceaMember ptct:TegsediMember 2023-01-01 2023-09-30 0001070081 us-gaap:NoncollaborativeArrangementTransactionsMember ptct:MarathonPharmaceuticalsLLCMember 2023-01-01 2023-09-30 0001070081 ptct:AgilisMember 2022-01-01 2022-12-31 0001070081 ptct:WellcomeTrustLimitedMember 2016-04-01 2016-06-30 0001070081 ptct:HopewellCampusMember 2020-07-01 0001070081 us-gaap:MutualFundMember 2023-01-01 2023-09-30 0001070081 us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2023-07-01 2023-09-30 0001070081 us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-09-30 0001070081 us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2022-07-01 2022-09-30 0001070081 us-gaap:RevenueFromContractWithCustomerMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-09-30 0001070081 us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2023-07-01 2023-09-30 0001070081 country:US us-gaap:RevenueFromContractWithCustomerMember 2023-07-01 2023-09-30 0001070081 us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2023-01-01 2023-09-30 0001070081 us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2022-07-01 2022-09-30 0001070081 us-gaap:RevenueFromContractWithCustomerMember us-gaap:GeographicConcentrationRiskMember 2022-01-01 2022-09-30 0001070081 us-gaap:CollaborativeArrangementMember ptct:SalesMilestonesMember 2022-09-01 2022-09-30 0001070081 ptct:MarathonPharmaceuticalsLLCMember ptct:EmflazaassetacquisitionMember us-gaap:AccountsPayableAndAccruedLiabilitiesMember 2023-09-30 0001070081 2022-09-30 0001070081 ptct:EmflazaassetacquisitionMember 2023-01-01 2023-09-30 0001070081 ptct:WarrenPremisesMember 2022-05-01 2022-05-31 0001070081 ptct:WarrenPremisesMember 2022-05-31 0001070081 ptct:ConvertibleSeniorNotes1.5DueSeptember152026Member 2022-09-01 2022-09-30 0001070081 ptct:ConvertibleSeniorNotes1.5DueSeptember152026Member 2022-04-01 2022-04-30 0001070081 us-gaap:FiniteLivedIntangibleAssetsMember ptct:WaylivraMember 2023-01-01 2023-09-30 0001070081 us-gaap:FiniteLivedIntangibleAssetsMember ptct:TegsediMember 2023-01-01 2023-09-30 0001070081 us-gaap:FiniteLivedIntangibleAssetsMember ptct:EmflazaMember 2023-01-01 2023-09-30 0001070081 us-gaap:FiniteLivedIntangibleAssetsMember 2023-01-01 2023-09-30 0001070081 us-gaap:MutualFundMember 2023-07-01 2023-09-30 0001070081 us-gaap:MutualFundMember 2022-07-01 2022-09-30 0001070081 us-gaap:MutualFundMember 2022-01-01 2022-09-30 0001070081 us-gaap:EmployeeStockMember 2016-06-01 2016-06-30 0001070081 ptct:WellcomeTrustLimitedMember us-gaap:ProductMember srt:MaximumMember 2023-09-30 0001070081 srt:MaximumMember ptct:BioElectronMember 2023-09-30 0001070081 ptct:AgilisMember 2020-04-29 0001070081 ptct:WellcomeTrustLimitedMember 2022-12-31 0001070081 ptct:FormerCensaSecurityholdersMember 2023-01-01 2023-09-30 0001070081 ptct:AgilisMember 2023-01-01 2023-09-30 0001070081 us-gaap:LineOfCreditMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2022-10-27 0001070081 us-gaap:LineOfCreditMember us-gaap:BaseRateMember 2022-10-27 0001070081 ptct:LineOfCreditCommittedLoanFacilityMember 2022-10-27 2022-10-27 0001070081 srt:MinimumMember us-gaap:LineOfCreditMember 2022-10-27 0001070081 ptct:ConvertibleSeniorNotes1.5DueSeptember152026Member us-gaap:ConvertibleDebtMember 2019-09-30 0001070081 us-gaap:LineOfCreditMember 2023-03-31 0001070081 2022-07-01 2022-09-30 0001070081 ptct:ConvertibleSeniorNotes1.5DueSeptember152026Member us-gaap:ConvertibleDebtMember 2019-09-01 2019-09-30 0001070081 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001070081 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001070081 srt:MinimumMember ptct:AgilisMember 2023-09-30 0001070081 srt:MaximumMember ptct:AgilisMember 2023-01-01 2023-09-30 0001070081 srt:MaximumMember ptct:AgilisMember 2023-09-30 0001070081 ptct:AgilisMember 2023-09-30 0001070081 ptct:AgilisMember ptct:RightsExchangeAgreementMember 2020-04-29 2020-04-29 0001070081 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001070081 us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0001070081 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001070081 us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001070081 2022-01-01 2022-09-30 0001070081 us-gaap:SubsequentEventMember ptct:AmendedAndRestatedRoyaltyPurchaseAgreementMember 2023-10-18 2023-10-18 0001070081 us-gaap:CorporateDebtSecuritiesMember 2022-12-31 0001070081 us-gaap:ConvertibleDebtSecuritiesMember 2020-01-31 0001070081 2020-07-17 0001070081 ptct:RoyaltyPharmaInvestments2019IcavMember ptct:RoyaltyPurchaseAgreementMember 2023-09-30 0001070081 ptct:RoyaltyPurchaseAgreementMember ptct:AssignedRoyaltyPaymentsMember 2020-07-17 0001070081 ptct:CensaMember srt:MaximumMember 2020-05-29 0001070081 ptct:CensaMember 2020-05-29 0001070081 us-gaap:SubsequentEventMember ptct:AmendedAndRestatedRoyaltyPurchaseAgreementMember 2023-10-18 0001070081 2023-09-30 0001070081 2022-12-31 0001070081 ptct:PierreGravierMember ptct:RestrictedStockUnitTradingArrangementMember 2023-07-01 2023-09-30 0001070081 2023-07-01 2023-09-30 0001070081 2023-10-24 0001070081 2023-01-01 2023-09-30 ptct:lease ptct:product ptct:item ptct:period utr:sqft ptct:D ptct:segment shares iso4217:USD pure iso4217:USD shares ptct:Option ptct:building ptct:country ptct:Distributor ptct:fund 0001070081 --12-31 2023 Q3 false 75459022 73104692 P5D P5D 10-Q true 2023-09-30 false 001-35969 PTC Therapeutics, Inc. DE 04-3416587 100 Corporate Court South Plainfield NJ 07080 908 222-7000 Common Stock, $0.001 par value per share PTCT NASDAQ Yes Yes Large Accelerated Filer false false false 75463145 165157000 279834000 129653000 130871000 165718000 155614000 35752000 21808000 44082000 105658000 540362000 693785000 85031000 72590000 423342000 705891000 82341000 82341000 94072000 102430000 34737000 48582000 1259885000 1705619000 370731000 320366000 1224000 1351000 11703000 9370000 2611000 3000000 105849000 72149000 492118000 406236000 573174000 571722000 39000000 164000000 51927000 102834000 99682000 100860000 17184000 18675000 657469000 685737000 141000 2641000 1930695000 2052705000 0.001 0.001 250000000 75459022 250000000 73104692 75000 72000 2447292000 2305020000 9609000 4796000 -3127786000 -2656974000 -670810000 -347086000 1259885000 1705619000 144038000 134186000 506187000 407720000 50017000 6000 50024000 50173000 32924000 117857000 73645000 2365000 6716000 196576000 217127000 630766000 531389000 9493000 14011000 36368000 33785000 58649000 31023000 145461000 80790000 164212000 165462000 545210000 462802000 80886000 80118000 256249000 233280000 -1500000 5300000 125000000 32200000 217800000 314740000 285314000 1076088000 778457000 -118164000 -68187000 -445322000 -247068000 -28160000 -20880000 -84905000 -66371000 -20266000 -38141000 -8832000 -84355000 -166590000 -127208000 -539059000 -397794000 -33620000 -17893000 -68247000 -9666000 -132970000 -109315000 -470812000 -388128000 75377997 75377997 71654671 71654671 74618611 74618611 71415849 71415849 -1.76 -1.76 -1.53 -1.53 -6.31 -6.31 -5.43 -5.43 -132970000 -109315000 -470812000 -388128000 19000 736000 470000 -2333000 11021000 25218000 4343000 62820000 -121930000 -83361000 -465999000 -327641000 75318233 75000 2416904000 -1431000 -2994816000 -579268000 113795 3446000 3446000 26994 26942000 26942000 -132970000 -132970000 11040000 11040000 75459022 75000 2447292000 9609000 -3127786000 -670810000 71505889 71000 2184230000 10251000 -2376770000 -182218000 331379 10005000 10005000 17624 28670000 28670000 -109315000 -109315000 25954000 25954000 71854892 71000 2222905000 36205000 -2486085000 -226904000 73104692 72000 2305020000 4796000 -2656974000 -347086000 806407 1000 23770000 23771000 773157 1000 1000 117304 3805000 3805000 657462 1000 29569000 29570000 85128000 85128000 -470812000 -470812000 4813000 4813000 75459022 75000 2447292000 9609000 -3127786000 -670810000 70828226 71000 2123606000 -24282000 -2097957000 1438000 456399 13203000 13203000 479004 91263 3107000 3107000 82989000 82989000 -388128000 -388128000 60487000 60487000 71854892 71000 2222905000 36205000 -2486085000 -226904000 -470812000 -388128000 155885000 89971000 8156000 7505000 50599000 31617000 56031000 55778000 217800000 -125000000 -32200000 -3107000 -1113000 -4594000 -2392000 5484000 -11319000 -782000 29570000 -135000 -81000 -50909000 89000 -1792000 1574000 1316000 85128000 82989000 -3394000 -71246000 14121000 768000 -59467000 35615000 9887000 24773000 -4597000 3752000 40434000 1568000 -1756000 -908000 -127000 -58130000 -190691000 22872000 23394000 40429000 26378000 22787000 21544000 341990000 12078000 104431000 2594000 69285000 102069000 -82319000 257742000 23771000 13203000 150000000 3805000 3107000 282000 1379000 1276000 25915000 -134966000 19000 -8792000 -114515000 -76707000 295925000 197218000 181410000 120511000 34020000 12679000 13631000 4029000 470000 -2333000 35294000 44963000 27828000 2500000 50000000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">1.        The Company</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">PTC Therapeutics, Inc. (the “Company” or “PTC”) is a science-driven global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. PTC’s ability to innovate to identify new therapies and to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines. PTC’s mission is to provide access to best-in-class treatments for patients who have little to no treatment options. PTC’s strategy is to leverage its strong scientific and clinical expertise and global commercial infrastructure to bring therapies to patients.  PTC believes that this allows it to maximize value for all of its stakeholders. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">PTC has a portfolio pipeline that includes several commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology, metabolism and oncology.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has two products, Translarna™ (ataluren) and Emflaza® (deflazacort), for the treatment of Duchenne muscular dystrophy (“DMD”), a rare, life threatening disorder. Translarna has marketing authorization in the European Economic Area (the “EEA”) for the treatment of nonsense mutation Duchenne muscular dystrophy (“nmDMD”) in ambulatory patients aged 2 years and older and in Russia for the treatment of nmDMD in patients aged two years and older. Translarna also has marketing authorization in Brazil for the treatment of nmDMD in ambulatory patients two years and older and for continued treatment of patients that become non-ambulatory. In July 2020, the European Commission (“EC”) approved the removal of the statement “efficacy has not been demonstrated in non-ambulatory patients” from the indication statement for Translarna. Emflaza is approved in the United States for the treatment of DMD in patients two years and older. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company’s marketing authorization for Translarna in the EEA is subject to annual review and renewal by the EC following reassessment by the European Medicines Agency (“EMA”) of the benefit-risk balance of the authorization, which the Company refers to as the annual EMA reassessment. In September 2022, the Company submitted a Type II variation to the EMA to support conversion of the conditional marketing authorization for Translarna to a standard marketing authorization, which included a report on the placebo-controlled trial of Study 041 and data from the open-label extension. In February 2023, the Company also submitted an annual marketing authorization renewal request to the EMA. <span style="background:#ffffff;">In September 2023, the Committee for Medicinal Products for Human Use (“CHMP’), gave a negative opinion on the conversion of the conditional marketing authorization to full marketing authorization of Translarna for the treatment of nmDMD and a negative opinion on the renewal of the existing conditional marketing authorization of Translarna for the treatment of nmDMD. The Company has requested re-examination of the CHMP opinion regarding the renewal of the existing conditional marketing authorization. In re-examination, the Company intends to address concerns raised during the previous review process on the benefit demonstrated in Translarna clinical trials and regarding the robustness of the Strategic Targeting of Registries and International Database of Excellence, or STRIDE, real world registry. In accordance with EMA guidelines, the Company expects the CHMP opinion following the re-examination process to occur in late January 2024, with EC ratification of the opinion within the following 67 days.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Translarna is an investigational new drug in the United States. Following the Company’s announcement of top-line results from the placebo-controlled trial of Study 041 in June 2022, the Company submitted a meeting request to the U.S. Food and Drug Administration (“FDA”) to gain clarity on the regulatory pathway for a potential re-submission of a New Drug Application (“NDA”) for Translarna. The FDA provided initial written feedback that Study 041 does not provide substantial evidence of effectiveness to support an NDA re-submission. The Company then had an informal meeting with the FDA, during which the Company discussed the potential path to an NDA re-submission for Translarna. Based on the meeting discussion, the Company has scheduled an additional Type C meeting with the FDA to review the totality of data </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">collected to date, including dystrophin and other mechanistic data as well as additional analyses that could support the benefit of Translarna.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has developed Upstaza (eladocagene exuparvovec), a gene therapy used for the treatment of Aromatic L-Amino Acid Decarboxylase (“AADC”) deficiency (“AADC deficiency”), a rare central nervous system (“CNS”) disorder arising from reductions in the enzyme AADC that results from mutations in the dopa decarboxylase gene. In July 2022, the EC approved Upstaza for the treatment of AADC deficiency for patients 18 months and older within the EEA. In November 2022, the Medicines and Healthcare Products Regulatory Agency approved Upstaza for the treatment of AADC deficiency for patients 18 months and older within the United Kingdom. The Company is also preparing a biologics license application (“BLA”) for Upstaza for the treatment of AADC deficiency in the United States and anticipates submitting the BLA shortly after its pre-BLA meeting that is scheduled for December 2023, pending the outcome of such meeting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company holds the rights for the commercialization of Tegsedi® (inotersen) and Waylivra® (volanesorsen) for the treatment of rare diseases in countries in Latin America and the Caribbean pursuant to the Collaboration and License Agreement (the “Tegsedi-Waylivra Agreement”), dated August 1, 2018, by and between the Company and Akcea Therapeutics, Inc. (“Akcea”), a subsidiary of Ionis Pharmaceuticals, Inc. Tegsedi has received marketing authorization in the United States, the European Union (the “EU”) and Brazil for the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis (“hATTR amyloidosis”). The Company began to make commercial sales of Tegsedi for the treatment of hATTR amyloidosis in Brazil in the second quarter of 2022 and it continues to make Tegsedi available in certain other countries within Latin America and the Caribbean through early access programs (“EAP Programs”). In August 2021, ANVISA, the Brazilian health regulatory authority, approved Waylivra as the first treatment for familial chylomicronemia syndrome (“FCS”) in Brazil and the Company began to make commercial sales of Waylivra in Brazil in the third quarter of 2022 while continuing to make Waylivra available in certain other countries within Latin America and the Caribbean through EAP Programs. In December 2022, ANVISA approved Waylivra for the treatment of familial partial lipodystrophy (“FPL”). Waylivra has also received marketing authorization in the EU for the treatment of FCS.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company also has a spinal muscular atrophy (“SMA”) collaboration with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc. (referred to collectively as “Roche”) and the Spinal Muscular Atrophy Foundation (“SMA Foundation”). The SMA program has one approved product, Evrysdi® (risdiplam), which was approved by the FDA in August 2020 for the treatment of SMA in adults and children two months and older and by the EC in March 2021 for the treatment of 5q SMA in patients two months and older with a clinical diagnosis of SMA Type 1, Type 2 or Type 3 or with one to four SMN2 copies. Evrysdi also received marketing authorization for the treatment of SMA in Brazil in October 2020 and Japan in June 2021. In May 2022, the FDA approved a label expansion for Evrysdi to include infants under two months old with SMA. In August 2023, the EC approved an extension of the Evrysdi marketing authorization to include infants under two months old in the EU. In addition to the Company’s SMA program, the Company’s splicing platform also includes PTC518, which is being developed for the treatment of Huntington’s disease (“HD”). The Company initiated a Phase 2 study of PTC518 for the treatment of HD in the first quarter of 2022, which consists of an initial 12-week placebo-controlled phase focused on safety, pharmacology and pharmacodynamic effects followed by a nine-month placebo-controlled phase focused on PTC518 biomarker effect. In June 2023, the Company announced interim data from the 12-week placebo-controlled phase. The Company expects the next data update from the Phase 2 study of PTC518 for the treatment of HD in the first half of 2024. In the Phase 2 study, enrollment outside of the United States remains active and ongoing while enrollment within the United States is paused as the FDA requested additional data to allow the Phase 2 study to proceed. The Company had a Type A meeting with the FDA to review the clinical safety data needed to enable resumption of enrollment in the United States. At that meeting, the FDA stated that the existing three-month safety data could support 12-week dosing and that six months of clinical safety data could support dosing in the 12-month Phase 2 study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The most advanced molecule in the Company’s metabolic platform is sepiapterin, a precursor to intracellular tetrahydrobiopterin, which is a critical enzymatic cofactor involved in metabolism and synthesis of numerous metabolic products, for orphan diseases. In May 2023, the Company announced that the primary endpoint was achieved in its registration-directed Phase 3 trial for sepiapterin for <span style="background:#ffffff;">phenylketonuria (“PKU”)</span>. The primary endpoint of the study was the achievement of statistically-significant reduction in blood Phe level. The Company participated in a pre-NDA meeting with the FDA in the third quarter of 2023. At that meeting, the FDA stated that the sepiapterin clinical safety and efficacy </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">data supported NDA submission for the treatment of pediatric and adult PKU patients. However, the FDA has requested that PTC completes a 26-week nonclinical mouse study to assess sepiapterin carcinogenicity potential prior to NDA submission. PTC expects to submit an NDA to the FDA for sepiapterin for the treatment of PKU by the end of the third quarter of 2024 and PTC intends to discuss with the FDA the potential for an earlier submission if PTC is permitted to submit the 26-week mouse study report during the review process of the NDA. Additionally, PTC expects to submit a marketing authorization application (“MAA”) to the EMA for sepiapterin for the treatment of PKU in the EEA in the first half of 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company’s Bio-e platform consists of small molecule compounds that target oxidoreductase enzymes that regulate oxidative stress and inflammatory pathways central to the pathology of a number of CNS diseases. The two most advanced molecules in the Company’s Bio-e platform are vatiquinone and utreloxastat. The Company announced topline results from a registration-directed Phase 3 trial of vatiquinone in children and young adults with Friedreich ataxia in May 2023. While the study did not meet its primary endpoint of statistically significant change, the Company participated in a Type C written response only meeting with the FDA in the third quarter of 2023 to discuss the potential for an NDA submission for vatiquinone for the treatment of Friedreich ataxia. In their written response, the FDA stated that while they see the value of upright stability as a clinically meaningful endpoint, they believed a confirmatory study would likely be needed to support NDA submission. PTC has requested a follow-up live meeting to address the issues raised by the FDA.  Additionally, PTC is participating in a scientific advice procedure with the EMA to determine if the data from the registration-directed Phase 3 trial of vatiquinone in children and young adults with Friedreich ataxia could support a conditional MAA in the EEA. The Company initiated a Phase 2 trial of utreloxastat for amyotrophic lateral sclerosis in the first quarter of 2022 and enrollment is ongoing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Unesbulin is the Company’s most advanced oncology agent. The Company completed its Phase 1 trials evaluating unesbulin in leiomyosarcoma (“LMS”) and diffuse intrinsic pontine glioma (“DIPG”) in the fourth quarter of 2021. The Company initiated a registration-directed Phase 2/3 trial of unesbulin for the treatment of LMS in the first quarter of 2022 and enrollment is ongoing. The Company is evaluating its plans for a potential initiation of a registration-directed Phase 2/3 trial of unesbulin for the treatment of DIPG.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition, the Company has a pipeline of product candidates and discovery programs that are in early clinical, pre-clinical and research and development stages focused on the development of new treatments for multiple therapeutic areas for rare diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As of September 30, 2023, the Company had an accumulated deficit of approximately $3,127.8 million. The Company has financed its operations to date primarily through the private offerings in September 2019 of 1.50% convertible senior notes due 2026 (see Note 9), public offerings of common stock in February 2014, October 2014, April 2018, January 2019, and September 2019, “at the market offering” of its common stock, its initial public offering of common stock in June 2013, proceeds from the Royalty Purchase Agreement dated as of July 17, 2020, by and among the Company, RPI 2019 Intermediate Finance Trust (“RPI”), and, solely for the limited purposes set forth therein, Royalty Pharma PLC (the “Royalty Purchase Agreement”) (see Note 2), net proceeds from the Company’s’ borrowings under its credit agreement with Blackstone (see Note 9), private placements of its convertible preferred stock and common stock, collaborations, bank and institutional lender debt, other convertible debt, grant funding and clinical trial support from governmental and philanthropic organizations and patient advocacy groups in the disease area addressed by the Company’s product candidates. The Company has also relied on revenue generated from net sales of Translarna for the treatment of nmDMD in territories outside of the United States since 2014, Emflaza for the treatment of DMD in the United States since 2017, and Upstaza for the treatment of AADC deficiency in the EEA since May 2022. The Company has also relied on revenue associated with milestone and royalty payments from Roche pursuant to the License and Collaboration Agreement (the “SMA License Agreement”) dated as of November 23, 2011, by and among the Company, Roche and, for the limited purposes set forth therein, the SMA Foundation, under its SMA program. The Company expects that cash flows from the sales of its products, milestone and royalty payments from Roche, together with the Company’s cash, cash equivalents and marketable securities, will be sufficient to fund its operations for at least the next twelve months.</p> 2 -3127800000 0.0150 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">2.        Summary of significant accounting policies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company’s complete listing of significant accounting policies is set forth in Note 2 of the notes to the Company’s audited financial statements as of December 31, 2022 included in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC") on February 21, 2023 (the "2022 Form 10-K"). Selected significant accounting policies are discussed in further detail below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basis of presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The accompanying financial information as of September 30, 2023 and for the three and nine months ended September 30, 2023 and 2022 has been prepared by the Company, without audit, pursuant to the rules and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States ("GAAP") have been condensed or omitted pursuant to such rules and regulations. These interim financial statements should be read in conjunction with the Company’s audited financial statements as of December 31, 2022 and notes thereto included in the 2022 Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In the opinion of management, the unaudited financial information as of September 30, 2023 and for the three and nine months ended September 30, 2023 and 2022 reflects all adjustments, which are normal recurring adjustments, necessary to present a fair statement of financial position, results of operations, stockholders’ (deficit) equity, and cash flows. The results of operations for the three and nine months ended September 30, 2023 are not necessarily indicative of the results to be expected for the year ended December 31, 2023 or for any other interim period or for any other future year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates in these consolidated financial statements have been made in connection with the calculation of net product sales, royalty revenue, certain accruals related to the Company’s research and development expenses, valuation procedures for liability for sale of future royalties, valuation procedures for convertible notes, fair value of the contingent consideration, and the provision for or benefit from income taxes. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Restricted cash</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Restricted cash included in deposits and other assets on the consolidated balance sheet contains an unconditional, irrevocable and transferable letter of credit that was entered into during the twelve-month period ended December 31, 2019 in connection with obligations under a facility lease for the Company’s leased biologics manufacturing facility in Hopewell Township, New Jersey. The amount of the letter of credit is $7.5 million, is to be maintained for a term of not less than five years and has the potential to be reduced to $3.8 million if after five years the Company is not in default of its lease. Restricted cash also contains an unconditional, irrevocable and transferable letter of credit that was entered into during June 2022 in connection with obligations for the Company’s new facility lease in Warren, New Jersey. The amount of the letter of credit is $8.1 million and has the potential to be reduced to $4.1 million if after five years the Company is not in default of its lease. Both amounts are classified within deposits and other assets on the consolidated balance sheet due to the long-term nature of the respective letters of credit. Restricted cash also includes a bank guarantee of $0.6 million denominated in a foreign currency. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheet that sum to the total of the same amounts shown in the statement of cash flows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">End of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Beginning of</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">period-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">period-</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:71.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 165,157</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 279,834</p></td></tr><tr><td style="vertical-align:bottom;width:71.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Restricted cash included in deposits and other assets </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 16,253</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 16,091</p></td></tr><tr><td style="vertical-align:bottom;width:71.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total Cash, cash equivalents and restricted cash per statement of cash flows</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 181,410</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 295,925</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Marketable securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company’s marketable securities consists of both debt securities and equity investments. The Company considers its investments in debt securities with original maturities of greater than 90 days to be available for sale securities. Securities under this classification are recorded at fair value and unrealized gains and losses within accumulated other comprehensive income. The estimated fair value of the available for sale securities is determined based on quoted market prices or rates for similar instruments. In addition, the cost of debt securities in this category is adjusted for amortization of premium and accretion of discount to maturity. For available for sale debt securities in an unrealized loss position, the Company assesses whether it intends to sell or if it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security’s amortized cost basis is written down to fair value. If the criteria are not met, the Company evaluates whether the decline in fair value has resulted from a credit loss or other factors. In making this assessment, management considers, among other factors, the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and adverse conditions specifically related to the security. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security are compared to the amortized cost basis of the security. If the present value of the cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded for the credit loss, limited by the amount that the fair value is less than the amortized costs basis. Any impairment that has not been recorded through an allowance for credit losses is recognized in other comprehensive income. For the three and nine months ended September 30, 2023 and 2022, no allowance was recorded for credit losses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Marketable securities that are equity investments are measured at fair value, as it is readily available, and as such are classified as Level 1 assets. Unrealized holding gains and losses for these equity investments are components of other (expense) income, net within the consolidated statement of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Inventory and cost of product sales</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Inventory</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Inventories are stated at the lower of cost and net realizable value with cost determined on a first-in, first-out basis by product. The Company capitalizes inventory costs associated with products following regulatory approval when future commercialization is considered probable and the future economic benefit is expected to be realized. Products which may be used in clinical development programs are included in inventory and charged to research and development expense when the product enters the research and development process and no longer can be used for commercial purposes. Inventory used for marketing efforts are charged to selling, general and administrative expense. Amounts related to clinical development programs and marketing efforts are immaterial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table summarizes the components of the Company’s inventory for the periods indicated:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 907</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,078</p></td></tr><tr><td style="vertical-align:bottom;width:68.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Work in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 24,595</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 14,074</p></td></tr><tr><td style="vertical-align:bottom;width:68.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 10,250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6,656</p></td></tr></table><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:68.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 35,752</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 21,808</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company periodically reviews its inventories for excess amounts or obsolescence and writes down obsolete or otherwise unmarketable inventory to its estimated net realizable value. For the three months ended September 30, 2023, the Company’s inventory write-downs were immaterial. For the nine months ended September 30, 2023, the Company recorded inventory write-downs of $0.4 million primarily related to product approaching expiration. For the three and nine months ended September 30, 2022, the Company recorded inventory write-downs of $0.3 million and $1.2 million, respectively, primarily related to product approaching expiration. Additionally, though the Company’s product is subject to strict quality control and monitoring which it performs throughout the manufacturing processes, certain batches or units of product may not meet quality specifications resulting in a charge to cost of product sales. For the three and nine months ended September 30, 2023 and 2022, these amounts were immaterial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Cost of product sales</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Cost of product sales consists of the cost of inventory sold, manufacturing and supply chain costs, storage costs, amortization of the acquired intangible asset, royalty payments associated with net product sales, and royalty payments to collaborative partners associated with royalty revenues and collaboration revenue related to milestones. Production costs are expensed as cost of product sales when the related products are sold or royalty revenues and collaboration revenue milestones are earned.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Revenue recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Net product revenue</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company’s net product revenue primarily consists of sales of Translarna in territories outside of the U.S. for the treatment of nmDMD and sales of Emflaza in the U.S. for the treatment of DMD. The Company recognizes revenue when its performance obligations with its customers have been satisfied. The Company’s performance obligations are to provide products based on customer orders from distributors, hospitals, specialty pharmacies or retail pharmacies. The performance obligations are satisfied at a point in time when the Company’s customer obtains control of the product, which is typically upon delivery. The Company invoices its customers after the products have been delivered and invoice payments are generally due within 30 to 90 days of the invoice date. The Company determines the transaction price based on fixed consideration in its contractual agreements. Contract liabilities arise in certain circumstances when consideration is due for goods the Company has yet to provide. As the Company has identified only one distinct performance obligation, the transaction price is allocated entirely to product sales. In determining the transaction price, a significant financing component does not exist since the timing from when the Company delivers product to when the customers pay for the product is typically less than one year. Customers in certain countries pay in advance of product delivery. In those instances, payment and delivery typically occur in the same month.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company records product sales net of any variable consideration, which includes discounts, allowances, rebates related to Medicaid and other government pricing programs, and distribution fees. The Company uses the expected value or most likely amount method when estimating its variable consideration, unless discount or rebate terms are specified within contracts. The identified variable consideration is recorded as a reduction of revenue at the time revenues from product sales are recognized. These estimates for variable consideration are adjusted to reflect known changes in factors and may impact such estimates in the quarter those changes are known. Revenue recognized does not include amounts of variable consideration that are constrained. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">For the three months ended September 30, 2023 and 2022, net product sales outside of the United States were $76.6 million and $79.4 million, respectively, consisting of sales of Translarna, Tegsedi, Waylivra, and Upstaza. Translarna net revenues made up $69.0 million and $76.6 million of the net product sales outside of the United States for the three months ended September 30, 2023 and 2022, respectively. For the three months ended September 30, 2023 and 2022, net product sales in the United States were $67.4 million and $54.8 million, respectively, consisting solely of sales of Emflaza. During the three months ended September 30, 2023, one country, the United States, accounted for at least 10% of the Company’s net product sales, representing $67.4 million of net product sales. During the three months ended September 30, 2022, two </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">countries, the United States and Russia, accounted for at least 10% of the Company’s net product sales, representing $54.8 million and $28.3 million of net product sales, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For the nine months ended September 30, 2023 and 2022, net product sales outside of the United States were $318.5 million and $247.6 million, respectively, consisting of Translarna, Tegsedi, Waylivra, and Upstaza. Translarna net revenues made up $280.6 million and $232.9 million of the net product sales outside of the United States for the nine months ended September 30, 2023 and 2022, respectively. For the nine months ended September 30, 2023 and 2022, net product sales in the United States were $187.7 million and $160.1 million, respectively, consisting solely of Emflaza. During the nine months ended September 30, 2023, three countries, the United States, Russia, and Brazil, accounted for at least 10% of the Company’s net product sales, representing $187.7 million, $69.0 million, and $52.5 million of net product sales, respectively. During the nine months ended September 30, 2022, two countries, the United States and Russia,  accounted for at least 10% of the Company’s net product sales, representing $160.1 million and $57.1 million of net product sales, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In relation to customer contracts, the Company incurs costs to fulfill a contract but does not incur costs to obtain a contract. These costs to fulfill a contract do not meet the criteria for capitalization and are expensed as incurred. The Company considers any shipping and handling costs that are incurred after the customer has obtained control of the product as a cost to fulfill a promise. Shipping and handling costs associated with finished goods delivered to customers are recorded as a selling expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Collaboration and royalty revenue</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The terms of these agreements typically include payments to the Company of one or more of the following: nonrefundable, upfront license fees; milestone payments; research funding and royalties on future product sales. In addition, the Company generates service revenue through agreements that generally provide for fees for research and development services and may include additional payments upon achievement of specified events.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">At the inception of a collaboration arrangement, the Company needs to first evaluate if the arrangement meets the criteria in Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 808 “Collaborative Arrangements” to then determine if ASC Topic 606 is applicable by considering whether the collaborator meets the definition of a customer. If the criteria are met, the Company assesses the promises in the arrangement to identify distinct performance obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For licenses of intellectual property, the Company assesses, at contract inception, whether the intellectual property is distinct from other performance obligations identified in the arrangement. If the licensing of intellectual property is determined to be distinct, revenue is recognized for nonrefundable, upfront license fees when the license is transferred to the customer and the customer can use and benefit from the license. If the licensing of intellectual property is determined not to be distinct, then the license will be bundled with other promises in the arrangement into one distinct performance obligation. The Company needs to determine if the bundled performance obligation is satisfied over time or at a point in time. If the Company concludes that the nonrefundable, upfront license fees will be recognized over time, the Company will need to assess the appropriate method of measuring proportional performance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For milestone payments, the Company assesses, at contract inception, whether the development or sales-based milestones are considered probable of being achieved. If it is probable that a significant revenue reversal will occur, the Company will not record revenue until the uncertainty has been resolved. Milestone payments that are contingent upon regulatory approval are not considered probable of being achieved until the applicable regulatory approvals or other external conditions are obtained as such conditions are not within the Company’s control. If it is probable that a significant revenue reversal will not occur, the Company will estimate the milestone payments using the most likely amount method. The Company will re-assess the development and sales-based milestones each reporting period to determine the probability of achievement. The Company recognizes royalties from product sales at the later of when the related sales occur or when the performance obligation to which the royalty has been allocated has been satisfied. If it is probable that a significant revenue reversal will not occur, the Company will estimate the royalty payments using the most likely amount method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company recognizes revenue for reimbursements of research and development costs under collaboration agreements as the services are performed. The Company records these reimbursements as revenue and not as a reduction of research and development expenses as the Company has the risks and rewards as the principal in the research and development activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">For the three months ended September 30, 2023, the Company did not recognize collaboration revenue related to the SMA License Agreement with Roche. For the three months ended September 30, 2022, the Company recognized $50.0 million of collaboration revenue related to the SMA License Agreement. For the nine months ended September 30, 2023, <span style="background:#ffffff;">the amounts recognized for the collaboration revenue related to the SMA License Agreement with Roche were immaterial. </span>For the nine months ended September 30, 2022, the Company recognized $50.0 million of collaboration revenue related to the SMA License Agreement with Roche. In September 2022, the Company recognized a sales milestone of $50.0 million for the achievement of $750.0 million in worldwide annual net sales from Evrysdi.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">For the three and nine months ended September 30, 2023, the Company has recognized $50.2 million and $117.9 million of royalty revenue, respectively, related to Evrysdi. For the three and nine months ended September 30, 2022, the Company has recognized $32.9 million and $73.6 million of royalty revenue, respectively, related to Evrysdi.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Manufacturing Revenue</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company has manufacturing services related to the production of plasmid deoxyribonucleic acid (“DNA”) and adeno-associated virus (“AAV”) vectors for gene therapy applications for external customers. Performance obligations vary but may include manufacturing plasmid DNA and/or AAV vectors, material testing, stability studies, and other services related to material development. The transaction prices for these arrangements are fixed and include amounts stated in the contracts for each promised service. Typically, the performance obligations within a manufacturing contract are highly interdependent, in which case, the Company will combine them into a single performance obligation. The Company has determined that the assets created have no alternative use to the Company, and the Company has an enforceable right to payment for the performance completed to date, therefore revenue related to these services are recognized over time and is measured using an output method based on performance of manufacturing milestones completed to date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Manufacturing service contracts may also include performance obligations related to project management services or obtaining materials from third parties. The Company has determined that these are separate performance obligations for which revenue is recognized at the point in time the services are performed. For performance obligations related to obtaining third party materials, the Company has determined that it is the principal as the Company has control of the materials and has discretion in setting the price. Therefore, the Company recognizes revenue on a gross basis related to obtaining third party materials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Certain arrangements require a portion of the contract consideration to be received in advance at the commencement of the contract, and such advance payment is initially recorded as a contract liability. A contract asset may be recognized in the event the Company’s satisfaction of performance obligations outpaces customer billings. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">For the three and nine months ended September 30, 2023, the Company recognized $2.4 million and $6.7 million of manufacturing revenue, respectively, related to plasmid DNA and AAV vector production for external customers. No manufacturing revenue was recognized for the three and nine months ended September 30, 2022. As of September 30, 2023, the Company has contract assets of $1.4 million and remaining performance obligations of $1.2 million related to the production of plasmid DNA and AAV vectors for gene therapy applications for external customers. For the period ended December 31, 2022, the Company had remaining performance obligations of $1.4 million and no contracts assets related to plasmid DNA and AAV production for external customers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Allowance for doubtful accounts</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company maintains an allowance for estimated losses resulting from the inability of its customers to make required payments. The Company estimates uncollectible amounts based upon current customer receivable balances, the age of customer receivable balances, the customer’s financial condition and current economic trends. The Company also assesses whether an allowance for expected credit losses may be required which includes a review of the Company’s receivables </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">portfolio, which are pooled on a customer basis or country basis.  In making its assessment of whether an allowance for credit losses is required, the Company considers its historical experience with customers, current balances, levels of delinquency, regulatory and legal environments, and other relevant current and future forecasted economic conditions. For the three and nine months ended September 30, 2023 and 2022, no allowance was recorded for credit losses. The allowance for doubtful accounts was $1.0 million as of September 30, 2023 and $0.3 million as of December 31, 2022. For the three and nine months ended September 30, 2023, bad debt expense was $0.4 million and $0.7 million, respectively. For the three and nine months ended September 30, 2022, bad debt expense was immaterial. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Liability for sale of future royalties </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;">On July 17, 2020, the Company, RPI, and, for the limited purposes set forth in the agreement, Royalty Pharma PLC, entered into the Royalty Purchase Agreement. Pursuant to the Royalty Purchase Agreement, the Company sold to RPI </span><span style="font-style:normal;">42.933%</span><span style="font-style:normal;"> (the “Assigned Royalty Rights”) of the Company’s right to receive sales-based royalty payments (the “Royalty”) on worldwide net sales of Evrysdi and any other product developed pursuant to the SMA License Agreement. In consideration for the sale of the Assigned Royalty Rights, RPI paid the Company </span><span style="font-style:normal;">$650.0</span><span style="font-style:normal;"> million in cash consideration. The Company has retained a </span><span style="font-style:normal;">57.067%</span><span style="font-style:normal;"> interest in the Royalty and all economic rights to receive the remaining potential regulatory and sales milestone payments under the SMA License Agreement, which remaining milestone payments equal </span><span style="font-style:normal;">$250.0</span><span style="font-style:normal;"> million in the aggregate as of September 30, 2023. The Royalty Purchase Agreement will terminate </span><span style="font-style:normal;">60 days</span><span style="font-style:normal;"> following the earlier of the date on which Roche is no longer obligated to make any payments of the Royalty pursuant to the SMA License Agreement and the date on which RPI has received </span><span style="font-style:normal;">$1.3</span><span style="font-style:normal;"> billion in respect of the Assigned Royalty Rights. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The cash consideration obtained pursuant to the Royalty Purchase Agreement is classified as debt and is recorded as “liability for sale of future royalties-current” and “liability for sale of future royalties-noncurrent” on the Company’s consolidated balance sheet based on the timing of the expected payments to be made to RPI. The fair value for the liability for sale of future royalties at the time of the transaction was based on the Company’s estimates of future royalties expected to be paid to RPI over the life of the arrangement, which was determined using forecasts from market data sources, which are considered Level 3 inputs. The liability is being amortized using the effective interest method over the life of the arrangement, in accordance with the respective guidance. The Company utilizes the prospective method to account for subsequent changes in the estimated future payments to be made to RPI.  Refer to Note 9 for further details.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Indefinite-lived intangible assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Indefinite-lived intangible assets consist of in process research and development ("IPR&amp;D"). IPR&amp;D acquired directly in a transaction other than a business combination is capitalized if the projects will be further developed or have an alternative future use; otherwise they are expensed. The fair values of IPR&amp;D projects and license agreement assets acquired in business combinations are capitalized. Several methods may be used to determine the estimated fair value of the IPR&amp;D and license agreement asset acquired in a business combination. The Company utilizes the "income method" and uses estimated future net cash flows that are derived from projected sales revenues and estimated costs. These projections are based on factors such as relevant market size, patent protection, and expected pricing and industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. These assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are amortized over the remaining useful life or written off, as appropriate. Intangible assets with indefinite lives, including IPR&amp;D, are tested for impairment if impairment indicators arise and, at a minimum, annually. However, an entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that an indefinite-lived intangible asset’s fair value is less than its carrying amount. Otherwise, no further impairment testing is required. The indefinite-lived intangible asset impairment test consists of a one-step analysis that compares the fair value of the intangible asset with its carrying amount. If the carrying amount of an intangible asset exceeds its fair value, an impairment loss is recognized in an amount equal to that excess. The Company considers many factors in evaluating whether the value of its intangible assets with indefinite lives may not be recoverable, including, but not limited to, expected growth rates, the cost of equity and debt capital, general economic conditions, the Company’s outlook and market performance of the Company’s industry and recent and forecasted financial performance. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In May 2023, as part of the Company’s strategic portfolio prioritization, the Company decided to discontinue its preclinical and early research programs in its gene therapy platform, which included Friedreich ataxia and Angelman syndrome. As a result, the Company determined that the Friedreich ataxia and Angelman syndrome indefinite lived intangible assets were fully impaired and recorded impairment expense of $217.8 million during the nine months ended September 30, 2023, which is recorded as intangible asset impairment in the statement of operations. Refer to Note 12 for further information regarding the Company’s intangible assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Goodwill</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Goodwill represents the amount of consideration paid in excess of the fair value of net assets acquired as a result of the Company’s business acquisitions accounted for using the acquisition method of accounting. Goodwill is not amortized and is subject to impairment testing at a reporting unit level on an annual basis or when a triggering event occurs that may indicate the carrying value of the goodwill is impaired. The Company reassesses its reporting units as part of its annual segment review. An entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that the fair value of the reporting unit is less than its carrying amount. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Organization for Economic Co-operation and Development (“OECD”), the European Community (“the EC”), and individual taxing jurisdictions where the Company and its affiliates do business have recently focused on issues related to the taxation of multinational corporations. The OECD has released its comprehensive plan to create an agreed set of international rules for fighting base erosion and profit shifting. In addition, the OECD, the EC and individual taxing jurisdictions are examining changes to how taxing rights should be allocated among countries considering the digital economy. As a result, the tax laws in the U.S. and other countries in which the Company and its affiliates do business could change on a prospective or retroactive basis and any such changes could materially adversely affect the Company’s business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On December 22, 2017, the U.S. government enacted the 2017 Tax Act, which significantly revised U.S. tax law by, among other provisions, lowering the U.S. federal statutory corporate income tax rate to 21%, imposing a mandatory one-time transition tax on previously deferred foreign earnings, and eliminating or reducing certain income tax deductions. The Global Intangible Low-Taxed Income ("GILTI") provisions of the 2017 Tax Act require the Company to include in its U.S. income tax return foreign subsidiary earnings in excess of an allowable return on the foreign subsidiary’s tangible assets. The Company has elected to account for GILTI tax in the period in which it is incurred, and therefore has not provided any deferred tax impacts of GILTI in its consolidated financial statements for the period ended September 30, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Starting in 2022, TCJA amendments to IRC Section 174 no longer permits an immediate deduction for research and development (R&amp;D) expenditures in the tax year that such costs are incurred. Instead, these IRC Section 174 development costs must now be capitalized and amortized over either a five- or 15-year period, depending on the location of the activities performed. The new amortization period begins with the midpoint of any taxable year that IRC Section 174 costs are first incurred, regardless of whether the expenditures were made prior to or after July 1, and runs until the midpoint of year five for activities conducted in the United States or year 15 in the case of development conducted on foreign soil. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and net operating loss and credit carryforwards. Deferred tax assets and liabilities are measured at rates expected to apply to taxable income in the years in which those temporary differences and carryforwards are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the statement of operations in the period that includes the enactment date. A valuation allowance is recorded when it is not more likely than not that all or a portion of the net deferred tax assets will be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On August 23, 2018, the Company completed its acquisition of Agilis Biotherapeutics, Inc. (“Agilis”), pursuant to an Agreement and Plan of Merger, dated as of July 19, 2018 (the “Agilis Merger Agreement”), by and among the Company, </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Agility Merger Sub, Inc., a Delaware corporation and the Company’s wholly owned, indirect subsidiary, Agilis and, solely in its capacity as the representative, agent and attorney-in-fact of the equityholders of Agilis, Shareholder Representative Services LLC, (the “Agilis Merger”). The Company recorded a deferred tax liability in conjunction with the Agilis Merger of $122.0 million in 2018, related to the tax basis difference in the IPRD indefinite-lived intangibles acquired. The Company’s policy is to record a deferred tax liability related to acquired IPR&amp;D which may eventually be realized either upon amortization of the asset when the research is completed, and a product is successfully launched or the write-off of the asset if it is abandoned or unsuccessful. In July 2022, the Company received EMEA approval for a portion of the IPR&amp;D assets, and thus, began the amortization of the intangible. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In May 2023, the Company announced the discontinuation of its preclinical and early research programs in gene therapy as part of a strategic portfolio prioritization. In conjunction with the announcement, the Company recorded an impairment to its indefinite-lived intangible for IP research and development relating to the Friedreich ataxia and Angelman syndrome gene therapy assets. As a result of the impairment, the Company recorded a deferred tax benefit of $50.9 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company determines if an arrangement is a lease at inception. This determination generally depends on whether the arrangement conveys to the Company the right to control the use of an explicitly or implicitly identified fixed asset for a period of time in exchange for consideration. Control of an underlying asset is conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using the underlying asset. The Company has lease agreements which include lease and non-lease components, which the Company accounts for as a single lease component for all leases. Operating and finance leases are classified as right of use ("ROU") assets, short term lease liabilities, and long term lease liabilities. Operating and finance lease ROU assets and lease liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. ROU assets are amortized and lease liabilities accrete to yield straight-line expense over the term of the lease. Lease payments included in the measurement of the lease liability are comprised of fixed payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Variable lease payments associated with the Company’s leases are recognized when the event, activity, or circumstance in the lease agreement on which those payments are assessed occurs. Variable lease payments are presented in the Company’s consolidated statements of operations in the same line item as expense arising from fixed lease payments for operating leases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheet and the Company recognizes lease expense for these leases on a straight-line basis over the lease term. The Company applies this policy to all underlying asset categories.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A lessee is required to discount its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental borrowing rate. As most of the Company’s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The Company gives consideration to its recent debt issuances as well as publicly available data for instruments with similar characteristics when calculating its incremental borrowing rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The lease term for all of the Company’s leases includes the non-cancellable period of the lease plus any additional periods covered by either a Company option to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor. Leasehold improvements are capitalized and depreciated over the lesser of useful life or lease term. See Note 3 Leases for additional information.  </p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Basis of presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The accompanying financial information as of September 30, 2023 and for the three and nine months ended September 30, 2023 and 2022 has been prepared by the Company, without audit, pursuant to the rules and regulations of the SEC. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States ("GAAP") have been condensed or omitted pursuant to such rules and regulations. These interim financial statements should be read in conjunction with the Company’s audited financial statements as of December 31, 2022 and notes thereto included in the 2022 Form 10-K.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In the opinion of management, the unaudited financial information as of September 30, 2023 and for the three and nine months ended September 30, 2023 and 2022 reflects all adjustments, which are normal recurring adjustments, necessary to present a fair statement of financial position, results of operations, stockholders’ (deficit) equity, and cash flows. The results of operations for the three and nine months ended September 30, 2023 are not necessarily indicative of the results to be expected for the year ended December 31, 2023 or for any other interim period or for any other future year.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates in these consolidated financial statements have been made in connection with the calculation of net product sales, royalty revenue, certain accruals related to the Company’s research and development expenses, valuation procedures for liability for sale of future royalties, valuation procedures for convertible notes, fair value of the contingent consideration, and the provision for or benefit from income taxes. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Restricted cash</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Restricted cash included in deposits and other assets on the consolidated balance sheet contains an unconditional, irrevocable and transferable letter of credit that was entered into during the twelve-month period ended December 31, 2019 in connection with obligations under a facility lease for the Company’s leased biologics manufacturing facility in Hopewell Township, New Jersey. The amount of the letter of credit is $7.5 million, is to be maintained for a term of not less than five years and has the potential to be reduced to $3.8 million if after five years the Company is not in default of its lease. Restricted cash also contains an unconditional, irrevocable and transferable letter of credit that was entered into during June 2022 in connection with obligations for the Company’s new facility lease in Warren, New Jersey. The amount of the letter of credit is $8.1 million and has the potential to be reduced to $4.1 million if after five years the Company is not in default of its lease. Both amounts are classified within deposits and other assets on the consolidated balance sheet due to the long-term nature of the respective letters of credit. Restricted cash also includes a bank guarantee of $0.6 million denominated in a foreign currency. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheet that sum to the total of the same amounts shown in the statement of cash flows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">End of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Beginning of</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">period-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">period-</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:71.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 165,157</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 279,834</p></td></tr><tr><td style="vertical-align:bottom;width:71.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Restricted cash included in deposits and other assets </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 16,253</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 16,091</p></td></tr><tr><td style="vertical-align:bottom;width:71.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total Cash, cash equivalents and restricted cash per statement of cash flows</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 181,410</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 295,925</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p> 7500000 P5Y 3800000 P5Y 8100000 4100000 P5Y 600000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">End of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Beginning of</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">period-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">period-</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:71.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.6%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 165,157</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 279,834</p></td></tr><tr><td style="vertical-align:bottom;width:71.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Restricted cash included in deposits and other assets </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 16,253</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 16,091</p></td></tr><tr><td style="vertical-align:bottom;width:71.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total Cash, cash equivalents and restricted cash per statement of cash flows</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 181,410</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 295,925</p></td></tr></table> 165157000 279834000 16253000 16091000 181410000 295925000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Marketable securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company’s marketable securities consists of both debt securities and equity investments. The Company considers its investments in debt securities with original maturities of greater than 90 days to be available for sale securities. Securities under this classification are recorded at fair value and unrealized gains and losses within accumulated other comprehensive income. The estimated fair value of the available for sale securities is determined based on quoted market prices or rates for similar instruments. In addition, the cost of debt securities in this category is adjusted for amortization of premium and accretion of discount to maturity. For available for sale debt securities in an unrealized loss position, the Company assesses whether it intends to sell or if it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security’s amortized cost basis is written down to fair value. If the criteria are not met, the Company evaluates whether the decline in fair value has resulted from a credit loss or other factors. In making this assessment, management considers, among other factors, the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and adverse conditions specifically related to the security. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security are compared to the amortized cost basis of the security. If the present value of the cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded for the credit loss, limited by the amount that the fair value is less than the amortized costs basis. Any impairment that has not been recorded through an allowance for credit losses is recognized in other comprehensive income. For the three and nine months ended September 30, 2023 and 2022, no allowance was recorded for credit losses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Marketable securities that are equity investments are measured at fair value, as it is readily available, and as such are classified as Level 1 assets. Unrealized holding gains and losses for these equity investments are components of other (expense) income, net within the consolidated statement of operations.</p> 0 0 0 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Inventory and cost of product sales</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Inventory</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Inventories are stated at the lower of cost and net realizable value with cost determined on a first-in, first-out basis by product. The Company capitalizes inventory costs associated with products following regulatory approval when future commercialization is considered probable and the future economic benefit is expected to be realized. Products which may be used in clinical development programs are included in inventory and charged to research and development expense when the product enters the research and development process and no longer can be used for commercial purposes. Inventory used for marketing efforts are charged to selling, general and administrative expense. Amounts related to clinical development programs and marketing efforts are immaterial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table summarizes the components of the Company’s inventory for the periods indicated:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 907</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,078</p></td></tr><tr><td style="vertical-align:bottom;width:68.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Work in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 24,595</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 14,074</p></td></tr><tr><td style="vertical-align:bottom;width:68.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 10,250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6,656</p></td></tr></table><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:68.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 35,752</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 21,808</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company periodically reviews its inventories for excess amounts or obsolescence and writes down obsolete or otherwise unmarketable inventory to its estimated net realizable value. For the three months ended September 30, 2023, the Company’s inventory write-downs were immaterial. For the nine months ended September 30, 2023, the Company recorded inventory write-downs of $0.4 million primarily related to product approaching expiration. For the three and nine months ended September 30, 2022, the Company recorded inventory write-downs of $0.3 million and $1.2 million, respectively, primarily related to product approaching expiration. Additionally, though the Company’s product is subject to strict quality control and monitoring which it performs throughout the manufacturing processes, certain batches or units of product may not meet quality specifications resulting in a charge to cost of product sales. For the three and nine months ended September 30, 2023 and 2022, these amounts were immaterial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Cost of product sales</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Cost of product sales consists of the cost of inventory sold, manufacturing and supply chain costs, storage costs, amortization of the acquired intangible asset, royalty payments associated with net product sales, and royalty payments to collaborative partners associated with royalty revenues and collaboration revenue related to milestones. Production costs are expensed as cost of product sales when the related products are sold or royalty revenues and collaboration revenue milestones are earned.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Raw materials</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 907</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,078</p></td></tr><tr><td style="vertical-align:bottom;width:68.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Work in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 24,595</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 14,074</p></td></tr><tr><td style="vertical-align:bottom;width:68.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Finished goods</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 10,250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 6,656</p></td></tr></table><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:68.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 35,752</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 21,808</p></td></tr></table> 907000 1078000 24595000 14074000 10250000 6656000 35752000 21808000 400000 300000 1200000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Revenue recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Net product revenue</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company’s net product revenue primarily consists of sales of Translarna in territories outside of the U.S. for the treatment of nmDMD and sales of Emflaza in the U.S. for the treatment of DMD. The Company recognizes revenue when its performance obligations with its customers have been satisfied. The Company’s performance obligations are to provide products based on customer orders from distributors, hospitals, specialty pharmacies or retail pharmacies. The performance obligations are satisfied at a point in time when the Company’s customer obtains control of the product, which is typically upon delivery. The Company invoices its customers after the products have been delivered and invoice payments are generally due within 30 to 90 days of the invoice date. The Company determines the transaction price based on fixed consideration in its contractual agreements. Contract liabilities arise in certain circumstances when consideration is due for goods the Company has yet to provide. As the Company has identified only one distinct performance obligation, the transaction price is allocated entirely to product sales. In determining the transaction price, a significant financing component does not exist since the timing from when the Company delivers product to when the customers pay for the product is typically less than one year. Customers in certain countries pay in advance of product delivery. In those instances, payment and delivery typically occur in the same month.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company records product sales net of any variable consideration, which includes discounts, allowances, rebates related to Medicaid and other government pricing programs, and distribution fees. The Company uses the expected value or most likely amount method when estimating its variable consideration, unless discount or rebate terms are specified within contracts. The identified variable consideration is recorded as a reduction of revenue at the time revenues from product sales are recognized. These estimates for variable consideration are adjusted to reflect known changes in factors and may impact such estimates in the quarter those changes are known. Revenue recognized does not include amounts of variable consideration that are constrained. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">For the three months ended September 30, 2023 and 2022, net product sales outside of the United States were $76.6 million and $79.4 million, respectively, consisting of sales of Translarna, Tegsedi, Waylivra, and Upstaza. Translarna net revenues made up $69.0 million and $76.6 million of the net product sales outside of the United States for the three months ended September 30, 2023 and 2022, respectively. For the three months ended September 30, 2023 and 2022, net product sales in the United States were $67.4 million and $54.8 million, respectively, consisting solely of sales of Emflaza. During the three months ended September 30, 2023, one country, the United States, accounted for at least 10% of the Company’s net product sales, representing $67.4 million of net product sales. During the three months ended September 30, 2022, two </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">countries, the United States and Russia, accounted for at least 10% of the Company’s net product sales, representing $54.8 million and $28.3 million of net product sales, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For the nine months ended September 30, 2023 and 2022, net product sales outside of the United States were $318.5 million and $247.6 million, respectively, consisting of Translarna, Tegsedi, Waylivra, and Upstaza. Translarna net revenues made up $280.6 million and $232.9 million of the net product sales outside of the United States for the nine months ended September 30, 2023 and 2022, respectively. For the nine months ended September 30, 2023 and 2022, net product sales in the United States were $187.7 million and $160.1 million, respectively, consisting solely of Emflaza. During the nine months ended September 30, 2023, three countries, the United States, Russia, and Brazil, accounted for at least 10% of the Company’s net product sales, representing $187.7 million, $69.0 million, and $52.5 million of net product sales, respectively. During the nine months ended September 30, 2022, two countries, the United States and Russia,  accounted for at least 10% of the Company’s net product sales, representing $160.1 million and $57.1 million of net product sales, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In relation to customer contracts, the Company incurs costs to fulfill a contract but does not incur costs to obtain a contract. These costs to fulfill a contract do not meet the criteria for capitalization and are expensed as incurred. The Company considers any shipping and handling costs that are incurred after the customer has obtained control of the product as a cost to fulfill a promise. Shipping and handling costs associated with finished goods delivered to customers are recorded as a selling expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Collaboration and royalty revenue</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The terms of these agreements typically include payments to the Company of one or more of the following: nonrefundable, upfront license fees; milestone payments; research funding and royalties on future product sales. In addition, the Company generates service revenue through agreements that generally provide for fees for research and development services and may include additional payments upon achievement of specified events.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">At the inception of a collaboration arrangement, the Company needs to first evaluate if the arrangement meets the criteria in Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 808 “Collaborative Arrangements” to then determine if ASC Topic 606 is applicable by considering whether the collaborator meets the definition of a customer. If the criteria are met, the Company assesses the promises in the arrangement to identify distinct performance obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For licenses of intellectual property, the Company assesses, at contract inception, whether the intellectual property is distinct from other performance obligations identified in the arrangement. If the licensing of intellectual property is determined to be distinct, revenue is recognized for nonrefundable, upfront license fees when the license is transferred to the customer and the customer can use and benefit from the license. If the licensing of intellectual property is determined not to be distinct, then the license will be bundled with other promises in the arrangement into one distinct performance obligation. The Company needs to determine if the bundled performance obligation is satisfied over time or at a point in time. If the Company concludes that the nonrefundable, upfront license fees will be recognized over time, the Company will need to assess the appropriate method of measuring proportional performance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For milestone payments, the Company assesses, at contract inception, whether the development or sales-based milestones are considered probable of being achieved. If it is probable that a significant revenue reversal will occur, the Company will not record revenue until the uncertainty has been resolved. Milestone payments that are contingent upon regulatory approval are not considered probable of being achieved until the applicable regulatory approvals or other external conditions are obtained as such conditions are not within the Company’s control. If it is probable that a significant revenue reversal will not occur, the Company will estimate the milestone payments using the most likely amount method. The Company will re-assess the development and sales-based milestones each reporting period to determine the probability of achievement. The Company recognizes royalties from product sales at the later of when the related sales occur or when the performance obligation to which the royalty has been allocated has been satisfied. If it is probable that a significant revenue reversal will not occur, the Company will estimate the royalty payments using the most likely amount method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company recognizes revenue for reimbursements of research and development costs under collaboration agreements as the services are performed. The Company records these reimbursements as revenue and not as a reduction of research and development expenses as the Company has the risks and rewards as the principal in the research and development activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">For the three months ended September 30, 2023, the Company did not recognize collaboration revenue related to the SMA License Agreement with Roche. For the three months ended September 30, 2022, the Company recognized $50.0 million of collaboration revenue related to the SMA License Agreement. For the nine months ended September 30, 2023, <span style="background:#ffffff;">the amounts recognized for the collaboration revenue related to the SMA License Agreement with Roche were immaterial. </span>For the nine months ended September 30, 2022, the Company recognized $50.0 million of collaboration revenue related to the SMA License Agreement with Roche. In September 2022, the Company recognized a sales milestone of $50.0 million for the achievement of $750.0 million in worldwide annual net sales from Evrysdi.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">For the three and nine months ended September 30, 2023, the Company has recognized $50.2 million and $117.9 million of royalty revenue, respectively, related to Evrysdi. For the three and nine months ended September 30, 2022, the Company has recognized $32.9 million and $73.6 million of royalty revenue, respectively, related to Evrysdi.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Manufacturing Revenue</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-style:italic;margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company has manufacturing services related to the production of plasmid deoxyribonucleic acid (“DNA”) and adeno-associated virus (“AAV”) vectors for gene therapy applications for external customers. Performance obligations vary but may include manufacturing plasmid DNA and/or AAV vectors, material testing, stability studies, and other services related to material development. The transaction prices for these arrangements are fixed and include amounts stated in the contracts for each promised service. Typically, the performance obligations within a manufacturing contract are highly interdependent, in which case, the Company will combine them into a single performance obligation. The Company has determined that the assets created have no alternative use to the Company, and the Company has an enforceable right to payment for the performance completed to date, therefore revenue related to these services are recognized over time and is measured using an output method based on performance of manufacturing milestones completed to date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Manufacturing service contracts may also include performance obligations related to project management services or obtaining materials from third parties. The Company has determined that these are separate performance obligations for which revenue is recognized at the point in time the services are performed. For performance obligations related to obtaining third party materials, the Company has determined that it is the principal as the Company has control of the materials and has discretion in setting the price. Therefore, the Company recognizes revenue on a gross basis related to obtaining third party materials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Certain arrangements require a portion of the contract consideration to be received in advance at the commencement of the contract, and such advance payment is initially recorded as a contract liability. A contract asset may be recognized in the event the Company’s satisfaction of performance obligations outpaces customer billings. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">For the three and nine months ended September 30, 2023, the Company recognized $2.4 million and $6.7 million of manufacturing revenue, respectively, related to plasmid DNA and AAV vector production for external customers. No manufacturing revenue was recognized for the three and nine months ended September 30, 2022. As of September 30, 2023, the Company has contract assets of $1.4 million and remaining performance obligations of $1.2 million related to the production of plasmid DNA and AAV vectors for gene therapy applications for external customers. For the period ended December 31, 2022, the Company had remaining performance obligations of $1.4 million and no contracts assets related to plasmid DNA and AAV production for external customers.</p> 76600000 79400000 69000000.0 76600000 67400000 54800000 1 0.10 67400000 2 0.10 54800000 28300000 318500000 247600000 280600000 232900000 187700000 160100000 3 0.10 187700000 69000000.0 52500000 2 0.10 160100000 57100000 0 50000000.0 50000000.0 50000000.0 750000000.0 50200000 117900000 32900000 73600000 2400000 6700000 0 0 1400000 1200000 1400000 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Allowance for doubtful accounts</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company maintains an allowance for estimated losses resulting from the inability of its customers to make required payments. The Company estimates uncollectible amounts based upon current customer receivable balances, the age of customer receivable balances, the customer’s financial condition and current economic trends. The Company also assesses whether an allowance for expected credit losses may be required which includes a review of the Company’s receivables </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">portfolio, which are pooled on a customer basis or country basis.  In making its assessment of whether an allowance for credit losses is required, the Company considers its historical experience with customers, current balances, levels of delinquency, regulatory and legal environments, and other relevant current and future forecasted economic conditions. For the three and nine months ended September 30, 2023 and 2022, no allowance was recorded for credit losses. The allowance for doubtful accounts was $1.0 million as of September 30, 2023 and $0.3 million as of December 31, 2022. For the three and nine months ended September 30, 2023, bad debt expense was $0.4 million and $0.7 million, respectively. For the three and nine months ended September 30, 2022, bad debt expense was immaterial. </p> 0 0 0 0 1000000.0 300000 400000 700000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Liability for sale of future royalties </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;">On July 17, 2020, the Company, RPI, and, for the limited purposes set forth in the agreement, Royalty Pharma PLC, entered into the Royalty Purchase Agreement. Pursuant to the Royalty Purchase Agreement, the Company sold to RPI </span><span style="font-style:normal;">42.933%</span><span style="font-style:normal;"> (the “Assigned Royalty Rights”) of the Company’s right to receive sales-based royalty payments (the “Royalty”) on worldwide net sales of Evrysdi and any other product developed pursuant to the SMA License Agreement. In consideration for the sale of the Assigned Royalty Rights, RPI paid the Company </span><span style="font-style:normal;">$650.0</span><span style="font-style:normal;"> million in cash consideration. The Company has retained a </span><span style="font-style:normal;">57.067%</span><span style="font-style:normal;"> interest in the Royalty and all economic rights to receive the remaining potential regulatory and sales milestone payments under the SMA License Agreement, which remaining milestone payments equal </span><span style="font-style:normal;">$250.0</span><span style="font-style:normal;"> million in the aggregate as of September 30, 2023. The Royalty Purchase Agreement will terminate </span><span style="font-style:normal;">60 days</span><span style="font-style:normal;"> following the earlier of the date on which Roche is no longer obligated to make any payments of the Royalty pursuant to the SMA License Agreement and the date on which RPI has received </span><span style="font-style:normal;">$1.3</span><span style="font-style:normal;"> billion in respect of the Assigned Royalty Rights. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The cash consideration obtained pursuant to the Royalty Purchase Agreement is classified as debt and is recorded as “liability for sale of future royalties-current” and “liability for sale of future royalties-noncurrent” on the Company’s consolidated balance sheet based on the timing of the expected payments to be made to RPI. The fair value for the liability for sale of future royalties at the time of the transaction was based on the Company’s estimates of future royalties expected to be paid to RPI over the life of the arrangement, which was determined using forecasts from market data sources, which are considered Level 3 inputs. The liability is being amortized using the effective interest method over the life of the arrangement, in accordance with the respective guidance. The Company utilizes the prospective method to account for subsequent changes in the estimated future payments to be made to RPI.  Refer to Note 9 for further details.</p> 0.42933 650000000.0 0.57067 250000000.0 P60D 1300000000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Indefinite-lived intangible assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Indefinite-lived intangible assets consist of in process research and development ("IPR&amp;D"). IPR&amp;D acquired directly in a transaction other than a business combination is capitalized if the projects will be further developed or have an alternative future use; otherwise they are expensed. The fair values of IPR&amp;D projects and license agreement assets acquired in business combinations are capitalized. Several methods may be used to determine the estimated fair value of the IPR&amp;D and license agreement asset acquired in a business combination. The Company utilizes the "income method" and uses estimated future net cash flows that are derived from projected sales revenues and estimated costs. These projections are based on factors such as relevant market size, patent protection, and expected pricing and industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. These assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are amortized over the remaining useful life or written off, as appropriate. Intangible assets with indefinite lives, including IPR&amp;D, are tested for impairment if impairment indicators arise and, at a minimum, annually. However, an entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that an indefinite-lived intangible asset’s fair value is less than its carrying amount. Otherwise, no further impairment testing is required. The indefinite-lived intangible asset impairment test consists of a one-step analysis that compares the fair value of the intangible asset with its carrying amount. If the carrying amount of an intangible asset exceeds its fair value, an impairment loss is recognized in an amount equal to that excess. The Company considers many factors in evaluating whether the value of its intangible assets with indefinite lives may not be recoverable, including, but not limited to, expected growth rates, the cost of equity and debt capital, general economic conditions, the Company’s outlook and market performance of the Company’s industry and recent and forecasted financial performance. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In May 2023, as part of the Company’s strategic portfolio prioritization, the Company decided to discontinue its preclinical and early research programs in its gene therapy platform, which included Friedreich ataxia and Angelman syndrome. As a result, the Company determined that the Friedreich ataxia and Angelman syndrome indefinite lived intangible assets were fully impaired and recorded impairment expense of $217.8 million during the nine months ended September 30, 2023, which is recorded as intangible asset impairment in the statement of operations. Refer to Note 12 for further information regarding the Company’s intangible assets.</p> 217800000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Goodwill</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Goodwill represents the amount of consideration paid in excess of the fair value of net assets acquired as a result of the Company’s business acquisitions accounted for using the acquisition method of accounting. Goodwill is not amortized and is subject to impairment testing at a reporting unit level on an annual basis or when a triggering event occurs that may indicate the carrying value of the goodwill is impaired. The Company reassesses its reporting units as part of its annual segment review. An entity is permitted to first assess qualitative factors to determine if a quantitative impairment test is necessary. Further testing is only required if the entity determines, based on the qualitative assessment, that it is more likely than not that the fair value of the reporting unit is less than its carrying amount. </p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Organization for Economic Co-operation and Development (“OECD”), the European Community (“the EC”), and individual taxing jurisdictions where the Company and its affiliates do business have recently focused on issues related to the taxation of multinational corporations. The OECD has released its comprehensive plan to create an agreed set of international rules for fighting base erosion and profit shifting. In addition, the OECD, the EC and individual taxing jurisdictions are examining changes to how taxing rights should be allocated among countries considering the digital economy. As a result, the tax laws in the U.S. and other countries in which the Company and its affiliates do business could change on a prospective or retroactive basis and any such changes could materially adversely affect the Company’s business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On December 22, 2017, the U.S. government enacted the 2017 Tax Act, which significantly revised U.S. tax law by, among other provisions, lowering the U.S. federal statutory corporate income tax rate to 21%, imposing a mandatory one-time transition tax on previously deferred foreign earnings, and eliminating or reducing certain income tax deductions. The Global Intangible Low-Taxed Income ("GILTI") provisions of the 2017 Tax Act require the Company to include in its U.S. income tax return foreign subsidiary earnings in excess of an allowable return on the foreign subsidiary’s tangible assets. The Company has elected to account for GILTI tax in the period in which it is incurred, and therefore has not provided any deferred tax impacts of GILTI in its consolidated financial statements for the period ended September 30, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Starting in 2022, TCJA amendments to IRC Section 174 no longer permits an immediate deduction for research and development (R&amp;D) expenditures in the tax year that such costs are incurred. Instead, these IRC Section 174 development costs must now be capitalized and amortized over either a five- or 15-year period, depending on the location of the activities performed. The new amortization period begins with the midpoint of any taxable year that IRC Section 174 costs are first incurred, regardless of whether the expenditures were made prior to or after July 1, and runs until the midpoint of year five for activities conducted in the United States or year 15 in the case of development conducted on foreign soil. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and net operating loss and credit carryforwards. Deferred tax assets and liabilities are measured at rates expected to apply to taxable income in the years in which those temporary differences and carryforwards are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the statement of operations in the period that includes the enactment date. A valuation allowance is recorded when it is not more likely than not that all or a portion of the net deferred tax assets will be realized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On August 23, 2018, the Company completed its acquisition of Agilis Biotherapeutics, Inc. (“Agilis”), pursuant to an Agreement and Plan of Merger, dated as of July 19, 2018 (the “Agilis Merger Agreement”), by and among the Company, </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Agility Merger Sub, Inc., a Delaware corporation and the Company’s wholly owned, indirect subsidiary, Agilis and, solely in its capacity as the representative, agent and attorney-in-fact of the equityholders of Agilis, Shareholder Representative Services LLC, (the “Agilis Merger”). The Company recorded a deferred tax liability in conjunction with the Agilis Merger of $122.0 million in 2018, related to the tax basis difference in the IPRD indefinite-lived intangibles acquired. The Company’s policy is to record a deferred tax liability related to acquired IPR&amp;D which may eventually be realized either upon amortization of the asset when the research is completed, and a product is successfully launched or the write-off of the asset if it is abandoned or unsuccessful. In July 2022, the Company received EMEA approval for a portion of the IPR&amp;D assets, and thus, began the amortization of the intangible. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In May 2023, the Company announced the discontinuation of its preclinical and early research programs in gene therapy as part of a strategic portfolio prioritization. In conjunction with the announcement, the Company recorded an impairment to its indefinite-lived intangible for IP research and development relating to the Friedreich ataxia and Angelman syndrome gene therapy assets. As a result of the impairment, the Company recorded a deferred tax benefit of $50.9 million.</p> 0.21 122000000.0 -50900000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company determines if an arrangement is a lease at inception. This determination generally depends on whether the arrangement conveys to the Company the right to control the use of an explicitly or implicitly identified fixed asset for a period of time in exchange for consideration. Control of an underlying asset is conveyed to the Company if the Company obtains the rights to direct the use of and to obtain substantially all of the economic benefits from using the underlying asset. The Company has lease agreements which include lease and non-lease components, which the Company accounts for as a single lease component for all leases. Operating and finance leases are classified as right of use ("ROU") assets, short term lease liabilities, and long term lease liabilities. Operating and finance lease ROU assets and lease liabilities are recognized at the commencement date based on the present value of lease payments over the lease term. ROU assets are amortized and lease liabilities accrete to yield straight-line expense over the term of the lease. Lease payments included in the measurement of the lease liability are comprised of fixed payments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Variable lease payments associated with the Company’s leases are recognized when the event, activity, or circumstance in the lease agreement on which those payments are assessed occurs. Variable lease payments are presented in the Company’s consolidated statements of operations in the same line item as expense arising from fixed lease payments for operating leases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Leases with an initial term of 12 months or less are not recorded on the consolidated balance sheet and the Company recognizes lease expense for these leases on a straight-line basis over the lease term. The Company applies this policy to all underlying asset categories.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A lessee is required to discount its unpaid lease payments using the interest rate implicit in the lease or, if that rate cannot be readily determined, its incremental borrowing rate. As most of the Company’s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The Company gives consideration to its recent debt issuances as well as publicly available data for instruments with similar characteristics when calculating its incremental borrowing rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The lease term for all of the Company’s leases includes the non-cancellable period of the lease plus any additional periods covered by either a Company option to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor. Leasehold improvements are capitalized and depreciated over the lesser of useful life or lease term. See Note 3 Leases for additional information.  </p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">3.        Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company leases office space in South Plainfield, New Jersey for its principal office under two noncancelable operating leases through August 2024, in addition to office and laboratory space in Bridgewater, New Jersey and other locations throughout the United States and office space in various countries for international employees primarily through workspace providers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company also leases approximately 220,500 square feet of office, manufacturing and laboratory space at a facility located in Hopewell Township, New Jersey pursuant to a Lease Agreement (the “Hopewell Lease”) with Hopewell Campus Owner LLC. The rental term of the Hopewell Lease commenced on July 1, 2020 and has an initial term of fifteen years (the “Hopewell Initial Term”), with two consecutive ten year renewal periods, each at the Company’s option. The aggregate rent for the Hopewell Initial Term will be approximately $111.5 million. The rental rate for the renewal periods will be 95% of the Prevailing Market Rate (as defined in the Hopewell Lease) and determined at the time of the exercise of the renewal. The Company is also responsible for maintaining certain insurance and the payment of proportional taxes, utilities and common area operating expenses. The Hopewell Lease contains customary events of default, representations, warranties and covenants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In May 2022, the Company entered into a Lease Agreement (the “Warren Lease”) with Warren CC Acquisitions, LLC (the “Warren Landlord”) relating to the lease of two entire buildings comprised of approximately 360,000 square feet of shell condition, modifiable space (the “Warren Premises”) at a facility located in Warren, New Jersey. The rental term of the Warren Lease commenced on June 1, 2022, with an initial term of seventeen years (the “Warren Initial Term”), followed by three consecutive five-year renewal periods at the Company’s option. The aggregate base rent for the Warren Initial Term will be approximately $163.0 million; provided, however, that if the Company is not subject to an Event of Default (as defined in the Warren Lease), the Company will be entitled to a base rent abatement over the first three years of the Warren Initial Term of approximately $18.6 million, reducing the Company’s total base rent obligation to $144.4 million. The rental rate for the renewal periods will be at the Fair Market Rental Value (as defined in the Warren Lease) and determined at the time of the exercise of the renewal. Beginning in the second lease year, the Company is also responsible for the payment of all taxes and operating expenses for the Warren Premises. As a result, the Company recorded an operating lease ROU asset of $28.9 million and an operating lease ROU liability of $28.9 million as of the commencement date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company is developing the Warren Premises into office and laboratory space. The Company is entitled to an allowance of approximately $36.2 million to be provided by the Warren Landlord to be used towards such improvements. The Landlord is providing the allowance to cover those assets that are real property improvements, such as structural components, roofs, flooring, etc., whose useful lives are typically longer in nature. The Company evaluated the leasehold improvements under ASC 842 and determined that the Company will be the owner of the improvements, and therefore the $36.2 million allowance and $5.0 million due from the Landlord were treated as lease incentives at the commencement of the lease and included in the calculation of the lease ROU asset and lease ROU liability, effectively reducing both at Commencement Date. In connection with the execution of the Warren Lease, the Company also committed to fund a construction account with $3.6 million to go towards the Company’s improvements of the Warren Premises. Subject to the terms of the Warren Lease, the Company has a right of first offer to purchase the Warren Premises if the Warren Landlord receives a bona fide third party offer to purchase the Warren Premises or the Warren Landlord decides to sell the Warren Premises.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On June 19, 2020, the Company entered into a commercial manufacturing service agreement for a term of 12.5 years with MassBiologics of the University of Massachusetts Medical School ("MassBio"). The Company determined that the agreement was a finance lease, for which the Company recorded a finance lease ROU asset for $41.4 million and corresponding finance lease liability for $41.4 million at the onset of the lease agreement. Given that the leased asset is designed for the production of PTC’s AADC program and would not have an alternate use outside the PTC gene therapy platform without incurring significant costs, the Company determined that the lease should be treated as research and development expense under ASC 730. Accordingly, the full $41.4 million relating to the finance lease ROU asset was written off and expensed to research and development during the year ended December 31, 2020. As of September 30, 2023, the balance of the finance lease liabilities-current and finance lease liabilities-noncurrent are $2.6 million and $17.2 million, respectively, and are directly related to the Company’s MassBio agreement. As of December 31, 2022, the balance of the finance lease liabilities-current and finance lease liabilities-noncurrent were $3.0 million and $18.7 million, respectively. Additionally, the Company recorded finance lease costs of $0.4 million and $1.1 million related to interest on the lease liability during the three and nine months ended September 30, 2023, respectively. The Company recorded finance lease costs of $0.4 million and $1.2 million related to interest on the lease liability during the three and nine months ended September 30, 2022, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company also leases certain vehicles, lab equipment, and office equipment under operating leases. The Company’s leases have remaining operating lease terms ranging from 0.4 years to 15.7 years and certain of the leases include renewal options to extend the lease for up to 20 years. Rent expense was $7.1 million and $6.8 million for the three months ended September 30, 2023 and 2022, respectively. Rent expense was $21.5 million and $18.0 million for the nine months ended September 30, 2023 and 2022, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The components of operating lease expense were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:25.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:25.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:25.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:25.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Operating Lease Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:25.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fixed lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,490</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,377</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 16,463</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 14,267</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:25.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Variable lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,376</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,151</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,140</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,152</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:25.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 271</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 262</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 866</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:25.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total operating lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 7,137</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 6,790</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 21,469</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 18,019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Total operating lease cost is a component of operating expenses on the consolidated statements of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Supplemental lease term and discount rate information related to leases was as follows as September 30, 2023 and December 31, 2022:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:67.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average remaining lease terms - operating leases (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 11.61</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 11.61</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average discount rate - operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 8.67</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 8.61</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:67.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average remaining lease terms - finance lease (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 9.26</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 10.01</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average discount rate - finance lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 7.80</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 7.80</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Supplemental cash flow information related to leases was as follows as of September 30, 2023 and 2022:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended September 30, </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash paid for amounts included in the measurement of lease liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating cash flows from operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 11,479</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 10,954</p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Financing cash flows from finance lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,379</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,276</p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating cash flows from finance lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,621</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,724</p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Right-of-use assets obtained in exchange for lease obligations:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 35,294</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Future minimum lease payments under non-cancelable leases as of September 30, 2023 were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.75211334%;padding-left:0pt;padding-right:0pt;width:101.5%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Operating Leases</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Finance Lease</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2023 (excludes the nine months ended September 30, 2023)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,077</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 18,369</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 20,438</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 19,988</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2027 and thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 193,792</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 18,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 257,664</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 27,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: Imputed Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 146,279</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 7,205</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 111,385</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 19,795</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p> 2 220500 P15Y 2 P10Y true 111500000 0.95 2 360000 P17Y 3 P5Y true 163000000.0 P3Y 18600000 144400000 28900000 28900000 36200000 36200000 5000000.0 3600000 P12Y6M 41400000 41400000 41400000 2600000 17200000 3000000.0 18700000 400000 1100000 400000 1200000 P0Y4M24D P15Y8M12D P20Y 7100000 6800000 21500000 18000000.0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:25.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:25.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:19.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:25.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:25.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Operating Lease Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:25.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fixed lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,490</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,377</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 16,463</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 14,267</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:25.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Variable lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,376</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,151</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,140</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,152</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:25.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Short-term lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 271</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 262</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 866</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:25.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total operating lease cost</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 7,137</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 6,790</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 21,469</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.87%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 18,019</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:67.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:67.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:67.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average remaining lease terms - operating leases (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 11.61</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 11.61</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average discount rate - operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 8.67</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 8.61</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:67.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average remaining lease terms - finance lease (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 9.26</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 10.01</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:67.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Weighted-average discount rate - finance lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 7.80</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 7.80</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table> 5490000 5377000 16463000 14267000 1376000 1151000 4140000 3152000 271000 262000 866000 600000 7137000 6790000 21469000 18019000 P11Y7M9D P11Y7M9D 0.0867 0.0861 P9Y3M3D P10Y3D 0.0780 0.0780 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended September 30, </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash paid for amounts included in the measurement of lease liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating cash flows from operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 11,479</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 10,954</p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Financing cash flows from finance lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,379</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,276</p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating cash flows from finance lease</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,621</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,724</p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Right-of-use assets obtained in exchange for lease obligations:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:73.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating leases</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 35,294</p></td></tr></table> 11479000 10954000 1379000 1276000 1621000 1724000 35294000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.75211334%;padding-left:0pt;padding-right:0pt;width:101.5%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Operating Leases</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Finance Lease</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2023 (excludes the nine months ended September 30, 2023)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,077</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 18,369</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 20,438</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 19,988</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2027 and thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 193,792</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 18,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 257,664</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 27,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: Imputed Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 146,279</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 7,205</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 111,385</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 19,795</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.75211334%;padding-left:0pt;padding-right:0pt;width:101.5%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Operating Leases</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Finance Lease</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2023 (excludes the nine months ended September 30, 2023)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,077</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 18,369</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 20,438</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 19,988</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2027 and thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 193,792</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 18,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total lease payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 257,664</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 27,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: Imputed Interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 146,279</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 7,205</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 111,385</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 19,795</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p> 5077000 18369000 3000000 20438000 3000000 19988000 3000000 193792000 18000000 257664000 27000000 146279000 7205000 111385000 19795000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">4.        Fair value of financial instruments and marketable securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company follows the fair value measurement rules, which provide<span style="display:inline-block;width:3.08pt;"></span>guidance on the use of fair value in accounting and disclosure for assets and liabilities when such accounting and disclosure is called for by other accounting literature. These rules establish a fair value hierarchy for inputs to be used to measure fair value of financial assets and liabilities. This hierarchy prioritizes the inputs to valuation techniques used to measure fair value into three levels: Level 1 (highest priority), Level 2, and Level 3 (lowest priority).</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 1—Unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the balance sheet date.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 2—Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates, yield curves, etc.), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Level 3—Inputs are unobservable and reflect the Company’s assumptions as to what market participants would use in pricing the asset or liability. The Company develops these inputs based on the best information available.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Cash equivalents and marketable securities are reflected in the accompanying financial statements at fair value. The carrying amount of receivables and accounts payable and accrued expenses approximates fair value due to the short-term nature of those instruments. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">The Company owns common stock in ClearPoint Neuro, Inc. (“ClearPoint”) (formerly MRI Interventions, Inc.), a publicly traded medical device company. The ClearPoint equity investments (collectively, the “ClearPoint Equity Investments”) represent financial instruments, and therefore, are recorded at fair value, which is readily determinable. The ClearPoint </span><span style="background:#ffffff;">Equity Investments are components of prepaids and other current assets on the consolidated balance sheet as of September 30, 2023, and deposits and other assets as of December 31, 2022. </span>During three and nine months ended September 30, 2023, the Company recorded unrealized losses of $2.0 million and $3.1 million, respectively. During the three and nine months ended September 30, 2022, the Company recorded unrealized losses of $3.5 million and $1.1 million, respectively. During the three months ended September 30, 2023, the Company did not record any realized gains or losses for the sale of ClearPoint Equity Investments. During the nine months ended September 30, 2023, the Company recorded a realized loss of $0.8 million for the sale of ClearPoint Equity Investments. During the three and nine months ended September 30, 2022, the Company did not record any realized gains or losses for the sale of Clearpoint Equity Investments. These unrealized and realized losses are components of other expense, net within the consolidated statement of operations. The fair value of the ClearPoint Equity Investments was $4.5 million and $11.0 million as of September 30, 2023 and December 31, 2022, respectively. The Company classifies the ClearPoint Equity Investments as Level 1 assets within the fair value hierarchy, as the value is based on a quoted market price in an active market, which is not adjusted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In January 2020, the Company purchased a $10.0 million convertible note from ClearPoint that the Company can convert into ClearPoint shares at a conversion rate of $6.00 per share at any point throughout the term of the loan, which matures five years from the purchase date. The Company determined that the convertible note represents an available for sale debt security and the Company has elected to record it at fair value under ASC 825. The Company classifies its ClearPoint convertible debt security as a Level 2 asset within the fair value hierarchy, as the value is based on inputs other than quoted prices that are observable. The fair value of the ClearPoint convertible debt security is determined at each reporting period by utilizing a Black-Scholes option pricing model, as well as a present value of expected cash flows from the debt security utilizing the risk free rate and the estimated credit spread as of the valuation date as the discount rate. During the three and nine months ended September 30, 2023, the Company recorded unrealized losses of $3.1 million and $4.6 million, respectively. During the three and nine months ended September 30, 2022, the Company recorded unrealized losses of $4.4 million and $2.4 million, respectively. These unrealized gains and losses are components of other expense, net within the consolidated statement of operations. The fair value of the convertible debt security was $10.6 million and $15.2 </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">million as of September 30, 2023 and December 31, 2022, respectively. The convertible debt security is considered to be long term and is included as a component of deposits and other assets on the consolidated balance sheet. Other than the ClearPoint Equity Investments and the ClearPoint convertible debt security, no other items included in deposits and other assets and prepaids and other current assets on the consolidated balance sheets are fair valued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">The Company has investments in mutual funds, including </span><span style="background:#ffffff;">one</span><span style="background:#ffffff;"> that is denominated in a foreign currency. All of these are equity investments and are classified as marketable securities on the Company’s consolidated balance sheets. These equity investments are reported at fair value, as they are readily available, and as such are classified as Level 1 assets. Unrealized holding gains and losses for these equity investments are included as components of other expense, net within the consolidated statement of operations. </span>For the three and nine months ended September 30, 2023, the Company had unrealized gains of $1.1 million and of $5.5 million, respectively, relating to the equity investments still held at the reporting date. For the three and nine months ended September 30, 2022, the Company had unrealized gains of $0.1 million and unrealized losses of $11.3 million relating to the equity investments still held at the reporting date, respectively. For the three and nine months ended September 30, 2023, the Company had redemptions of $7.8 million and $12.1 million, respectively, which were primarily due to liquidation of one of the mutual funds. For the three and nine months ended September 30, 2022, the Company had redemptions of $100.8 million and $104.4 million, respectively, which were primarily due to liquidation of one of the mutual funds. For the three months ended September 30, 2023, the Company had foreign currency unrealized losses of $1.4 million relating to these equity investments. For the nine months ended September 30, 2023, the amounts recognized for foreign currency unrealized losses relating to these investments were immaterial. For the three and nine months ended September 30, 2022, the Company had foreign currency unrealized losses of $1.4 million and $1.0 million, respectively, relating to these equity investments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Fair value of marketable securities that are classified as available for sale debt securities is based upon market prices using quoted prices in active markets for identical assets quoted on the last day of the period. In establishing the estimated fair value of the remaining available for sale debt securities, the Company used the fair value as determined by its investment advisors using observable inputs other than quoted prices.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following represents the fair value using the hierarchy described above for the Company’s financial assets and liabilities that are required to be measured at fair value on a recurring basis as of September 30, 2023 and December 31, 2022:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:54.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Quoted prices</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">in active</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">markets for</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">unobservable</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">identical assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">inputs</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(level 1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(level 2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(level 3)</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Marketable securities - available for sale</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,625</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,625</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:43.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Marketable securities - equity investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 128,028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 128,028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:43.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">ClearPoint Equity Investments - available for sale </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,482</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,482</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:43.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">ClearPoint convertible debt security</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,637</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,637</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:43.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Contingent consideration payable- development and regulatory milestones</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26,400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26,400</p></td></tr><tr><td style="vertical-align:bottom;width:43.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Contingent consideration payable- net sales milestones and royalties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,600</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:54.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted prices</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">in active</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">markets for</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">unobservable</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">identical assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">inputs</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(level 1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(level 2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(level 3)</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marketable securities - available for sale</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22,610</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22,610</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:43.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marketable securities - equity investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 108,261</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 108,261</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:43.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ClearPoint Equity Investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,965</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,965</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:43.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ClearPoint convertible debt security</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,231</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,231</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr></table><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:43.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contingent consideration payable- development and regulatory milestones</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 82,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 82,500</p></td></tr><tr><td style="vertical-align:bottom;width:43.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contingent consideration payable- net sales milestones and royalties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 81,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 81,500</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">No transfers of assets between Level 1, Level 2, or Level 3 of the fair value measurement hierarchy occurred during the periods ended September 30, 2023 and December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following is a summary of marketable securities accounted for as available for sale debt securities at September 30, 2023 and December 31, 2022:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:45.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gross Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,649</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (24)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,625</p></td></tr><tr><td style="vertical-align:bottom;width:52.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,649</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (24)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,625</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:45.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gross Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,419</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,424</p></td></tr><tr><td style="vertical-align:bottom;width:52.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,685</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (499)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,186</p></td></tr><tr><td style="vertical-align:bottom;width:52.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23,104</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (499)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 22,610</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For available for sale debt securities in an unrealized loss position, the Company assesses whether it intends to sell or if it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security’s amortized cost basis is written down to fair value. For the three and nine months ended September 30, 2023 and 2022, no write downs occurred. The Company does not intend to sell the investments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost basis, which may be maturity. The Company also reviews its available for sale debt securities in an unrealized loss position and evaluates whether the decline in fair value has resulted from credit losses or other factors. This review is subjective, as it requires management to evaluate whether an event or change in circumstances has occurred in that period that may be related to credit issues. For the three and nine months ended September 30, 2023 and 2022, no allowance was recorded for credit losses. Unrealized gains and losses are reported as a component of accumulated other comprehensive (loss) income in stockholders’ equity. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For the three months ended September 30, 2023, the Company did not have any realized gains or losses from the sale of available for sale debt securities. For the nine months ended September 30, 2023, the Company had $0.3 million of realized losses from the sale of available for sale debt securities. For the three and nine months ended September 30, 2022, the Company had $1.3 million and $1.6 million of realized losses from the sale of available for sale debt securities, respectively.  Realized gains and losses are reported as a component of interest expense, net in the consolidated statement of operations. <span style="background:#ffffff;">Reclassified amounts from other comprehensive items were determined using the actual realized gains and losses from the sales of marketable securities.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The unrealized losses and fair values of available for sale debt securities that have been in an unrealized loss position for a period of less than and greater than or equal to 12 months as of September 30, 2023 are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:21.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:21.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="17" style="vertical-align:bottom;white-space:nowrap;width:77.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:21.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Securities in an unrealized loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Securities in an unrealized loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:21.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">position less than 12 months</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">position greater than or equal to 12 months</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:21.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">   </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">   </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">   </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">   </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">   </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">   </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:21.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (24)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,625</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (24)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,625</p></td></tr><tr><td style="vertical-align:bottom;width:21.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (24)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,625</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (24)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,625</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The unrealized losses and fair values of available for sale debt securities that have been in an unrealized loss position for a period of less than and greater than or equal to 12 months as of December 31, 2022 are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:21.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:21.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="17" style="vertical-align:bottom;white-space:nowrap;width:77.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:21.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Securities in an unrealized loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Securities in an unrealized loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:21.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">position less than 12 months</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">position greater than or equal to 12 months</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:21.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">   </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">   </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">   </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">   </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">   </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">   </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:21.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (499)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,186</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (499)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,186</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:21.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (499)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,186</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (499)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,186</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Available for sale debt securities at September 30, 2023 and December 31, 2022 mature as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Less Than</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">More Than</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">12 Months</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">12 Months</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,625</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:74.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,625</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Less Than</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">More Than</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">12 Months</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">12 Months</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,424</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:74.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,186</p></td></tr><tr><td style="vertical-align:bottom;width:74.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,424</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,186</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company classifies all of its marketable securities as current as they are all either available for sale debt securities or equity investments and are available for current operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Convertible senior notes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In September 2019, the Company issued $287.5 million of 1.50% convertible senior notes due September 15, 2026 (the “2026 Convertible Notes,”). The fair value of the 2026 Convertible Notes, which differs from their carrying values, is influenced by interest rates, the Company’s stock price and stock price volatility and is determined by prices for the 2026 Convertible Notes observed in market trading which are Level 2 inputs. The estimated fair value of the 2026 Convertible Notes at September 30, 2023 and December 31, 2022 was $228.8 million and $281.7 million, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Level 3 valuation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The contingent consideration payable is fair valued each reporting period with the change in fair value recorded as a gain or loss within the change in the fair value of contingent consideration on the consolidated statements of operations. The fair value of the development and regulatory milestones is estimated utilizing a probability adjusted, discounted cash flow approach. The discount rates are estimated utilizing Corporate B rated bonds maturing in the years of expected payments based on the Company’s estimated development timelines for the acquired product candidate. The fair value of the net sales milestones is determined utilizing a valuation framework that estimates net sales volatility to simulate a range of possible payment scenarios. The average of the payments in these scenarios is then discounted to calculate present fair value.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In May 2023, as part of the Company’s strategic portfolio prioritization, the Company decided to discontinue its preclinical and early research programs in its gene therapy platform, which included Friedreich ataxia and Angelman syndrome. As a result, the Company fully impaired the Friedreich ataxia and Angelman syndrome intangible assets and determined that the fair value for all of the contingent consideration payable related to Friedreich ataxia and Angelman syndrome was $0. The change in fair value for the contingent consideration payable related to Friedreich ataxia and Angelman syndrome for the nine months ended September 30, 2023 was $129.8 million and is included in the change in fair value of the contingent consideration in the statement of operations. The remaining contingent consideration as of September 30, 2023 is $39.0 million, which is solely related to the development and regulatory milestones, and net sales milestones, for Upstaza.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of September 30, 2023, the weighted average discount rate for the Upstaza development and regulatory milestones was 7.1% and the weighted average probability of success was 90%. As of September 30, 2023, the weighted average discount rate for the Upstaza net sales milestones was 12.0% and the weighted average probability of success for the net sales milestones was 93%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The table presented below is a summary of changes in the fair value of the Company’s Level 3 valuations for the contingent consideration payable for the periods ended September 30, 2023 and September 30, 2022:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:24.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:22.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:52.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 3 liabilities</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:25.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contingent consideration payable-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contingent consideration payable-</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:25.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">development and regulatory</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">net sales milestones and royalties</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:25.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">milestones</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Beginning balance as of December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 82,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 81,500</p></td></tr><tr><td style="vertical-align:bottom;width:45.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Additions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:45.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (56,100)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (68,900)</p></td></tr><tr><td style="vertical-align:bottom;width:45.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:45.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Ending balance as of September 30, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26,400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,600</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:24.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:22.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:52.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 3 liabilities</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:25.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contingent consideration payable-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contingent consideration payable-</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:25.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">development and regulatory</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">net sales milestones and royalties</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:25.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">milestones</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Beginning balance as of December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 139,300</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 100,600</p></td></tr><tr><td style="vertical-align:bottom;width:45.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Additions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td></tr><tr><td style="vertical-align:bottom;width:45.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (10,800)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (21,400)</p></td></tr><tr><td style="vertical-align:bottom;width:45.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Reclass to accounts payable and accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (50,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td></tr><tr><td style="vertical-align:bottom;width:45.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td></tr><tr><td style="vertical-align:bottom;width:45.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Ending balance as of September 30, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 78,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 79,200</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following significant unobservable inputs were used in the valuation of the contingent consideration payable for the periods ended September 30, 2023 and December 31, 2022:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:18.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:18.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:79.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:18.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Valuation Technique</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unobservable Input</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Range</b></p></td></tr><tr><td style="vertical-align:middle;width:18.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Contingent consideration payable-<br/>development and regulatory milestones</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$26,400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:middle;width:15.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> Probability-adjusted discounted cash flow </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:top;width:33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Potential development and regulatory milestones<br/>Probabilities of success<br/>Discount rates<br/>Projected years of payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:17.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$0 - $31 million<br/>85% - 92%<br/>6.9% - 7.6%<br/>2023 - 2026</p></td></tr><tr><td style="vertical-align:middle;width:18.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Contingent considerable payable- net sales<br/>milestones and royalties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$12,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:middle;width:15.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Option-pricing model with Monte Carlo simulation  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Potential net sales milestones<br/>Probabilities of success<br/>Potential percentage of net sales for royalties<br/>Discount rate<br/>Projected years of payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:17.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$0 - $50 million<br/>85% - 100%<br/>0%<br/>12%<br/>2025 - 2034</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:18.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:33.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:18.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:79.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:18.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Valuation Technique</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unobservable Input</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Range</b></p></td></tr><tr><td style="vertical-align:middle;width:18.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Contingent consideration payable-<br/>development and regulatory milestones</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:7.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$82,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:middle;width:14.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> Probability-adjusted discounted cash flow </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:top;width:33.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Potential development and regulatory milestones<br/>Probabilities of success<br/>Discount rates<br/>Projected years of payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:18.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$0 - $331 million<br/>25% - 92%<br/>6.2% - 8.3%<br/>2023 - 2029</p></td></tr><tr><td style="vertical-align:middle;width:18.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Contingent considerable payable- net sales<br/>milestones and royalties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$81,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:middle;width:14.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Option-pricing model with Monte Carlo simulation  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:top;width:33.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Potential net sales milestones<br/>Probabilities of success<br/>Potential percentage of net sales for royalties<br/>Discount rate<br/>Projected years of payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:18.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$0 - $150 million<br/>25% - 100%<br/>2% - 6%<br/>11.5%<br/>2025 - 2041</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The contingent consideration payables are classified Level 3 liabilities as their valuation requires substantial judgment and estimation of factors that are not currently observable in the market. If different assumptions were used for the various inputs to the valuation approaches, including but not limited to, assumptions involving probability adjusted sales estimates </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">for the gene therapy platform and estimated discount rates, the estimated fair value could be significantly higher or lower than the fair value determined.</p> -2000000.0 -3100000 -3500000 -1100000 0 -800000 4500000 11000000.0 10000000.0 6.00 P5Y -3100000 -4600000 -4400000 -2400000 10600000 15200000 1 1100000 5500000 100000 -11300000 7800000 12100000 100800000 104400000 1 -1400000 -1400000 -1000000.0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:54.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Quoted prices</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">in active</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Significant</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">markets for</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">unobservable</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">identical assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">inputs</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(level 1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(level 2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(level 3)</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Marketable securities - available for sale</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,625</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,625</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:43.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Marketable securities - equity investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 128,028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 128,028</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:43.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">ClearPoint Equity Investments - available for sale </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,482</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,482</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:43.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">ClearPoint convertible debt security</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,637</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,637</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:43.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Contingent consideration payable- development and regulatory milestones</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26,400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 26,400</p></td></tr><tr><td style="vertical-align:bottom;width:43.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Contingent consideration payable- net sales milestones and royalties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,600</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:54.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted prices</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">in active</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">markets for</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">unobservable</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">identical assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">inputs</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(level 1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(level 2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(level 3)</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marketable securities - available for sale</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22,610</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 22,610</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:43.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marketable securities - equity investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 108,261</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 108,261</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:43.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ClearPoint Equity Investments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,965</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,965</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:43.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ClearPoint convertible debt security</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,231</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 15,231</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr></table><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:43.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contingent consideration payable- development and regulatory milestones</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 82,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 82,500</p></td></tr><tr><td style="vertical-align:bottom;width:43.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contingent consideration payable- net sales milestones and royalties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 81,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 81,500</p></td></tr></table> 1625000 1625000 128028000 128028000 4482000 4482000 10637000 10637000 26400000 26400000 12600000 12600000 22610000 22610000 108261000 108261000 10965000 10965000 15231000 15231000 82500000 82500000 81500000 81500000 0 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:45.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gross Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,649</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (24)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,625</p></td></tr><tr><td style="vertical-align:bottom;width:52.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,649</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (24)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,625</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:52.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:52.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:45.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gross Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:52.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Gains</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.66%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:52.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,419</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12,424</p></td></tr><tr><td style="vertical-align:bottom;width:52.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,685</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (499)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,186</p></td></tr><tr><td style="vertical-align:bottom;width:52.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 23,104</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (499)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.3%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 22,610</p></td></tr></table> 1649000 0 24000 1625000 1649000 24000 1625000 12419000 5000 0 12424000 10685000 499000 10186000 23104000 5000 499000 22610000 0 0 0 0 0 0 0 0 0 -300000 -1300000 -1600000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:21.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:21.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="17" style="vertical-align:bottom;white-space:nowrap;width:77.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:21.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Securities in an unrealized loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Securities in an unrealized loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:21.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">position less than 12 months</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">position greater than or equal to 12 months</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:21.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">   </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">   </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">   </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">   </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">   </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">   </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:21.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (24)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,625</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (24)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,625</p></td></tr><tr><td style="vertical-align:bottom;width:21.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (24)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,625</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (24)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.04%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.7%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,625</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:21.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:21.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="17" style="vertical-align:bottom;white-space:nowrap;width:77.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:21.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Securities in an unrealized loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Securities in an unrealized loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:21.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.59%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">position less than 12 months</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:30.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">position greater than or equal to 12 months</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:21.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:21.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">   </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">   </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">   </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">   </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">   </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized losses</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">   </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:21.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (499)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,186</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (499)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,186</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:21.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.72%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.09%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (499)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,186</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (499)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.79%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,186</p></td></tr></table> 24000 1625000 24000 1625000 24000 1625000 24000 1625000 499000 10186000 499000 10186000 499000 10186000 499000 10186000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Less Than</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">More Than</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">12 Months</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">12 Months</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,625</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:74.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,625</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Less Than</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">More Than</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">12 Months</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">12 Months</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commercial paper</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,424</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:74.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate debt securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,186</p></td></tr><tr><td style="vertical-align:bottom;width:74.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,424</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.35%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.2%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,186</p></td></tr></table> 1625000 1625000 12424000 10186000 12424000 10186000 287500000 0.0150 228800000 281700000 0 129800000 39000000.0 0.071 0.90 0.120 0.93 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:24.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:22.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:52.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 3 liabilities</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:25.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contingent consideration payable-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contingent consideration payable-</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:25.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">development and regulatory</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">net sales milestones and royalties</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:25.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">milestones</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Beginning balance as of December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 82,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 81,500</p></td></tr><tr><td style="vertical-align:bottom;width:45.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Additions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:45.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (56,100)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (68,900)</p></td></tr><tr><td style="vertical-align:bottom;width:45.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:45.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Ending balance as of September 30, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26,400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,600</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:24.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:22.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:52.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 3 liabilities</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:25.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contingent consideration payable-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Contingent consideration payable-</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:25.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">development and regulatory</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">net sales milestones and royalties</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:25.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">milestones</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:24.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Beginning balance as of December 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 139,300</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 100,600</p></td></tr><tr><td style="vertical-align:bottom;width:45.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Additions</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td></tr><tr><td style="vertical-align:bottom;width:45.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (10,800)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (21,400)</p></td></tr><tr><td style="vertical-align:bottom;width:45.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Reclass to accounts payable and accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (50,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td></tr><tr><td style="vertical-align:bottom;width:45.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.18%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.82%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td></tr><tr><td style="vertical-align:bottom;width:45.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Ending balance as of September 30, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.18%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 78,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.82%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 79,200</p></td></tr></table> 82500000 81500000 0 0 -56100000 -68900000 0 0 26400000 12600000 139300000 100600000 0 0 -10800000 -21400000 50000000 0 0 0 78500000 79200000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:18.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:18.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:79.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:18.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Valuation Technique</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:33%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unobservable Input</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Range</b></p></td></tr><tr><td style="vertical-align:middle;width:18.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Contingent consideration payable-<br/>development and regulatory milestones</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:8.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$26,400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:middle;width:15.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> Probability-adjusted discounted cash flow </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:top;width:33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Potential development and regulatory milestones<br/>Probabilities of success<br/>Discount rates<br/>Projected years of payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:17.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$0 - $31 million<br/>85% - 92%<br/>6.9% - 7.6%<br/>2023 - 2026</p></td></tr><tr><td style="vertical-align:middle;width:18.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Contingent considerable payable- net sales<br/>milestones and royalties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:8.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$12,600</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:middle;width:15.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Option-pricing model with Monte Carlo simulation  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:top;width:33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Potential net sales milestones<br/>Probabilities of success<br/>Potential percentage of net sales for royalties<br/>Discount rate<br/>Projected years of payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:17.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$0 - $50 million<br/>85% - 100%<br/>0%<br/>12%<br/>2025 - 2034</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:18.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:33.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:18.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:79.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:18.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Valuation Technique</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:33.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Unobservable Input</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Range</b></p></td></tr><tr><td style="vertical-align:middle;width:18.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Contingent consideration payable-<br/>development and regulatory milestones</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:7.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$82,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:middle;width:14.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"> Probability-adjusted discounted cash flow </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:top;width:33.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Potential development and regulatory milestones<br/>Probabilities of success<br/>Discount rates<br/>Projected years of payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:18.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$0 - $331 million<br/>25% - 92%<br/>6.2% - 8.3%<br/>2023 - 2029</p></td></tr><tr><td style="vertical-align:middle;width:18.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Contingent considerable payable- net sales<br/>milestones and royalties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:7.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$81,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:middle;width:14.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">Option-pricing model with Monte Carlo simulation  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:top;width:33.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">Potential net sales milestones<br/>Probabilities of success<br/>Potential percentage of net sales for royalties<br/>Discount rate<br/>Projected years of payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:18.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">$0 - $150 million<br/>25% - 100%<br/>2% - 6%<br/>11.5%<br/>2025 - 2041</p></td></tr></table> 26400000 0 31000000 0.85 0.92 0.069 0.076 12600000 0 50000000 0.85 1 0 0.12 82500000 0 331000000 0.25 0.92 0.062 0.083 81500000 0 150000000 0.25 1 0.02 0.06 0.115 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">5.        Accounts payable and accrued expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Accounts payable and accrued expenses at September 30, 2023 and December 31, 2022 consist of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Employee compensation, benefits, and related accruals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 70,778</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 62,669</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Income tax payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,822</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,712</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Consulting and contracted research</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 21,236</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 38,882</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,067</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,093</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sales allowance </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 72,202</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 63,787</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sales rebates</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 119,971</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 67,355</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Royalties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 52,087</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 40,546</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 19,152</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 27,268</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 9,416</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 12,054</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 370,731</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 320,366</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">During the three and nine month periods ended September 30, 2023, the Company incurred $22.6 million and $30.6 million, respectively, of restructuring costs from a reduction in workforce in connection with the Company’s strategic pipeline prioritization and discontinuation of its preclinical and early research programs in its gene therapy platform. The costs are included in research and development and selling, general, and administrative expenses on the Company’s consolidated statement of operations. <span style="background:#ffffff;">As of September 30, 2023, the remaining </span><span style="background:#ffffff;">$23.4</span><span style="background:#ffffff;"> million of accrued restructuring costs are included above within employee compensation, benefits, and related accruals. </span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Employee compensation, benefits, and related accruals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 70,778</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 62,669</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Income tax payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,822</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,712</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Consulting and contracted research</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 21,236</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 38,882</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Professional fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,067</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,093</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sales allowance </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 72,202</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 63,787</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sales rebates</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 119,971</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 67,355</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Royalties</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 52,087</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 40,546</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 19,152</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 27,268</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 9,416</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 12,054</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 370,731</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.34%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 320,366</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table> 70778000 62669000 2822000 4712000 21236000 38882000 3067000 3093000 72202000 63787000 119971000 67355000 52087000 40546000 19152000 27268000 9416000 12054000 370731000 320366000 22600000 30600000 23400000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">6.        Capitalization</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In August 2019, the Company entered into an At the Market Offering Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald and RBC Capital Markets, LLC (together, the “Sales Agents”), pursuant to which, the Company may offer and sell shares of its common stock, having an aggregate offering price of up to $125.0 million from time to time through the Sales Agents by any method that is deemed to be an “at the market offering” as defined in Rule 415(a)(4) promulgated under the Securities Act of 1933, as amended. No shares were sold during the three and nine months ended September 30, 2023 and 2022. The remaining shares of the Company’s common stock available to be issued and sold, under the At the Market Offering, have an aggregate offering price of up to $93.0 million as of September 30, 2023.</p> 125000000.0 0 0 0 0 93000000.0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">7.        Net loss per share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Basic and diluted net loss per share is computed by dividing net loss by the weighted-average number of common shares outstanding. Potentially dilutive securities were excluded from the diluted calculation because their effect would be anti-dilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following tables set forth the computation of basic and diluted net loss per share:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.13908768%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Numerator</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (132,970)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (109,315)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (470,812)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (388,128)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Denominator</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Denominator for basic and diluted net loss per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 75,377,997</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 71,654,671</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 74,618,611</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 71,415,849</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net loss per share:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1.76)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1.53)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6.31)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5.43)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;">*     In the three and nine months ended September 30, 2023 and 2022, the Company experienced a net loss and therefore did not report any dilutive share impact.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table shows historical dilutive common share equivalents outstanding, which are not included in the above historical calculation, as the effect of their inclusion is anti-dilutive during each period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:31.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td></tr><tr><td style="vertical-align:bottom;width:64.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock Options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 11,436,783</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 11,478,421</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested restricted stock awards and units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,414,102</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,488,944</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:64.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 14,850,885</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 13,967,365</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.13908768%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Three Months Ended September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Nine Months Ended September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Numerator</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (132,970)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (109,315)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (470,812)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (388,128)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Denominator</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Denominator for basic and diluted net loss per share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 75,377,997</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 71,654,671</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 74,618,611</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 71,415,849</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Net loss per share:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1.76)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.27%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1.53)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.2%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6.31)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.19%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (5.43)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">*</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt;margin:0pt 0pt 12pt 0pt;">*     In the three and nine months ended September 30, 2023 and 2022, the Company experienced a net loss and therefore did not report any dilutive share impact.</p> -132970000 -132970000 -109315000 -109315000 -470812000 -470812000 -388128000 -388128000 75377997 75377997 71654671 71654671 74618611 74618611 71415849 71415849 -1.76 -1.76 -1.53 -1.53 -6.31 -6.31 -5.43 -5.43 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:31.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td></tr><tr><td style="vertical-align:bottom;width:64.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock Options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 11,436,783</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 11,478,421</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested restricted stock awards and units</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,414,102</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,488,944</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:bottom;width:64.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.13%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 14,850,885</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 13,967,365</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p> 11436783 11478421 3414102 2488944 14850885 13967365 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">8.        Stock award plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In May 2013, the Company’s Board of Directors and stockholders approved the 2013 Long-Term Incentive Plan, which became effective upon the closing of the Company’s initial public offering. On June 8, 2022 (the “Restatement Effective Date”), the Company’s stockholders approved the Amended and Restated 2013 Long-Term Incentive Plan (the “Amended 2013 LTIP”). The Amended 2013 LTIP provides for the grant of incentive stock options, nonstatutory stock options, restricted stock units and other stock-based awards. The number of shares of common stock reserved for issuance under the Amended 2013 LTIP is the sum of (A) the number of shares of the Company’s common stock (up to 16,724,212 shares) that is equal to the sum of (1) the number of shares issued under the 2013 Long-Term Incentive Plan prior to the Restatement Effective Date, (2) the number of shares that remain available for issuance under the 2013 Long-Term Incentive Plan immediately prior to the Restatement Effective Date and (3) the number of shares subject to awards granted under the 2013 Long-Term Incentive Plan prior to the Restatement Effective Date that are outstanding as of the Restatement Effective Date, plus (B) from and after the Restatement Effective Date, an additional 8,475,000 shares of Common Stock. As of September 30, 2023, awards for 6,802,210 shares of common stock are available for issuance under the Amended 2013 LTIP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">There are no additional shares of common stock available for issuance under the Company’s 1998 Employee, Director and Consultant Stock Option Plan, 2009 Equity and Long Term Incentive Plan or 2013 Stock Incentive Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In January 2020, the Company’s Board of Directors approved the 2020 Inducement Stock Incentive Plan. The 2020 Inducement Stock Incentive Plan provides for the grant of incentive stock options, nonstatutory stock options, restricted stock awards and other stock-based awards for, initially, up to at the time, an aggregate of 1,000,000 shares of common stock. Any grants made under the 2020 Inducement Stock Incentive Plan must be made pursuant to the Nasdaq Listing Rule 5635(c)(4) inducement grant exception as a material component of the Company’s new hires’ employment compensation. <span style="background:#ffffff;"> In December 2020, the Company’s Board of Directors approved an additional </span><span style="background:#ffffff;">1,000,000</span><span style="background:#ffffff;"> shares of common stock that may be issued under the 2020 Inducement Stock Incentive Plan.  In April 2022, the Company’s Board of Directors approved a reduction in the total number of shares of common stock that may be issued under the 2020 Inducement Stock Incentive Plan to </span><span style="background:#ffffff;">1,300,000</span><span style="background:#ffffff;"> shares. In December 2022, the Company’s Board of Directors approved an additional </span><span style="background:#ffffff;">1,700,000</span><span style="background:#ffffff;"> shares of common stock that may be issued under the 2020 Inducement Stock Incentive Plan.  </span>As of September 30, 2023, awards for 1,705,941 shares of common stock were available for issuance under the 2020 Inducement Stock Incentive Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Board of Directors has the authority to select the individuals to whom options are granted and determine the terms of each option, including (i) the number of shares of common stock subject to the option; (ii) the date on which the option becomes exercisable; (iii) the option exercise price, which, in the case of incentive stock options, must be at least 100% (110% in the case of incentive stock options granted to a stockholder owning in excess of 10% of the Company’s stock) of the fair market value of the common stock as of the date of grant; and (iv) the duration of the option (which, in the case of incentive stock options, may not exceed ten years). Options typically vest over a four-year period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Inducement stock option awards</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">From January 1, 2023 through September 30, 2023, the Company issued a total of 1,059,054 stock options to various employees. Of those, 121,460 were inducement grants for non-statutory stock options, all of which were made pursuant to the 2020 Inducement Stock Incentive Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Stock option activity</i>—A summary of stock option activity is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">  </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">value(in </b></p></td></tr><tr><td style="vertical-align:bottom;width:46.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">term</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 11,502,417</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 43.33</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:46.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,059,054</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 41.29</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:46.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (806,407)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 29.48</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:46.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited/Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (318,281)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 47.84</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:46.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at September 30, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 11,436,783</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 43.99</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5.87</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,084</p></td></tr><tr><td style="vertical-align:bottom;width:46.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested or Expected to vest at September 30, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,357,250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 46.72</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 8.23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:46.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable at September 30, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 8,533,144</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 43.18</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5.05</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,084</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The fair value of grants made in the nine months ended September 30, 2023 was contemporaneously estimated on the date of grant using the following assumptions:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:28.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine months ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:68.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.54% - 3.91%</p></td></tr><tr><td style="vertical-align:bottom;width:68.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">53% - 54%</p></td></tr><tr><td style="vertical-align:bottom;width:68.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5.5 years</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company assumed no expected dividends for all grants. The weighted average grant date fair value of options granted during the nine months ended September 30, 2023 was $21.83 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The expected term of options was estimated based on the Company’s historical exercise data and the expected volatility of options was estimated based on the Company’s historical stock volatility. The risk-free rate of the options was based on U.S. Government Securities Treasury Constant Maturities yields at the date of grant for a term similar to the expected term of the option.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Restricted Stock Awards and Restricted Stock Units</i>—Restricted stock awards and restricted stock units are granted subject to certain restrictions, including in some cases service or time conditions (restricted stock). The grant-date fair value of restricted stock awards and restricted stock units, which have been determined based upon the market value of the Company’s shares on the grant date, are expensed over the vesting period.  From January 1, 2023, through September 30, 2023, the Company issued a total of 1,973,973 restricted stock units to various employees. Of those, 83,210 were inducement grants for restricted stock units, all of which were made pursuant to the 2020 Inducement Stock Incentive Plan.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The following table summarizes information on the Company’s restricted stock awards and units:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:24.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Restricted Stock Awards and Units</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Grant</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested at December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,516,336</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 45.67</p></td></tr><tr><td style="vertical-align:bottom;width:73.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,973,973</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 40.00</p></td></tr><tr><td style="vertical-align:bottom;width:73.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (778,442)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 46.34</p></td></tr><tr><td style="vertical-align:bottom;width:73.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (297,765)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 42.65</p></td></tr><tr><td style="vertical-align:bottom;width:73.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested at September 30, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,414,102</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 42.50</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Employee Stock Purchase Plan</i>—In June 2016, the Company established an Employee Stock Purchase Plan (as amended, “ESPP” or the "Plan”), for certain eligible employees. The Plan is administered by the Company’s Board of Directors or a committee appointed by the Company’s Board of Directors. In June 2021, the Plan was amended to increase the total number of shares available for purchase under the Plan from one million shares to two million shares of the Company’s common stock. Employees may participate over a six month period through payroll withholdings and may purchase, at the end of the six month period, the Company’s common stock at a purchase price of at least 85% of the closing price of a share of the Company’s common stock on the first business day of the offering period or the closing price of a share of the Company’s common stock on the last business day of the offering period, whichever is lower. No participant will be granted a right to purchase the Company’s common stock under the Plan if such participant would own more than 5% of the total combined voting power of the Company or any subsidiary of the Company after such purchase. For the three and nine months ended September 30, 2023, the Company recorded $0.7 million and $2.0 million, respectively, in compensation expense related to the ESPP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company recorded share-based compensation expense in the statement of operations related to incentive stock options, nonstatutory stock options, restricted stock awards, restricted stock units and the ESPP as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100.67%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 13,986</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 15,063</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 44,828</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 41,896</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Selling, general and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 12,956</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 13,607</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 40,300</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 41,093</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 26,942</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 28,670</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 85,128</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 82,989</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As of September 30, 2023, there was approximately $179.3 million of total unrecognized compensation cost related to unvested share-based compensation arrangements granted under the Company’s equity award plans. This cost is expected to be recognized as share-based compensation expense over the weighted average remaining service period of approximately 1.9 years.</p> 16724212 8475000 6802210 0 1000000 1000000 1300000 1700000 1705941 1 1.10 0.10 P10Y P4Y 1059054 121460 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">  </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted-</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">value(in </b></p></td></tr><tr><td style="vertical-align:bottom;width:46.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">options</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">term</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 11,502,417</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 43.33</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:46.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,059,054</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 41.29</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:46.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (806,407)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 29.48</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:46.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited/Cancelled</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (318,281)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 47.84</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:46.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding at September 30, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 11,436,783</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 43.99</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5.87</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,084</p></td></tr><tr><td style="vertical-align:bottom;width:46.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested or Expected to vest at September 30, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,357,250</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 46.72</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 8.23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:46.66%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercisable at September 30, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 8,533,144</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 43.18</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5.05</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,084</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p> 11502417 43.33 1059054 41.29 806407 29.48 318281 47.84 11436783 43.99 P5Y10M13D 5084000 2357250 46.72 P8Y2M23D 8533144 43.18 P5Y18D 5084000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:28.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine months ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:68.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.54% - 3.91%</p></td></tr><tr><td style="vertical-align:bottom;width:68.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">53% - 54%</p></td></tr><tr><td style="vertical-align:bottom;width:68.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:28.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">5.5 years</p></td></tr></table> 0.0354 0.0391 0.53 0.54 P5Y6M 0 21.83 1973973 83210 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:24.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Restricted Stock Awards and Units</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Weighted</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Average</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Grant</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested at December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,516,336</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 45.67</p></td></tr><tr><td style="vertical-align:bottom;width:73.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,973,973</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 40.00</p></td></tr><tr><td style="vertical-align:bottom;width:73.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Vested</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (778,442)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 46.34</p></td></tr><tr><td style="vertical-align:bottom;width:73.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (297,765)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 42.65</p></td></tr><tr><td style="vertical-align:bottom;width:73.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Unvested at September 30, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,414,102</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 42.50</p></td></tr></table> 2516336 45.67 1973973 40.00 778442 46.34 297765 42.65 3414102 42.50 1000000 2000000 P6M 0.85 0.05 700000 2000000.0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100.67%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 13,986</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 15,063</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 44,828</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 41,896</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Selling, general and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 12,956</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 13,607</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 40,300</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 41,093</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 26,942</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 28,670</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.79%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 85,128</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 82,989</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p> 13986000 15063000 44828000 41896000 12956000 13607000 40300000 41093000 26942000 28670000 85128000 82989000 179300000 P1Y10M24D <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">9.        Debt</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Liability for sale of future royalties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In July 2020, the Company entered into the Royalty Purchase Agreement. As RPI’s interest is explicitly limited, the $650.0 million cash consideration was classified as debt and is recorded as “liability for sale of future royalties-current” and “liability for sale of future royalties-noncurrent” on the Company’s consolidated balance sheet based on the timing of the expected payments to be made to RPI. The fair value for the liability for sale of future royalties at the time of the transaction was based on the Company’s estimates of future royalties expected to be paid to RPI over the life of the arrangement, which was determined using forecasts from market data sources, which are considered Level 3 inputs. The liability is being amortized using the effective interest method over the life of the arrangement, in accordance with ASC 470 and ASC 835. The initial annual effective interest rate was determined to be 11.0%. The Company utilizes the prospective method to account for subsequent changes in the estimated future payments to be made to RPI and updates the effective interest rate on a quarterly basis. Issuance costs related to the transaction were determined to be immaterial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table shows the activity within the “liability for sale of future royalties- current” and “liability for sale of future royalties- noncurrent” accounts for the nine months ended September 30, 2023:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:22.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:69.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:27.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Liability for sale of future royalties- (current and noncurrent)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:27.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Beginning balance as of December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 757,886</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: Non-cash royalty revenue payable to RPI</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (50,599)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Plus: Non-cash interest expense recognized</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 56,031</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Ending balance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 763,318</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Effective interest rate as of September 30, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">9.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Non-cash interest expense is recorded in the statement of operations within “Interest expense, net”.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-style:italic;">Senior Secured Term Loan</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">On October 27, 2022 (the “Closing Date”), the Company entered into a credit agreement (the “Blackstone Credit Agreement”) for fundings of up to $950.0 million consisting of a committed loan facility of $450.0 million and further contemplating the potential for up to $500.0 million of additional financing, to the extent that the Company requests such additional financing and subject to the Lenders’ agreement to provide such additional financing and to mutual agreement on terms, among the Company, certain subsidiaries of the Company (together with the Company, the “Loan Parties”) and funds and other affiliated entities advised or managed by Blackstone Life Sciences and Blackstone Credit (collectively, “Blackstone”, and such lenders, together with their permitted assignees, the “Lenders” and each a “Lender”) and Wilmington Trust, National Association, as the administrative agent for the Lenders.  </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;">The Blackstone Credit Agreement provides for a senior secured term loan facility funded on the Closing Date in the aggregate principal amount of </span><span style="font-size:10pt;">$300.0</span><span style="font-size:10pt;"> million (the “Initial Loans”) and a committed delayed draw term loan facility of up to </span><span style="font-size:10pt;">$150.0</span><span style="font-size:10pt;"> million (the “Delayed Draw Loans” and, together with the Initial Loans, the “Loans”) to be funded at the Company’s request within </span><span style="font-size:10pt;">18 months</span><span style="font-size:10pt;"> of the Closing Date subject to specified conditions. In addition, the Blackstone Credit Agreement contemplates the potential for further financings by Blackstone, by providing for incremental discretionary uncommitted further financings of up to </span><span style="font-size:10pt;">$500.0</span><span style="font-size:10pt;"> million. The Company capitalized approximately </span><span style="font-size:10pt;">$11.6</span><span style="font-size:10pt;"> million of debt issuance costs which are presented on the balance sheet as a direct deduction from the debt liability and are being amortized over the term of the senior secured term loan facility using the effective interest rate method.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;">The Loans mature on the date that is </span><span style="font-size:10pt;">seven years</span><span style="font-size:10pt;"> from the Closing Date. Borrowings under the Blackstone Credit Agreement bear interest at a variable rate equal to, at the Company’s option, either an adjusted Term SOFR rate plus seven and a quarter percent </span><span style="font-size:10pt;">(7.25%)</span><span style="font-size:10pt;"> or the Base Rate plus six and a quarter percent </span><span style="font-size:10pt;">(6.25%)</span><span style="font-size:10pt;">, subject to a floor of one percent </span><span style="font-size:10pt;">(1%)</span><span style="font-size:10pt;"> and two percent </span><span style="font-size:10pt;">(2%)</span><span style="font-size:10pt;"> with respect to Term SOFR rate and Base Rate (each as defined in the Blackstone Credit Agreement), respectively. Payment of the Loans are subject to certain premiums specified in the Blackstone Credit Agreement, in each case, from the date the applicable Loan is funded.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">All obligations under the Blackstone Credit Agreement are secured, subject to certain exceptions and specified inclusions, by security interests in certain assets of the Loan Parties, including (1) intellectual property and other assets related to Translarna, Emflaza, Upstaza, sepiapterin and, until certain release conditions are met, vatiquinone, in each case, together with any other forms, formulations, or methods of delivery of any such products, and regardless of trade or brand name, (2) future acquired intellectual property (but not internally developed intellectual property unrelated to other intellectual property collateral) and other related assets, and (3) the equity interests held by the Loan Parties in certain of their subsidiaries. The Blackstone Credit Agreement contains certain negative covenants with which the Company must remain in compliance. The Blackstone Credit Agreement also requires that the Company maintains consolidated liquidity of at least $100.0 million as of the last day of each fiscal quarter, which shall be increased to $200.0 million upon the Company consummating acquisitions meeting certain consolidated thresholds described therein. In addition, the Company will be required under conditions specified in the Blackstone Credit Agreement to fund a reserve account up to certain amounts specified therein, including $50.0 million that the Company funded into the reserve account during the quarter ended March 31, 2023 and was released back to the Company during the quarter ended June 30, 2023.  The funds in the reserve </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">account are available to prepay the Loans at any time at the Company’s option, and are, if funded, subject to release upon certain further conditions. Upon any such release, such funds are freely available for use by the Company subject to the generally applicable terms and conditions of the Blackstone Credit Agreement. The Blackstone Credit Agreement contains certain customary representations and warranties, affirmative covenants and provisions relating to events of default.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Blackstone Credit Agreement consists of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Principal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 300,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 300,000</p></td></tr><tr><td style="vertical-align:bottom;width:50.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: Debt issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (10,742)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (11,322)</p></td></tr><tr><td style="vertical-align:bottom;width:50.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net carrying amount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 289,258</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 288,678</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;">As of September 30, 2023, the remaining contractual life of the Blackstone Credit Agreement is approximately </span><span style="font-size:10pt;">6.1</span><span style="font-size:10pt;"> years.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table sets forth total interest expense recognized related to the Blackstone Credit Agreement:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:56.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:middle;width:56.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contractual interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 9,554</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 28,087</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:middle;width:56.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization of debt issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 280</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 702</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:middle;width:56.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 9,834</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 28,789</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:middle;width:56.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Effective interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">13.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">13.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">2026 Convertible Notes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In September 2019, the Company issued, at par value, $287.5 million aggregate principal amount of 1.50% convertible senior notes due 2026, which included an option to purchase up to an additional $37.5 million in aggregate principal amount of the 2026 Convertible Notes, which was exercised in full by the initial purchasers. The 2026 Convertible Notes bear cash interest at a rate of 1.50% per year, payable semi-annually on March 15 and September 15 of each year, beginning on March 15, 2020. The 2026 Convertible Notes will mature on September 15, 2026, unless earlier repurchased or converted. The net proceeds to the Company from the offering were $279.3 million after deducting the initial purchasers’ discounts and commissions and the offering expenses payable by the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The 2026 Convertible Notes are governed by an indenture (the "2026 Convertible Notes Indenture") with U.S Bank National Association as trustee (the "2026 Convertible Notes Trustee").</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Holders of the 2026 Convertible Notes may convert their 2026 Convertible Notes at their option at any time prior to the close of business on the business day immediately preceding March 15, 2026 only under the following circumstances:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">during any calendar quarter commencing on or after December 31, 2019 (and only during such calendar quarter), if the last reported sale price of the Company’s common stock for at least </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">20</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> trading days (whether or not consecutive) during a period of </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">30</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">130%</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> of the conversion price on each applicable trading day;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">during the </span><span style="-sec-ix-hidden:Hidden_mLvQVxSOYkCfWoLeDKQwEw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">five</span></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> business day period after any </span><span style="-sec-ix-hidden:Hidden_FRn73_e7W02RODAKJFXzCQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">five</span></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> consecutive trading day period (the “measurement period”) in which the trading price (as defined in the 2026 Convertible Notes Indenture) per $1,000 principal amount of 2026 Convertible Notes for each trading day of the measurement period was less than </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">98%</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> of the product of the last reported sale price of the Company’s common stock and the conversion rate on each such trading day;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">during any period after the Company has issued notice of redemption until the close of business on the scheduled trading day immediately preceding the relevant redemption date; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">upon the occurrence of specified corporate events.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On or after March 15, 2026, until the close of business on the business day immediately preceding the maturity date, holders may convert their 2026 Convertible Notes at any time, regardless of the foregoing circumstances. Upon conversion, the Company will pay or deliver, as the case may be, cash, shares of the Company’s common stock or any combination thereof at the Company’s election.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The conversion rate for the 2026 Convertible Notes was initially, and remains, 19.0404 shares of the Company’s common stock per $1,000 principal amount of the 2026 Convertible Notes, which is equivalent to an initial conversion price of approximately $52.52 per share of the Company’s common stock. The conversion rate may be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company was not permitted to redeem the 2026 Convertible Notes prior to September 20, 2023. The Company may redeem for cash all or any portion of the 2026 Convertible Notes, at its option, if the last reported sale price of its common stock has been at least 130% of the conversion price then in effect on the last trading day of, and for at least 19 other trading days (whether or not consecutive) during, any 30 consecutive trading day period ending on, and including, the trading day immediately preceding the date on which the Company provides notice of redemption, at a redemption price equal to 100% of the principal amount of the 2026 Convertible Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date. No sinking fund is provided for the 2026 Convertible Notes, which means that the Company is not required to redeem or retire the 2026 Convertible Notes periodically.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">If the Company undergoes a “fundamental change” (as defined in the 2026 Convertible Notes Indenture), subject to certain conditions, holders of the 2026 Convertible Notes may require the Company to repurchase for cash all or part of their 2026 Convertible Notes at a repurchase price equal to 100% of the principal amount of the 2026 Convertible Notes to be repurchased, plus accrued and unpaid interest to, but excluding, the fundamental change repurchase date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The 2026 Convertible Notes represent senior unsecured obligations and will rank senior in right of payment to the Company’s future indebtedness that is expressly subordinated in right of payment to the notes, equal in right of payment to the Company’s existing and future unsecured indebtedness that is not so subordinated, effectively junior in right of payment to any of the Company’s secured indebtedness to the extent of the value of the assets securing such indebtedness, and structurally subordinated to all existing and future indebtedness and other liabilities (including trade payables) incurred by the Company’s subsidiaries. The 2026 Convertible Notes Indenture contains customary events of default with respect to the 2026 Convertible Notes, including that upon certain events of default (including the Company’s failure to make any payment of principal or interest on the 2026 Convertible Notes when due and payable) occurring and continuing, the 2026 Convertible Notes Trustee by notice to the Company, or the holders of at least 25% in principal amount of the outstanding 2026 Convertible Notes by notice to the Company and the Convertible Notes Trustee, may, and the 2026 Convertible Notes Trustee at the request of such holders (subject to the provisions of the 2026 Convertible Notes Indenture) shall, declare 100% of the principal of and accrued and unpaid interest, if any, on all the 2026 Convertible Notes to be due and payable. In case of certain events of bankruptcy, insolvency or reorganization, involving the Company or a significant subsidiary, 100% of the principal of and accrued and unpaid interest on the 2026 Convertible Notes will automatically become due and payable. Upon such a declaration of acceleration, such principal and accrued and unpaid interest, if any, will be due and payable immediately.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The 2026 Convertible Notes consist of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Principal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 287,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 287,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: Debt issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,584)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,456)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net carrying amount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 283,916</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 283,044</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of September 30, 2023, the remaining contractual life of the 2026 Convertible Notes is approximately 3.0 years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table sets forth total interest expense recognized related to the 2026 Convertible Notes:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr></table><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:43.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;">    </span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:middle;width:43.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contractual interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,080</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,081</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,215</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,217</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:middle;width:43.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization of debt issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 294</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 289</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 872</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 856</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:middle;width:43.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,374</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,370</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,087</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,073</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:middle;width:43.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Effective interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In April 2022, under the terms of the 2026 Convertible Notes Indenture, the Company paid additional interest on the 2026 Convertible Notes at a rate equal to 0.5% per annum, for a total interest payment of approximately $2.1 million, for the period beginning September 25, 2020 and ending March 14, 2022. In September 2022, under the terms of the 2026 Convertible Notes Indenture, the Company paid additional interest on the 2026 Convertible Notes at a rate equal to 0.5% per annum, for a total interest payment of approximately $0.1 million, for the period beginning March 15, 2022 and ending April 8, 2022. These amounts are not included in the table above, but were recorded as interest expense, net within the statement of operations for the nine months ended September 30, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">2022 Convertible Notes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In August 2015, the Company issued, at par value, $150.0 million aggregate principal amount of 3.00% convertible senior notes due 2022, (the “2022 Convertible Notes”). On August 15, 2022, the Company repaid the outstanding principal amount and accrued interest, totaling $152.3 million, of the 2022 Convertible Notes that was due upon maturity in accordance with the terms of the notes. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table sets forth total interest expense recognized related to the 2022 Convertible Notes:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contractual interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 559</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,800</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization of debt issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 92</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 460</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 651</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,260</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Effective interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p> 650000000.0 0.110 <p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:22.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:69.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:27.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Liability for sale of future royalties- (current and noncurrent)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:27.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Beginning balance as of December 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 757,886</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: Non-cash royalty revenue payable to RPI</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (50,599)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Plus: Non-cash interest expense recognized</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.19%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 56,031</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Ending balance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.19%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 763,318</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Effective interest rate as of September 30, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:22.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">9.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table> 757886000 50599000 56031000 763318000 0.093 950000000.0 450000000.0 500000000.0 300000000.0 150000000.0 P18M 500000000.0 11600000 P7Y 0.0725 0.0625 0.01 0.02 100000000.0 200000000.0 50000000.0 <p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:50.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Principal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 300,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 300,000</p></td></tr><tr><td style="vertical-align:bottom;width:50.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: Debt issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (10,742)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (11,322)</p></td></tr><tr><td style="vertical-align:bottom;width:50.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net carrying amount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 289,258</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.61%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 288,678</p></td></tr></table> 300000000 300000000 10742000 11322000 289258000 288678000 P6Y1M6D <p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:56.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.8%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:middle;width:56.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contractual interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 9,554</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.8%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 28,087</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:middle;width:56.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization of debt issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 280</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 702</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:middle;width:56.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 9,834</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.8%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 28,789</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:middle;width:56.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Effective interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">13.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.8%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">13.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table> 9554000 28087000 280000 702000 9834000 28789000 0.131 0.131 287500000 0.0150 37500000 0.0150 279300000 20 30 1.30 0.98 19.0404 52.52 1.30 19 30 1 0 1 0.25 1 1 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:69.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:69.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">September 30, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Principal</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 287,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 287,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Less: Debt issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (3,584)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (4,456)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:69.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net carrying amount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.26%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 283,916</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.84%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0.05pt 0pt;"> 283,044</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.11%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table> 287500000 287500000 3584000 4456000 283916000 283044000 P3Y <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:1pt;margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr></table><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:43.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;">    </span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:middle;width:43.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contractual interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,080</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,081</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,215</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,217</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:middle;width:43.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization of debt issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 294</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 289</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 872</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 856</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:middle;width:43.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,374</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,370</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,087</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,073</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:middle;width:43.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Effective interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.69%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.97%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table> 1080000 1081000 3215000 3217000 294000 289000 872000 856000 1374000 1370000 4087000 4073000 0.019 0.019 0.019 0.019 0.005 2100000 0.005 100000 150000000.0 0.0300 152300000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended September 30, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Contractual interest expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 559</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,800</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Amortization of debt issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 92</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 460</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 651</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3,260</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:43.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Effective interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.22%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.45%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.87%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 3.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p> 559000 2800000 92000 460000 651000 3260000 0.035 0.035 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">10.        Commitments and contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Under various agreements, the Company will be required to pay royalties and milestone payments upon the successful development and commercialization of products. The Company has entered into funding agreements with The Wellcome Trust Limited ("Wellcome Trust") for the research and development of small molecule compounds in connection with the Company’s oncology and antibacterial programs. As the Company has discontinued development under its antibacterial program, it no longer expects that milestone and royalty payments from the Company to Wellcome Trust will apply under that agreement, resulting in a change to the total amount of development and regulatory milestone payments the Company may become obligated to pay for this program. Under the oncology program funding agreement, to the extent that the Company develops and commercializes program intellectual property on a for-profit basis itself or in collaboration with a partner (provided the Company retains overall control of worldwide commercialization), the Company may become obligated to pay to Wellcome Trust development and regulatory milestone payments and single-digit royalties on sales of any research program product. The Company’s obligation to pay such royalties would continue on a country-by-country basis until the longer of the expiration of the last patent in the program intellectual property in such country covering the research program product and the expiration of market exclusivity of such product in such country. The Company made the first development milestone payment of $0.8 million to Wellcome Trust under the oncology platform funding agreement during the second quarter of 2016. During the year ended December 31, 2022, the Company incurred $2.5 million of development milestones in connection with the enrollment of patients in the registration-directed Phase 2/3 trial of unesbulin for the treatment of LMS, which is recorded in accounts payable and accrued expenses on the balance sheet and will be payable upon the earlier to occur of the first dose administered to the last patient enrolled in the study or the </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">termination of dosing of all patients in the study. Additional milestone payments of up to an aggregate of $14.5 million may become payable by the Company to Wellcome Trust under this agreement.</p><p style="font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';">The Company has also entered into a collaboration agreement with the SMA Foundation. The Company is obligated to pay the SMA Foundation single-digit royalties on worldwide net product sales of any collaboration product that is successfully developed and subsequently commercialized or, with respect to collaboration products the Company outlicenses, including Evrysdi, a specified percentage of certain payments the Company receives from its licensee. Since inception, the SMA Foundation has earned </span><span style="font-family:'Times New Roman','Times','serif';">$40.3</span><span style="font-family:'Times New Roman','Times','serif';"> million, </span><span style="font-family:'Times New Roman','Times','serif';">$35.3</span><span style="font-family:'Times New Roman','Times','serif';"> million which was paid and </span><span style="font-family:'Times New Roman','Times','serif';">$5.0</span><span style="font-family:'Times New Roman','Times','serif';"> million which was accrued as of September 30, 2023. The Company’s obligation to make such payments would end upon the Company’s payment to the SMA Foundation of an aggregate of </span><span style="font-family:'Times New Roman','Times','serif';">$52.5</span><span style="font-family:'Times New Roman','Times','serif';"> million.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Pursuant to the asset purchase agreement ("Asset Purchase Agreement") between the Company and Marathon Pharmaceuticals, LLC (now known as Complete Pharma Holdings, LLC) (“Marathon”), Marathon is entitled to receive contingent payments from the Company based on annual net sales of Emflaza up to a specified aggregate maximum amount over the expected commercial life of the asset. In addition, Marathon received a $50.0 million sales-based milestone during the nine months ended September 30, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Pursuant to the Agilis Merger Agreement, Agilis equityholders were previously entitled to receive contingent consideration payments from the Company based on (i) the achievement of certain development milestones up to an aggregate maximum amount of $60.0 million, (ii) the achievement of certain regulatory approval milestones together with a milestone payment following the receipt of a priority review voucher up to an aggregate maximum amount of $535.0 million, (iii) the achievement of certain net sales milestones up to an aggregate maximum amount of $150.0 million, and (iv) a percentage of annual net sales for Friedreich ataxia and Angelman syndrome during specified terms, ranging from 2%-6%. The Company was required to pay $40.0 million of the development milestone payments upon the passing of the second anniversary of the closing of the Agilis Merger, regardless of whether the applicable milestones have been achieved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Pursuant to the terms of the Rights Exchange Agreement, the Participating Rightholders canceled and forfeited their rights under the Agilis Merger Agreement to receive (i) $174.0 million, in the aggregate, of potential milestone payments based on the achievement of certain regulatory milestones and (ii) $37.6 million, in the aggregate, of $40.0 million in development milestone payments that would have been due upon the passing of the second anniversary of the closing of the Agilis Merger, regardless of whether the milestones are achieved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Rights Exchange Agreement has no effect on the Agilis Merger Agreement other than to provide for the cancellation and forfeiture of the Participating Rightholders’ rights to receive $211.6 million, in the aggregate, of the milestone payments described above. As a result, all other rights and obligations under the Agilis Merger Agreement remain in effect pursuant to their terms, including the Company’s obligation to pay up to an aggregate maximum amount of $20.0 million upon the achievement of certain development milestones (representing the remaining portion of potential development milestone payments for which rights were not canceled and forfeited pursuant to the Rights Exchange Agreement while excluding the remaining $2.4 million milestone payment that was due and paid upon the passing of the second anniversary of the closing of the Agilis Merger), up to an aggregate maximum amount of $361.0 million upon the achievement of certain regulatory milestones (representing the remaining portion of potential regulatory milestone payments for which rights were not canceled and forfeited pursuant to the Rights Exchange Agreement), up to a maximum aggregate amount of $150.0 million upon the achievement of certain net sales milestones and a percentage of annual net sales for Friedreich ataxia and Angelman syndrome during specified terms, ranging from 2% to 6%, pursuant to the terms of the Agilis Merger Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">In July 2022, the European Commission approved Upstaza for the treatment of AADC deficiency for patients 18 months and older within the EEA. As a result of such approval, the Company paid the former equityholders of Agilis $50.0 million in accordance with the terms of the Agilis Merger Agreement in the year ended December 31, 2022. In May 2023, as part of the Company’s strategic portfolio prioritization, the Company decided to discontinue its preclinical and early research programs in its gene therapy platform, which included Friedreich ataxia and Angelman syndrome. As a result, the Company does not expect the milestones related to Friedreich ataxia and Angelman syndrome to be achieved. In addition, the Company does not expect to pay the 2% to 6% royalties on annual net sales related to Friedreich ataxia and Angelman syndrome. As of September 30, 2023, the remaining potential development and regulatory milestones the Company </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">expects to achieve is $31.1 million, and the remaining potential sales milestones the Company expects to achieve is $50.0 million, both of which relate solely to Upstaza. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On October 25, 2019, the Company completed the acquisition of substantially all of the assets of BioElectron Technology Corporation (“BioElectron”), a Delaware corporation, including certain compounds that the Company has begun to develop as part of its Bio-e platform, pursuant to an asset purchase agreement by and between the Company and BioElectron, dated October 1, 2019 (the “BioElectron Asset Purchase Agreement”). BioElectron was a private company with a pipeline focused on inflammatory and central nervous system (CNS) disorders. The lead program, vatiquinone, is in late stage development for CNS disorders with substantial unmet need and significant commercial opportunity that are complementary to PTC’s existing pipeline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Subject to the terms and conditions of the BioElectron Asset Purchase Agreement, BioElectron may become entitled to receive contingent milestone payments of up to $200.0 million (in cash or in shares of the Company’s common stock, as determined by the Company) from the Company based on the achievement of certain regulatory and net sales milestones. Subject to the terms and conditions of the BioElectron Asset Purchase Agreement, BioElectron may also become entitled to receive contingent payments based on a percentage of net sales of certain products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Subject to the terms and conditions of the Agreement and Plan of Merger, dated as of May 5, 2020 (the “Censa Merger Agreement”) by and among the Company, Hydro Merger Sub, Inc., the Company’s wholly owned, indirect subsidiary, and, solely in its capacity as the representative, agent and attorney-in-fact of the securityholders of Censa, Shareholder Representative Services LLC (such merger pursuant thereto, the “Censa Merger”), former Censa securityholders may become entitled to receive contingent payments from the Company based on (i) the achievement of certain development and regulatory milestones up to an aggregate maximum amount of $217.5 million for <span style="background:#ffffff;">sepiapterin</span>’s two most advanced programs and receipt of a priority review voucher from the FDA as set forth in the Censa Merger Agreement, (ii) $109.0 million in development and regulatory milestones for each additional indication of <span style="background:#ffffff;">sepiapterin</span>, (iii) the achievement of certain net sales milestones up to an aggregate maximum amount of $160.0 million, (iv) a percentage of annual net sales during specified terms, ranging from single to low double digits of the applicable net sales threshold amount, and (v) any sublicense fees paid to the Company in consideration of any sublicense of Censa’s intellectual property to commercialize <span style="background:#ffffff;">sepiapterin</span>, on a country-by-country basis, which contingent payment shall equal to a mid-double digit percentage of any such sublicense fees. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In February 2023, the Company completed enrollment of its Phase 3 placebo-controlled clinical trial for sepiapterin for PKU.  In connection with this event and pursuant to the Censa Merger Agreement, the Company paid a $30.0 million development milestone to the former Censa securityholders during the nine months ended September 30, 2023. The Company elected to pay this milestone in the form of shares of its common stock, less certain cash payments in accordance with the Censa Merger Agreement. Pursuant to such election, the Company issued 657,462 shares of its common stock and paid $0.4 million to the former Censa securityholders. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company also has the Tegsedi-Waylivra Agreement for the commercialization of Tegsedi and Waylivra, and products containing those compounds in countries in Latin America and the Caribbean. Akcea is entitled to receive royalty payments subject to certain terms set forth in the Tegsedi-Waylivra Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has employment agreements with certain employees which require the funding of a specific level of payments, if certain events, such as a change in control or termination without cause, occur. Additionally, the Company has royalty payments associated with Translarna, Emflaza, and Upstaza net product revenue, payable quarterly or annually in accordance with the terms of the related agreements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">From time to time in the ordinary course of its business, the Company is subject to claims, legal proceedings and disputes. The Company is not currently aware of any material legal proceedings against it.</p> 800000 2500000 14500000 40300000 35300000 5000000.0 52500000 50000000.0 60000000.0 535000000.0 150000000.0 0.02 0.06 40000000.0 174000000.0 37600000 40000000.0 211600000 20000000.0 2400000 361000000.0 150000000.0 0.02 0.06 50000000.0 0.02 0.06 31100000 50000000.0 200000000.0 217500000 109000000.0 160000000.0 30000000.0 657462 400000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">11.        Revenue recognition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Net product sales</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company views its operations and manages its business in one operating segment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the three months ended September 30, 2023 and 2022, net product sales outside of the United States were $76.6 million and $79.4 million, respectively, consisting of sales of Translarna, Tegsedi, Waylivra, and Upstaza. Translarna net revenues made up $69.0 million and $76.6 million of the net product sales outside of the United States for the three months ended September 30, 2023 and 2022, respectively. During the three months ended September 30, 2023, and 2022, net product sales in the United States were $67.4 million and $54.8 million, respectively, consisting solely of sales of Emflaza. During the three months ended September 30, 2023, one country, the United States, accounted for at least 10% of the Company’s net product sales, representing $67.4 million of the net product sales. During the three months ended September 30, 2022, two countries, the United States and Russia, accounted for at least 10% of the Company’s net product sales, representing $54.8 million and $28.3 million of the net product sales, respectively. For the three months ended September 30, 2023 and 2022, the Company had a total of three and two distributors, respectively, that each accounted for over 10% of the Company’s net product sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">During the nine months ended September 30, 2023 and 2022, net product sales outside of the United States were $318.5 million and $247.6 million, respectively, consisting of Translarna, Tegsedi, Waylivra, and Upstaza. Translarna net revenues made up $280.6 million and $232.9 million of the net product sales outside of the United States for the nine months ended September 30, 2023 and 2022, respectively. For the nine months ended September 30, 2023 and 2022, net product sales in the United States were $187.7 million and $160.1 million, respectively, consisting solely of Emflaza. During the nine months ended September 30, 2023, three countries, the United States, Russia, and Brazil, accounted for at least 10% of the Company’s net product sales, representing $187.7 million, $69.0 million, and $52.5 million of net product sales, respectively. During the nine months ended September 30, 2022, two countries, the United States and Russia, accounted for at least 10% of the Company’s net product sales, representing $160.1 million and $57.1 million of net product sales, respectively. For the nine months ended September 30, 2023 and 2022, the Company had a total of two and two distributors, respectively, that each accounted for over 10% of the Company's net product sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of September 30, 2023 and December 31, 2022, the Company does not have a contract liabilities balance related to net product sales, and has not made significant changes to the judgments made in applying ASC Topic 606.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Collaboration and Royalty revenue</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In November 2011, the Company and the SMA Foundation entered into the SMA License Agreement with Roche. Under the terms of the SMA License Agreement, Roche acquired an exclusive worldwide license to the Company’s SMA program.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Under the SMA License Agreement, the Company is eligible to receive additional payments from Roche if specified events are achieved with respect to each licensed product, including up to $135.0 million in research and development event milestones, up to $325.0 million in sales milestones upon achievement of specified sales events, and up to double digit royalties on worldwide annual net sales of a commercial product. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The SMA program currently has one approved product, Evrysdi, which was approved in August 2020 by the FDA for the treatment of SMA in adults and children two months and older. As of September 30, 2023, the Company does not have any remaining research and development event milestones that can be received. The remaining potential sales milestones that can be received is $250.0 million. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">For the three months ended September 30, 2023, the Company did not recognize collaboration revenue related to the SMA License Agreement with Roche. For the three months ended September 30, 2022, the Company recognized $50.0 million of collaboration revenue related to the SMA License Agreement. For the nine months ended September 30, 2023, the amounts recognized for the collaboration revenue related to the SMA License Agreement with Roche were immaterial. For the nine months ended September 30, 2022, the Company recognized $50.0 million of collaboration revenue related </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">to the SMA License Agreement. In September 2022, the Company recognized a sales milestone of $50.0 million for the achievement of $750.0 million in worldwide annual net sales from Evrysdi.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In addition to research and development and sales milestones, the Company is eligible to receive up to double-digit royalties on worldwide annual net sales of a commercial product under the SMA License Agreement. For the three and nine months ended September 30, 2023, the Company has recognized $50.2 million and $117.9 million of royalty revenue related to Evrysdi, respectively. For the three and nine months ended September 30, 2022, the Company has recognized $32.9 million and $73.6 million of royalty revenue, respectively, related to Evrysdi.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">Manufacturing Revenue</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">For the three and nine months ended September 30, 2023, the Company recognized $2.4 million and $6.7 million of manufacturing revenue, respectively, related to the <span style="background:#ffffff;">production of plasmid DNA and AAV vectors for gene therapy applications for external customers.</span> No manufacturing revenue was recognized for the three and nine months ended September 30, 2022. The Company has not made significant changes to the judgments made in applying ASC Topic 606 for the three and nine months ended September 30, 2023 and 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of September 30, 2023 and December 31, 2022, the Company has a contract liabilities balance of $1.2 million and $1.4 million, respectively, related to the production of plasmid DNA and AAV vectors for gene therapy applications for external customers, which is recorded within deferred revenue on the consolidated balance sheet. For the three-month period ended September 30, 2023, the Company did not recognize any revenue related to the amount included in the contract liability balance at the beginning of the period. For the nine-month period ended September 30, 2023, the Company recognized $1.4 million related to the amounts included in the contract liability balance at the beginning of the period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">As of September 30, 2023, the Company has contract assets of $1.4 million related to plasmid DNA and AAV production for external customers, which is recorded within prepaid expenses and other current assets on the consolidated balance sheet. The Company did not have any contract assets for the period ending December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Remaining performance obligations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">As of September 30, 2023 and December 31, 2022, the Company has remaining performance obligations of $1.2 million and $1.4 million, respectively, related to the production of plasmid DNA and AAV vectors for gene therapy applications for external customers. The Company expects to recognize revenue over the next one year, as the specific timing for satisfying the performance obligations is contingent upon a number of factors, including customers’ needs and schedules. </p> 1 1 1 1 76600000 79400000 69000000.0 76600000 67400000 54800000 1 0.10 67400000 2 0.10 54800000 28300000 3 2 0.10 0.10 318500000 247600000 280600000 232900000 187700000 160100000 3 0.10 187700000 69000000.0 52500000 2 0.10 160100000 57100000 2 2 0.10 0.10 0 0 135000000.0 325000000.0 0 250000000.0 0 50000000.0 50000000.0 50000000.0 750000000.0 50200000 117900000 32900000 73600000 2400000 6700000 0 0 1200000 1400000 0 1400000 1400000 1200000 1400000 P1Y <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">12.        Intangible assets and goodwill</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 12pt 0pt;">Definite-lived intangibles</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Definite-lived intangible assets consisted of the following at September 30, 2023 and December 31, 2022:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:19.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:19.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">Ending Balance at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">Reclass from</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">Foreign</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">Ending Balance at</b></p></td></tr><tr><td style="vertical-align:bottom;width:19.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Definite-lived</b></p></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">Indefinite Lived to</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">currency</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">September 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:19.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">intangibles assets, gross</b></p></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">Additions</b></p></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">Definite Lived</b></p></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">Impairment</b></p></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">translation</b></p></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:19.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Emflaza</p></td><td style="vertical-align:bottom;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 420,253</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 76,454</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 496,707</p></td></tr><tr><td style="vertical-align:bottom;width:19.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Waylivra</p></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 9,316</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 157</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (96)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 9,377</p></td></tr><tr><td style="vertical-align:bottom;width:19.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tegsedi</p></td><td style="vertical-align:bottom;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 7,109</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,299</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (183)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 11,225</p></td></tr><tr><td style="vertical-align:bottom;width:19.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Upstaza</p></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 89,550</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 89,550</p></td></tr><tr><td style="vertical-align:bottom;width:19.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Total definite-lived intangibles, gross</b></p></td><td style="vertical-align:bottom;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 526,228</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 80,910</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (279)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 606,859</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">Ending Balance at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">Foreign</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">Ending Balance at</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Definite-lived</b></p></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">currency</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">September 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">intangibles assets, accumulated amortization</b></p></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">Amortization</b></p></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">translation</b></p></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Emflaza</p></td><td style="vertical-align:bottom;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (266,023)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (138,038)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (404,061)</p></td></tr></table><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:43.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Waylivra</p></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,751)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (791)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 45</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,497)</p></td></tr><tr><td style="vertical-align:bottom;width:43.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tegsedi</p></td><td style="vertical-align:bottom;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,709)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,035)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 36</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,708)</p></td></tr><tr><td style="vertical-align:bottom;width:43.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Upstaza</p></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,420)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,597)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9,017)</p></td></tr><tr><td style="vertical-align:bottom;width:43.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Total definite-lived intangibles, accumulated amortization</b></p></td><td style="vertical-align:bottom;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (273,903)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (145,461)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 81</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (419,283)</p></td></tr><tr><td style="vertical-align:bottom;width:43.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:middle;width:43.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 18pt;"><b style="font-weight:bold;">Total definite-lived intangibles, net</b></p></td><td style="vertical-align:middle;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:8pt;font-weight:bold;margin-left:0pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 187,576</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Marathon is entitled to receive contingent payments from the Company based on annual net sales of Emflaza beginning in 2018, up to a specified aggregate maximum amount over the expected commercial life of the asset. In accordance with the guidance for an asset acquisition, the Company records the milestone payment when it becomes payable to Marathon and increases the cost basis for the Emflaza rights intangible asset. For the nine months ended September 30, 2023, total milestone payments of $76.5 million were recorded. These payments are being amortized over the remaining useful life of the Emflaza rights asset on a straight line basis. As of September 30, 2023, a milestone payable to Marathon of $43.9 million was recorded on the consolidated balance sheet within accounts payable and accrued expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Akcea is also entitled to receive royalty payments subject to certain terms set forth in the Tegsedi-Waylivra Agreement related to sales of Waylivra and Tegsedi. In accordance with the guidance for an asset acquisition, the Company records royalty payments when they become payable to Akcea and increase the cost basis for the Waylivra and Tegsedi intangible assets. For the nine months ended September 30, 2023, royalty payments of $4.3 million and $0.2 million were recorded for Tegsedi and Waylivra, respectively. As of September 30, 2023, a royalty payable of $0.9 million and $0.2 million for Tegsedi and Waylivra, respectively, was recorded on the consolidated balance sheet within accounts payable and accrued expenses. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">For the three months ended September 30, 2023 and 2022, the Company recognized amortization expense of $58.6 million and $31.0 million, respectively, related to the Emflaza rights, Upstaza, Waylivra, and Tegsedi intangible assets. For the nine months ended September 30, 2023 and 2022, the Company recognized amortization expense of $145.5 million and $80.8 million, respectively, related to the Emflaza rights, Upstaza, Waylivra, and Tegsedi intangible assets. The estimated future amortization of the Emflaza rights, Upstaza, Waylivra, and Tegsedi intangible assets is expected to be as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:24.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:26.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of September 30, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 58,640</p></td></tr><tr><td style="vertical-align:bottom;width:71.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 46,557</p></td></tr><tr><td style="vertical-align:bottom;width:71.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 10,041</p></td></tr><tr><td style="vertical-align:bottom;width:71.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 10,041</p></td></tr><tr><td style="vertical-align:bottom;width:71.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2027 and thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 62,297</p></td></tr><tr><td style="vertical-align:bottom;width:71.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 187,576</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">The weighted average remaining amortization period of the definite-lived intangibles as of September 30, 2023 is 5.3 years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 6pt 0pt;">Indefinite-lived intangibles</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">Indefinite-lived intangible assets consisted of the following at September 30, 2023 and December 31, 2022:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:19.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:19.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">Ending Balance at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">Reclass from</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">Foreign</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">Ending Balance at</b></p></td></tr><tr><td style="vertical-align:bottom;width:19.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Indefinite-lived</b></p></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">Indefinite Lived to</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">currency</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">September 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:19.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">intangibles assets</b></p></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">Additions</b></p></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">Definite Lived</b></p></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">Impairment</b></p></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">translation</b></p></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:19.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Upstaza</p></td><td style="vertical-align:bottom;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 235,766</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_Unumh6ZzlU-3bNHAj0IoqQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> —</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 235,766</p></td></tr><tr><td style="vertical-align:bottom;width:19.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PTC-FA</p></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 112,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_E0Td9w0E0U6F3uffNfNckg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> —</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (112,500)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:19.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PTC-AS</p></td><td style="vertical-align:bottom;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 105,300</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_5x376mMUaU6xqxSX1B2yKA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> —</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (105,300)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:19.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Total indefinite-lived intangibles</b></p></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 453,566</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_3elHy9YAcE2U_I8Yp2VG8w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> —</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (217,800)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 235,766</p></td></tr><tr><td style="vertical-align:bottom;width:19.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:19.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 18pt;"><b style="font-weight:bold;">Total intangible assets, net</b></p></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:8pt;font-weight:bold;margin-left:0pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 423,342</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">In connection with the acquisition of the Company’s gene therapy platform from Agilis, the Company acquired rights to Upstaza, for the treatment of AADC deficiency. AADC deficiency is a rare CNS disorder arising from reductions in the enzyme AADC that result from mutations in the dopa decarboxylase gene. The gene therapy platform also includes PTC-FA, an asset targeting Friedreich ataxia, a rare and life-shortening neurodegenerative disease caused by a single defect in the FXN gene which causes reduced production of the frataxin protein. Additionally, the gene therapy platform includes two other programs targeting CNS disorders, including PTC-AS for Angelman syndrome, a rare, genetic, neurological disorder characterized by severe developmental delays. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">In accordance with the acquisition method of accounting, the Company allocated the acquisition cost for the Agilis Merger to the underlying assets acquired and liabilities assumed, based upon the estimated fair values of those assets and liabilities at the date of acquisition. The Company classified the fair value of the acquired IPR&amp;D as indefinite lived intangible assets until the successful completion or abandonment of the associated research and development efforts. As of December 31, 2022, the value allocated to the indefinite lived intangible assets was $453.6 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">In May 2023, as part of the Company’s strategic portfolio prioritization, the Company decided to discontinue its preclinical and early research programs in its gene therapy platform, which included PTC-FA and PTC-AS. As a result, the Company determined that the PTC-FA and PTC-AS indefinite-lived intangible assets were fully impaired and recorded impairment expense of $217.8 million during the nine month period ended September 30, 2023, which is recorded as intangible asset impairment in the statement of operations. As of September 30, 2023, the remaining indefinite lived intangible asset balance is $235.8 million, consisting solely of Upstaza, which the Company plans to continue to develop and commercialize. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 6pt 0pt;">Goodwill</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">As a result of the Agilis Merger on August 23, 2018, the Company recorded $82.3 million of goodwill. As of September 30, 2023, there have been no changes to the balance of goodwill since the date of the Agilis Merger. Accordingly, the goodwill balance as of September 30, 2023 is $82.3 million.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Definite-lived intangible assets consisted of the following at September 30, 2023 and December 31, 2022:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:19.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:19.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">Ending Balance at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">Reclass from</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">Foreign</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">Ending Balance at</b></p></td></tr><tr><td style="vertical-align:bottom;width:19.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Definite-lived</b></p></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">Indefinite Lived to</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">currency</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">September 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:19.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">intangibles assets, gross</b></p></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">Additions</b></p></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">Definite Lived</b></p></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">Impairment</b></p></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">translation</b></p></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:19.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Emflaza</p></td><td style="vertical-align:bottom;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 420,253</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 76,454</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 496,707</p></td></tr><tr><td style="vertical-align:bottom;width:19.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Waylivra</p></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 9,316</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 157</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (96)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 9,377</p></td></tr><tr><td style="vertical-align:bottom;width:19.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tegsedi</p></td><td style="vertical-align:bottom;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 7,109</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,299</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (183)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 11,225</p></td></tr><tr><td style="vertical-align:bottom;width:19.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Upstaza</p></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 89,550</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 89,550</p></td></tr><tr><td style="vertical-align:bottom;width:19.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Total definite-lived intangibles, gross</b></p></td><td style="vertical-align:bottom;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 526,228</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 80,910</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (279)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 606,859</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:43.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:43.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">Ending Balance at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">Foreign</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">Ending Balance at</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Definite-lived</b></p></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">currency</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">September 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">intangibles assets, accumulated amortization</b></p></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">Amortization</b></p></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">translation</b></p></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:43.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Emflaza</p></td><td style="vertical-align:bottom;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (266,023)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (138,038)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (404,061)</p></td></tr></table><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:43.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Waylivra</p></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,751)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (791)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 45</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,497)</p></td></tr><tr><td style="vertical-align:bottom;width:43.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Tegsedi</p></td><td style="vertical-align:bottom;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,709)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,035)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 36</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,708)</p></td></tr><tr><td style="vertical-align:bottom;width:43.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Upstaza</p></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,420)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,597)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9,017)</p></td></tr><tr><td style="vertical-align:bottom;width:43.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Total definite-lived intangibles, accumulated amortization</b></p></td><td style="vertical-align:bottom;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (273,903)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (145,461)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 81</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (419,283)</p></td></tr><tr><td style="vertical-align:bottom;width:43.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:middle;width:43.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 18pt;"><b style="font-weight:bold;">Total definite-lived intangibles, net</b></p></td><td style="vertical-align:middle;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:8pt;font-weight:bold;margin-left:0pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:10.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.36%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 187,576</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p> 420253000 76454000 496707000 9316000 157000 -96000 9377000 7109000 4299000 -183000 11225000 89550000 89550000 526228000 80910000 -279000 606859000 266023000 138038000 404061000 2751000 791000 45000 3497000 1709000 1035000 36000 2708000 3420000 5597000 9017000 273903000 145461000 81000 419283000 187576000 76500000 43900000 4300000 200000 900000 200000 58600000 31000000.0 145500000 80800000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:24.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:26.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of September 30, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 58,640</p></td></tr><tr><td style="vertical-align:bottom;width:71.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 46,557</p></td></tr><tr><td style="vertical-align:bottom;width:71.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 10,041</p></td></tr><tr><td style="vertical-align:bottom;width:71.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 10,041</p></td></tr><tr><td style="vertical-align:bottom;width:71.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2027 and thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 62,297</p></td></tr><tr><td style="vertical-align:bottom;width:71.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:24.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 187,576</p></td></tr></table> 58640000 46557000 10041000 10041000 62297000 187576000 P5Y3M18D <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 6pt 0pt;">Indefinite-lived intangible assets consisted of the following at September 30, 2023 and December 31, 2022:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:19.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:19.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">Ending Balance at</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">Reclass from</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">Foreign</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">Ending Balance at</b></p></td></tr><tr><td style="vertical-align:bottom;width:19.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Indefinite-lived</b></p></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">Indefinite Lived to</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">currency</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">September 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:19.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">intangibles assets</b></p></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">Additions</b></p></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">Definite Lived</b></p></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">Impairment</b></p></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">translation</b></p></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:19.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Upstaza</p></td><td style="vertical-align:bottom;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 235,766</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_Unumh6ZzlU-3bNHAj0IoqQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> —</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 235,766</p></td></tr><tr><td style="vertical-align:bottom;width:19.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PTC-FA</p></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 112,500</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_E0Td9w0E0U6F3uffNfNckg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> —</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (112,500)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:19.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PTC-AS</p></td><td style="vertical-align:bottom;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 105,300</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_5x376mMUaU6xqxSX1B2yKA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> —</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (105,300)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:19.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">Total indefinite-lived intangibles</b></p></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 453,566</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_3elHy9YAcE2U_I8Yp2VG8w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> —</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (217,800)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 235,766</p></td></tr><tr><td style="vertical-align:bottom;width:19.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:19.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 18pt;"><b style="font-weight:bold;">Total intangible assets, net</b></p></td><td style="vertical-align:bottom;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;"><span style="font-size:8pt;font-weight:bold;margin-left:0pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.38%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.03%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 423,342</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p> 235766000 235766000 112500000 112500000 105300000 105300000 453566000 217800000 235766000 423342000 453600000 217800000 235800000 82300000 0 82300000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-bottom:6pt;margin:0pt;">13.        Subsequent events</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><i style="font-style:italic;">Royalty Purchase Agreement</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="font-style:italic;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">On October 18, 2023, the Company, Royalty Pharma Investments 2019 ICAV (“Royalty Pharma”), and, for the limited purposes set forth in the agreement, Royalty Pharma plc, entered into an Amended and Restated Royalty Purchase Agreement (the “A&amp;R Royalty Purchase Agreement”), which amends and restates in its entirety the Royalty Purchase Agreement.  Pursuant to the A&amp;R Royalty Purchase Agreement, the Company has sold or agreed to sell to Royalty Pharma certain portions of the Company’s remaining Royalty on worldwide net sales of Evrysdi and any other product (the “Products”) developed pursuant to the SMA License Agreement (all such retained Royalty rights of the Company, the “Retained Royalty Rights,” and all such Royalty rights that are sold to Royalty Pharma pursuant to the A&amp;R Royalty Purchase Agreement, the “A&amp;R Assigned Royalty Rights”). At closing, Royalty Pharma paid the Company $1.0 billion in cash consideration for 38.0447% of the Company’s Retained Royalty Rights (which is in addition to the 42.9330% assigned to Royalty Pharma in connection with the Royalty Purchase Agreement, for a total of 80.9777% of the total Royalty) until such time as Royalty Pharma has received payments in respect of the A&amp;R Assigned Royalty Rights equal to $1.3 billion in the aggregate, and thereafter 66.6667% of the total Royalty. In addition, the Company may sell to Royalty Pharma the remainder of the Company’s Retained Royalty Rights in exchange for an aggregate of $500.0 million in additional cash consideration after the closing of the A&amp;R Royalty Purchase Agreement, less royalties received in respect of the Retained Royalty Rights put to Royalty Pharma, which will be payable by Royalty Pharma pursuant to five put options held by the Company that are exercisable at the Company’s option between January 1, 2024 and December 31, 2025. If the Company exercises two or fewer of the put options, Royalty Pharma may exercise a call option during the period from and after January 1, 2026 until and including March 31, 2026 for up to 50% of the remainder of the Company’s Retained Royalty Rights less amounts exercised by the Company via its put options at a purchase price that is proportional to the purchase price of the Company’s unexercised put options. Royalty Pharma’s exercise of the call option would result in Royalty Pharma owning 90.4888% of the total Royalty until such time as Royalty Pharma has received payments in respect of the A&amp;R Assigned Royalty Rights equal to $1.3 billion in the aggregate, and thereafter 83.3333% of the total Royalty. The Company is evaluating the accounting impact of the A&amp;R Royalty Purchase Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"> <span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">Under the A&amp;R Royalty Purchase Agreement, and in connection with its sale of the A&amp;R Assigned Royalty Rights, the Company has agreed to specified negative and affirmative covenants with respect to the exercise of its rights under the SMA License Agreement, including the Company’s right to amend, modify, assign or terminate the SMA License Agreement.  Subject to certain customary exceptions, the Company has agreed not to grant a security interest in its interest in the SMA License Agreement, the Products or the patent rights that cover the Products. The A&amp;R Royalty Purchase Agreement also contains representations and warranties, covenants and other provisions, including information rights and confidentiality obligations, customary for transactions of this nature. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">The A&amp;R Royalty Purchase Agreement will terminate 60 days following the date on which Roche is no longer obligated to make any payments of the Royalty pursuant to the License Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><i style="font-style:italic;">Senior Secured Term Loan Termination</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt;">On October 19, 2023, the Company terminated the Blackstone Credit Agreement. In connection with the termination of the Blackstone Credit Agreement, the Company repaid outstanding principal and accrued interest thereunder totaling $302.1 million and paid an additional $82.1 million in prepayment premiums, expenses and other exit fees. All liens and security interests securing the loans made pursuant to the Blackstone Credit Agreement were released upon termination.</p> 1000000000.0 0.380447 0.429330 0.809777 1300000000 0.666667 500000000.0 5 2 0.50 0.904888 1300000000 0.833333 P60D 302100000 82100000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Director and Officer Trading Arrangements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">A portion of the compensation of our directors and officers (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended, or the Exchange Act) is in the form of equity awards and, from time to time, directors and officers engage in open-market transactions with respect to the securities acquired pursuant to such equity awards or other Company securities, including to satisfy tax withholding obligations when equity awards vest or are exercised, and for diversification or other personal reasons.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Transactions in Company securities by directors and officers are required to be made in accordance with our insider trading policy, which requires that the transactions be in accordance with applicable U.S. federal securities laws that prohibit trading while in possession of material nonpublic information. Rule 10b5-1 under the Exchange Act provides an affirmative defense that enables directors and officers to prearrange transactions in Company securities in a manner that avoids concerns about initiating transactions while in possession of material nonpublic information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The following table describes, for the quarterly period covered by this report, each trading arrangement for the sale or purchase of Company securities adopted or terminated by our directors and officers that is either (1) a contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c), or a “Rule 10b5-1 trading arrangement”, or (2) a “non-Rule 10b5-1 trading arrangement” (as defined in Item 408(c) of Regulation S-K):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:13.9%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"></td><td style="vertical-align:top;width:15.84%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"></td><td style="vertical-align:top;width:16.23%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"></td><td style="vertical-align:top;width:17.1%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"></td><td style="vertical-align:top;width:18.82%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"></td><td style="vertical-align:top;width:18.08%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"></td></tr><tr><td style="vertical-align:top;width:13.9%;background:#d9d9d9;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Name<br/>(Title)</p></td><td style="vertical-align:top;width:15.84%;background:#d9d9d9;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Action Taken<br/>(Date of Action)</p></td><td style="vertical-align:top;width:16.23%;background:#d9d9d9;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Type of Trading<br/>Arrangement</p></td><td style="vertical-align:top;width:17.1%;background:#d9d9d9;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Nature of Trading<br/>Arrangement </p></td><td style="vertical-align:top;width:18.82%;background:#d9d9d9;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Duration of Trading<br/>Arrangement</p></td><td style="vertical-align:top;width:18.08%;background:#d9d9d9;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Aggregate Number<br/>of Securities </p></td></tr><tr><td style="vertical-align:top;width:13.9%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Pierre Gravier<br/>(Chief Financial Officer)</p></td><td style="vertical-align:top;width:15.84%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Adoption<br/>(July 13, 2023)</p></td><td style="vertical-align:top;width:16.23%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Rule 10b5-1 trading arrangement for sell-to-cover transactions for RSUs granted on July 13, 2023</p></td><td style="vertical-align:top;width:17.1%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Sale</p></td><td style="vertical-align:top;width:18.82%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Until final settlement of RSUs on or around July 13, 2027 </p></td><td style="vertical-align:top;width:18.08%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt 5.15pt 0pt 5.15pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Indeterminable (1)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">(1) The number of shares subject to this RSU grant that will be sold to satisfy applicable tax withholding obligations upon vesting is unknown as the number will vary based on the extent to which vesting conditions are satisfied and the market price of the Company’s common stock at the time of settlement.  This trading arrangement provides for the automatic sale of shares that would otherwise be issuable on each settlement date of the RSU in an amount sufficient to satisfy the applicable withholding obligation, with the proceeds of the sale delivered to the Company in satisfaction of the applicable withholding obligation. </p> Pierre Gravier Chief Financial Officer July 13, 2023 true July 13, 2027 EXCEL 88 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 90 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 91 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 382 455 1 false 107 0 false 16 false false R1.htm 00090 - Document - Cover Sheet http://www.ptcbio.com/role/DocumentCover Cover Cover 1 false false R2.htm 00100 - Statement - Consolidated Balance Sheets Sheet http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 00105 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.ptcbio.com/role/StatementConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00200 - Statement - Consolidated Statements of Operations Sheet http://www.ptcbio.com/role/StatementConsolidatedStatementsOfOperations Consolidated Statements of Operations Statements 4 false false R5.htm 00300 - Statement - Consolidated Statements of Comprehensive Loss Sheet http://www.ptcbio.com/role/StatementConsolidatedStatementsOfComprehensiveLoss Consolidated Statements of Comprehensive Loss Statements 5 false false R6.htm 00400 - Statement - Consolidated Statements of Stockholders' (Deficit) Equity Sheet http://www.ptcbio.com/role/StatementConsolidatedStatementsOfStockholdersDeficitEquity Consolidated Statements of Stockholders' (Deficit) Equity Statements 6 false false R7.htm 00500 - Statement - Consolidated Statements of Cash Flows Sheet http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows Consolidated Statements of Cash Flows Statements 7 false false R8.htm 10101 - Disclosure - The Company Sheet http://www.ptcbio.com/role/DisclosureCompany The Company Notes 8 false false R9.htm 10201 - Disclosure - Summary of significant accounting policies Sheet http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of significant accounting policies Notes 9 false false R10.htm 10301 - Disclosure - Leases Sheet http://www.ptcbio.com/role/DisclosureLeases Leases Notes 10 false false R11.htm 10401 - Disclosure - Fair value of financial instruments and investments Sheet http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestments Fair value of financial instruments and investments Notes 11 false false R12.htm 10501 - Disclosure - Accounts payable and accrued expenses Sheet http://www.ptcbio.com/role/DisclosureAccountsPayableAndAccruedExpenses Accounts payable and accrued expenses Notes 12 false false R13.htm 10601 - Disclosure - Capitalization Sheet http://www.ptcbio.com/role/DisclosureCapitalization Capitalization Notes 13 false false R14.htm 10701 - Disclosure - Net loss per share Sheet http://www.ptcbio.com/role/DisclosureNetLossPerShare Net loss per share Notes 14 false false R15.htm 10801 - Disclosure - Stock award plan Sheet http://www.ptcbio.com/role/DisclosureStockAwardPlan Stock award plan Notes 15 false false R16.htm 10901 - Disclosure - Debt Sheet http://www.ptcbio.com/role/DisclosureDebt Debt Notes 16 false false R17.htm 11001 - Disclosure - Commitments and contingencies Sheet http://www.ptcbio.com/role/DisclosureCommitmentsAndContingencies Commitments and contingencies Notes 17 false false R18.htm 11101 - Disclosure - Revenue recognition Sheet http://www.ptcbio.com/role/DisclosureRevenueRecognition Revenue recognition Notes 18 false false R19.htm 11201 - Disclosure - Intangible assets and goodwill Sheet http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwill Intangible assets and goodwill Notes 19 false false R20.htm 11301 - Disclosure - Subsequent events Sheet http://www.ptcbio.com/role/DisclosureSubsequentEvents Subsequent events Notes 20 false false R21.htm 20202 - Disclosure - Summary of significant accounting policies (Policies) Sheet http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of significant accounting policies (Policies) Policies 21 false false R22.htm 30203 - Disclosure - Summary of significant accounting policies (Tables) Sheet http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables Summary of significant accounting policies (Tables) Tables http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPolicies 22 false false R23.htm 30303 - Disclosure - Leases - (Tables) Sheet http://www.ptcbio.com/role/DisclosureLeasesTables Leases - (Tables) Tables 23 false false R24.htm 30403 - Disclosure - Fair value of financial instruments and investments - (Tables) Sheet http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsTables Fair value of financial instruments and investments - (Tables) Tables http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestments 24 false false R25.htm 30503 - Disclosure - Accounts payable and accrued expenses - (Tables) Sheet http://www.ptcbio.com/role/DisclosureAccountsPayableAndAccruedExpensesTables Accounts payable and accrued expenses - (Tables) Tables http://www.ptcbio.com/role/DisclosureAccountsPayableAndAccruedExpenses 25 false false R26.htm 30703 - Disclosure - Net loss per share - (Tables) Sheet http://www.ptcbio.com/role/DisclosureNetLossPerShareTables Net loss per share - (Tables) Tables http://www.ptcbio.com/role/DisclosureNetLossPerShare 26 false false R27.htm 30803 - Disclosure - Stock award plan - (Tables) Sheet http://www.ptcbio.com/role/DisclosureStockAwardPlanTables Stock award plan - (Tables) Tables http://www.ptcbio.com/role/DisclosureStockAwardPlan 27 false false R28.htm 30903 - Disclosure - Debt - (Tables) Sheet http://www.ptcbio.com/role/DisclosureDebtTables Debt - (Tables) Tables 28 false false R29.htm 31203 - Disclosure - Intangible assets and goodwill - (Tables) Sheet http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillTables Intangible assets and goodwill - (Tables) Tables http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwill 29 false false R30.htm 40101 - Disclosure - The Company (Details) Sheet http://www.ptcbio.com/role/DisclosureCompanyDetails The Company (Details) Details http://www.ptcbio.com/role/DisclosureCompany 30 false false R31.htm 40201 - Disclosure - Summary of significant accounting policies - Narrative (Details) Sheet http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails Summary of significant accounting policies - Narrative (Details) Details 31 false false R32.htm 40202 - Disclosure - Summary of significant accounting policies - Reconciliation of cash (Details) Sheet http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashDetails Summary of significant accounting policies - Reconciliation of cash (Details) Details 32 false false R33.htm 40204 - Disclosure - Summary of significant accounting policies - Inventory (Details) Sheet http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesInventoryDetails Summary of significant accounting policies - Inventory (Details) Details 33 false false R34.htm 40205 - Disclosure - Summary of significant accounting policies - Collaboration and Royalty Revenue (Details) Sheet http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCollaborationAndRoyaltyRevenueDetails Summary of significant accounting policies - Collaboration and Royalty Revenue (Details) Details 34 false false R35.htm 40206 - Disclosure - Summary of significant accounting policies - Manufacturing Revenue (Details) Sheet http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesManufacturingRevenueDetails Summary of significant accounting policies - Manufacturing Revenue (Details) Details 35 false false R36.htm 40207 - Disclosure - Summary of significant accounting policies - Liability for Sale of Future Royalties (Details) Sheet http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLiabilityForSaleOfFutureRoyaltiesDetails Summary of significant accounting policies - Liability for Sale of Future Royalties (Details) Details 36 false false R37.htm 40301 - Disclosure - Leases - Narrative (Details) Sheet http://www.ptcbio.com/role/DisclosureLeasesNarrativeDetails Leases - Narrative (Details) Details 37 false false R38.htm 40302 - Disclosure - Leases - Lease costs (Details) Sheet http://www.ptcbio.com/role/DisclosureLeasesLeaseCostsDetails Leases - Lease costs (Details) Details 38 false false R39.htm 40303 - Disclosure - Leases - Supplemental lease terms (Details) Sheet http://www.ptcbio.com/role/DisclosureLeasesSupplementalLeaseTermsDetails Leases - Supplemental lease terms (Details) Details 39 false false R40.htm 40304 - Disclosure - Leases - Cash flow (Details) Sheet http://www.ptcbio.com/role/DisclosureLeasesCashFlowDetails Leases - Cash flow (Details) Details 40 false false R41.htm 40305 - Disclosure - Leases - Lease payments (Details) Sheet http://www.ptcbio.com/role/DisclosureLeasesLeasePaymentsDetails Leases - Lease payments (Details) Details 41 false false R42.htm 40401 - Disclosure - Fair value of financial instruments and investments - Marketable Securities (Details) Sheet http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsMarketableSecuritiesDetails Fair value of financial instruments and investments - Marketable Securities (Details) Details 42 false false R43.htm 40402 - Disclosure - Fair value of financial instruments and investments - Hierarchy (Details) Sheet http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsHierarchyDetails Fair value of financial instruments and investments - Hierarchy (Details) Details http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsTables 43 false false R44.htm 40403 - Disclosure - Fair value of financial instruments and investments - Marketable Securities, Unrealized Gains (Losses) (Details) Sheet http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsMarketableSecuritiesUnrealizedGainsLossesDetails Fair value of financial instruments and investments - Marketable Securities, Unrealized Gains (Losses) (Details) Details 44 false false R45.htm 40404 - Disclosure - Fair value of financial instruments and investments - Available-for-sale securities (Details) Sheet http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsAvailableForSaleSecuritiesDetails Fair value of financial instruments and investments - Available-for-sale securities (Details) Details 45 false false R46.htm 40405 - Disclosure - Fair value of financial instruments and investments - Marketable Securities, Balance Sheet Disclosures (Details) Sheet http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsMarketableSecuritiesBalanceSheetDisclosuresDetails Fair value of financial instruments and investments - Marketable Securities, Balance Sheet Disclosures (Details) Details 46 false false R47.htm 40406 - Disclosure - Fair value of financial instruments and investments - Convertible senior notes (Details) Notes http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsConvertibleSeniorNotesDetails Fair value of financial instruments and investments - Convertible senior notes (Details) Details 47 false false R48.htm 40407 - Disclosure - Fair value of financial instruments and investments - Summary of changes in the fair value of the Company's Level 3 valuation (Details) Sheet http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsSummaryOfChangesInFairValueOfCompanySLevel3ValuationDetails Fair value of financial instruments and investments - Summary of changes in the fair value of the Company's Level 3 valuation (Details) Details 48 false false R49.htm 40408 - Disclosure - Fair value of financial instruments and investments - Fair Value Liabilities Measured (Details) Sheet http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsFairValueLiabilitiesMeasuredDetails Fair value of financial instruments and investments - Fair Value Liabilities Measured (Details) Details 49 false false R50.htm 40501 - Disclosure - Accounts payable and accrued expenses - Components (Details) Sheet http://www.ptcbio.com/role/DisclosureAccountsPayableAndAccruedExpensesComponentsDetails Accounts payable and accrued expenses - Components (Details) Details 50 false false R51.htm 40502 - Disclosure - Accounts payable and accrued expenses - Restructuring (Details) Sheet http://www.ptcbio.com/role/DisclosureAccountsPayableAndAccruedExpensesRestructuringDetails Accounts payable and accrued expenses - Restructuring (Details) Details 51 false false R52.htm 40601 - Disclosure - Capitalization - Narrative (Details) Sheet http://www.ptcbio.com/role/DisclosureCapitalizationNarrativeDetails Capitalization - Narrative (Details) Details 52 false false R53.htm 40701 - Disclosure - Net loss per share - Numerator and Denominator (Details) Sheet http://www.ptcbio.com/role/DisclosureNetLossPerShareNumeratorAndDenominatorDetails Net loss per share - Numerator and Denominator (Details) Details 53 false false R54.htm 40702 - Disclosure - Net loss per share - Antidilutive (Details) Sheet http://www.ptcbio.com/role/DisclosureNetLossPerShareAntidilutiveDetails Net loss per share - Antidilutive (Details) Details 54 false false R55.htm 40801 - Disclosure - Stock award plan - Narrative (Details) Sheet http://www.ptcbio.com/role/DisclosureStockAwardPlanNarrativeDetails Stock award plan - Narrative (Details) Details 55 false false R56.htm 40802 - Disclosure - Stock award plan - Stock Option Activity (Details) Sheet http://www.ptcbio.com/role/DisclosureStockAwardPlanStockOptionActivityDetails Stock award plan - Stock Option Activity (Details) Details 56 false false R57.htm 40803 - Disclosure - Stock award plan - Assumptions Used (Details) Sheet http://www.ptcbio.com/role/DisclosureStockAwardPlanAssumptionsUsedDetails Stock award plan - Assumptions Used (Details) Details 57 false false R58.htm 40804 - Disclosure - Stock award plan - Restricted Stock (Details) Sheet http://www.ptcbio.com/role/DisclosureStockAwardPlanRestrictedStockDetails Stock award plan - Restricted Stock (Details) Details 58 false false R59.htm 40805 - Disclosure - Stock award plan - Share-based compensation expense (Details) Sheet http://www.ptcbio.com/role/DisclosureStockAwardPlanShareBasedCompensationExpenseDetails Stock award plan - Share-based compensation expense (Details) Details 59 false false R60.htm 40901 - Disclosure - Debt - Liability for Sale of Future Royalties (Details) Sheet http://www.ptcbio.com/role/DisclosureDebtLiabilityForSaleOfFutureRoyaltiesDetails Debt - Liability for Sale of Future Royalties (Details) Details 60 false false R61.htm 40902 - Disclosure - Debt - Senior Secured Term Loan (Details) Sheet http://www.ptcbio.com/role/DisclosureDebtSeniorSecuredTermLoanDetails Debt - Senior Secured Term Loan (Details) Details 61 false false R62.htm 40903 - Disclosure - Debt - Narrative (Details) Sheet http://www.ptcbio.com/role/DisclosureDebtNarrativeDetails Debt - Narrative (Details) Details 62 false false R63.htm 40904 - Disclosure - Debt - Convertible Notes (Details) Notes http://www.ptcbio.com/role/DisclosureDebtConvertibleNotesDetails Debt - Convertible Notes (Details) Details 63 false false R64.htm 40905 - Disclosure - Debt - Convertible Notes Interest Expense (Details) Notes http://www.ptcbio.com/role/DisclosureDebtConvertibleNotesInterestExpenseDetails Debt - Convertible Notes Interest Expense (Details) Details 64 false false R65.htm 41001 - Disclosure - Commitments and contingencies - Narrative (Details) Sheet http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails Commitments and contingencies - Narrative (Details) Details 65 false false R66.htm 41101 - Disclosure - Revenue recognition - Net Product Sales (Details) Sheet http://www.ptcbio.com/role/DisclosureRevenueRecognitionNetProductSalesDetails Revenue recognition - Net Product Sales (Details) Details 66 false false R67.htm 41102 - Disclosure - Revenue recognition - Collaboration and Royalty Revenue (Details) Sheet http://www.ptcbio.com/role/DisclosureRevenueRecognitionCollaborationAndRoyaltyRevenueDetails Revenue recognition - Collaboration and Royalty Revenue (Details) Details 67 false false R68.htm 41103 - Disclosure - Revenue recognition - Manufacturing Revenue (Details) Sheet http://www.ptcbio.com/role/DisclosureRevenueRecognitionManufacturingRevenueDetails Revenue recognition - Manufacturing Revenue (Details) Details 68 false false R69.htm 41104 - Disclosure - Revenue recognition - Performance Obligations (Details) Sheet http://www.ptcbio.com/role/DisclosureRevenueRecognitionPerformanceObligationsDetails Revenue recognition - Performance Obligations (Details) Details 69 false false R70.htm 41201 - Disclosure - Intangible assets and goodwill - Definite-lived Intangibles (Details) Sheet http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillDefiniteLivedIntangiblesDetails Intangible assets and goodwill - Definite-lived Intangibles (Details) Details 70 false false R71.htm 41202 - Disclosure - Intangible assets and goodwill - Future Amortization (Details) Sheet http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillFutureAmortizationDetails Intangible assets and goodwill - Future Amortization (Details) Details 71 false false R72.htm 41203 - Disclosure - Intangible assets and goodwill - Indefinite-lived Intangibles (Details) Sheet http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillIndefiniteLivedIntangiblesDetails Intangible assets and goodwill - Indefinite-lived Intangibles (Details) Details 72 false false R73.htm 41204 - Disclosure - Intangible assets and goodwill - Goodwill (Details) Sheet http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillGoodwillDetails Intangible assets and goodwill - Goodwill (Details) Details 73 false false R74.htm 41301 - Disclosure - Subsequent events (Details) Sheet http://www.ptcbio.com/role/DisclosureSubsequentEventsDetails Subsequent events (Details) Details http://www.ptcbio.com/role/DisclosureSubsequentEvents 74 false false R75.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Uncategorized 75 false false R76.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Cover 76 false false All Reports Book All Reports tmb-20230930.xsd tmb-20230930_cal.xml tmb-20230930_def.xml tmb-20230930_lab.xml tmb-20230930_pre.xml tmb-20230930x10q.htm http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 http://xbrl.sec.gov/ecd/2023 true true JSON 94 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tmb-20230930x10q.htm": { "nsprefix": "ptct", "nsuri": "http://www.ptcbio.com/20230930", "dts": { "schema": { "local": [ "tmb-20230930.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-sub-2023.xsd" ] }, "calculationLink": { "local": [ "tmb-20230930_cal.xml" ] }, "definitionLink": { "local": [ "tmb-20230930_def.xml" ] }, "labelLink": { "local": [ "tmb-20230930_lab.xml" ] }, "presentationLink": { "local": [ "tmb-20230930_pre.xml" ] }, "inline": { "local": [ "tmb-20230930x10q.htm" ] } }, "keyStandard": 336, "keyCustom": 119, "axisStandard": 39, "axisCustom": 1, "memberStandard": 48, "memberCustom": 52, "hidden": { "total": 13, "http://www.ptcbio.com/20230930": 2, "http://fasb.org/us-gaap/2023": 6, "http://xbrl.sec.gov/dei/2023": 5 }, "contextCount": 382, "entityCount": 1, "segmentCount": 107, "elementCount": 810, "unitCount": 16, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 956, "http://xbrl.sec.gov/ecd/2023": 5, "http://xbrl.sec.gov/dei/2023": 29 }, "report": { "R1": { "role": "http://www.ptcbio.com/role/DocumentCover", "longName": "00090 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_zooc4MtLrUmmagQRUJLY7w", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_zooc4MtLrUmmagQRUJLY7w", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets", "longName": "00100 - Statement - Consolidated Balance Sheets", "shortName": "Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "As_Of_9_30_2023_U7-26fnmXE-1quvtU04Bqw", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD_Y31f_4CLNEKbtVCyYm1dXg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2023_U7-26fnmXE-1quvtU04Bqw", "name": "us-gaap:MarketableSecuritiesCurrent", "unitRef": "Unit_Standard_USD_Y31f_4CLNEKbtVCyYm1dXg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "unique": true } }, "R3": { "role": "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheetsParenthetical", "longName": "00105 - Statement - Consolidated Balance Sheets (Parenthetical)", "shortName": "Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "As_Of_9_30_2023_U7-26fnmXE-1quvtU04Bqw", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "Unit_Divide_USD_shares_fpMqlnwgm0agnassNyRL1A", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2023_U7-26fnmXE-1quvtU04Bqw", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "Unit_Divide_USD_shares_fpMqlnwgm0agnassNyRL1A", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfOperations", "longName": "00200 - Statement - Consolidated Statements of Operations", "shortName": "Consolidated Statements of Operations", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_9_30_2023_ANcExXKl1k2ZHC8RXTO5oA", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit_Standard_USD_Y31f_4CLNEKbtVCyYm1dXg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_9_30_2023_ANcExXKl1k2ZHC8RXTO5oA", "name": "ptct:CostofGoodsandServiceExcludingAmortizationOfIntangibleAssets", "unitRef": "Unit_Standard_USD_Y31f_4CLNEKbtVCyYm1dXg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "unique": true } }, "R5": { "role": "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfComprehensiveLoss", "longName": "00300 - Statement - Consolidated Statements of Comprehensive Loss", "shortName": "Consolidated Statements of Comprehensive Loss", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_9_30_2023_ANcExXKl1k2ZHC8RXTO5oA", "name": "us-gaap:NetIncomeLoss", "unitRef": "Unit_Standard_USD_Y31f_4CLNEKbtVCyYm1dXg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_9_30_2023_ANcExXKl1k2ZHC8RXTO5oA", "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "unitRef": "Unit_Standard_USD_Y31f_4CLNEKbtVCyYm1dXg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "unique": true } }, "R6": { "role": "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfStockholdersDeficitEquity", "longName": "00400 - Statement - Consolidated Statements of Stockholders' (Deficit) Equity", "shortName": "Consolidated Statements of Stockholders' (Deficit) Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_S5UtMPpMwUKHFNMrP9IbMA", "name": "us-gaap:SharesIssued", "unitRef": "Unit_Standard_shares_OaxkKXbBmUmMkA_gGC3tZQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_S5UtMPpMwUKHFNMrP9IbMA", "name": "us-gaap:SharesIssued", "unitRef": "Unit_Standard_shares_OaxkKXbBmUmMkA_gGC3tZQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "span", "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows", "longName": "00500 - Statement - Consolidated Statements of Cash Flows", "shortName": "Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_zooc4MtLrUmmagQRUJLY7w", "name": "us-gaap:NetIncomeLoss", "unitRef": "Unit_Standard_USD_Y31f_4CLNEKbtVCyYm1dXg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_zooc4MtLrUmmagQRUJLY7w", "name": "us-gaap:DepreciationDepletionAndAmortization", "unitRef": "Unit_Standard_USD_Y31f_4CLNEKbtVCyYm1dXg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "unique": true } }, "R8": { "role": "http://www.ptcbio.com/role/DisclosureCompany", "longName": "10101 - Disclosure - The Company", "shortName": "The Company", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_zooc4MtLrUmmagQRUJLY7w", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_zooc4MtLrUmmagQRUJLY7w", "name": "us-gaap:NatureOfOperations", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPolicies", "longName": "10201 - Disclosure - Summary of significant accounting policies", "shortName": "Summary of significant accounting policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_zooc4MtLrUmmagQRUJLY7w", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_zooc4MtLrUmmagQRUJLY7w", "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.ptcbio.com/role/DisclosureLeases", "longName": "10301 - Disclosure - Leases", "shortName": "Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_zooc4MtLrUmmagQRUJLY7w", "name": "ptct:LeaseDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_zooc4MtLrUmmagQRUJLY7w", "name": "ptct:LeaseDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestments", "longName": "10401 - Disclosure - Fair value of financial instruments and investments", "shortName": "Fair value of financial instruments and investments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_zooc4MtLrUmmagQRUJLY7w", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_zooc4MtLrUmmagQRUJLY7w", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.ptcbio.com/role/DisclosureAccountsPayableAndAccruedExpenses", "longName": "10501 - Disclosure - Accounts payable and accrued expenses", "shortName": "Accounts payable and accrued expenses", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_zooc4MtLrUmmagQRUJLY7w", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_zooc4MtLrUmmagQRUJLY7w", "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.ptcbio.com/role/DisclosureCapitalization", "longName": "10601 - Disclosure - Capitalization", "shortName": "Capitalization", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_zooc4MtLrUmmagQRUJLY7w", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_zooc4MtLrUmmagQRUJLY7w", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.ptcbio.com/role/DisclosureNetLossPerShare", "longName": "10701 - Disclosure - Net loss per share", "shortName": "Net loss per share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_zooc4MtLrUmmagQRUJLY7w", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_zooc4MtLrUmmagQRUJLY7w", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.ptcbio.com/role/DisclosureStockAwardPlan", "longName": "10801 - Disclosure - Stock award plan", "shortName": "Stock award plan", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_zooc4MtLrUmmagQRUJLY7w", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_zooc4MtLrUmmagQRUJLY7w", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.ptcbio.com/role/DisclosureDebt", "longName": "10901 - Disclosure - Debt", "shortName": "Debt", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_zooc4MtLrUmmagQRUJLY7w", "name": "us-gaap:LongTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_zooc4MtLrUmmagQRUJLY7w", "name": "us-gaap:LongTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.ptcbio.com/role/DisclosureCommitmentsAndContingencies", "longName": "11001 - Disclosure - Commitments and contingencies", "shortName": "Commitments and contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_zooc4MtLrUmmagQRUJLY7w", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_zooc4MtLrUmmagQRUJLY7w", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.ptcbio.com/role/DisclosureRevenueRecognition", "longName": "11101 - Disclosure - Revenue recognition", "shortName": "Revenue recognition", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_zooc4MtLrUmmagQRUJLY7w", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_zooc4MtLrUmmagQRUJLY7w", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwill", "longName": "11201 - Disclosure - Intangible assets and goodwill", "shortName": "Intangible assets and goodwill", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_zooc4MtLrUmmagQRUJLY7w", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_zooc4MtLrUmmagQRUJLY7w", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.ptcbio.com/role/DisclosureSubsequentEvents", "longName": "11301 - Disclosure - Subsequent events", "shortName": "Subsequent events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_zooc4MtLrUmmagQRUJLY7w", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_zooc4MtLrUmmagQRUJLY7w", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "longName": "20202 - Disclosure - Summary of significant accounting policies (Policies)", "shortName": "Summary of significant accounting policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "21", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_zooc4MtLrUmmagQRUJLY7w", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_zooc4MtLrUmmagQRUJLY7w", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables", "longName": "30203 - Disclosure - Summary of significant accounting policies (Tables)", "shortName": "Summary of significant accounting policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "22", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_zooc4MtLrUmmagQRUJLY7w", "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_zooc4MtLrUmmagQRUJLY7w", "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.ptcbio.com/role/DisclosureLeasesTables", "longName": "30303 - Disclosure - Leases - (Tables)", "shortName": "Leases - (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_zooc4MtLrUmmagQRUJLY7w", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_zooc4MtLrUmmagQRUJLY7w", "name": "us-gaap:LeaseCostTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsTables", "longName": "30403 - Disclosure - Fair value of financial instruments and investments - (Tables)", "shortName": "Fair value of financial instruments and investments - (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_zooc4MtLrUmmagQRUJLY7w", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_zooc4MtLrUmmagQRUJLY7w", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.ptcbio.com/role/DisclosureAccountsPayableAndAccruedExpensesTables", "longName": "30503 - Disclosure - Accounts payable and accrued expenses - (Tables)", "shortName": "Accounts payable and accrued expenses - (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_zooc4MtLrUmmagQRUJLY7w", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_zooc4MtLrUmmagQRUJLY7w", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.ptcbio.com/role/DisclosureNetLossPerShareTables", "longName": "30703 - Disclosure - Net loss per share - (Tables)", "shortName": "Net loss per share - (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_zooc4MtLrUmmagQRUJLY7w", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_zooc4MtLrUmmagQRUJLY7w", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.ptcbio.com/role/DisclosureStockAwardPlanTables", "longName": "30803 - Disclosure - Stock award plan - (Tables)", "shortName": "Stock award plan - (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_zooc4MtLrUmmagQRUJLY7w", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_zooc4MtLrUmmagQRUJLY7w", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.ptcbio.com/role/DisclosureDebtTables", "longName": "30903 - Disclosure - Debt - (Tables)", "shortName": "Debt - (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_zooc4MtLrUmmagQRUJLY7w", "name": "ptct:LiabilityForSaleOfFutureRoyaltiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_zooc4MtLrUmmagQRUJLY7w", "name": "ptct:LiabilityForSaleOfFutureRoyaltiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillTables", "longName": "31203 - Disclosure - Intangible assets and goodwill - (Tables)", "shortName": "Intangible assets and goodwill - (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_zooc4MtLrUmmagQRUJLY7w", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_zooc4MtLrUmmagQRUJLY7w", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.ptcbio.com/role/DisclosureCompanyDetails", "longName": "40101 - Disclosure - The Company (Details)", "shortName": "The Company (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "30", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_zooc4MtLrUmmagQRUJLY7w", "name": "ptct:NumberOfProducts", "unitRef": "Unit_Standard_product_tnfzmO94gUmVE7tUU00u0g", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:NatureOfOperations", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_zooc4MtLrUmmagQRUJLY7w", "name": "ptct:NumberOfProducts", "unitRef": "Unit_Standard_product_tnfzmO94gUmVE7tUU00u0g", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:NatureOfOperations", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails", "longName": "40201 - Disclosure - Summary of significant accounting policies - Narrative (Details)", "shortName": "Summary of significant accounting policies - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "31", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_9_30_2023_ANcExXKl1k2ZHC8RXTO5oA", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "Unit_Standard_segment_k2coI04TH0-X6hen7ifkrg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "us-gaap:NumberOfOperatingSegments", "us-gaap:NumberOfOperatingSegments", "us-gaap:NumberOfOperatingSegments", "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2022_hEh39iYfXU-Y4MnDSux-iQ", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivable", "unitRef": "Unit_Standard_USD_Y31f_4CLNEKbtVCyYm1dXg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "unique": true } }, "R32": { "role": "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashDetails", "longName": "40202 - Disclosure - Summary of significant accounting policies - Reconciliation of cash (Details)", "shortName": "Summary of significant accounting policies - Reconciliation of cash (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "As_Of_9_30_2023_U7-26fnmXE-1quvtU04Bqw", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD_Y31f_4CLNEKbtVCyYm1dXg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2023_U7-26fnmXE-1quvtU04Bqw", "name": "us-gaap:RestrictedCash", "unitRef": "Unit_Standard_USD_Y31f_4CLNEKbtVCyYm1dXg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "unique": true } }, "R33": { "role": "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesInventoryDetails", "longName": "40204 - Disclosure - Summary of significant accounting policies - Inventory (Details)", "shortName": "Summary of significant accounting policies - Inventory (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "As_Of_9_30_2023_U7-26fnmXE-1quvtU04Bqw", "name": "us-gaap:InventoryRawMaterials", "unitRef": "Unit_Standard_USD_Y31f_4CLNEKbtVCyYm1dXg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ptct:InventoriesAndCostOfProductSalesPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2023_U7-26fnmXE-1quvtU04Bqw", "name": "us-gaap:InventoryRawMaterials", "unitRef": "Unit_Standard_USD_Y31f_4CLNEKbtVCyYm1dXg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ptct:InventoriesAndCostOfProductSalesPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCollaborationAndRoyaltyRevenueDetails", "longName": "40205 - Disclosure - Summary of significant accounting policies - Collaboration and Royalty Revenue (Details)", "shortName": "Summary of significant accounting policies - Collaboration and Royalty Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_9_30_2023_ANcExXKl1k2ZHC8RXTO5oA", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit_Standard_USD_Y31f_4CLNEKbtVCyYm1dXg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true }, "uniqueAnchor": null }, "R35": { "role": "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesManufacturingRevenueDetails", "longName": "40206 - Disclosure - Summary of significant accounting policies - Manufacturing Revenue (Details)", "shortName": "Summary of significant accounting policies - Manufacturing Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_9_30_2023_ANcExXKl1k2ZHC8RXTO5oA", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit_Standard_USD_Y31f_4CLNEKbtVCyYm1dXg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true }, "uniqueAnchor": null }, "R36": { "role": "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLiabilityForSaleOfFutureRoyaltiesDetails", "longName": "40207 - Disclosure - Summary of significant accounting policies - Liability for Sale of Future Royalties (Details)", "shortName": "Summary of significant accounting policies - Liability for Sale of Future Royalties (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "Duration_7_1_2020_To_7_31_2020_0fmX4GqWiEy_-vVJhVjDCg", "name": "ptct:ProceedsFromSaleOfFutureRoyalties", "unitRef": "Unit_Standard_USD_Y31f_4CLNEKbtVCyYm1dXg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:LongTermDebtTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_7_17_2020_yumU8uwY7UGavZTMdVkNNA", "name": "ptct:AssignedRoyaltyPaymentRetainedPercentage", "unitRef": "Unit_Standard_pure_0NKO0qHUwUGEF4mqEQfw0A", "xsiNil": "false", "lang": null, "decimals": "5", "ancestors": [ "span", "p", "ptct:LiabilityForSaleOfFutureRoyaltiesPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "unique": true } }, "R37": { "role": "http://www.ptcbio.com/role/DisclosureLeasesNarrativeDetails", "longName": "40301 - Disclosure - Leases - Narrative (Details)", "shortName": "Leases - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "As_Of_9_30_2023_U7-26fnmXE-1quvtU04Bqw", "name": "ptct:NumberOfOperatingLeases", "unitRef": "Unit_Standard_lease_HxAMuc_c30qTPcNKPUwW0A", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ptct:LeaseDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_9_30_2023_ANcExXKl1k2ZHC8RXTO5oA", "name": "us-gaap:OperatingLeaseExpense", "unitRef": "Unit_Standard_USD_Y31f_4CLNEKbtVCyYm1dXg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "unique": true } }, "R38": { "role": "http://www.ptcbio.com/role/DisclosureLeasesLeaseCostsDetails", "longName": "40302 - Disclosure - Leases - Lease costs (Details)", "shortName": "Leases - Lease costs (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_9_30_2023_ANcExXKl1k2ZHC8RXTO5oA", "name": "us-gaap:OperatingLeaseCost", "unitRef": "Unit_Standard_USD_Y31f_4CLNEKbtVCyYm1dXg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_9_30_2023_ANcExXKl1k2ZHC8RXTO5oA", "name": "us-gaap:OperatingLeaseCost", "unitRef": "Unit_Standard_USD_Y31f_4CLNEKbtVCyYm1dXg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:LeaseCostTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.ptcbio.com/role/DisclosureLeasesSupplementalLeaseTermsDetails", "longName": "40303 - Disclosure - Leases - Supplemental lease terms (Details)", "shortName": "Leases - Supplemental lease terms (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "As_Of_9_30_2023_U7-26fnmXE-1quvtU04Bqw", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2023_U7-26fnmXE-1quvtU04Bqw", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.ptcbio.com/role/DisclosureLeasesCashFlowDetails", "longName": "40304 - Disclosure - Leases - Cash flow (Details)", "shortName": "Leases - Cash flow (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_zooc4MtLrUmmagQRUJLY7w", "name": "us-gaap:OperatingLeasePayments", "unitRef": "Unit_Standard_USD_Y31f_4CLNEKbtVCyYm1dXg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ptct:LeaseSupplementalCashFlowDisclosureTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_zooc4MtLrUmmagQRUJLY7w", "name": "us-gaap:OperatingLeasePayments", "unitRef": "Unit_Standard_USD_Y31f_4CLNEKbtVCyYm1dXg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ptct:LeaseSupplementalCashFlowDisclosureTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.ptcbio.com/role/DisclosureLeasesLeasePaymentsDetails", "longName": "40305 - Disclosure - Leases - Lease payments (Details)", "shortName": "Leases - Lease payments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "As_Of_9_30_2023_U7-26fnmXE-1quvtU04Bqw", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "Unit_Standard_USD_Y31f_4CLNEKbtVCyYm1dXg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2023_U7-26fnmXE-1quvtU04Bqw", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "unitRef": "Unit_Standard_USD_Y31f_4CLNEKbtVCyYm1dXg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:FinanceLeaseLiabilityMaturityTableTextBlock", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsMarketableSecuritiesDetails", "longName": "40401 - Disclosure - Fair value of financial instruments and investments - Marketable Securities (Details)", "shortName": "Fair value of financial instruments and investments - Marketable Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_zooc4MtLrUmmagQRUJLY7w", "name": "us-gaap:PaymentsToAcquireMarketableSecurities", "unitRef": "Unit_Standard_USD_Y31f_4CLNEKbtVCyYm1dXg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_9_30_2023_us-gaap_InvestmentTypeAxis_ptct_ClearpointEquityInvestmentMember_wy-D4atl00m7-UhlbDzPPQ", "name": "us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss", "unitRef": "Unit_Standard_USD_Y31f_4CLNEKbtVCyYm1dXg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "unique": true } }, "R43": { "role": "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsHierarchyDetails", "longName": "40402 - Disclosure - Fair value of financial instruments and investments - Hierarchy (Details)", "shortName": "Fair value of financial instruments and investments - Hierarchy (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "As_Of_9_30_2023_U7-26fnmXE-1quvtU04Bqw", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "unitRef": "Unit_Standard_USD_Y31f_4CLNEKbtVCyYm1dXg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2023_U7-26fnmXE-1quvtU04Bqw", "name": "ptct:FairValueAssetsTransfersBetweenLevel1Level2AndLevel3Amount", "unitRef": "Unit_Standard_USD_Y31f_4CLNEKbtVCyYm1dXg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "unique": true } }, "R44": { "role": "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsMarketableSecuritiesUnrealizedGainsLossesDetails", "longName": "40403 - Disclosure - Fair value of financial instruments and investments - Marketable Securities, Unrealized Gains (Losses) (Details)", "shortName": "Fair value of financial instruments and investments - Marketable Securities, Unrealized Gains (Losses) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "As_Of_9_30_2023_U7-26fnmXE-1quvtU04Bqw", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "Unit_Standard_USD_Y31f_4CLNEKbtVCyYm1dXg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2022_hEh39iYfXU-Y4MnDSux-iQ", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "unitRef": "Unit_Standard_USD_Y31f_4CLNEKbtVCyYm1dXg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "unique": true } }, "R45": { "role": "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsAvailableForSaleSecuritiesDetails", "longName": "40404 - Disclosure - Fair value of financial instruments and investments - Available-for-sale securities (Details)", "shortName": "Fair value of financial instruments and investments - Available-for-sale securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "As_Of_9_30_2023_U7-26fnmXE-1quvtU04Bqw", "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss", "unitRef": "Unit_Standard_USD_Y31f_4CLNEKbtVCyYm1dXg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2023_U7-26fnmXE-1quvtU04Bqw", "name": "us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss", "unitRef": "Unit_Standard_USD_Y31f_4CLNEKbtVCyYm1dXg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsMarketableSecuritiesBalanceSheetDisclosuresDetails", "longName": "40405 - Disclosure - Fair value of financial instruments and investments - Marketable Securities, Balance Sheet Disclosures (Details)", "shortName": "Fair value of financial instruments and investments - Marketable Securities, Balance Sheet Disclosures (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "As_Of_9_30_2023_U7-26fnmXE-1quvtU04Bqw", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "unitRef": "Unit_Standard_USD_Y31f_4CLNEKbtVCyYm1dXg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:MarketableSecuritiesTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2023_U7-26fnmXE-1quvtU04Bqw", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "unitRef": "Unit_Standard_USD_Y31f_4CLNEKbtVCyYm1dXg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:MarketableSecuritiesTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsConvertibleSeniorNotesDetails", "longName": "40406 - Disclosure - Fair value of financial instruments and investments - Convertible senior notes (Details)", "shortName": "Fair value of financial instruments and investments - Convertible senior notes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "As_Of_9_30_2023_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes1.5DueSeptember152026Member_ykR5__NqRUyahwMLceFO4Q", "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage", "unitRef": "Unit_Standard_pure_0NKO0qHUwUGEF4mqEQfw0A", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2023_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes1.5DueSeptember152026Member_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_OEYzB9K5k0m1bvQxzWs94w", "name": "us-gaap:DebtInstrumentFairValue", "unitRef": "Unit_Standard_USD_Y31f_4CLNEKbtVCyYm1dXg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "unique": true } }, "R48": { "role": "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsSummaryOfChangesInFairValueOfCompanySLevel3ValuationDetails", "longName": "40407 - Disclosure - Fair value of financial instruments and investments - Summary of changes in the fair value of the Company's Level 3 valuation (Details)", "shortName": "Fair value of financial instruments and investments - Summary of changes in the fair value of the Company's Level 3 valuation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_ptct_PtcFaAndPtcAsMember_uVeCyO094UGXcITVVY371Q", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "unitRef": "Unit_Standard_USD_Y31f_4CLNEKbtVCyYm1dXg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_ptct_PtcFaAndPtcAsMember_uVeCyO094UGXcITVVY371Q", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "unitRef": "Unit_Standard_USD_Y31f_4CLNEKbtVCyYm1dXg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsFairValueLiabilitiesMeasuredDetails", "longName": "40408 - Disclosure - Fair value of financial instruments and investments - Fair Value Liabilities Measured (Details)", "shortName": "Fair value of financial instruments and investments - Fair Value Liabilities Measured (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "As_Of_9_30_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityDevelopmentandRegulatoryMilestoneMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_ptct_DevelopmentandRegulatoryMilestoneMember_us-gaap_ValuationTechniqueAxis_us-gaap_ValuationTechniqueDiscountedCashFlowMember_eH_oSQaPpk6aHzfOZVWM3Q", "name": "ptct:RightsExchangeSettlementPotentialMilestonesValue", "unitRef": "Unit_Standard_USD_Y31f_4CLNEKbtVCyYm1dXg", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "p", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2023_srt_RangeAxis_srt_MinimumMember_us-gaap_BusinessAcquisitionAxis_ptct_AgilisMember_us-gaap_ContingentConsiderationByTypeAxis_ptct_LiabilityDevelopmentandRegulatoryMilestoneMember_us-gaap_FairValueByLiabilityClassAxis_us-gaap_CommitmentsMember_us-gaap_MeasurementInputTypeAxis_ptct_DevelopmentandRegulatoryMilestoneMember_us-gaap_ValuationTechniqueAxis_us-gaap_ValuationTechniqueDiscountedCashFlowMember_eH_oSQaPpk6aHzfOZVWM3Q", "name": "ptct:RightsExchangeSettlementPotentialMilestonesValue", "unitRef": "Unit_Standard_USD_Y31f_4CLNEKbtVCyYm1dXg", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "p", "td", "tr", "table", "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.ptcbio.com/role/DisclosureAccountsPayableAndAccruedExpensesComponentsDetails", "longName": "40501 - Disclosure - Accounts payable and accrued expenses - Components (Details)", "shortName": "Accounts payable and accrued expenses - Components (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "As_Of_9_30_2023_U7-26fnmXE-1quvtU04Bqw", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "Unit_Standard_USD_Y31f_4CLNEKbtVCyYm1dXg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2023_U7-26fnmXE-1quvtU04Bqw", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "Unit_Standard_USD_Y31f_4CLNEKbtVCyYm1dXg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.ptcbio.com/role/DisclosureAccountsPayableAndAccruedExpensesRestructuringDetails", "longName": "40502 - Disclosure - Accounts payable and accrued expenses - Restructuring (Details)", "shortName": "Accounts payable and accrued expenses - Restructuring (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_9_30_2023_ANcExXKl1k2ZHC8RXTO5oA", "name": "us-gaap:RestructuringCharges", "unitRef": "Unit_Standard_USD_Y31f_4CLNEKbtVCyYm1dXg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_9_30_2023_ANcExXKl1k2ZHC8RXTO5oA", "name": "us-gaap:RestructuringCharges", "unitRef": "Unit_Standard_USD_Y31f_4CLNEKbtVCyYm1dXg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.ptcbio.com/role/DisclosureCapitalizationNarrativeDetails", "longName": "40601 - Disclosure - Capitalization - Narrative (Details)", "shortName": "Capitalization - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_9_30_2023_us-gaap_TypeOfArrangementAxis_ptct_AtMarketOfferingSalesAgreementMember_QlbjDf40fUagdZAXHBdnlA", "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction", "unitRef": "Unit_Standard_shares_OaxkKXbBmUmMkA_gGC3tZQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction", "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction", "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_9_30_2023_us-gaap_TypeOfArrangementAxis_ptct_AtMarketOfferingSalesAgreementMember_QlbjDf40fUagdZAXHBdnlA", "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction", "unitRef": "Unit_Standard_shares_OaxkKXbBmUmMkA_gGC3tZQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction", "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction", "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.ptcbio.com/role/DisclosureNetLossPerShareNumeratorAndDenominatorDetails", "longName": "40701 - Disclosure - Net loss per share - Numerator and Denominator (Details)", "shortName": "Net loss per share - Numerator and Denominator (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_9_30_2023_ANcExXKl1k2ZHC8RXTO5oA", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "unitRef": "Unit_Standard_USD_Y31f_4CLNEKbtVCyYm1dXg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_9_30_2023_ANcExXKl1k2ZHC8RXTO5oA", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "unitRef": "Unit_Standard_USD_Y31f_4CLNEKbtVCyYm1dXg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.ptcbio.com/role/DisclosureNetLossPerShareAntidilutiveDetails", "longName": "40702 - Disclosure - Net loss per share - Antidilutive (Details)", "shortName": "Net loss per share - Antidilutive (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_zooc4MtLrUmmagQRUJLY7w", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Unit_Standard_shares_OaxkKXbBmUmMkA_gGC3tZQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_zooc4MtLrUmmagQRUJLY7w", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Unit_Standard_shares_OaxkKXbBmUmMkA_gGC3tZQ", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.ptcbio.com/role/DisclosureStockAwardPlanNarrativeDetails", "longName": "40801 - Disclosure - Stock award plan - Narrative (Details)", "shortName": "Stock award plan - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_9_30_2023_ANcExXKl1k2ZHC8RXTO5oA", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "Unit_Standard_USD_Y31f_4CLNEKbtVCyYm1dXg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember_jyHtzHJAykuzsakug77hiw", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "unitRef": "Unit_Standard_pure_0NKO0qHUwUGEF4mqEQfw0A", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "unique": true } }, "R56": { "role": "http://www.ptcbio.com/role/DisclosureStockAwardPlanStockOptionActivityDetails", "longName": "40802 - Disclosure - Stock award plan - Stock Option Activity (Details)", "shortName": "Stock award plan - Stock Option Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember_Dd-iUHmoUU2n2QDv0iMHGQ", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Unit_Standard_shares_OaxkKXbBmUmMkA_gGC3tZQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2022_us-gaap_AwardTypeAxis_us-gaap_StockOptionMember_Dd-iUHmoUU2n2QDv0iMHGQ", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Unit_Standard_shares_OaxkKXbBmUmMkA_gGC3tZQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.ptcbio.com/role/DisclosureStockAwardPlanAssumptionsUsedDetails", "longName": "40803 - Disclosure - Stock award plan - Assumptions Used (Details)", "shortName": "Stock award plan - Assumptions Used (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_zooc4MtLrUmmagQRUJLY7w", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_zooc4MtLrUmmagQRUJLY7w", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.ptcbio.com/role/DisclosureStockAwardPlanRestrictedStockDetails", "longName": "40804 - Disclosure - Stock award plan - Restricted Stock (Details)", "shortName": "Stock award plan - Restricted Stock (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "As_Of_12_31_2022_us-gaap_AwardTypeAxis_ptct_RestrictedStockAndRestrictedStockUnitsMember_giST9omlbUeQhB0SOOdoOQ", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Unit_Standard_shares_OaxkKXbBmUmMkA_gGC3tZQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2022_us-gaap_AwardTypeAxis_ptct_RestrictedStockAndRestrictedStockUnitsMember_giST9omlbUeQhB0SOOdoOQ", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "Unit_Standard_shares_OaxkKXbBmUmMkA_gGC3tZQ", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true } }, "R59": { "role": "http://www.ptcbio.com/role/DisclosureStockAwardPlanShareBasedCompensationExpenseDetails", "longName": "40805 - Disclosure - Stock award plan - Share-based compensation expense (Details)", "shortName": "Stock award plan - Share-based compensation expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_9_30_2023_ANcExXKl1k2ZHC8RXTO5oA", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "Unit_Standard_USD_Y31f_4CLNEKbtVCyYm1dXg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_9_30_2023_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_oNKznRoq0kG7Qa_dA1Tszg", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "Unit_Standard_USD_Y31f_4CLNEKbtVCyYm1dXg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "unique": true } }, "R60": { "role": "http://www.ptcbio.com/role/DisclosureDebtLiabilityForSaleOfFutureRoyaltiesDetails", "longName": "40901 - Disclosure - Debt - Liability for Sale of Future Royalties (Details)", "shortName": "Debt - Liability for Sale of Future Royalties (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "Duration_7_1_2020_To_7_31_2020_0fmX4GqWiEy_-vVJhVjDCg", "name": "ptct:ProceedsFromSaleOfFutureRoyalties", "unitRef": "Unit_Standard_USD_Y31f_4CLNEKbtVCyYm1dXg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:LongTermDebtTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2022_hEh39iYfXU-Y4MnDSux-iQ", "name": "ptct:LiabilitySaleOfFutureRoyalties", "unitRef": "Unit_Standard_USD_Y31f_4CLNEKbtVCyYm1dXg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ptct:LiabilityForSaleOfFutureRoyaltiesTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "unique": true } }, "R61": { "role": "http://www.ptcbio.com/role/DisclosureDebtSeniorSecuredTermLoanDetails", "longName": "40902 - Disclosure - Debt - Senior Secured Term Loan (Details)", "shortName": "Debt - Senior Secured Term Loan (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_zooc4MtLrUmmagQRUJLY7w", "name": "us-gaap:AmortizationOfFinancingCosts", "unitRef": "Unit_Standard_USD_Y31f_4CLNEKbtVCyYm1dXg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_10_27_2022_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_hB-O7OdU1UaO797m4D3t7w", "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity", "unitRef": "Unit_Standard_USD_Y31f_4CLNEKbtVCyYm1dXg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "unique": true } }, "R62": { "role": "http://www.ptcbio.com/role/DisclosureDebtNarrativeDetails", "longName": "40903 - Disclosure - Debt - Narrative (Details)", "shortName": "Debt - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "As_Of_9_30_2023_U7-26fnmXE-1quvtU04Bqw", "name": "us-gaap:LongTermDebtNoncurrent", "unitRef": "Unit_Standard_USD_Y31f_4CLNEKbtVCyYm1dXg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_3_15_2022_To_4_8_2022_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes1.5DueSeptember152026Member_OjSfGM7Jzk6cjH2n8VQgZw", "name": "us-gaap:DebtInstrumentInterestRateIncreaseDecrease", "unitRef": "Unit_Standard_pure_0NKO0qHUwUGEF4mqEQfw0A", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "unique": true } }, "R63": { "role": "http://www.ptcbio.com/role/DisclosureDebtConvertibleNotesDetails", "longName": "40904 - Disclosure - Debt - Convertible Notes (Details)", "shortName": "Debt - Convertible Notes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "As_Of_9_30_2023_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes1.5DueSeptember152026Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_83BXG4mkzEOhRTT8syFo-g", "name": "us-gaap:DebtInstrumentFaceAmount", "unitRef": "Unit_Standard_USD_Y31f_4CLNEKbtVCyYm1dXg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ConvertibleDebtTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2023_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes1.5DueSeptember152026Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_83BXG4mkzEOhRTT8syFo-g", "name": "us-gaap:UnamortizedDebtIssuanceExpense", "unitRef": "Unit_Standard_USD_Y31f_4CLNEKbtVCyYm1dXg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ConvertibleDebtTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "unique": true } }, "R64": { "role": "http://www.ptcbio.com/role/DisclosureDebtConvertibleNotesInterestExpenseDetails", "longName": "40905 - Disclosure - Debt - Convertible Notes Interest Expense (Details)", "shortName": "Debt - Convertible Notes Interest Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_zooc4MtLrUmmagQRUJLY7w", "name": "us-gaap:AmortizationOfFinancingCosts", "unitRef": "Unit_Standard_USD_Y31f_4CLNEKbtVCyYm1dXg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2022_To_9_30_2022_us-gaap_DebtInstrumentAxis_ptct_ConvertibleSeniorNotes3.0PercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_ConvertibleDebtMember_pvjl3ei350WS18PsnlQM_Q", "name": "us-gaap:InterestExpenseDebtExcludingAmortization", "unitRef": "Unit_Standard_USD_Y31f_4CLNEKbtVCyYm1dXg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "ptct:ScheduleOfInterestExpenseRecognizedRelatedToConvertibleDebtTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "unique": true } }, "R65": { "role": "http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails", "longName": "41001 - Disclosure - Commitments and contingencies - Narrative (Details)", "shortName": "Commitments and contingencies - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "As_Of_9_30_2023_U7-26fnmXE-1quvtU04Bqw", "name": "ptct:MilestonePayable", "unitRef": "Unit_Standard_USD_Y31f_4CLNEKbtVCyYm1dXg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2022_srt_CounterpartyNameAxis_ptct_WellcomeTrustLimitedMember_IZLeLgQOQUuPj_M1_wmlRg", "name": "ptct:DevelopmentMilestonePaymentObligations", "unitRef": "Unit_Standard_USD_Y31f_4CLNEKbtVCyYm1dXg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "unique": true } }, "R66": { "role": "http://www.ptcbio.com/role/DisclosureRevenueRecognitionNetProductSalesDetails", "longName": "41101 - Disclosure - Revenue recognition - Net Product Sales (Details)", "shortName": "Revenue recognition - Net Product Sales (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_9_30_2023_ANcExXKl1k2ZHC8RXTO5oA", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "Unit_Standard_segment_k2coI04TH0-X6hen7ifkrg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "us-gaap:NumberOfOperatingSegments", "us-gaap:NumberOfOperatingSegments", "us-gaap:NumberOfOperatingSegments", "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_9_30_2023_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember_X5Tt8wU_Z0mZdeoMEEEK4g", "name": "ptct:Numberofdistributors", "unitRef": "Unit_Standard_Distributor_6Gc5n3unpE2eW0xnByYFAg", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "unique": true } }, "R67": { "role": "http://www.ptcbio.com/role/DisclosureRevenueRecognitionCollaborationAndRoyaltyRevenueDetails", "longName": "41102 - Disclosure - Revenue recognition - Collaboration and Royalty Revenue (Details)", "shortName": "Revenue recognition - Collaboration and Royalty Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "As_Of_9_30_2023_U7-26fnmXE-1quvtU04Bqw", "name": "ptct:RevenueRecognitionMilestonePotentialAchievements", "unitRef": "Unit_Standard_USD_Y31f_4CLNEKbtVCyYm1dXg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "span", "p", "ptct:LiabilityForSaleOfFutureRoyaltiesPolicyTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_11_30_2011_ptct_MilestoneAxis_ptct_ResearchAndDevelopmentEventMilestonesMember_srt_RangeAxis_srt_MaximumMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember_ipPSfJPSLEWxDulKXQpgFw", "name": "ptct:RevenueRecognitionMilestonePotentialAchievements", "unitRef": "Unit_Standard_USD_Y31f_4CLNEKbtVCyYm1dXg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:RevenueFromContractWithCustomerTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "unique": true } }, "R68": { "role": "http://www.ptcbio.com/role/DisclosureRevenueRecognitionManufacturingRevenueDetails", "longName": "41103 - Disclosure - Revenue recognition - Manufacturing Revenue (Details)", "shortName": "Revenue recognition - Manufacturing Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_9_30_2023_ANcExXKl1k2ZHC8RXTO5oA", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit_Standard_USD_Y31f_4CLNEKbtVCyYm1dXg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_9_30_2023_srt_ProductOrServiceAxis_ptct_ManufacturingMember_bb9ysARHTUanMMNOMiD4Ww", "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized", "unitRef": "Unit_Standard_USD_Y31f_4CLNEKbtVCyYm1dXg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "unique": true } }, "R69": { "role": "http://www.ptcbio.com/role/DisclosureRevenueRecognitionPerformanceObligationsDetails", "longName": "41104 - Disclosure - Revenue recognition - Performance Obligations (Details)", "shortName": "Revenue recognition - Performance Obligations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "As_Of_9_30_2023_U7-26fnmXE-1quvtU04Bqw", "name": "us-gaap:RevenueRemainingPerformanceObligation", "unitRef": "Unit_Standard_USD_Y31f_4CLNEKbtVCyYm1dXg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2023_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_ptct_cnst_date_20231001_JyKvhueckEqdTRnV7ic0mg", "name": "us-gaap:RevenueRemainingPerformanceObligation", "unitRef": "Unit_Standard_USD_Y31f_4CLNEKbtVCyYm1dXg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "unique": true } }, "R70": { "role": "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillDefiniteLivedIntangiblesDetails", "longName": "41201 - Disclosure - Intangible assets and goodwill - Definite-lived Intangibles (Details)", "shortName": "Intangible assets and goodwill - Definite-lived Intangibles (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "As_Of_9_30_2023_U7-26fnmXE-1quvtU04Bqw", "name": "ptct:MilestonePayable", "unitRef": "Unit_Standard_USD_Y31f_4CLNEKbtVCyYm1dXg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_us-gaap_AssetAcquisitionAxis_ptct_EmflazaassetacquisitionMember_V-E4yJe4zkqSbe-L2vAS4Q", "name": "ptct:MilestoneObligationsRecorded", "unitRef": "Unit_Standard_USD_Y31f_4CLNEKbtVCyYm1dXg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "unique": true } }, "R71": { "role": "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillFutureAmortizationDetails", "longName": "41202 - Disclosure - Intangible assets and goodwill - Future Amortization (Details)", "shortName": "Intangible assets and goodwill - Future Amortization (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "As_Of_9_30_2023_U7-26fnmXE-1quvtU04Bqw", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "unitRef": "Unit_Standard_USD_Y31f_4CLNEKbtVCyYm1dXg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2023_U7-26fnmXE-1quvtU04Bqw", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "unitRef": "Unit_Standard_USD_Y31f_4CLNEKbtVCyYm1dXg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true } }, "R72": { "role": "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillIndefiniteLivedIntangiblesDetails", "longName": "41203 - Disclosure - Intangible assets and goodwill - Indefinite-lived Intangibles (Details)", "shortName": "Intangible assets and goodwill - Indefinite-lived Intangibles (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "Duration_1_1_2023_To_9_30_2023_zooc4MtLrUmmagQRUJLY7w", "name": "us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill", "unitRef": "Unit_Standard_USD_Y31f_4CLNEKbtVCyYm1dXg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2022_us-gaap_FairValueByAssetClassAxis_us-gaap_IndefinitelivedIntangibleAssetsMember_GsFUmw1YX0i7NSoLaSYaqg", "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill", "unitRef": "Unit_Standard_USD_Y31f_4CLNEKbtVCyYm1dXg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "unique": true } }, "R73": { "role": "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillGoodwillDetails", "longName": "41204 - Disclosure - Intangible assets and goodwill - Goodwill (Details)", "shortName": "Intangible assets and goodwill - Goodwill (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "As_Of_9_30_2023_U7-26fnmXE-1quvtU04Bqw", "name": "us-gaap:Goodwill", "unitRef": "Unit_Standard_USD_Y31f_4CLNEKbtVCyYm1dXg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_8_23_2018_To_9_30_2023_3yT9_2bovUChtkmuMSkuEQ", "name": "us-gaap:GoodwillPeriodIncreaseDecrease", "unitRef": "Unit_Standard_USD_Y31f_4CLNEKbtVCyYm1dXg", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "unique": true } }, "R74": { "role": "http://www.ptcbio.com/role/DisclosureSubsequentEventsDetails", "longName": "41301 - Disclosure - Subsequent events (Details)", "shortName": "Subsequent events (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "As_Of_9_30_2023_srt_CounterpartyNameAxis_ptct_RoyaltyPharmaInvestments2019IcavMember_us-gaap_TypeOfArrangementAxis_ptct_RoyaltyPurchaseAgreementMember_lHVk8kvVjkW09HNMW4i9uw", "name": "ptct:AssignedRoyaltyPaymentPercentage", "unitRef": "Unit_Standard_pure_0NKO0qHUwUGEF4mqEQfw0A", "xsiNil": "false", "lang": null, "decimals": "6", "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_9_30_2023_srt_CounterpartyNameAxis_ptct_RoyaltyPharmaInvestments2019IcavMember_us-gaap_TypeOfArrangementAxis_ptct_RoyaltyPurchaseAgreementMember_lHVk8kvVjkW09HNMW4i9uw", "name": "ptct:AssignedRoyaltyPaymentPercentage", "unitRef": "Unit_Standard_pure_0NKO0qHUwUGEF4mqEQfw0A", "xsiNil": "false", "lang": null, "decimals": "6", "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true } }, "R75": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Uncategorized", "order": "75", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_9_30_2023_ANcExXKl1k2ZHC8RXTO5oA", "name": "us-gaap:NetIncomeLoss", "unitRef": "Unit_Standard_USD_Y31f_4CLNEKbtVCyYm1dXg", "xsiNil": "false", "lang": null, "decimals": "-3", "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true }, "uniqueAnchor": null }, "R76": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Cover", "order": "76", "firstAnchor": { "contextRef": "Duration_7_1_2023_To_9_30_2023_ANcExXKl1k2ZHC8RXTO5oA", "name": "ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_7_1_2023_To_9_30_2023_ANcExXKl1k2ZHC8RXTO5oA", "name": "ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "tmb-20230930x10q.htm", "first": true, "unique": true } } }, "tag": { "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsFairValueLiabilitiesMeasuredDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsHierarchyDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsSummaryOfChangesInFairValueOfCompanySLevel3ValuationDetails" ], "lang": { "en-us": { "role": { "label": "Significant unobservable inputs (level 3)", "terseLabel": "Significant unobservable inputs (Level 3)", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r387", "r441", "r442", "r443", "r444", "r445", "r446", "r545", "r609", "r822", "r823", "r834", "r835", "r836" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsConvertibleSeniorNotesDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsHierarchyDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Significant other observable inputs (level 2)", "terseLabel": "Significant other observable inputs (Level 2)", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r387", "r441", "r446", "r545", "r608", "r822", "r823", "r834", "r835", "r836" ] }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "presentation": [ "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillDefiniteLivedIntangiblesDetails", "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillIndefiniteLivedIntangiblesDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Asset Class [Domain]", "documentation": "Class of asset." } } }, "auth_ref": [ "r15" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.ptcbio.com/role/DisclosureLeasesLeasePaymentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ptcbio.com/role/DisclosureLeasesLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payments, Due Next Twelve Months", "terseLabel": "2024", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r594" ] }, "us-gaap_ForeignCurrencyTransactionGainLossUnrealized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyTransactionGainLossUnrealized", "crdr": "credit", "calculation": { "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 13.0 } }, "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Foreign Currency Transaction Gain (Loss), Unrealized", "negatedLabel": "Unrealized foreign currency transaction losses, net", "documentation": "Amount, before tax, of unrealized gain (loss) from foreign currency transaction." } } }, "auth_ref": [ "r123", "r742", "r855", "r1029", "r1030", "r1053" ] }, "us-gaap_ValuationTechniqueDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationTechniqueDomain", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsFairValueLiabilitiesMeasuredDetails" ], "lang": { "en-us": { "role": { "label": "Valuation Approach and Technique [Domain]", "documentation": "Valuation approach and technique." } } }, "auth_ref": [ "r14" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsFairValueLiabilitiesMeasuredDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsSummaryOfChangesInFairValueOfCompanySLevel3ValuationDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value by Liability Class [Domain]", "documentation": "Represents classes of liabilities measured and disclosed at fair value." } } }, "auth_ref": [ "r15" ] }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfStockholdersDeficitEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Issuance of common stock in connection with an employee stock purchase plan (in shares)", "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan." } } }, "auth_ref": [ "r13", "r100", "r101", "r138" ] }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures", "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfStockholdersDeficitEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures", "verboseLabel": "Restricted stock vesting and issuance (in shares)", "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited." } } }, "auth_ref": [ "r13", "r100", "r101", "r138" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.ptcbio.com/role/DisclosureLeasesLeasePaymentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.ptcbio.com/role/DisclosureLeasesLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payments, Due Year Three", "terseLabel": "2026", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r594" ] }, "us-gaap_ValuationTechniqueAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationTechniqueAxis", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsFairValueLiabilitiesMeasuredDetails" ], "lang": { "en-us": { "role": { "label": "Valuation Approach and Technique [Axis]", "documentation": "Information by valuation approach and technique." } } }, "auth_ref": [ "r14" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.ptcbio.com/role/DisclosureLeasesLeasePaymentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.ptcbio.com/role/DisclosureLeasesLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payments, Due Year Two", "terseLabel": "2025", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r594" ] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://www.ptcbio.com/role/DisclosureStockAwardPlanStockOptionActivityDetails", "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfStockholdersDeficitEquity" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "negatedLabel": "Exercised (in shares)", "terseLabel": "Exercise of options (in shares)", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r13", "r100", "r101", "r138", "r461" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": { "http://www.ptcbio.com/role/DisclosureLeasesLeasePaymentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ptcbio.com/role/DisclosureLeasesLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payments, Remainder of Fiscal Year", "terseLabel": "2023 (excludes the nine months ended September 30, 2023)", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year." } } }, "auth_ref": [ "r1035" ] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.ptcbio.com/role/DisclosureLeasesTables" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]", "terseLabel": "Schedule of future lease payments - Operating leases", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r1035" ] }, "us-gaap_OperatingLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseExpense", "crdr": "debit", "presentation": [ "http://www.ptcbio.com/role/DisclosureLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Expense", "terseLabel": "Operating lease, expense", "documentation": "Amount of operating lease expense. Excludes sublease income." } } }, "auth_ref": [ "r1032" ] }, "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 5.0 }, "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillIndefiniteLivedIntangiblesDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails", "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)", "negatedLabel": "Impairment", "terseLabel": "Impairment of indefinite-lived intangibles excluding goodwill", "verboseLabel": "Intangible asset impairment", "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value." } } }, "auth_ref": [ "r954", "r982" ] }, "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss", "crdr": "credit", "presentation": [ "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-sale, Allowance for Credit Loss", "terseLabel": "Allowance for credit loss", "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r281", "r329", "r336", "r338" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Income Tax Expense (Benefit)", "negatedLabel": "Income tax benefit", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r158", "r167", "r232", "r233", "r261", "r493", "r504", "r664" ] }, "us-gaap_RoyaltyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RoyaltyMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureRevenueRecognitionCollaborationAndRoyaltyRevenueDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCollaborationAndRoyaltyRevenueDetails", "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Royalty revenue", "documentation": "Money for usage-based right to asset." } } }, "auth_ref": [ "r994" ] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityAxis", "presentation": [ "http://www.ptcbio.com/role/DisclosureDebtSeniorSecuredTermLoanDetails", "http://www.ptcbio.com/role/DisclosureDebtTables", "http://www.ptcbio.com/role/DisclosureSubsequentEventsDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLossPeriodIncreaseDecrease", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsMarketableSecuritiesUnrealizedGainsLossesDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-sale, Allowance for Credit Loss, Period Increase (Decrease)", "terseLabel": "Increase in allowance for credit losses", "documentation": "Amount of increase (decrease) in allowance for credit loss of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r978" ] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialInstrumentAxis", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsAvailableForSaleSecuritiesDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsHierarchyDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsMarketableSecuritiesBalanceSheetDisclosuresDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsMarketableSecuritiesUnrealizedGainsLossesDetails" ], "lang": { "en-us": { "role": { "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r321", "r322", "r326", "r327", "r328", "r330", "r334", "r335", "r395", "r412", "r529", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r659", "r819", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r971", "r972", "r973", "r974" ] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityDomain", "presentation": [ "http://www.ptcbio.com/role/DisclosureDebtSeniorSecuredTermLoanDetails", "http://www.ptcbio.com/role/DisclosureDebtTables", "http://www.ptcbio.com/role/DisclosureSubsequentEventsDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "us-gaap_ProductMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProductMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails", "http://www.ptcbio.com/role/DisclosureRevenueRecognitionNetProductSalesDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails", "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Net product revenue", "documentation": "Article or substance produced by nature, labor or machinery." } } }, "auth_ref": [ "r827" ] }, "us-gaap_DebtInstrumentCumulativeSinkingFundPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentCumulativeSinkingFundPayments", "crdr": "debit", "presentation": [ "http://www.ptcbio.com/role/DisclosureDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Cumulative Sinking Fund Payments", "terseLabel": "Sinking fund", "documentation": "Cumulative amount paid into a fund, which is used to retire the debt instrument." } } }, "auth_ref": [ "r68", "r989" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": [ "http://www.ptcbio.com/role/DisclosureStockAwardPlanStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted- average exercise price" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "presentation": [ "http://www.ptcbio.com/role/DisclosureStockAwardPlanNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Purchase Price of Common Stock, Percent", "terseLabel": "Purchase price of common stock, percent", "documentation": "Purchase price of common stock expressed as a percentage of its fair value." } } }, "auth_ref": [] }, "ptct_InducementStockIncentivePlan2020Member": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "InducementStockIncentivePlan2020Member", "presentation": [ "http://www.ptcbio.com/role/DisclosureStockAwardPlanNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Information pertaining to the 2020 Inducement Stock Incentive Plan.", "label": "2020 Inducement Stock Incentive Plan" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "ptct_RightsExchangeSettlementPotentialMilestonesValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "RightsExchangeSettlementPotentialMilestonesValue", "crdr": "credit", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsFairValueLiabilitiesMeasuredDetails" ], "lang": { "en-us": { "role": { "documentation": "The potential milestone payments due under the Rights Exchange Settlement.", "label": "Rights Exchange Settlement, Potential Milestones, Value", "terseLabel": "Potential milestones" } } }, "auth_ref": [] }, "us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureDebtSeniorSecuredTermLoanDetails" ], "lang": { "en-us": { "role": { "label": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]", "terseLabel": "Adjusted Term SOFR", "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap that has its variable-rate leg referenced to Secured Overnight Financing Rate (SOFR) with no additional spread over SOFR on variable-rate leg." } } }, "auth_ref": [ "r1023" ] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "presentation": [ "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwill" ], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "Intangible assets and goodwill", "documentation": "The entire disclosure for goodwill and intangible assets." } } }, "auth_ref": [ "r126" ] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationAxis", "presentation": [ "http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsMarketableSecuritiesDetails", "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillDefiniteLivedIntangiblesDetails", "http://www.ptcbio.com/role/DisclosureRevenueRecognitionManufacturingRevenueDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Balance Sheet Location [Axis]", "documentation": "Information by location on balance sheet (statement of financial position)." } } }, "auth_ref": [] }, "ptct_PaymentOfRoyaltyObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "PaymentOfRoyaltyObligation", "crdr": "credit", "presentation": [ "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillDefiniteLivedIntangiblesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for royalty obligations paid.", "label": "Payment of Royalty Obligation", "terseLabel": "Royalty payments" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsAvailableForSaleSecuritiesDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsMarketableSecuritiesBalanceSheetDisclosuresDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsMarketableSecuritiesUnrealizedGainsLossesDetails" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-sale [Line Items]", "terseLabel": "Debt Securities, Available-for-sale [Line Items]", "verboseLabel": "Debt Securities, Available-for-sale [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289" ] }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxLiabilitiesNet", "crdr": "credit", "calculation": { "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Deferred Income Tax Liabilities, Net", "terseLabel": "Deferred tax liability", "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting." } } }, "auth_ref": [ "r491", "r492", "r651" ] }, "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "crdr": "credit", "calculation": { "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsMarketableSecuritiesDetails", "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments to Acquire Debt Securities, Available-for-sale", "negatedLabel": "Purchases of marketable securities - available for sale", "terseLabel": "Purchase of convertible note", "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r40", "r205", "r277" ] }, "ptct_WaylivraMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "WaylivraMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillDefiniteLivedIntangiblesDetails" ], "lang": { "en-us": { "role": { "documentation": "Information pertaining to the drug Waylivra.", "label": "Waylivra [Member]", "terseLabel": "Waylivra" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt", "crdr": "debit", "calculation": { "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from Sale of Debt Securities, Available-for-sale", "terseLabel": "Sale and redemption of marketable securities- available for sale", "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r39", "r205", "r277", "r308" ] }, "ptct_TegsediMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "TegsediMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillDefiniteLivedIntangiblesDetails" ], "lang": { "en-us": { "role": { "documentation": "Information pertaining to the drug Tegesdi.", "label": "Tegsedi [Member]", "terseLabel": "Tegsedi" } } }, "auth_ref": [] }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 17.0 } }, "presentation": [ "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails", "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Deferred Income Tax Expense (Benefit)", "negatedLabel": "Deferred tax benefit", "terseLabel": "Deferred income taxes", "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r9", "r141", "r166", "r505", "r506", "r959" ] }, "ptct_EquitySecuritiesFvNiUnrealizedGainLossForeignCurrency": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "EquitySecuritiesFvNiUnrealizedGainLossForeignCurrency", "crdr": "credit", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) from foreign currency on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Equity Securities, FV-NI, Unrealized Gain (Loss), Foreign Currency", "terseLabel": "Unrealized foreign currency gains (losses) on equity investments" } } }, "auth_ref": [] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementClassOfStockAxis", "presentation": [ "http://www.ptcbio.com/role/DisclosureStockAwardPlanNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "documentation": "Information by the different classes of stock of the entity." } } }, "auth_ref": [ "r170", "r185", "r186", "r187", "r213", "r239", "r240", "r247", "r249", "r255", "r256", "r309", "r370", "r372", "r373", "r374", "r377", "r378", "r400", "r401", "r404", "r407", "r414", "r557", "r688", "r689", "r690", "r691", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r722", "r744", "r762", "r784", "r785", "r786", "r787", "r788", "r933", "r956", "r963" ] }, "ptct_ClearpointEquityInvestmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "ClearpointEquityInvestmentMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "documentation": "ClearPoint", "label": "ClearPoint Equity Investment [Member]", "terseLabel": "ClearPoint Equity Investment" } } }, "auth_ref": [] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": [ "r918" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": [ "http://www.ptcbio.com/role/DisclosureStockAwardPlanStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Exercisable at the end of the period (in dollars)", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": [ "r70" ] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosure of cash information" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://www.ptcbio.com/role/DisclosureSubsequentEvents" ], "lang": { "en-us": { "role": { "label": "Subsequent Events [Text Block]", "terseLabel": "Subsequent events", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r601", "r603" ] }, "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentFederalStateAndLocalTaxExpenseBenefitAbstract", "presentation": [ "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Current Federal, State and Local, Tax Expense (Benefit) [Abstract]", "terseLabel": "Income taxes" } } }, "auth_ref": [] }, "ptct_MilestoneObligationsRecorded": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "MilestoneObligationsRecorded", "crdr": "credit", "presentation": [ "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillDefiniteLivedIntangiblesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of milestone obligation payments recorded during the period.", "label": "Milestone Obligations Recorded", "terseLabel": "Milestone obligation payments recorded" } } }, "auth_ref": [] }, "ptct_DebtInstrumentConversionPeriodOnOrAfterSeptember202023Member": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "DebtInstrumentConversionPeriodOnOrAfterSeptember202023Member", "presentation": [ "http://www.ptcbio.com/role/DisclosureDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the debt instrument redemption period on or after September 20, 2023.", "label": "Redemption on or after September 20, 2023" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "ptct_ConvertibleDebtSecurity": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "ConvertibleDebtSecurity", "crdr": "debit", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsHierarchyDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of investment in convertible debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Convertible Debt Security", "terseLabel": "ClearPoint convertible debt security" } } }, "auth_ref": [] }, "ptct_SalesRebatesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "SalesRebatesCurrent", "crdr": "credit", "calculation": { "http://www.ptcbio.com/role/DisclosureAccountsPayableAndAccruedExpensesComponentsDetails": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.ptcbio.com/role/DisclosureAccountsPayableAndAccruedExpensesComponentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for sales rebates. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Sales Rebates, Current", "terseLabel": "Sales rebates" } } }, "auth_ref": [] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": [ "r872", "r880", "r890", "r907", "r915", "r919", "r927" ] }, "ptct_LeaseDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "LeaseDisclosureTextBlock", "presentation": [ "http://www.ptcbio.com/role/DisclosureLeases" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of information about leases.", "label": "Lease Disclosure [Text Block]", "terseLabel": "Leases" } } }, "auth_ref": [] }, "us-gaap_DeferredIncomeTaxLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxLiabilities", "crdr": "credit", "presentation": [ "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Liabilities, Gross", "verboseLabel": "Deferred tax liability", "documentation": "Amount of deferred tax liability attributable to taxable temporary differences." } } }, "auth_ref": [ "r98", "r99", "r148", "r497" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "ptct_AvailableForSaleDebtSecuritiesConversionPrice": { "xbrltype": "perShareItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "AvailableForSaleDebtSecuritiesConversionPrice", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "documentation": "The price per share of the conversion feature embedded in the available-for-sale convertible debt securities.", "label": "Available-for-sale Debt Securities, Conversion Price", "terseLabel": "Conversion price - convertible note" } } }, "auth_ref": [] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Selling, General and Administrative Expense", "terseLabel": "Selling, general and administrative", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r116" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "verboseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "auth_ref": [] }, "us-gaap_InventoryWriteDown": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryWriteDown", "crdr": "debit", "presentation": [ "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesInventoryDetails" ], "lang": { "en-us": { "role": { "label": "Inventory Write-down", "terseLabel": "Inventory write-down", "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels." } } }, "auth_ref": [ "r339" ] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": [ "r872", "r880", "r890", "r907", "r915", "r919", "r927" ] }, "ptct_NetSalesThresholdAchievedSalesMilestone": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "NetSalesThresholdAchievedSalesMilestone", "crdr": "credit", "presentation": [ "http://www.ptcbio.com/role/DisclosureRevenueRecognitionCollaborationAndRoyaltyRevenueDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCollaborationAndRoyaltyRevenueDetails" ], "lang": { "en-us": { "role": { "documentation": "The net sales threshold achieved which triggered a sales milestone payment under the licensing agreement.", "label": "Net Sales Threshold Achieved, Sales Milestone", "terseLabel": "Net sales milestone threshold achieved" } } }, "auth_ref": [] }, "ptct_MilestonePayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "MilestonePayable", "crdr": "credit", "presentation": [ "http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails", "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillDefiniteLivedIntangiblesDetails", "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The amount of recorded milestone payments payable.", "label": "Milestone Payable", "terseLabel": "Milestone payable" } } }, "auth_ref": [] }, "ptct_RightsExchangeSettlementMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "RightsExchangeSettlementMeasurementInput", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsFairValueLiabilitiesMeasuredDetails" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure Rights Exchange Settlement.", "label": "Rights Exchange Settlement, Measurement Input", "terseLabel": "Rights Exchange Settlement measurement" } } }, "auth_ref": [] }, "ptct_LeaseSupplementalCashFlowDisclosureTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "LeaseSupplementalCashFlowDisclosureTableTextBlock", "presentation": [ "http://www.ptcbio.com/role/DisclosureLeasesTables" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of supplemental cash flow information related to leases.", "label": "Lease Supplemental Cash Flow Disclosure [Table Text Block]", "terseLabel": "Schedule of supplemental cash flow information related to leases" } } }, "auth_ref": [] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of presentation", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "ptct_PotentialRoyaltiesDueNetProductSales": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "PotentialRoyaltiesDueNetProductSales", "crdr": "credit", "presentation": [ "http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of potential royalties due on worldwide net product sales per terms of the collaboration agreement.", "label": "Potential Royalties Due, Net Product Sales", "terseLabel": "Potential royalty payments due on net product sales" } } }, "auth_ref": [] }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpensesMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureStockAwardPlanShareBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Selling, general and administrative", "terseLabel": "Selling, general and administrative", "documentation": "Primary financial statement caption encompassing selling, general and administrative expense." } } }, "auth_ref": [] }, "ptct_FiniteLivedIntangibleAssetsAmortizationExpenseYearFourAndThereafter": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFourAndThereafter", "crdr": "debit", "calculation": { "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillFutureAmortizationDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillFutureAmortizationDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year and years thereafter following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Four and Thereafter", "terseLabel": "2027 and thereafter" } } }, "auth_ref": [] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfOperatingSegments", "presentation": [ "http://www.ptcbio.com/role/DisclosureRevenueRecognitionNetProductSalesDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Number of Operating Segments", "terseLabel": "Number of operating segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r965" ] }, "ptct_ResearchAndDevelopmentAndSalesMilestonesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "ResearchAndDevelopmentAndSalesMilestonesMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureRevenueRecognitionCollaborationAndRoyaltyRevenueDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to certain research and development events and certain sales events on the basis of which certain milestones are achieved.", "label": "Research and Development and Sales Milestones [Member]", "terseLabel": "Research and Development and Sales Milestones" } } }, "auth_ref": [] }, "us-gaap_ConvertibleDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebtTableTextBlock", "presentation": [ "http://www.ptcbio.com/role/DisclosureDebtTables" ], "lang": { "en-us": { "role": { "label": "Convertible Debt [Table Text Block]", "terseLabel": "Summary of convertible notes", "documentation": "Tabular disclosure of convertible debt instrument. Includes, but is not limited to, principal amount and amortized premium or discount." } } }, "auth_ref": [] }, "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff", "crdr": "debit", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsMarketableSecuritiesUnrealizedGainsLossesDetails" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-sale, Allowance for Credit Loss, Writeoff", "terseLabel": "Write downs of available for sale debt securities", "documentation": "Amount of writeoff of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r337" ] }, "srt_RealEstateAndAccumulatedDepreciationNameOfPropertyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RealEstateAndAccumulatedDepreciationNameOfPropertyDomain", "presentation": [ "http://www.ptcbio.com/role/DisclosureLeasesNarrativeDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Name of Property [Domain]" } } }, "auth_ref": [ "r802", "r1061", "r1062", "r1063", "r1064", "r1065", "r1066", "r1067", "r1068" ] }, "srt_RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RealEstateAndAccumulatedDepreciationDescriptionOfPropertyAxis", "presentation": [ "http://www.ptcbio.com/role/DisclosureLeasesNarrativeDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Name of Property [Axis]" } } }, "auth_ref": [ "r802", "r1061", "r1062", "r1063", "r1064", "r1065", "r1066", "r1067", "r1068" ] }, "ptct_ClearpointEquityInvestmentFvniUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "ClearpointEquityInvestmentFvniUnrealizedGainLoss", "crdr": "credit", "calculation": { "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on ClearPoint equity investment measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "ClearPoint Equity Investment, FvNi Unrealized Gain (Loss)", "negatedLabel": "Unrealized loss on ClearPoint Equity Investments" } } }, "auth_ref": [] }, "ptct_EmflazaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "EmflazaMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillDefiniteLivedIntangiblesDetails", "http://www.ptcbio.com/role/DisclosureRevenueRecognitionNetProductSalesDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Information pertaining to the product Emflaza.", "label": "Emflaza", "terseLabel": "Emflaza" } } }, "auth_ref": [] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameDomain", "presentation": [ "http://www.ptcbio.com/role/DisclosureStockAwardPlanNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r996", "r997", "r998", "r999", "r1000", "r1001", "r1002", "r1003", "r1004", "r1005", "r1006", "r1007", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": [ "r894" ] }, "ptct_EmployeeDirectorAndConsultantStockOptionPlan1998EquityAndLongTermIncentivePlan2009AndStockIncentivePlan2013Member": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "EmployeeDirectorAndConsultantStockOptionPlan1998EquityAndLongTermIncentivePlan2009AndStockIncentivePlan2013Member", "presentation": [ "http://www.ptcbio.com/role/DisclosureStockAwardPlanNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Pertains to information pertaining to the 1998 Employee, Director and Consultant Stock Option Plan, 2009 Equity and Long Term Incentive Plan and 2013 Stock Incentive Plan.", "label": "1998 Employee, Director, and Consultant Stock Option Plan, 2009 Equity and Long-term Incentive Plan, and 2013 Stock Incentive Plan" } } }, "auth_ref": [] }, "ptct_ClearpointEquityInvestmentsFvNi": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "ClearpointEquityInvestmentsFvNi", "crdr": "debit", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsHierarchyDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity security of ClearPoint Neuro, Inc. measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "ClearPoint Equity Investments, FV-NI", "terseLabel": "ClearPoint Equity Investments" } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureNetLossPerShareAntidilutiveDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameAxis", "presentation": [ "http://www.ptcbio.com/role/DisclosureStockAwardPlanNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r996", "r997", "r998", "r999", "r1000", "r1001", "r1002", "r1003", "r1004", "r1005", "r1006", "r1007", "r1008", "r1009", "r1010", "r1011", "r1012", "r1013", "r1014", "r1015", "r1016", "r1017", "r1018", "r1019", "r1020", "r1021" ] }, "ptct_TranslarnaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "TranslarnaMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureRevenueRecognitionNetProductSalesDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Information pertaining to the product Translarna.", "label": "Translarna" } } }, "auth_ref": [] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets", "totalLabel": "Total assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r145", "r182", "r213", "r257", "r264", "r268", "r309", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r514", "r516", "r557", "r650", "r734", "r844", "r856", "r990", "r991", "r1036" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://www.ptcbio.com/role/DisclosureNetLossPerShareTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of computation of basic and diluted net loss available to common stockholders", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r964" ] }, "ptct_DevelopmentandRegulatoryMilestoneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "DevelopmentandRegulatoryMilestoneMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsFairValueLiabilitiesMeasuredDetails" ], "lang": { "en-us": { "role": { "documentation": "Development and Regulatory Milestone [Member]", "label": "Development and Regulatory Milestone" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsRollForward", "presentation": [ "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillDefiniteLivedIntangiblesDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets [Roll Forward]", "terseLabel": "Definite-lived intangibles", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "calculation": { "http://www.ptcbio.com/role/DisclosureDebtConvertibleNotesDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ptcbio.com/role/DisclosureDebtConvertibleNotesDetails", "http://www.ptcbio.com/role/DisclosureDebtNarrativeDetails", "http://www.ptcbio.com/role/DisclosureDebtSeniorSecuredTermLoanDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsConvertibleSeniorNotesDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Face Amount", "terseLabel": "Principal", "verboseLabel": "Debt principal amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r88", "r90", "r379", "r572", "r822", "r823" ] }, "us-gaap_DebtInstrumentFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFairValue", "crdr": "credit", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsConvertibleSeniorNotesDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Fair Value Disclosure", "terseLabel": "Fair value of convertible notes", "documentation": "Fair value portion of debt instrument payable, including, but not limited to, notes payable and loans payable." } } }, "auth_ref": [ "r387", "r556", "r822", "r823" ] }, "ptct_LiabilityNetSalesMilestonesandRoyaltiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "LiabilityNetSalesMilestonesandRoyaltiesMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsFairValueLiabilitiesMeasuredDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsHierarchyDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsSummaryOfChangesInFairValueOfCompanySLevel3ValuationDetails" ], "lang": { "en-us": { "role": { "documentation": "Liability, Net Sales Milestones and Royalties [Member]", "label": "Liability, Net Sales Milestones and Royalties [Member]", "terseLabel": "Net Sales Milestones and Royalties" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract", "presentation": [ "http://www.ptcbio.com/role/DisclosureNetLossPerShareNumeratorAndDenominatorDetails" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]", "terseLabel": "Numerator" } } }, "auth_ref": [] }, "us-gaap_DebtSecuritiesTradingRealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesTradingRealizedGainLoss", "crdr": "credit", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsMarketableSecuritiesUnrealizedGainsLossesDetails" ], "lang": { "en-us": { "role": { "label": "Marketable Securities, Realized Gain (Loss)", "terseLabel": "Realized gain (loss) from sale of marketable securities", "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in net income (trading)." } } }, "auth_ref": [ "r113", "r968" ] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment, Net", "terseLabel": "Fixed assets, net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r10", "r648", "r656", "r844" ] }, "ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage", "presentation": [ "http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Contingent Liability, Milestone, Potential Achievements, Product Sales Percentage", "label": "Contingent Liability, Milestone, Potential Achievements, Product Sales Percentage", "terseLabel": "Product sales (as a percent)" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of financial assets and liabilities that are required to be measured at fair value on a recurring basis", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r544", "r545" ] }, "ptct_PercentageofSalesforRoyaltiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "PercentageofSalesforRoyaltiesMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsFairValueLiabilitiesMeasuredDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of Sales for Royalties [Member]", "label": "Percentage of Sales for Royalties" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "presentation": [ "http://www.ptcbio.com/role/DisclosureAccountsPayableAndAccruedExpensesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of components of accounts payable and accrued expenses", "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses." } } }, "auth_ref": [] }, "us-gaap_InvestmentTypeCategorizationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentTypeCategorizationMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Investment", "documentation": "Asset obtained to generate income or appreciate in value." } } }, "auth_ref": [ "r705", "r707", "r708", "r710", "r712", "r767", "r769", "r771", "r774", "r775", "r776", "r777", "r779", "r780", "r781", "r782", "r783", "r849" ] }, "us-gaap_ProvisionForDoubtfulAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProvisionForDoubtfulAccounts", "crdr": "debit", "presentation": [ "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "terseLabel": "Bad debt expense", "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable." } } }, "auth_ref": [ "r203", "r324" ] }, "ptct_ConvertibleSeniorNotes1.5DueSeptember152026Member": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "ConvertibleSeniorNotes1.5DueSeptember152026Member", "presentation": [ "http://www.ptcbio.com/role/DisclosureCompanyDetails", "http://www.ptcbio.com/role/DisclosureDebtConvertibleNotesDetails", "http://www.ptcbio.com/role/DisclosureDebtConvertibleNotesInterestExpenseDetails", "http://www.ptcbio.com/role/DisclosureDebtNarrativeDetails", "http://www.ptcbio.com/role/DisclosureDebtTables", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsConvertibleSeniorNotesDetails" ], "lang": { "en-us": { "role": { "documentation": "Convertible Senior Notes, 1.5%, Due September 15, 2026 [Member]", "label": "1.50% Convertible senior notes due 2026" } } }, "auth_ref": [] }, "ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmountNetofCancellationandForfeiture": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmountNetofCancellationandForfeiture", "crdr": "debit", "presentation": [ "http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Contingent Liability, Milestone, Potential Achievements, Priority Review Voucher Amount, Net of Cancellation and Forfeiture", "label": "Contingent Liability, Milestone, Potential Achievements, Priority Review Voucher Amount, Net of Cancellation and Forfeiture", "terseLabel": "Contingent liability, milestone, potential achievements, priority review voucher amount, net of cancellation and forfeiture" } } }, "auth_ref": [] }, "ptct_RoyaltyPurchaseAgreementPaymentMaximum": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "RoyaltyPurchaseAgreementPaymentMaximum", "crdr": "debit", "presentation": [ "http://www.ptcbio.com/role/DisclosureSubsequentEventsDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLiabilityForSaleOfFutureRoyaltiesDetails" ], "lang": { "en-us": { "role": { "documentation": "The aggregate amount of royalties to be received after which the percentage is adjusted under terms of the Amended and Restated Royalty Purchase Agreement.", "label": "Royalty Purchase Agreement, Payment Maximum", "terseLabel": "Royalty purchase agreement, payment maximum" } } }, "auth_ref": [] }, "ptct_ContingentLiabilityCancellationAndForfeitureMilestonePotentialAchievementsPriorityReviewVoucherAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "ContingentLiabilityCancellationAndForfeitureMilestonePotentialAchievementsPriorityReviewVoucherAmount", "crdr": "debit", "presentation": [ "http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Contingent Liability cancellation and forfeiture, Milestone, Potential Achievements, Priority Review Voucher Amount", "label": "Contingent Liability cancellation and forfeiture, Milestone, Potential Achievements, Priority Review Voucher Amount", "terseLabel": "Contingent liability cancellation and forfeiture of potential milestone payments" } } }, "auth_ref": [] }, "ptct_RoyaltyPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "RoyaltyPurchaseAgreementMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureSubsequentEventsDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLiabilityForSaleOfFutureRoyaltiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Information pertaining to the Royalty Purchase Agreement which sold a percentage of future royalty payments in exchange for cash consideration.", "label": "Royalty Purchase Agreement" } } }, "auth_ref": [] }, "ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueRollForward": { "xbrltype": "stringItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueRollForward", "presentation": [ "http://www.ptcbio.com/role/DisclosureStockAwardPlanStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "documentation": "", "label": "Share Based Compensation Arrangement by Share Based Payment Award Options Intrinsic Value [Roll Forward]", "terseLabel": "Aggregate intrinsic value (in thousands)" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Inventory, Current [Table Text Block]", "terseLabel": "Schedule of Inventory", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r24", "r107", "r108", "r109" ] }, "ptct_RoyaltyPurchaseAgreementTerminationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "RoyaltyPurchaseAgreementTerminationPeriod", "presentation": [ "http://www.ptcbio.com/role/DisclosureSubsequentEventsDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLiabilityForSaleOfFutureRoyaltiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Royalty purchase agreement termination period once there are no further royalty payment obligations.", "label": "Royalty Purchase Agreement, Termination Period", "terseLabel": "Royalty purchase agreement termination period once there are no further royalty payment obligations" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": [ "http://www.ptcbio.com/role/DisclosureStockAwardPlanRestrictedStockDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Forfeited (in dollars per share)", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": [ "r469" ] }, "us-gaap_PaymentsForRoyalties": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForRoyalties", "crdr": "credit", "presentation": [ "http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Payments for Royalties", "terseLabel": "Royalty payments", "documentation": "The amount of cash paid for royalties during the current period." } } }, "auth_ref": [ "r7" ] }, "ptct_Percentageofnetproductsales": { "xbrltype": "percentItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "Percentageofnetproductsales", "presentation": [ "http://www.ptcbio.com/role/DisclosureRevenueRecognitionNetProductSalesDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of net product sales", "label": "Percentage of net product sales", "terseLabel": "Percentage of net product sales threshold" } } }, "auth_ref": [] }, "ptct_DebtInstrumentConvertibleThresholdConsecutiveTradingDayPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDayPeriod", "presentation": [ "http://www.ptcbio.com/role/DisclosureDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Threshold period of specified consecutive trading days within which the maximum product of the closing sale price of shares of the entity's common stock and the applicable conversion rate for such trading day triggers the conversion feature.", "label": "Debt Instrument Convertible Threshold Consecutive Trading Day Period", "terseLabel": "Consecutive trading-day period" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "presentation": [ "http://www.ptcbio.com/role/DisclosureStockAwardPlanRestrictedStockDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted Average Grant Date Fair Value" } } }, "auth_ref": [] }, "ptct_ContingentLiabilityCancellationAndForfeiture": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "ContingentLiabilityCancellationAndForfeiture", "crdr": "debit", "presentation": [ "http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Contingent Liability, Cancellation and Forfeiture", "label": "Contingent Liability, Cancellation and Forfeiture", "terseLabel": "Contingent liability, cancellation and forfeiture" } } }, "auth_ref": [] }, "ptct_PaymentOfFinanceLeasePrincipal": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "PaymentOfFinanceLeasePrincipal", "crdr": "credit", "calculation": { "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Payment of Finance Lease Principal", "label": "Payment of Finance Lease Principal", "negatedTerseLabel": "Payment of finance lease principal" } } }, "auth_ref": [] }, "us-gaap_RoyaltyExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RoyaltyExpense", "crdr": "debit", "presentation": [ "http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Royalty Expense", "terseLabel": "Royalty expense", "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property." } } }, "auth_ref": [ "r115" ] }, "ptct_ConvertibleSeniorNotes3.0PercentDue2022Member": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "ConvertibleSeniorNotes3.0PercentDue2022Member", "presentation": [ "http://www.ptcbio.com/role/DisclosureDebtConvertibleNotesInterestExpenseDetails", "http://www.ptcbio.com/role/DisclosureDebtNarrativeDetails", "http://www.ptcbio.com/role/DisclosureDebtTables" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to 3.00% convertible senior notes due 2022.", "label": "3.00% Convertible senior notes due 2022" } } }, "auth_ref": [] }, "ptct_AssetAcquisitionNetSalesMilestone": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "AssetAcquisitionNetSalesMilestone", "crdr": "credit", "presentation": [ "http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Net Sales Milestone", "label": "Asset Acquisition, Net Sales Milestone", "terseLabel": "Asset acquisition, net sales milestone" } } }, "auth_ref": [] }, "ptct_HopewellCampusMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "HopewellCampusMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureLeasesNarrativeDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Hopewell Campus", "label": "Hopewell Campus" } } }, "auth_ref": [] }, "ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsForNonStatutoryStockOptions": { "xbrltype": "sharesItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsInducementGrantsForNonStatutoryStockOptions", "presentation": [ "http://www.ptcbio.com/role/DisclosureStockAwardPlanNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the inducement grants for non-statutory stock options.", "label": "Inducement Grants For Non-Statutory Stock Options", "terseLabel": "Inducement grants for non-statutory stock options (in shares)" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateEffectivePercentage", "presentation": [ "http://www.ptcbio.com/role/DisclosureDebtConvertibleNotesInterestExpenseDetails", "http://www.ptcbio.com/role/DisclosureDebtLiabilityForSaleOfFutureRoyaltiesDetails", "http://www.ptcbio.com/role/DisclosureDebtSeniorSecuredTermLoanDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Interest Rate, Effective Percentage", "terseLabel": "Effective interest rate of the liability component", "verboseLabel": "Effective interest rate", "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium." } } }, "auth_ref": [ "r31", "r88", "r397", "r572" ] }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss", "crdr": "debit", "calculation": { "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsAvailableForSaleSecuritiesDetails": { "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsAvailableForSaleSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss", "negatedTerseLabel": "Securities in an unrealized loss position greater than 12 months - Unrealized losses", "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": [ "r157", "r333" ] }, "ptct_NumberOfOperatingLeases": { "xbrltype": "integerItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "NumberOfOperatingLeases", "presentation": [ "http://www.ptcbio.com/role/DisclosureLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Number Of Operating Leases", "label": "Number Of Operating Leases", "terseLabel": "Number of operating leases" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": [ "http://www.ptcbio.com/role/DisclosureCompanyDetails", "http://www.ptcbio.com/role/DisclosureDebtNarrativeDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsConvertibleSeniorNotesDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Interest rate ( as a percent )", "documentation": "Contractual interest rate for funds borrowed, under the debt agreement." } } }, "auth_ref": [ "r31", "r380" ] }, "ptct_ProbabilityofSuccessMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "ProbabilityofSuccessMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsFairValueLiabilitiesMeasuredDetails" ], "lang": { "en-us": { "role": { "documentation": "Probability of Success [Member]", "label": "Probability of Success [Member]", "terseLabel": "Probability of Success" } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ptcbio.com/role/DisclosureDebtNarrativeDetails", "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r102", "r844", "r1052" ] }, "us-gaap_DebtSecuritiesAvailableForSaleTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleTerm", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-sale, Term", "terseLabel": "Term of convertible note", "documentation": "Period between issuance and maturity of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1027" ] }, "us-gaap_IndefinitelivedIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefinitelivedIntangibleAssetsMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillIndefiniteLivedIntangiblesDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Indefinite-Lived Intangible Assets [Member]", "terseLabel": "Indefinite-lived intangible assets", "documentation": "Assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit." } } }, "auth_ref": [] }, "us-gaap_DebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsHierarchyDetails" ], "lang": { "en-us": { "role": { "label": "Marketable securities", "documentation": "Debt instrument issued by corporations, governments and governmental agencies, municipalities, and other institutions." } } }, "auth_ref": [ "r59", "r849", "r1057" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://www.ptcbio.com/role/DisclosureStockAwardPlanAssumptionsUsedDetails", "http://www.ptcbio.com/role/DisclosureStockAwardPlanNarrativeDetails", "http://www.ptcbio.com/role/DisclosureStockAwardPlanRestrictedStockDetails", "http://www.ptcbio.com/role/DisclosureStockAwardPlanShareBasedCompensationExpenseDetails", "http://www.ptcbio.com/role/DisclosureStockAwardPlanStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r449", "r451", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://www.ptcbio.com/role/DisclosureStockAwardPlanRestrictedStockDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Balance at the end of the period (in shares)", "periodStartLabel": "Balance at the beginning of the period (in shares)", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r464", "r465" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive income", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r36", "r37", "r110", "r188", "r653", "r679", "r683" ] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": [ "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue recognition", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": [ "r169", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r805" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": [ "http://www.ptcbio.com/role/DisclosureStockAwardPlanNarrativeDetails", "http://www.ptcbio.com/role/DisclosureStockAwardPlanRestrictedStockDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period", "verboseLabel": "Granted (in shares)", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r467" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": [ "http://www.ptcbio.com/role/DisclosureStockAwardPlanRestrictedStockDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedLabel": "Forfeited (in shares)", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": [ "r469" ] }, "us-gaap_InterestExpenseDebtExcludingAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpenseDebtExcludingAmortization", "crdr": "debit", "calculation": { "http://www.ptcbio.com/role/DisclosureDebtSeniorSecuredTermLoanDetails": { "parentTag": "us-gaap_InterestExpenseDebt", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ptcbio.com/role/DisclosureDebtConvertibleNotesInterestExpenseDetails", "http://www.ptcbio.com/role/DisclosureDebtSeniorSecuredTermLoanDetails" ], "lang": { "en-us": { "role": { "label": "Interest Expense, Debt, Excluding Amortization", "terseLabel": "Contractual interest expense", "documentation": "Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs." } } }, "auth_ref": [ "r119", "r393", "r824", "r825" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.ptcbio.com/role/DisclosureStockAwardPlanRestrictedStockDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Granted (in dollars per share)", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r467" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.ptcbio.com/role/DisclosureStockAwardPlanRestrictedStockDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Balance at the end of the period (in dollars per share)", "periodStartLabel": "Balance at the beginning of the period (in dollars per share)", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r464", "r465" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized", "crdr": "debit", "presentation": [ "http://www.ptcbio.com/role/DisclosureStockAwardPlanNarrativeDetails", "http://www.ptcbio.com/role/DisclosureStockAwardPlanShareBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized compensation cost", "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement." } } }, "auth_ref": [ "r482" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://www.ptcbio.com/role/DisclosureStockAwardPlanRestrictedStockDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedLabel": "Vested (in shares)", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r468" ] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.ptcbio.com/role/DocumentCover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.ptcbio.com/role/DisclosureStockAwardPlanRestrictedStockDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested (in dollars per share)", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": [ "r468" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.ptcbio.com/role/DocumentCover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r857" ] }, "us-gaap_FiniteLivedIntangibleAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillDefiniteLivedIntangiblesDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets [Member]", "terseLabel": "Definite-lived intangible assets", "documentation": "Assets, excluding financial assets, that lack physical substance, having a limited useful life." } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://www.ptcbio.com/role/DocumentCover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "terseLabel": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r858" ] }, "us-gaap_ProceedsFromDebtNetOfIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromDebtNetOfIssuanceCosts", "crdr": "debit", "presentation": [ "http://www.ptcbio.com/role/DisclosureDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Proceeds from Debt, Net of Issuance Costs", "terseLabel": "Net proceeds from issuance of convertible notes", "documentation": "The cash inflow from additional borrowings, net of cash paid to third parties in connection with debt origination." } } }, "auth_ref": [ "r206" ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://www.ptcbio.com/role/DocumentCover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "terseLabel": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r858" ] }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForDoubtfulAccountsReceivable", "crdr": "credit", "presentation": [ "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Accounts Receivable, Allowance for Credit Loss", "terseLabel": "Allowance for doubtful accounts receivable", "documentation": "Amount of allowance for credit loss on accounts receivable." } } }, "auth_ref": [ "r189", "r274", "r320", "r323", "r325", "r1048" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.ptcbio.com/role/DocumentCover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "srt_CounterpartyNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CounterpartyNameAxis", "presentation": [ "http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails", "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillDefiniteLivedIntangiblesDetails", "http://www.ptcbio.com/role/DisclosureLeasesNarrativeDetails", "http://www.ptcbio.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "auth_ref": [ "r215", "r216", "r382", "r402", "r600", "r812", "r814" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://www.ptcbio.com/role/DocumentCover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "terseLabel": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r858" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r869", "r880", "r890", "r915" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.ptcbio.com/role/DocumentCover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r859" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": [ "http://www.ptcbio.com/role/DisclosureStockAwardPlanNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized", "terseLabel": "Number of shares authorized (in shares)", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [ "r842" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": [ "http://www.ptcbio.com/role/DisclosureStockAwardPlanNarrativeDetails", "http://www.ptcbio.com/role/DisclosureStockAwardPlanShareBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant", "terseLabel": "Number of shares available for issuance", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": [ "r70" ] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": [ "http://www.ptcbio.com/role/DisclosureDebtNarrativeDetails", "http://www.ptcbio.com/role/DisclosureDebtSeniorSecuredTermLoanDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Debt instrument, basis spread on variable rate", "verboseLabel": "Basis spread on variable rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r869", "r880", "r890", "r915" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.ptcbio.com/role/DocumentCover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r858" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [ "http://www.ptcbio.com/role/DisclosureStockAwardPlanStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Forfeited/Cancelled (in shares)", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": [ "r462" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.ptcbio.com/role/DisclosureStockAwardPlanNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average grant date fair value (in dollars per share)", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": [ "r470" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r869", "r880", "r890", "r915" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.ptcbio.com/role/DisclosureStockAwardPlanStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value", "verboseLabel": "Outstanding at the end of the period (in dollars)", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r70" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://www.ptcbio.com/role/DisclosureStockAwardPlanStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding at the end of the period (in shares)", "periodStartLabel": "Outstanding at the beginning of the period (in shares)", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r456", "r457" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.ptcbio.com/role/DisclosureStockAwardPlanStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Outstanding at the end of the period (in dollars per share)", "periodStartLabel": "Outstanding at the beginning of the period (in dollars per share)", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r456", "r457" ] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities, Current", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r30", "r178", "r213", "r309", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r515", "r516", "r517", "r557", "r844", "r990", "r1036", "r1037" ] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndAccruedLiabilitiesMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails", "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillDefiniteLivedIntangiblesDetails" ], "lang": { "en-us": { "role": { "label": "Accounts payable and accrued expenses", "terseLabel": "Accounts payable and accrued expenses", "documentation": "Primary financial statement caption encompassing accounts payable and accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://www.ptcbio.com/role/DisclosureStockAwardPlanStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number", "terseLabel": "Exercisable at the end of the period (in shares)", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r458" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.ptcbio.com/role/DocumentCover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": [ "http://www.ptcbio.com/role/DisclosureStockAwardPlanStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Exercisable at the end of the period (in dollars per share)", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [ "r458" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r870", "r881", "r891", "r916" ] }, "us-gaap_PaymentsOfDebtExtinguishmentCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfDebtExtinguishmentCosts", "crdr": "credit", "presentation": [ "http://www.ptcbio.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Payment for Debt Extinguishment or Debt Prepayment Cost", "terseLabel": "Prepayment premiums, expenses and other exit fees", "documentation": "Amount of cash outflow for cost from early extinguishment and prepayment of debt. Includes, but is not limited to, third-party cost, premium paid, and other fee paid to lender directly for debt extinguishment or debt prepayment. Excludes accrued interest." } } }, "auth_ref": [ "r5" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://www.ptcbio.com/role/DisclosureStockAwardPlanNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Expected dividend yield (as a percent)", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r476" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [ "http://www.ptcbio.com/role/DisclosureStockAwardPlanAssumptionsUsedDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Expected volatility (as a percent)", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r475" ] }, "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpensesAndOtherCurrentAssetsMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureRevenueRecognitionManufacturingRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Prepaid Expenses and Other Current Assets [Member]", "terseLabel": "Prepaids and other current assets", "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets." } } }, "auth_ref": [] }, "us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommercialPaperNotIncludedWithCashAndCashEquivalentsMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsMarketableSecuritiesBalanceSheetDisclosuresDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsMarketableSecuritiesUnrealizedGainsLossesDetails" ], "lang": { "en-us": { "role": { "label": "Commercial paper", "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds that is excluded from cash and cash equivalents." } } }, "auth_ref": [ "r995", "r1025" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://www.ptcbio.com/role/DisclosureStockAwardPlanAssumptionsUsedDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate (as a percent)", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r477" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.ptcbio.com/role/DisclosureStockAwardPlanAssumptionsUsedDetails", "http://www.ptcbio.com/role/DisclosureStockAwardPlanNarrativeDetails", "http://www.ptcbio.com/role/DisclosureStockAwardPlanRestrictedStockDetails", "http://www.ptcbio.com/role/DisclosureStockAwardPlanShareBasedCompensationExpenseDetails", "http://www.ptcbio.com/role/DisclosureStockAwardPlanStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "terseLabel": "Stock option plan", "verboseLabel": "Restricted Stock Awards and Units", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r449", "r451", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities", "totalLabel": "Total liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r28", "r213", "r309", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r515", "r516", "r517", "r557", "r721", "r816", "r856", "r990", "r1036", "r1037" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.ptcbio.com/role/DisclosureStockAwardPlanAssumptionsUsedDetails", "http://www.ptcbio.com/role/DisclosureStockAwardPlanNarrativeDetails", "http://www.ptcbio.com/role/DisclosureStockAwardPlanRestrictedStockDetails", "http://www.ptcbio.com/role/DisclosureStockAwardPlanStockOptionActivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478" ] }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": [ "http://www.ptcbio.com/role/DisclosureLeasesCashFlowDetails", "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Right-of-use assets obtained in exchange for operating lease obligations", "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability." } } }, "auth_ref": [ "r591", "r843" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfStockholdersDeficitEquity" ], "lang": { "en-us": { "role": { "label": "Accumulated deficit", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r173", "r218", "r219", "r220", "r223", "r231", "r233", "r313", "r319", "r484", "r485", "r486", "r502", "r503", "r521", "r524", "r525", "r528", "r539", "r674", "r676", "r693", "r1054" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, outstanding shares (in shares)", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r13", "r101", "r722", "r740", "r1054", "r1055" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfStockholdersDeficitEquity" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r13", "r35", "r173", "r198", "r199", "r200", "r218", "r219", "r220", "r223", "r231", "r233", "r254", "r313", "r319", "r415", "r484", "r485", "r486", "r502", "r503", "r521", "r523", "r524", "r525", "r526", "r528", "r539", "r562", "r563", "r564", "r565", "r566", "r567", "r599", "r674", "r675", "r676", "r693", "r762" ] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "US", "presentation": [ "http://www.ptcbio.com/role/DisclosureRevenueRecognitionNetProductSalesDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "United States" } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilitiesPaymentsDueAbstract", "presentation": [ "http://www.ptcbio.com/role/DisclosureLeasesLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Finance Lease, Liability, Payment, Due [Abstract]", "terseLabel": "Finance leases" } } }, "auth_ref": [] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Common Stock, Value, Issued", "verboseLabel": "Common stock, $0.001 par value. Authorized 250,000,000 shares; issued and outstanding 75,459,022 shares at September 30, 2023. Authorized 250,000,000 shares; issued and outstanding 73,104,692 shares at December 31, 2022", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r101", "r652", "r844" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfStockholdersDeficitEquity" ], "lang": { "en-us": { "role": { "label": "Additional paid-in capital", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r484", "r485", "r486", "r693", "r960", "r961", "r962", "r1024", "r1054" ] }, "country_RU": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "RU", "presentation": [ "http://www.ptcbio.com/role/DisclosureRevenueRecognitionNetProductSalesDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "RUSSIAN FEDERATION", "terseLabel": "Russia" } } }, "auth_ref": [] }, "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "presentation": [ "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "terseLabel": "Schedule of estimated future amortization of intangible assets", "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets." } } }, "auth_ref": [ "r65" ] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueLineItems", "presentation": [ "http://www.ptcbio.com/role/DisclosureRevenueRecognitionCollaborationAndRoyaltyRevenueDetails", "http://www.ptcbio.com/role/DisclosureRevenueRecognitionManufacturingRevenueDetails", "http://www.ptcbio.com/role/DisclosureRevenueRecognitionNetProductSalesDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesManufacturingRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Revenue recognition", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r436", "r827", "r828", "r829", "r830", "r831", "r832", "r833" ] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfStockholdersDeficitEquity" ], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r13", "r173", "r198", "r199", "r200", "r218", "r219", "r220", "r223", "r231", "r233", "r254", "r313", "r319", "r415", "r484", "r485", "r486", "r502", "r503", "r521", "r523", "r524", "r525", "r526", "r528", "r539", "r562", "r563", "r564", "r565", "r566", "r567", "r599", "r674", "r675", "r676", "r693", "r762" ] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "calculation": { "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercise of options", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r4", "r18" ] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTable", "presentation": [ "http://www.ptcbio.com/role/DisclosureRevenueRecognitionCollaborationAndRoyaltyRevenueDetails", "http://www.ptcbio.com/role/DisclosureRevenueRecognitionManufacturingRevenueDetails", "http://www.ptcbio.com/role/DisclosureRevenueRecognitionNetProductSalesDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesManufacturingRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r436", "r827", "r828", "r829", "r830", "r831", "r832", "r833" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfStockholdersDeficitEquity" ], "lang": { "en-us": { "role": { "label": "AOCI Attributable to Parent", "terseLabel": "Accumulated other comprehensive income (loss)", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r3", "r12", "r37", "r523", "r526", "r599", "r674", "r675", "r950", "r951", "r952", "r960", "r961", "r962" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsHierarchyDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Financial assets and liabilities measured at fair value on recurring basis", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r544", "r545", "r551" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsSummaryOfChangesInFairValueOfCompanySLevel3ValuationDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3." } } }, "auth_ref": [ "r15", "r84" ] }, "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "label": "Basis of Presentation and Significant Accounting Policies [Text Block]", "terseLabel": "Summary of significant accounting policies", "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). Accounting policies describe all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r124" ] }, "ptct_LiabilitySaleOfFutureRoyaltiesInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "LiabilitySaleOfFutureRoyaltiesInterestExpense", "crdr": "credit", "presentation": [ "http://www.ptcbio.com/role/DisclosureDebtLiabilityForSaleOfFutureRoyaltiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of interest expense recognized related to the liability for the sale of future royalties per terms of the agreement.", "label": "Liability, Sale of Future Royalties, Interest Expense", "terseLabel": "Plus: non-cash interest expense recognized" } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureStockAwardPlanShareBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Research and development", "terseLabel": "Research and development", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "us-gaap_RevenueRemainingPerformanceObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRemainingPerformanceObligation", "crdr": "credit", "presentation": [ "http://www.ptcbio.com/role/DisclosureRevenueRecognitionPerformanceObligationsDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesManufacturingRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Revenue, Remaining Performance Obligation, Amount", "terseLabel": "Remaining performance obligations", "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue." } } }, "auth_ref": [ "r164" ] }, "us-gaap_FairValueByLiabilityClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByLiabilityClassAxis", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsFairValueLiabilitiesMeasuredDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsSummaryOfChangesInFairValueOfCompanySLevel3ValuationDetails" ], "lang": { "en-us": { "role": { "label": "Liability Class [Axis]", "documentation": "Information by class of liability." } } }, "auth_ref": [ "r84", "r143" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.ptcbio.com/role/DocumentCover" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfStockholdersDeficitEquity" ], "lang": { "en-us": { "role": { "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Share-based compensation expense", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r73", "r74", "r450" ] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://www.ptcbio.com/role/DocumentCover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r860" ] }, "ptct_PercentOfMarketRate": { "xbrltype": "percentItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "PercentOfMarketRate", "presentation": [ "http://www.ptcbio.com/role/DisclosureLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Percent Of Market Rate", "label": "Percent Of Market Rate", "terseLabel": "Percent of market rate" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.ptcbio.com/role/DisclosureLeasesSupplementalLeaseTermsDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted-average discount rate - operating leases", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r593", "r843" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://www.ptcbio.com/role/DocumentCover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "terseLabel": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r893" ] }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "crdr": "debit", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsAvailableForSaleSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-sale, Unrealized Loss Position", "terseLabel": "Total - Fair Value", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss." } } }, "auth_ref": [ "r155", "r331", "r819" ] }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss", "crdr": "debit", "calculation": { "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsAvailableForSaleSecuritiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsAvailableForSaleSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss", "negatedTotalLabel": "Total - Unrealized losses", "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": [ "r156", "r332" ] }, "us-gaap_FairValueByAssetClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByAssetClassAxis", "presentation": [ "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillDefiniteLivedIntangiblesDetails", "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillIndefiniteLivedIntangiblesDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Asset Class [Axis]", "documentation": "Information by class of asset." } } }, "auth_ref": [ "r82", "r84" ] }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsTables" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table Text Block]", "terseLabel": "Summary of unrealized losses and fair values of available-for-sale debt securities in a continuous unrealized loss position", "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": [ "r154", "r819", "r977" ] }, "ptct_LiabilityForSaleOfFutureRoyaltiesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "LiabilityForSaleOfFutureRoyaltiesPolicyTextBlock", "presentation": [ "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for liability resulting from the sale of future royalties.", "label": "Liability for Sale of Future Royalties [Policy Text Block]", "terseLabel": "Liability for sale of future royalties" } } }, "auth_ref": [] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsConvertibleSeniorNotesDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsFairValueLiabilitiesMeasuredDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsHierarchyDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsMarketableSecuritiesDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsSummaryOfChangesInFairValueOfCompanySLevel3ValuationDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r387", "r441", "r442", "r443", "r444", "r445", "r446", "r545", "r607", "r608", "r609", "r822", "r823", "r834", "r835", "r836" ] }, "us-gaap_FinanceLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.ptcbio.com/role/DisclosureLeasesSupplementalLeaseTermsDetails" ], "lang": { "en-us": { "role": { "label": "Finance Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted-average discount rate - finance lease", "documentation": "Weighted average discount rate for finance lease calculated at point in time." } } }, "auth_ref": [ "r593", "r843" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsTables" ], "lang": { "en-us": { "role": { "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Summary of changes in the fair value of the Company's Level 3 valuation for contingent consideration payable", "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability." } } }, "auth_ref": [ "r15", "r84" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsHierarchyDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r544", "r545", "r547", "r548", "r552" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": [ "r871", "r882", "r892", "r917" ] }, "ptct_FairValueAssetsTransfersBetweenLevel1Level2AndLevel3Amount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "FairValueAssetsTransfersBetweenLevel1Level2AndLevel3Amount", "crdr": "credit", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsHierarchyDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of transfers of assets measured on a recurring basis between Level 1, Level 2, and Level 3 of the fair value hierarchy.", "label": "Fair Value, Assets, Transfers Between Level 1, Level 2 and Level 3, Amount", "terseLabel": "Transfers of assets measured between Level 1, Level 2, and Level 3" } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsSummaryOfChangesInFairValueOfCompanySLevel3ValuationDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "verboseLabel": "Fair Value", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EquitySecuritiesFvNi": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesFvNi", "crdr": "debit", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsHierarchyDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Equity Securities, FV-NI", "terseLabel": "Marketable securities - equity investments", "verboseLabel": "Fair value of equity investment", "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current." } } }, "auth_ref": [ "r183", "r555", "r810" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "crdr": "credit", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsSummaryOfChangesInFairValueOfCompanySLevel3ValuationDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "terseLabel": "Change in fair value", "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)." } } }, "auth_ref": [ "r549" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.ptcbio.com/role/DisclosureLeasesNarrativeDetails": { "parentTag": "ptct_LesseeOperatingLeaseLiabilityToBePaidNetOfBaseRentAbatement", "weight": 1.0, "order": 1.0 }, "http://www.ptcbio.com/role/DisclosureLeasesLeasePaymentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ptcbio.com/role/DisclosureLeasesLeasePaymentsDetails", "http://www.ptcbio.com/role/DisclosureLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payments, Due", "terseLabel": "Aggregate rent, Initial term", "totalLabel": "Total lease payments", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r594" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsSummaryOfChangesInFairValueOfCompanySLevel3ValuationDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "terseLabel": "Changes in the fair value of warrant liability and SARs liability", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Other Liabilities, Noncurrent", "terseLabel": "Other long-term liabilities", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r34" ] }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfComprehensiveLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent", "verboseLabel": "Foreign currency translation gain, net of tax", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity." } } }, "auth_ref": [ "r6", "r11", "r142" ] }, "us-gaap_MarketableSecuritiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketableSecuritiesCurrent", "crdr": "debit", "calculation": { "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Marketable Securities, Current", "terseLabel": "Marketable securities", "documentation": "Amount of investment in marketable security, classified as current." } } }, "auth_ref": [ "r945" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r926" ] }, "ptct_DepositsAndOtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "DepositsAndOtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "documentation": "Represents the carrying value of amounts transferred to third parties for security purposes and other noncurrent assets that are expected to be returned or applied towards payment after one year or beyond the operating cycle, if longer.", "label": "Deposits and Other Assets Noncurrent", "terseLabel": "Deposits and other assets" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventLineItems", "presentation": [ "http://www.ptcbio.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r568", "r602" ] }, "ptct_DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing", "crdr": "credit", "presentation": [ "http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the development milestones payments which the entity is obligated to pay under certain contractual agreements.", "label": "Development Milestone Payment Obligations, Due on Second Anniversary Year of Merger Closing", "terseLabel": "Development milestone payments which the entity is obligated to pay" } } }, "auth_ref": [] }, "us-gaap_IndefiniteLivedIntangibleAssetsRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedIntangibleAssetsRollForward", "presentation": [ "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillIndefiniteLivedIntangiblesDetails" ], "lang": { "en-us": { "role": { "label": "Indefinite-Lived Intangible Assets [Roll Forward]", "terseLabel": "Indefinite-lived intangibles", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r926" ] }, "ptct_MarathonPharmaceuticalsLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "MarathonPharmaceuticalsLLCMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails", "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillDefiniteLivedIntangiblesDetails" ], "lang": { "en-us": { "role": { "documentation": "Marathon Pharmaceuticals, LLC [Member]", "label": "Marathon Pharmaceuticals, LLC", "terseLabel": "Marathon" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "ptct_DebtInstrumentFloorInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "DebtInstrumentFloorInterestRate", "presentation": [ "http://www.ptcbio.com/role/DisclosureDebtNarrativeDetails", "http://www.ptcbio.com/role/DisclosureDebtSeniorSecuredTermLoanDetails" ], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Floor Interest Rate", "label": "Debt Instrument, Floor Interest Rate", "terseLabel": "Debt instrument, floor interest rate", "verboseLabel": "Floor interest rate" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTable", "presentation": [ "http://www.ptcbio.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Table]", "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued." } } }, "auth_ref": [ "r568", "r602" ] }, "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfComprehensiveLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Available-for-sale Securities Adjustment, Net of Tax, Portion Attributable to Parent", "terseLabel": "Unrealized gain (loss) on marketable securities, net of tax", "verboseLabel": "Unrealized gain (loss) on marketable securities, net of tax", "documentation": "Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent." } } }, "auth_ref": [ "r6", "r11", "r142" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://www.ptcbio.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r568", "r602" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": [ "r926" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": [ "r907" ] }, "ptct_AssetAcquisitionMilestoneAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "AssetAcquisitionMilestoneAmount", "crdr": "credit", "presentation": [ "http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Milestone, Amount", "label": "Asset Acquisition, Milestone, Amount", "terseLabel": "Asset acquisition, milestone, amount" } } }, "auth_ref": [] }, "ptct_SalesAllowanceAndOtherRelatedCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "SalesAllowanceAndOtherRelatedCosts", "crdr": "credit", "calculation": { "http://www.ptcbio.com/role/DisclosureAccountsPayableAndAccruedExpensesComponentsDetails": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.ptcbio.com/role/DisclosureAccountsPayableAndAccruedExpensesComponentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Sales Allowance And Other Related Costs", "label": "Sales Allowance And Other Related Costs", "terseLabel": "Sales allowance" } } }, "auth_ref": [] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": [ "r919" ] }, "ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone", "crdr": "credit", "presentation": [ "http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Contingent Liability, Milestone, Potential Achievements, Net Sales Milestone And Regulatory Approval", "label": "Contingent Liability, Milestone, Potential Achievements, Net Sales Milestone", "terseLabel": "Potential sales milestones" } } }, "auth_ref": [] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://www.ptcbio.com/role/DisclosureDebtConvertibleNotesDetails", "http://www.ptcbio.com/role/DisclosureDebtConvertibleNotesInterestExpenseDetails", "http://www.ptcbio.com/role/DisclosureDebtNarrativeDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsConvertibleSeniorNotesDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLiabilityForSaleOfFutureRoyaltiesDetails" ], "lang": { "en-us": { "role": { "label": "Long-term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r33", "r67" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": [ "r907" ] }, "us-gaap_ScheduleOfCapitalizationEquityTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCapitalizationEquityTable", "presentation": [ "http://www.ptcbio.com/role/DisclosureCapitalizationNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Capitalization, Equity [Table]", "documentation": "Summarization of information required and determined to be disclosed concerning the equity component of the capitalization of the entity. The table may be detailed by subsidiary (legal entity) (if applicable) and include information by component of equity as may be included in the Statement of Changes in Shareholders' Equity." } } }, "auth_ref": [] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": [ "r927" ] }, "ptct_ConvertibleInstrumentsPrincipalAndUnpaidInterestPayableUponEventsOfDefault": { "xbrltype": "percentItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "ConvertibleInstrumentsPrincipalAndUnpaidInterestPayableUponEventsOfDefault", "presentation": [ "http://www.ptcbio.com/role/DisclosureDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the debt instrument principal and unpaid interest payable upon events of default.", "label": "Convertible Instruments Principal And Unpaid Interest Payable Upon Events Of Default", "terseLabel": "Convertible instruments principal and unpaid interest payable upon events of default" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://www.ptcbio.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r568", "r602" ] }, "ptct_NoncashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "NoncashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties", "crdr": "debit", "calculation": { "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Amount of interest expense included in net income relating to the liability for sale of future royalties that results in no cash flow.", "label": "Noncash Interest Expense, Liability Related to Sale of Future Royalties", "terseLabel": "Non-cash interest expense on liability related to sale of future royalties" } } }, "auth_ref": [] }, "ptct_LiabilitySaleOfFutureRoyaltiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "LiabilitySaleOfFutureRoyaltiesCurrent", "crdr": "credit", "calculation": { "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "documentation": "Amount of liabilities related to the sale of future royalties due within one year or the normal operating cycle, if longer.", "label": "Liability, Sale of Future Royalties, Current", "terseLabel": "Liability for sale of future royalties - current" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCapitalizationEquityLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCapitalizationEquityLineItems", "presentation": [ "http://www.ptcbio.com/role/DisclosureCapitalizationNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Capitalization, Equity [Line Items]", "terseLabel": "Common stock", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "ptct_NoncashRoyaltyRevenueSaleOfFutureRoyalties": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "NoncashRoyaltyRevenueSaleOfFutureRoyalties", "crdr": "credit", "calculation": { "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Amount of royalty revenue included in net income relating to sale of future royalties that results in no cash inflow (outflow).", "label": "Noncash Royalty Revenue, Sale of Future Royalties", "negatedLabel": "Non-cash royalty revenue related to sale of future royalties" } } }, "auth_ref": [] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r927" ] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://www.ptcbio.com/role/DisclosureRevenueRecognitionNetProductSalesDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r51", "r54", "r85", "r86", "r273", "r791" ] }, "ptct_AssignedRoyaltyPaymentPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "AssignedRoyaltyPaymentPercentage", "presentation": [ "http://www.ptcbio.com/role/DisclosureSubsequentEventsDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLiabilityForSaleOfFutureRoyaltiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Assigned Royalty Payment, Percentage", "label": "Assigned Royalty Payment, Percentage", "terseLabel": "Assigned royalty payment, percentage", "verboseLabel": "Previously assigned royalty payment, percentage" } } }, "auth_ref": [] }, "ptct_DevelopmentMilestonePaymentObligationsCancellationAndForfeiture": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "DevelopmentMilestonePaymentObligationsCancellationAndForfeiture", "crdr": "debit", "presentation": [ "http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Development Milestone Payment Obligations, Cancellation and Forfeiture", "label": "Development Milestone Payment Obligations, Cancellation and Forfeiture", "terseLabel": "Development milestone payment obligations, cancellation and forfeiture" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://www.ptcbio.com/role/DisclosureStockAwardPlanNarrativeDetails", "http://www.ptcbio.com/role/DisclosureStockAwardPlanStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Granted (in shares)", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r460" ] }, "us-gaap_NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1", "crdr": "debit", "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Noncash or Part Noncash Acquisition, Intangible Assets Acquired", "terseLabel": "Acquisition of product rights and licenses", "documentation": "The amount of intangibles that an Entity acquires in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r46", "r47", "r48" ] }, "ptct_RightsExchangeAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "RightsExchangeAgreementMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Rights Exchange Agreement [Member]", "label": "Rights Exchange Agreement [Member]", "terseLabel": "Rights Exchange Agreement" } } }, "auth_ref": [] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": [ "r918" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashDetails", "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r43", "r179", "r808" ] }, "ptct_AgilisMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "AgilisMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsFairValueLiabilitiesMeasuredDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsSummaryOfChangesInFairValueOfCompanySLevel3ValuationDetails", "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillGoodwillDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Agilis [Member]", "label": "Agilis" } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://www.ptcbio.com/role/DisclosureRevenueRecognitionNetProductSalesDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r51", "r54", "r85", "r86", "r273", "r684", "r791" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": [ "r928" ] }, "ptct_InventoriesAndCostOfProductSalesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "InventoriesAndCostOfProductSalesPolicyTextBlock", "presentation": [ "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for inventories and cost of revenue.", "label": "Inventories And Cost Of Product Sales [Policy Text Block]", "terseLabel": "Inventory and cost of product sales" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "crdr": "debit", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsMarketableSecuritiesBalanceSheetDisclosuresDetails" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Fair Value", "terseLabel": "Marketable securities, Less Than 12 Months", "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r286", "r647" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": [ "r927" ] }, "ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount", "crdr": "debit", "presentation": [ "http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Contingent Liability, Milestone, Potential Achievements, Priority Review Voucher Amount", "label": "Contingent Liability, Milestone, Potential Achievements, Priority Review Voucher Amount", "terseLabel": "Priority review voucher amount" } } }, "auth_ref": [] }, "ptct_AccruedConsultingAndContractedResearchCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "AccruedConsultingAndContractedResearchCurrent", "crdr": "credit", "calculation": { "http://www.ptcbio.com/role/DisclosureAccountsPayableAndAccruedExpensesComponentsDetails": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.ptcbio.com/role/DisclosureAccountsPayableAndAccruedExpensesComponentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the carrying value as of the balance sheet date of obligations incurred through that date and payable for consulting and contracted research.", "label": "Accrued Consulting and Contracted Research Current", "terseLabel": "Consulting and contracted research" } } }, "auth_ref": [] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": [ "r929" ] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": [ "r928" ] }, "ptct_DevelopmentMilestonePaymentObligationsNetofCancellationandForfeiture": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "DevelopmentMilestonePaymentObligationsNetofCancellationandForfeiture", "crdr": "debit", "presentation": [ "http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Development Milestone Payment Obligations, net of cancellation and forfeiture", "label": "Development Milestone Payment Obligations, Net of Cancellation and Forfeiture", "terseLabel": "Development milestone payment obligations, net of cancellation and forfeiture" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "presentation": [ "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]", "terseLabel": "Reconciliation of cash", "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage." } } }, "auth_ref": [ "r21", "r144", "r1047" ] }, "us-gaap_StockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockOptionMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureStockAwardPlanAssumptionsUsedDetails", "http://www.ptcbio.com/role/DisclosureStockAwardPlanNarrativeDetails", "http://www.ptcbio.com/role/DisclosureStockAwardPlanStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Stock option", "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option)." } } }, "auth_ref": [ "r849" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": [ "r907" ] }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan", "crdr": "credit", "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfStockholdersDeficitEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan", "terseLabel": "Issuance of common stock in connection with an employee stock purchase plan", "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan." } } }, "auth_ref": [ "r13", "r100", "r101", "r138" ] }, "ptct_RestrictedStockAndRestrictedStockUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "RestrictedStockAndRestrictedStockUnitsMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureNetLossPerShareAntidilutiveDetails", "http://www.ptcbio.com/role/DisclosureStockAwardPlanRestrictedStockDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Restricted Stock and Restricted Stock Units (RSUs).", "label": "Restricted Stock and Restricted Stock Units [Member]", "terseLabel": "Restricted stock awards and units" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "presentation": [ "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Restricted Cash", "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits." } } }, "auth_ref": [ "r44", "r144" ] }, "ptct_Termforletterofcredit": { "xbrltype": "durationItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "Termforletterofcredit", "presentation": [ "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Term for letter of credit", "label": "Term for letter of credit", "terseLabel": "Term for letter of credit (in years)" } } }, "auth_ref": [] }, "us-gaap_NoncollaborativeArrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncollaborativeArrangementTransactionsMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Non-collaborative Arrangement Transactions", "terseLabel": "Agilis Merger Agreement", "documentation": "Arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [] }, "ptct_AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "AvailableForSaleSecuritiesDebtMaturitiesOverOneYearFairValue", "crdr": "debit", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsMarketableSecuritiesBalanceSheetDisclosuresDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of available-for-sale debt securities at fair value maturing after the next fiscal year following the latest fiscal year.", "label": "Available For Sale Securities Debt Maturities Over One Year Fair Value", "terseLabel": "Marketable securities, More Than 12 Months" } } }, "auth_ref": [] }, "ptct_MassBioMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "MassBioMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "MassBio", "label": "MassBio" } } }, "auth_ref": [] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": [ "r907" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": [ "r930" ] }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures", "crdr": "credit", "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfStockholdersDeficitEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures", "verboseLabel": "Restricted stock vesting and issuance, net", "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited." } } }, "auth_ref": [ "r13", "r138" ] }, "ptct_MilestoneAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "MilestoneAxis", "presentation": [ "http://www.ptcbio.com/role/DisclosureRevenueRecognitionCollaborationAndRoyaltyRevenueDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCollaborationAndRoyaltyRevenueDetails" ], "lang": { "en-us": { "role": { "documentation": "Information by categories of milestones achieved.", "label": "Milestone [Axis]" } } }, "auth_ref": [] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": [ "r861", "r931" ] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfStockholdersDeficitEquity" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Stock Options Exercised", "terseLabel": "Exercise of options", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r13", "r35", "r138" ] }, "ptct_DebtInstrumentAdditionalAmountAvailableForRepurchase": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "DebtInstrumentAdditionalAmountAvailableForRepurchase", "crdr": "debit", "presentation": [ "http://www.ptcbio.com/role/DisclosureDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Debt Instrument Additional Amount Available For Repurchase", "label": "Debt Instrument Additional Amount Available For Repurchase", "terseLabel": "Debt instrument additional amount available for repurchase" } } }, "auth_ref": [] }, "ptct_ScheduleOfInterestExpenseRecognizedRelatedToConvertibleDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "ScheduleOfInterestExpenseRecognizedRelatedToConvertibleDebtTableTextBlock", "presentation": [ "http://www.ptcbio.com/role/DisclosureDebtTables" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of interest expense recognized related to convertible debt.", "label": "Schedule Of Interest Expense Recognized Related To Convertible Debt [Table Text Block]", "terseLabel": "Summary of interest expense recognized related to the Convertible Notes" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesAbstract", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-sale [Abstract]", "terseLabel": "ClearPoint Convertible note" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "calculation": { "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsMarketableSecuritiesUnrealizedGainsLossesDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsHierarchyDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsMarketableSecuritiesUnrealizedGainsLossesDetails" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-sale", "terseLabel": "Marketable securities - available for sale", "verboseLabel": "Fair Value", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r280", "r329", "r643", "r966" ] }, "ptct_AssignedRoyaltyPaymentRetainedPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "AssignedRoyaltyPaymentRetainedPercentage", "presentation": [ "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLiabilityForSaleOfFutureRoyaltiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Assigned Royalty Payment, Retained Percentage", "label": "Assigned Royalty Payment, Retained Percentage", "terseLabel": "Assigned royalty payment, retained percentage" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityAbstract", "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "verboseLabel": "Stockholders' deficit:" } } }, "auth_ref": [] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": [ "r861", "r931" ] }, "ptct_CensaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "CensaMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Censa", "label": "Censa [Member]", "terseLabel": "Censa" } } }, "auth_ref": [] }, "ptct_RevenueRecognitionMilestonePotentialAchievements": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "RevenueRecognitionMilestonePotentialAchievements", "crdr": "credit", "presentation": [ "http://www.ptcbio.com/role/DisclosureRevenueRecognitionCollaborationAndRoyaltyRevenueDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLiabilityForSaleOfFutureRoyaltiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Remaining potential milestones that can be achieved.", "label": "Revenue Recognition, Milestone, Potential Achievements", "terseLabel": "Remaining potential milestones that can be achieved" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.ptcbio.com/role/DisclosureCapitalization" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note Disclosure [Text Block]", "verboseLabel": "Capitalization", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r134", "r212", "r399", "r401", "r403", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r413", "r415", "r530", "r765", "r766", "r789" ] }, "ptct_DebtInstrumentConvertibleThresholdBusinessDays": { "xbrltype": "durationItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "DebtInstrumentConvertibleThresholdBusinessDays", "presentation": [ "http://www.ptcbio.com/role/DisclosureDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Threshold period of specified business days within which the maximum product of the closing sale price of shares of the entity's common stock and the applicable conversion rate for such trading day triggers the conversion feature.", "label": "Debt Instrument Convertible Threshold Business Days", "terseLabel": "Business days, period" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]", "verboseLabel": "Other comprehensive income (loss):" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteAbstract", "lang": { "en-us": { "role": { "label": "Stockholders' Equity Note [Abstract]" } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r895" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": [ "r861", "r931" ] }, "ptct_FifthAnniversaryMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "FifthAnniversaryMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Fifth Anniversary [Member]", "label": "Fifth Anniversary" } } }, "auth_ref": [] }, "us-gaap_RestructuringChargesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringChargesAbstract", "presentation": [ "http://www.ptcbio.com/role/DisclosureAccountsPayableAndAccruedExpensesRestructuringDetails" ], "lang": { "en-us": { "role": { "label": "Restructuring Charges [Abstract]", "terseLabel": "Restructuring costs" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "crdr": "credit", "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfStockholdersDeficitEquity" ], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "terseLabel": "Comprehensive income", "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity." } } }, "auth_ref": [ "r6", "r11", "r142", "r193", "r196" ] }, "us-gaap_RestructuringCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestructuringCharges", "crdr": "debit", "presentation": [ "http://www.ptcbio.com/role/DisclosureAccountsPayableAndAccruedExpensesRestructuringDetails" ], "lang": { "en-us": { "role": { "label": "Restructuring Charges", "terseLabel": "Restructuring costs", "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation." } } }, "auth_ref": [ "r9", "r362", "r363", "r984" ] }, "ptct_ResearchAndDevelopmentEventMilestonesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "ResearchAndDevelopmentEventMilestonesMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureRevenueRecognitionCollaborationAndRoyaltyRevenueDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to certain research and development events on the basis of which certain milestones are achieved.", "label": "Research And Development Event Milestones", "terseLabel": "Research And Development Event Milestones" } } }, "auth_ref": [] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": [ "r895" ] }, "ptct_FiniteLivedIntangibleAssetsAdditions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "FiniteLivedIntangibleAssetsAdditions", "crdr": "debit", "presentation": [ "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillDefiniteLivedIntangiblesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life.", "label": "Finite-Lived Intangible Assets, Additions", "terseLabel": "Additions" } } }, "auth_ref": [] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r920" ] }, "ptct_StockIssuedDuringPeriodValueMilestonePayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "StockIssuedDuringPeriodValueMilestonePayable", "crdr": "credit", "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfStockholdersDeficitEquity" ], "lang": { "en-us": { "role": { "documentation": "Aggregate change in value for stock issued during the period as a result of milestone payable.", "label": "Stock Issued During Period, Value, Milestone Payable", "terseLabel": "Issuance of common stock in connection with a milestone payable" } } }, "auth_ref": [] }, "ptct_NumberOfMutualFundsLiquidated": { "xbrltype": "integerItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "NumberOfMutualFundsLiquidated", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "documentation": "The number of mutual funds liquidated.", "label": "Number of Mutual Funds Liquidated", "terseLabel": "Number of mutual funds liquidated" } } }, "auth_ref": [] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "auth_ref": [ "r925" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "presentation": [ "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillDefiniteLivedIntangiblesDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]", "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r62", "r65", "r637" ] }, "ptct_ManufacturingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "ManufacturingMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureRevenueRecognitionManufacturingRevenueDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesManufacturingRevenueDetails", "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "documentation": "Manufacturing product for third parties.", "label": "Manufacturing [Member]", "terseLabel": "Manufacturing revenue" } } }, "auth_ref": [] }, "ptct_NumberOfCountriesExceedingTenPercentNetSalesThreshold": { "xbrltype": "integerItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "NumberOfCountriesExceedingTenPercentNetSalesThreshold", "presentation": [ "http://www.ptcbio.com/role/DisclosureRevenueRecognitionNetProductSalesDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of countries exceeding the ten percent net product sales threshold.", "label": "Number of Countries Exceeding Ten Percent Net Sales Threshold", "terseLabel": "Number of countries exceeding 10% of net product sales" } } }, "auth_ref": [] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r101" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r869", "r880", "r890", "r915" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": [ "r922" ] }, "ptct_PierreGravierMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "PierreGravierMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Pierre Gravier.", "label": "Pierre Gravier [Member]", "terseLabel": "Pierre Gravier" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockDomain", "presentation": [ "http://www.ptcbio.com/role/DisclosureStockAwardPlanNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock." } } }, "auth_ref": [ "r170", "r185", "r186", "r187", "r213", "r239", "r240", "r247", "r249", "r255", "r256", "r309", "r370", "r372", "r373", "r374", "r377", "r378", "r400", "r401", "r404", "r407", "r414", "r557", "r688", "r689", "r690", "r691", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r701", "r702", "r703", "r704", "r722", "r744", "r762", "r784", "r785", "r786", "r787", "r788", "r933", "r956", "r963" ] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "calculation": { "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ptcbio.com/role/DisclosureDebtNarrativeDetails", "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Long-term Debt, Excluding Current Maturities", "verboseLabel": "Long-term debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": [ "r184" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": [ "r918" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "Loss before income tax benefit", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r0", "r111", "r152", "r257", "r263", "r267", "r269", "r646", "r657", "r817" ] }, "ptct_DeferredRevenueMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "DeferredRevenueMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureRevenueRecognitionManufacturingRevenueDetails" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing deferred revenues.", "label": "Deferred Revenue [Member]", "terseLabel": "Deferred revenue" } } }, "auth_ref": [] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": [ "r919" ] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureCapitalizationNarrativeDetails", "http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails", "http://www.ptcbio.com/role/DisclosureRevenueRecognitionCollaborationAndRoyaltyRevenueDetails", "http://www.ptcbio.com/role/DisclosureSubsequentEventsDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCollaborationAndRoyaltyRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r513" ] }, "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesFvNiUnrealizedGainLoss", "crdr": "credit", "calculation": { "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsMarketableSecuritiesDetails", "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)", "negatedLabel": "Unrealized (gain) loss on marketable securities - equity investments", "terseLabel": "Net unrealized gain (loss) on equity investments", "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": [ "r663", "r975" ] }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "presentation": [ "http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCollaborationAndRoyaltyRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r513" ] }, "us-gaap_EquitySecuritiesFvNiRealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesFvNiRealizedGainLoss", "crdr": "credit", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Equity Securities, FV-NI, Realized Gain (Loss)", "negatedLabel": "Loss on sale of equity investments", "documentation": "Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": [ "r662", "r975" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r949" ] }, "ptct_NumberOfMutualFundsInvestedInDenominatedInForeignCurrency": { "xbrltype": "integerItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "NumberOfMutualFundsInvestedInDenominatedInForeignCurrency", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "documentation": "The number of mutual funds invested in that are denominated in a foreign currency.", "label": "Number of Mutual Funds Invested In, Denominated in Foreign Currency", "terseLabel": "Number of mutual funds denominated in a foreign currency" } } }, "auth_ref": [] }, "us-gaap_InterestExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpenseAbstract", "presentation": [ "http://www.ptcbio.com/role/DisclosureDebtSeniorSecuredTermLoanDetails" ], "lang": { "en-us": { "role": { "label": "Interest Expense [Abstract]", "terseLabel": "Interest expense" } } }, "auth_ref": [] }, "ptct_IndefiniteLivedIntangibleAssetsAccumulatedDepreciationForeignCurrencyTranslationGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "IndefiniteLivedIntangibleAssetsAccumulatedDepreciationForeignCurrencyTranslationGainLoss", "crdr": "debit", "presentation": [ "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillDefiniteLivedIntangiblesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) accumulated amortization of an asset, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.", "label": "Indefinite-Lived Intangible Assets, Accumulated Depreciation, Foreign Currency Translation Gain (Loss)", "terseLabel": "Foreign Currency Translation - Accumulated amortization" } } }, "auth_ref": [] }, "ptct_SummaryOfInterestExpenseRecognizedRelatedToDebtTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "SummaryOfInterestExpenseRecognizedRelatedToDebtTableTextBlock", "presentation": [ "http://www.ptcbio.com/role/DisclosureDebtTables" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of interest expense recognized related to debt.", "label": "Summary of Interest Expense Recognized Related to Debt [Table Text Block]", "terseLabel": "Summary of interest expense recognized related to debt" } } }, "auth_ref": [] }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation": [ "http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCollaborationAndRoyaltyRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "verboseLabel": "Collaboration and royalty revenue", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r513" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": [ "r921" ] }, "us-gaap_CommitmentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsFairValueLiabilitiesMeasuredDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsSummaryOfChangesInFairValueOfCompanySLevel3ValuationDetails" ], "lang": { "en-us": { "role": { "label": "Commitments", "documentation": "This element represents significant arrangements with third parties, which includes operating lease arrangements and arrangements in which the entity has agreed to expend funds to procure goods or services, or has agreed to commit resources to supply goods or services, and operating lease arrangements." } } }, "auth_ref": [ "r97", "r150" ] }, "ptct_StockIssuedDuringPeriodSharesMilestonePayable": { "xbrltype": "sharesItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "StockIssuedDuringPeriodSharesMilestonePayable", "presentation": [ "http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails", "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfStockholdersDeficitEquity" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of a milestone payable.", "label": "Stock Issued During Period, Shares, Milestone Payable", "terseLabel": "Issuance of common stock in connection with a milestone payable (in shares)", "verboseLabel": "Shares issued for milestone payment" } } }, "auth_ref": [] }, "ptct_IssuanceOfStockForMilestonePayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "IssuanceOfStockForMilestonePayment", "crdr": "debit", "calculation": { "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Fair value of stock issued as payment of milestone.", "label": "Issuance of Stock for Milestone Payment", "terseLabel": "Non-cash stock consideration, milestone payment" } } }, "auth_ref": [] }, "ptct_ContingentLiabilityMilestonePotentialAchievementsDevelopmentalAndRegulatoryMilestones": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "ContingentLiabilityMilestonePotentialAchievementsDevelopmentalAndRegulatoryMilestones", "crdr": "credit", "presentation": [ "http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of potential payments which may be due for developmental and regulatory milestones if achieved.", "label": "Contingent Liability, Milestone, Potential Achievements, Developmental and Regulatory Milestones", "terseLabel": "Potential developmental and regulatory milestones" } } }, "auth_ref": [] }, "us-gaap_InterestExpenseDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpenseDebt", "crdr": "debit", "calculation": { "http://www.ptcbio.com/role/DisclosureDebtSeniorSecuredTermLoanDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ptcbio.com/role/DisclosureDebtConvertibleNotesInterestExpenseDetails", "http://www.ptcbio.com/role/DisclosureDebtSeniorSecuredTermLoanDetails" ], "lang": { "en-us": { "role": { "label": "Interest Expense, Debt", "totalLabel": "Total", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt." } } }, "auth_ref": [ "r117", "r392", "r398", "r824", "r825" ] }, "us-gaap_GuarantyLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GuarantyLiabilities", "crdr": "credit", "presentation": [ "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Guaranty Liabilities", "terseLabel": "Bank guarantee", "documentation": "This item represents a non-contingent liability for the fair value of an obligation to stand ready to perform over the term of a guaranty issued in the event that specified triggering events or conditions occur." } } }, "auth_ref": [ "r91", "r988" ] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebt", "crdr": "credit", "calculation": { "http://www.ptcbio.com/role/DisclosureDebtConvertibleNotesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ptcbio.com/role/DisclosureDebtConvertibleNotesDetails", "http://www.ptcbio.com/role/DisclosureDebtNarrativeDetails", "http://www.ptcbio.com/role/DisclosureDebtSeniorSecuredTermLoanDetails" ], "lang": { "en-us": { "role": { "label": "Long-term Debt", "terseLabel": "Net carrying amount", "totalLabel": "Net carrying amount", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r23", "r149", "r386", "r396", "r822", "r823", "r1046" ] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r926" ] }, "ptct_ClearpointEquityInvestmentFvNiRealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "ClearpointEquityInvestmentFvNiRealizedGainLoss", "crdr": "credit", "calculation": { "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Amount of realized gain (loss) from sale of Clearpoint Equity Investment measured at fair value with change in fair value recognized in net income (FV-NI).", "label": "Clearpoint Equity Investment, FV-NI, Realized Gain (Loss)", "negatedLabel": "Realized loss for the sale of Clearpoint Equity Investment" } } }, "auth_ref": [] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": [ "r869", "r880", "r890", "r907", "r915" ] }, "ptct_PtcFaAndPtcAsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "PtcFaAndPtcAsMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsSummaryOfChangesInFairValueOfCompanySLevel3ValuationDetails", "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillIndefiniteLivedIntangiblesDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Information pertaining to PTC-FA and PTC-AS gene therapies targeting Friedreich ataxia and Angelman syndrome.", "label": "PTC-FA and PTC-AS [Member]", "terseLabel": "PTC-FA and PTC-AS" } } }, "auth_ref": [] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": [ "r923" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://www.ptcbio.com/role/DisclosureNetLossPerShareNumeratorAndDenominatorDetails", "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r238", "r249" ] }, "ptct_CreditAgreementReserveForBorrowedFunds": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "CreditAgreementReserveForBorrowedFunds", "crdr": "debit", "presentation": [ "http://www.ptcbio.com/role/DisclosureDebtSeniorSecuredTermLoanDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashDetails" ], "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of reserve related to funding under a credit agreement for which the cash is restricted as to withdrawal or usage.", "label": "Credit Agreement, Reserve for Borrowed Funds", "terseLabel": "Credit agreement reserve", "verboseLabel": "Restricted cash current included in prepaid expenses and other current assets" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfStockholdersDeficitEquity" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": [ "r924" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [ "http://www.ptcbio.com/role/DisclosureStockAwardPlanTables" ], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Schedule of share-based compensation expense recorded in the statement of operations", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": [ "r72" ] }, "us-gaap_DebtSecuritiesTradingAndEquitySecuritiesFvNiAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesTradingAndEquitySecuritiesFvNiAbstract", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Trading, and Equity Securities, FV-NI [Abstract]", "terseLabel": "Equity Investments" } } }, "auth_ref": [] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": [ "r869", "r880", "r890", "r915" ] }, "ptct_CollaborationRevenueMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "CollaborationRevenueMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureRevenueRecognitionCollaborationAndRoyaltyRevenueDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCollaborationAndRoyaltyRevenueDetails", "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "documentation": "Revenue generated under a collaboration agreement.", "label": "Collaboration Revenue [Member]", "terseLabel": "Collaboration revenue" } } }, "auth_ref": [] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": [ "r925" ] }, "ptct_DevelopmentMilestoneObligationPaymentsMadeCash": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "DevelopmentMilestoneObligationPaymentsMadeCash", "crdr": "credit", "presentation": [ "http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of development milestone obligation cash payments made during the period.", "label": "Development Milestone Obligation, Payments Made, Cash", "terseLabel": "Development milestone obligation cash payments made" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://www.ptcbio.com/role/DisclosureNetLossPerShareNumeratorAndDenominatorDetails", "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r236", "r249" ] }, "ptct_AccruedRestructuringCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "AccruedRestructuringCosts", "crdr": "credit", "presentation": [ "http://www.ptcbio.com/role/DisclosureAccountsPayableAndAccruedExpensesRestructuringDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the carrying value as of the balance sheet date of obligations incurred through that date and payable for restructuring costs.", "label": "Accrued Restructuring Costs", "terseLabel": "Accrued restructuring costs" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "calculation": { "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillFutureAmortizationDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillFutureAmortizationDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months", "terseLabel": "2024", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r128" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "calculation": { "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillFutureAmortizationDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillFutureAmortizationDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Two", "terseLabel": "2025", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r128" ] }, "ptct_ProceedsFromSaleAndMaturityOfClearpointEquityInvestment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "ProceedsFromSaleAndMaturityOfClearpointEquityInvestment", "crdr": "debit", "calculation": { "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of Clearpoint Equity Investment during the period.", "label": "Proceeds From Sale And Maturity Of Clearpoint Equity Investment", "terseLabel": "Sale and redemption of ClearPoint Equity Investments" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "calculation": { "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillFutureAmortizationDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillFutureAmortizationDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Three", "terseLabel": "2026", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r128" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": [ "r868", "r879", "r889", "r914" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1", "presentation": [ "http://www.ptcbio.com/role/DisclosureStockAwardPlanNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period", "terseLabel": "Award requisite service period", "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r840" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://www.ptcbio.com/role/DisclosureStockAwardPlanNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period", "terseLabel": "Vesting period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r840" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "crdr": "debit", "calculation": { "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillFutureAmortizationDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillFutureAmortizationDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Amortization Expense, Remainder of Fiscal Year", "terseLabel": "2023", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year." } } }, "auth_ref": [] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": [ "r925" ] }, "ptct_FinanceLeaseLiabilityToBePaidYearFourAndAfter": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "FinanceLeaseLiabilityToBePaidYearFourAndAfter", "crdr": "credit", "calculation": { "http://www.ptcbio.com/role/DisclosureLeasesLeasePaymentsDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.ptcbio.com/role/DisclosureLeasesLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in fourth fiscal year and after following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Finance Lease, Liability, to be Paid, Year Four and After", "terseLabel": "2027 and thereafter" } } }, "auth_ref": [] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": [ "r918" ] }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger", "crdr": "debit", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsAvailableForSaleSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-sale, Continuous Unrealized Loss Position, 12 Months or Longer", "terseLabel": "Securities in an unrealized loss position greater than 12 months - Fair Value", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": [ "r157", "r333", "r819" ] }, "ptct_RestrictedStockUnitTradingArrangementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "RestrictedStockUnitTradingArrangementMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to company restricted stock units granted.", "label": "Restricted Stock Unit Trading Arrangement [Member]", "terseLabel": "Restricted Stock Unit Trading Arrangement" } } }, "auth_ref": [] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r926" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.ptcbio.com/role/DisclosureNetLossPerShareNumeratorAndDenominatorDetails", "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted", "verboseLabel": "Net loss per share - Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r202", "r226", "r227", "r228", "r229", "r230", "r239", "r247", "r248", "r249", "r253", "r540", "r541", "r645", "r661", "r815" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://www.ptcbio.com/role/DisclosureStockAwardPlanNarrativeDetails", "http://www.ptcbio.com/role/DisclosureStockAwardPlanShareBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Weighted average remaining service period for recognition of unrecognized compensation cost", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r482" ] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "presentation": [ "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of definite lived intangible assets", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment." } } }, "auth_ref": [ "r62", "r65" ] }, "ptct_FormerCensaSecurityholdersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "FormerCensaSecurityholdersMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "information pertaining to former Censa securityholders.", "label": "Former Censa Securityholders [Member]", "terseLabel": "Former Censa Securityholders" } } }, "auth_ref": [] }, "ptct_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "TrdArrExpirationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "documentation": "Trd Arr Expiration Date", "label": "Trd Arr Expiration Date", "terseLabel": "Expiration Date" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "presentation": [ "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of indefinite lived intangible assets", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment." } } }, "auth_ref": [ "r19", "r129" ] }, "us-gaap_ScheduleOfLineOfCreditFacilitiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfLineOfCreditFacilitiesTextBlock", "presentation": [ "http://www.ptcbio.com/role/DisclosureDebtTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Line of Credit Facilities [Table Text Block]", "terseLabel": "Schedule of credit agreement", "documentation": "Tabular disclosure of short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line." } } }, "auth_ref": [ "r26" ] }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable", "presentation": [ "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillIndefiniteLivedIntangiblesDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Indefinite-Lived Intangible Assets [Table]", "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity." } } }, "auth_ref": [ "r19", "r129" ] }, "ptct_ProceedsFromSaleOfFutureRoyalties": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "ProceedsFromSaleOfFutureRoyalties", "crdr": "debit", "presentation": [ "http://www.ptcbio.com/role/DisclosureDebtLiabilityForSaleOfFutureRoyaltiesDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLiabilityForSaleOfFutureRoyaltiesDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Cash received for sale of future royalties during the current period.", "label": "Proceeds From Sale of Future Royalties", "terseLabel": "Cash consideration received from Royalty Purchase Agreement", "verboseLabel": "Proceeds from sale of future royalties" } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://www.ptcbio.com/role/DisclosureNetLossPerShareAntidilutiveDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r50" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashDetails", "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents, and restricted cash end of period", "periodStartLabel": "Cash and cash equivalents, and restricted cash beginning of period", "terseLabel": "Total Cash, cash equivalents and restricted cash per statement of cash flows", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r43", "r121", "r211" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://www.ptcbio.com/role/DisclosureNetLossPerShareAntidilutiveDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Net loss per share", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInContractWithCustomerLiability", "crdr": "debit", "calculation": { "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 24.0 } }, "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Contract with Customer, Liability", "terseLabel": "Deferred revenue", "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r635", "r953" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net decrease in cash and cash equivalents", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r2", "r121" ] }, "us-gaap_IncreaseDecreaseInReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInReceivables", "crdr": "credit", "calculation": { "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 20.0 } }, "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Receivables", "negatedLabel": "Trade and royalty receivables, net", "documentation": "The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r8" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.ptcbio.com/role/DisclosureNetLossPerShareAntidilutiveDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Total shares excluded from calculation (in shares)", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r250" ] }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "crdr": "debit", "calculation": { "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 23.0 } }, "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Other Operating Liabilities", "terseLabel": "Other liabilities", "documentation": "Amount of increase (decrease) in operating liabilities classified as other." } } }, "auth_ref": [ "r8" ] }, "us-gaap_GainLossOnDispositionOfAssets1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnDispositionOfAssets1", "crdr": "credit", "calculation": { "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 25.0 } }, "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Gain (Loss) on Disposition of Assets", "negatedLabel": "Disposal of asset", "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee." } } }, "auth_ref": [ "r954" ] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "Net loss per share-basic and diluted (in dollars per share)" } } }, "auth_ref": [] }, "us-gaap_SecuredDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SecuredDebtMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureDebtSeniorSecuredTermLoanDetails", "http://www.ptcbio.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Secured Debt [Member]", "terseLabel": "Senior Secured Term Loan", "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromStockPlans": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromStockPlans", "crdr": "debit", "calculation": { "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from Stock Plans", "terseLabel": "Proceeds from employee stock purchase plan", "documentation": "The cash inflow associated with the amount received from the stock plan during the period." } } }, "auth_ref": [ "r4" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ptcbio.com/role/DisclosureLeasesNarrativeDetails", "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Research and Development Expense", "terseLabel": "Research and development", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r94", "r488", "r1044" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.ptcbio.com/role/DisclosureDebtNarrativeDetails", "http://www.ptcbio.com/role/DisclosureDebtSeniorSecuredTermLoanDetails" ], "lang": { "en-us": { "role": { "label": "Line of Credit Facility, Maximum Borrowing Capacity", "terseLabel": "Maximum borrowing capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r26" ] }, "us-gaap_InventoryFinishedGoods": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryFinishedGoods", "crdr": "debit", "calculation": { "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesInventoryDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesInventoryDetails" ], "lang": { "en-us": { "role": { "label": "Inventory, Finished Goods, Gross", "terseLabel": "Finished goods", "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer." } } }, "auth_ref": [ "r946" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://www.ptcbio.com/role/DisclosureNetLossPerShareTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of historical dilutive common share equivalents outstanding", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r50" ] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureStockAwardPlanNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Restricted stock units", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "crdr": "credit", "presentation": [ "http://www.ptcbio.com/role/DisclosureNetLossPerShareNumeratorAndDenominatorDetails" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "terseLabel": "Net loss - Diluted", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r204", "r238", "r241", "r242", "r243", "r244", "r246", "r249" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://www.ptcbio.com/role/DisclosureNetLossPerShareAntidilutiveDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities." } } }, "auth_ref": [ "r50" ] }, "us-gaap_DebtInstrumentConvertibleThresholdConsecutiveTradingDays1": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleThresholdConsecutiveTradingDays1", "presentation": [ "http://www.ptcbio.com/role/DisclosureDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Convertible, Threshold Consecutive Trading Days", "terseLabel": "Consecutive trading days, period", "documentation": "Threshold period of specified consecutive trading days within which common stock price to conversion price of convertible debt instrument must exceed threshold percentage for specified number of trading days to trigger conversion feature." } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems", "presentation": [ "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r171", "r172", "r173", "r174", "r175", "r221", "r222", "r223", "r224", "r225", "r228", "r234", "r253", "r275", "r276", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r360", "r484", "r485", "r486", "r500", "r501", "r502", "r503", "r509", "r510", "r511", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r553", "r554", "r558", "r559", "r560", "r561", "r569", "r570", "r573", "r574", "r575", "r576", "r595", "r596", "r597", "r598", "r599", "r638", "r639", "r640", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r685" ] }, "us-gaap_LineOfCreditFacilityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityAbstract", "presentation": [ "http://www.ptcbio.com/role/DisclosureDebtSeniorSecuredTermLoanDetails" ], "lang": { "en-us": { "role": { "label": "Line of Credit Facility [Abstract]", "terseLabel": "Debt Facility" } } }, "auth_ref": [] }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis", "presentation": [ "http://www.ptcbio.com/role/DisclosureRevenueRecognitionPerformanceObligationsDetails" ], "lang": { "en-us": { "role": { "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]", "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format." } } }, "auth_ref": [ "r165" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsHierarchyDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring and Nonrecurring [Table]", "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r544", "r545", "r551" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityTable", "presentation": [ "http://www.ptcbio.com/role/DisclosureDebtSeniorSecuredTermLoanDetails" ], "lang": { "en-us": { "role": { "label": "Line of Credit Facility [Table]", "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line." } } }, "auth_ref": [ "r26", "r957" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsHierarchyDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Quoted prices in active markets for identical assets (level 1)", "terseLabel": "Quoted prices in active markets for identical assets (Level 1)", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r387", "r441", "r446", "r545", "r607", "r834", "r835", "r836" ] }, "us-gaap_SharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesIssued", "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfStockholdersDeficitEquity" ], "lang": { "en-us": { "role": { "label": "Shares, Issued", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)", "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury." } } }, "auth_ref": [ "r13" ] }, "us-gaap_OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": [ "http://www.ptcbio.com/role/DisclosureLeasesCashFlowDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Payments", "terseLabel": "Operating cash flows from operating leases", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } }, "auth_ref": [ "r582", "r590" ] }, "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable", "presentation": [ "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Accounting Standards Update and Change in Accounting Principle [Table]", "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]", "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items." } } }, "auth_ref": [ "r49", "r171", "r172", "r173", "r174", "r175", "r221", "r222", "r223", "r224", "r225", "r228", "r234", "r253", "r275", "r276", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r360", "r484", "r485", "r486", "r500", "r501", "r502", "r503", "r509", "r510", "r511", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r553", "r554", "r558", "r559", "r560", "r561", "r569", "r570", "r573", "r574", "r575", "r576", "r595", "r596", "r597", "r598", "r599", "r638", "r639", "r640", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r680", "r681", "r682", "r683", "r685" ] }, "us-gaap_LineOfCreditFacilityLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityLineItems", "presentation": [ "http://www.ptcbio.com/role/DisclosureDebtSeniorSecuredTermLoanDetails" ], "lang": { "en-us": { "role": { "label": "Line of Credit Facility [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r957" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsFairValueLiabilitiesMeasuredDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]", "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": [ "r14" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsFairValueLiabilitiesMeasuredDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]", "terseLabel": "Fair Value Valuation Inputs", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsTables" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques", "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": [ "r14" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfOperations", "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfStockholdersDeficitEquity" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r218", "r219", "r220", "r254", "r636", "r686", "r704", "r715", "r716", "r717", "r718", "r719", "r720", "r722", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r735", "r736", "r737", "r738", "r739", "r741", "r745", "r746", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r762", "r850" ] }, "us-gaap_FinanceLeasePrincipalPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeasePrincipalPayments", "crdr": "credit", "presentation": [ "http://www.ptcbio.com/role/DisclosureLeasesCashFlowDetails" ], "lang": { "en-us": { "role": { "label": "Finance Lease, Principal Payments", "terseLabel": "Financing cash flows from finance lease", "documentation": "Amount of cash outflow for principal payment on finance lease." } } }, "auth_ref": [ "r580", "r590" ] }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "crdr": "debit", "calculation": { "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Right-of-Use Asset, Amortization Expense", "terseLabel": "Non-cash operating lease expense", "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease." } } }, "auth_ref": [ "r954" ] }, "us-gaap_LineOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureDebtSeniorSecuredTermLoanDetails", "http://www.ptcbio.com/role/DisclosureDebtTables", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Line of Credit [Member]", "terseLabel": "Blackstone Credit Agreement", "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars." } } }, "auth_ref": [] }, "us-gaap_ReceivablesNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReceivablesNetCurrent", "crdr": "debit", "calculation": { "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Receivables, Net, Current", "terseLabel": "Trade and royalty receivables, net", "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value." } } }, "auth_ref": [ "r844" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 }, "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesInventoryDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesInventoryDetails", "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Inventory, Net", "terseLabel": "Inventory, net", "totalLabel": "Total inventory", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r190", "r809", "r844" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": [ "r899" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.ptcbio.com/role/DisclosureStockAwardPlanStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised (in dollars per share)", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r461" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.ptcbio.com/role/DocumentCover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_IndefinitelivedIntangibleAssetsAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefinitelivedIntangibleAssetsAcquired", "crdr": "debit", "presentation": [ "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillIndefiniteLivedIntangiblesDetails" ], "lang": { "en-us": { "role": { "label": "Indefinite-lived Intangible Assets Acquired", "verboseLabel": "Additions", "documentation": "Amount of increase in assets, excluding financial assets and goodwill, lacking physical substance with an indefinite life, from an acquisition." } } }, "auth_ref": [] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": [ "r898" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r897" ] }, "ptct_SaleOfStockSharesAvailableToBeIssuedAndSoldValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "SaleOfStockSharesAvailableToBeIssuedAndSoldValue", "crdr": "credit", "presentation": [ "http://www.ptcbio.com/role/DisclosureCapitalizationNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Value of shares available to be issued and sold in stock transaction.", "label": "Sale of Stock, Shares Available to be Issued and Sold, Value", "terseLabel": "Value of shares available to be issued and sold in transaction" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.ptcbio.com/role/DisclosureStockAwardPlanStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Granted (in dollars per share)", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r460" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.ptcbio.com/role/DisclosureStockAwardPlanStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Forfeited/Cancelled (in dollars per share)", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": [ "r462" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails", "http://www.ptcbio.com/role/DisclosureRevenueRecognitionCollaborationAndRoyaltyRevenueDetails", "http://www.ptcbio.com/role/DisclosureRevenueRecognitionManufacturingRevenueDetails", "http://www.ptcbio.com/role/DisclosureRevenueRecognitionNetProductSalesDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCollaborationAndRoyaltyRevenueDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesManufacturingRevenueDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails", "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r270", "r636", "r665", "r666", "r667", "r668", "r669", "r670", "r806", "r827", "r845", "r936", "r986", "r987", "r993", "r1049" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r896" ] }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "crdr": "debit", "calculation": { "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 22.0 } }, "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "terseLabel": "Accounts payable and accrued expenses", "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid." } } }, "auth_ref": [ "r8" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r896" ] }, "us-gaap_LesseeFinanceLeaseTermOfContract1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeFinanceLeaseTermOfContract1", "presentation": [ "http://www.ptcbio.com/role/DisclosureLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Finance Lease, Term of Contract", "terseLabel": "Finance lease, term of contract", "documentation": "Term of lessee's finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1033" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.ptcbio.com/role/DocumentCover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "us-gaap_MeasurementInputTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputTypeDomain", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsFairValueLiabilitiesMeasuredDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Domain]", "documentation": "Measurement input used to determine value of asset and liability." } } }, "auth_ref": [] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails", "http://www.ptcbio.com/role/DisclosureRevenueRecognitionCollaborationAndRoyaltyRevenueDetails", "http://www.ptcbio.com/role/DisclosureRevenueRecognitionManufacturingRevenueDetails", "http://www.ptcbio.com/role/DisclosureRevenueRecognitionNetProductSalesDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCollaborationAndRoyaltyRevenueDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesManufacturingRevenueDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails", "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r270", "r636", "r665", "r666", "r667", "r668", "r669", "r670", "r806", "r827", "r845", "r936", "r986", "r987", "r993", "r1049" ] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://www.ptcbio.com/role/DisclosureRevenueRecognitionNetProductSalesDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r51", "r54", "r85", "r86", "r273", "r791" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r897" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets", "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfStockholdersDeficitEquity" ], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance at the end of the period", "periodStartLabel": "Balance at the beginning of the period", "totalLabel": "Total stockholders' deficit", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r101", "r104", "r105", "r125", "r724", "r740", "r763", "r764", "r844", "r856", "r958", "r976", "r1028", "r1054" ] }, "us-gaap_FinanceLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.ptcbio.com/role/DisclosureLeasesSupplementalLeaseTermsDetails" ], "lang": { "en-us": { "role": { "label": "Finance Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted-average remaining lease terms - finance lease (years)", "documentation": "Weighted average remaining lease term for finance lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r592", "r843" ] }, "ptct_EmflazaassetacquisitionMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "EmflazaassetacquisitionMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillDefiniteLivedIntangiblesDetails" ], "lang": { "en-us": { "role": { "documentation": "Emflaza asset acquisition [Member]", "label": "Emflaza asset acquisition" } } }, "auth_ref": [] }, "us-gaap_ValuationTechniqueDiscountedCashFlowMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationTechniqueDiscountedCashFlowMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsFairValueLiabilitiesMeasuredDetails" ], "lang": { "en-us": { "role": { "label": "Valuation Technique, Discounted Cash Flow", "documentation": "Valuation technique calculating present value of future cash flows." } } }, "auth_ref": [ "r1026" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.ptcbio.com/role/DocumentCover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "us-gaap_ValuationTechniqueOptionPricingModelMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ValuationTechniqueOptionPricingModelMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsFairValueLiabilitiesMeasuredDetails" ], "lang": { "en-us": { "role": { "label": "Valuation Technique, Option Pricing Model", "documentation": "Valuation technique calculating price of option." } } }, "auth_ref": [ "r1026" ] }, "ptct_CostofGoodsandServiceExcludingAmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "CostofGoodsandServiceExcludingAmortizationOfIntangibleAssets", "crdr": "debit", "calculation": { "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "documentation": "Cost of Goods and Service, Excluding Amortization Of Intangible Assets", "label": "Cost of Goods and Service, Excluding Amortization Of Intangible Assets", "terseLabel": "Cost of product sales, excluding amortization of acquired intangible assets" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r898" ] }, "country_BR": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "BR", "presentation": [ "http://www.ptcbio.com/role/DisclosureRevenueRecognitionNetProductSalesDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "BRAZIL", "terseLabel": "Brazil" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": [ "r898" ] }, "ptct_AssetAcquisitionDevelopmentAndRegulatoryMilestones": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "AssetAcquisitionDevelopmentAndRegulatoryMilestones", "crdr": "credit", "presentation": [ "http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Asset Acquisition, Development And Regulatory Milestones", "label": "Asset Acquisition, Development And Regulatory Milestones", "terseLabel": "Asset acquisition, development and regulatory milestones" } } }, "auth_ref": [] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r898" ] }, "ptct_SaleOfStockRemainingSharesAvailableForSaleAggregateOfferingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "SaleOfStockRemainingSharesAvailableForSaleAggregateOfferingValue", "crdr": "debit", "presentation": [ "http://www.ptcbio.com/role/DisclosureCapitalizationNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "The aggregate value of remaining shares to be issued and sold under a sales agreement.", "label": "Sale of Stock, Remaining Shares Available for Sale, Aggregate Offering Value", "verboseLabel": "Aggregate value of remaining shares to be issued and sold" } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.ptcbio.com/role/DocumentCover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInDepositOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInDepositOtherAssets", "crdr": "credit", "calculation": { "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 21.0 } }, "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Deposit Assets", "negatedLabel": "Deposits and other assets", "documentation": "The increase (decrease) during the reporting period in moneys or securities given as security including, but not limited to, contract, escrow, or earnest money deposits, retainage (if applicable), deposits with clearing organizations and others, collateral, or margin deposits." } } }, "auth_ref": [ "r8" ] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.ptcbio.com/role/DisclosureAccountsPayableAndAccruedExpensesComponentsDetails": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.ptcbio.com/role/DisclosureAccountsPayableAndAccruedExpensesComponentsDetails" ], "lang": { "en-us": { "role": { "label": "Accounts Payable, Current", "terseLabel": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r25", "r844" ] }, "us-gaap_ContingentConsiderationByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContingentConsiderationByTypeAxis", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsFairValueLiabilitiesMeasuredDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsHierarchyDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsSummaryOfChangesInFairValueOfCompanySLevel3ValuationDetails" ], "lang": { "en-us": { "role": { "label": "Contingent Consideration by Type [Axis]", "documentation": "Information by type of contingent consideration." } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": [ "r899" ] }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "crdr": "debit", "calculation": { "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsMarketableSecuritiesDetails", "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from Sale and Maturity of Marketable Securities", "terseLabel": "Sale and redemption of marketable securities - equity investments", "verboseLabel": "Redemption of marketable securities- equity investments", "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period." } } }, "auth_ref": [] }, "ptct_LiabilityForSaleOfFutureRoyaltiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "LiabilityForSaleOfFutureRoyaltiesTableTextBlock", "presentation": [ "http://www.ptcbio.com/role/DisclosureDebtTables" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of activity related to the liability resulting from the sale of future royalties.", "label": "Liability for Sale of Future Royalties [Table Text Block]", "terseLabel": "Summary of liability for sale of future royalties" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 }, "http://www.ptcbio.com/role/DisclosureAccountsPayableAndAccruedExpensesComponentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ptcbio.com/role/DisclosureAccountsPayableAndAccruedExpensesComponentsDetails", "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts Payable and Accrued Liabilities, Current", "terseLabel": "Accounts payable and accrued expenses", "totalLabel": "Accounts payable and accrued expenses", "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits." } } }, "auth_ref": [ "r27" ] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": [ "r899" ] }, "ptct_LeaseCostExcludingFinanceLeaseCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "LeaseCostExcludingFinanceLeaseCosts", "crdr": "debit", "calculation": { "http://www.ptcbio.com/role/DisclosureLeasesLeaseCostsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ptcbio.com/role/DisclosureLeasesLeaseCostsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contracts, excluding finance lease costs.", "label": "Lease Cost, Excluding Finance Lease Costs", "totalLabel": "Total operating lease cost" } } }, "auth_ref": [] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": [ "r918" ] }, "us-gaap_DebtInstrumentRedemptionPricePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentRedemptionPricePercentage", "presentation": [ "http://www.ptcbio.com/role/DisclosureDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Redemption Price, Percentage", "terseLabel": "Redemption price as percent of principal amount", "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer." } } }, "auth_ref": [ "r20" ] }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseRenewalTerm", "presentation": [ "http://www.ptcbio.com/role/DisclosureLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Renewal Term", "terseLabel": "Renewal term", "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1033" ] }, "us-gaap_DebtInstrumentRedemptionPeriodAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentRedemptionPeriodAxis", "presentation": [ "http://www.ptcbio.com/role/DisclosureDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Redemption, Period [Axis]", "documentation": "Information about timing of debt redemption features under terms of the debt agreement." } } }, "auth_ref": [ "r20" ] }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": [ "http://www.ptcbio.com/role/DisclosureLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Term of Contract", "terseLabel": "Operating lease, term of contract", "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r1033" ] }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1", "presentation": [ "http://www.ptcbio.com/role/DisclosureRevenueRecognitionPerformanceObligationsDetails" ], "lang": { "en-us": { "role": { "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period", "terseLabel": "Revenue, performance obligation, period", "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r165" ] }, "us-gaap_DebtInstrumentRedemptionPeriodDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentRedemptionPeriodDomain", "presentation": [ "http://www.ptcbio.com/role/DisclosureDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Redemption, Period [Domain]", "documentation": "Period as defined under terms of the debt agreement for debt redemption features." } } }, "auth_ref": [ "r20" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.ptcbio.com/role/DisclosureLeasesSupplementalLeaseTermsDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted-average remaining lease terms - operating leases (years)", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r592", "r843" ] }, "us-gaap_ContingentConsiderationTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContingentConsiderationTypeDomain", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsFairValueLiabilitiesMeasuredDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsHierarchyDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsSummaryOfChangesInFairValueOfCompanySLevel3ValuationDetails" ], "lang": { "en-us": { "role": { "label": "Contingent Consideration Type [Domain]", "documentation": "Description of contingent payment arrangement." } } }, "auth_ref": [] }, "ptct_DepositsAndOtherNoncurrentAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "DepositsAndOtherNoncurrentAssetsMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing deposits and other noncurrent assets.", "label": "Deposits and Other Noncurrent Assets [Member]", "terseLabel": "Deposits and other assets" } } }, "auth_ref": [] }, "ptct_LesseeOperatingLeaseBaseRentAbatement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "LesseeOperatingLeaseBaseRentAbatement", "crdr": "debit", "calculation": { "http://www.ptcbio.com/role/DisclosureLeasesNarrativeDetails": { "parentTag": "ptct_LesseeOperatingLeaseLiabilityToBePaidNetOfBaseRentAbatement", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.ptcbio.com/role/DisclosureLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of base rent abatement available if lessee is not subject to an event of default as defined in the lease agreement.", "label": "Lessee, Operating Lease, Base Rent Abatement", "terseLabel": "Base rent abatement" } } }, "auth_ref": [] }, "ptct_LineOfCreditUncommittedLoanFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "LineOfCreditUncommittedLoanFacilityMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureDebtSeniorSecuredTermLoanDetails" ], "lang": { "en-us": { "role": { "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time and the lender is not obligated to loan funds.", "label": "Line of Credit, Uncommitted Loan Facility [Member]", "terseLabel": "Uncommitted Incremental Facility" } } }, "auth_ref": [] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r867", "r878", "r888", "r913" ] }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "crdr": "credit", "calculation": { "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 14.0 } }, "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Accretion (Amortization) of Discounts and Premiums, Investments", "negatedLabel": "Amortization of (discounts) premiums on investments, net", "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r123" ] }, "ptct_DebtInstrumentCovenantMinimumLiquidAssetsIncreasedThresholdAfterQualiedAcquisitions": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "DebtInstrumentCovenantMinimumLiquidAssetsIncreasedThresholdAfterQualiedAcquisitions", "crdr": "debit", "presentation": [ "http://www.ptcbio.com/role/DisclosureDebtSeniorSecuredTermLoanDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of increased minimum liquid assets, after consummation of acquisitions meeting specified thresholds, required to be maintained by the entity at designated measurement dates to comply with the financial covenants of a debt agreement.", "label": "Debt Instrument, Covenant, Minimum Liquid Assets, Increased Threshold After Qualified Acquisitions", "verboseLabel": "Increased minimum consolidated liquidity covenant after consummation of acquisitions meeting specified thresholds" } } }, "auth_ref": [] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "terseLabel": "Cash paid for interest", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r207", "r209", "r210" ] }, "ptct_PtcFaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "PtcFaMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillIndefiniteLivedIntangiblesDetails" ], "lang": { "en-us": { "role": { "documentation": "Information pertaining to PTC-FA, gene therapy targeting Friedreich ataxia.", "label": "PTC-FA [Member]", "terseLabel": "PTC-FA" } } }, "auth_ref": [] }, "ptct_LesseeOperatingLeaseLiabilityToBePaidYearFourAndAfter": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "LesseeOperatingLeaseLiabilityToBePaidYearFourAndAfter", "crdr": "credit", "calculation": { "http://www.ptcbio.com/role/DisclosureLeasesLeasePaymentsDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.ptcbio.com/role/DisclosureLeasesLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due fourth fiscal year and after following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four and After", "terseLabel": "2027 and thereafter" } } }, "auth_ref": [] }, "ptct_PtcAsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "PtcAsMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillIndefiniteLivedIntangiblesDetails" ], "lang": { "en-us": { "role": { "documentation": "Information pertaining to PTC-FA, gene therapy targeting Angelman syndrome.", "label": "PTC-AS [Member]", "terseLabel": "PTC-AS" } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfConvertibleDebt", "crdr": "credit", "calculation": { "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Repayments of Convertible Debt", "negatedLabel": "Repayment of Convertible Notes", "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder." } } }, "auth_ref": [ "r41" ] }, "ptct_UpstazaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "UpstazaMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsSummaryOfChangesInFairValueOfCompanySLevel3ValuationDetails", "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillDefiniteLivedIntangiblesDetails", "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillIndefiniteLivedIntangiblesDetails" ], "lang": { "en-us": { "role": { "documentation": "Information pertaining to Upstaza, gene therapy for treatment of AADC deficiency.", "label": "Upstaza [Member]", "terseLabel": "Upstaza" } } }, "auth_ref": [] }, "ptct_DebtInstrumentDelayedDrawTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "DebtInstrumentDelayedDrawTerm", "presentation": [ "http://www.ptcbio.com/role/DisclosureDebtSeniorSecuredTermLoanDetails" ], "lang": { "en-us": { "role": { "documentation": "Period of time after closing of the credit agreement during which funds can be drawn subject to specified conditions.", "label": "Debt Instrument, Delayed Draw Term", "verboseLabel": "Fund draw term" } } }, "auth_ref": [] }, "ptct_DebtInstrumentCovenantMinimumLiquidAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "DebtInstrumentCovenantMinimumLiquidAssets", "crdr": "debit", "presentation": [ "http://www.ptcbio.com/role/DisclosureDebtSeniorSecuredTermLoanDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of minimum liquid assets required to be maintained by the entity at designated measurement dates to comply with the financial covenants of a debt agreement.", "label": "Debt Instrument, Covenant, Minimum Liquid Assets", "terseLabel": "Minimum consolidated liquidity covenant" } } }, "auth_ref": [] }, "ptct_DepositsAndOtherAssetsNoncurrentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "DepositsAndOtherAssetsNoncurrentMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing noncurrent deposits and other assets.", "label": "Deposits and Other Assets, Noncurrent [Member]", "terseLabel": "Deposits and Other Assets, Noncurrent" } } }, "auth_ref": [] }, "ptct_MilestoneReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "MilestoneReceivable", "crdr": "debit", "presentation": [ "http://www.ptcbio.com/role/DisclosureRevenueRecognitionCollaborationAndRoyaltyRevenueDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCollaborationAndRoyaltyRevenueDetails" ], "lang": { "en-us": { "role": { "documentation": "Milestone payments earned but not yet received.", "label": "Milestone Receivable", "terseLabel": "Milestone payments due" } } }, "auth_ref": [] }, "us-gaap_AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "calculation": { "http://www.ptcbio.com/role/DisclosureAccountsPayableAndAccruedExpensesComponentsDetails": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.ptcbio.com/role/DisclosureAccountsPayableAndAccruedExpensesComponentsDetails" ], "lang": { "en-us": { "role": { "label": "Accrued Professional Fees, Current", "terseLabel": "Professional fees", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r29" ] }, "ptct_LineOfCreditCommittedDelayedDrawTermLoanFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "LineOfCreditCommittedDelayedDrawTermLoanFacilityMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureDebtSeniorSecuredTermLoanDetails" ], "lang": { "en-us": { "role": { "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time and the lender is committed to providing the funds.", "label": "Line of Credit, Committed Delayed Draw Term Loan Facility [Member]", "terseLabel": "Committed Delayed Draw Term Loan Facility" } } }, "auth_ref": [] }, "ptct_OperatingLeaseAllowanceForLeaseImprovements": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "OperatingLeaseAllowanceForLeaseImprovements", "crdr": "credit", "presentation": [ "http://www.ptcbio.com/role/DisclosureLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of allowance for lease improvements provided by lessor under the terms of the lease agreement.", "label": "Operating Lease, Allowance for Lease Improvements", "terseLabel": "Allowance for lease improvements" } } }, "auth_ref": [] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": [ "r866", "r877", "r887", "r912" ] }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsHierarchyDetails", "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Business Combination, Contingent Consideration, Liability, Noncurrent", "terseLabel": "Contingent consideration payable", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r1", "r79" ] }, "ptct_AtMarketOfferingSalesAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "AtMarketOfferingSalesAgreementMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureCapitalizationNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "information pertaining to the At the Market Offering Sales Agreement.", "label": "At the Market Offering Sales Agreement [Member]", "terseLabel": "Sales Agreement" } } }, "auth_ref": [] }, "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock", "presentation": [ "http://www.ptcbio.com/role/DisclosureStockAwardPlanTables" ], "lang": { "en-us": { "role": { "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]", "terseLabel": "Summary of information on the Company's restricted stock", "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares." } } }, "auth_ref": [ "r22" ] }, "ptct_LesseeOperatingLeaseLiabilityToBePaidNetOfBaseRentAbatement": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "LesseeOperatingLeaseLiabilityToBePaidNetOfBaseRentAbatement", "crdr": "credit", "calculation": { "http://www.ptcbio.com/role/DisclosureLeasesNarrativeDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ptcbio.com/role/DisclosureLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease net of eligible base rent abatement.", "label": "Lessee, Operating Lease, Liability, to be Paid, Net of Base Rent Abatement", "totalLabel": "Aggregate rent net of base rate abatement, initial term" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": [ "http://www.ptcbio.com/role/DisclosureStockAwardPlanNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period", "terseLabel": "Expiration period", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r841" ] }, "srt_WeightedAverageMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "WeightedAverageMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsFairValueLiabilitiesMeasuredDetails", "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillDefiniteLivedIntangiblesDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average [Member]", "terseLabel": "Weighted Average" } } }, "auth_ref": [ "r803", "r804", "r1038", "r1040", "r1043" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccruedRoyaltiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedRoyaltiesCurrent", "crdr": "credit", "calculation": { "http://www.ptcbio.com/role/DisclosureAccountsPayableAndAccruedExpensesComponentsDetails": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.ptcbio.com/role/DisclosureAccountsPayableAndAccruedExpensesComponentsDetails", "http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails", "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillDefiniteLivedIntangiblesDetails" ], "lang": { "en-us": { "role": { "label": "Accrued Royalties, Current", "terseLabel": "Royalties", "verboseLabel": "Accrued royalties", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r29", "r811" ] }, "ptct_AmendedAndRestated2013LongTermIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "AmendedAndRestated2013LongTermIncentivePlanMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureStockAwardPlanNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to the Amended and Restated 2013 Long Term Incentive Plan.", "label": "Amended and Restated 2013 Long Term Incentive Plan [Member]", "terseLabel": "Amended 2013 LTIP" } } }, "auth_ref": [] }, "ptct_OperatingLeaseConstructionAccountFundingCommitment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "OperatingLeaseConstructionAccountFundingCommitment", "crdr": "debit", "presentation": [ "http://www.ptcbio.com/role/DisclosureLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of lessee commitment to fund a construction account for lease improvements provided under the terms of the lease agreement.", "label": "Operating Lease, Construction Account Funding Commitment", "terseLabel": "Commitment to fund construction account" } } }, "auth_ref": [] }, "ptct_NumberOfProducts": { "xbrltype": "integerItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "NumberOfProducts", "presentation": [ "http://www.ptcbio.com/role/DisclosureCompanyDetails" ], "lang": { "en-us": { "role": { "documentation": "The number of products of the company.", "label": "Number of Products", "terseLabel": "Number of products" } } }, "auth_ref": [] }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": [ "http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails", "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillDefiniteLivedIntangiblesDetails", "http://www.ptcbio.com/role/DisclosureLeasesNarrativeDetails", "http://www.ptcbio.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]" } } }, "auth_ref": [ "r215", "r216", "r382", "r402", "r600", "r813", "r814" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": [ "r865", "r876", "r886", "r911" ] }, "ptct_WarrenPremisesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "WarrenPremisesMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureLeasesNarrativeDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Information pertaining to the leased premises in Warren, New Jersey.", "label": "Warren Premises [Member]", "terseLabel": "Warren Premises" } } }, "auth_ref": [] }, "ptct_PeriodAfterWhichLetterOfCreditMayBeReducedIfLeaseNotInDefault": { "xbrltype": "durationItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "PeriodAfterWhichLetterOfCreditMayBeReducedIfLeaseNotInDefault", "presentation": [ "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Period after which Letter of Credit may be reduced if lease is not in default.", "label": "Period After Which Letter of Credit May be Reduced if Lease Not in Default", "terseLabel": "Period after which letter of credit may be reduced if lease is not in default" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://www.ptcbio.com/role/DisclosureStockAwardPlanTables" ], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Summary of stock option activity", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r16", "r17", "r71" ] }, "ptct_NumberOfBuildingsLeased": { "xbrltype": "integerItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "NumberOfBuildingsLeased", "presentation": [ "http://www.ptcbio.com/role/DisclosureLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of buildings leased during the period.", "label": "Number Of Buildings Leased", "terseLabel": "Number of buildings leased" } } }, "auth_ref": [] }, "us-gaap_MutualFundMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MutualFundMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Mutual Fund [Member]", "terseLabel": "Mutual Funds", "documentation": "Regulated investment instrument that pools funds from multiple investors to invest principally in a portfolio of securities and money market instruments to match the investment objective." } } }, "auth_ref": [ "r995" ] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [ "http://www.ptcbio.com/role/DisclosureStockAwardPlanTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of assumptions used to estimate fair values of grants made on the date of grant", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r140" ] }, "us-gaap_LongTermDebtTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtTextBlock", "presentation": [ "http://www.ptcbio.com/role/DisclosureDebt" ], "lang": { "en-us": { "role": { "label": "Long-term Debt [Text Block]", "terseLabel": "Debt", "documentation": "The entire disclosure for long-term debt." } } }, "auth_ref": [ "r131" ] }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireIntangibleAssets", "crdr": "credit", "calculation": { "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments to Acquire Intangible Assets", "negatedLabel": "Acquisition of product rights and licenses", "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill." } } }, "auth_ref": [ "r120" ] }, "us-gaap_FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsForeignCurrencyTranslationGainLoss", "crdr": "credit", "presentation": [ "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillDefiniteLivedIntangiblesDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Foreign Currency Translation Gain (Loss)", "terseLabel": "Foreign Currency Translation", "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CustomerConcentrationRiskMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureRevenueRecognitionNetProductSalesDetails" ], "lang": { "en-us": { "role": { "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer concentration risk", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": [ "r52", "r273" ] }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleTable", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsAvailableForSaleSecuritiesDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsMarketableSecuritiesBalanceSheetDisclosuresDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsMarketableSecuritiesUnrealizedGainsLossesDetails" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-sale [Table]", "terseLabel": "Debt Securities, Available-for-sale [Table]", "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289" ] }, "ptct_OperatingLeaseLessorPaymentDueAtIssuanceOfTemporaryCertificateOfOccupancy": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "OperatingLeaseLessorPaymentDueAtIssuanceOfTemporaryCertificateOfOccupancy", "crdr": "debit", "presentation": [ "http://www.ptcbio.com/role/DisclosureLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of payment due from lessor at issuance of temporary certificate of occupancy that lessee has committed to fund into the construction account for lease improvements provided under the terms of the lease agreement.", "label": "Operating Lease, Lessor Payment Due At Issuance of Temporary Certificate of Occupancy", "terseLabel": "Payment due from lessor at issuance of temporary certificate of occupancy" } } }, "auth_ref": [] }, "ptct_SmaFoundationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "SmaFoundationMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to the SMA Foundation.", "label": "SMA Foundation [Member]", "terseLabel": "SMA Foundation" } } }, "auth_ref": [] }, "us-gaap_CorporateDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CorporateDebtSecuritiesMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsAvailableForSaleSecuritiesDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsMarketableSecuritiesBalanceSheetDisclosuresDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsMarketableSecuritiesUnrealizedGainsLossesDetails" ], "lang": { "en-us": { "role": { "label": "Corporate debt securities", "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment." } } }, "auth_ref": [ "r834", "r836", "r1050" ] }, "ptct_LesseeOperatingLeaseBaseRentAbatementPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "LesseeOperatingLeaseBaseRentAbatementPeriod", "presentation": [ "http://www.ptcbio.com/role/DisclosureLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Period of lessee's base rent abatement entitlement per terms of lease agreement.", "label": "Lessee, Operating Lease, Base Rent Abatement Period", "terseLabel": "Base rent abatement period" } } }, "auth_ref": [] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCostTableTextBlock", "presentation": [ "http://www.ptcbio.com/role/DisclosureLeasesTables" ], "lang": { "en-us": { "role": { "label": "Lease, Cost [Table Text Block]", "terseLabel": "Schedule of lease costs", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [ "r1034" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": [ "r870", "r881", "r891", "r916" ] }, "ptct_LineOfCreditCommittedLoanFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "LineOfCreditCommittedLoanFacilityMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureDebtSeniorSecuredTermLoanDetails" ], "lang": { "en-us": { "role": { "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time and the lender is committed to providing the funds.", "label": "Line of Credit, Committed Loan Facility [Member]", "terseLabel": "Committed Loan Facility" } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsAvailableForSaleSecuritiesDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsHierarchyDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsMarketableSecuritiesBalanceSheetDisclosuresDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsMarketableSecuritiesUnrealizedGainsLossesDetails" ], "lang": { "en-us": { "role": { "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r395", "r412", "r529", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r659", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r971", "r972", "r973", "r974" ] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "presentation": [ "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillDefiniteLivedIntangiblesDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "negatedPeriodEndLabel": "Ending balance - Accumulated amortization", "negatedPeriodStartLabel": "Beginning balance - Accumulated amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r181", "r356" ] }, "ptct_RepaymentsOfConvertibleDebtIncludingAccruedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "RepaymentsOfConvertibleDebtIncludingAccruedInterest", "crdr": "credit", "presentation": [ "http://www.ptcbio.com/role/DisclosureDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "The cash outflow from the repayment of a long-term debt instrument, including accrued interest, which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.", "label": "Repayments of Convertible Debt Including Accrued Interest", "terseLabel": "Repayment of convertible notes including accrued interest" } } }, "auth_ref": [] }, "ptct_IncrementalInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "IncrementalInterestExpense", "crdr": "debit", "presentation": [ "http://www.ptcbio.com/role/DisclosureDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of the incremental cost of borrowed funds over a specified period per the terms of the debt instrument.", "label": "Incremental Interest Expense", "terseLabel": "Additional interest paid" } } }, "auth_ref": [] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": [ "http://www.ptcbio.com/role/DisclosureStockAwardPlanNarrativeDetails", "http://www.ptcbio.com/role/DisclosureStockAwardPlanShareBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Expense", "terseLabel": "Share-based compensation expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r479", "r487" ] }, "us-gaap_DebtInstrumentTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTerm", "presentation": [ "http://www.ptcbio.com/role/DisclosureDebtNarrativeDetails", "http://www.ptcbio.com/role/DisclosureDebtSeniorSecuredTermLoanDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Term", "terseLabel": "Term of the convertible notes", "verboseLabel": "Loan term", "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleUnrealizedGainLoss", "crdr": "credit", "calculation": { "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 12.0 } }, "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsMarketableSecuritiesDetails", "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-sale, Unrealized Gain (Loss)", "negatedLabel": "Unrealized loss on ClearPoint convertible debt security", "terseLabel": "Unrealized gain (loss) on convertible note", "documentation": "Amount of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r969", "r970" ] }, "us-gaap_EmployeeStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureStockAwardPlanNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Employee Stock [Member]", "terseLabel": "Employee Stock Purchase Plan", "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://www.ptcbio.com/role/DisclosureNetLossPerShareAntidilutiveDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r50" ] }, "us-gaap_LesseeLeaseDescriptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeaseDescriptionLineItems", "presentation": [ "http://www.ptcbio.com/role/DisclosureLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Lease, Description [Line Items]", "terseLabel": "Leases", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r584" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.ptcbio.com/role/DocumentCover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r932" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.ptcbio.com/role/DisclosureNetLossPerShare" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Text Block]", "terseLabel": "Net loss per share", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r235", "r250", "r251", "r252" ] }, "us-gaap_MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputTypeAxis", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsFairValueLiabilitiesMeasuredDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Axis]", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } }, "auth_ref": [ "r546" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit", "calculation": { "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsMarketableSecuritiesUnrealizedGainsLossesDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsMarketableSecuritiesUnrealizedGainsLossesDetails" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax", "negatedLabel": "Gross Unrealized, Loss", "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r283" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://www.ptcbio.com/role/DisclosureStockAwardPlanAssumptionsUsedDetails", "http://www.ptcbio.com/role/DisclosureStockAwardPlanNarrativeDetails", "http://www.ptcbio.com/role/DisclosureStockAwardPlanRestrictedStockDetails", "http://www.ptcbio.com/role/DisclosureStockAwardPlanStockOptionActivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r471", "r472", "r473", "r474", "r475", "r476", "r477", "r478" ] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 16.0 } }, "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement, Noncash Expense", "terseLabel": "Share-based compensation expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r8" ] }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireMarketableSecurities", "crdr": "credit", "calculation": { "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsMarketableSecuritiesDetails", "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments to Acquire Marketable Securities", "negatedLabel": "Purchases of marketable securities - equity investments", "verboseLabel": "Purchase of marketable securities - equity investments", "documentation": "Amount of cash outflow for purchase of marketable security." } } }, "auth_ref": [ "r967" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://www.ptcbio.com/role/DisclosureCapitalizationNarrativeDetails", "http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails", "http://www.ptcbio.com/role/DisclosureDebtSeniorSecuredTermLoanDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsFairValueLiabilitiesMeasuredDetails", "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillDefiniteLivedIntangiblesDetails", "http://www.ptcbio.com/role/DisclosureLeasesNarrativeDetails", "http://www.ptcbio.com/role/DisclosureRevenueRecognitionCollaborationAndRoyaltyRevenueDetails", "http://www.ptcbio.com/role/DisclosureStockAwardPlanAssumptionsUsedDetails", "http://www.ptcbio.com/role/DisclosureStockAwardPlanNarrativeDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r366", "r367", "r368", "r369", "r440", "r447", "r475", "r476", "r477", "r610", "r634", "r671", "r713", "r714", "r768", "r770", "r772", "r773", "r778", "r803", "r804", "r818", "r826", "r839", "r846", "r849", "r983", "r992", "r1039", "r1040", "r1041", "r1042", "r1043" ] }, "us-gaap_LesseeLeaseDescriptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeaseDescriptionTable", "presentation": [ "http://www.ptcbio.com/role/DisclosureLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Lease, Description [Table]", "terseLabel": "Lessee, Lease, Description [Table]", "documentation": "Disclosure of information about lessee's leases." } } }, "auth_ref": [ "r584" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "crdr": "debit", "calculation": { "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsMarketableSecuritiesUnrealizedGainsLossesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsMarketableSecuritiesUnrealizedGainsLossesDetails" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-sale, Amortized Cost", "totalLabel": "Amortized Cost", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r279", "r329", "r649" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "calculation": { "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsMarketableSecuritiesUnrealizedGainsLossesDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsMarketableSecuritiesUnrealizedGainsLossesDetails" ], "lang": { "en-us": { "role": { "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax", "terseLabel": "Gross Unrealized, Gain", "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r282" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.ptcbio.com/role/DisclosureCompanyDetails", "http://www.ptcbio.com/role/DisclosureDebtConvertibleNotesDetails", "http://www.ptcbio.com/role/DisclosureDebtConvertibleNotesInterestExpenseDetails", "http://www.ptcbio.com/role/DisclosureDebtNarrativeDetails", "http://www.ptcbio.com/role/DisclosureDebtTables", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsConvertibleSeniorNotesDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLiabilityForSaleOfFutureRoyaltiesDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r33", "r217", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r572", "r821", "r822", "r823", "r824", "r825", "r957" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of fixed assets", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r120" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 18.0 } }, "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Inventories", "negatedTerseLabel": "Inventory, net", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r8" ] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureCapitalizationNarrativeDetails", "http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsFairValueLiabilitiesMeasuredDetails", "http://www.ptcbio.com/role/DisclosureLeasesNarrativeDetails", "http://www.ptcbio.com/role/DisclosureRevenueRecognitionCollaborationAndRoyaltyRevenueDetails", "http://www.ptcbio.com/role/DisclosureStockAwardPlanAssumptionsUsedDetails", "http://www.ptcbio.com/role/DisclosureStockAwardPlanNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Maximum" } } }, "auth_ref": [ "r366", "r367", "r368", "r369", "r447", "r634", "r671", "r713", "r714", "r768", "r770", "r772", "r773", "r778", "r803", "r804", "r818", "r826", "r839", "r846", "r992", "r1038", "r1039", "r1040", "r1041", "r1042", "r1043" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureCapitalizationNarrativeDetails", "http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails", "http://www.ptcbio.com/role/DisclosureDebtSeniorSecuredTermLoanDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsFairValueLiabilitiesMeasuredDetails", "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillDefiniteLivedIntangiblesDetails", "http://www.ptcbio.com/role/DisclosureLeasesNarrativeDetails", "http://www.ptcbio.com/role/DisclosureRevenueRecognitionCollaborationAndRoyaltyRevenueDetails", "http://www.ptcbio.com/role/DisclosureStockAwardPlanAssumptionsUsedDetails", "http://www.ptcbio.com/role/DisclosureStockAwardPlanNarrativeDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r366", "r367", "r368", "r369", "r440", "r447", "r475", "r476", "r477", "r610", "r634", "r671", "r713", "r714", "r768", "r770", "r772", "r773", "r778", "r803", "r804", "r818", "r826", "r839", "r846", "r849", "r983", "r992", "r1039", "r1040", "r1041", "r1042", "r1043" ] }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]", "terseLabel": "Summary of marketable securities accounted for as available-for-sale debt securities", "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value." } } }, "auth_ref": [] }, "us-gaap_AccruedIncomeTaxesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedIncomeTaxesCurrent", "crdr": "credit", "calculation": { "http://www.ptcbio.com/role/DisclosureAccountsPayableAndAccruedExpensesComponentsDetails": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ptcbio.com/role/DisclosureAccountsPayableAndAccruedExpensesComponentsDetails" ], "lang": { "en-us": { "role": { "label": "Accrued Income Taxes, Current", "terseLabel": "Income tax payable", "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations." } } }, "auth_ref": [ "r96", "r147" ] }, "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock", "presentation": [ "http://www.ptcbio.com/role/DisclosureAccountsPayableAndAccruedExpenses" ], "lang": { "en-us": { "role": { "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]", "terseLabel": "Accounts payable and accrued expenses", "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period." } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails", "http://www.ptcbio.com/role/DisclosureDebtSeniorSecuredTermLoanDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsFairValueLiabilitiesMeasuredDetails", "http://www.ptcbio.com/role/DisclosureLeasesNarrativeDetails", "http://www.ptcbio.com/role/DisclosureStockAwardPlanAssumptionsUsedDetails", "http://www.ptcbio.com/role/DisclosureStockAwardPlanNarrativeDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Minimum" } } }, "auth_ref": [ "r366", "r367", "r368", "r369", "r447", "r634", "r671", "r713", "r714", "r768", "r770", "r772", "r773", "r778", "r803", "r804", "r818", "r826", "r839", "r846", "r992", "r1038", "r1039", "r1040", "r1041", "r1042", "r1043" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": [ "http://www.ptcbio.com/role/DisclosureNetLossPerShareNumeratorAndDenominatorDetails", "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]", "terseLabel": "Weighted-average shares outstanding:", "verboseLabel": "Denominator" } } }, "auth_ref": [] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfArrangementAxis", "presentation": [ "http://www.ptcbio.com/role/DisclosureCapitalizationNarrativeDetails", "http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails", "http://www.ptcbio.com/role/DisclosureRevenueRecognitionCollaborationAndRoyaltyRevenueDetails", "http://www.ptcbio.com/role/DisclosureSubsequentEventsDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCollaborationAndRoyaltyRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r513" ] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.ptcbio.com/role/DisclosureStockAwardPlanShareBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } }, "auth_ref": [ "r359", "r361", "r747" ] }, "us-gaap_MarketableSecuritiesPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketableSecuritiesPolicy", "presentation": [ "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Marketable Securities, Policy [Policy Text Block]", "terseLabel": "Marketable securities", "documentation": "Disclosure of accounting policy for investment classified as marketable security." } } }, "auth_ref": [ "r92" ] }, "us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOwnershipPlanESOPPlanDomain", "presentation": [ "http://www.ptcbio.com/role/DisclosureStockAwardPlanNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Employee Stock Ownership Plan (ESOP), Plan [Domain]", "documentation": "Entities identify multiple employee stock ownership plans by unique name." } } }, "auth_ref": [ "r76" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.ptcbio.com/role/DisclosureStockAwardPlanShareBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Income Statement Location [Domain]", "documentation": "Location in the income statement." } } }, "auth_ref": [ "r361", "r747" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r568", "r602" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentLineItems", "presentation": [ "http://www.ptcbio.com/role/DisclosureCompanyDetails", "http://www.ptcbio.com/role/DisclosureDebtConvertibleNotesDetails", "http://www.ptcbio.com/role/DisclosureDebtConvertibleNotesInterestExpenseDetails", "http://www.ptcbio.com/role/DisclosureDebtNarrativeDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsConvertibleSeniorNotesDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLiabilityForSaleOfFutureRoyaltiesDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Line Items]", "terseLabel": "Long-term debt", "verboseLabel": "Assigned royalty payments", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r217", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r572", "r821", "r822", "r823", "r824", "r825", "r957" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.ptcbio.com/role/DisclosureCompanyDetails", "http://www.ptcbio.com/role/DisclosureDebtConvertibleNotesDetails", "http://www.ptcbio.com/role/DisclosureDebtConvertibleNotesInterestExpenseDetails", "http://www.ptcbio.com/role/DisclosureDebtNarrativeDetails", "http://www.ptcbio.com/role/DisclosureDebtTables", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsConvertibleSeniorNotesDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLiabilityForSaleOfFutureRoyaltiesDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r23", "r95", "r96", "r146", "r149", "r217", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r572", "r821", "r822", "r823", "r824", "r825", "r957" ] }, "us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis", "presentation": [ "http://www.ptcbio.com/role/DisclosureStockAwardPlanNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Employee Stock Ownership Plan (ESOP) Name [Axis]", "documentation": "Information by name of employee stock ownership plan." } } }, "auth_ref": [ "r75" ] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTable", "presentation": [ "http://www.ptcbio.com/role/DisclosureCompanyDetails", "http://www.ptcbio.com/role/DisclosureDebtConvertibleNotesDetails", "http://www.ptcbio.com/role/DisclosureDebtConvertibleNotesInterestExpenseDetails", "http://www.ptcbio.com/role/DisclosureDebtNarrativeDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsConvertibleSeniorNotesDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLiabilityForSaleOfFutureRoyaltiesDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Long-term Debt Instruments [Table]", "terseLabel": "Schedule of Long-term Debt Instruments [Table]", "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r33", "r68", "r69", "r87", "r88", "r90", "r93", "r135", "r137", "r217", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r572", "r821", "r822", "r823", "r824", "r825", "r957" ] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsHierarchyDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsConvertibleSeniorNotesDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsFairValueLiabilitiesMeasuredDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsHierarchyDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsMarketableSecuritiesDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsSummaryOfChangesInFairValueOfCompanySLevel3ValuationDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r387", "r441", "r442", "r443", "r444", "r445", "r446", "r607", "r608", "r609", "r822", "r823", "r834", "r835", "r836" ] }, "us-gaap_PaymentsOfDebtIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsOfDebtIssuanceCosts", "crdr": "credit", "calculation": { "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Payments of Debt Issuance Costs", "negatedLabel": "Debt issuance costs related to secured term loan", "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt." } } }, "auth_ref": [ "r42" ] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "crdr": "debit", "calculation": { "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Effect of Exchange Rate on Cash and Cash Equivalents", "terseLabel": "Effect of exchange rate changes on cash", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r1031" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": [ "r918" ] }, "us-gaap_MeasurementInputDiscountRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputDiscountRateMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsFairValueLiabilitiesMeasuredDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Discount Rate", "terseLabel": "Discount Rate", "documentation": "Measurement input using interest rate to determine present value of future cash flows." } } }, "auth_ref": [ "r1026" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "presentation": [ "http://www.ptcbio.com/role/DisclosureStockAwardPlanNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized", "terseLabel": "Number of additional shares authorized (in shares)", "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_RestrictedCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCash", "crdr": "debit", "presentation": [ "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesReconciliationOfCashDetails" ], "lang": { "en-us": { "role": { "label": "Restricted Cash", "terseLabel": "Restricted cash included in deposits and other assets", "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r944", "r955", "r1045", "r1047" ] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 19.0 } }, "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r8" ] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfOperations", "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfStockholdersDeficitEquity" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "terseLabel": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r218", "r219", "r220", "r254", "r636", "r686", "r704", "r715", "r716", "r717", "r718", "r719", "r720", "r722", "r725", "r726", "r727", "r728", "r729", "r730", "r731", "r732", "r733", "r735", "r736", "r737", "r738", "r739", "r741", "r745", "r746", "r748", "r749", "r750", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r758", "r759", "r762", "r850" ] }, "ptct_PaymentOfMilestoneObligation": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "PaymentOfMilestoneObligation", "crdr": "credit", "presentation": [ "http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for milestone obligations paid.", "label": "Payment of Milestone Obligation", "terseLabel": "Milestone obligation payments made" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleConversionPrice1", "presentation": [ "http://www.ptcbio.com/role/DisclosureDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Convertible, Conversion Price", "terseLabel": "Conversion price per share (in dollars per share)", "documentation": "The price per share of the conversion feature embedded in the debt instrument." } } }, "auth_ref": [ "r133", "r381" ] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationDomain", "presentation": [ "http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsMarketableSecuritiesDetails", "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillDefiniteLivedIntangiblesDetails", "http://www.ptcbio.com/role/DisclosureRevenueRecognitionManufacturingRevenueDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Balance Sheet Location [Domain]", "documentation": "Location in the balance sheet (statement of financial position)." } } }, "auth_ref": [ "r80", "r81" ] }, "ptct_DevelopmentMilestoneObligationPaymentsMade": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "DevelopmentMilestoneObligationPaymentsMade", "crdr": "debit", "presentation": [ "http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of development milestone obligation payments made during the period.", "label": "Development Milestone Obligation Payments Made", "terseLabel": "Development milestone obligation payments made" } } }, "auth_ref": [] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillIndefiniteLivedIntangiblesDetails", "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets, net", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": [ "r60", "r64" ] }, "us-gaap_ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReceivablesTradeAndOtherAccountsReceivableAllowanceForDoubtfulAccountsPolicy", "presentation": [ "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]", "terseLabel": "Allowance for doubtful accounts", "documentation": "Disclosure of accounting policy for determining the allowance for doubtful accounts for trade and other accounts receivable balances, and when impairments, charge-offs or recoveries are recognized." } } }, "auth_ref": [ "r58" ] }, "ptct_LiabilitySaleOfFutureRoyaltiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "LiabilitySaleOfFutureRoyaltiesNoncurrent", "crdr": "credit", "calculation": { "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "documentation": "Amount of liabilities related to the sale of future royalties due after one year or the normal operating cycle, if longer.", "label": "Liability, Sale of Future Royalties, Noncurrent", "terseLabel": "Liability for sale of future royalties- noncurrent" } } }, "auth_ref": [] }, "us-gaap_GeographicConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeographicConcentrationRiskMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureRevenueRecognitionNetProductSalesDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Geographic Concentration Risk [Member]", "terseLabel": "Geographic concentration risk", "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa)." } } }, "auth_ref": [ "r53", "r791" ] }, "us-gaap_AssetAcquisitionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionDomain", "presentation": [ "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillDefiniteLivedIntangiblesDetails" ], "lang": { "en-us": { "role": { "label": "Asset Acquisition [Domain]", "documentation": "Asset acquisition." } } }, "auth_ref": [ "r1022" ] }, "us-gaap_AssetAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionAxis", "presentation": [ "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillDefiniteLivedIntangiblesDetails" ], "lang": { "en-us": { "role": { "label": "Asset Acquisition [Axis]", "documentation": "Information by asset acquisition." } } }, "auth_ref": [ "r1022" ] }, "ptct_LiabilitySaleOfFutureRoyaltiesRoyaltyRevenuePayable": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "LiabilitySaleOfFutureRoyaltiesRoyaltyRevenuePayable", "crdr": "debit", "presentation": [ "http://www.ptcbio.com/role/DisclosureDebtLiabilityForSaleOfFutureRoyaltiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of royalty revenue recognized during the period relating to the sale of future royalties payable under terms of the agreement.", "label": "Liability, Sale of Future Royalties, Royalty Revenue Payable", "negatedLabel": "Less: Non-cash royalty revenue payable to RPI" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract", "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]", "terseLabel": "Cash flows from financing activities" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.ptcbio.com/role/DisclosureNetLossPerShareNumeratorAndDenominatorDetails", "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic", "terseLabel": "Basic", "verboseLabel": "Net loss per share - Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r202", "r226", "r227", "r228", "r229", "r230", "r236", "r239", "r247", "r248", "r249", "r253", "r540", "r541", "r645", "r661", "r815" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillFutureAmortizationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillDefiniteLivedIntangiblesDetails", "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillFutureAmortizationDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Net", "totalLabel": "Total", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r127", "r637" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsRecurringMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsHierarchyDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Recurring basis", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r543", "r552" ] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillGoodwillDetails", "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Goodwill", "terseLabel": "Goodwill", "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r180", "r341", "r642", "r820", "r844", "r980", "r981" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract", "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]", "terseLabel": "Cash flows from investing activities" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "presentation": [ "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillDefiniteLivedIntangiblesDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Gross", "periodEndLabel": "Ending balance - Definite-lived assets, Gross", "periodStartLabel": "Beginning balance - Definite-lived assets, Gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r127", "r641" ] }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1", "crdr": "credit", "calculation": { "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Asset", "negatedTerseLabel": "Change in the fair value of contingent consideration", "documentation": "Amount of increase (decrease) in the value of right to a contingent consideration asset." } } }, "auth_ref": [ "r512", "r953" ] }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "crdr": "debit", "calculation": { "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "terseLabel": "Change in valuation of contingent consideration", "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement." } } }, "auth_ref": [ "r512", "r953" ] }, "us-gaap_FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsRemainingAmortizationPeriod1", "presentation": [ "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillDefiniteLivedIntangiblesDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Remaining Amortization Period", "terseLabel": "Remaining amortization period", "documentation": "Remaining amortization period of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r637" ] }, "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy", "presentation": [ "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets, Intangible Assets, Indefinite-Lived, Policy [Policy Text Block]", "terseLabel": "Indefinite-lived intangible assets", "documentation": "Disclosure of accounting policy for indefinite-lived intangible assets (that is, those intangible assets not subject to amortization). This accounting policy also may address how the entity assesses whether events and circumstances continue to support an indefinite useful life and how the entity assesses and measures impairment of such assets." } } }, "auth_ref": [ "r129" ] }, "ptct_LiabilityDevelopmentandRegulatoryMilestoneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "LiabilityDevelopmentandRegulatoryMilestoneMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsFairValueLiabilitiesMeasuredDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsHierarchyDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsSummaryOfChangesInFairValueOfCompanySLevel3ValuationDetails" ], "lang": { "en-us": { "role": { "documentation": "Liability, Development and Regulatory Milestone [Member]", "label": "Development and Regulatory Milestones", "terseLabel": "Development and Regulatory Milestones" } } }, "auth_ref": [] }, "us-gaap_GoodwillLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillLineItems", "presentation": [ "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillGoodwillDetails" ], "lang": { "en-us": { "role": { "label": "Goodwill [Line Items]", "terseLabel": "Goodwill", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r820" ] }, "us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsGoodwillPolicy", "presentation": [ "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]", "terseLabel": "Goodwill", "documentation": "Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined." } } }, "auth_ref": [ "r340", "r352", "r820" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill", "crdr": "debit", "presentation": [ "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillIndefiniteLivedIntangiblesDetails" ], "lang": { "en-us": { "role": { "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance", "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": [ "r129" ] }, "us-gaap_ScheduleOfGoodwillTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfGoodwillTable", "presentation": [ "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillGoodwillDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Goodwill [Table]", "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons." } } }, "auth_ref": [ "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r820" ] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": [ "http://www.ptcbio.com/role/DisclosureLeasesLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "terseLabel": "Less: Imputed Interest expense", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r594" ] }, "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": { "xbrltype": "booleanItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend", "presentation": [ "http://www.ptcbio.com/role/DisclosureLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]", "documentation": "Indicates (true false) whether lessee has option to extend operating lease." } } }, "auth_ref": [ "r585" ] }, "us-gaap_LesseeLeasesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeLeasesPolicyTextBlock", "presentation": [ "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases", "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee." } } }, "auth_ref": [ "r583" ] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": [ "http://www.ptcbio.com/role/DisclosureLeasesLeasePaymentsDetails", "http://www.ptcbio.com/role/DisclosureLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability", "verboseLabel": "Total", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r578" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease liabilities- current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r578" ] }, "ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedExercisePriceAsPercentageOfFairMarketValueOfCommonStock": { "xbrltype": "percentItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedExercisePriceAsPercentageOfFairMarketValueOfCommonStock", "presentation": [ "http://www.ptcbio.com/role/DisclosureStockAwardPlanNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the exercise price expressed as a percentage of the fair market value of the common stock as of the date of grant, at which grantees can acquire the shares reserved for issuance of stock options awarded.", "label": "Share Based Compensation Arrangement by Share Based Payment Award Options Granted Exercise Price as Percentage of Fair Market Value of Common Stock", "terseLabel": "Stock options granted, exercise price as percentage of the fair market value of common stock at grant date" } } }, "auth_ref": [] }, "us-gaap_InventoryRawMaterials": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryRawMaterials", "crdr": "debit", "calculation": { "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesInventoryDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesInventoryDetails" ], "lang": { "en-us": { "role": { "label": "Inventory, Raw Materials, Gross", "terseLabel": "Raw materials", "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r948" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureStockAwardPlanNarrativeDetails", "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfStockholdersDeficitEquity" ], "lang": { "en-us": { "role": { "label": "Common stock", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r847", "r848", "r849", "r851", "r852", "r853", "r854", "r960", "r961", "r1024", "r1051", "r1054" ] }, "ptct_MilestoneDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "MilestoneDomain", "presentation": [ "http://www.ptcbio.com/role/DisclosureRevenueRecognitionCollaborationAndRoyaltyRevenueDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCollaborationAndRoyaltyRevenueDetails" ], "lang": { "en-us": { "role": { "documentation": "Different categories of milestones defined by agreements.", "label": "Milestone [Domain]" } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.ptcbio.com/role/DisclosureStockAwardPlanStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Vested or Expected to vest at the end of the period", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r473" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liabilities- noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r578" ] }, "ptct_DebtInstrumentConvertibleThresholdSalePriceOfCommonStockConversionRateProductPercentageMaximum": { "xbrltype": "percentItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "DebtInstrumentConvertibleThresholdSalePriceOfCommonStockConversionRateProductPercentageMaximum", "presentation": [ "http://www.ptcbio.com/role/DisclosureDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the maximum product of the closing sale price of shares of the entity's common stock and the applicable conversion rate for such trading day.", "label": "Debt Instrument Convertible Threshold Sale Price Of Common Stock Conversion Rate Product Percentage Maximum", "terseLabel": "Maximum product of the closing sale price of shares of the Company's common stock and the applicable conversion rate for such trading day" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentInterestRateIncreaseDecrease": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateIncreaseDecrease", "presentation": [ "http://www.ptcbio.com/role/DisclosureDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Interest Rate, Increase (Decrease)", "terseLabel": "Incremental interest rate per annum", "documentation": "Incremental percentage increase (decrease) in the stated rate on a debt instrument." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://www.ptcbio.com/role/DisclosureStockAwardPlanStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Outstanding at the end of the period", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r139" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.ptcbio.com/role/DisclosureCompanyDetails", "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Accumulated deficit", "verboseLabel": "Retained earnings (accumulated deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r103", "r138", "r654", "r678", "r683", "r692", "r723", "r844" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r55", "r56", "r57", "r160", "r161", "r162", "r163" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.ptcbio.com/role/DisclosureStockAwardPlanStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Exercisable at the end of the period", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r70" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://www.ptcbio.com/role/DisclosureStockAwardPlanAssumptionsUsedDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected term (in years)", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r474" ] }, "us-gaap_BaseRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BaseRateMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureDebtSeniorSecuredTermLoanDetails" ], "lang": { "en-us": { "role": { "label": "Base Rate [Member]", "terseLabel": "Base Rate", "documentation": "Minimum rate investor will accept." } } }, "auth_ref": [] }, "us-gaap_AreaOfRealEstateProperty": { "xbrltype": "areaItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AreaOfRealEstateProperty", "presentation": [ "http://www.ptcbio.com/role/DisclosureLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Area of Real Estate Property", "terseLabel": "Area of real estate property", "documentation": "Area of a real estate property." } } }, "auth_ref": [] }, "us-gaap_InventoryWorkInProcess": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryWorkInProcess", "crdr": "debit", "calculation": { "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesInventoryDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesInventoryDetails" ], "lang": { "en-us": { "role": { "label": "Inventory, Work in Process, Gross", "terseLabel": "Work in progress", "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r947" ] }, "ptct_Numberofdistributors": { "xbrltype": "integerItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "Numberofdistributors", "presentation": [ "http://www.ptcbio.com/role/DisclosureRevenueRecognitionNetProductSalesDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of Distributors", "label": "Number of distributors", "terseLabel": "Number of distributors" } } }, "auth_ref": [] }, "us-gaap_VariableRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateDomain", "presentation": [ "http://www.ptcbio.com/role/DisclosureDebtSeniorSecuredTermLoanDetails" ], "lang": { "en-us": { "role": { "label": "Variable Rate [Domain]", "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "auth_ref": [] }, "us-gaap_VariableRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateAxis", "presentation": [ "http://www.ptcbio.com/role/DisclosureDebtSeniorSecuredTermLoanDetails" ], "lang": { "en-us": { "role": { "label": "Variable Rate [Axis]", "documentation": "Information by type of variable rate." } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "presentation": [ "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "verboseLabel": "Federal income tax statutory rate", "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)." } } }, "auth_ref": [ "r214", "r494", "r507" ] }, "ptct_DevelopmentMilestonePaymentObligations": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "DevelopmentMilestonePaymentObligations", "crdr": "credit", "presentation": [ "http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the development milestones payments which the entity is obligated to pay under certain contractual agreements.", "label": "Development Milestone Payment Obligation", "terseLabel": "Development milestone payment obligations" } } }, "auth_ref": [] }, "ptct_AssignedRoyaltyPaymentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "AssignedRoyaltyPaymentsMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLiabilityForSaleOfFutureRoyaltiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Debt related to payment of assigned future sales-based royalty payments.", "label": "Assigned Royalty Payments" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentRedemptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentRedemptionTable", "presentation": [ "http://www.ptcbio.com/role/DisclosureDebtTables" ], "lang": { "en-us": { "role": { "label": "Debt Instrument Redemption [Table]", "terseLabel": "Debt Instrument Redemption [Table]", "documentation": "Disclosure of information about debt instruments or arrangements with redemption features. Includes, but is not limited to, description of debt redemption features, percentage price at which debt can be redeemed by the issuer, and period start and end for debt maturity or redemption." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": [ "http://www.ptcbio.com/role/DisclosureCapitalizationNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Sale of Stock, Number of Shares Issued in Transaction", "terseLabel": "Number of shares issued in transaction (in shares)", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": [] }, "ptct_MinimumPercentageOfDebtPrincipalAmountByInstrumentHolders": { "xbrltype": "percentItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "MinimumPercentageOfDebtPrincipalAmountByInstrumentHolders", "presentation": [ "http://www.ptcbio.com/role/DisclosureDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the minimum percentage of debt principal amount by instrument holders.", "label": "Minimum Percentage Of Debt Principal Amount By Instrument Holders", "terseLabel": "Minimum percentage of principal held by convertible debt instrument holders required to issue notice for declaration of principal and unpaid interest payable upon events of default" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Contract with Customer, Liability, Current", "terseLabel": "Deferred revenue", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": [ "r416", "r417", "r437" ] }, "us-gaap_DebtInstrumentRedemptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentRedemptionLineItems", "presentation": [ "http://www.ptcbio.com/role/DisclosureDebtTables" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Redemption [Line Items]", "terseLabel": "Debt Instrument, Redemption [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiability", "crdr": "credit", "presentation": [ "http://www.ptcbio.com/role/DisclosureRevenueRecognitionManufacturingRevenueDetails", "http://www.ptcbio.com/role/DisclosureRevenueRecognitionNetProductSalesDetails" ], "lang": { "en-us": { "role": { "label": "Contract with Customer, Liability", "terseLabel": "Contract with customer, liability", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r416", "r417", "r437" ] }, "us-gaap_ConvertibleDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebtSecuritiesMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Convertible Debt Securities [Member]", "terseLabel": "ClearPoint convertible debt", "documentation": "Debt securities that can be exchanged for equity of the debt issuer at the option of the issuer or the holder." } } }, "auth_ref": [ "r995" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsLineItems", "presentation": [ "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillDefiniteLivedIntangiblesDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets [Line Items]", "verboseLabel": "Definite-lived intangible assets", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r637" ] }, "ptct_RoyaltyPharmaInvestments2019IcavMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "RoyaltyPharmaInvestments2019IcavMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Royalty Pharma Investments 2019 ICAV.", "label": "Royalty Pharma Investments 2019 ICAV [Member]", "terseLabel": "Royalty Pharma" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract", "presentation": [ "http://www.ptcbio.com/role/DisclosureStockAwardPlanAssumptionsUsedDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]", "terseLabel": "Valuation assumptions" } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillDefiniteLivedIntangiblesDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r62", "r65" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber", "presentation": [ "http://www.ptcbio.com/role/DisclosureStockAwardPlanStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number", "terseLabel": "Vested or Expected to vest at the end of the period (in shares)", "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r473" ] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillDefiniteLivedIntangiblesDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r353", "r355", "r356", "r358", "r637", "r641" ] }, "ptct_AdditionalCashConsiderationReceivableForRemainderRetainedRoyaltyRights": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "AdditionalCashConsiderationReceivableForRemainderRetainedRoyaltyRights", "crdr": "debit", "presentation": [ "http://www.ptcbio.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of additional cash consideration receivable after the closing of the A&R Royalty Purchase Agreement less royalties received in respect of the Retained Royalty Rights.", "label": "Additional Cash Consideration Receivable for Remainder Retained Royalty Rights", "terseLabel": "Additional cash consideration" } } }, "auth_ref": [] }, "ptct_NumberOfPutOptionsHeldByCompany": { "xbrltype": "integerItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "NumberOfPutOptionsHeldByCompany", "presentation": [ "http://www.ptcbio.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of put options held by the company.", "label": "Number of Put Options Held by Company", "terseLabel": "Number of put options held by the company" } } }, "auth_ref": [] }, "ptct_AmendedAndRestatedRoyaltyPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "AmendedAndRestatedRoyaltyPurchaseAgreementMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the information pertaining to Amended and Restated Royalty Purchase Agreement.", "label": "Amended and Restated Royalty Purchase Agreement [Member]", "terseLabel": "A&R Royalty Purchase Agreement" } } }, "auth_ref": [] }, "ptct_BioElectronMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "BioElectronMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "BioElectron [Member]", "label": "BioElectron" } } }, "auth_ref": [] }, "ptct_PercentageOfRetainedRoyaltyRightsSold": { "xbrltype": "percentItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "PercentageOfRetainedRoyaltyRightsSold", "presentation": [ "http://www.ptcbio.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of retained royalty rights sold.", "label": "Percentage of Retained Royalty Rights Sold", "terseLabel": "Retained Royalty Rights percentage sold" } } }, "auth_ref": [] }, "ptct_PercentageOfMaximumRoyaltyPayableUntilAssignedRoyaltyRights": { "xbrltype": "percentItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "PercentageOfMaximumRoyaltyPayableUntilAssignedRoyaltyRights", "presentation": [ "http://www.ptcbio.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of maximum royalty payable until assigned royalty rights", "label": "Percentage of Maximum Royalty Payable Until Assigned Royalty Rights", "terseLabel": "Percentage of maximum royalty payable until assigned royalty rights" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": [ "http://www.ptcbio.com/role/DisclosureStockAwardPlanStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Number of options", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "calculation": { "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillDefiniteLivedIntangiblesDetails", "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Amortization of Intangible Assets", "negatedLabel": "Amortization", "terseLabel": "Amortization of intangible assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r9", "r61", "r66" ] }, "ptct_PercentageOfTotalRoyaltyPayableAfterThresholdRoyaltiesReceived": { "xbrltype": "percentItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "PercentageOfTotalRoyaltyPayableAfterThresholdRoyaltiesReceived", "presentation": [ "http://www.ptcbio.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of total royalty payable after threshold royalties received.", "label": "Percentage of Total Royalty Payable After Threshold Royalties Received", "verboseLabel": "Percentage of total royalty payable after threshold royalties received" } } }, "auth_ref": [] }, "us-gaap_AmortizationOfFinancingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AmortizationOfFinancingCosts", "crdr": "debit", "calculation": { "http://www.ptcbio.com/role/DisclosureDebtSeniorSecuredTermLoanDetails": { "parentTag": "us-gaap_InterestExpenseDebt", "weight": 1.0, "order": 2.0 }, "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 15.0 } }, "presentation": [ "http://www.ptcbio.com/role/DisclosureDebtConvertibleNotesInterestExpenseDetails", "http://www.ptcbio.com/role/DisclosureDebtSeniorSecuredTermLoanDetails", "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Amortization of Debt Issuance Costs", "terseLabel": "Amortization of debt issuance costs", "documentation": "Amount of amortization expense attributable to debt issuance costs." } } }, "auth_ref": [ "r114", "r394", "r571", "r954" ] }, "ptct_CashConsiderationForRetainedRoyaltyPercentage": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "CashConsiderationForRetainedRoyaltyPercentage", "crdr": "debit", "presentation": [ "http://www.ptcbio.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of cash inflow from royalty purchase agreement as consideration for royalty for company's retained royalty percentage.", "label": "Cash Consideration for Retained Royalty Percentage", "terseLabel": "Cash consideration" } } }, "auth_ref": [] }, "ptct_MaximumNumberOfPutOptionsWhichCanBeExercisedBeforeCallOptionCanBeTriggered": { "xbrltype": "integerItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "MaximumNumberOfPutOptionsWhichCanBeExercisedBeforeCallOptionCanBeTriggered", "presentation": [ "http://www.ptcbio.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of put options which can be exercised before a call option can be triggered under the terms of the agreement.", "label": "Maximum Number of Put Options Which Can Be Exercised Before Call Option Can Be Triggered", "terseLabel": "Maximum number of put options which can be exercised before Royalty Pharma can exercise a call option" } } }, "auth_ref": [] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r895" ] }, "ptct_PercentageOfTotalRoyaltyAssigned": { "xbrltype": "percentItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "PercentageOfTotalRoyaltyAssigned", "presentation": [ "http://www.ptcbio.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Total percentage of royalty rights assigned.", "label": "Percentage of Total Royalty Assigned", "terseLabel": "Total percentage of royalty rights assigned" } } }, "auth_ref": [] }, "ptct_MaximumPercentageOfRemainingRetainedRoyaltyRightsAvailableUnderCallOption": { "xbrltype": "percentItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "MaximumPercentageOfRemainingRetainedRoyaltyRightsAvailableUnderCallOption", "presentation": [ "http://www.ptcbio.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Maximum percentage of remaining retained royalty rights that are available upon exercise of call option under terms for agreement.", "label": "Maximum Percentage of Remaining Retained Royalty Rights Available Under Call Option", "verboseLabel": "Maximum percentage of remaining retained royalty rights that are available upon exercise of call option" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "presentation": [ "http://www.ptcbio.com/role/DisclosureStockAwardPlanStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]", "terseLabel": "Weighted- average remaining contractual term" } } }, "auth_ref": [] }, "ptct_WellcomeTrustLimitedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "WellcomeTrustLimitedMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to The Wellcome Trust Limited.", "label": "Wellcome trust", "terseLabel": "Wellcome Trust" } } }, "auth_ref": [] }, "ptct_PercentageOfMaximumRoyaltyPayableThereafterAssignedRoyaltyRights": { "xbrltype": "percentItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "PercentageOfMaximumRoyaltyPayableThereafterAssignedRoyaltyRights", "presentation": [ "http://www.ptcbio.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of maximum royalty payable thereafter assigned royalty rights.", "label": "Percentage of Maximum Royalty Payable Thereafter Assigned Royalty Rights", "terseLabel": "Percentage of maximum royalty payable thereafter assigned royalty rights" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets, Current", "totalLabel": "Total current assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r177", "r191", "r213", "r309", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r514", "r516", "r557", "r844", "r990", "r991", "r1036" ] }, "us-gaap_ConvertibleDebtFairValueDisclosures": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebtFairValueDisclosures", "crdr": "credit", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Convertible Debt, Fair Value Disclosures", "terseLabel": "ClearPoint convertible debt security", "documentation": "Fair value portion of borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "presentation": [ "http://www.ptcbio.com/role/DisclosureStockAwardPlanRestrictedStockDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Number of Shares", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": [ "r918" ] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation and amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r9", "r260" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfComprehensiveLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 }, "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows", "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfComprehensiveLoss", "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfOperations", "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfStockholdersDeficitEquity", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss attributable to common stockholders", "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r112", "r123", "r153", "r176", "r192", "r195", "r200", "r213", "r222", "r226", "r227", "r228", "r229", "r232", "r233", "r245", "r257", "r263", "r267", "r269", "r309", "r370", "r371", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r541", "r557", "r658", "r743", "r760", "r761", "r817", "r855", "r990" ] }, "us-gaap_ShortTermLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermLeaseCost", "crdr": "debit", "calculation": { "http://www.ptcbio.com/role/DisclosureLeasesLeaseCostsDetails": { "parentTag": "ptct_LeaseCostExcludingFinanceLeaseCosts", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ptcbio.com/role/DisclosureLeasesLeaseCostsDetails" ], "lang": { "en-us": { "role": { "label": "Short-term Lease, Cost", "terseLabel": "Short-term lease cost", "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less." } } }, "auth_ref": [ "r588", "r843" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "presentation": [ "http://www.ptcbio.com/role/DisclosureNetLossPerShareNumeratorAndDenominatorDetails" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Basic", "terseLabel": "Net loss - Basic", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r204", "r226", "r227", "r228", "r229", "r236", "r237", "r246", "r249", "r257", "r263", "r267", "r269", "r817" ] }, "us-gaap_OperatingLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseCost", "crdr": "debit", "calculation": { "http://www.ptcbio.com/role/DisclosureLeasesLeaseCostsDetails": { "parentTag": "ptct_LeaseCostExcludingFinanceLeaseCosts", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.ptcbio.com/role/DisclosureLeasesLeaseCostsDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Cost", "terseLabel": "Fixed lease cost", "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability." } } }, "auth_ref": [ "r587", "r843" ] }, "us-gaap_InvestmentTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentTypeAxis", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "label": "Investment Type [Axis]", "documentation": "Information by type of investments." } } }, "auth_ref": [ "r705", "r707", "r708", "r710", "r712", "r767", "r769", "r771", "r774", "r775", "r776", "r777", "r779", "r780", "r781", "r782", "r783", "r849" ] }, "us-gaap_VariableLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableLeaseCost", "crdr": "debit", "calculation": { "http://www.ptcbio.com/role/DisclosureLeasesLeaseCostsDetails": { "parentTag": "ptct_LeaseCostExcludingFinanceLeaseCosts", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ptcbio.com/role/DisclosureLeasesLeaseCostsDetails" ], "lang": { "en-us": { "role": { "label": "Variable Lease, Cost", "terseLabel": "Variable lease cost", "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases." } } }, "auth_ref": [ "r589", "r843" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice", "presentation": [ "http://www.ptcbio.com/role/DisclosureStockAwardPlanStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price", "terseLabel": "Vested or Expected to vest at the end of the period (in dollars per share)", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r473" ] }, "us-gaap_FinanceLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": [ "http://www.ptcbio.com/role/DisclosureLeasesLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Finance Lease, Liability, Undiscounted Excess Amount", "terseLabel": "Less: Imputed Interest expense", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for finance lease." } } }, "auth_ref": [ "r594" ] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.ptcbio.com/role/DisclosureAccountsPayableAndAccruedExpensesComponentsDetails": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ptcbio.com/role/DisclosureAccountsPayableAndAccruedExpensesComponentsDetails" ], "lang": { "en-us": { "role": { "label": "Employee-related Liabilities, Current", "terseLabel": "Employee compensation, benefits, and related accruals", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r29" ] }, "us-gaap_OtherCommitmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherCommitmentsAbstract", "presentation": [ "http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Other Commitments [Abstract]", "terseLabel": "Other Commitments" } } }, "auth_ref": [] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": [ "r899" ] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ptcbio.com/role/DisclosureRevenueRecognitionCollaborationAndRoyaltyRevenueDetails", "http://www.ptcbio.com/role/DisclosureRevenueRecognitionManufacturingRevenueDetails", "http://www.ptcbio.com/role/DisclosureRevenueRecognitionNetProductSalesDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCollaborationAndRoyaltyRevenueDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesManufacturingRevenueDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails", "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Revenue", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r258", "r259", "r262", "r265", "r266", "r270", "r271", "r273", "r435", "r436", "r636" ] }, "us-gaap_FinanceLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiability", "crdr": "credit", "presentation": [ "http://www.ptcbio.com/role/DisclosureLeasesLeasePaymentsDetails", "http://www.ptcbio.com/role/DisclosureLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Finance Lease, Liability", "terseLabel": "Total", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease." } } }, "auth_ref": [ "r578", "r594" ] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r899" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.ptcbio.com/role/DocumentCover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r858" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": [ "r899" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.ptcbio.com/role/DocumentCover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiabilityRevenueRecognized", "crdr": "credit", "presentation": [ "http://www.ptcbio.com/role/DisclosureRevenueRecognitionManufacturingRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Contract with Customer, Liability, Revenue Recognized", "terseLabel": "Contract liability revenues recognized in period", "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due." } } }, "auth_ref": [ "r438" ] }, "us-gaap_FinanceLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.ptcbio.com/role/DisclosureLeasesNarrativeDetails", "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Finance Lease, Liability, Current", "terseLabel": "Finance lease liabilities- current", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current." } } }, "auth_ref": [ "r578" ] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LegalEntityAxis", "presentation": [ "http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": [ "r900" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Other Nonoperating Income (Expense)", "verboseLabel": "Other expense, net", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r118" ] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityDomain", "presentation": [ "http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "us-gaap_DeferredFinanceCostsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredFinanceCostsGross", "crdr": "debit", "presentation": [ "http://www.ptcbio.com/role/DisclosureDebtSeniorSecuredTermLoanDetails" ], "lang": { "en-us": { "role": { "label": "Debt Issuance Costs, Gross", "terseLabel": "Debt issuance costs capitalized", "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": [ "r89" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDue", "crdr": "credit", "calculation": { "http://www.ptcbio.com/role/DisclosureLeasesLeasePaymentsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ptcbio.com/role/DisclosureLeasesLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Finance Lease, Liability, Payment, Due", "totalLabel": "Total lease payments", "documentation": "Amount of lessee's undiscounted obligation for lease payments for finance lease." } } }, "auth_ref": [ "r594" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": [ "r900" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": [ "r900" ] }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable", "presentation": [ "http://www.ptcbio.com/role/DisclosureRevenueRecognitionPerformanceObligationsDetails" ], "lang": { "en-us": { "role": { "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]", "documentation": "Disclosure of information about expected timing for satisfying remaining performance obligation." } } }, "auth_ref": [] }, "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems", "presentation": [ "http://www.ptcbio.com/role/DisclosureRevenueRecognitionPerformanceObligationsDetails" ], "lang": { "en-us": { "role": { "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]", "terseLabel": "Remaining Performance Obligation", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.ptcbio.com/role/DocumentCover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": [ "r900" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.ptcbio.com/role/DocumentCover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r858" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": [ "r900" ] }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.ptcbio.com/role/DisclosureLeasesNarrativeDetails", "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Finance Lease, Liability, Noncurrent", "terseLabel": "Finance lease liabilities- noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent." } } }, "auth_ref": [ "r578" ] }, "us-gaap_ContractWithCustomerAssetNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerAssetNetCurrent", "crdr": "debit", "presentation": [ "http://www.ptcbio.com/role/DisclosureRevenueRecognitionManufacturingRevenueDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesManufacturingRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Current", "terseLabel": "Contract with customer, asset", "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current." } } }, "auth_ref": [ "r416", "r418", "r437" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": [ "r900" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.ptcbio.com/role/DocumentCover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "us-gaap_NonUsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonUsMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureRevenueRecognitionNetProductSalesDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Non-US", "documentation": "Countries excluding the United States of America (US)." } } }, "auth_ref": [ "r1056", "r1058", "r1059", "r1060" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": [ "r862", "r873", "r883", "r908" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.ptcbio.com/role/DocumentCover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureRevenueRecognitionNetProductSalesDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer Benchmark [Member]", "terseLabel": "Net product revenue", "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": [ "r273", "r934" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": [ "r900" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementGeographicalAxis", "presentation": [ "http://www.ptcbio.com/role/DisclosureRevenueRecognitionNetProductSalesDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "auth_ref": [ "r271", "r272", "r706", "r709", "r711", "r769", "r771", "r775", "r779", "r790", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r807", "r828", "r849", "r993", "r1049" ] }, "ptct_AkceaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "AkceaMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails", "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillDefiniteLivedIntangiblesDetails" ], "lang": { "en-us": { "role": { "documentation": "Akcea [Member]", "label": "Akcea" } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowElementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowElementsAbstract", "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Elements [Abstract]", "terseLabel": "Supplemental disclosure of non-cash investing and financing activity" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": [ "http://www.ptcbio.com/role/DisclosureRevenueRecognition" ], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "Revenue recognition", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": [ "r169", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r439" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": [ "r901" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "calculation": { "http://www.ptcbio.com/role/DisclosureLeasesLeasePaymentsDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ptcbio.com/role/DisclosureLeasesLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Finance Lease, Liability, to be Paid, Year One", "terseLabel": "2024", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r594" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": [ "r864", "r875", "r885", "r910" ] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.ptcbio.com/role/DisclosureAccountsPayableAndAccruedExpensesComponentsDetails": { "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.ptcbio.com/role/DisclosureAccountsPayableAndAccruedExpensesComponentsDetails" ], "lang": { "en-us": { "role": { "label": "Other Accrued Liabilities, Current", "terseLabel": "Other", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r29" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.ptcbio.com/role/DocumentCover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "crdr": "credit", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsFairValueLiabilitiesMeasuredDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsSummaryOfChangesInFairValueOfCompanySLevel3ValuationDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "periodEndLabel": "Ending Balance", "periodStartLabel": "Beginning Balance", "verboseLabel": "Fair value", "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r15" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": { "http://www.ptcbio.com/role/DisclosureLeasesLeasePaymentsDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.ptcbio.com/role/DisclosureLeasesLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Finance Lease, Liability, Payments, Due Year Three", "terseLabel": "2026", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r594" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": [ "r903" ] }, "us-gaap_FinanceLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": { "http://www.ptcbio.com/role/DisclosureLeasesLeasePaymentsDetails": { "parentTag": "us-gaap_FinanceLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ptcbio.com/role/DisclosureLeasesLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Finance Lease, Liability, Payments, Due Year Two", "terseLabel": "2025", "documentation": "Amount of lessee's undiscounted obligation for lease payment for finance lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r594" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": [ "r902" ] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": [ "r906" ] }, "us-gaap_FinanceLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.ptcbio.com/role/DisclosureLeasesTables" ], "lang": { "en-us": { "role": { "label": "Finance Lease, Liability, Fiscal Year Maturity [Table Text Block]", "terseLabel": "Schedule of future lease payments - Finance leases", "documentation": "Tabular disclosure of undiscounted cash flows of finance lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to finance lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r1035" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": [ "r862", "r873", "r883", "r908" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": [ "r904" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.ptcbio.com/role/DocumentCover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r858" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": [ "r905" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": [ "r905" ] }, "us-gaap_UnamortizedDebtIssuanceExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnamortizedDebtIssuanceExpense", "crdr": "debit", "calculation": { "http://www.ptcbio.com/role/DisclosureDebtConvertibleNotesDetails": { "parentTag": "us-gaap_LongTermDebt", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.ptcbio.com/role/DisclosureDebtConvertibleNotesDetails", "http://www.ptcbio.com/role/DisclosureDebtSeniorSecuredTermLoanDetails" ], "lang": { "en-us": { "role": { "label": "Unamortized Debt Issuance Expense", "negatedLabel": "Less: Debt issuance costs", "documentation": "The remaining balance of debt issuance expenses that were capitalized and are being amortized against income over the lives of the respective bond issues. This does not include the amounts capitalized as part of the cost of the utility plant or asset." } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseInterestPaymentOnLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseInterestPaymentOnLiability", "crdr": "credit", "presentation": [ "http://www.ptcbio.com/role/DisclosureLeasesCashFlowDetails" ], "lang": { "en-us": { "role": { "label": "Finance Lease, Interest Payment on Liability", "terseLabel": "Operating cash flows from finance leases", "documentation": "Amount of interest paid on finance lease liability." } } }, "auth_ref": [ "r581", "r590" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://www.ptcbio.com/role/DisclosureStockAwardPlan" ], "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Text Block]", "terseLabel": "Stock award plan", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r448", "r452", "r480", "r481", "r483", "r840" ] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://www.ptcbio.com/role/DisclosureDebtConvertibleNotesDetails", "http://www.ptcbio.com/role/DisclosureDebtConvertibleNotesInterestExpenseDetails", "http://www.ptcbio.com/role/DisclosureDebtNarrativeDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsConvertibleSeniorNotesDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesLiabilityForSaleOfFutureRoyaltiesDetails" ], "lang": { "en-us": { "role": { "label": "Long-term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r33" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.ptcbio.com/role/DocumentCover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.ptcbio.com/role/DocumentCover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.ptcbio.com/role/DocumentCover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r865", "r876", "r886", "r911" ] }, "us-gaap_NatureOfOperations": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NatureOfOperations", "presentation": [ "http://www.ptcbio.com/role/DisclosureCompany" ], "lang": { "en-us": { "role": { "label": "Nature of Operations [Text Block]", "terseLabel": "The Company", "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward." } } }, "auth_ref": [ "r159", "r168" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "SegmentGeographicalDomain", "presentation": [ "http://www.ptcbio.com/role/DisclosureRevenueRecognitionNetProductSalesDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]" } } }, "auth_ref": [ "r271", "r272", "r706", "r709", "r711", "r769", "r771", "r775", "r779", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r807", "r828", "r849", "r993", "r1049" ] }, "us-gaap_DebtInstrumentConvertibleConversionRatio1": { "xbrltype": "pureItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleConversionRatio1", "presentation": [ "http://www.ptcbio.com/role/DisclosureDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Convertible, Conversion Ratio", "terseLabel": "Conversion ratio", "documentation": "Ratio applied to the conversion of debt instrument into equity with equity shares divided by debt principal amount." } } }, "auth_ref": [ "r32", "r68", "r136", "r137", "r381" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.ptcbio.com/role/DocumentCover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseInterestExpense", "crdr": "debit", "presentation": [ "http://www.ptcbio.com/role/DisclosureLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Finance Lease, Interest Expense", "terseLabel": "Finance lease cost", "documentation": "Amount of interest expense on finance lease liability." } } }, "auth_ref": [ "r579", "r586", "r843" ] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": [ "r863", "r874", "r884", "r909" ] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Income Taxes Paid, Net", "terseLabel": "Cash paid for income taxes", "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes." } } }, "auth_ref": [ "r45" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.ptcbio.com/role/DisclosureCommitmentsAndContingencies" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and contingencies", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r130", "r364", "r365", "r792", "r985" ] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r197", "r489", "r490", "r495", "r496", "r498", "r499", "r687" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues", "crdr": "credit", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsSummaryOfChangesInFairValueOfCompanySLevel3ValuationDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances", "terseLabel": "Additions", "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r83" ] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Operating Income (Loss)", "totalLabel": "Loss from operations", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r257", "r263", "r267", "r269", "r817" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements", "crdr": "debit", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsSummaryOfChangesInFairValueOfCompanySLevel3ValuationDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements", "negatedLabel": "Rights Exchange settlement", "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r83" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfComprehensiveLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfComprehensiveLoss" ], "lang": { "en-us": { "role": { "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r38", "r194", "r196", "r201", "r644", "r660" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsFairValueLiabilitiesMeasuredDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsSummaryOfChangesInFairValueOfCompanySLevel3ValuationDetails", "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillGoodwillDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r77", "r78", "r508", "r837", "r838" ] }, "ptct_SalesMilestonesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "SalesMilestonesMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsFairValueLiabilitiesMeasuredDetails", "http://www.ptcbio.com/role/DisclosureRevenueRecognitionCollaborationAndRoyaltyRevenueDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCollaborationAndRoyaltyRevenueDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to certain sales events on the basis of which certain milestones are achieved.", "label": "Sales Milestones" } } }, "auth_ref": [] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "label": "Leases" } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationLiabilityTransfersOutOfLevel3", "crdr": "debit", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsSummaryOfChangesInFairValueOfCompanySLevel3ValuationDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Liability, Transfers out of Level 3", "negatedLabel": "Reclass to accounts payable and accrued expenses", "documentation": "Amount of transfers of financial instrument classified as a liability out of level 3 of the fair value hierarchy." } } }, "auth_ref": [ "r550" ] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsFairValueLiabilitiesMeasuredDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsSummaryOfChangesInFairValueOfCompanySLevel3ValuationDetails", "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillGoodwillDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r508", "r837", "r838" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' deficit", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r106", "r151", "r655", "r844", "r958", "r976", "r1028" ] }, "us-gaap_LettersOfCreditOutstandingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LettersOfCreditOutstandingAmount", "crdr": "credit", "presentation": [ "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Letters of Credit Outstanding, Amount", "terseLabel": "Letters of credit", "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date." } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "verboseLabel": "Liabilities and stockholders' (deficit) equity" } } }, "auth_ref": [] }, "us-gaap_RevenuesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenuesAbstract", "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "terseLabel": "Revenues:" } } }, "auth_ref": [] }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestIncomeExpenseNonoperatingNet", "crdr": "credit", "calculation": { "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Interest Income (Expense), Nonoperating, Net", "terseLabel": "Interest expense, net", "documentation": "The net amount of nonoperating interest income (expense)." } } }, "auth_ref": [] }, "us-gaap_MarketableSecuritiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketableSecuritiesTextBlock", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsTables" ], "lang": { "en-us": { "role": { "label": "Marketable Securities [Table Text Block]", "terseLabel": "Schedule of marketable securities on the balance sheet", "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets." } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://www.ptcbio.com/role/DisclosureRevenueRecognitionNetProductSalesDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r51", "r54", "r85", "r86", "r273", "r791", "r935" ] }, "ptct_LiabilitySaleOfFutureRoyalties": { "xbrltype": "monetaryItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "LiabilitySaleOfFutureRoyalties", "crdr": "credit", "presentation": [ "http://www.ptcbio.com/role/DisclosureDebtLiabilityForSaleOfFutureRoyaltiesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of liabilities related to the sale of future royalties.", "label": "Liability, Sale of Future Royalties", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance" } } }, "auth_ref": [] }, "ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockholdersSpecifiedOwnershipPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardStockholdersSpecifiedOwnershipPercentage", "presentation": [ "http://www.ptcbio.com/role/DisclosureStockAwardPlanNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the stockholder's specified ownership percentage of the entity's common stock used in determination of the exercise price of stock options granted.", "label": "Share Based Compensation Arrangement by Share Based Payment Award Stockholders Specified Ownership Percentage", "terseLabel": "Stockholder's specified ownership percentage" } } }, "auth_ref": [] }, "us-gaap_CollaborativeArrangementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CollaborativeArrangementMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureCommitmentsAndContingenciesNarrativeDetails", "http://www.ptcbio.com/role/DisclosureRevenueRecognitionCollaborationAndRoyaltyRevenueDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesCollaborationAndRoyaltyRevenueDetails" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement", "terseLabel": "SMA License Agreement", "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity." } } }, "auth_ref": [ "r513" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Share-based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfSeniorDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfSeniorDebt", "crdr": "credit", "presentation": [ "http://www.ptcbio.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Repayments of Senior Debt", "terseLabel": "Outstanding principal and accrued interest repaid", "documentation": "The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period." } } }, "auth_ref": [ "r41" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r121", "r122", "r123" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.ptcbio.com/role/DisclosureLeasesNarrativeDetails", "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease ROU assets", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r577" ] }, "us-gaap_GoodwillPeriodIncreaseDecrease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillPeriodIncreaseDecrease", "presentation": [ "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillGoodwillDetails" ], "lang": { "en-us": { "role": { "label": "Goodwill, Period Increase (Decrease)", "terseLabel": "Changes in goodwill", "documentation": "Amount of increase (decrease) of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r979" ] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Operating Expenses", "totalLabel": "Total operating expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleThresholdPercentageOfStockPriceTrigger", "presentation": [ "http://www.ptcbio.com/role/DisclosureDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Convertible, Threshold Percentage of Stock Price Trigger", "terseLabel": "Stock price trigger", "documentation": "Minimum percentage of common stock price to conversion price of convertible debt instruments to determine eligibility of conversion." } } }, "auth_ref": [] }, "us-gaap_FinanceLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseRightOfUseAsset", "crdr": "debit", "presentation": [ "http://www.ptcbio.com/role/DisclosureLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Finance Lease, Right-of-Use Asset", "verboseLabel": "Finance lease ROU asset", "documentation": "Amount, after accumulated amortization, of right-of-use asset from finance lease." } } }, "auth_ref": [ "r577" ] }, "us-gaap_ConvertibleDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebtMember", "presentation": [ "http://www.ptcbio.com/role/DisclosureDebtConvertibleNotesDetails", "http://www.ptcbio.com/role/DisclosureDebtConvertibleNotesInterestExpenseDetails", "http://www.ptcbio.com/role/DisclosureDebtNarrativeDetails", "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsConvertibleSeniorNotesDetails" ], "lang": { "en-us": { "role": { "label": "Convertible debt", "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock." } } }, "auth_ref": [ "r132", "r379", "r380", "r385", "r386", "r387", "r390", "r391", "r392", "r393", "r394", "r821", "r822", "r823", "r824", "r825" ] }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsSummaryOfChangesInFairValueOfCompanySLevel3ValuationDetails", "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillIndefiniteLivedIntangiblesDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company." } } }, "auth_ref": [ "r63", "r129" ] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestmentsSummaryOfChangesInFairValueOfCompanySLevel3ValuationDetails", "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillIndefiniteLivedIntangiblesDetails", "http://www.ptcbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Indefinite-lived Intangible Assets [Axis]", "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit." } } }, "auth_ref": [ "r354", "r357" ] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "auth_ref": [] }, "ptct_Numberofterms": { "xbrltype": "integerItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "Numberofterms", "presentation": [ "http://www.ptcbio.com/role/DisclosureLeasesNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of renewable terms.", "label": "Number of terms", "terseLabel": "Number of renewable terms" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract", "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]", "terseLabel": "Cash flows from operating activities" } } }, "auth_ref": [] }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems", "presentation": [ "http://www.ptcbio.com/role/DisclosureIntangibleAssetsAndGoodwillIndefiniteLivedIntangiblesDetails" ], "lang": { "en-us": { "role": { "label": "Indefinite-Lived Intangible Assets [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://www.ptcbio.com/role/DisclosureFairValueOfFinancialInstrumentsAndInvestments" ], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Text Block]", "verboseLabel": "Fair value of financial instruments and investments", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r543" ] }, "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleThresholdTradingDays", "presentation": [ "http://www.ptcbio.com/role/DisclosureDebtNarrativeDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Convertible, Threshold Trading Days", "terseLabel": "Trading days, number", "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature." } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by (used in) financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r208" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash (used in) provided by investing activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r208" ] }, "ptct_EmployeeStockPurchasePlanVotingPercentageLimitPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "EmployeeStockPurchasePlanVotingPercentageLimitPercent", "presentation": [ "http://www.ptcbio.com/role/DisclosureStockAwardPlanNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Employee Stock Purchase Plan, Voting Percentage Limit, Percent", "label": "Employee Stock Purchase Plan, Voting Percentage Limit, Percent", "terseLabel": "Employee stock purchase plan, voting percentage limit" } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, issued shares (in shares)", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r101" ] }, "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract", "presentation": [ "http://www.ptcbio.com/role/DisclosureLeasesLeasePaymentsDetails" ], "lang": { "en-us": { "role": { "label": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]", "terseLabel": "Operating leases" } } }, "auth_ref": [] }, "ptct_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedToStockholdersWithSpecifiedOwnershipPercentageExercisePriceAsPercentageOfFairMarketValueOfCommonStock": { "xbrltype": "percentItemType", "nsuri": "http://www.ptcbio.com/20230930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantedToStockholdersWithSpecifiedOwnershipPercentageExercisePriceAsPercentageOfFairMarketValueOfCommonStock", "presentation": [ "http://www.ptcbio.com/role/DisclosureStockAwardPlanNarrativeDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the exercise price expressed as a percentage of the fair market value of the common stock as of the date of grant, at which grantees with specified common stock ownership percentage can acquire the shares reserved for issuance of stock options awarded.", "label": "Share Based Compensation Arrangement by Share Based Payment Award Options Granted to Stockholders with Specified Ownership Percentage Exercise Price as Percentage of Fair Market Value of Common Stock", "terseLabel": "Stock options granted to stockholder with specified ownership percentage, exercise price as percentage of the fair market value of common stock at grant date" } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.ptcbio.com/role/StatementConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, authorized shares (in shares)", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r101", "r722" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Subparagraph": "b", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479613/805-30-35-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(g)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(g)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c),(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "820", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b),(d)", "SubTopic": "30", "Topic": "350", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "e", "SubTopic": "470", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Subparagraph": "(c)", "Paragraph": "2", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19,20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "250", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "310", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-9" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "320", "Publisher": "FASB", "URI": "https://asc.fasb.org//320/tableOfContent" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "((a)(1),(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "40", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480489/718-40-50-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "40", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480489/718-40-50-1" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "25", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-6" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.15)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "320", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-5" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//350/tableOfContent" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-10" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-5" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r152": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r154": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-6" }, "r155": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-6" }, "r156": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-6" }, "r157": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-7" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(1)", "SubTopic": "10", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//275/tableOfContent" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//606/tableOfContent" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-11" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-6" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 11.M.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480530/250-10-S99-5" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//260/tableOfContent" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-40" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481925/310-20-65-2" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-5" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-2" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//350-20/tableOfContent" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147477123/405-50-65-1" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.P.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-1" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-4" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-3" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479845/805-20-65-3" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-4" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-2" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482477/820-10-65-13" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482736/825-10-45-1A" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482833/825-10-65-6" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "832", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "832", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483482/832-10-65-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479832/842-10-65-5" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//855/tableOfContent" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482312/912-310-45-11" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483194/926-20-65-2" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-3A" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(d)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(d)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480424/946-10-50-3" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "27", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7" }, "r704": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r705": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r706": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r707": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r708": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r709": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2" }, "r710": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r713": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r725": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r726": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r727": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r728": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r729": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r730": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r731": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r732": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r733": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r734": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r735": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r736": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r737": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r738": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r739": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r740": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r741": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r742": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-6" }, "r743": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r744": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3" }, "r745": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r746": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r747": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r748": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r749": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r750": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r751": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r752": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r753": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r754": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r755": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r756": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r757": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r758": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r759": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r760": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r761": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r762": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r763": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r764": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r765": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r766": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r767": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r768": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r769": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r770": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r771": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r772": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r773": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r774": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r775": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r776": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5D", "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D" }, "r777": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5D", "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5D" }, "r778": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r779": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r780": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r781": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r782": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r783": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r784": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1" }, "r785": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r786": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r787": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r788": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r789": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r790": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1" }, "r791": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2" }, "r792": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r793": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r794": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r795": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r796": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r797": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r798": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r799": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r800": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r801": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r802": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r803": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r804": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r805": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r806": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r807": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r808": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r809": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r810": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r811": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "8", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8" }, "r812": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16" }, "r813": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21" }, "r814": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r815": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r816": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r817": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r818": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r819": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8" }, "r820": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24" }, "r821": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r822": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r823": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r824": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r825": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r826": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r827": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r828": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r829": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r830": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r831": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r832": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r833": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r834": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r835": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r836": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r837": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r838": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6" }, "r839": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r840": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r841": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r842": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r843": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r844": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r845": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2" }, "r846": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r847": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r848": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r849": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r850": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r851": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r852": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r853": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r854": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r855": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r856": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r857": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r858": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r859": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r860": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r861": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r862": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r863": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r864": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r865": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r866": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r867": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r868": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r869": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r870": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r871": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r872": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii", "Section": "6" }, "r873": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r874": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r875": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r876": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r877": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r878": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r879": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r880": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r881": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r882": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r883": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r884": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r885": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r886": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r887": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r888": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r889": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r890": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r891": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r892": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r893": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r894": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r895": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r896": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r897": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r898": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r899": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r900": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r901": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r902": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r903": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r904": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r905": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r906": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r907": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r908": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r909": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r910": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r911": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r912": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r913": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r914": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r915": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r916": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r917": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r918": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r919": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r920": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r921": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r922": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r923": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r924": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r925": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r926": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r927": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r928": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r929": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r930": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r931": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r932": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r933": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3" }, "r934": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18" }, "r935": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B" }, "r936": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r937": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r938": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(1)", "Publisher": "SEC" }, "r939": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(2)", "Publisher": "SEC" }, "r940": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(3)", "Publisher": "SEC" }, "r941": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r942": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r943": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r944": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r945": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r946": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r947": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r948": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r949": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r950": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r951": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r952": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r953": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r954": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r955": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r956": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r957": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r958": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r959": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r960": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r961": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r962": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r963": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "55", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55" }, "r964": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r965": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18" }, "r966": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1" }, "r967": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11" }, "r968": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-14" }, "r969": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r970": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r971": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9" }, "r972": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r973": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r974": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r975": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-4" }, "r976": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r977": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4" }, "r978": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9" }, "r979": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r980": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r981": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r982": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3" }, "r983": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r984": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482047/420-10-45-3" }, "r985": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r986": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r987": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r988": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482050/460-10-25-4" }, "r989": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-1" }, "r990": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r991": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r992": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r993": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r994": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r995": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r996": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r997": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r998": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r999": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1000": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1001": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1002": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1003": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1004": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1005": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1006": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1007": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1008": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1009": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1010": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1011": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1012": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1013": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1014": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1015": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1016": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1017": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1018": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1019": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1020": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1021": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r1022": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480123/805-50-15-3" }, "r1023": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480682/815-20-25-6A" }, "r1024": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r1025": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r1026": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r1027": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r1028": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r1029": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-1" }, "r1030": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481926/830-20-50-1" }, "r1031": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r1032": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4" }, "r1033": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r1034": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r1035": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r1036": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r1037": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r1038": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r1039": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r1040": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r1041": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r1042": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r1043": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r1044": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r1045": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r1046": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r1047": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r1048": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r1049": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r1050": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480109/944-80-50-1" }, "r1051": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r1052": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r1053": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r1054": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r1055": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r1056": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r1057": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r1058": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r1059": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r1060": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r1061": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r1062": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r1063": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r1064": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r1065": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r1066": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r1067": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r1068": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" } } } ZIP 95 0001070081-23-000065-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001070081-23-000065-xbrl.zip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�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end

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